PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Meiling-Wesse, K; Barth, H; Voss, C; Eskelinen, EL; Epple, UD; Thumm, M				Meiling-Wesse, K; Barth, H; Voss, C; Eskelinen, EL; Epple, UD; Thumm, M			Atg21 is required for effective recruitment of Atg8 to the preautophagosomal structure during the Cvt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; PRE-AUTOPHAGOSOMAL STRUCTURE; SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; MAMMALIAN-CELLS; CYTOPLASM; PROTEIN; MEMBRANE; COMPLEX; TRANSPORT	Atg21 and Atg18 are homologue yeast proteins. Whereas Atg18 is essential for the Cvt pathway and autophagy, a lack of Atg21 only blocks the Cvt pathway. Our proteinase protection experiments now demonstrate that growing atg21Delta cells fail to form proaminopeptidase I-containing Cvt vesicles. Quantitative measurement of autophagy in starving atg21Delta cells showed only 35% of the wild-type rate. This suggests that Atg21 plays a nonessential role in improving the fidelity of autophagy. The intracellular localization of Atg21 is unique among the Atg proteins. In cells containing multiple vacuoles, Atg21-yellow fluorescent protein clearly localizes to the vertices of the vacuole junctions. Cells with a single vacuole show most of the protein at few perivacuolar punctae. This distribution pattern is reminiscent to the Vps class C( HOPS) ( homotypic fusion and vacuolar protein sorting) protein complex. In growing cells, Atg21 is required for effective recruitment of Atg8 to the preautophagosomal structure. Consistently, the covalent linkage of Atg8 to the lipid phosphatidylethanolamine is significantly retarded. Lipidated Atg8 is supposed to act during the elongation of autophagosome precursors. However, despite the reduced autophagic rate and the retardation of Atg8 lipidation, electron microscopy of starved atg21Delta ypt7Delta double mutant cells demonstrates the formation of normally sized autophagosomes with an average diameter of 450 nm.	Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany; Univ Kiel, Inst Biochem, D-24118 Kiel, Germany	University of Gottingen; University of Kiel	Thumm, M (corresponding author), Univ Gottingen, Ctr Biochem & Mol Cell Biol, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany.	mthumm@uni-goettingen.de	Thumm, Michael/A-8033-2015; Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Thumm, Michael/0000-0003-3238-4857				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Barth H, 2002, FEBS LETT, V512, P173, DOI 10.1016/S0014-5793(02)02252-4; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Campbell CL, 1998, J CELL SCI, V111, P2455; Del Roso A, 2003, EXP GERONTOL, V38, P519, DOI 10.1016/S0531-5565(03)00002-0; Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203; Epple UD, 2003, J BIOL CHEM, V278, P7810, DOI 10.1074/jbc.M209309200; Georgakopoulos T, 2001, YEAST, V18, P1155, DOI 10.1002/yea.764; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Leber R, 2001, J BIOL CHEM, V276, P29210, DOI 10.1074/jbc.M101438200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; Meiling-Wesse K, 2002, FEBS LETT, V526, P71, DOI 10.1016/S0014-5793(02)03119-8; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nice DC, 2002, J BIOL CHEM, V277, P30198, DOI 10.1074/jbc.M204736200; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Prescianotto-Baschong C, 2002, TRAFFIC, V3, P37, DOI 10.1034/j.1600-0854.2002.30106.x; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Reggiori F, 2003, J BIOL CHEM, V278, P5009, DOI 10.1074/jbc.M210436200; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Thumm M, 2002, MOL CELL, V10, P1257, DOI 10.1016/S1097-2765(02)00794-3; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	56	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37741	37750		10.1074/jbc.M401066200	http://dx.doi.org/10.1074/jbc.M401066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15194695	hybrid			2022-12-25	WOS:000223554600066
J	Seong, YM; Choi, JY; Park, HJ; Kim, KJ; Ahn, SG; Seong, GH; Kim, IK; Kang, S; Rhim, H				Seong, YM; Choi, JY; Park, HJ; Kim, KJ; Ahn, SG; Seong, GH; Kim, IK; Kang, S; Rhim, H			Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE OMI/HTRA2; ESCHERICHIA-COLI; APOPTOSIS PROTEINS; RAPID PURIFICATION; INTRAMEMBRANE PROTEOLYSIS; MAMMALIAN PROTEIN; STRUCTURAL BASIS; CYTOCHROME-C; PDZ DOMAINS; HTRA FAMILY	A mature form of nuclear-encoded mitochondrial serine protease HtrA2/Omi is pivotal in regulating apoptotic cell death; however, the underlying mechanism of the processing event of HtrA2/Omi and its relevant biological function remain to be clarified. Here, we describe that HtrA2/Omi is autocatalytically processed to the 36-kDa protein fragment, which is required for the cytochrome c-dependent caspase activation along with neutralizing XIAP-mediated inhibition of caspases through interaction with XIAP, eventually promoting apoptotic cell death. We have shown that the autocatalytic processing of HtrA2/Omi occurs via an intermolecular event, demonstrated by incubating an in vitro translated HtrA2/Omi (S306A) mutant with the enzymatically active glutathione S-transferase-HtrA2/Omi protein. Using N-terminal amino acid sequencing and mutational analysis, we identified that the autocatalytic cleavage site is the carboxyl side of alanine 133 of HtrA2/ Omi, resulting in exposure of an inhibitor of apoptosis protein binding motif in its N terminus. Our study provides evidence that the autocatalytic processing of HtrA2/ Omi is crucial for regulating HtrA2/ Omi-mediated apoptotic cell death.	Catholic Univ Korea, Catholic Res Inst Med Sci, Res Inst Mol Genet, Seoul 137701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biomed Sci, Seoul 137701, South Korea; Sangmyung Univ, Dept Biol, Seoul 110743, South Korea	Catholic University of Korea; Korea University; Catholic University of Korea; Catholic University of Korea; Sang Myung University	Kang, S (corresponding author), Catholic Univ Korea, Catholic Res Inst Med Sci, Res Inst Mol Genet, 505 Banpo Dong, Seoul 137701, South Korea.	skang@korea.ac.kr; hrhim@catholic.ac.kr						Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Choi JY, 2002, BIOTECHNOL APPL BIOC, V36, P33, DOI 10.1042/BA20020004; Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Jones CH, 2002, J BACTERIOL, V184, P5762, DOI 10.1128/JB.184.20.5762-5771.2002; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kipp RA, 2002, BIOCHEMISTRY-US, V41, P7344, DOI 10.1021/bi0121454; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martins LM, 2002, CELL DEATH DIFFER, V9, P699, DOI 10.1038/sj.cdd.4401044; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Park HJ, 2003, BIOTECHNOL LETT, V25, P1597, DOI 10.1023/A:1025630013679; RHIM H, 1993, J VIROL, V67, P1110, DOI 10.1128/JVI.67.2.1110-1121.1993; RHIM HS, 1993, PROTEIN EXPRES PURIF, V4, P24, DOI 10.1006/prep.1993.1004; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Seong YM, 2004, PROTEIN EXPRES PURIF, V33, P200, DOI 10.1016/j.pep.2003.10.002; Sik A, 2004, J BIOL CHEM, V279, P15323, DOI 10.1074/jbc.M313756200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	53	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37588	37596		10.1074/jbc.M401408200	http://dx.doi.org/10.1074/jbc.M401408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201285	hybrid			2022-12-25	WOS:000223554600050
J	Wang, YG; Nnakwe, C; Lane, WS; Modesti, M; Frank, KM				Wang, YG; Nnakwe, C; Lane, WS; Modesti, M; Frank, KM			Phosphorylation and regulation of DNA ligase IV stability by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; RAY-SENSITIVE MUTANTS; END-JOINING PROTEINS; HAMSTER OVARY CELL; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; XRCC4 PROTEIN; CANCER SUSCEPTIBILITY; GENOMIC INSTABILITY; EMBRYONIC LETHALITY	DNA ligase IV (Lig4), x-ray cross-complementation group 4 (XRCC4), and DNA-dependent protein kinase (DNA-PK) are essential mammalian nonhomologous end joining proteins used for V(D)J recombination and DNA repair. Previously a Lig4 peptide was reported to be an in vitro substrate for DNA-PK, but the phosphorylation state of Lig4 protein in vivo is not known. In this study, we report that a full-length Lig4 construct was expressed as a phosphoprotein in the cell. Also the full-length Lig4 protein, in complex with XRCC4, was an in vitro substrate for DNA-PK. Using tandem mass spectrometry, we identified a DNA-PK phosphorylation site at Thr-650 in human Lig4 and a potential second phosphorylation site at Ser-668 or Ser-672. Phosphorylation of Lig4 per se was not required for Lig4 DNA end joining activity. Substitution of these amino acids with alanine, individually or in combination, led to changes in Lig4 protein stability of mouse Lig4. The phosphomimetic mutation S650D returned Lig4 stability to that of the wild-type protein. Furthermore DNA-PK was found to negatively regulate Lig4 protein stability. Our results suggest that Lig4 stability is regulated by multiple factors, including interaction with XRCC4, phosphorylation status, and possibly Lig4 conformation.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Erasmus Med Ctr, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of Chicago; Harvard University; Erasmus University Rotterdam; Erasmus MC	Frank, KM (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	kfrank@uchicago.edu	Modesti, Mauro/D-6258-2017	Modesti, Mauro/0000-0002-4964-331X	NIAID NIH HHS [K08 AI01428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Brady N, 2003, CANCER RES, V63, P1798; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fu YP, 2003, CANCER RES, V63, P2440; Fukumura R, 1998, J BIOL CHEM, V273, P13058, DOI 10.1074/jbc.273.21.13058; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Grawunder U, 2001, CURR OPIN IMMUNOL, V13, P186, DOI 10.1016/S0952-7915(00)00203-X; Hamer G, 2003, BIOL REPROD, V68, P717, DOI 10.1095/biolreprod.102.008920; HAN J, 2003, CARCINOGENESIS; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Kuschel B, 2002, HUM MOL GENET, V11, P1399, DOI 10.1093/hmg/11.12.1399; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee KJ, 2002, J IMMUNOL, V169, P3413, DOI 10.4049/jimmunol.169.6.3413; Lee Y, 2002, CANCER RES, V62, P6395; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Mauldin SK, 2002, NUCLEIC ACIDS RES, V30, P4075, DOI 10.1093/nar/gkf529; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Przewloka MR, 2003, MOL BIOL CELL, V14, P685, DOI 10.1091/mbc.e01-11-0117; Roddam PL, 2002, J MED GENET, V39, P900, DOI 10.1136/jmg.39.12.900; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	67	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37282	37290		10.1074/jbc.M401217200	http://dx.doi.org/10.1074/jbc.M401217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15194694	hybrid			2022-12-25	WOS:000223554600012
J	Wu, AY; Tang, XB; Martinez, SE; Ikeda, K; Beavo, JA				Wu, AY; Tang, XB; Martinez, SE; Ikeda, K; Beavo, JA			Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP-STIMULATED PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; BOVINE ADRENAL-TISSUE; GAF-DOMAIN; MUTATIONAL ANALYSIS; ADENYLYL-CYCLASE; GENE FAMILY; AMINO-ACIDS; CALF LIVER; RAT-LIVER	Binding of cGMP to the GAF-B domain of phosphodiesterase 2A allosterically activates catalytic activity. We report here a series of mutagenesis studies on the GAF-B domain of PDE2A that support a novel mechanism for molecular recognition of cGMP. Alanine mutations of Phe-438, Asp-439, and Thr-488, amino acids that interact with the pyrimidine ring, decrease cGMP affinity slightly but increase cAMP affinity by up to 8-fold. Each interaction is required to provide for cAMP/cGMP specificity. Mutations of any of the residues that interact with the phosphate-ribose moiety or the imidazole ring abolish cGMP binding. Thus, residues that interact with the pyrimidine ring collectively control cAMP/cGMP specificity, whereas residues that bind the phosphate-ribose moiety and imidazole ring are critical for high affinity binding. Similar decreases in binding were found for mutations made in a bacterially expressed GAF-A/B plus catalytic domain construct. Because these constructs had very high catalytic activity, it appears that these mutations did not cause a global denaturation. The affinities of cAMP and cGMP for wild-type GAF-B alone were similar to4-fold greater than for the holoenzyme, suggesting that the presence of neighboring domains alters the conformation of GAF-B. More importantly, the PDE2A GAF-B, GAF-A/B, GAF-A/B + C domains, and holoenzyme all bind cGMP with much higher affinity than has previously been reported. This high affinity suggests that cGMP binding to PDE2 GAF-B activates the enzyme rapidly, stoichiometrically, and in an all or none fashion, rather than variably over a large range of cyclic nucleotide concentrations.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	beavo@u.washington.edu		Wu, Albert/0000-0002-1360-8248	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44948] Funding Source: Medline; NIDDK NIH HHS [DK-21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BEAVO JA, 1971, J BIOL CHEM, V246, P3841; Bowers PM, 1996, NAT STRUCT BIOL, V3, P522, DOI 10.1038/nsb0696-522; BRAUMANN T, 1986, BIOCHIM BIOPHYS ACTA, V871, P199, DOI 10.1016/0167-4838(86)90174-3; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dickinson NT, 1997, BIOCHEM J, V323, P371, DOI 10.1042/bj3230371; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; ERNEUX C, 1985, J CYCLIC NUCL PROT, V10, P463; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HAMMEN PK, 1995, PROTEIN SCI, V4, P936; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; KEELY SL, 1977, AM J PHYSIOL, V233, pH269, DOI 10.1152/ajpheart.1977.233.2.H269; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MIOT F, 1985, EUR J BIOCHEM, V149, P59, DOI 10.1111/j.1432-1033.1985.tb08893.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MOSS J, 1977, J BIOL CHEM, V252, P5211; MUMBY MC, 1982, J BIOL CHEM, V257, P13283; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; REPASKE DR, 1993, NEUROSCIENCE, V56, P673, DOI 10.1016/0306-4522(93)90364-L; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Scott SP, 2001, BIOCHEMISTRY-US, V40, P7464, DOI 10.1021/bi002804x; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sopory S, 2003, FEBS LETT, V539, P161, DOI 10.1016/S0014-5793(03)00219-9; STROOP SD, 1991, J BIOL CHEM, V266, P23802; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Turko IV, 1999, J BIOL CHEM, V274, P29038, DOI 10.1074/jbc.274.41.29038; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WADA H, 1987, J BIOL CHEM, V262, P13938; WADA H, 1987, BIOCHEMISTRY-US, V26, P6565, DOI 10.1021/bi00394a042; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; White M D, 1988, Adv Biotechnol Processes, V8, P51; Wykes V, 2002, J NEUROCHEM, V83, P37, DOI 10.1046/j.1471-4159.2002.01106.x; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	55	59	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37928	37938		10.1074/jbc.M404287200	http://dx.doi.org/10.1074/jbc.M404287200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15210692	Green Published, hybrid			2022-12-25	WOS:000223554600086
J	Chastain, PD; Bowers, JL; Lee, DG; Bell, SP; Griffith, JD				Chastain, PD; Bowers, JL; Lee, DG; Bell, SP; Griffith, JD			Mapping subunit location on the Saccharomyces cerevisiae origin recognition complex free and bound to DNA using a novel nanoscale biopointer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL ELEMENTS; PROTEIN COMPLEXES; ATPASE ACTIVITY; REPLICATION; BINDING; BIOTINYLATION; SUBSTRATE; DOMAIN; CELLS; SITE	The Saccharomyces cerevisiae origin recognition complex (ORC) is composed of six subunits and is an essential component in the assembly of the replication apparatus. To probe the organization of this multiprotein complex by electron microscopy, each subunit was tagged on either its C or N terminus with biotin and assembled into a complex with the five other unmodified subunits. A nanoscale biopointer consisting of a short DNA duplex with streptavidin at one end was used to map the location of the N and C termini of each subunit. These observations were made using ORC free in solution and bound to the ARS1 origin of replication. This mapping confirms and extends previous studies mapping the sites of subunit interaction with origin DNA. In particular, we provide new information concerning the stoichiometry of the ORC-ARS1 complex and the changes in conformation that are associated with DNA binding by ORC. This versatile, new approach to mapping protein structure has potential for many applications.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [GM 19014, GM 31819, GM 53229] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM053229] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BERLINER E, 1994, J BIOL CHEM, V269, P8610; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Duffy S, 1998, ANAL BIOCHEM, V262, P122, DOI 10.1006/abio.1998.2770; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Stenlund A, 2003, NAT REV MOL CELL BIO, V4, P777, DOI 10.1038/nrm1226; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36354	36362		10.1074/jbc.M403501200	http://dx.doi.org/10.1074/jbc.M403501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201282	Green Published, hybrid			2022-12-25	WOS:000223453600025
J	Klampfer, L; Huang, J; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L; Huang, J; Sasazuki, T; Shirasawa, S; Augenlicht, L			Oncogenic Ras promotes butyrate-induced apoptosis through inhibition of gelsolin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONIC EPITHELIAL-CELLS; CHAIN FATTY-ACIDS; K-RAS; GENE-EXPRESSION; MUTATED GELSOLIN; PROTEIN-KINASE; IN-VIVO; C-MYC; CANCER; ACTIVATION	Activation of Ras promotes oncogenesis by altering a multiple of cellular processes, such as cell cycle progression, differentiation, and apoptosis. Oncogenic Ras can either promote or inhibit apoptosis, depending on the cell type and the nature of the apoptotic stimuli. The response of normal and transformed colonic epithelial cells to the short chain fatty acid butyrate, a physiological regulator of epithelial cell maturation, is also divergent: normal epithelial cells proliferate, and transformed cells undergo apoptosis in response to butyrate. To investigate the role of k-ras mutations in butyrate-induced apoptosis, we utilized HCT116 cells, which harbor an oncogenic k-ras mutation and two isogenic clones with targeted inactivation of the mutant k-ras allele, Hkh2, and Hke-3. We demonstrated that the targeted deletion of the mutant k-ras allele is sufficient to protect epithelial cells from butyrate-induced apoptosis. Consistent with this, we showed that apigenin, a dietary flavonoid that has been shown to inhibit Ras signaling and to reverse transformation of cancer cell lines, prevented butyrate-induced apoptosis in HCT116 cells. To investigate the mechanism whereby activated k-ras sensitizes colonic cells to butyrate, we performed a genome-wide analysis of Ras target genes in the isogenic cell lines HCT116, Hkh2, and Hke-3. The gene exhibiting the greatest down-regulation by the activating k-ras mutation was gelsolin, an actin-binding protein whose expression is frequently reduced or absent in colorectal cancer cell lines and primary tumors. We demonstrated that silencing of gelsolin expression by small interfering RNA sensitized cells to butyrate-induced apoptosis through amplification of the activation of caspase-9 and caspase-7. These data therefore demonstrate that gelsolin protects cells from butyrate-induced apoptosis and suggest that Ras promotes apoptosis, at least in part, through its ability to down-regulate the expression of gelsolin.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U01CA088104] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88104] Funding Source: Medline; PHS HHS [P0 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Asch HL, 1999, BREAST CANCER RES TR, V55, P179; Asch HL, 1996, CANCER RES, V56, P4841; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Baba I, 2000, CANCER RES, V60, P6886; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Clarke KO, 2001, CANCER LETT, V171, P57, DOI 10.1016/S0304-3835(01)00574-2; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Csordas A, 1996, EUR J CANCER PREV, V5, P221, DOI 10.1097/00008469-199608000-00002; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Dong Y, 1999, INT J CANCER, V81, P930, DOI 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Dosaka-Akita H, 1998, CANCER RES, V58, P322; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fujita H, 1999, ANN NY ACAD SCI, V886, P217, DOI 10.1111/j.1749-6632.1999.tb09420.x; Geng YJ, 1998, EUR J CELL BIOL, V77, P294, DOI 10.1016/S0171-9335(98)80088-5; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; ISHIZAKI A, 1995, EXP CELL RES, V217, P448, DOI 10.1006/excr.1995.1108; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Konishi T, 2000, INT J ONCOL, V16, P501; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Kuzumaki N, 1997, Gan To Kagaku Ryoho, V24, P1436; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lawson KR, 2000, CANCER EPIDEM BIOMAR, V9, P1155; Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mariadason JM, 2001, GASTROENTEROLOGY, V120, P889, DOI 10.1053/gast.2001.22472; Mariadason JM, 2000, CANCER RES, V60, P4561; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; MULLAUER L, 1993, ONCOGENE, V8, P2531; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Posey SC, 2000, BLOOD, V95, P3483, DOI 10.1182/blood.V95.11.3483.011k05_3483_3488; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; SCHEPPACH W, 1995, EUR J CANCER, V31A, P1077, DOI 10.1016/0959-8049(95)00165-F; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Velazquez OC, 1996, DIGEST DIS SCI, V41, P727, DOI 10.1007/BF02213129; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P169; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yin F, 1999, ANTICANCER RES, V19, P4297; Yin F, 2001, ANTICANCER RES, V21, P413; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	73	42	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36680	36688		10.1074/jbc.M405197200	http://dx.doi.org/10.1074/jbc.M405197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213223	hybrid			2022-12-25	WOS:000223453600067
J	Ronning, DR; Vissa, V; Besra, GS; Belisle, JT; Sacchettini, JC				Ronning, DR; Vissa, V; Besra, GS; Belisle, JT; Sacchettini, JC			Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE IMMUNITY; PROTEIN; FIBRONECTIN; EXPRESSION; MECHANISM; RESIDUES; EFFICACY; VACCINES; COMPLEX; H37RV	The maintenance of the highly hydrophobic cell wall is central to the survival of Mycobacterium tuberculosis within its host environment. The antigen 85 proteins (85A, 85B, and 85C) of M. tuberculosis help maintain the integrity of the cell wall 1) by catalyzing the transfer of mycolic acids to the cell wall arabinogalactan and 2) through the synthesis of trehalose dimycolate (cord factor). Additionally, these secreted proteins allow for rapid invasion of alveolar macrophages via direct interactions between the host immune system and the invading bacillus. Here we describe two crystal structures: the structure of antigen 85C co-crystallized with octylthioglucoside as substrate, resolved to 2.0 Angstrom, and the crystal structure of antigen 85A, which was solved at a resolution of 2.7 Angstrom. The structure of 85C with the substrate analog identifies residues directly involved in substrate binding. Elucidation of the antigen 85A structure, the last of the three antigen 85 homologs to be solved, shows that the active sites of the three antigen 85 proteins are virtually identical, indicating that these share the same substrate. However, in contrast to the high level of conservation within the substrate-binding site and the active site, surface residues disparate from the active site are quite variable, indicating that three antigen 85 enzymes are needed to evade the host immune system.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Texas A&M University System; Texas A&M University College Station; University of Birmingham; Colorado State University	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.	sacchett@tamu.edu	Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798; Besra, Gurdyal/0000-0002-5605-0395; Ronning, Donald/0000-0003-2583-8849	NCRR NIH HHS [RR 07707] Funding Source: Medline; NIGMS NIH HHS [GM 62410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; Anderson DH, 2001, J MOL BIOL, V307, P671, DOI 10.1006/jmbi.2001.4461; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DRENTH J, 1994, PRINCIPLES PROTEIN X, P71; Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Harth G, 2002, P NATL ACAD SCI USA, V99, P15614, DOI 10.1073/pnas.242612299; Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamath AT, 2000, CLIN EXP IMMUNOL, V120, P476, DOI 10.1046/j.1365-2249.2000.01240.x; Kamath AT, 1999, INFECT IMMUN, V67, P1702; Mariani F, 2000, GENE, V253, P281, DOI 10.1016/S0378-1119(00)00249-3; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miki K, 2004, INFECT IMMUN, V72, P2014, DOI 10.1128/IAI.72.4.2014-2021.2004; Naito M, 2000, BIOCHEM J, V347, P725, DOI 10.1042/0264-6021:3470725; Naito M, 1998, J BIOL CHEM, V273, P2905, DOI 10.1074/jbc.273.5.2905; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; Puech V, 2002, MOL MICROBIOL, V44, P1109, DOI 10.1046/j.1365-2958.2002.02953.x; ROCHE PW, 1994, INFECT IMMUN, V62, P5319, DOI 10.1128/IAI.62.12.5319-5326.1994; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	31	72	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36771	36777		10.1074/jbc.M400811200	http://dx.doi.org/10.1074/jbc.M400811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192106	hybrid			2022-12-25	WOS:000223453600078
J	Bae, E; Sakai, T; Mosher, DF				Bae, E; Sakai, T; Mosher, DF			Assembly of exogenous fibronectin by fibronectin-null cells is dependent on the adhesive substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED EIIIB; PLASMA FIBRONECTIN; ALPHA(5)BETA(1) INTEGRIN; LYSOPHOSPHATIDIC ACID; VASCULAR DEVELOPMENT; ISOFORM DISTRIBUTION; MATRIX ADHESIONS; FOCAL ADHESIONS; MOUSE EMBRYOS; V-SEGMENT	The role of endogenously synthesized fibronectin (FN) in assembly was studied with cells lacking or expressing FN. Cells were cultured as homogeneous or mixed populations on surfaces coated with different matrix proteins. Compared with FN-expressing cells, FN-null cells poorly assembled exogenous plasma FN (pFN) when adhered to vitronectin or the recombinant cell-binding domain (III7-10) of FN. Vitronectin had a suppressive effect that was overcome by co-adsorbed pFN or laminin-1 but not by soluble FN. In co-cultures of FN-expressing cells and FN-null cells, endogenous FN was preferentially assembled around FN-expressing cells regardless of the adhesive ligand. If the adhesive ligand was vitronectin, exogenous pFN assembled preferentially around cells expressing cellular FN or recombinant EDa- or EDa+ FN. In co-cultures on vitronectin of FN-null cells and beta(1) integrin subunit-null cells, fibrils of cellular FN and pFN were preferentially deposited by FN-null (beta(1)-expressing) cells immediately adjacent to (FN-secreting) beta(1)-null cells. In co-cultures on vitronectin of FN-null cells and beta(1)-null cells expressing a chimera with the extracellular domain of beta(1) and the cytoplasmic domain of beta(3), preferential assembly was by the chimera-expressing cells. These results indicate that the adhesive ligand is a determinant of FN assembly by cells not secreting endogenous FN (suppressive if vitronectin, non-suppressive but non-supportive if III7-10, supportive if pFN or laminin-1) and suggest that efficient interaction of freshly secreted cellular FN with a beta(1) integrin, presumably alpha(5)beta(1), substitutes for integrin-mediated adherence to a preformed matrix of laminin-1 or pFN to support assembly of FN.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Rm 4285,Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NHLBI NIH HHS [HL 21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1994, J BIOL CHEM, V269, P24756; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; Chen F, 1996, J BIOL CHEM, V271, P9084, DOI 10.1074/jbc.271.15.9084; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; DUFOUR S, 1991, EXP CELL RES, V193, P331, DOI 10.1016/0014-4827(91)90104-3; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Francis SE, 2002, ARTERIOSCL THROM VAS, V22, P927, DOI 10.1161/01.ATV.0000016045.93313.F2; Fukuda T, 2002, CANCER RES, V62, P5603; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hocking DC, 1999, J BIOL CHEM, V274, P27257, DOI 10.1074/jbc.274.38.27257; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1990, SPRINGER SERIES MOL, P24; Ilic D, 1997, J CELL SCI, V110, P401; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; Li FY, 2003, BIOPHYS J, V84, P1252, DOI 10.1016/S0006-3495(03)74940-6; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; Mosher, 1989, FIBRONECTIN, P1; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; Peters JH, 1996, CELL ADHES COMMUN, V4, P103, DOI 10.3109/15419069609010766; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Sottile J, 2000, J CELL SCI, V113, P4287; THIERY JP, 1989, FIBRONECTIN, P181; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang QH, 1999, J BIOL CHEM, V274, P368, DOI 10.1074/jbc.274.1.368; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	58	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35749	35759		10.1074/jbc.M406283200	http://dx.doi.org/10.1074/jbc.M406283200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199047	hybrid			2022-12-25	WOS:000223303400074
J	Boopathi, E; Lenka, N; Prabu, SK; Fang, JK; Wilkinson, F; Atchison, M; Giallongo, A; Avadhani, NG				Boopathi, E; Lenka, N; Prabu, SK; Fang, JK; Wilkinson, F; Atchison, M; Giallongo, A; Avadhani, NG			Regulation of murine cytochrome c oxidase Vb gene expression during Myogenesis - YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein (JKTBP1) reciprocally regulate transcription activity by physical interaction with the BERF-1/ZBP-89 factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SUBUNIT-IV GENE; MUSCLE-SPECIFIC ENHANCER; ZINC-FINGER PROTEIN; G-RICH-BOX; BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; STRUCTURAL ORGANIZATION; AFFINITY-CHROMATOGRAPHY; CATALYTIC-ACTIVITY	A transcription suppressor element (sequence -481 to -320) containing a G-rich motif (designated GTG) and a newly identified CAT-rich motif (designated CATR) was previously shown to modulate expression of the mouse cytochrome c oxidase Vb gene during myogenesis. Here, we show that the GTG element is critical for transcription activation in both undifferentiated and differentiated myocytes. Mutations of the CATR motif abolished transcription repression in myoblasts while limiting transcription activation in differentiated myotubes, suggesting contrasting functional attributes of this DNA motif at different stages of myogenesis. Results show that the activity of the transcription suppressor motif is modulated by an orchestrated interplay between ubiquitous transcription factors: ZBP-89, YY-1, and a member of the heterogeneous nuclear ribonucleoprotein D-like protein (also known as JKTBP1) family. In undifferentiated muscle cells, GTG motif-bound ZBP-89 physically and functionally interacted with CATR motif-bound YY-1 to mediate transcription repression. In differentiated myotubes, heterogeneous nuclear ribonucleoprotein D-like protein/JKTBP1 bound to the CATR motif exclusive of YY-1 and interacted with ZBP-89 in attenuating repressor activity, leading to transcription activation. Our results show a novel mechanism of protein factor switching in transcription regulation of the cytochrome c oxidase Vb gene during myogenesis.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; CNR, Ist Biomed & Immunol Mol, I-90146 Palermo, Italy	University of Pennsylvania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Lenka, Nibedita/ABX-3824-2022; Giallongo, Agata/ABD-1103-2020	Giallongo, Agata/0000-0001-9998-4481; Wilkinson, Frank/0000-0001-6003-3478; Ettickan, Boopathi/0000-0001-9431-7719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER; NIDDK NIH HHS [T-32 DKO7708] Funding Source: Medline; NIGMS NIH HHS [GM49683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akagi T, 2000, GENE, V245, P267, DOI 10.1016/S0378-1119(00)00032-9; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P98, DOI 10.1016/0167-4781(90)90128-O; BASU A, 1991, J BIOL CHEM, V266, P15450; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; Bemark M, 1998, J BIOL CHEM, V273, P18881, DOI 10.1074/jbc.273.30.18881; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FEO S, 1995, MOL CELL BIOL, V15, P5991; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Lenka N, 1996, J BIOL CHEM, V271, P30281, DOI 10.1074/jbc.271.47.30281; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Mikheev AM, 2000, NUCLEIC ACIDS RES, V28, P3762, DOI 10.1093/nar/28.19.3762; Min CH, 1996, NUCLEIC ACIDS RES, V24, P3806, DOI 10.1093/nar/24.19.3806; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; PARHAM P, 1983, METHOD ENZYMOL, V92, P110; Park H, 2003, BLOOD, V101, P894, DOI 10.1182/blood-2002-03-0680; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Rushlow WJ, 1999, NEUROSCIENCE, V94, P637, DOI 10.1016/S0306-4522(99)00342-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; TAANMAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P283, DOI 10.1016/0167-4781(91)90027-J; THOMPSON CC, 1991, SCIENCE, V253, P742; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691	71	18	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35242	35254		10.1074/jbc.M403160200	http://dx.doi.org/10.1074/jbc.M403160200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190078	hybrid			2022-12-25	WOS:000223303400015
J	Kurahashi, H; Inagaki, H; Yamada, K; Ohye, T; Taniguchi, M; Emanuel, BS; Toda, T				Kurahashi, H; Inagaki, H; Yamada, K; Ohye, T; Taniguchi, M; Emanuel, BS; Toda, T			Cruciform DNA structure underlies the etiology for palindrome-mediated human chromosomal translocations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECURRENT CONSTITUTIONAL T(11/22); AT-RICH PALINDROMES; LOW COPY REPEATS; GENOMIC INSTABILITY; SUPERCOILED DNA; BREAKPOINT; SEQUENCE; TRANSITION; EXTRUSION; HAIRPIN	There is accumulating evidence to suggest that palindromic AT-rich repeats (PATRRs) represent hot spots of double-strand breakage that lead to recurrent chromosomal translocations in humans. As a mechanism for such rearrangements, we proposed that the PATRR forms a cruciform structure that is the source of genomic instability. To test this hypothesis, we have investigated the tertiary structure of a cloned PATRR. We have observed that a plasmid containing this PATRR undergoes a conformational change, causing temperature-dependent mobility changes upon agarose gel electrophoresis. The mobility shift is observed in physiologic salt concentrations and is most prominent when the plasmid DNA is incubated at room temperature prior to electrophoresis. Analysis using two-dimensional gel electrophoresis indicates that the mobility shift results from the formation of a cruciform structure. S1 nuclease and T7 endonuclease both cut the plasmid into a linear form, also suggesting cruciform formation. Furthermore, anti-cruciform DNA antibody reduces the electrophoretic mobility of the PATRR-containing fragment. Finally, we have directly visualized cruciform extrusions from the plasmid DNA with the size expected of hairpin arms using atomic force microscopy. Our data imply that for human chromosomes, translocation susceptibility is mediated by PATRRs and likely results from their unstable conformation.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, Aichi 4701192, Japan; Osaka Univ, Grad Sch Med, Dept Post Gen & Dis, Div Funct Gen, Osaka 5650871, Japan; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Fujita Health University; Osaka University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Kurahashi, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, 1-98 dengakugakubo,Kutsukake Cho, Aichi 4701192, Japan.	kura@fujita-hu.ac.jp	Taniguchi-Ikeda, Mariko/GPP-1368-2022		NCI NIH HHS [R01 CA039926, CA39926] Funding Source: Medline; NCRR NIH HHS [M01 RR000240-390443, M01 RR000240] Funding Source: Medline; NICHD NIH HHS [HD26079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039926] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; COUREY AJ, 1983, CELL, V33, P817, DOI 10.1016/0092-8674(83)90024-7; Dai X, 1997, P NATL ACAD SCI USA, V94, P2174, DOI 10.1073/pnas.94.6.2174; Debeer P, 2002, CLIN GENET, V62, P410, DOI 10.1034/j.1399-0004.2002.620510.x; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Edelmann L, 2001, AM J HUM GENET, V68, P1, DOI 10.1086/316952; Emanuel BS, 2001, NAT REV GENET, V2, P791, DOI 10.1038/35093500; FRAPPIER L, 1987, J MOL BIOL, V193, P751, DOI 10.1016/0022-2836(87)90356-1; Gotter AL, 2004, HUM MOL GENET, V13, P103, DOI 10.1093/hmg/ddh004; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; KehrerSawatzki H, 1997, HUM GENET, V99, P237, DOI 10.1007/s004390050346; Kim EL, 1998, NUCLEIC ACIDS RES, V26, P1793, DOI 10.1093/nar/26.7.1793; Kurahashi H, 2000, AM J HUM GENET, V67, P763, DOI 10.1086/303054; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; Kurahashi H, 2003, AM J HUM GENET, V72, P733, DOI 10.1086/368062; Kurahashi H, 2001, HUM MOL GENET, V10, P2605, DOI 10.1093/hmg/10.23.2605; Kurahashi H, 2001, NAT GENET, V29, P139, DOI 10.1038/ng1001-139; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; LYAMICHEV V, 1984, J BIOMOL STRUCT DYN, V2, P291, DOI 10.1080/07391102.1984.10507568; MIZUUCHI K, 1982, J MOL BIOL, V156, P229, DOI 10.1016/0022-2836(82)90325-4; Nimmakayalu MA, 2003, HUM MOL GENET, V12, P2817, DOI 10.1093/hmg/ddg301; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; PANYUTIN I, 1984, J BIOMOL STRUCT DYN, V1, P1311, DOI 10.1080/07391102.1984.10507522; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Rhodes CH, 1997, CYTOGENET CELL GENET, V78, P247, DOI 10.1159/000134667; Shaikh TH, 2000, HUM MOL GENET, V9, P489, DOI 10.1093/hmg/9.4.489; Shlyakhtenko LS, 1998, J MOL BIOL, V280, P61, DOI 10.1006/jmbi.1998.1855; Spiteri E, 2003, HUM MOL GENET, V12, P1823, DOI 10.1093/hmg/ddg203; Tapia-Paez I, 2001, HUM GENET, V109, P167; Vologodskaia MY, 1999, J MOL BIOL, V289, P851, DOI 10.1006/jmbi.1999.2811	32	92	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35377	35383		10.1074/jbc.M400354200	http://dx.doi.org/10.1074/jbc.M400354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208332	hybrid, Green Accepted			2022-12-25	WOS:000223303400031
J	Leterrier, C; Bonnard, D; Carrel, D; Rossier, J; Lenkei, Z				Leterrier, C; Bonnard, D; Carrel, D; Rossier, J; Lenkei, Z			Constitutive endocytic cycle of the CB1 cannabinoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CELL-SURFACE EXPRESSION; DELTA-OPIOID RECEPTOR; INVERSE AGONIST; PHARMACOLOGICAL CHAPERONES; RAB GTPASES; GTP-BINDING; INTERNALIZATION; TRAFFICKING; DESENSITIZATION	The CB1 cannabinoid receptor (CB1R) displays a significant level of ligand-independent (i.e. constitutive) activity, either when heterologously expressed in non-neuronal cells or in neurons where CB1Rs are endogenous. The present study investigates the consequences of constitutive activity on the intracellular trafficking of CB1R. When transfected in HEK-293 cells, CB1R is present at the plasma membrane, but a substantial proportion (similar to85%) of receptors is localized in intracellular vesicles. Detailed analysis of CB1-EGFP expressed in HEK-293 cells shows that the intracellular CB1R population is mostly of endocytic origin and that treatment with inverse agonist AM281 traps CB1R at the plasma membrane through a monensin-sensitive recycling pathway. Co-transfection with dominant positive or dominant negative mutants of the small GTPases Rab5 and Rab4, but not Rab11, profoundly modifies the steady-state and ligand-induced intracellular distribution of CB1R, indicating that constitutive endocytosis is Rab5-dependent, whereas constitutive recycling is mediated by Rab4. In conclusion, our results indicate that, due to its natural constitutive activity, CB1R permanently and constitutively cycles between plasma membrane and endosomes, leading to a predominantly intracellular localization at steady state.	Ecole Super Phys & Chim Ind Ville Paris, Lab Neurobiol & Diversite Cellulaire, CNRS, UMR 7637, F-75231 Paris 05, France; Univ Paris 06, INSERM, U288, F-75634 Paris 13, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Lenkei, Z (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, Lab Neurobiol & Diversite Cellulaire, CNRS, UMR 7637, 10 Rue Vauquelin, F-75231 Paris 05, France.	zsolt.lenkei@espci.fr	Leterrier, Christophe/G-6975-2011; Carrel, Damien/N-5251-2014; Lenkei, Zsolt/G-4369-2013	Leterrier, Christophe/0000-0002-2957-2032; Carrel, Damien/0000-0003-2992-2693; Lenkei, Zsolt/0000-0002-1142-5931; Bonnard, Damien/0000-0001-9529-5785				Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Coutts AA, 2001, J NEUROSCI, V21, P2425; Daly CJ, 2003, PHARMACOL THERAPEUT, V100, P101, DOI 10.1016/j.pharmthera.2003.08.001; Darmon M, 1998, J NEUROCHEM, V71, P2294; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; GATLEY SJ, 1997, LIFE SCI, V61, P191; Haskell-Luevano C, 2001, REGUL PEPTIDES, V99, P1, DOI 10.1016/S0167-0115(01)00234-8; Hillard CJ, 1999, FEBS LETT, V459, P277, DOI 10.1016/S0014-5793(99)01253-3; Hillard CJ, 1999, J PHARMACOL EXP THER, V289, P1427; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jin WZ, 1999, J NEUROSCI, V19, P3773; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Marion S, 2004, J BIOL CHEM, V279, P2945, DOI 10.1074/jbc.M308742200; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Pan XH, 1998, MOL PHARMACOL, V54, P1064, DOI 10.1124/mol.54.6.1064; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V287, P1038; Roche JP, 1999, MOL PHARMACOL, V56, P611, DOI 10.1124/mol.56.3.611; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stevens PA, 2000, MOL PHARMACOL, V58, P438, DOI 10.1124/mol.58.2.438; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	53	184	188	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36013	36021		10.1074/jbc.M403990200	http://dx.doi.org/10.1074/jbc.M403990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210689	Green Published, hybrid			2022-12-25	WOS:000223303400103
J	Hidaka, S; Konecke, V; Osten, L; Witzgall, R				Hidaka, S; Konecke, V; Osten, L; Witzgall, R			PIGEA-14, a novel coiled-coil protein affecting the intracellular distribution of polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE PROTEIN; CATION CHANNEL; PKD2; GENE; IDENTIFICATION; INTERACTS	Employing a yeast two-hybrid screen with the COOH terminus of polycystin-2, one of the proteins mutated in patients with polycystic kidney disease, we were able to isolate a novel protein that we call PIGEA-14 ( polycystin-2 interactor, Golgi- and endoplasmic reticulum-associated protein with a molecular mass of 14 kDa). Molecular modeling only predicts a coiled-coil motif, but no other functional domains, in PIGEA-14. In a subsequent two-hybrid screen using PIGEA-14 as a bait, we found GM130, a component of the cis-compartment of the Golgi apparatus. Co-expression of the PIGEA-14 and PKD2 cDNAs in LLC-PK1 and HeLa cells resulted in a redistribution of PIGEA-14 and polycystin-2 to the trans-Golgi network, which suggests that PIGEA-14 plays an important role in regulating the intracellular location of polycystin-2 and possibly other intracellular proteins. Our results also indicate that the intracellular trafficking of polycystin-2 is regulated both at the level of the endoplasmic reticulum and that of the trans-Golgi network.	Univ Regensburg, Inst Mol & Cellular Anat, D-93053 Regensburg, Germany	University of Regensburg	Witzgall, R (corresponding author), Univ Regensburg, Inst Mol & Cellular Anat, Univ Str 31, D-93053 Regensburg, Germany.	ralph.witzgall@vkl.uni-regensburg.de		Witzgall, Ralph/0000-0002-5283-4846				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Deltas CC, 2001, HUM MUTAT, V18, P13, DOI 10.1002/humu.1145; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; GAI Y, 1999, J BIOL CHEM, V274, P28557; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gallagher AR, 2002, CELL MOL LIFE SCI, V59, P682, DOI 10.1007/s00018-002-8457-z; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315	24	55	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35009	35016		10.1074/jbc.M314206200	http://dx.doi.org/10.1074/jbc.M314206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194699	hybrid			2022-12-25	WOS:000223134800113
J	Kilian, K; Dernedde, J; Mueller, EC; Bahr, I; Tauber, R				Kilian, K; Dernedde, J; Mueller, EC; Bahr, I; Tauber, R			The interaction of protein kinase C isozymes alpha, iota, and theta with the cytoplasmic domain of L-selectin is modulated by phosphorylation of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; TYROSINE PHOSPHORYLATION; ADHESION MOLECULE-1; HUMAN NEUTROPHILS; PKC; ASSOCIATION; INTEGRINS; BINDING; IDENTIFICATION; LYMPHOCYTES	The leukocyte adhesion molecule L-selectin has an important role in the initial steps of leukocyte extravasation during inflammation and lymphocyte homing. Its cytoplasmic domain is involved in signal transduction after L-selectin cross-linking and in the regulation of receptor binding activity in response to intracellular signals. However, the signaling events occurring at the level of the receptor are largely unknown. This study therefore addressed the question of whether protein kinases associate with the cytoplasmic domain of the receptor and mediate its phosphorylation. Using a glutathione S-transferase fusion protein of the L-selectin cytoplasmic domain, we isolated a kinase activity from cellular extracts of the human leukemic Jurkat T-cell line that phosphorylated L-selectin on serine residues. This kinase showed characteristics of the protein kinase C (PKC) family. Moreover, the Ca2+-independent PKC isozymes theta and iota were found associated with the cytoplasmic domain of L-selectin. Pseudosubstrate inhibitors of these isozymes abolished phosphorylation of the cytoplasmic domain, demonstrating that these kinases are responsible for the phosphorylation. Analysis of proteins specifically bound to the phosphorylated cytoplasmic tail of L-selectin revealed that PKCalpha and -theta are strongly associated with the phosphorylated cytoplasmic domain of L-selectin. Binding of these isozymes to L-selectin was also found in intact cells after phorbol ester treatment inducing serine phosphorylation of the receptor. Furthermore, stimulation of Jurkat T-cells by CD3 cross-linking induced association of PKCalpha and -theta with L-selectin, indicating a role of these kinases in the regulation of L-selectin through the T-cell receptor complex. The phosphorylation-regulated association of PKC isozymes with the cytoplasmic domain of L-selectin indicates an important role of this kinase family in L-selectin signal transduction.	Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Schering AG, Prot Chem, D-13342 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kilian, K (corresponding author), Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany.	karin.kilian@charite.de	Dernedde, Jens/H-4097-2017	Dernedde, Jens/0000-0001-5319-7677				Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Evans SS, 1999, J IMMUNOL, V162, P3615; Fagerholm S, 2002, J BIOL CHEM, V277, P1728, DOI 10.1074/jbc.M106856200; Fieger C B, 2001, Biochim Biophys Acta, V1524, P75; Giblin PA, 1997, J IMMUNOL, V159, P3498; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Ivetic A, 2002, J BIOL CHEM, V277, P2321, DOI 10.1074/jbc.M109460200; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KANSAS GS, 1992, APMIS, V100, P287, DOI 10.1111/j.1699-0463.1992.tb00874.x; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Meller N, 1999, CELL IMMUNOL, V193, P185, DOI 10.1006/cimm.1999.1478; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sikorski MA, 1996, CELL ADHES COMMUN, V4, P355, DOI 10.3109/15419069609010778; SIMON SI, 1995, J IMMUNOL, V155, P1502; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tsang YTM, 1997, J IMMUNOL, V159, P4566; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1	47	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34472	34480		10.1074/jbc.M405916200	http://dx.doi.org/10.1074/jbc.M405916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192100	hybrid			2022-12-25	WOS:000223134800049
J	Xu, CQ; Brone, B; Wicher, D; Bozkurt, O; Lu, WY; Huys, I; Han, YH; Tytgat, J; Van Kerkhove, E; Chi, CW				Xu, CQ; Brone, B; Wicher, D; Bozkurt, O; Lu, WY; Huys, I; Han, YH; Tytgat, J; Van Kerkhove, E; Chi, CW			BmBKTx1, a novel Ca2+-activated K+ channel blocker purified from the Asian scorpion Buthus martensi Karsch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; MAXI-K; LOCUSTA-MIGRATORIA; BINDING-SITES; LEIUROTOXIN-I; CHARYBDOTOXIN; TOXINS; NEURONS; PURIFICATION; IBERIOTOXIN	BmBKTx1 is a novel short chain toxin purified from the venom of the Asian scorpion Buthus martensi Karsch. It is composed of 31 residues and is structurally related to SK toxins. However, when tested on the cloned rat SK2 channel, it only partially inhibited rSK2 currents, even at a concentration of 1 muM. To screen for other possible targets, BmBKTx1 was then tested on isolated metathoracic dorsal unpaired median neurons of Locusta migratoria, in which a wide variety of ion channels are expressed. The results suggested that BmBKTx1 could specifically block voltage-gated Ca2+-activated K+ currents (BK-type). This was confirmed by testing the BmBKTx1 effect on the alpha subunits of BK channels of the cockroach (pSlo), fruit fly (dSlo), and human (hSlo), heterologously expressed in HEK293 cells. The IC50 for channel blocking by BmBKTx1 was 82 nM for pSlo and 194 nM for dSlo. Interestingly, BmBKTx1 hardly affected hSlo currents, even at concentrations as high as 10 muM, suggesting that the toxin might be insect specific. In contrast to most other scorpion BK blockers that also act on the Kv1.3 channel, BmBKTx1 did not affect this channel as well as other Kv channels. These results show that BmBKTx1 is a novel kind of blocker of BK-type Ca2+-activated K+ channels. As the first reported toxin active on the Drosophila Slo channel dSlo, it will also greatly facilitate studying the physiological role of BK channels in this model organism.	Chinese Acad Sci, Grad Sch,Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Limburgs Univ Ctr, Ctr Milieukunde CMK, Physiol Lab, B-3590 Diepenbeek, Belgium; Saxon Acad Sci, Res Grp Neurohormonal Mech, D-07743 Jena, Germany; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; Univ Louvain, Toxicol Lab, B-3000 Louvain, Belgium; Tongji Univ, Inst Prot Res, Shanghai 200092, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Hasselt University; University System of Maryland; University of Maryland Baltimore; Tongji University	Chi, CW (corresponding author), Chinese Acad Sci, Grad Sch,Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China.	chi@sunm.shcnc.ac.cn	Huys, Isabelle/M-8673-2016; Tytgat, Jan/F-1560-2010; Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017; Van Kerkhove, Emmy/H-6358-2016	Lu, Wuyuan/0000-0003-1318-9968; Xu, Chenqi/0000-0002-4968-6782; Tytgat, Jan/0000-0003-1778-6022; Brone, Bert/0000-0002-4851-9480				Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ASHBY G., 1972, UFAW HDB CARE MANAGE, P582; Ashcroft FM, 2000, ION CHANNELS DIS; AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Brone B, 2003, J INSECT PHYSIOL, V49, P171, DOI 10.1016/S0022-1910(02)00263-9; Cai Z, 2004, BIOCHEMISTRY-US, V43, P3764, DOI 10.1021/bi035412+; Corona M, 2002, FEBS LETT, V532, P121, DOI 10.1016/S0014-5793(02)03652-9; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Derst C, 2003, EUR J NEUROSCI, V17, P1197, DOI 10.1046/j.1460-9568.2003.02550.x; FLINN JP, 1995, INT J PEPT PROT RES, V45, P320; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; GIANGIACOMO KM, 1993, BIOCHEMISTRY-US, V32, P2363, DOI 10.1021/bi00060a030; Giangiacomo KM, 2000, BIOCHEMISTRY-US, V39, P6115, DOI 10.1021/bi992865z; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; GROLLEAU F, 1995, J NEUROPHYSIOL, V73, P160, DOI 10.1152/jn.1995.73.1.160; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huys I, 2002, EUR J BIOCHEM, V269, P1854, DOI 10.1046/j.1432-1033.2002.02833.x; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; Myers MP, 2000, NEUROPHARMACOLOGY, V39, P11, DOI 10.1016/S0028-3908(99)00074-X; NOVICK J, 1991, BIOPHYS J, V59, P78; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; RomiLebrun R, 1997, BIOCHEMISTRY-US, V36, P13473, DOI 10.1021/bi971044w; RomiLebrun R, 1997, EUR J BIOCHEM, V245, P457, DOI 10.1111/j.1432-1033.1997.00457.x; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SCHNEIDER MJ, 1989, FEBS LETT, V250, P433, DOI 10.1016/0014-5793(89)80771-9; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schroeder N, 2002, FEBS LETT, V527, P298, DOI 10.1016/S0014-5793(02)03256-8; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Tytgat J, 1996, FEBS LETT, V390, P280, DOI 10.1016/0014-5793(96)00674-6; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wang CG, 2001, EUR J BIOCHEM, V268, P2480, DOI 10.1046/j.1432-1327.2001.02132.x; WEGENER JW, 1992, J INSECT PHYSIOL, V38, P237, DOI 10.1016/0022-1910(92)90124-V; Wicher D, 2001, PROG NEUROBIOL, V64, P431, DOI 10.1016/S0301-0082(00)00066-6; Wickenden AD, 2002, PHARMACOL THERAPEUT, V94, P157, DOI 10.1016/S0163-7258(02)00201-2; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932	43	33	37	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34562	34569		10.1074/jbc.M312798200	http://dx.doi.org/10.1074/jbc.M312798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178692	hybrid			2022-12-25	WOS:000223134800060
J	Zou, ZY; Chung, B; Nguyen, T; Mentone, S; Thomson, B; Biemesderfer, D				Zou, ZY; Chung, B; Nguyen, T; Mentone, S; Thomson, B; Biemesderfer, D			Linking receptor-mediated endocytosis and cell signaling - Evidence for regulated intramembrane proteolysis of megalin in proximal tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RENAL BRUSH-BORDER; HEYMANN NEPHRITIS; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; SOLUBLE FORM; MEMBRANE; CLEAVAGE; GP330	Megalin, a member of the low density lipoprotein receptor gene family, is required for efficient protein absorption in the proximal tubule. Recent studies have shown that the low density lipoprotein receptor-related protein, another member of this gene family, is proteolytically processed by gamma-secretase implying a role for low density lipoprotein receptor-related protein in a Notch-like signaling pathway. This pathway has been shown to involve: 1) metalloprotease-mediated ectodomain shedding and gamma-secretase-mediated intramembrane proteolysis of some receptors. Experiments were performed to determine whether megalin undergoes similar processing. By immunocytochemistry, immunoblotting, and a fluorogenic enzyme assay presenilin-1 ( required for gamma-secretase activity) and gamma-secretase activity were found in the brush border of proximal kidney tubules where megalin is localized. Using a fluorogenic peptide containing an amyloid precursor protein gamma-secretase cleavage site and Compound E, a specific gamma-secretase inhibitor, we found high levels of gamma-secretase activity in renal brush border membrane vesicles. Immunoblotting analysis of renal microsomes and opossum kidney proximal tubule (OKP) cells using antibodies directed to the cytosolic domain of megalin showed a 35-40-kDa, membrane-associated, carboxyl-terminal fragment of megalin (MCTF). When cells were incubated with 200 nM phorbol 12-myristate 13-acetate, the appearance of the MCTF increased 2.5-fold and was blocked by metalloprotease inhibitors. When the cells were incubated with gamma-secretase inhibitor Compound E, it caused a 2-fold increase in MCTF. Finally, incubating the cells with 1 muM vitamin D-binding protein resulted in a 25% increase in the appearance of the MCTF. In summary, the MCTF is produced by protein kinase C regulated, metalloprotease-mediated ectodomain shedding and is the substrate for gamma-secretase. We postulate that the enzymatic processing of megalin represents part of a novel ligand-dependent signaling pathway in the proximal tubule that links receptor-mediated endocytosis with cell signaling.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,TAC S255,POB 208029, New Haven, CT 06520 USA.	daniel.biemesderfer@yale.edu			NIDDK NIH HHS [DK 543933] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BACHINSKY DR, 1993, AM J PATHOL, V143, P598; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell WA, 2003, J NEUROCHEM, V85, P1563, DOI 10.1046/j.1471-4159.2003.01799.x; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; CZEKAY RP, 1995, J CELL SCI, V108, P1433; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Farquhar MG, 1996, AM J PATHOL, V148, P1331; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; KERJASCHKI D, 1987, J EXP MED, V166, P109, DOI 10.1084/jem.166.1.109; KERJASCHKI D, 1992, P NATL ACAD SCI USA, V89, P11179, DOI 10.1073/pnas.89.23.11179; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MAY P, 2003, SCI STKE; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Rutherford PA, 1997, EXP NEPHROL, V5, P490; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	46	125	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34302	34310		10.1074/jbc.M405608200	http://dx.doi.org/10.1074/jbc.M405608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180987	hybrid			2022-12-25	WOS:000223134800029
J	Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS				Ramaswamy, M; Efimova, EV; Martinez, O; Mulherkar, NU; Singh, SP; Prabhakar, BS			IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC	ONCOGENE			English	Article						IG20; MADD; TRAIL; DISC; caspase-8; apoptosis; cancer	NUCLEOTIDE EXCHANGE PROTEIN; DEATH DOMAIN; TUMORICIDAL ACTIVITY; NEOPLASTIC-CELLS; RECEPTOR FAMILY; DECOY RECEPTORS; IN-VIVO; DENN-SV; EXPRESSION; LIGAND	Recently, we identified (I) under bar nsulinoma -(G) under bar lucagonoma clone 20 (IG20) that can render cells more susceptible to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis. In addition, it can slow cell proliferation, and enhance drug- and radiation-induced cell death. TNF-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in some cancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or no effect on most normal cells. In this study, we investigated the potential of IG20 to enhance TRAIL-induced apoptosis and found that it can render cells more susceptible to TRAIL treatment through enhanced activation of caspases. Further, we showed that this effect can be suppressed by caspase inhibitors, p35 and CrmA, and a (d) under bar ominant-(n) under bar egative (F) under bar as- (a) under bar ssociated (d) under bar eath (d) under bar omain-containing protein (DN-FADD). Results from colocalization and immunoprecipitation studies showed that IG20 can interact with TRAIL death receptors (DR), DR4 and DR5 and increase recruitment of FADD and caspase-8 into the TRAIL death-inducing signaling complex (DISC). These results indicate that IG20 is a novel protein that can enhance TRAIL-induced apoptosis by facilitating DISC formation.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Illinois, Ctr Mol Biol & Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-705,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328; Martinez, Osvaldo/0000-0001-7335-4342; Singh, Surya/0000-0001-5668-1712				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brown TL, 1998, CURR BIOL, V8, pR191; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Coppola T, 2002, BIOCHEM J, V362, P273, DOI 10.1042/0264-6021:3620273; Cunningham SJ, 1996, THESIS U TEXAS MED B; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; NEZNANOV N, 2002, MED SCI MONIT, V8, P391; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6083	6094		10.1038/sj.onc.1207804	http://dx.doi.org/10.1038/sj.onc.1207804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208670				2022-12-25	WOS:000223261000008
J	Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J				Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J			Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas	ONCOGENE			English	Article						mammary cancer; Fgf10; Wnt1; MMTV; insertional mutagenesis	KERATINOCYTE GROWTH-FACTOR; PROVIRAL INSERTION; IN-VIVO; EXPRESSION; GENE; CANCER; VIRUS; DIFFERENTIATION; TUMORIGENESIS; RECEPTOR	Mouse mammary tumor virus (MMTV) infection causes a high incidence of murine mammary carcinomas by insertion of its proviral DNA in the genome of mammary epithelial cells. Retroviral insertion can activate flanking proto-oncogenes by a process called insertional mutagenesis. By sequencing the DNA adjacent to MMTV proviral insertions in mammary tumors from BALB/c mice infected with C3H-MMTV, we have found a common MMTV insertion site in the Fgf10 locus. RT-PCR studies showed that Fgf10 is expressed only in those tumors harboring a MMTV proviral insertion in this locus, suggesting that Fgf10 is a proto-oncogene. The oncogenicity of Fgf10 was evaluated in vivo by subcutaneous transplantation of retrovirally transduced HC11 mammary epithelial cells into BALB/c mice. Highly vascularized invasive subcutaneous tumors developed indicating that Fgf10 can act as an oncogene. A survey of primary human breast carcinomas revealed strongly elevated Fgf10 mRNA levels in approximately 10% of the tumors tested, suggesting that Fgf10 may also be involved in oncogenicity of a subset of human breast cancers.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Oncol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.hilkens@nki.nl	Theodorou, Vasiliki/GON-4996-2022; Jonkers, Jos/AAG-3246-2019; Theodorou, Vasiliki/H-1576-2016	Jonkers, Jos/0000-0002-9264-9792; Theodorou, Vasiliki/0000-0003-1614-700X; Hilkens, John/0000-0002-0932-7793				Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bittner J J, 1939, Am J Cancer, V35, P90; Bosma AJ, 2002, CLIN CANCER RES, V8, P1871; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Jackson D, 1997, J MAMMARY GLAND BIOL, V2, P385, DOI 10.1023/A:1026351414004; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mailleux AA, 2002, DEVELOPMENT, V129, P53; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MERLO GR, 1993, ANN NY ACAD SCI, V698, P108, DOI 10.1111/j.1749-6632.1993.tb17195.x; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mikkers H, 2002, ONCOGENE, V21, P6559, DOI 10.1038/sj.onc.1205930; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; MORRIS VL, 1991, ONCOGENE RES, V6, P53; Ngan ESW, 2002, P NATL ACAD SCI USA, V99, P11187, DOI 10.1073/pnas.172366199; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 2001, GENOME BIOL, V2; Palmieri C, 2003, J ENDOCRINOL, V177, P65, DOI 10.1677/joe.0.1770065; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QURESHI SJ, 1994, GENET ANAL-BIOMOL E, V11, P95, DOI 10.1016/1050-3862(94)90046-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Spencer-Dene B, 2001, ENDOCR-RELAT CANCER, V8, P211, DOI 10.1677/erc.0.0080211; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Suzuki K, 2000, FEBS LETT, V481, P53, DOI 10.1016/S0014-5793(00)01968-2; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka A, 2002, VIRCHOWS ARCH, V441, P380, DOI 10.1007/s00428-002-0687-9; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P45; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	51	58	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6047	6055		10.1038/sj.onc.1207816	http://dx.doi.org/10.1038/sj.onc.1207816			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208658				2022-12-25	WOS:000223261000004
J	Yao, R; Natsume, Y; Noda, T				Yao, R; Natsume, Y; Noda, T			MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap	ONCOGENE			English	Article						firzzled; MAGI-3; Ltap; JNK; PDZ	CONVERGENT EXTENSION MOVEMENTS; D-ASPARTATE RECEPTORS; TISSUE POLARITY GENE; PDZ DOMAIN; GUANYLATE KINASE; CELL-POLARITY; VERTEBRATE GASTRULATION; PLANAR POLARITY; LOOP-TAIL; DROSOPHILA	A seven-transmembrane protein, frizzled, has been implicated in a planar cell polarity (PCP) pathway as well as the canonical Wnt signaling pathway. Although both pathways require a cytoplasmic protein, dishevelled, the molecular mechanism by which frizzled regulates intracellular signaling remains to be elucidated. In the mouse, nine frizzled family members have been identified and six of them contain a PDZ-binding motif at their carboxyl-termini. In this study, we show that a multi-PDZ containing protein, MAGI-3, specifically binds to frizzled-4 and -7. Furthermore, we also demonstrate that MAGI-3 interacts with Ltap, a mouse homolog of the Drosophila PCP protein, stbm, and that these three molecules can form a ternary complex. In epithelial cells, MAGI-3, frizzled-4, and Ltap colocalized at cell contact sites, indicating that these molecules form a physiologically significant complex. Finally, we found that MAGI-3 strongly activated JNK in conjunction with frizzled-4 and Ltap, and that this activation required the small GTPase, Rac. These results indicate that MAGI-3 functions as a scaffold protein for frizzled-4 and Ltap and regulates the JNK signaling cascade.	Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, Sendai, Miyagi 9808575, Japan; JFCR Canc Inst, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; RIKEN, Gen Sci Ctr, Mouse Funct Gen Res Grp, Totsuka Ku, Kanagawa 2440804, Japan	Tohoku University; Japanese Foundation for Cancer Research; RIKEN	Noda, T (corresponding author), Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, 2-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	tnoda@ims.u-tokyo.ac.jp	Noda, Tetsuo/B-1667-2016					Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Taylor J, 1998, GENETICS, V150, P199; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang YS, 2002, J NEUROSCI, V22, P8563; Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430	37	56	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6023	6030		10.1038/sj.onc.1207817	http://dx.doi.org/10.1038/sj.onc.1207817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195140				2022-12-25	WOS:000223261000001
J	Ho, YS; Xiong, Y; Ma, WC; Spector, A; Ho, DS				Ho, YS; Xiong, Y; Ma, WC; Spector, A; Ho, DS			Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; GLUTATHIONE-PEROXIDASE; HYPOCATALASEMIC MOUSE; HYDROGEN-PEROXIDE; MITOCHONDRIAL-FUNCTION; ANTIOXIDANT DEFENSE; OXIDATIVE STRESS; EPITHELIAL-CELLS; BLOOD CATALASE; RAT LENSES	Catalase plays a major role in cellular antioxidant defense by decomposing hydrogen peroxide, thereby preventing the generation of hydroxyl radical by the Fenton reaction. The degree of catalase deficiency in acatalasemic and hypocatalasemic mice varies from tissue to tissue. They therefore may not be suitable for studying the function of this enzyme in certain models of oxidant-mediated tissue injury. We sought to generate a new line of catalase null mice by the gene targeting technique. The mouse catalase (Cat or Cas1) gene was disrupted by replacing parts of intron 4 and exon 5 with a neomycin resistance cassette. Homozygous Cat knockout mice, which are completely deficient in catalase expression, develop normally and show no gross abnormalities. Slices of liver and lung and lenses from the knockout mice exhibited a retarded rate in decomposing extracellular hydrogen peroxide compared with those of wild-type mice. However, mice deficient in catalase were not more vulnerable to hyperoxia-induced lung injury; nor did their lenses show any increased susceptibility to oxidative stress generated by photochemical reaction, suggesting that the antioxidant function of catalase in these two models of oxidant injury is negligible. Further studies showed that cortical injury from physical impact caused a significant decrease in NAD-linked electron transfer activities and energy coupling capacities in brain mitochondria of Cat knockout mice but not wild-type mice. The observed decrease in efficiency of mitochondrial respiration may be a direct result of an increase in mitochondrion-associated calcium, which is secondary to the increased oxidative stress. These studies suggest that the role of catalase in antioxidant defense is dependent on the type of tissue and the model of oxidant-mediated tissue injury.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA	Wayne State University; Wayne State University; Columbia University	Ho, YS (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave,Rm 4000, Detroit, MI 48201 USA.	yho@wayne.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056421, R01HL063317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBI H, 1968, BIOCHEM GENET, V2, P245, DOI 10.1007/BF01474764; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARNHOLD J, 1991, J BIOLUM CHEMILUM, V6, P189, DOI 10.1002/bio.1170060309; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BERG JM, 2002, BIOCHEMISTRY-US, P205; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Eaton JW, 1995, METABOLIC MOL BASES, P2371; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; FEINSTEI.RN, 1967, ARCH BIOCHEM BIOPHYS, V120, P165, DOI 10.1016/0003-9861(67)90609-1; FEINSTEIN RN, 1967, ARCH BIOCHEM BIOPHYS, V122, P338, DOI 10.1016/0003-9861(67)90203-2; FEINSTEIN RN, 1966, GENETICS, V53, P923; FEINSTEIN RN, 1968, BIOCHEM GENET, V1, P277, DOI 10.1007/BF00485182; FEINSTEIN RN, 1968, SCIENCE, V159, P638, DOI 10.1126/science.159.3815.638; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Flohe L, 2003, BIOFACTORS, V19, P3, DOI 10.1002/biof.5520190102; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FREEMAN BA, 1984, ENVIRON HEALTH PERSP, V56, P51; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JONES GL, 1976, ARCH BIOCHEM BIOPHYS, V173, P463, DOI 10.1016/0003-9861(76)90283-6; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Keilin D, 1936, PROC R SOC SER B-BIO, V119, P141, DOI 10.1098/rspb.1936.0003; KEILIN D, 1945, BIOCHEM J, V39, P293, DOI 10.1042/bj0390293; Lee C. P., 1993, V2, P41; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDAUSHEPARD BA, 1993, FREE RADICAL BIO MED, V15, P581, DOI 10.1016/0891-5849(93)90160-V; MAKINO N, 1994, J BIOL CHEM, V269, P1020; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; OSHINO N, 1973, BIOCHEM J, V131, P555, DOI 10.1042/bj1310555; Povlishock J T, 1992, Hum Cell, V5, P345; RADI R, 1991, J BIOL CHEM, V266, P22028; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; REIMER DL, 1994, GENOMICS, V21, P325, DOI 10.1006/geno.1994.1273; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; SHAFFER JB, 1990, BIOCHEM BIOPH RES CO, V173, P1043, DOI 10.1016/S0006-291X(05)80891-5; SHAFFER JB, 1987, J BIOL CHEM, V262, P12908; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1993, P NATL ACAD SCI USA, V90, P7485, DOI 10.1073/pnas.90.16.7485; SPERANZA MJ, 1993, J BIOL CHEM, V268, P19039; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; SUZUKI K, 1991, ACTA MED OKAYAMA, V45, P363; Takahara S., 1948, J OTORHINOLARYNG SOC, V51, P163; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Wang DH, 2001, BBA-GENE STRUCT EXPR, V1522, P217, DOI 10.1016/S0167-4781(01)00316-5; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang H, 2003, AM J HYPERTENS, V16, P1, DOI 10.1016/S0895-7061(02)03086-8; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959	66	276	290	2	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32804	32812		10.1074/jbc.M404800200	http://dx.doi.org/10.1074/jbc.M404800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178682	hybrid			2022-12-25	WOS:000222849700100
J	Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O				Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O			The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation	ONCOGENE			English	Article						EpCAM; carcinoma; c-myc; cyclines	EPSTEIN-BARR-VIRUS; MOLECULE EP-CAM; BREAST-CANCER; TARGET; CYCLE; OVEREXPRESSION; EXPRESSION; RECEPTOR; GROWTH; 17-1A	Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed on adenomatous and simple epithelia, where it is involved in homophilic adhesion at the basolateral membrane. Carcinomas strongly overexpress EpCAM through an, as yet, unknown mechanism. Interestingly, otherwise EpCAM-negative squamous epithelia are seen to express EpCAM concomitant with their transformation and de-differentiation. The amount of EpCAM and the number of expressing cells both increase with the grade of dysplasia. Despite an important amount of data correlating the expression of EpCAM with cellular proliferation and de-differentiation, such as the coexpression with Ki-67, a marker for proliferation, it is unknown whether EpCAM may directly contribute to carcinogenesis. Here, we show that EpCAM has a direct impact on cell cycle and proliferation, and the ability to rapidly upregulate the proto-oncogene c-myc and cyclin A/E. Human epithelial 293 cells as well as murine NIH3T3 fibroblasts expressing EpCAM had a decreased requirement for growth factors, enhanced metabolic activity and colony formation capacity. Importantly, the inhibition of EpCAM expression with antisense mRNA led to a strong decrease in proliferation and metabolism in human carcinoma cells. Moreover, domain swapping experiments demonstrated that the intracellular part of EpCAM is necessary and sufficient to transduce the effects described. Thus, the data presented here highlight the role of EpCAM, demonstrating for the first time a direct link to cell cycle and proliferation.	Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Univ Munich, Head & Neck Res Dept, D-81377 Munich, Germany; Vaecgene Biotech Inc, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich	Gires, O (corresponding author), Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, Marchioninistr 15, D-81377 Munich, Germany.	ogires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017	Gires, Olivier/0000-0002-2292-7064				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chaubal S, 1999, ANTICANCER RES, V19, P2237; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Litvinov SV, 1996, AM J PATHOL, V148, P865; Meden H, 1997, EUR J OBSTET GYN R B, V71, P173, DOI 10.1016/S0301-2115(96)02630-9; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Packeisen J, 1999, HYBRIDOMA, V18, P37, DOI 10.1089/hyb.1999.18.37; Pauli C, 2003, CANCER LETT, V193, P25, DOI 10.1016/S0304-3835(03)00003-X; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Piyathilake CJ, 2000, HUM PATHOL, V31, P482, DOI 10.1053/hp.2000.6711; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Rodrigo JP, 1996, ARCH OTOLARYNGOL, V122, P504; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Spizzo G, 2002, INT J CANCER, V98, P883, DOI 10.1002/ijc.10270; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; TANDON AK, 1990, CANCER RES, V50, P3317; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	32	283	306	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5748	5758		10.1038/sj.onc.1207610	http://dx.doi.org/10.1038/sj.onc.1207610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195135				2022-12-25	WOS:000222629800004
J	Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA				Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA			RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling	ONCOGENE			English	Article						Src; tyrosine kinase; RACK1; PKC; Sam68; p190RhoGAP	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; BETA-SUBUNIT; ACTIVATION; GROWTH; REGION; P190; MECHANISMS; INHIBITOR; SUBSTRATE	RACK1 is the founding member of a family of receptors for activated C kinase collectively called RACKs. Upon activation of PKC, RACK1 co-localizes with the Src tyrosine kinase at the plasma membrane and functions as a substrate, binding partner and inhibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells. To further analyze the function of RACK1 in Src and PKC signaling, we utilized cell-permeable peptides that modulate the interaction of RACK1 and betaIIPKC, thereby affecting betaIIPKC translocation and function. We found that the association of betaIIPKC and RACK1 is necessary for Src phosphorylation of RACK1. Src activity is required for tyrosine phosphorylation of RACK1, and for RACK1 binding to Src, but not to betaIIPKC. Endogenous Src kinase activity, as measured by phosphorylation of Sam68 (a mitotic-specific Src substrate involved in cell cycle regulation and RNA splicing) or p190RhoGAP (a Src substrate and GTPase-activating protein involved in actin reorganization), increases with disruption of the Src-RACK1 complex, and decreases with enhanced complex formation. RACK1 inhibits Src-mediated p190RhoGAP signaling and actin cytoskeleton rearrangement. Thus, RACK1 functions as an endogenous inhibitor of the Src kinase in diverse signaling pathways that regulate distinct cellular functions. Our results demonstrate the potential for using peptide modulators of Src activity as a tool for uncovering the function of Src in cells.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [R01 HL52141] Funding Source: Medline; NIDDK NIH HHS [DK65339, R01 DK43743] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fincham VJ, 1999, J CELL SCI, V112, P947; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	28	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5682	5686		10.1038/sj.onc.1207735	http://dx.doi.org/10.1038/sj.onc.1207735			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184885				2022-12-25	WOS:000222629500013
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR	ONCOGENE			English	Article						MBD4; MMR; DNA methylation; cancer	MSH2; MED1; CARCINOMAS; APOPTOSIS; GENE	Mbd4 (methyl-binding domain 4) has been shown to be mutated in a high percentage of mismatch repair (MMR)deficient colorectal tumours that exhibit microsatellite instability (MSI). However, the significance of these mutations is still unclear as they are predominantly monoallelic and the majority occur at a poly-A tract. Apart from MMR-deficient tumours, no other reports of mutations of Mbd4 in human neoplasia are as yet published. To address the significance of loss of Mbd4 in the absence of MMR, we have crossed Mbd4-deficient mice to mice lacking DNA MMR. We show that, in the context of MMR deficiency, additional loss of Mbd4 does not alter spontaneous mutation frequency at the endogenous DIb-1b locus, nor does it modify tumour onset, tumour spectrum or MSI compared to singly mutant Msh2 or Mlh1 mice. Taken together, these findings show that nullizygosity or heterozygosity for Mbd4 does not affect MMR-dependent tumorigenesis.	Univ Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372				Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cortellino S, 2003, P NATL ACAD SCI USA, V100, P15071, DOI 10.1073/pnas.2334585100; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, ONCOGENE, V22, P7130, DOI 10.1038/sj.onc.1206850; Sansom OJ, 2003, DNA REPAIR, V2, P1029, DOI 10.1016/S1568-7864(03)00111-3; Sansom OJ, 2001, CANCER RES, V61, P7060; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	23	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5693	5696		10.1038/sj.onc.1207767	http://dx.doi.org/10.1038/sj.onc.1207767			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184874				2022-12-25	WOS:000222629500015
J	Sethi, N; Palefsky, J				Sethi, N; Palefsky, J			Transcriptional profiling of dysplastic lesions in K14-HPV16 transgenic mice using laser microdissection	FASEB JOURNAL			English	Article						HPV16 transgenic mice; HPV E2 transcripts; real-time PCR; functional genomics	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL INTRAEPITHELIAL NEOPLASIA; POLYMERASE-CHAIN-REACTION; CARCINOMA CELL-LINES; ACTIVE ANTIRETROVIRAL THERAPY; MESSENGER-RNAS; E2 PROTEIN; QUANTITATIVE DETECTION; EXPRESSION; GENE	In the K14-HPV16 transgenic mouse model of human papillomavirus (HPV)-associated squamous cell cancers, HPV16 E6 and E7 oncogenes and E1 and E2 regulatory genes are driven by the K14 keratinocyte-specific promoter. HPV transcription varies within the different layers of the epithelium. The correlation between HPV transcription patterns and disease pathogenesis is not well understood. Understanding these patterns is critical to designing and testing new HPV-specific therapeutic strategies. We examined HPV gene expression in homogenous populations of cells microdissected from the stratum basale, stratum spinosum, and stratum corneum of lesions from the transgenic mice using PALM microlaser technology. RNA extracted from each cell layer was subjected to two-step gene-specific RT-PCR and real-time quantitative nested PCR. To ensure specific amplification of spliced transcripts, the primers used for real-time nested PCR spanned the splice sites. High levels of E2 were detected in the basal and supra-basal layers of hyperplastic and dysplastic lesions. E7 and E6* levels increased significantly over time in stratum basale and stratum spinosum. E6** was expressed at much lower levels. We showed that the transgenic mice express correctly spliced E2 transcripts and are suitable as a preclinical model to test a therapeutic strategy using transcriptional regulation by the E2 protein.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Palefsky, J (corresponding author), Univ Calif San Francisco, Dept Med, Gen Clin Res Ctr, Box 0126,505 Parnassus Ave,Room 1203, San Francisco, CA 94143 USA.	joelp@medicine.ucsf.edu			NIDCR NIH HHS [DE CA1192] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alloul N, 1999, J GEN VIROL, V80, P2461, DOI 10.1099/0022-1317-80-9-2461; Alloul N, 1999, J GEN VIROL, V80, P29, DOI 10.1099/0022-1317-80-1-29; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Blackshaw SE, 2003, J NEUROBIOL, V55, P355, DOI 10.1002/neu.10214; Casas L, 1999, INT J CANCER, V83, P449, DOI 10.1002/(SICI)1097-0215(19991112)83:4&lt;449::AID-IJC3&gt;3.0.CO;2-0; Chang JT, 2002, CLIN BIOCHEM, V35, P591, DOI 10.1016/S0009-9120(02)00403-4; Coussens LM, 1996, AM J PATHOL, V149, P1899; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Holly EA, 2001, J NATL CANCER I, V93, P843, DOI 10.1093/jnci/93.11.843; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Jiang SS, 2004, CLIN INFECT DIS, V38, P293, DOI 10.1086/380841; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Lanham S, 2001, J CLIN PATHOL, V54, P304, DOI 10.1136/jcp.54.4.304; Maitland NJ, 1998, J PATHOL, V186, P275, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;275::AID-PATH159&gt;3.0.CO;2-E; MATSUKURA T, 1986, J VIROL, V58, P979, DOI 10.1128/JVI.58.3.979-982.1986; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; O'Neill HJ, 2002, J CLIN VIROL, V25, P335, DOI 10.1016/S1386-6532(02)00124-5; O'Neill HJ, 2003, J MED VIROL, V71, P557, DOI 10.1002/jmv.10516; Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007; Palefsky JM, 2001, J ACQ IMMUN DEF SYND, V28, P422, DOI 10.1097/00042560-200112150-00003; Parhar IS, 2003, ENDOCRINOLOGY, V144, P3297, DOI 10.1210/en.2003-0386; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Ratge D, 2002, J CLIN VIROL, V24, P161, DOI 10.1016/S1386-6532(01)00244-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Sethi N, 2003, HUM GENE THER, V14, P45, DOI 10.1089/10430340360464705; SHERMAN L, 1992, VIROLOGY, V191, P953, DOI 10.1016/0042-6822(92)90271-P; SHERMAN L, 1992, INT J CANCER, V50, P356, DOI 10.1002/ijc.2910500305; SHIRASAWA H, 1987, J GEN VIROL, V68, P583, DOI 10.1099/0022-1317-68-2-583; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stevenson M, 2000, J GEN VIROL, V81, P1825, DOI 10.1099/0022-1317-81-7-1825; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STOLER MH, 1986, HUM PATHOL, V17, P1250, DOI 10.1016/S0046-8177(86)80569-X; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	39	8	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1243	+		10.1096/fj.03-0946fje	http://dx.doi.org/10.1096/fj.03-0946fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180960				2022-12-25	WOS:000222327500036
J	Verdier-Sevain, S; Yaar, M; Cantatore, J; Traish, A; Gilchrest, BA				Verdier-Sevain, S; Yaar, M; Cantatore, J; Traish, A; Gilchrest, BA			Estradiol induces proliferation of keratinocytes via receptor-mediated mechanisms	FASEB JOURNAL			English	Article						estrogen receptor; mitogen-activated protein kinase; ERE	ACTIVATED PROTEIN-KINASE; MEMBRANE ESTROGEN-RECEPTOR; PITUITARY-TUMOR CELLS; NERVE GROWTH-FACTOR; PLASMA-MEMBRANE; PROGESTERONE-RECEPTORS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; DOWN-REGULATION; SEX STEROIDS	In this study, we investigated the effects of estradiol on the proliferation of neonatal keratinocytes, the expression of estrogen receptor isoforms, and the signaling mechanisms by which estradiol mediates cell growth. We demonstrate that estradiol binds neonatal keratinocytes with high affinity (K-d=5.2nM) and limited capacity (B-max of 14.2fmol/mg of protein), confirming the presence of estrogen binding sites. Using specific antibodies, we demonstrate that keratinocytes express both estrogen receptor (ER)-alpha and ER-beta. At physiological concentrations, estradiol up-regulates the level of ER-alpha receptors in keratinocytes and induces keratinocyte proliferation. The proliferative effect of estradiol requires the availability of functional estrogen receptors, as it is abrogated by anti-estrogen administration. Estradiol effect on keratinocyte proliferation is most likely mediated in part by activation of a nongenomic, membrane-associated, signaling pathway involving activation of the extracellular signal regulated kinases 1 and 2 and in part by the genomic signaling pathway through activation of nuclear receptors.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu						ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BAYARD F, 1978, J CLIN ENDOCR METAB, V46, P635, DOI 10.1210/jcem-46-4-635; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Berard A, 2001, PHARMACOEPIDEM DR S, V10, P245, DOI 10.1002/pds.582; BESTBELPOMME M, 1975, EUR J BIOCHEM, V57, P537, DOI 10.1111/j.1432-1033.1975.tb02329.x; BLAUSTEIN JD, 1992, ENDOCRINOLOGY, V131, P1336, DOI 10.1210/en.131.3.1336; Brandenberger AW, 1997, J CLIN ENDOCR METAB, V82, P3509, DOI 10.1210/jc.82.10.3509; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; Calvin M, 1998, BRIT J OBSTET GYNAEC, V105, P223, DOI 10.1111/j.1471-0528.1998.tb10057.x; Chaturvedi K, 2004, ENDOCRINOLOGY, V145, P706, DOI 10.1210/en.2003-1063; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; HASSELQUIST MB, 1980, J CLIN ENDOCR METAB, V50, P76, DOI 10.1210/jcem-50-1-76; HUETHUDSON YM, 1990, MOL ENDOCRINOL, V4, P510, DOI 10.1210/mend-4-3-510; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; Jisa E, 2003, J STEROID BIOCHEM, V84, P141, DOI 10.1016/S0960-0760(03)00023-2; JORGENSEN O, 1962, Acta Chir Scand, V124, P1; Kanda N, 2003, J INVEST DERMATOL, V120, P411, DOI 10.1046/j.1523-1747.2003.12066.x; Kanda N, 2003, J INVEST DERMATOL, V120, P420, DOI 10.1046/j.1523-1747.2003.12067.x; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee YJ, 1998, MOL CELL ENDOCRINOL, V137, P85, DOI 10.1016/S0303-7207(97)00235-9; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; MAHEUX R, 1994, AM J OBSTET GYNECOL, V170, P642, DOI 10.1016/S0002-9378(94)70242-X; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; Margolis DJ, 2002, LANCET, V359, P675, DOI 10.1016/S0140-6736(02)07806-6; Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276; Marino M, 2002, MOL BIOL CELL, V13, P3720, DOI 10.1091/mbc.E02-03-0153; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Milner TA, 2001, J COMP NEUROL, V429, P355; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; NAKAO J, 1981, ATHEROSCLEROSIS, V38, P75, DOI 10.1016/0021-9150(81)90105-2; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKEEFE JA, 1990, DEV BRAIN RES, V57, P119, DOI 10.1016/0165-3806(90)90191-Z; Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75; Onuma H, 2001, ARCH DERMATOL RES, V293, P133, DOI 10.1007/s004030000195; Powell CE, 2001, J STEROID BIOCHEM, V77, P97, DOI 10.1016/S0960-0760(01)00040-1; PUNNONEN R, 1971, ACTA OBSTET GYN SCAN, V50, P32; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REE AH, 1989, ENDOCRINOLOGY, V124, P2577, DOI 10.1210/endo-124-5-2577; Revelli A, 1998, GYNECOL ENDOCRINOL, V12, P61, DOI 10.3109/09513599809024971; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SCHMIDT JB, 1994, MATURITAS, V20, P25, DOI 10.1016/0378-5122(94)90097-3; Shah M G, 2001, Am J Clin Dermatol, V2, P143; Singh M, 1999, J NEUROSCI, V19, P1179; Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625; Steinhoff M, 2001, CURR OPIN ALLERGY CL, V1, P469, DOI 10.1097/00130832-200110000-00014; TAMMI R, 1982, ACTA DERM-VENEREOL, V62, P107; Thornton MJ, 2003, EXP DERMATOL, V12, P181, DOI 10.1034/j.1600-0625.2003.120209.x; Thornton MJ, 2002, EXP DERMATOL, V11, P487, DOI 10.1034/j.1600-0625.2002.110601.x; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; TRAISH AM, 1986, STEROIDS, V47, P157, DOI 10.1016/0039-128X(86)90086-3; URANO R, 1995, J DERMATOL SCI, V9, P176, DOI 10.1016/0923-1811(94)00375-O; WAKELING AE, 1991, CANCER RES, V51, P3867; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WELSHONS WV, 1988, MOL CELL ENDOCRINOL, V57, P169, DOI 10.1016/0303-7207(88)90072-X; White RE, 2002, VASC PHARMACOL, V38, P73, DOI 10.1016/S0306-3623(02)00129-5; WOODLEY DT, 1993, DERMATOL CLIN, V11, P641, DOI 10.1016/S0733-8635(18)30217-1; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	77	80	85	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1252	+		10.1096/fj.03-1088fje	http://dx.doi.org/10.1096/fj.03-1088fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208259				2022-12-25	WOS:000222327500021
J	Kim, SY; Ahn, BH; Min, KJ; Lee, YH; Joe, EH; Min, DS				Kim, SY; Ahn, BH; Min, KJ; Lee, YH; Joe, EH; Min, DS			Phospholipase D isozymes mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLO-OXYGENASE-2 GENE-EXPRESSION; P38 MAP KINASE; INDUCIBLE CYCLOOXYGENASE; PHORBOL ESTER; ARACHIDONIC-ACID; EPITHELIAL-CELLS; RAT MICROGLIA; PC12 CELLS; TEA	Little is known about the effect of epigallocatechin-3 gallate (EGCG), a major constituent of green tea, on the expression of cyclooxygenase (COX)-2. Here, we studied the role of phospholipase D (PLD) isozymes in EGCG-induced COX-2 expression. Stimulation of human astrocytoma cells (U87) with EGCG induced formation of phosphatidylbutanol, a specific product of PLD activity, and synthesis of COX-2 protein and its product, prostaglandin E-2 (PGE(2)). Pretreatment of cells with 1-butanol, but not 3-butanol, suppressed EGCG-induced COX-2 expression and PGE(2) synthesis. Furthermore, evidence that PLD was involved in EGCG-induced COX-2 expression was provided by the observations that COX-2 expression was stimulated by overexpression of PLD1 or PLD2 isozymes and treatment with phosphatidic acid (PA), and that prevention of PA dephosphorylation by 1-propranolol significantly potentiated COX-2 expression induced by EGCG. EGCG induced activation of p38 mitogen-activated protein kinase (p38 MAPK), and specific inhibition of p38 MAPK dramatically abolished EGCG-induced PLD activation, COX-2 expression, and PGE(2) formation. Moreover, protein kinase C (PKC) inhibition suppressed EGCG-induced p38 MAPK activation, COX-2 expression, and PGE(2) accumulation. The same pathways as those obtained in the astrocytoma cells were active in primary rat astrocytes, suggesting the relevance of the findings. Collectively, our results demonstrate for the first time that PLD isozymes mediate EGCG-induced COX-2 expression through PKC and p38 in immortalized astroglial line and normal astrocyte cells.	Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Ajou Univ, Dept Pharmacol, Suwon 44721, South Korea; Hanyang Univ, Coll Sci & Technol, Div Mol & Life Sci, Ansan 426791, South Korea	Catholic University of Korea; Ajou University; Hanyang University	Min, DS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.		Min, Kyung-Jin/AAG-5774-2020	Min, Kyung-Jin/0000-0001-5829-6842				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Ahmed S, 2002, FREE RADICAL BIO MED, V33, P1097, DOI 10.1016/S0891-5849(02)01004-3; Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; ANGEL J, 1994, J IMMUNOL, V152, P5032; Banno Y, 2001, NEUROREPORT, V12, P2271, DOI 10.1097/00001756-200107200-00045; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bolli R, 2002, CARDIOVASC RES, V55, P506, DOI 10.1016/S0008-6363(02)00414-5; Bordoni A, 2002, J NUTR BIOCHEM, V13, P103, DOI 10.1016/S0955-2863(01)00203-0; CHEN J, 1995, NEUROREPORT, V6, P245; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dufresne CJ, 2001, J NUTR BIOCHEM, V12, P404, DOI 10.1016/S0955-2863(01)00155-3; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Habib A, 1997, J IMMUNOL, V158, P3845; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Kaneki H, 1998, BONE, V23, P213, DOI 10.1016/S8756-3282(98)00100-8; Katiyar S K, 1996, World Rev Nutr Diet, V79, P154; Kim JI, 2003, J BIOL CHEM, V278, P31731, DOI 10.1074/jbc.M300625200; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kundu JK, 2003, J NUTR, V133, p3805S, DOI 10.1093/jn/133.11.3805S; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Li ZG, 2002, INT J ONCOL, V21, P1275; Lipsky PE, 2000, ARCH INTERN MED, V160, P913, DOI 10.1001/archinte.160.7.913; Liu SF, 1996, CLIN SCI, V90, P301, DOI 10.1042/cs0900301; Liu XH, 1998, CANCER RES, V58, P4245; Min DS, 2002, EXP MOL MED, V34, P38, DOI 10.1038/emm.2002.6; Min DS, 2001, NEUROPHARMACOLOGY, V41, P384, DOI 10.1016/S0028-3908(01)00070-3; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; Nie GJ, 2002, ARCH BIOCHEM BIOPHYS, V397, P84, DOI 10.1006/abbi.2001.2636; Nogawa S, 1997, J NEUROSCI, V17, P2746; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P721, DOI 10.1006/bbrc.2001.5415; Pistritto G, 1998, NEUROSCI LETT, V246, P45, DOI 10.1016/S0304-3940(98)00226-2; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Steed P. M., 2001, Current Pharmaceutical Biotechnology, V2, P241, DOI 10.2174/1389201013378644; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; STONER GD, 1995, J CELL BIOCHEM, P169; van Ryn J, 1999, INFLAMM RES, V48, P247, DOI 10.1007/s000110050455; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wu KK, 1998, CIRCULATION, V98, P95, DOI 10.1161/01.CIR.98.2.95; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S	58	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38125	38133		10.1074/jbc.M402085200	http://dx.doi.org/10.1074/jbc.M402085200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15210717	hybrid			2022-12-25	WOS:000223684100010
J	Vargas, GA; von Zastrow, M				Vargas, GA; von Zastrow, M			Identification of a novel endocytic recycling signal in the D1 dopamine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN LUTROPIN RECEPTOR; C-TERMINAL TAIL; OPIOID RECEPTORS; CYTOPLASMIC TAIL; CARBOXYL TAIL; DESENSITIZATION; TRAFFICKING; PHOSPHORYLATION; MOTIF	A critical event determining the functional consequences of G protein-coupled receptor ( GPCR) endocytosis is the molecular sorting of internalized receptors between divergent recycling and degradative membrane pathways. The D1 dopamine receptor recycles rapidly and efficiently to the plasma membrane after agonist-induced endocytosis and is remarkably resistant to proteolytic down-regulation. Whereas the mechanism mediating agonist-induced endocytosis of D1 receptors has been investigated in some detail, little is known about how receptors are sorted after endocytosis. We have identified a sequence present in the carboxyl-terminal cytoplasmic domain of the human D1 dopamine receptor that is specifically required for the efficient recycling of endocytosed receptors back to the plasma membrane. This sequence is distinct from previously identified membrane trafficking signals and is located in a proximal portion of the carboxyl-terminal cytoplasmic domain, in contrast to previously identified GPCR recycling signals present at the distal tip. Nevertheless, fusion of this sequence to the carboxyl terminus of a chimeric mutant delta opioid neuropeptide receptor is sufficient to re-route internalized receptors from lysosomal to recycling membrane pathways, defining this sequence as a bona fide endocytic recycling signal that can function in both proximal and distal locations. These results identify a novel sorting signal controlling the endocytic trafficking itinerary of a physiologically important dopamine receptor, provide the first example of such a sorting signal functioning in a proximal portion of the carboxyl-terminal cytoplasmic domain, and suggest the existence of a diverse array of sorting signals in the GPCR superfamily that mediate subtype-specific regulation of receptors via endocytic membrane trafficking.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vargas, GA (corresponding author), Univ Calif San Francisco, Dept Psychiat, N-216 Genetech Hall,600 16th St, San Francisco, CA 94143 USA.	gvargas@itsa.ucsf.edu						Ariano MA, 1997, SYNAPSE, V27, P313, DOI 10.1002/(SICI)1098-2396(199712)27:4<313::AID-SYN5>3.3.CO;2-0; Barboi AC, 1999, CLIN NEUROPHARMACOL, V22, P184; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; Chaar ZY, 2001, J NEUROCHEM, V79, P1047, DOI 10.1046/j.1471-4159.2001.00648.x; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Dumartin B, 1998, J NEUROSCI, V18, P1650; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Galet C, 2004, MOL ENDOCRINOL, V18, P434, DOI 10.1210/me.2003-0293; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEIN L, 1994, J BIOL CHEM, V269, P27719; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nestler EJ, 1997, NATURE, V385, P578, DOI 10.1038/385578a0; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200	35	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37461	37469		10.1074/jbc.M401034200	http://dx.doi.org/10.1074/jbc.M401034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15192107	hybrid			2022-12-25	WOS:000223554600034
J	Mukamel, Z; Kimchi, A				Mukamel, Z; Kimchi, A			Death-associated protein 3 localizes to the mitochondria and is involved in the process of mitochondrial fragmentation during cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; RIBOSOMAL-PROTEINS; APOPTOSIS; YEAST; DAP3; DYNAMICS; MEDIATOR; IDENTIFICATION; MORPHOLOGY; DIVISION	Death-associated protein 3 (DAP3) was previously isolated in our laboratory as a positive mediator of cell death. It is a 46-kDa protein containing a GTP binding domain that was shown to be essential for the induction of cell death. DAP3 functions downstream of the receptor signaling complex, and its death-promoting effects depend on caspase activity. Recent reports have suggested that DAP3 is localized to the mitochondria, but no functional significance of this localization has been reported so far. Here, we study the sub-cellular localization and cellular function of human DAP3 (hDAP3). We found that hDAP3 is localized to the mitochondria and, in contrast to cytochrome c, is not released to the cytoplasm following several cell death signals. Overexpression of hDAP3 induced dramatic changes in the mitochondrial structure involving increased fragmentation of the mitochondria. Both the mitochondrial localization of hDAP3 and its GTP-binding activity were essential for the fragmentation. The punctiform mitochondrial morphology was similar to that observed upon treatment of HeLa cells with staurosporine. In fact, reduction of endogenous hDAP3 protein by RNA interference partially attenuated staurosporine-induced mitochondrial fission. Thus, hDAP3 is a necessary component in the molecular pathway that culminates in fragmented mitochondria, probably reflecting its involvement in the fission process. These results, for the first time, provide a specific functional role for hDAP3 in mitochondrial maintenance.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il						Berger T, 2000, J CELL SCI, V113, P3603; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hulkko SM, 2000, BIOCHEM J, V349, P885, DOI 10.1042/bj3490885; Hulkko SM, 2002, BIOCHEM BIOPH RES CO, V295, P749, DOI 10.1016/S0006-291X(02)00713-1; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messerschmitt M, 2003, J CELL BIOL, V160, P553, DOI 10.1083/jcb.200211113; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan CJ, 2001, BIOCHEM BIOPH RES CO, V280, P177, DOI 10.1006/bbrc.2000.4119; Saveanu C, 2001, J BIOL CHEM, V276, P15861, DOI 10.1074/jbc.M010864200; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J	24	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36732	36738		10.1074/jbc.M400041200	http://dx.doi.org/10.1074/jbc.M400041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15175341	hybrid			2022-12-25	WOS:000223453600073
J	Rayes, D; De Rosa, MAJ; Bartos, M; Bouzat, C				Rayes, D; De Rosa, MAJ; Bartos, M; Bouzat, C			Molecular basis of the differential sensitivity of nematode and mammalian muscle to the anthelmintic agent levamisole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL CURRENTS; ACETYLCHOLINE-RECEPTORS; AGONIST BINDING; ASCARIS MUSCLE; MUTATION; DOMAIN; INHIBITION; ACTIVATION; MECHANISM; PYRANTEL	Levamisole is an anthelmintic agent that exerts its therapeutic effect by acting as a full agonist of the nicotinic receptor (AChR) of nematode muscle. Its action at the mammalian muscle AChR has not been elucidated to date despite its wide use as an anthelmintic in humans and cattle. By single channel and macroscopic current recordings, we investigated the interaction of levamisole with the mammalian muscle AChR. Levamisole activates mammalian AChRs. However, single channel openings are briefer than those activated by acetylcholine (ACh) and do not appear in clusters at high concentrations. The peak current induced by levamisole is about 3% that activated by ACh. Thus, the anthelmintic acts as a weak agonist of the mammalian AChR. Levamisole also produces open channel blockade of the AChR. The apparent affinity for block (190 muM at -70 mV) is similar to that of the nematode AChR, suggesting that differences in channel activation kinetics govern the different sensitivity of nematode and mammalian muscle to anthelmintics. To identify the structural basis of this different sensitivity, we performed mutagenesis targeting residues in the alpha subunit that differ between vertebrates and nematodes. The replacement of the conserved alphaGly-153 with the homologous glutamic acid of nematode AChR significantly increases the efficacy of levamisole to activate channels. Channel activity takes place in clusters having two different kinetic modes. The kinetics of the high open probability mode are almost identical when the agonist is ACh or levamisole. It is concluded that alphaGly-153 is involved in the low efficacy of levamisole to activate mammalian muscle AChRs.	UNS, CONICET, Inst Invest Bioquim Bahia Blanca, Bahia Blanca, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South	Bouzat, C (corresponding author), UNS, CONICET, Inst Invest Bioquim Bahia Blanca, CC857,Camino La Carrindanga Km 7-B8000FWB, Bahia Blanca, Buenos Aires, Argentina.	inbouzat@criba.edu.ar	, Diego/AAH-4523-2020	DE ROSA, MARIA JOSE/0000-0002-2149-6127	FIC NIH HHS [1R03 TW 01185-01] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001185] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ACEVES J, 1970, BRIT J PHARMACOL, V38, P602, DOI 10.1111/j.1476-5381.1970.tb10601.x; Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; ATCHISON WD, 1992, TOXICOL APPL PHARM, V112, P133, DOI 10.1016/0041-008X(92)90289-5; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 1998, MOL PHARMACOL, V54, P146, DOI 10.1124/mol.54.1.146; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; BOUZAT C, 1994, NEURON, V13, P1395, DOI 10.1016/0896-6273(94)90424-3; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Corringer PJ, 1998, J NEUROSCI, V18, P648; Dilger JP, 1997, J GEN PHYSIOL, V109, P401, DOI 10.1085/jgp.109.3.401; DILGER JP, 1992, MOL PHARMACOL, V41, P127; Engel AG, 2002, MOL NEUROBIOL, V26, P347, DOI 10.1385/MN:26:2-3:347; Evans AM, 1996, BRIT J PHARMACOL, V118, P1127, DOI 10.1111/j.1476-5381.1996.tb15515.x; Fleming JT, 1997, J NEUROSCI, V17, P5843; Grutter T, 2003, EMBO J, V22, P1990, DOI 10.1093/emboj/cdg197; Gumilar F, 2003, NEUROPHARMACOLOGY, V45, P964, DOI 10.1016/S0028-3908(03)00247-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARROW ID, 1985, PESTIC SCI, V16, P662, DOI 10.1002/ps.2780160612; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; Le Novere N, 1999, NUCLEIC ACIDS RES, V27, P340, DOI 10.1093/nar/27.1.340; Levandoski MM, 2003, EUR J PHARMACOL, V471, P9, DOI 10.1016/S0014-2999(03)01796-5; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; LIU Y, 1993, SYNAPSE, V13, P57, DOI 10.1002/syn.890130108; Martin R.J., 1991, Parasitology, V102, P41; Martin RJ, 1996, PARASITOLOGY, V113, pS137, DOI 10.1017/S0031182000077945; NARANJO D, 1993, SCIENCE, V260, P1811, DOI 10.1126/science.8511590; NEHER E, 1983, J PHYSIOL-LONDON, V339, P663, DOI 10.1113/jphysiol.1983.sp014741; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Rayes D, 2001, NEUROPHARMACOLOGY, V41, P238, DOI 10.1016/S0028-3908(01)00057-0; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Spitzmaul G, 2001, MOL PHARMACOL, V60, P235, DOI 10.1124/mol.60.2.235; Spitzmaul GF, 1999, NEUROREPORT, V10, P2175, DOI 10.1097/00001756-199907130-00032; Wang HL, 2000, J GEN PHYSIOL, V116, P449, DOI 10.1085/jgp.116.3.449; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; Wiley LJ, 1996, GENE, V182, P97, DOI 10.1016/S0378-1119(96)00520-3	42	24	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36372	36381		10.1074/jbc.M403096200	http://dx.doi.org/10.1074/jbc.M403096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201284	hybrid, Green Published			2022-12-25	WOS:000223453600027
J	Soriano, ME; Nicolosi, L; Bernardi, P				Soriano, ME; Nicolosi, L; Bernardi, P			Desensitization of the permeability transition pore by cyclosporin A prevents activation of the mitochondrial apoptotic pathway and liver damage by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; ARACHIDONIC-ACID; FACTOR RECEPTOR; GD3 GANGLIOSIDE; INNER MEMBRANE; CYCLOPHILIN; RESISTANT; CERAMIDE; INJURY	We studied the effects of cyclosporin A (CsA) administration 1) on the properties of the permeability transition pore (PTP) in mitochondria isolated from the liver and 2) on the susceptibility to hepatotoxicity induced by lipopolysaccharide of Escherichia coli (LPS) plus D-galactosamine (D-GalN) in rats. CsA exerted a marked PTP inhibition ex vivo, with an effect that peaked between 2 and 9 h of drug treatment and decayed with an apparent half-time of about 13 h. Administration of LPS plus D-GalN to naive rats caused the expected increased serum levels of tumor necrosis factor (TNF)-alpha, liver inflammation with BID cleavage, activation of caspase 3, appearance of terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling-positive nuclei, and release of alanine aminotransferase and aspartate aminotransferase into the bloodstream. Treatment with CsA before or within 5 h of the administration of LPS plus D-GalN protected rats from hepatotoxicity despite the normal increase of serum TNF-alpha and BID cleavage. These results indicate that CsA prevents the hepatotoxic effects of TNF-alpha by blocking the mitochondrial proapoptotic pathway through inhibition of the PTP and provides a viable strategy for the treatment of liver diseases that depend on increased production and/or liver sensitization to TNF-alpha.	Univ Padua, Inst Neurosci, Consiglio Nazl Ric, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine	Bernardi, P (corresponding author), Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736; Soriano, Maria Eugenia/0000-0002-7971-2961	Telethon [GGP02123] Funding Source: Medline	Telethon(Fondazione Telethon)		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gramaglia D, 2004, CELL DEATH DIFFER, V11, P342, DOI 10.1038/sj.cdd.4401326; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kawakami T, 2000, HEPATOL RES, V18, P284, DOI 10.1016/S1386-6346(00)00088-7; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krauskopf A, 2003, J BIOL CHEM, V278, P41685, DOI 10.1074/jbc.M301181200; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1998, Rev Physiol Biochem Pharmacol, V133, P109; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Mari M, 2004, J CLIN INVEST, V113, P895, DOI 10.1172/JCI200419852; Nguyen NSD, 1999, FREE RADICAL BIO MED, V27, P1267, DOI 10.1016/S0891-5849(99)00160-4; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALSH CT, 1992, J BIOL CHEM, V267, P13115; Wasaki S, 1997, LIVER, V17, P107; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YOSHIBA M, 1995, J GASTROENTEROL, V30, P67, DOI 10.1007/BF01211377; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	65	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36803	36808		10.1074/jbc.M405297200	http://dx.doi.org/10.1074/jbc.M405297200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15201276	hybrid			2022-12-25	WOS:000223453600082
J	Mimura, H; Nakanishi, Y; Hirono, M; Maeshima, M				Mimura, H; Nakanishi, Y; Hirono, M; Maeshima, M			Membrane topology of the H+-pyrophosphatase of Streptomyces coelicolor determined by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; METAL-TETRACYCLINE/H+ ANTIPORTER; PROTON-PUMPING PYROPHOSPHATASE; SUBSTRATE-BINDING SITE; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; TERMINAL REGION; ANION-EXCHANGER; RESIDUES; INHIBITION	The H+-translocating pyrophosphatase (H+-PPase) is a proton pump that is found in a wide variety of organisms. It consists of a single polypeptide chain that is thought to possess between 14 and 17 transmembrane domains. To determine the topological arrangement of its conserved motifs and transmembrane domains, we carried out a cysteine-scanning analysis by determining the membrane topology of cysteine substitution mutants of Streptomyces coelicolor H+-PPase expressed in Escherichia coli using chemical reagents. First, we prepared a synthetic DNA that encoded the enzyme and constructed a functional cysteine-less mutant by substituting the four cysteine residues. We then introduced cysteine residues individually into 42 sites in its hydrophilic regions and N- and C-terminal segments. Thirty-six of the mutant enzymes retained both pyrophosphatase and H+-translocating activities. Analysis of 29 of these mutant forms using membrane-permeable and - impermeable sulfhydryl reagents revealed that S. coelicolor H+-PPase contains 17 transmembrane domains and that several conserved segments, such as the substrate-binding domains, are exposed to the cytoplasm. Four essential serine residues that were located on the cytoplasmic side were also identified. A marked characteristic of the S. coelicolor enzyme is a long additional sequence that includes a transmembrane domain at the C terminus. We propose that the basic structure of H+-PPases has 16 transmembrane domains with several large cytoplasmic loops containing functional motifs.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan	Nagoya University	Maeshima, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.	maeshima@agr.nagoya-u.ac.jp	Maeshima, Masayoshi/D-3073-2013	Maeshima, Masayoshi/0000-0002-1611-5481				Baltscheffsky M, 1999, FEBS LETT, V452, P121, DOI 10.1016/S0014-5793(99)00617-1; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; Belogurov GA, 2002, J BIOL CHEM, V277, P22209, DOI 10.1074/jbc.M202951200; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Gaxiola RA, 2001, P NATL ACAD SCI USA, V98, P11444, DOI 10.1073/pnas.191389398; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; Kamiya T, 2004, J BIOL CHEM, V279, P812, DOI 10.1074/jbc.M309726200; Kimura T, 1997, J BIOL CHEM, V272, P580; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; MAESHIMA M, 1991, EUR J BIOCHEM, V196, P11, DOI 10.1111/j.1432-1033.1991.tb15779.x; McIntosh MT, 2002, INT J PARASITOL, V32, P1, DOI 10.1016/S0020-7519(01)00325-3; Nakanishi Y, 2003, J BIOCHEM, V134, P615, DOI 10.1093/jb/mvg184; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Perez-Castineira JR, 2002, P NATL ACAD SCI USA, V99, P15914, DOI 10.1073/pnas.242625399; Perez-Castineira JR, 2002, BIOCHEM BIOPH RES CO, V294, P567, DOI 10.1016/S0006-291X(02)00517-X; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Saliba KJ, 2003, J BIOL CHEM, V278, P5605, DOI 10.1074/jbc.M208648200; Schultz A, 2003, BBA-BIOENERGETICS, V1607, P141, DOI 10.1016/j.bbabio.2003.09.003; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Takasu A, 1997, J BIOCHEM-TOKYO, V122, P883, DOI 10.1093/oxfordjournals.jbchem.a021837; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	34	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35106	35112		10.1074/jbc.M406264200	http://dx.doi.org/10.1074/jbc.M406264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187077	hybrid			2022-12-25	WOS:000223134800123
J	Wei, ZY; Zhang, P; Zhou, ZC; Cheng, ZJ; Wan, M; Gong, WM				Wei, ZY; Zhang, P; Zhou, ZC; Cheng, ZJ; Wan, M; Gong, WM			Crystal structure of human eIF3k, the first structure of eIF3 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION; COMPLEX; BINDING; DOMAIN; RECOGNITION; YEAST; INTERACTS; MODEL; CORE; FOKI	eIF3k, the smallest subunit of eukaryotic initiation factor 3 (eIF3), interacts with several other subunits of eIF3 and the 40 S ribosomal subunit. eIF3k is conserved among high eukaryotes, including mammals, insects, and plants, and it is ubiquitously expressed in human tissues. Interestingly, eIF3k does not exist in some species of yeast. Thus, eIF3k may play a unique regulatory role in higher organisms. Here we report the crystal structure of human eIF3k, the first high-resolution structure of an eIF3 component. This novel structure contains two distinct domains, a HEAT ( named for Huntington, elongation factor 3, A subunit of protein phosphatase 2A, target of rapamycin) repeat-like HAM ( HEAT analogous motif) domain and a winged-helix-like WH domain. Through structural comparison and sequence conservation analysis, we show that eIF3k has three putative protein-binding surfaces and has potential RNA binding activity. The structure provides key information for understanding the structure and function of the eIF3 complex.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gong, WM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	wgong@sun5.ibp.ac.cn	Wei, Zhiyi/C-4315-2014; Wei, Zhiyi/N-9995-2019; Wei, Zhiyi/B-5001-2010; Cheng, zhongjun/D-6929-2011	Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; GROVES MR, 1999, P NATL ACAD SCI USA, V86, P8669; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim TH, 2001, TRENDS PLANT SCI, V6, P379, DOI 10.1016/S1360-1385(01)02015-5; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; KORADI R, 1998, PDB NEWSLETT, V84, P5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; Selmer M, 2002, EMBO J, V21, P4145, DOI 10.1093/emboj/cdf408; Sinha SC, 2003, J BACTERIOL, V185, P4087, DOI 10.1128/JB.185.14.4087-4098.2003; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	47	48	49	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34983	34990		10.1074/jbc.M405158200	http://dx.doi.org/10.1074/jbc.M405158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180986	hybrid			2022-12-25	WOS:000223134800110
J	Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G				Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G			Mechanisms underlying differential expression of interleukin-8 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8	NF-KAPPA-B; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; PROSTATE-CANCER; GROWTH-FACTOR; ANGIOGENESIS; BINDING; BETA; PROLIFERATION; MELANOMA	We have recently reported that interleukin-8 (IL-8) expression was inversely correlated to estrogen receptor (ER) status and was overexpressed in invasive breast cancer cells. In the present study, we show that IL-8 overexpression in breast cancer cells involves a higher transcriptional activity of IL-8 gene promoter. Cloning of IL-8 promoter from MDA-MB-231 and MCF-7 cells expressing high and low levels of IL-8, respectively, shows the integrity of the promoter in both cell lines. Deletion and site-directed mutagenesis of the promoter demonstrate that NF-kappaB and AP-1 and to a lesser extent C/EBP binding sites play a crucial role in the control of IL-8 promoter activity in MDA-MB-231 cells. Knock-down of NF-kappaB and AP-1 activities by adenovirus-mediated expression of an NF-kappaB super-repressor and RNA interference, respectively, decreased IL-8 expression in MDA-MB-231 cells. On the contrary, restoration of Fra-1, Fra-2, c-Jun, p50, p65, C/EBPalpha and C/EBPbeta expression levels in MCF-7 cells led to a promoter activity comparable to that observed in MDA-MB-231 cells. Our data constitute the first extensive study of IL-8 gene overexpression in breast cancer cells and suggest that the high expression of IL-8 in invasive cancer cells requires a complex cooperation between NF-kappaB, AP-1 and C/EBP transcription factors.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	lazennec@montp.inserm.fr	Jolivel, Valérie/ABB-1136-2021; Jolivel, Valerie/A-6810-2017; Durand, Sebastien/Q-2138-2019	Jolivel, Valérie/0000-0002-4114-4559; Jolivel, Valerie/0000-0002-4114-4559; Durand, Sebastien/0000-0002-9960-9099; Chavey, Carine/0000-0002-5267-5638; Lazennec, Gwendal/0000-0002-8522-1763				Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brew R, 1996, EUR J CANCER, V32A, P2142, DOI 10.1016/S0959-8049(96)00221-3; BROWN PH, 1993, ONCOGENE, V8, P877; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Patel PS, 2002, J INTERF CYTOK RES, V22, P427, DOI 10.1089/10799900252952217; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; SHEIKH MS, 1994, INVAS METAST, V14, P329; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zerbini LF, 2003, CANCER RES, V63, P2206	33	86	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6105	6114		10.1038/sj.onc.1207815	http://dx.doi.org/10.1038/sj.onc.1207815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208657	Green Accepted, Green Submitted			2022-12-25	WOS:000223261000010
J	Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI				Flores, I; Murphy, DJ; Swigart, LB; Knies, U; Evan, GI			Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia	ONCOGENE			English	Article						Myc; epidermis; hyperplasia; differentiation; oncogene inactivation	TERMINALLY DIFFERENTIATING CELLS; B-INDUCED APOPTOSIS; C-MYC; STEM-CELLS; EPIDERMAL DIFFERENTIATION; MOUSE EPIDERMIS; EXPRESSION; P63; KERATINOCYTES; PROLIFERATION	The homeostatic integrity of skin epidermis is maintained by a balance between keratinocyte proliferation, on one hand, and terminal differentiation combined with outward migration and shedding, on the other. Perturbation of this balance in favor of proliferation can result in hyperplasia and, potentially, tumorigenesis. We have previously described a reversible transgenic mouse model of epidermal neoplasia in which expression of an acutely regulatable form of Myc, MycER(TAM), is targeted to epidermis via the involucrin promoter. In this model, sustained activation of MycER(TM) induces a complex neoplastic lesion involving marked hyperplasia of less-differentiated suprabasal cells, angiogenesis and overt papillomatosis. Subsequent deactivation of MycER(TAM) triggers complete papilloma regression. Here, we provide evidence that Myc-induced papillomas are self-limiting because of the eventual differentiation of MycER(TAM)-expressing keratinocytes. Thus, keratinocyte differentiation eventually prevails over Myc-induced proliferation. We also show that regression of Myc-induced papillomas following MycER(TAM) deactivation occurs through a combination of growth arrest and irreversible differentiation. Finally, we demonstrate that transient deactivation of Myc is sufficient to expel keratinocytes irreversibly from the proliferative compartment and render them refractory to the mitogenic influence of subsequent Myc reactivation. Such observations illustrate the potential utility of even short-term inhibition of oncogenic lesions in the treatment of cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA; John Radcliffe Hosp, Inst Mol Med, Canc Res United Kingdom, Mol Oncol Labs, Oxford OX3 9DS, England	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Research UK; University of Oxford	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, 2340 Sutter St,Room S236, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Murphy, Daniel/V-1079-2019; Flores, Ignacio/E-8304-2016	Murphy, Daniel/0000-0002-5538-5468; Flores, Ignacio/0000-0001-8789-6396				Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liefer KM, 2000, CANCER RES, V60, P4016; MOORE JP, 1987, ONCOGENE RES, V2, P65; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; ROOP DR, 1988, CANCER RES, V48, P3245; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	26	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5923	5930		10.1038/sj.onc.1207796	http://dx.doi.org/10.1038/sj.onc.1207796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208685				2022-12-25	WOS:000222941100006
J	Joseph, JD; Daigle, SN; Means, AR				Joseph, JD; Daigle, SN; Means, AR			PINA is essential for growth and positively influences NIMA function in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; CELL-CYCLE; BINDING-PROTEIN; CA2+/CALMODULIN-DEPENDENT KINASE; SACCHAROMYCES-CEREVISIAE; PREMATURE MITOSIS; NUCLEAR DIVISION; CYCLOPHILIN-A; GENE	The phospho-Ser/Thr-directed prolyl-isomerase Pin1 was originally identified in vertebrate systems as a negative regulator of NIMA, a Ser/Thr protein kinase that regulates the G(2)/M transition in Aspergillus nidulans. Here we explore the physiological roles of the Pin1 orthologue, PINA, in A. nidulans and evaluate the relevance of the interaction of PINA with NIMA in this fungus. We find pinA to be an essential gene in A. nidulans. In addition, when PINA levels are reduced 50-fold the cells grow at a reduced rate. Upon germination under conditions that repress PINA expression, the cells are delayed in the interphase activation of NIMXcdc2, whereas they traverse the other phases of the cell cycle at a similar rate to controls. These results indicate that a marked reduction of PINA results in a lengthening of G(1). Additionally, PINA repression increases the rate at which the cells enter mitosis following release from a hydroxyurea arrest without altering the sensitivity of the fungus to agents that activate the replication or DNA damage checkpoints. In contrast to predictions based on Pin1, the physical interaction between PINA and NIMA is primarily dependent upon the prolylisomerase domain of PINA and the C-terminal 303 amino acids of NIMA. Finally, reduction of PINA levels exacerbates the nimA5 temperature-sensitive mutant, whereas overexpression of PINA decreases the severity of this mutation, results that are consistent with a positive genetic interaction between PINA and NIMA. Thus, although PINA is essential and positively regulates NIMA function, A. nidulans is most sensitive to a reduction in PINA concentration in G(1) rather than in G(2)/M.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NCI NIH HHS [CA82845] Funding Source: Medline; NIDDK NIH HHS [2T32DK07568-13] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atchison FW, 2003, BIOL REPROD, V69, P1989, DOI 10.1095/biolreprod.103.020859; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dayton JS, 1997, J BIOL CHEM, V272, P3223, DOI 10.1074/jbc.272.6.3223; Dayton JS, 1996, MOL BIOL CELL, V7, P1511, DOI 10.1091/mbc.7.10.1511; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; De Souza CPC, 1999, MOL BIOL CELL, V10, P3661, DOI 10.1091/mbc.10.11.3661; Devasahayam G, 2002, GENETICS, V160, P37; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Fujimori F, 2001, BIOCHEM BIOPH RES CO, V289, P181, DOI 10.1006/bbrc.2001.5925; GUTHRIE C, 2002, METHOD ENZYMOL, P351; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SD, 1994, GENETICS, V136, P517; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Huang HK, 2001, J CELL SCI, V114, P3779; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Jacobs DM, 2003, J BIOL CHEM, V278, P26174, DOI 10.1074/jbc.M300796200; JAMES SW, 1995, J CELL SCI, V108, P3485; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1993, METH MOL G, V2, P255; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Miyashita H, 2003, ONCOL REP, V10, P455; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	57	18	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32373	32384		10.1074/jbc.M405415200	http://dx.doi.org/10.1074/jbc.M405415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178679	hybrid			2022-12-25	WOS:000222849700050
J	Rodriguez, JM; Ruiz-Sala, P; Ugarte, M; Penalva, MA				Rodriguez, JM; Ruiz-Sala, P; Ugarte, M; Penalva, MA			Fungal metabolic model for type I 3-methylglutaconic aciduria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ASPERGILLUS-NIDULANS; MOLECULAR-BASIS; GENE; IDENTIFICATION; ALKAPTONURIA; MUTATIONS; AUH; PEROXISOMES; LYASE	Aspergillus nidulans catabolizes Leu to acetyl-CoA and acetoacetate through a pathway homologous to that used by humans. Fungal hlyA encodes a bifunctional polypeptide comprising the last two enzymes in this pathway, 3-methylglutaconyl-CoA hydratase and 3-hydroxy-3-methylglutaryl-CoA lyase. hlyA transcription is specifically induced by Leu. A DeltahlyA mutation removing the complete 3-methylglutaconyl-CoA hydratase C-terminal domain prevents growth on Leu but not on lactose or other amino acids and, in agreement with the predicted enzyme function, leads to Leu-dependent accumulation of 3-methylglutaconic acid in the culture supernatant. These data represent a formal demonstration in vivo of the specific involvement of 3-methylglutaconyl-CoA hydratase in Leu catabolism. Type I 3-methylglutaconic aciduria patients deficient in 3-methylglutaconyl-CoA hydratase show urinary excretion of 3-methylglutaconic acid and, in contrast to the other three types of methylglutaconic acidurias, 3-hydroxy-isovaleric acid excretion. Gas chromatography-mass spectrometry analysis revealed an accumulation of both diagnostic compounds in DeltahlyA culture supernatants, illustrating that the metabolic consequences of equivalent inborn errors of metabolism are conserved from fungi to humans. Using our fungal type I 3-methylglutaconic aciduria model, we show that metabolites accumulating in the deficient strain are toxic, although less so than those accumulating in a DeltamccB strain deficient for the upstream enzyme 3-methylcrotonyl-CoA carboxylase. Diagnostic metabolite accumulation is Leu concentration-dependent, in agreement with the ability of Leu intake restriction to reduce the levels of offending metabolites. DeltamccB and DeltahlyA mutations show additive Leu toxicities. The double mutant accumulates 3-methylglutaconic acid, which can therefore be synthesized through 3-methylcrotonyl-CoA carboxylase-dependent and -independent reactions.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28040, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Madrid 28034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Penalva, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro de Maeztu 9, Madrid 28040, Spain.	penalva@cib.csic.es	Penalva, Miguel A/G-2295-2015	Penalva, Miguel A/0000-0002-3102-2806; Ruiz-Sala, Pedro/0000-0003-1785-4988				Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651; ARMITT S, 1970, FEBS LETT, V7, P231, DOI 10.1016/0014-5793(70)80168-5; ARMITT S, 1971, FEBS LETT, V12, P276, DOI 10.1016/0014-5793(71)80198-9; Ashmarina LI, 1999, J LIPID RES, V40, P70; Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Brennan LE, 1999, GENE, V228, P85, DOI 10.1016/S0378-1119(99)00003-7; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DURAN M, 1982, J PEDIATR-US, V101, P551, DOI 10.1016/S0022-3476(82)80698-7; EDMOND J, 1974, J BIOL CHEM, V249, P66; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; FERNANDEZCANON JM, 1995, J BIOL CHEM, V270, P21199, DOI 10.1074/jbc.270.36.21199; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; FernandezCanon JM, 1996, NAT GENET, V14, P19, DOI 10.1038/ng0996-19; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Gallardo ME, 2001, AM J HUM GENET, V68, P334, DOI 10.1086/318202; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Ijlst L, 2002, AM J HUM GENET, V71, P1463, DOI 10.1086/344712; KORNBERG HL, 1966, BIOCHEM J, V99, P1; Ly TBN, 2003, HUM MUTAT, V21, P401, DOI 10.1002/humu.10202; Penalva MA, 2001, FUNGAL GENET BIOL, V34, P1, DOI 10.1006/fgbi.2001.1284; Rodriguez JM, 2000, HUM MOL GENET, V9, P2341, DOI 10.1093/oxfordjournals.hmg.a018927; Rodriguez JM, 2004, J BIOL CHEM, V279, P4578, DOI 10.1074/jbc.M310055200; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sweetman L., 2001, METABOLIC MOL BASES, P2125; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; Vaz FM, 2003, J BIOL CHEM, V278, P43089, DOI 10.1074/jbc.M305956200; Walsh R, 1999, J INHERIT METAB DIS, V22, P251, DOI 10.1023/A:1005573819137; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804	31	9	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32385	32392		10.1074/jbc.M313044200	http://dx.doi.org/10.1074/jbc.M313044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15181004	hybrid, Green Published			2022-12-25	WOS:000222849700051
J	Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Benoit, E; Zinner, MJ; Ashley, SW; Whang, EE			Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness	ONCOGENE			English	Article						pancreatic adenocarcinoma; cancer; CEACAM6; insulin-like growth factor I; IGF-I invasion; Akt; Src; MMP-2	PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; TUMOR-NECROSIS-FACTOR; REACTING ANTIGEN NCA; FACTOR RECEPTOR; CANCER CELLS; CARCINOMA-CELLS; IGF-I; MATRIX METALLOPROTEINASE-2; ANTIBODY BY114; FAMILY-MEMBERS	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers. We have recently reported that suppression of CEACAM6 expression impairs pancreatic adenocarcinoma progression in vivo. In order to characterize the mechanisms through which CEACAM6 influences the malignant phenotype, CEA-CAM6-overexpressing Capan2 pancreatic adenocarcinoma cells were established by stable transfection. We determined the effect of CEACAM6 overexpression on cellular invasiveness towards insulin-like growth factor I (IGF-I), a peptide of critical importance in pancreatic cancer malignant cellular behavior and tumor progression. IGF-I-induced cellular invasiveness and IGF-IR expression were significantly increased in clones overexpressing CEACAM6. Using inhibitory anti-IGF-IR antibody, a requirement for IGF-IR signaling in the enhanced invasiveness towards IGF-I induced by CEACAM6 overexpression was confirmed. CEACAM6-overexpressing clones exhibited increased Akt and c-Src kinase activities, as well as higher levels of matrix metalloproteinase-2 (MMP-2) expression and activity in the presence of IGF-I. While Akt kinase is both necessary and sufficient to induce IGF-IR upregulation, c-Sre kinase activity is necessary, but alone is insufficient to upregulate IGF-IR expression. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior and, together with its downstream targets, warrants further investigation as a therapeutic target in this disease.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BERGMANN U, 1995, CANCER RES, V55, P2007; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dunn SE, 1998, CANCER RES, V58, P3353; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; Guirouilh J, 2000, INT J ONCOL, V17, P777; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KALTHOFF H, 1993, ONCOGENE, V8, P289; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LOHR M, 1994, BRIT J CANCER, V69, P144, DOI 10.1038/bjc.1994.24; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Murphy LO, 2001, BRIT J CANCER, V84, P926, DOI 10.1054/bjoc.2001.1698; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Ordonez C, 2000, CANCER RES, V60, P3419; Ouban A, 2003, HUM PATHOL, V34, P803, DOI 10.1016/S0046-8177(03)00291-0; Park BK, 2001, CANCER RES, V61, P7647; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005; RESNICOFF M, 1994, CANCER RES, V54, P2218; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; SELL C, 1995, CANCER RES, V55, P303; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Tanno S, 2001, CANCER RES, V61, P589; Tooze JA, 1995, EXP HEMATOL, V23, P1484; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Wu YP, 2002, CANCER RES, V62, P1030; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zeng HY, 2003, BIOCHEM BIOPH RES CO, V302, P46, DOI 10.1016/S0006-291X(03)00107-4; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	58	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5834	5842		10.1038/sj.onc.1207775	http://dx.doi.org/10.1038/sj.onc.1207775			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208677				2022-12-25	WOS:000222629800013
J	Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K				Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K			Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators	ONCOGENE			English	Article						CD99; Ewing's sarcoma; homotypic aggregation; apoptosis; zyxin; actin	MIC2 GENE-PRODUCT; REED-STERNBERG PHENOTYPE; PSEUDOAUTOSOMAL GENE; CD99 ENGAGEMENT; NEUROECTODERMAL TUMOR; MEMBRANE-PROTEIN; DOWN-REGULATION; T-CELLS; APOPTOSIS; PHOSPHATIDYLSERINE	CD99 is a unique 32-kDa cell surface molecule with broad cellular expression but still poorly understood biological functions. In cancer cells, CD99 is highly expressed in virtually all Ewing's sarcoma (ES). Engagement of CD99 induces fast homotypic aggregation of ES cells and caspase-independent apoptosis. In this study, we analysed signal transduction after CD99 engagement on ES cells. Findings obtained with selective inhibitors indicated that only actin cytoskeleton integrity was essential for cell-cell adhesion and apoptosis of ES cells. Indeed, CD99 stimulation induced actin repolymerization, further supporting the role of cytoskeleton in CD99 signaling. Gene expression profiling of ES cells after CD99 engagement showed modulation in the expression of 32 genes. Among the pool of upregulated genes reported to be involved in cell adhesion, we chose to analyse the role of zyxin, a cytoplasmic adherens junction protein found to play a role in the regulation of the actin cytoskeleton. Overexpression of zyxin after CD99 ligation was confirmed by real-time PCR and Western blot. Treatment of ES cells with zyxin antisense otigonucleotides inhibited CD99-induced cell aggregation and apoptosis, suggesting a functional role for this protein. Therefore, our findings indicate that CD99 functions occur through reorganization of cytoskeleton and identify actin and zyxin as the early signaling events driven by CD99 engagement.	Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, FIN-00014 Helsinki, Finland; Hosp Archet, UMR 576, Unite INSERM, Nice 3, France; Univ Bologna, Dipartimento Clin Sci Radiol & Istocitopatol, Bologna, Italy; Ist Ortoped Rizzoli, ITOI CNR, Unit Bologna, I-40136 Bologna, Italy; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	IRCCS Istituto Ortopedico Rizzoli; University of Helsinki; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Bologna; IRCCS Istituto Ortopedico Rizzoli; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Colombo, Mario P./V-7166-2017; Nagy, Balint/F-6943-2012; LATTANZI, GIOVANNA/P-8214-2015; Manara, Maria Cristina/K-3366-2018; Lattanzi, Giovanna/AAY-3186-2020; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Scotlandi, Katia/0000-0001-6114-9499; Colombo, Mario P./0000-0003-0042-7955; LATTANZI, GIOVANNA/0000-0002-7103-8722; Manara, Maria Cristina/0000-0001-5686-720X; Lattanzi, Giovanna/0000-0002-7103-8722; BENINI, STEFANIA/0000-0003-0958-9088; Picci, Piero/0000-0002-8519-4101; CENACCHI, GIOVANNA/0000-0001-5824-3118				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BANTING GS, 1989, MOL IMMUNOL, V26, P181, DOI 10.1016/0161-5890(89)90100-4; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Choi FY, 1998, J IMMUNOL, V161, P749; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Fidler I.J., 1997, CANC PRINCIPLES PRAC; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GELIN C, 1995, LEUCOCYTE TYPING, V5; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; Granter SR, 1996, HUM PATHOL, V27, P1273, DOI 10.1016/S0046-8177(96)90336-6; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim MK, 2003, FEBS LETT, V546, P379, DOI 10.1016/S0014-5793(03)00567-2; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; KOVAR H, 1990, ONCOGENE, V5, P1067; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; PREDA P, 1995, MICROSC RES TECHNIQ, V32, P75, DOI 10.1002/jemt.1070320108; RAMANI P, 1993, HISTOPATHOLOGY, V23, P557, DOI 10.1111/j.1365-2559.1993.tb01243.x; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; Shen JC, 1998, MOL CARCINOGEN, V23, P13, DOI 10.1002/(SICI)1098-2744(199809)23:1<13::AID-MC2>3.0.CO;2-I; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Wingett D, 1999, CELL IMMUNOL, V193, P17, DOI 10.1006/cimm.1999.1470; Yoon SS, 2003, FEBS LETT, V540, P217, DOI 10.1016/S0014-5793(03)00268-0; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0	47	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5664	5674		10.1038/sj.onc.1207741	http://dx.doi.org/10.1038/sj.onc.1207741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184883				2022-12-25	WOS:000222629500011
J	Coers, J; Ranft, C; Skoda, RC				Coers, J; Ranft, C; Skoda, RC			A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SOLUBLE CYTOKINE RECEPTORS; MOLECULAR-CLONING; ERYTHROPOIETIN RECEPTOR; TRANSGENIC MICE; ALPHA-SUBUNIT; EGF RECEPTOR; CELL-GROWTH; HALF-LIFE; PROTEIN	Thrombopoietin and its cognate receptor c-Mpl are the primary regulators of megakaryopoiesis and platelet production. They also play an important role in the maintenance of hematopoietic stem cells. Here, we have analyzed the function of a truncated Mpl receptor isoform (Mpl-tr), which results from alternative splicing. The mpl-tr variant is the only alternate mpl isoform conserved between mouse and humans, suggesting a relevant function in regulating Mpl signaling. Despite the presence of a signal peptide and the lack of a transmembrane domain, Mpl-tr is retained intracellularly. Our results provide evidence that Mpl-tr exerts a dominant-negative effect on thrombopoietin-dependent cell proliferation and survival. We demonstrate that this inhibitory effect is due to down-regulation of the full-length Mpl protein. The C terminus of Mpl-tr, consisting of 30 amino acids of unique sequence, is essential for the suppression of thrombopoietin-dependent proliferation and Mpl protein down-regulation. Cathepsin inhibitor-1 (CATI-1), an inhibitor of cathepsin-like cysteine proteases, counteracts the effect of Mpl-tr on Mpl protein expression, suggesting that Mpl-tr targets Mpl for lysosomal degradation. Together, these data suggest a new paradigm for the regulation of cytokine receptor expression and function through a proteolytic process directed by a truncated isoform of the same receptor.	Univ Basel Hosp, Dept Res Expt Hematol, CH-4031 Basel, Switzerland	University of Basel	Skoda, RC (corresponding author), Univ Basel Hosp, Dept Res Expt Hematol, Hebelstr 20, CH-4031 Basel, Switzerland.	radek.skoda@unibas.ch		Coers, Jorn/0000-0001-8707-4608				ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; AREND WP, 1994, J IMMUNOL, V153, P4766; ARMSTRONG J, 1990, J CELL SCI, V95, P191; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; Bormann P, 1999, MOL CELL NEUROSCI, V13, P167, DOI 10.1006/mcne.1999.0742; BROWN CB, 1995, BLOOD, V85, P1488, DOI 10.1182/blood.V85.6.1488.bloodjournal8561488; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; HEANEY ML, 1995, P NATL ACAD SCI USA, V92, P2365, DOI 10.1073/pnas.92.6.2365; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kaushansky K, 2002, ONCOGENE, V21, P3359, DOI 10.1038/sj.onc.1205323; KOMATSU N, 1991, CANCER RES, V51, P341; Kralovics R, 2003, BLOOD, V102, P1869, DOI 10.1182/blood-2003-03-0744; Li JZ, 2000, CYTOKINE, V12, P835, DOI 10.1006/cyto.1999.0654; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; Nakamura Y, 1998, EXP HEMATOL, V26, P1105; Ogata A, 1997, J IMMUNOL, V159, P2212; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Sabath DF, 2002, BBA-GENE STRUCT EXPR, V1574, P383, DOI 10.1016/S0167-4781(01)00357-8; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Slater NJ, 2003, BRIT J HAEMATOL, V122, P150, DOI 10.1046/j.1365-2141.2003.04383.x; Stoffel R, 1996, BLOOD, V87, P567, DOI 10.1182/blood.V87.2.567.bloodjournal872567; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TSURUOKA N, 1993, ARCH BIOCHEM BIOPHYS, V307, P133, DOI 10.1006/abbi.1993.1571; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VELDHUIS JD, 1993, J CLIN INVEST, V91, P629, DOI 10.1172/JCI116243; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Wagner K, 2001, BLOOD, V98, P2689, DOI 10.1182/blood.V98.9.2689; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	48	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36397	36404		10.1074/jbc.M401386200	http://dx.doi.org/10.1074/jbc.M401386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210714	hybrid			2022-12-25	WOS:000223453600030
J	Jenkins, CE; Swiatoniowski, A; Issekutz, AC; Lin, TJ				Jenkins, CE; Swiatoniowski, A; Issekutz, AC; Lin, TJ			Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; DIPHTHERIA-TOXIN; CYSTIC-FIBROSIS; TRANSENDOTHELIAL MIGRATION; DNA FRAGMENTATION; PROTEIN-SYNTHESIS; EPITHELIAL-CELLS; CHIMERIC PROTEIN; DEATH; RECEPTOR	Mast cells play an important role in both allergy and innate immunity. Recently, we demonstrated an active interaction between human mast cells and Pseudomonas aeruginosa leading to the production of multiple cytokines. Here, we show that both primary cultured human cord blood-derived mast cells and the human mast cell line HMC-1 undergo apoptosis as determined by single-stranded DNA (ssDNA) formation after stimulation with P. aeruginosa exotoxin A (ETA), a major toxin produced by this bacterium. ETA-induced ssDNA formation was completely inhibited by Z-VAD (where Z is benzyloxycarbonyl), which blocks multiple caspases, suggesting a role for caspases in this process. Active caspase-3 formation in mast cells after an ETA challenge was detected by both Western blotting and flow cytometry analysis. ETA-induced caspase-3 activity in human mast cells was demonstrated by the detection of a characteristic 23 kDa product of D4-GDI (where GDI is guanine nucleotide dissociation inhibitor), an endogenous caspase-3 substrate. Interestingly, a specific caspase-8 inhibitor, Z-IETD-fmk (where fmk is fluoromethyl ketone), blocked ETA-induced cleavage of D4-GDI, but a caspase-9 inhibitor (Z-LEHD-fmk) did not. Treatment of mast cells with caspase-3 inhibitor Z-DEVD-fmk or caspase-8 inhibitor Z-IETD-fmk reduced the generation of ssDNA induced by ETA, suggesting a role for caspase-8 and -3 in ETA-induced mast cell apoptosis. Furthermore, treatment of mast cells with ETA induced decreases of the short form and a long form (p43) of Fas-associated death domain protein (FADD)-like interleukin-1beta-converting enzyme (FLICE) (caspase-8)-inhibitory proteins (FLIPs), which are endogenous caspase-8 inhibitors. Taken together, these results suggest that ETA-induced mast cell apoptosis involves down-regulation of antiapoptotic proteins, FLIPs, and activation of caspase-8 and -3 pathways.	Dalhousie Univ, Dept Pediat, IWK Hlth Ctr, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3J 3G9, Canada	Dalhousie University; Dalhousie University	Lin, TJ (corresponding author), Dalhousie Univ, Dept Pediat, IWK Hlth Ctr, 5850 Univ Ave, Halifax, NS B3J 3G9, Canada.	tong-jun.lin@dal.ca						Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Boudreau RTM, 2002, J BIOL CHEM, V277, P5322, DOI 10.1074/jbc.M108623200; CROSS AS, 1980, J INFECT DIS, V142, P538, DOI 10.1093/infdis/142.4.538; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Fishman A, 1997, EUR J IMMUNOL, V27, P486, DOI 10.1002/eji.1830270220; Fishman A, 2000, CLIN EXP IMMUNOL, V119, P398, DOI 10.1046/j.1365-2249.2000.01151.x; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311; Gallant CV, 2000, MICROBIOL-SGM, V146, P1891, DOI 10.1099/00221287-146-8-1891; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Hamood AN, 1996, J SURG RES, V61, P425, DOI 10.1006/jsre.1996.0140; HIRAKATA Y, 1993, INFECT IMMUN, V61, P2468, DOI 10.1128/IAI.61.6.2468-2473.1993; JAFFARBANDJEE MC, 1995, J CLIN MICROBIOL, V33, P924, DOI 10.1128/JCM.33.4.924-929.1995; Kawakami M, 2002, MOL CANCER THER, V1, P999; Keppler-Hafkemeyer A, 2000, INT J CANCER, V87, P86, DOI 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I; Keppler-Hafkemeyer A, 1998, BIOCHEMISTRY-US, V37, P16934, DOI 10.1021/bi980995m; KOCH C, 1993, LANCET, V341, P1065, DOI 10.1016/0140-6736(93)92422-P; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin TJ, 2003, INFECT IMMUN, V71, P365, DOI 10.1128/IAI.71.1.365-373.2003; Lin TJ, 2002, J IMMUNOL, V169, P4522, DOI 10.4049/jimmunol.169.8.4522; Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; McHugh L, 2002, J BIOL CHEM, V277, P34383, DOI 10.1074/jbc.M205456200; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MORIMOTO H, 1992, J IMMUNOL, V149, P2089; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; Park BS, 2000, IMMUNOL INVEST, V29, P51, DOI 10.3109/08820130009060877; Park HI, 2001, LIFE SCI, V69, P553, DOI 10.1016/S0024-3205(01)01140-7; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; Plotkowski MC, 2002, AM J RESP CELL MOL, V26, P617, DOI 10.1165/ajrcmb.26.5.4489; Schumann J, 1998, J IMMUNOL, V161, P5745; Schumann J, 2000, IMMUNOL LETT, V74, P165, DOI 10.1016/S0165-2478(00)00240-6; Shelburne CP, 2001, IMMUNOL REV, V179, P82, DOI 10.1034/j.1600-065X.2001.790109.x; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; WICK MJ, 1990, MOL MICROBIOL, V4, P527, DOI 10.1111/j.1365-2958.1990.tb00620.x; Yoshikawa H, 2000, J IMMUNOL, V165, P6262, DOI 10.4049/jimmunol.165.11.6262	50	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37201	37207		10.1074/jbc.M405594200	http://dx.doi.org/10.1074/jbc.M405594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205454	hybrid			2022-12-25	WOS:000223453600124
J	Mongrand, S; Morel, J; Laroche, J; Claverol, S; Carde, JP; Hartmann, MA; Bonneu, M; Simon-Plas, F; Lessire, R; Bessoule, JJ				Mongrand, S; Morel, J; Laroche, J; Claverol, S; Carde, JP; Hartmann, MA; Bonneu, M; Simon-Plas, F; Lessire, R; Bessoule, JJ			Lipid rafts in higher plant cells - Purification and characterization of triton X-100-insoluble microdomains from tobacco plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER CHROMATOGRAPHY; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; CARBONIC-ANHYDRASE; PROTEIN; ARABIDOPSIS; STEROLS; ELONGATION; BINDING; PHOSPHOLIPIDS	A large body of evidence from the past decade supports the existence of functional microdomains in membranes of animal and yeast cells, which play important roles in protein sorting, signal transduction, or infection by pathogens. They are based on the dynamic clustering of sphingolipids and cholesterol or ergosterol and are characterized by their insolubility, at low temperature, in nonionic detergents. Here we show that similar microdomains also exist in plant plasma membrane isolated from both tobacco leaves and BY2 cells. Tobacco lipid rafts were found to be greatly enriched in a sphingolipid, identified as glycosylceramide, as well as in a mixture of stigmasterol, sitosterol, 24-methylcholesterol, and cholesterol. Phospho- and glycoglycerolipids of the plasma membrane were largely excluded from lipid rafts. Membrane proteins were separated by one- and two-dimensional gel electrophoresis and identified by tandem mass spectrometry or use of specific antibody. The data clearly indicate that tobacco microdomains are able to recruit a specific set of the plasma membrane proteins and exclude others. We demonstrate the recruitment of the NADPH oxidase after elicitation by cryptogein and the presence of the small G protein NtRac5, a negative regulator of NADPH oxidase, in lipid rafts.	Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, FRE 2694, Bordeaux, France; Univ Bourgogne, INRA, UMR 692, Phytopharm Lab, F-21065 Dijon, France; Univ Bordeaux 2, Univ Bordeaux 1, INRA, UMR 6191,Inst Biol Vegetale Mol, F-33883 Villenave Dornon, France; Univ Strasbourg, CNRS, UPR 2357, Inst Biol Mol Plantes, F-67083 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; INRAE; Universite de Bourgogne; INRAE; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mongrand, S (corresponding author), Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, FRE 2694, 146 Rue Leo Saignat,BP 33076, Bordeaux, France.	sebastien.mongrand@biomemb.u-bordeaux2.fr						Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Assossou O, 2003, FEMS MICROBIOL LETT, V224, P161, DOI 10.1016/S0378-1097(03)00479-8; Bagnat M, 2002, BIOL CHEM, V383, P1475, DOI 10.1515/BC.2002.169; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Berczi Alajos, 2003, Acta Biologica Szegediensis, V47, P7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bohn M, 2001, ARCH BIOCHEM BIOPHYS, V387, P35, DOI 10.1006/abbi.2000.2224; BOUCHEPILLON S, 1994, PLANT PHYSIOL, V105, P691, DOI 10.1104/pp.105.2.691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Clouse SD, 2002, PLANT CELL, V14, P1995, DOI 10.1105/tpc.140930; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; FETT JP, 1994, PLANT PHYSIOL, V105, P707, DOI 10.1104/pp.105.2.707; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; GRONEWALD JW, 1982, PHYTOCHEMISTRY, V21, P859, DOI 10.1016/0031-9422(82)80080-0; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hartmann MA, 1998, TRENDS PLANT SCI, V3, P170, DOI 10.1016/S1360-1385(98)01233-3; HARTMANN MA, 1983, PLANT SCI LETT, V30, P239, DOI 10.1016/0304-4211(83)90223-7; JACINTO T, 1993, PLANT PHYSIOL, V103, P1393, DOI 10.1104/pp.103.4.1393; JUGUELIN H, 1986, DEV BRAIN RES, V25, P249, DOI 10.1016/0165-3806(86)90214-2; Kawamura Y, 2003, PLANT J, V36, P141, DOI 10.1046/j.1365-313X.2003.01864.x; Klahre U, 1998, PLANT CELL, V10, P1677, DOI 10.1105/tpc.10.10.1677; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; LARSSON C, 1994, METHOD ENZYMOL, V228, P451; Lindsey K, 2003, TRENDS PLANT SCI, V8, P521, DOI 10.1016/j.tplants.2003.09.012; Luche S, 2003, PROTEOMICS, V3, P249, DOI 10.1002/pmic.200390037; MACALA LJ, 1983, J LIPID RES, V24, P1243; MARTIN H, 1994, J NEUROCHEM, V63, P2259; MOORE AL, 1983, ISOLATION MEMBRANES, P153; Morel J, 2004, PLANT J, V37, P282, DOI 10.1046/j.1365-313X.2003.01957.x; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Peskan T, 2000, EUR J BIOCHEM, V267, P6989, DOI 10.1046/j.1432-1327.2000.01776.x; Rahier A., 1989, ANAL STEROLS OTHER B, P223, DOI [10.1016/B978-0-12-515445-1.50016-1, DOI 10.1016/B978-0-12-515445-1.50016-1]; Reymond P, 1996, PLANT CELL, V8, P2265, DOI 10.1105/tpc.8.12.2265; ROSENBERRY TL, 1989, J BIOL CHEM, V264, P7096; Rumeau D, 1996, PLANTA, V199, P79, DOI 10.1007/BF00196884; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; Santoni V, 1999, BIOCHIMIE, V81, P655, DOI 10.1016/S0300-9084(99)80122-9; Schindelman G, 2001, GENE DEV, V15, P1115, DOI 10.1101/gad.879101; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Simon-Plas F, 2002, PLANT J, V31, P137, DOI 10.1046/j.1365-313X.2002.01342.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; Sperling P, 2003, BBA-MOL CELL BIOL L, V1632, P1, DOI 10.1016/S1388-1981(03)00033-7; Sullards MC, 2000, J MASS SPECTROM, V35, P347, DOI 10.1002/(SICI)1096-9888(200003)35:3<347::AID-JMS941>3.0.CO;2-3; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; van Duyl BY, 2003, FEBS LETT, V547, P101, DOI 10.1016/S0014-5793(03)00678-1; VITIELLO F, 1978, J CHROMATOGR, V166, P637, DOI 10.1016/S0021-9673(00)95654-1; WHITEHEART SW, 1989, J BIOL CHEM, V264, P14334; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; YANG W, 1994, J BIOL CHEM, V269, P3852; Zheng XJ, 2003, J INVEST DERMATOL, V121, P1487, DOI 10.1111/j.1523-1747.2003.12614.x	58	372	394	0	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36277	36286		10.1074/jbc.M403440200	http://dx.doi.org/10.1074/jbc.M403440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190066	hybrid			2022-12-25	WOS:000223453600016
J	Torra, IP; Freedman, LP; Garabedian, MJ				Torra, IP; Freedman, LP; Garabedian, MJ			Identification of DRIP205 as a coactivator for the farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ORPHAN NUCLEAR RECEPTOR; VITAMIN-D-RECEPTOR; BILE-ACID; THYROID-HORMONE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; TRAP220 COMPONENT; RESPONSE ELEMENT	Farnesoid X receptor (FXR) is a bile acid sensor that regulates the expression of a number of genes the products of which control bile acid and cholesterol homeostasis; however, the role of DRIP205 in FXR-mediated gene regulation remains unexplored. In this study we demonstrate that DRIP205 binds FXR in a ligand-dependent manner in vitro and in vivo. Glutathione S-transferase pull-down assays showed that DRIP205 binds FXR in response to bile acid ligands in a dose-dependent fashion and that the potency of this interaction is associated with the ability of the ligand to activate FXR. In addition, the FXR-DRIP205 interaction required the presence of an intact LXXLL nuclear receptor box 1 (N-terminal) motif of DRIP205. In gel shift assays FXR was also able to recruit DRIP205 in the context of a DNA-bound FXR/RXR (retinoid X receptor) heterodimer. In transient transfection assays, DRIP205 efficiently enhanced a bile acid-activated FXRE-driven reporter gene in a dose-dependent manner in cells overexpressing FXR/RXR, demonstrating that DRIP205 enhances FXR-mediated transactivation. By contrast, an FXRW469A mutant in the activation function 2 domain that does not bind to DRIP205 was unable to activate ligand-stimulated FXR transcription, indicating that DRIP205 is recruited to activation function 2 of FXR. Requirement for the FXR/RXR heterodimer in the DRIP205-FXR interaction was evaluated using an RXR heterodimerization-deficient FXR mutant (FXRL433R). FXRL433R was not able to bind to DRIP205 and failed to enhance an FXRE-driven reporter gene. In addition, DRIP205 was unable to induce FXR-mediated transactivation in the absence of RXR overexpression, indicating that FXR heterodimerization with RXR is required for coactivation by DRIP205. Finally, in HepG2 cells, overexpression or reduction of DRIP205 levels modulated the induction of endogenous FXR target gene mRNA expression by ligand. Together, these results demonstrate that DRIP205 acts as a bona fide coactivator of FXR and underscore the importance of DRIP205 in modulating the bile acid response of FXR target genes.	NYU, Sch Med, Dept Microbiol & Urol, New York, NY 10016 USA; Merck Res Labs, Dept Mol Endocrinol, W Point, PA 19486 USA	New York University; Merck & Company	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol & Urol, 550 1st Ave,MSB 235, New York, NY 10016 USA.	garabm01@med.nyu.edu		Pineda Torra, Ines/0000-0002-7349-2208				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Cavarretta ITR, 2002, MOL ENDOCRINOL, V16, P253, DOI 10.1210/me.16.2.253; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Claudel T, 2002, J CLIN INVEST, V109, P961; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kassam A, 2003, J BIOL CHEM, V278, P10028, DOI 10.1074/jbc.M208312200; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Maeda Y, 2002, MOL ENDOCRINOL, V16, P1502, DOI 10.1210/me.16.7.1502; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Malik S, 2002, MOL CELL BIOL, V22, P5626, DOI 10.1128/MCB.22.15.5626-5637.2002; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	54	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36184	36191		10.1074/jbc.M405126200	http://dx.doi.org/10.1074/jbc.M405126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15187081	hybrid			2022-12-25	WOS:000223453600005
J	Cao, J; Semenova, MM; Solovyan, VT; Han, JH; Coffey, ET; Courtney, MJ				Cao, J; Semenova, MM; Solovyan, VT; Han, JH; Coffey, ET; Courtney, MJ			Distinct requirements for p38 alpha and c-jun N-terminal kinase stress-activated protein kinases in different forms of apoptotic neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DNA LOOP DOMAINS; CELL-DEATH; SYMPATHETIC NEURONS; CASPASE ACTIVATION; MOUSE HIPPOCAMPUS; CEREBRAL-ISCHEMIA; P38; JNK; INHIBITION	The stress-activated protein kinases c-Jun-activated kinase (JNK) and p38 are implicated in neuronal apoptosis. Early studies in cell lines suggested a requirement for both in the apoptosis induced by withdrawal of nerve growth factor. However, studies in neuronal cells typically implicate JNK but not p38 in apoptosis. In some cases, p38 is implicated, but the role of JNK is undefined. It remains unclear whether p38 and JNK have differing roles dependent on cell type, apoptotic stimulus, or mechanism of cell death or whether they are redundant and each sufficient to induce identical forms of cell death. We investigate the relative roles of these protein kinases in different death mechanisms in a single system, cultured cerebellar granule neurons. Apoptosis induced by withdrawal of trophic support and glutamate are mechanistically different in terms of caspase activation, DNA fragmentation profile, chromatin morphology, and dependence on de novo gene expression. Caspase-independent apoptosis induced by glutamate is accompanied by strong activation of p38, and dominant negatives and inhibitors of the p38 pathway prevent this apoptosis. In contrast, withdrawal of trophic support induces caspase-dependent death accompanied by JNK-dependent phosphorylation of c-Jun, and inhibition of JNK is sufficient to prevent the death induced by withdrawal of trophic support. Inhibition of p38 does not block withdrawal of trophic support-induced death, nor does inhibition of JNK block glutamate-induced death. We propose that mechanistically different forms of apoptosis have differing requirements for p38 and JNK activities in neurons and demonstrate that only inhibition of the appropriate kinase will prevent neurons from undergoing apoptosis.	Univ Kuopio, AI Virtanen Inst, Dept Neurobiol, FIN-70211 Kuopio, Finland; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Abo Akad, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Univ Turku, FIN-20521 Turku, Finland	University of Eastern Finland; Scripps Research Institute; Abo Akademi University; University of Turku	Courtney, MJ (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Neurobiol, Neulaniementie 2,POB 1627, FIN-70211 Kuopio, Finland.	courtney@messi.uku.fi	Courtney, Michael J/D-6648-2016; Han, J/G-4671-2010	Courtney, Michael J/0000-0001-8693-3933; Coffey, Eleanor/0000-0002-9717-5610				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Armstrong RC, 1997, J NEUROSCI, V17, P553; BALAZS R, 1990, NEUROSCIENCE, V37, P251, DOI 10.1016/0306-4522(90)90211-L; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bezvenyuk Z, 2000, MOL BRAIN RES, V81, P191, DOI 10.1016/S0169-328X(00)00174-1; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Castilho RF, 1998, J NEUROSCI, V18, P10277; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Didenko VV, 2002, MOL MED, V8, P347, DOI 10.1007/BF03402015; Eilers A, 1998, J NEUROSCI, V18, P1713; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fukuda T, 1999, NEUROSCI RES, V33, P49, DOI 10.1016/S0168-0102(98)00111-4; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; GOLD K, 2003, P NATL ACAD SCI USA, V100, P15434; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; HELLER C, 1989, NUCLEIC ACIDS RES, V17, P5989, DOI 10.1093/nar/17.15.5989; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LINDQVIST C, 1995, CELL IMMUNOL, V165, P71, DOI 10.1006/cimm.1995.1188; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Schwarzschild MA, 1999, J NEUROCHEM, V72, P2248, DOI 10.1046/j.1471-4159.1999.0722248.x; Sheldon RA, 2001, NEUROSCI LETT, V304, P165, DOI 10.1016/S0304-3940(01)01788-8; Solovyan VT, 2002, J BIOL CHEM, V277, P21458, DOI 10.1074/jbc.M110621200; Watson A, 1998, J NEUROSCI, V18, P751; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhao M, 1999, MOL CELL BIOL, V19, P21	51	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35903	35913		10.1074/jbc.M402353200	http://dx.doi.org/10.1074/jbc.M402353200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192112	hybrid			2022-12-25	WOS:000223303400091
J	Kampf, JP; Kleinfeld, AM				Kampf, JP; Kleinfeld, AM			Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; FLIP-FLOP; BINDING-PROTEIN; RAT ADIPOCYTES; OLEIC-ACID; LONG; DIFFERENTIATION; EXPRESSION; MECHANISM; DIFFUSION	Transport of free fatty acids (FFA) across the adipocyte plasma membrane is critical for maintaining homeostasis. To determine the membrane's role in regulating transport we describe here the first measurements of the intracellular (unbound) FFA concentration ([FFA(i)]) and their use in monitoring transport of FFA across 3T3F442A adipocytes. [FFA(i)] was measured by microinjecting cells with ADIFAB, a fluorescently labeled fatty acid-binding protein that is used to measure unbound FFA levels. We used ratio fluorescence microscopy of intracellular ADIFAB to image unbound FFA levels and determined the time course of [FFA(i)] in response to changing the extracellular unbound FFA concentration ([FFA(o)]). [FFA(o)] was clamped at defined levels using complexes of FFA and bovine serum albumin. We show that FFA influx is slow, requiring about 300 s to reach steady state (rate constant similar to0.02 s(-1)) and saturable (K-o similar to 200 nM). Efflux is twice as fast as influx, for zero [FFA(o)], but decreases with increasing [FFA(o)]. Surprisingly, at steady state [FFA(i)] is 2-5-fold (average 2-fold) greater than [FFA(o)] and this [FFA(i)]/[FFA(o)] gradient is abolished by depleting cellular ATP. Our results indicate that FFA transport across adipocyte membranes is highly regulated, involving an ATP-driven pump and a mechanism for gating efflux that is sensitive to [FFA(o)]. These characteristics are well described by a membrane carrier model but are not consistent with FFA transport across the membrane's lipid phase. We suggest that these characteristics are important in regulating circulating FFA levels by the adipocyte.	Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Torrey Pines Institute for Molecular Studies, California	Kleinfeld, AM (corresponding author), Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA.	akleinfeld@tpims.org		Kampf, James/0000-0003-3050-3998	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058762] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58762] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Apple F.S., 2004, CLIN PROTEOMICS, V1, P41, DOI [10.1385/CP:1:1:041, DOI 10.1385/CP:1:1:041]; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Carlsson M, 2000, ARTERIOSCL THROM VAS, V20, P1588, DOI 10.1161/01.ATV.20.6.1588; Caserta F, 2001, AM J PHYSIOL-ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238; Civelek VN, 1996, P NATL ACAD SCI USA, V93, P10139, DOI 10.1073/pnas.93.19.10139; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; Hamilton JA, 1998, J LIPID RES, V39, P467; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kamp F, 2003, J BIOL CHEM, V278, P7988, DOI 10.1074/jbc.M206648200; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; Kleinfeld AM, 2000, J MEMBRANE BIOL, V175, P79, DOI 10.1007/s002320001056; Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; Nielsen S, 2003, J CLIN INVEST, V111, P981, DOI [10.1172/JCI16253, 10.1172/JCI200316253]; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1995, ANAL BIOCHEM, V229, P256, DOI 10.1006/abio.1995.1410; Richieri GV, 1999, MOL CELL BIOCHEM, V192, P87, DOI 10.1023/A:1006878421990; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; STORCH J, 1991, J BIOL CHEM, V266, P13473; STORCH J, 1989, J BIOL CHEM, V264, P10527; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Stump DD, 2001, J LIPID RES, V42, P509; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; WEISS TF, 1996, CELLULAR BIOPHYSICS, P360; Zakim D, 2000, J MEMBRANE BIOL, V176, P101, DOI 10.1007/s002320001080; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	42	39	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35775	35780		10.1074/jbc.M403630200	http://dx.doi.org/10.1074/jbc.M403630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199061	hybrid			2022-12-25	WOS:000223303400077
J	Todaka, H; Taniguchi, J; Satoh, J; Mizuno, A; Suzuki, M				Todaka, H; Taniguchi, J; Satoh, J; Mizuno, A; Suzuki, M			Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING TRPV4; CAPSAICIN-RECEPTOR; INFLAMMATORY HYPERALGESIA; CUTANEOUS THERMORECEPTORS; PAIN; HEAT; CARRAGEENAN; EXPRESSION; ACTIVATION; SENSATION	Animals sense various ranges of temperatures by cutaneous thermal stimuli. Transient receptor potential vanilloid 4 (TRPV4) is a cation channel activated at a warm temperature (over 30 degreesC) in exogenously expressed cells. We found in the present study that TRPV4 is essential in thermal hyperalgesia at a warm temperature in vivo. TRPV4-/- and TRPV4+/+ mice exhibited the same latency of escape from 35-50 degreesC hotplates. Neuronal activity in the femoral nerve, however, revealed that the number and activity level of neurons decreased in response to a warm temperature in TRPV4-/- mice. TRPV4-/- mice displayed a significantly longer latency to escape from the plates at 35-45 degreesC when hyperalgesia was induced by carrageenan without changes in foot volumes. TRPV4 therefore determines the sensitivity rather than the threshold of painful heat detection and plays an essential role in thermal hyperalgesia.	Jichi Med Sch, Dept Pharmacol, Div Mol Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, Div Mol Pharmacol, 3311-1 YAkushiji, Minami Kawachi, Tochigi 3290498, Japan.							Adelson DW, 1997, J NEUROPHYSIOL, V77, P2989, DOI 10.1152/jn.1997.77.6.2989; Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; ATANABE H, 2003, NATURE, V424, P434; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DIROSA M, 1972, J PHARM PHARMACOL, V24, P89, DOI 10.1111/j.2042-7158.1972.tb08940.x; HARDY JD, 1951, SCIENCE, V114, P149, DOI 10.1126/science.114.2954.149; HENSEL H, 1960, J PHYSIOL-LONDON, V153, P113, DOI 10.1113/jphysiol.1960.sp006522; IGGO A, 1969, J PHYSIOL-LONDON, V200, P403, DOI 10.1113/jphysiol.1969.sp008701; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Mansikka H, 2002, NEUROSCIENCE, V113, P339, DOI 10.1016/S0306-4522(02)00189-6; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Nackley AG, 2003, NEUROSCIENCE, V119, P747, DOI 10.1016/S0306-4522(03)00126-X; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tao F, 2003, NEUROSCIENCE, V120, P847, DOI 10.1016/S0306-4522(03)00362-2; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Wu WP, 2002, NEUROSCIENCE, V114, P523, DOI 10.1016/S0306-4522(02)00273-7; Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304-3959(00)00378-X	28	136	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35133	35138		10.1074/jbc.M406260200	http://dx.doi.org/10.1074/jbc.M406260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187078	hybrid			2022-12-25	WOS:000223303400003
J	Lee, GE; Yu, EY; Cho, CH; Lee, J; Muller, MT; Chung, IK				Lee, GE; Yu, EY; Cho, CH; Lee, J; Muller, MT; Chung, IK			DNA-protein kinase catalytic subunit-interacting protein KIP binds telomerase by interacting with human telomerase reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-STRAND OVERHANG; MAMMALIAN TELOMERASE; LENGTH MAINTENANCE; IMMORTAL CELLS; CANCER; PKCS; GENE; IDENTIFICATION; REPLICATION; REPEATS	Telomere homeostasis, a process that is essential for continued cell proliferation and genomic stability, is regulated by endogenous telomerase and a collection of associated proteins. In this paper, a protein called KIP ( previously reported as a protein that binds specifically to DNA-dependent protein kinase), has been identified as a telomerase-regulating activity based on the following pieces of evidence. First, complexes between KIP and the catalytic subunit of telomerase ( hTERT) were identified using the yeast two-hybrid technique. Second, antibodies specific to KIP immunoprecipitate human telomerase in cell-free extracts. Third, immunolocalization experiments demonstrate that KIP is a nuclear protein that co-localizes with hTERT in cells. Fourth, KIP binds to hTERT both in vitro and in vivo in the absence of human telomerase RNA or telomeric DNA, thus defining the catalytic subunit of telomerase as the site of physical interaction. Fifth, co-immunoprecipitation experiments suggest that KIP-hTERT complexes form readily in cells and that overexpression of KIP in telomerase-positive cells increases endogenous telomerase activity. Finally, continued overexpression of KIP ( 60 population doublings) resulted in cells with elongated telomeres; thus, KIP directly or indirectly stimulates telomerase activity through hTERT and contributes to telomere lengthening. The collective data in this paper suggest that KIP plays a positive role in telomere length maintenance and/or regulation and may represent a novel target for anti-cancer drug development.	Yonsei Univ, Dept Biol & Mol Aging Res Ctr, Seoul 120749, South Korea; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	Yonsei University; State University System of Florida; University of Central Florida	Chung, IK (corresponding author), Yonsei Univ, Dept Biol, Coll Sci, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr			NATIONAL CANCER INSTITUTE [R01CA098214] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chai WH, 2002, J BIOL CHEM, V277, P47242, DOI 10.1074/jbc.M208542200; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Danska JS, 1996, MOL CELL BIOL, V16, P5507; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hande P, 1999, GENOMICS, V56, P221, DOI 10.1006/geno.1998.5668; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kim JH, 2003, BIOCHEM J, V373, P523, DOI 10.1042/BJ20030363; Kim JH, 2003, MOL PHARMACOL, V63, P1117, DOI 10.1124/mol.63.5.1117; Kim JH, 2002, MOL CELLS, V13, P228; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Saito T, 1999, MAMM GENOME, V10, P315, DOI 10.1007/s003359900994; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	40	41	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34750	34755		10.1074/jbc.M401843200	http://dx.doi.org/10.1074/jbc.M401843200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190070	hybrid, Green Published			2022-12-25	WOS:000223134800081
J	Reiser, J; Oh, J; Shirato, I; Asanuma, K; Hug, A; Mundel, TM; Honey, K; Ishidoh, K; Kominami, E; Kreidberg, JA; Tomino, Y; Mundel, P				Reiser, J; Oh, J; Shirato, I; Asanuma, K; Hug, A; Mundel, TM; Honey, K; Ishidoh, K; Kominami, E; Kreidberg, JA; Tomino, Y; Mundel, P			Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha(3) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; ALPHA-3-BETA-1 INTEGRIN; MICE LACKING; AMINONUCLEOSIDE NEPHROSIS; EXTRACELLULAR-MATRIX; GLOMERULAR PROTEIN; PROCATHEPSIN-L; IN-VITRO; EXPRESSION; NEPHRIN	Podocyte foot process effacement and disruption of the slit diaphragm are typically associated with glomerular proteinuria and can be induced in rats by the injection of puromycin aminonucleoside. Here, we show that the induction of puromycin aminonucleoside nephrosis involves podocyte migration conducted by a coordinated interplay between the cysteine protease cathepsin L and alpha(3) integrin. Puromycin aminonucleoside treatment up-regulates cathepsin L expression in podocytes in vivo as well as expression and enzymatic activity of cathepsin L in podocytes in vitro. Isolated podocytes from mice lacking cathepsin L are protected from cell puromycin aminonucleoside-induced cell detachment. The functional significance of cathepsin L expression was underscored by the observation that puromycin aminonucleoside-induced cell migration was slowed down in cathepsin L-deficient podocytes and by the preservation of cell-cell contacts and expression of vital slit diaphragm protein CD2AP. Cathepsin L expression and activity were induced in podocytes lacking alpha(3) integrin. Similarly, acute functional inhibition of alpha(3) integrin in wild type podocytes with a blocking antibody increased the expression of cathepsin L activity. Downregulation of alpha(3) integrin protected against puromycin aminonucleoside-induced podocyte detachment. In summary, these data establish that podocyte foot process effacement is a migratory event involving a novel interplay between cathepsin L and alpha(3) integrin.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Juntendo Univ, Dept Med, Tokyo 1138421, Japan; Juntendo Univ, Dept Biochem, Tokyo 1138421, Japan; Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Munster, Dept Surg, D-48149 Munster, Germany; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Juntendo University; Juntendo University; Ruprecht Karls University Heidelberg; University of Munster; University of Washington; University of Washington Seattle; Harvard University; Boston Children's Hospital	Mundel, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Nephrol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	mundel@aecom.yu.edu	Kominami, Eiki/D-3802-2009; Hug, Andreas/O-5508-2014	Hug, Andreas/0000-0002-7764-1813	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064236, R01DK057683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 057683, DK 064236] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1992, AM J PATHOL, V141, P571; Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Asanuma K, 2002, KIDNEY INT, V62, P822, DOI 10.1046/j.1523-1755.2002.00539.x; AUTHIER F, 1995, J BIOL CHEM, V270, P15798, DOI 10.1074/jbc.270.26.15798; BARICOS WH, 1991, ARCH BIOCHEM BIOPHYS, V288, P468, DOI 10.1016/0003-9861(91)90222-5; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Cheng ZZ, 2003, KIDNEY INT, V63, P107, DOI 10.1046/j.1523-1755.2003.00726.x; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; JAT PS, 1991, P NATL ACAD SCI US, V88; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; KRETZLER M, 1996, AM J PHYSIOL, V271, P770; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NAKAMURA T, 1991, LAB INVEST, V64, P640; NISHIMURA Y, 1989, ARCH BIOCHEM BIOPHYS, V271, P400, DOI 10.1016/0003-9861(89)90289-0; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Saleem MA, 2002, AM J PATHOL, V161, P1459, DOI 10.1016/S0002-9440(10)64421-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Van den Berg JG, 2000, J AM SOC NEPHROL, V11, P413, DOI 10.1681/ASN.V113413; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; Wagner LA, 1999, EUR J IMMUNOL, V29, P2530, DOI 10.1002/(SICI)1521-4141(199908)29:08<2530::AID-IMMU2530>3.0.CO;2-2; Wang ZM, 1999, J CELL SCI, V112, P2925; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; WHITESIDE C, 1989, LAB INVEST, V61, P650	44	138	150	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34827	34832		10.1074/jbc.M401973200	http://dx.doi.org/10.1074/jbc.M401973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197181	hybrid			2022-12-25	WOS:000223134800091
J	Sarker, KP; Lee, KY				Sarker, KP; Lee, KY			L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway	ONCOGENE			English	Article						myoblast; differentiation; Cdk5; signaling	CYCLIN-DEPENDENT KINASE-5; P70 S6 KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; TYROSINE KINASE; GENE-EXPRESSION; GROWTH-FACTORS; MAP KINASE; ACTIVATION	Cdk5 regulates myogenesis but the signaling cascade through which Cdk5 modulates this process remains to be characterized. Here, we investigated whether PI3K, Akt, p70S6K, p38 MAPK, p44/42 MAPK, and Egr-1 serve as upstream regulators of Cdk5 during L6 myoblast differentiation. Upon serum reduction, we found that besides elevated expression of Cdk5 and its activator, p35, and increased Cdk5/p35 activity, Egr-1, Akt, p70S6K, and p38 MAPK activity were upregulated in differentiating L6 cells. However, p44/42 MAPK was downregulated and SAPK/JNK was unaffected. LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. The lack of LY294002 effect on p38 MAPK suggests that p38 MAPK activation is not associated with PI3K activation. Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation. LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation. Overexpression of dominant-negative-Akt also reduced Cdk5/p35 activity and myogenin expression, indicating that the PI3K-p70S6K-Egr-1-Cdk5 signaling cascade is linked to Akt activation. SB2023580, a p38 MAPK inhibitor, had no effect on p70S6K, Egr-1, or Cdk5 activity, suggesting that p38 MAPK activation lies in a pathway distinct from the PI3K-Akt-p70S6K-Egr-1 pathway that we identify as the upstream modulator of Cdk5 activity during L6 myoblast differentiation.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Cell Biol & Anat, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca						Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ARNOLD HH, 1992, SYM SOC EXP BIOL, V46, P37; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chen F, 2001, BLOOD, V97, P3763, DOI 10.1182/blood.V97.12.3763; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Gao CY, 1997, DEV GENET, V20, P267; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guidato S, 1998, J NEUROCHEM, V70, P335; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada S, 2001, DNA CELL BIOL, V20, P223, DOI 10.1089/104454901750219107; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LIU JW, 1991, J BIOL CHEM, V266, P5929; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2000, J MOL NEUROSCI, V15, P243, DOI 10.1385/JMN:15:3:243; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Winter B, 2000, J CELL SCI, V113, P4211; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zetser A, 2001, DEV BIOL, V240, P168, DOI 10.1006/dbio.2001.0465; ZHANG H, 1993, MOL BIOL CELL, V9, P897	46	40	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6064	6070		10.1038/sj.onc.1207819	http://dx.doi.org/10.1038/sj.onc.1207819			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208659				2022-12-25	WOS:000223261000006
J	Bertram, JG; Bloom, LB; D'Donnell, M; Goodman, MF				Bertram, JG; Bloom, LB; D'Donnell, M; Goodman, MF			Increased dNTP binding affinity reveals a nonprocessive role for Escherichia coli beta clamp with DNA polymerase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; SLIDING CLAMP; ERROR-PRONE; HOLOENZYME; PROCESSIVITY; MECHANISM; FIDELITY; REPLICATION; EXONUCLEASE; MUTATION	Replication forks often stall at undamaged or damaged template sites in Escherichia coli. Subsequent resumption of DNA synthesis occurs by replacing DNA polymerase III, which is bound to DNA by the beta-sliding clamp, with one of three damage-induced DNA polymerases II, IV, or V. The principal role of the beta clamp is to tether the normally weakly bound polmerases to DNA thereby increasing their processivities. DNA polymerase IV binds dNTP substrates with about 10-fold lower affinity compared with the other E. coli polymerases, which if left unchecked could hinder its ability to synthesize DNA in vivo. Here we report a new property for the beta clamp, which when bound to DNA polymerase IV results in a large increase in dNTP binding affinity that concomitantly increases the efficiency of nucleotide incorporation at normal and transiently slipped mispaired primer/template ends. Primer-template DNA slippage resulting in single nucleotide deletions is a biological hallmark of DNA polymerase IV infidelity responsible for enhancing cell fitness in response to stress. We show that the increased DNA polymerase IV-dNTP binding affinity is an intrinsic property of the DNA polymerase IV-beta clamp interaction and not an indirect consequence of an increased binding of DNA polymerase IV to DNA.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	University of Southern California; University of Southern California; State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, SHS172,Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@usc.edu	Bloom, Linda B/F-3684-2014		NIEHS NIH HHS [ES012259] Funding Source: Medline; NIGMS NIH HHS [GM55596, R01 GM055596, GM21422, GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM055596, R37GM038839, R01GM038839, R01GM021422] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Bull HJ, 2001, P NATL ACAD SCI USA, V98, P8334, DOI 10.1073/pnas.151009798; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Cai H, 1995, METHOD ENZYMOL, V262, P13; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Foster PL, 2000, COLD SPRING HARB SYM, V65, P21, DOI 10.1101/sqb.2000.65.21; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P54; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Wagner J, 2000, EMBO REP, V1, P484; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199	26	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33047	33050		10.1074/jbc.C400265200	http://dx.doi.org/10.1074/jbc.C400265200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15210708	hybrid			2022-12-25	WOS:000223039700004
J	Meyer, AS; Blandino, M; Spratt, TE				Meyer, AS; Blandino, M; Spratt, TE			Escherichia coli DNA polymerase I (Klenow fragment) uses a hydrogen-bonding fork from Arg(668) to the primer terminus and incoming deoxynucleotide triphosphate to catalyze DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE; NUCLEOTIDE INCORPORATION; REVERSE-TRANSCRIPTASE; TERNARY COMPLEXES; ACTIVE-SITE; SIDE-CHAINS; FIDELITY; BETA; RECOGNITION; CRYSTAL	Interactions between the minor groove of the DNA and DNA polymerases appear to play a major role in the catalysis and fidelity of DNA replication. In particular, Arg(668) of Escherichia coli DNA polymerase I ( Klenow fragment) makes a critical contact with the N-3-position of guanine at the primer terminus. We investigated the interaction between Arg(668) and the ring oxygen of the incoming deoxynucleotide triphosphate ( dNTP) using a combination of site-specific mutagenesis of the protein and atomic substitution of the DNA and dNTP. Hydrogen bonds from Arg(668) were probed with the site-specific mutant R668A. Hydrogen bonds from the DNA were probed with oligodeoxynucleotides containing either guanine or 3-deazaguanine (3DG) at the primer terminus. Hydrogen bonds from the incoming dNTP were probed with (1'R, 3'R, 4'R)- 1-[3-hydroxy-4-(triphosphorylmethyl) cyclopent-1-yl] uracil (dcUTP), an analog of dUTP in which the ring oxygen of the deoxyribose moiety was replaced by a methylene group. We found that the pre-steady-state parameter k(pol) was decreased 1,600 to 2,000-fold with each of the single substitutions. When the substitutions were combined, there was no additional decrease ( R668A and 3DG), a 5-fold decrease ( 3DG and dcUTP), and a 50-fold decrease ( R668A and dcUTP) in k(pol). These results are consistent with a hydrogen-bonding fork from Arg(668) to the primer terminus and incoming dNTP. These interactions may play an important role in fidelity as well as catalysis of DNA replication.	Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Valhalla, NY 10595 USA	American Health Foundation	Spratt, TE (corresponding author), Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, 1 Dana Rd, Valhalla, NY 10595 USA.	tspratt@ifcp.us	Blandino, Massimo/AAN-5871-2020	Blandino, Massimo/0000-0003-3719-2520; Spratt, Thomas/0000-0002-6805-3729	NATIONAL CANCER INSTITUTE [R01CA075074] Funding Source: NIH RePORTER; NCI NIH HHS [CA75074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Borer P., 1977, HDB BIOCH MOL BIOL, P589; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P4771; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dunn D. B., 1986, HDB BIOCH MOL BIOL, P65; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FRIEDMAN RA, 1995, BIOPHYS J, V69, P1528, DOI 10.1016/S0006-3495(95)80023-8; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Guckian KM, 2000, J AM CHEM SOC, V122, P2213, DOI 10.1021/ja9934854; Guo MJ, 1998, NUCLEIC ACIDS RES, V26, P1863, DOI 10.1093/nar/26.8.1863; Hendrickson CL, 2004, NUCLEIC ACIDS RES, V32, P2241, DOI 10.1093/nar/gkh542; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6717; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; PARKER WB, 1992, ANTIVIR RES, V19, P325, DOI 10.1016/0166-3542(92)90013-U; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEMIZAROV DG, 1994, FEBS LETT, V354, P187, DOI 10.1016/0014-5793(94)01123-0; Smirnov S, 2000, J BIOMOL STRUCT DYN, V17, P981, DOI 10.1080/07391102.2000.10506586; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; Spratt TE, 2001, BIOCHEMISTRY-US, V40, P2647, DOI 10.1021/bi002641c; Thompson EHZ, 2002, BIOCHEMISTRY-US, V41, P713, DOI 10.1021/bi0114271; Washington MT, 2003, P NATL ACAD SCI USA, V100, P5113, DOI 10.1073/pnas.0837578100; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202	40	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33043	33046		10.1074/jbc.C400232200	http://dx.doi.org/10.1074/jbc.C400232200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15210707	hybrid			2022-12-25	WOS:000223039700003
J	Tchen, CR; Brook, M; Saklatvala, J; Clark, AR				Tchen, CR; Brook, M; Saklatvala, J; Clark, AR			The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AU-RICH-ELEMENT; ZINC-FINGER PROTEINS; COLONY-STIMULATING FACTOR; EARLY-RESPONSE GENES; T-CELL-ACTIVATION; FACTOR-ALPHA; POSTTRANSCRIPTIONAL REGULATION; TNF-ALPHA; SIGNALING CASCADE	Tristetraprolin (TTP) is an mRNA-destabilizing protein that negatively regulates the expression of proinflammatory mediators such as tumor necrosis factor alpha, granulocyte/macrophage colony-stimulating factor, and cyclooxygenase 2. Here we investigate the regulation of TTP expression in the mouse macrophage cell line RAW264.7. We show that TTP mRNA is expressed in a biphasic manner following stimulation of cells with lipopolysaccharide and that the second phase of expression, like the first, is dependent on mitogen-activated protein kinase (MAPK) p38. MAPK p38 acts through a downstream kinase to stabilize TTP mRNA, and this stabilization is mediated by an adenosine/uridine-rich region at the 3'-end of the TTP 3'-untranslated region. Hence TTP is post-transcriptionally regulated in a similar manner to several proinflammatory genes. We also demonstrate that TTP is able to bind to its own 3'-untranslated region and negatively regulate its own expression, forming a feedback loop to limit expression levels.	Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Imperial College London; University of Oxford	Clark, AR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, 1 Aspenlea Rd, London W6 8LH, England.	andy.clark@ic.ac.uk	Clark, Andrew/AAN-4043-2021; Brook, Matthew/I-5828-2019	Brook, Matthew/0000-0003-1245-7385; Clark, Andy/0000-0003-4996-8322				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Fairhurst AM, 2003, ARTHRITIS RES THER, V5, pR214, DOI 10.1186/ar778; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; MA QF, 1994, ONCOGENE, V9, P3329; Maclean KN, 1998, BRIT J BIOMED SCI, V55, P184; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Ogawa K, 2003, J BIOL CHEM, V278, P30373, DOI 10.1074/jbc.M304856200; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Shim J, 2002, MOL CELLS, V14, P323; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Suzuki K, 2003, J EXP MED, V198, P1717, DOI 10.1084/jem.20031701; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Yu H, 2003, J BIOL CHEM, V278, P13912, DOI 10.1074/jbc.M213027200; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	67	122	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32393	32400		10.1074/jbc.M402059200	http://dx.doi.org/10.1074/jbc.M402059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15187092	hybrid			2022-12-25	WOS:000222849700052
J	Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S				Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S			Interplay between scatter factor receptors and B plexins controls invasive growth	ONCOGENE			English	Article						Scatter Factor Receptors; B plexins; invasive growth; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE; SEMAPHORIN RECEPTORS; MET PROTOONCOGENE; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-PRODUCT; ACTIVE RAC; RON GENE; HGF	Met and Ron tyrosine kinases are members of the Scatter Factor Receptor family. Met is the receptor for hepatocyte growth factor while Ron is that for macrophage stimulating protein. On ligand stimulation, activation of these receptors induces 'invasive growth', a complex biological response involved in tissue morphogenesis and, when deregulated, in tumor progression and metastasis. Scatter Factor Receptors share structural homology with Plexins, transmembrane receptors for Semaphorins, a family of ligands originally identified as axon guidance molecules. A physical and functional association between Met and Plexin B1, the prototype of class B Plexin subfamily, has been previously demonstrated. Here, we show that both Met and Ron receptors can interact with each of the three members of class B Plexins, even in the absence of their ligands and that Plexin B1 ligand, Sema 4D, can induce activation of Met and Ron receptors, promoting an invasive response. Furthermore, in some human neoplastic cell lines Plexin B1 is overexpressed, constitutively tyrosine phosphorylated, and associated with Scatter Factor Receptors. These data extend the crosstalk previously described between Met and Plexin B1 to the entire families of Scatter Factor Receptors and class B Plexins and show that interaction with multiple upstream activators can finely tune the invasive growth process both in physiological conditions and in tumor growth and metastatization.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy	University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503				Artigiani S, 2003, J BIOL CHEM, V278, P10094, DOI 10.1074/jbc.M210156200; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park WS, 1999, CANCER RES, V59, P307; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	38	136	153	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5131	5137		10.1038/sj.onc.1207650	http://dx.doi.org/10.1038/sj.onc.1207650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15184888				2022-12-25	WOS:000222382500003
J	Cho, HY; Reddy, SPM; Yamamoto, M; Kleeberger, SR				Cho, HY; Reddy, SPM; Yamamoto, M; Kleeberger, SR			The transcription factor NRF2 protects against pulmonary fibrosis	FASEB JOURNAL			English	Article						bleomycin; reactive oxygen species; oxidative stress; lung; knockout mice; antioxidant	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED LUNG INJURY; GENE-EXPRESSION; ALVEOLAR BRONCHIOLIZATION; INTRATRACHEAL BLEOMYCIN; SUPEROXIDE-DISMUTASE; AIRWAY EPITHELIUM; OXIDATIVE STRESS; KNOCKOUT MICE; INDUCTION	The molecular mechanisms of pulmonary fibrosis are poorly understood, although reactive oxygen species are thought to have an important role. NRF2 is a transcription factor that protects cells and tissues from oxidative stress by activating protective antioxidant and detoxifying enzymes. We hypothesized that NRF2 protects lungs from injury and fibrosis induced by bleomycin, an anti-neoplastic agent that causes pulmonary fibrosis in susceptible patients. To test this hypothesis, mice with targeted deletion of Nrf2 (Nrf2(-/-)) and wild-type (Nrf2(+/+)) mice were treated with bleomycin or vehicle, and pulmonary injury and fibrotic responses were compared. Bleomycin-induced increases in lung weight, epithelial cell death, and inflammation were significantly greater in Nrf2(-/-) mice than in Nrf2(+/+) mice. Indices of lung fibrosis (hydroxyproline content, collagen accumulation, fibrotic score, cell proliferation) were significantly greater in bleomycin-treated Nrf2(-/-) mice, compared with Nrf2(+/+) mice. NRF2 expression and activity were elevated in Nrf2(+/+) mice by bleomycin. Bleomycin caused greater up-regulation of several NRF2-inducible antioxidant enzyme genes and protein products in Nrf2(+/+) mice compared with Nrf2(-/-) mice. Further, bleomycin-induced transcripts and protein levels of lung injury and fibrosis markers were significantly attenuated in Nrf2(+/+) mice compared with Nrf2(-/-) mice. Results demonstrated that NRF2 has a critical role in protection against pulmonary fibrosis, presumably through enhancement of cellular antioxidant capacity. This study has important implications for the development of intervention strategies against fibrosis.	NIEHS, Resp Biol Lab, Res Triangle Pk, NC 27709 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; University of Tsukuba; University of Tsukuba	Cho, HY (corresponding author), NIEHS, Resp Biol Lab, 111 TW Alexander Dr,Bd 101,MD D-201, Res Triangle Pk, NC 27709 USA.	cho2@niehs.nih.gov	Yamamoto, Masayuki/A-4873-2010; Kleeberger, Steven R/F-1807-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Kleeberger, Steven R/0000-0003-2948-8452	NHLBI NIH HHS [HL-66109] Funding Source: Medline; NIEHS NIH HHS [ES-03819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES100513, P30ES003819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMSON IY, 1997, LAB INVEST, V36, P26; ADAMSON IYR, 1984, AM J PATHOL, V117, P37; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Arras M, 2001, AM J RESP CELL MOL, V24, P368, DOI 10.1165/ajrcmb.24.4.4249; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Beeh KM, 2002, EUR RESPIR J, V19, P1119, DOI 10.1183/09031936.02.00262402; Betsuyaku T, 2000, AM J PATHOL, V157, P525, DOI 10.1016/S0002-9440(10)64563-4; Bowler RP, 2002, AM J PHYSIOL-LUNG C, V282, pL719, DOI 10.1152/ajplung.00058.2001; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; CHANG M, 1990, J BIOL CHEM, V265, P5418; Chen ES, 2001, AM J RESP CELL MOL, V24, P545, DOI 10.1165/ajrcmb.24.5.4064; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Daly HE, 1998, LAB INVEST, V78, P393; Day RM, 2002, AM J PHYSIOL-LUNG C, V282, pL1349, DOI 10.1152/ajplung.00338.2001; Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FANTONE JC, 1988, FREE RADICAL BIO MED, V4, P399, DOI 10.1016/0891-5849(88)90091-3; Gon Y, 2001, LIFE SCI, V68, P1877, DOI 10.1016/S0024-3205(01)00980-8; HECHT SM, 1986, FASEB J, V45, P2784; Hoshino T, 2003, AM J RESP CRIT CARE, V168, P1075, DOI 10.1164/rccm.200209-982OC; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; ISHIDA R, 1975, BIOCHEM BIOPH RES CO, V66, P1432, DOI 10.1016/0006-291X(75)90519-7; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Keane MP, 2001, AM J PHYSIOL-LUNG C, V281, pL92, DOI 10.1152/ajplung.2001.281.1.L92; Kunugi S, 2001, LAB INVEST, V81, P1309, DOI 10.1038/labinvest.3780344; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; LEDWOZYW A, 1991, ACTA VET HUNG, V39, P215; Liu JY, 2001, AM J RESP CELL MOL, V25, P3, DOI 10.1165/ajrcmb.25.1.4481; NETTESHEIM P, 1972, LAB INVEST, V26, P210; Poli P, 1999, MUTAGENESIS, V14, P233, DOI 10.1093/mutage/14.2.233; Sekhar KR, 2003, CANCER RES, V63, P5636; SELMAN M, 1989, EXP MOL PATHOL, V50, P147, DOI 10.1016/0014-4800(89)90027-0; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; TOH K, 1999, GENE DEV, V13, P76; White ES, 2003, J PATHOL, V201, P343, DOI 10.1002/path.1446; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	45	278	287	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1258	+		10.1096/fj.03-1127fje	http://dx.doi.org/10.1096/fj.03-1127fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208274				2022-12-25	WOS:000222327500020
J	Cellini, B; Bertoldi, M; Paiardini, A; D'Aguanno, S; Voltattorni, CB				Cellini, B; Bertoldi, M; Paiardini, A; D'Aguanno, S; Voltattorni, CB			Site-directed mutagenesis provides insight into racemization and transamination of alanine catalyzed by Treponema denticola cystalysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; BACILLUS-STEAROTHERMOPHILUS; SERINE HYDROXYMETHYLTRANSFERASE; ASPARTATE-AMINOTRANSFERASE; PYRIDOXAL 5'-PHOSPHATE; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; LYSINE 39; RACEMASE	In addition to alpha, beta-elimination of L-cysteine, Treponema denticola cystalysin catalyzes the racemization of both enantiomers of alanine accompanied by an overall transamination. Lys-238 and Tyr-123 or a water molecule located on the si and re face of the cofactor, respectively, have been proposed to act as the acid/base catalysts in the proton abstraction/ donation at Calpha/C4' of the external aldimine. In this investigation, two site-directed mutants, K238A and Y123F, have been characterized. The Lys --> Ala mutation results in the complete loss of either lyase activity or racemase activity in both directions or transaminase activity toward L-alanine. However, the K238A mutant is able to catalyze the overall transamination of D-alanine, and only D-alanine is the product of the reverse transamination. For Y123F the k(cat)/K-m is reduced 3.5-fold for alpha,beta-elimination, whereas it is reduced 300-400-fold for racemization. Y123F has similar to18% of wild type transaminase activity with L-alanine and an extremely low transaminase activity with D-alanine. Moreover, the catalytic properties of the Y124F and Y123F/Y124F mutants rule out the possibility that the residual racemase and transaminase activities displayed by Y123F are due to Tyr-124. All these data, together with computational results, indicate a two-base racemization mechanism for cystalysin in which Lys-238 has been unequivocally identified as the catalyst acting on the si face of the cofactor. Moreover, this study highlights the importance of the interaction of Tyr-123 with water molecules for efficient proton abstraction/ donation function on the re face.	Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; CNR, Ctr Biol Mol, I-00185 Rome, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Voltattorni, CB (corresponding author), Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, Str Le Grazie 8, I-37134 Verona, Italy.	carla.borrivoltattorni@univr.it	Bertoldi, Mariarita/F-1154-2010; Paiardini, Alessandro/G-8058-2011; D'Aguanno, Simona/H-2179-2016; Cellini, Barbara/AAC-6401-2019	Bertoldi, Mariarita/0000-0002-2337-9928; D'Aguanno, Simona/0000-0002-1224-4454; Cellini, Barbara/0000-0002-5221-9288; Paiardini, Alessandro/0000-0001-9078-7545				Bertoldi M, 2003, J BIOL CHEM, V278, P37336, DOI 10.1074/jbc.M305967200; Bertoldi M, 2002, BIOCHEMISTRY-US, V41, P9153, DOI 10.1021/bi025649q; Bertoldi M, 2003, BIOCHEM J, V371, P473, DOI 10.1042/BJ20020875; Bertoldi M, 2000, BIOCHEM J, V352, P533, DOI 10.1042/0264-6021:3520533; CHEN HY, 1993, BIOCHEMISTRY-US, V32, P11591, DOI 10.1021/bi00094a016; CHU L, 1995, INFECT IMMUN, V63, P4448, DOI 10.1128/IAI.63.11.4448-4455.1995; Chu L, 1997, INFECT IMMUN, V65, P3231, DOI 10.1128/IAI.65.8.3231-3238.1997; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Kielkopf CL, 2002, BIOCHEMISTRY-US, V41, P11711, DOI 10.1021/bi020393+; KOCHHAR S, 1992, EUR J BIOCHEM, V203, P563, DOI 10.1111/j.1432-1033.1992.tb16584.x; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; MALASHKEVICH VN, 1995, BIOCHEMISTRY-US, V34, P405, DOI 10.1021/bi00002a004; Mustata GI, 2003, BIOPOLYMERS, V70, P186, DOI 10.1002/bip.10425; Okamoto A, 1998, J MOL BIOL, V280, P443, DOI 10.1006/jmbi.1998.1869; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; Sugio S, 1998, PROTEIN ENG, V11, P613, DOI 10.1093/protein/11.8.613; Sun SX, 1999, BIOCHEMISTRY-US, V38, P4058, DOI 10.1021/bi982924t; Trivedi V, 2002, J BIOL CHEM, V277, P17161, DOI 10.1074/jbc.M111976200; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189; Watanabe A, 1999, J BIOCHEM-TOKYO, V126, P781, DOI 10.1093/oxfordjournals.jbchem.a022517; Watanabe A, 2002, J BIOL CHEM, V277, P19166, DOI 10.1074/jbc.M201615200	23	10	10	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36898	36905		10.1074/jbc.M404449200	http://dx.doi.org/10.1074/jbc.M404449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210695	hybrid			2022-12-25	WOS:000223453600092
J	Reynolds, PR; Mucenski, ML; Le Cras, TD; Nichols, WC; Whitsett, JA				Reynolds, PR; Mucenski, ML; Le Cras, TD; Nichols, WC; Whitsett, JA			Midkine is regulated by hypoxia and causes pulmonary vascular remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; GROWTH-FACTOR MIDKINE; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; LUNG MORPHOGENESIS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; MOUSE EMBRYOGENESIS; HIGH-ALTITUDE; BETA-CATENIN	Midkine (MK) is expressed in a precise temporal-spatial pattern during lung morphogenesis; however, its role in pulmonary homeostasis is unknown. Increased MK staining and mRNA expression were observed in the lungs of hypoxia-susceptible CAST/eiJ mice during hypoxia. MK expression was induced by hypoxia in cell lines in vitro. Because the transcription factor hypoxia-inducible factor-1alpha (HIF-1alpha) modulates cellular responses to hypoxia, we tested whether increased expression of MK in the lung was mediated by HIF-1alpha. HIF-1alpha enhanced the transcription of MK, acting on HIF-1alpha regulatory elements located in the MK gene promoter. Site-directed mutagenesis of the 3' HIF response element in the MK promoter blocked the stimulatory effects of HIF-1alpha. To directly assess the role of MK on lung morphogenesis, transgenic mice were generated in which MK was expressed in the respiratory epithelial cells of the developing lung. MK increased muscularization of small pulmonary arteries, increasing alpha-smooth muscle actin and caldesmon staining and the expression of myocardin. MK directly enhanced the expression of myocardin and the smooth muscle-specific genes alpha-smooth muscle actin, calponin, and SM-22 in vascular smooth muscle precursor cells. Expression of MK in the respiratory epithelium is regulated by hypoxia and HIF-1alpha. These data provide a model wherein the respiratory epithelium responds to hypoxia via HIF-1alpha-dependent regulation of MK, enhancing myocardin expression to influence pulmonary vascular gene expression.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Whitsett, JA (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org		Le Cras, Timothy/0000-0001-8538-2703; Reynolds, Paul/0000-0002-0931-3025	NHLBI NIH HHS [HL 75770, HL 72058, HL 56387, HL 38859] Funding Source: Medline; NICHD NIH HHS [HD 07463] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, R01HL038859, P50HL056387, P01HL072058, R37HL038859, R01HL075770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akeson AL, 2000, DEV DYNAM, V217, P11, DOI 10.1002/(SICI)1097-0177(200001)217:1<11::AID-DVDY2>3.0.CO;2-L; Arakawa E, 2000, FEBS LETT, V481, P193, DOI 10.1016/S0014-5793(00)01995-5; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Choudhuri R, 1997, CANCER RES, V57, P1814; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GHARMA ZW, 2003, CLEVE CLIN J MED S1, V70, P2; Gorenflo M, 2003, CARDIOL YOUNG, V13, P219, DOI 10.1017/S1047951103000453; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kaplan F, 2003, AM J RESP CELL MOL, V28, P33, DOI 10.1165/rcmb.2002-0047OC; Kulikova N, 2003, J MUSCLE RES CELL M, V24, P7, DOI 10.1023/A:1024843409429; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Le Cras TD, 2003, AM J PHYSIOL-LUNG C, V285, pL1046, DOI 10.1152/ajplung.00045.2003; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Llorente-Cortes V, 2002, CIRCULATION, V106, P3104, DOI 10.1161/01.CIR.0000041434.28573.0B; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Niermeyer S, 2003, HIGH ALT MED BIOL, V4, P225, DOI 10.1089/152702903322022820; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RABINOVITCH M, 1979, AM J PHYSIOL, V236, P818; Reynolds PR, 2003, DEV DYNAM, V227, P227, DOI 10.1002/dvdy.10304; Rossi GP, 2002, CARDIOVASC RES, V55, P178, DOI 10.1016/S0008-6363(02)00400-5; Schoene RB, 1999, ADV EXP MED BIOL, V474, P47; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shibata Y, 2002, MOL CELL BIOL, V22, P6788, DOI 10.1128/MCB.22.19.6788-6796.2002; Takada T, 1997, J BIOCHEM-TOKYO, V122, P453; Thomas BJ, 2003, EUR J PHARMACOL, V477, P153, DOI 10.1016/j.ejphar.2003.08.015; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; Toriyama K, 1997, DIFFERENTIATION, V61, P161, DOI 10.1046/j.1432-0436.1997.6130161.x; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; Veyssier-Belot C, 1999, CARDIOVASC RES, V44, P274, DOI 10.1016/S0008-6363(99)00230-8; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; YU H, 1993, J HYPERTENS, V11, P1347, DOI 10.1097/00004872-199312000-00005; Zaidi SHE, 2002, CIRCULATION, V105, P516, DOI 10.1161/hc0402.102866; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	51	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37124	37132		10.1074/jbc.M405254200	http://dx.doi.org/10.1074/jbc.M405254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15197188	hybrid			2022-12-25	WOS:000223453600116
J	Villafuerte, BC; Phillips, LS; Rane, MJ; Zhao, WD				Villafuerte, BC; Phillips, LS; Rane, MJ; Zhao, WD			Insulin-response element-binding protein 1 - A novel Akt substrate involved in transcriptional action of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; FORKHEAD; IDENTIFICATION; FKHR; PHOSPHORYLATION; TRANSDUCTION; RECOGNITION; METABOLISM; CLEAVAGE; CLONING	Although the cis-acting elements that mediate the actions of insulin on gene transcription have been defined for a significant number of genes, the transcription factors responsible for the transactivation of these target sequences remain unknown. In this report, we identified a novel transcription factor that binds and transactivates the insulin-response elements of the insulin-like growth factor-binding protein-3 and other insulin responsive genes. This factor is a target of insulin signal transduction downstream of the phosphatidylinositol 3'-kinase/protein kinase B (Akt) pathway. Akt phosphorylates this factor in vivo and in vitro. Changes in expression level, phosphorylation, and nuclear translocation modulate the transactivation effects of the factor, and its expression is decreased in conditions of diabetes and insulin deficiency. Identification of a novel target of Akt that appears to mediate signals specific for insulin action should provide further insight into the mechanism of insulin action at the genomic level.	Univ Louisville, Dept Med, Div Endocrinol & Metab, Louisville, KY 40202 USA; Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Atlanta, GA 30322 USA; Univ Louisville, Dept Med, Div Nephrol, Louisville, KY 40202 USA	University of Louisville; Emory University; University of Louisville	Villafuerte, BC (corresponding author), Univ Louisville, Dept Med, Div Endocrinol & Metab, Louisville, KY 40202 USA.	bcvill01@louisville.edu			NIDDK NIH HHS [DK 52965] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052965] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO;2-M; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; Heldin CH, 2001, SCIENCE, V294, P2111, DOI 10.1126/science.1067628; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kimble J, 1998, TRENDS BIOCHEM SCI, V23, P353, DOI 10.1016/S0968-0004(98)01263-8; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Krammer A, 1999, P NATL ACAD SCI USA, V96, P1351, DOI 10.1073/pnas.96.4.1351; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Lim SP, 2000, J VIROL, V74, P1632, DOI 10.1128/JVI.74.4.1632-1640.2000; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SCHMID RM, 1992, AM J PHYSIOL, V262, pG971, DOI 10.1152/ajpgi.1992.262.6.G971; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; VILLAFUERTE BC, 1994, ENDOCRINOLOGY, V134, P2044, DOI 10.1210/en.134.5.2044; Villafuerte BC, 1997, J BIOL CHEM, V272, P5024, DOI 10.1074/jbc.272.8.5024; VILLAFUERTE BC, 1991, DIABETES, V40, P837, DOI 10.2337/diabetes.40.7.837; Zhu JL, 1999, ENDOCRINOLOGY, V140, P4761, DOI 10.1210/en.140.10.4761; Zhu JL, 2000, MOL CELL ENDOCRINOL, V164, P205, DOI 10.1016/S0303-7207(00)00207-0	40	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36650	36659		10.1074/jbc.M404349200	http://dx.doi.org/10.1074/jbc.M404349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194686	hybrid			2022-12-25	WOS:000223453600064
J	Ahn, SK; Shenoy, SK; Wei, HJ; Lefkowitz, RJ				Ahn, SK; Shenoy, SK; Wei, HJ; Lefkowitz, RJ			Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; MAP KINASE; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT DEGRADATION; CLATHRIN ADAPTER; TRANSDUCTION; INTERNALIZATION; BETA-ARRESTIN-2; ENDOCYTOSIS	The seven-membrane-spanning angiotensin II type 1A receptor activates the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2) by distinct pathways dependent on either G protein (likely G(q)/G(11)) or beta-arrestin2. Here we sought to distinguish the kinetic and spatial patterns that characterize ERK1/2 activated by these two mechanisms. We utilized beta-arrestin RNA interference, the protein kinase C inhibitor Ro-31-8425, a mutant angiotensin II receptor (DRY/AAY), and a mutant angiotensin II peptide (SII-angiotensin), which are incapable of activating G proteins, to isolate the two pathways in HEK-293 cells. G protein-dependent activation was rapid (peak<2 min), quite transient (t(1/2) similar to 2 min), and led to nuclear translocation of the activated ERK1/2 as assessed by confocal microscopy. In contrast, beta-arrestin2-dependent activation was slower (peak 5-10 min), quite persistent with little decrement noted out to 90 min, and entirely confined to the cytoplasm. Moreover, ERK1/2 activated via beta-arrestin2 accumulated in a pool of cytoplasmic endosomal vesicles that also contained the internalized receptors and beta-arrestin. Such differential regulation of the temporal and spatial patterns of ERK1/2 activation via these two pathways strongly implies the existence of distinct physiological endpoints.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Shenoy, Sudha/AAN-4075-2021; Lefkowitz, Robert/AAW-2649-2021	Shenoy, Sudha/0000-0002-2565-4663; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 70631, R01 HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE RM, 1992, J BIOL CHEM, V267, P1088; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; RAY LB, 1988, J BIOL CHEM, V263, P12721; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	40	403	413	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35518	35525		10.1074/jbc.M405878200	http://dx.doi.org/10.1074/jbc.M405878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205453	hybrid			2022-12-25	WOS:000223303400046
J	Xin, H; Pereira-Smith, OM; Choubey, D				Xin, H; Pereira-Smith, OM; Choubey, D			Role of IFI 16 in cellular senescence of human fibroblasts	ONCOGENE			English	Article						interferon-inducible IFI 16; fibroblasts; senescence; immortalization; DNA methylation	HUMAN TELOMERASE; NEGATIVE REGULATOR; ID PROTEINS; INTERFERON; EXPRESSION; GENE; FAMILY; CELLS; P202; P53	Defects in interferon (IFN) signaling that result in loss of expression of IFN-inducible proteins are associated with cellular immortalization, an important early event in the development of human cancer. Here we report that loss of IFN-inducible IFI 16 expression in human fibroblasts allows bypass of cellular senescence. We found that levels of IFI 16 mRNA and protein were higher in human old versus young fibroblasts and immortalization of fibroblasts with telomerase resulted in decreased expression of IFI 16. Moreover, overexpression of IFI 16 in immortalized fibroblasts strongly inhibited cell proliferation. Interestingly, knockdown of IFI 16 expression in fibroblasts inhibited p53-mediated transcription, downregulated p21(WAF1) expression, and extended the proliferation potential. Importantly, treatment of immortal cell lines with 5-aza-2'-deoxycytidine, an inhibitor of DNA methyltransferase, resulted in upregulation of IFI 16. Our observations support the idea that increased levels of IFI 16 in older populations of human fibroblasts contribute to cellular senescence.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Ctr Longet & Aging Studies, San Antonio, TX USA	Loyola University Chicago; University of Texas System; University of Texas Health San Antonio	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NATIONAL INSTITUTE ON AGING [P01AG020752, R03AG022124] Funding Source: NIH RePORTER; NIA NIH HHS [AG022124, P01 AG20752] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Akca H, 2003, SCAND J CLIN LAB INV, V63, P505, DOI 10.1080/00365510310003382; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUJIUCHI N, 2004, J BIOL CHEM     0227; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Kwak JC, 2003, J BIOL CHEM, V278, P40899, DOI 10.1074/jbc.M308012200; Lee SH, 2003, ONCOGENE, V22, P381, DOI 10.1038/sj.onc.1206133; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Untergasser G, 2002, CANCER RES, V62, P6255; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200	44	55	59	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6209	6217		10.1038/sj.onc.1207836	http://dx.doi.org/10.1038/sj.onc.1207836			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208661				2022-12-25	WOS:000223399000005
J	Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Gonnelli, L; Mangani, S				Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Gonnelli, L; Mangani, S			Solution structure of Cox11, a novel type of beta-immunoglobulin-like fold involved in Cu-B site formation of cytochrome C oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; TORSION ANGLE DYNAMICS; COPPER CHAPERONE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; NMR STRUCTURE; SUPEROXIDE-DISMUTASE; REGULATORY DOMAIN; BACILLUS-SUBTILIS; PROTEIN NMR	Cytochrome c oxidase assembly process involves many accessory proteins including Cox11, which is a copper-binding protein required for Cu incorporation into the Cu-B site of cytochrome c oxidase. In a genome wide search, a number of Cox11 homologs are found in all of the eukaryotes with complete genomes and in several Gram-negative bacteria. All of them possess a highly homologous soluble domain and contain an N-terminal fragment that anchors the protein to the membrane. An anchor-free construct of 164 amino acids was obtained from Sinorhizobium meliloti, and the first structure of this class of proteins is reported here. The apoform has an immunoglobulin-like fold with a novel type of beta-strand organization. The copper binding motif composed of two highly conserved cysteines is located on one side of the beta-barrel structure. The apoprotein is monomeric in the presence of dithiothreitol, whereas it dimerizes in the absence of the reductant. When copper(I) binds, NMR and extended x-ray absorption fine structure (EXAFS) data indicate a dimeric protein state with two thiolates bridging two copper(I) ions. The present results advance the knowledge on the poorly understood molecular aspects of cytochrome c oxidase assembly.	Univ Florence, CERM, Magnet Resonance Ctr, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy	University of Florence; University of Florence; University of Siena	Bertini, I (corresponding author), Univ Florence, CERM, Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Florence, Italy.	ivanobertini@cerm.unifi.it	Ciofi-Baffoni, Simone/AAH-9778-2021; Cantini, Francesca/O-1220-2015	Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774; Ciofi Baffoni, Simone/0000-0002-2376-3321				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; ATKINSON ER, 1985, INORG CHIM A-ART LET, V100, P285, DOI 10.1016/S0020-1693(00)85299-8; Banci L, 2003, BIOCHEMISTRY-US, V42, P2467, DOI 10.1021/bi0205810; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Bertinia I, 2003, J BIOMOL NMR, V26, P355, DOI 10.1023/A:1024092421649; Binsted N, 1996, J SYNCHROTRON RADIAT, V3, P185, DOI 10.1107/S0909049596005651; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bullock TL, 1996, J MOL BIOL, V263, P284, DOI 10.1006/jmbi.1996.0575; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Einstein A, 1956, INVESTIGATIONS THEOR; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; LYTLE FW, 1989, PHYS REV B, V11, P2795; Mattatall NR, 2000, J BIOL CHEM, V275, P28802, DOI 10.1074/jbc.M002741200; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; PARNES JR, 1989, ADV IMMUNOL, V44, P265; Pearlman DA, 1997, AMBER 5 0; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; Stokes G. G., 1856, T CAMBRIDGE PHILOS S, V9, P5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8	64	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34833	34839		10.1074/jbc.M403655200	http://dx.doi.org/10.1074/jbc.M403655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181013	hybrid			2022-12-25	WOS:000223134800092
J	Erler, I; Hirnet, D; Wissenbach, U; Flockerzi, V; Niemeyer, BA				Erler, I; Hirnet, D; Wissenbach, U; Flockerzi, V; Niemeyer, BA			Ca2+-selective transient receptor potential V channel architecture and function require a specific ankyrin repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; K+ CHANNELS; VANILLOID RECEPTOR-1; CAT-LIKE; TRPV6; EXPRESSION; PROTEIN; ASSOCIATION; COMPLEX; DOMAIN	Transient receptor potential (TRP) proteins form cation-conducting ion channels with currently 28 known genes encoding TRP channel monomers in mammals. These monomers are thought to coassemble to form homo- or heterotetrameric channels, but the signals governing their assembly are unknown. Within the TRPV subgroup, TRPV5 and TRPV6 show exclusive calcium selectivity and play an important role in calcium uptake. To identify signals that mediate assembly of functional TRPV6, we screened domains for self-association using co-immunoprecipitation, sucrose gradient centrifugation, bacterial two-hybrid assays, and patch clamp analysis. Of the two identified interaction domains within the N-terminal region, we showed that the first domain encompassing the third ankyrin repeat is the stringent requirement for physical assembly of TRPV6 subunits and when transferred to an unrelated protein enables its interaction with TRPV6. Deletion of this repeat or mutation of critical residues within this repeat rendered nonfunctional channels that do not co-immunoprecipitate or form tetramers. Suppression of dominant-negative inhibitors of TRPV6-specific currents was achieved by deletion of ankyrin (ANK) 3. We propose that the third ANK repeat initiates a molecular zippering process that proceeds past the fifth ANK repeat and creates an intracellular anchor that is necessary for functional subunit assembly.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany	Saarland University	Niemeyer, BA (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, Geb 46, D-66421 Homburg, Germany.	barbara.niemeyer@uniklinik-saarland.de	Niemeyer, Barbara A./AAL-8972-2021	Niemeyer, Barbara A./0000-0002-6963-0575				Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jonas-Straube E, 2001, J BIOL CHEM, V276, P24654, DOI 10.1074/jbc.M100153200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mery L, 2002, J CELL SCI, V115, P3497; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTELL C, 2001, SCI STKE, V90, P1; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Sheng ZF, 1997, BIOCHEMISTRY-US, V36, P15501; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	30	101	108	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34456	34463		10.1074/jbc.M404778200	http://dx.doi.org/10.1074/jbc.M404778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192090	hybrid			2022-12-25	WOS:000223134800047
J	Hermit, MB; Greenwood, JR; Brauner-Osborne, H				Hermit, MB; Greenwood, JR; Brauner-Osborne, H			Mutation-induced quisqualic acid and ibotenic acid affinity at the metabotropic glutamate receptor subtype 4 - Ligand selectivity results from a synergy of several amino acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; MGLUR4 SUBTYPE; ACTIVATION; MUTAGENESIS; EXPRESSION; POCKET; RAT	The metabotropic glutamate receptors (mGluRs) are key modulators of excitatory neurotransmission in the central nervous system. The eight mGluR subtypes are seven trans-membrane-spanning proteins that possess a large extracellular amino-terminal domain in which the endogenous ligand binding pocket resides. In this study, we have identified four non-conserved amino acid residues that are essential for differentiating mGluR1 from mGluR4. Our approach has been to increase the affinity of the classic mGluR1 agonists, quisqualic acid and ibotenic acid, at mGluR4 by making various point mutations that mimicked mGluR1 residues. Based on ligand docking to homology models, the non-conserved residues, Lys-74, Glu-287, Ser-313, and Lys-317, were chosen for the mutational studies and all of the mutations proved capable of partially or completely restoring the affinities of the ligands. In particular, the mutations K74Y and K317R induced dramatic triple-order-of-magnitude increases in the affinity of ibotenic acid at mGluR4, making the affinity equivalent to that of mGluR1. Furthermore, the affinity of quisqualic acid at mGluR4 was increased to the same level as mGluR1 by the two double mutations, K74Y/K317R and K74Y/E287G. Advanced analysis of ligand conformation and docking procedures were used for the interpretation of these results. The study shows that mGluR subtype selectivity results from a complex interplay of residues shaping the binding pocket, rather than being attributable to a single specific ligand-receptor interaction.	Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark	University of Copenhagen	Brauner-Osborne, H (corresponding author), Danish Univ Pharmaceut Sci, Dept Med Chem, Univ Pk 2, DK-2100 Copenhagen, Denmark.	hbo@molpharm.net	Bräuner-Osborne, Hans/D-7260-2011	Bräuner-Osborne, Hans/0000-0001-9495-7388				Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Brauner-Osborne H, 1998, EUR J PHARMACOL, V350, P311, DOI 10.1016/S0014-2999(98)00246-5; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Eriksen L, 1995, BRIT J PHARMACOL, V116, P3279, DOI 10.1111/j.1476-5381.1995.tb15136.x; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hermit MB, 2004, EUR J PHARMACOL, V486, P241, DOI 10.1016/j.ejphar.2003.12.033; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Kowal D, 1998, NEUROPHARMACOLOGY, V37, P179, DOI 10.1016/S0028-3908(98)00011-2; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; Mathiesen JM, 2003, BRIT J PHARMACOL, V138, P1026, DOI 10.1038/sj.bjp.0705159; Monastyrskaia K, 1999, BRIT J PHARMACOL, V128, P1027, DOI 10.1038/sj.bjp.0702885; MOTULSKY H, 1997, CURRENT PROTOCOLS NE; Mutel V, 2000, J NEUROCHEM, V75, P2590, DOI 10.1046/j.1471-4159.2000.0752590.x; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pagano A, 2001, J NEUROSCI, V21, P1189; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Rosemond E, 2002, J BIOL CHEM, V277, P7333, DOI 10.1074/jbc.M110476200; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Yao Y, 2003, J NEUROCHEM, V86, P947, DOI 10.1046/j.1471-4159.2003.01906.x	32	16	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34811	34817		10.1074/jbc.M404109200	http://dx.doi.org/10.1074/jbc.M404109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184361	hybrid			2022-12-25	WOS:000223134800089
J	Mandard, S; Zandbergen, F; Tan, NS; Escher, P; Patsouris, D; Koenig, W; Kleemann, R; Bakker, A; Veenman, F; Wahli, W; Muller, M; Kersten, S				Mandard, S; Zandbergen, F; Tan, NS; Escher, P; Patsouris, D; Koenig, W; Kleemann, R; Bakker, A; Veenman, F; Wahli, W; Muller, M; Kersten, S			The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-4; NECROSIS-FACTOR-ALPHA; ADIPOCYTE DIFFERENTIATION; PROPROTEIN CONVERTASES; LIPOPROTEIN-LIPASE; LIPID-METABOLISM; SECRETORY FACTOR; IN-VIVO; GENE; EXPRESSION	The fasting-induced adipose factor (FIAF, ANGPTL4, PGAR, HFARP) was previously identified as a novel adipocytokine that was up-regulated by fasting, by peroxisome proliferator-activated receptor agonists, and by hypoxia. To further characterize FIAF, we studied regulation of FIAF mRNA and protein in liver and adipose cell lines as well as in human and mouse plasma. Expression of FIAF mRNA was up-regulated by peroxisome proliferator-activated receptor alpha( PPARalpha) and PPARbeta/delta agonists in rat and human hepatoma cell lines and by PPARgamma and PPARbeta/delta agonists in mouse and human adipocytes. Transactivation, chromatin immunoprecipitation, and gel shift experiments identified a functional PPAR response element within intron 3 of the FIAF gene. At the protein level, in human and mouse blood plasma, FIAF was found to be present both as the native protein and in a truncated form. Differentiation of mouse 3T3-L1 adipocytes was associated with the production of truncated FIAF, whereas in human white adipose tissue and SGBS adipocytes, only native FIAF could be detected. Interestingly, truncated FIAF was produced by human liver. Treatment with fenofibrate, a potent PPARalpha agonist, markedly increased plasma levels of truncated FIAF, but not native FIAF, in humans. Levels of both truncated and native FIAF showed marked interindividual variation but were not associated with body mass index and were not influenced by prolonged semistarvation. Together, these data suggest that FIAF, similar to other adipocytokines such as adiponectin, may partially exert its function via a truncated form.	Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, NL-6700 EV Wageningen, Netherlands; Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Univ Basel, Pharmazentrum, Inst Physiol, CH-4056 Basel, Switzerland; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	Wageningen University & Research; University of Lausanne; University of Basel; Ulm University; Netherlands Organization Applied Science Research; Maastricht University	Kersten, S (corresponding author), Univ Wageningen & Res Ctr, Div Human Nutr, Nutr Metab & Genom Grp, POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@wur.nl	Muller, Michael/M-5724-2019; Wahli, Walter/I-3194-2019; Kersten, Sander/A-1116-2011; Tan, Nguan Soon/A-2220-2011; Muller, Michael/B-5795-2008; Wahli, Walter/B-1398-2009; Mandard, Stéphane/J-4800-2019	Muller, Michael/0000-0002-5930-9905; Kersten, Sander/0000-0003-4488-7734; Tan, Nguan Soon/0000-0003-0136-7341; Muller, Michael/0000-0002-5930-9905; Wahli, Walter/0000-0002-5966-9089; Mandard, Stéphane/0000-0002-7298-821X				Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Chen J, 2002, J ENDOCRINOL, V175, P499, DOI 10.1677/joe.0.1750499; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; Croissandeau G, 2002, J CELL SCI, V115, P1203; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Hansmannel F, 2003, BIOCHEM BIOPH RES CO, V311, P149, DOI 10.1016/j.bbrc.2003.09.185; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hukshorn CJ, 2003, AM J CLIN NUTR, V77, P771, DOI 10.1093/ajcn/77.4.771; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mars M, 2003, INT J OBESITY, V27, P574, DOI 10.1038/sj.ijo.0802266; Ono M, 2003, J BIOL CHEM, V278, P41804, DOI 10.1074/jbc.M302861200; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Trayhurn P, 2000, AM J PHYSIOL-REG I, V279, pR2329, DOI 10.1152/ajpregu.2000.279.6.R2329; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	219	230	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34411	34420		10.1074/jbc.M403058200	http://dx.doi.org/10.1074/jbc.M403058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190076	hybrid, Green Published			2022-12-25	WOS:000223134800042
J	Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M				Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M			Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc	ONCOGENE			English	Article						USF; c-Myc; CDK4; breast cancer; promoter; transcription activation; E box; dominant-negative mutants; mammary epithelial cells	TRANSCRIPTION FACTOR USF; DNA-BINDING; ACTIVATES TRANSCRIPTION; DEPENDENT KINASES; PROTEIN; CELLS; GENE; EXPRESSION; PROLIFERATION; UPSTREAM	USF and c-Myc are basic helix-loop-helix transcription factors with similar DNA-binding specificities, but antagonistic effects on cellular transformation. In order to determine how these opposite functions correlate with the transcriptional activities of the two factors on particular downstream targets, we investigated the roles of USF and c-Myc in expression of CDK4, a known direct target of cMyc. Overexpression of either c-Myc or USF2, but not USF1, stimulated the expression of CDK4 promoter-driven reporter genes in the non-tumorigenic mammary epithelial MCF-10A cells. Dominant-negative mutants specific to either Myc or USF family proteins inhibited reporter gene activity as well as endogenous CDK4 expression, demonstrating involvement of both USF and Myc in CDK4 transcriptional control. In contrast, in two different breast cancer cell lines where USF is transcriptionally inactive and c-Myc is overexpressed, CDK4 promoter activity was no longer responsive to either transcription factor. Accordingly, chromatin immunoprecipitation revealed significantly lower levels of both USF and c-Myc bound to the endogenous CDK4 promoter in breast cancer cells than in MCF-10A cells, with a concomitant decrease in associated histone H3 acetylation. These results suggest that a major switch in the transcriptional control of CDK4 occurs during breast carcinogenesis, with likely alteration of cell cycle regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Texas System; UTMD Anderson Cancer Center; Max Planck Society	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	msawadog@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA079578] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA79578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Hadsell DL, 2003, MOL ENDOCRINOL, V17, P2251, DOI 10.1210/me.2002-0031; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Ito, 1996, Breast Cancer, V3, P93, DOI 10.1007/BF02966969; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Sasano H, 1997, ANTICANCER RES, V17, P3685; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	45	25	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6125	6135		10.1038/sj.onc.1207806	http://dx.doi.org/10.1038/sj.onc.1207806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208653				2022-12-25	WOS:000223261000012
J	Kennedy, KA; Gachelet, EG; Traxler, B				Kennedy, KA; Gachelet, EG; Traxler, B			Evidence for multiple pathways in the assembly of the Escherichia coli maltose transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ACETYLCHOLINE-RECEPTOR; INSERTION MUTANTS; MEMBRANE-PROTEINS; SYSTEM; ABC; PURIFICATION; MALFGK(2); SITES	We used the maltose transport complex MalFGK(2) of the Escherichia coli cytoplasmic membrane as a model for the study of the assembly of hetero-oligomeric membrane protein complexes. Analysis of other membrane protein complexes has led to a general model in which a unique, ordered pathway is followed from subunit monomers to a final oligomeric structure. In contrast, the studies reported here point to a fundamentally different mode for assembly of this transporter. Using coimmunoprecipitation and quantification of interacting partners, we found that all subunits of the maltose transport complex efficiently form heteromeric complexes in vivo. The pairwise complexes were stable over time, suggesting that they all represent assembly intermediates for the final MalFGK(2) transporter. These results indicate that several paths can lead to assembly of this oligomer. We also characterized MalF and MalG mutants that caused reduced association between some or all of the subunits of the complex with this assay. The mutant analysis highlights some important motifs for subunit contacts and suggests that the promiscuous interactions between these Mal proteins contribute to the efficiency of complex assembly. The behaviors of the wild type and mutant proteins in the co-immunoprecipitations support a model of multiple assembly pathways for this complex.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Traxler, B (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	btraxler@u.washington.edu						AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Lee MH, 1999, J BACTERIOL, V181, P6108, DOI 10.1128/JB.181.19.6108-6113.1999; Lippincott J, 1997, J BACTERIOL, V179, P1337, DOI 10.1128/jb.179.4.1337-1343.1997; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nelson BD, 1998, J BACTERIOL, V180, P2507, DOI 10.1128/JB.180.9.2507-2514.1998; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852	25	12	12	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33290	33297		10.1074/jbc.M403796200	http://dx.doi.org/10.1074/jbc.M403796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15192116	hybrid			2022-12-25	WOS:000223039700035
J	Wu, CCN; Lee, JD; Raz, E; Corr, M; Carson, DA				Wu, CCN; Lee, JD; Raz, E; Corr, M; Carson, DA			Necessity of oligonucleotide aggregation for toll-like receptor 9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTER CPG OLIGONUCLEOTIDES; DEOXYRIBOGUANOSINE RUN CONJUGATION; NF-KAPPA-B; IMMUNOSTIMULATORY DNA; BACTERIAL-DNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE; ANTIPROLIFERATIVE ACTIVITY; SIGNAL-TRANSDUCTION; DENDRITIC CELLS; PROTEIN-KINASE	Toll-like receptor 9 (TLR9), a member of the interleukin-1 (IL-1) family of pathogen-associated molecular pattern receptors, is activated by unmethylated CpG-containing sequences in bacterial DNA or synthetic oligonucleotides (ODNs) in the endosomal compartment. The stimulation of an IL-1 response is thought to require the aggregation of its receptor. By analogy, we postulated that the potency of a TLR9 ligand should depend first on its ability to enter cells and gain access to TLR9 and second on its capacity to form a multimeric complex capable of cross-linking these receptors. Previously, we selected from a random library a series of phosphodiester ODNs with enhanced ability to permeate cells. Here, we studied the structural requirements for these penetrating ODNs to elicit a functional TLR9 response, as assessed by cytokine production from bone marrow-derived mouse mononuclear cells. The presence of a prototypic murine immunostimulatory DNA hexameric sequence (purine-purine-CG-pyrimidine-pyrimidine) in the ODNs was not sufficient for stimulation. In addition, the TLR9-activating ODNs had to have the ability to form aggregates and often to form secondary structures near the core CpG motifs. Multimerization was promoted by the presence of a guanine-rich 3'-terminus. The phosphodiester ODNs with CpG motifs that did not aggregate antagonized the effects of the multimeric TLR9 activators. These findings suggest that an optimal TLR9 agonist needs to contain a spatially distinct multimerization domain and a receptor binding CpG domain. This concept may prove useful for the design of new TLR9-modulating agents.	Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wu, CCN (corresponding author), 9500 Gilman Dr,0663, La Jolla, CA 92093 USA.	c5wu@ucsd.edu		Lee, Jongdae/0000-0002-6270-4658	NIAID NIH HHS [AI56453, AI40682] Funding Source: Medline; NIAMS NIH HHS [AR44850, AR07567] Funding Source: Medline; NIGMS NIH HHS [GM23200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056453, P01AI040682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044850, T32AR007567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bhagat L, 2003, BIOCHEM BIOPH RES CO, V300, P853, DOI 10.1016/S0006-291X(02)02943-1; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/00001432-200306000-00003; Dalpke AH, 2002, IMMUNOLOGY, V106, P102, DOI 10.1046/j.1365-2567.2002.01410.x; Dapic V, 2002, BIOCHEMISTRY-US, V41, P3676, DOI 10.1021/bi0119520; Elias F, 2003, J IMMUNOL, V171, P3697, DOI 10.4049/jimmunol.171.7.3697; Fearon K, 2003, EUR J IMMUNOL, V33, P2114, DOI 10.1002/eji.200323948; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Ishii KJ, 2002, J EXP MED, V196, P269, DOI 10.1084/jem.20020773; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Kandimalla ER, 2001, BIOORGAN MED CHEM, V9, P807, DOI 10.1016/S0968-0896(00)00316-3; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lederman S, 1996, ANTISENSE NUCLEIC A, V6, P281, DOI 10.1089/oli.1.1996.6.281; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lee SW, 2000, J IMMUNOL, V165, P3631, DOI 10.4049/jimmunol.165.7.3631; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Park Y, 2001, J ALLERGY CLIN IMMUN, V108, P570; Prasad V, 1999, ANTIMICROB AGENTS CH, V43, P2689, DOI 10.1128/AAC.43.11.2689; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Shen WY, 2002, ANTISENSE NUCLEIC A, V12, P155, DOI 10.1089/108729002760220752; Suzuki K, 1999, EUR J BIOCHEM, V260, P855, DOI 10.1046/j.1432-1327.1999.00233.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Wu CCN, 2003, HUM GENE THER, V14, P849, DOI 10.1089/104303403765701141; YAMAMOTO T, 1994, ANTISENSE RES DEV, V4, P119, DOI 10.1089/ard.1994.4.119; Yu D, 2000, BIOORG MED CHEM LETT, V10, P2585, DOI 10.1016/S0960-894X(00)00537-0; Yu D, 2001, BIOORG MED CHEM LETT, V11, P2263, DOI 10.1016/S0960-894X(01)00418-8; Zimmermann S, 2003, VACCINE, V21, P990, DOI 10.1016/S0264-410X(02)00550-9; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	55	73	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33071	33078		10.1074/jbc.M311662200	http://dx.doi.org/10.1074/jbc.M311662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184382	hybrid			2022-12-25	WOS:000223039700008
J	Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M				Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M			BRAF alterations are associated with complex mutational profiles in malignant melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; PTEN; TP53; CDKN2A	N-RAS MUTATIONS; TUMOR-SUPPRESSOR GENE; CUTANEOUS MELANOMA; CELL LINES; P53 MUTATIONS; METASTATIC MELANOMA; HUMAN CANCER; PTEN; SUSCEPTIBILITY; PATHWAYS	To evaluate the mutational profiles associated with BRAF mutations in human melanoma, we have studied BRAF, RAS, PTEN, TP53, CDKN2A and CDK4 genes and their expression in melanoma lesions. Owing to the lack of sufficient material from fresh specimens, we employed short-term cell lines obtained from melanoma biopsies. In all, 41 melanoma obtained from eight primary lesions, 20 nodal, 11 cutaneous and two visceral metastases from patients with sporadic (n=31), familial (n=4) and multiple melanoma (n=2) were analysed. The results revealed novel missense mutations in the BRAF, PTEN, CDKN2A and CDK4 genes. Overall, activating mutations of BRAF and loss of functional p16 and ARF were detected in the majority of melanomas (29/41, 36/41 and 29/41, respectively), while PTEN alterations/loss, NRAS and TP53 mutations occurred less frequently (6/41, 6/41 and 10/41, respectively). In the resulting 12 mutational profiles, p16/ARF loss associated with mutated BRAF(V599E) was the most represented (n=15). In addition, TP53 and PTEN mutations were always accompanied with BRAF alterations, while PTEN loss was found in association with CDKN2A or TP53 mutations in the absence of BRAF activation. The p16/ARFDelta+BRAF/RAS profile was significantly associated with a longer survival, while complex mutational profiles were detected in highly aggressive disease and poor survival. These data support the existence of several molecularly defined melanoma groups which likely reflect different clinical/biological behaviour, thus suggesting that a more extensive molecular classification of melanoma would significantly impact its clinical management.	Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Mol Mech Tumour Growth & Progress, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Human Tumour Immunobiol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumours, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Rodolfo, M (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, Via Venezian 1, I-20133 Milan, Italy.	monica.rodolfo@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; rodolfo, monica/H-2671-2012; Perrone, Federica/S-6171-2016; Anichini, Andrea/K-1434-2016; Vallacchi, Viviana/K-5709-2016	Pierotti, Marco Alessandro/0000-0002-7431-8332; rodolfo, monica/0000-0002-9196-0298; Perrone, Federica/0000-0003-4406-8245; Anichini, Andrea/0000-0001-5096-5538; Vallacchi, Viviana/0000-0002-2819-0630				ALBINO AP, 1989, ONCOGENE, V4, P1363; Bertram CG, 2002, J INVEST DERMATOL, V119, P961, DOI 10.1046/j.1523-1747.2002.01825.x; Brose MS, 2002, CANCER RES, V62, P6997; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Castellano M, 1997, CANCER RES, V57, P4868; Ceha HM, 1998, BIOCHEM BIOPH RES CO, V249, P550, DOI 10.1006/bbrc.1998.9183; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deichmann M, 2002, BRIT J CANCER, V87, P1431, DOI 10.1038/sj.bjc.6600653; Dong JL, 2003, CANCER RES, V63, P3883; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Esteller M, 2000, CANCER RES, V60, P129; EYCHENE A, 1995, ONCOGENE, V10, P1159; Fargnoli MC, 1998, J INVEST DERMATOL, V111, P1202, DOI 10.1046/j.1523-1747.1998.00412.x; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Hayward NK, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P207; Hussein MR, 2003, EUR J CANCER PREV, V12, P93, DOI 10.1097/00008469-200304000-00002; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ragnarsson-Olding BK, 2002, MELANOMA RES, V12, P453, DOI 10.1097/00008390-200209000-00007; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Satyamoorthy K, 2003, CANCER RES, V63, P756; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	44	151	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5968	5977		10.1038/sj.onc.1207780	http://dx.doi.org/10.1038/sj.onc.1207780			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195137				2022-12-25	WOS:000222941100011
J	Altomare, DA; Wang, HQ; Skele, KL; De Rienzo, A; Klein-Szanto, AJ; Godwin, AK; Testa, JR				Altomare, DA; Wang, HQ; Skele, KL; De Rienzo, A; Klein-Szanto, AJ; Godwin, AK; Testa, JR			AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth	ONCOGENE			English	Article						AKT; protein kinase B; mTOR; LY294002; ovarian cancer; rapamycin	AKT/PROTEIN KINASE-B; UP-REGULATION; CONSTITUTIVE ACTIVATION; OVEREXPRESSION; CHEMOTHERAPY; INHIBITION; RESISTANCE; PATHWAY; BREAST; LEADS	Activation of the PI3K/AKT pathway may contribute to tumorigenesis. AKT mediates survival signals that protect cells from apoptosis and, thus, is a potentially important therapeutic target. To determine the frequency of AKT activation in human ovarian cancer, we screened a tumor tissue microarray with a phospho-specific pan-AKT (Ser473) antibody, which revealed elevated staining in 21 of 31 (68%) ovarian carcinomas. Phospho-AKT staining was associated with that of phospho (active)mTOR in 27 of 31 (87%) ovarian tumors, with 17 (55%) tumors showing elevated phospho-mTOR positivity. We tested the effects of AKT/mTOR activation on the therapeutic sensitivity of ovarian cancer cells. Pretreatment of SKOV3 cells, which exhibit constitutive AKT activity under low serum conditions, with the PI3K inhibitor LY294002 augmented cisplatin-induced apoptosis. In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002. In addition, inhibition of mTOR activity with rapamycin resulted in 1 arrest in SKOV3 cells, but not in OVCAR4 or OVCAR5 cells. Collectively, these findings indicate that active AKT and downstream mTOR represent potentially important therapeutic and/or chemopreventive targets in ovarian cancer.	Fox Chase Canc Ctr, Ovarian Canc Programs, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Programs, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jr_testa@fccc.edu			NCI NIH HHS [P50 CA083638, CA77429, CA83638, P30 CA006927, CA06927, R01 CA077429] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927, P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Arboleda MJ, 2003, CANCER RES, V63, P196; Brognard J, 2001, CANCER RES, V61, P3986; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Dhawan P, 2002, CANCER RES, V62, P7335; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Hu LM, 2002, CANCER RES, V62, P1087; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Page C, 2000, ANTICANCER RES, V20, P407; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	18	335	347	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5853	5857		10.1038/sj.onc.1207721	http://dx.doi.org/10.1038/sj.onc.1207721			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208673				2022-12-25	WOS:000222629800015
J	Penninkhof, F; Grootegoed, JA; Blok, LJ				Penninkhof, F; Grootegoed, JA; Blok, LJ			Identification of REPS2 as a putative modulator of NF-kappa B activity in prostate cancer cells	ONCOGENE			English	Article						REPS2; p65; NF-kappa B/p65; prostate cancer; apoptosis; cell survival	TYROSINE KINASE SUBSTRATE; INTERLEUKIN-6 EXPRESSION; CONSTITUTIVE ACTIVATION; CRYSTAL-STRUCTURE; EH DOMAINS; PROTEIN; YEAST; EPS15; TRANSFORMATION; SPECIFICITY	The protein REPS2 is implicated in growth factor receptor-mediated endocytosis and signalling, and its expression is downregulated in androgen-independent prostate cancer cells. Herein, the NF-kappaB subunit p65 is identified as a human REPS2 protein partner, interacting with the EH domain of REPS2. Using crystal structure data from literature and experimental data from yeast and mammalian two-hybrid analysis, the results indicate that the NPF-motif in p65 acts as binding site for the EH domain in REPS2. However, in cultured prostate cancer cells, the REPS2-p65 interaction is triggered upon stimulation with phorbol ester (PMA). This indicates that PMA-sensitive signalling pathways can affect the interaction between REPS2 and p65. During prostate cancer progression from androgen-dependent to androgen-independent growth, downregulation of REPS2 is accompanied by upregulation of NF-kappaB activity. This might involve loss of REPS2-p65 interaction, which would lead to increased NF-kappaB activity. Androgen-deprivation causes apoptosis of prostate cancer cells, and activated NF-kappaB is a known inhibitor of apoptosis. Hence, decreased expression of REPS2 might be a key factor, causing prostate cancer cells to become resistant to induction of apoptosis by androgen deprivation.	Erasmus Univ, Med Ctr, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Med Ctr, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.	l.blok@erasmusmc.nl						Chang GTG, 1997, CANCER RES, V57, P4075; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Oosterhoff JK, 2003, ONCOGENE, V22, P2920, DOI 10.1038/sj.onc.1206397; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Zerbini LF, 2003, CANCER RES, V63, P2206	28	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5607	5615		10.1038/sj.onc.1207750	http://dx.doi.org/10.1038/sj.onc.1207750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184881	Green Published			2022-12-25	WOS:000222629500005
J	El-Agnaf, OMA; Paleologou, KE; Greer, B; Abogrein, AM; King, JE; Salem, SA; Fullwood, NJ; Benson, FE; Hewitt, R; Ford, KJ; Martin, FL; Harriot, P; Cookson, MR; Allsop, D				El-Agnaf, OMA; Paleologou, KE; Greer, B; Abogrein, AM; King, JE; Salem, SA; Fullwood, NJ; Benson, FE; Hewitt, R; Ford, KJ; Martin, FL; Harriot, P; Cookson, MR; Allsop, D			A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders	FASEB JOURNAL			English	Article						amyloid fibrils; drug discovery; neurodegeneration; peptide delivery	MULTIPLE-SYSTEM ATROPHY; SHEET BREAKER PEPTIDES; APOPTOTIC CELL-DEATH; BETA-SHEET; NEURODEGENERATIVE DISEASES; LEWY BODIES; WILD-TYPE; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; HYDROGEN-PEROXIDE	Convergent biochemical and genetic evidence suggests that the formation of alpha-synuclein (alpha-syn) protein deposits is an important and, probably, seminal step in the development of Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). It has been reported that transgenic animals overexpressing human alpha-syn develop lesions similar to those found in the brain in PD, together with a progressive loss of dopaminergic cells and associated abnormalities of motor function. Inhibiting and/or reversing alpha-syn self-aggregation could, therefore, provide a novel approach to treating the underlying cause of these diseases. We synthesized a library of overlapping 7-mer peptides spanning the entire alpha-syn sequence, and identified amino acid residues 64-100 of alpha-syn as the binding region responsible for its self-association. Modified short peptides containing alpha-syn amino acid sequences from part of this binding region (residues 69-72), named alpha-syn inhibitors (ASI), were found to interact with full-length alpha-syn and block its assembly into both early oligomers and mature amyloid-like fibrils. We also developed a cell-permeable inhibitor of alpha-syn aggregation (ASID), using the polyarginine peptide delivery system. This ASID peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with alpha-syn(A53T), a familial PD-associated mutation. ASI peptides without this delivery system did not reverse levels of Fe(II)-induced DNA damage. Furthermore, the ASID peptide increased (P<0.0005) the number of cells stained positive for Bcl-2, while significantly (P<0.05) decreasing the percentage of cells stained positive for BAX. These short peptides could serve as lead compounds for the design of peptidomimetic drugs to treat PD and related disorders.	Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England; Queens Univ Belfast, Sch Biol & Biochem, Belfast BT9 7BL, Antrim, North Ireland; NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Lancaster University; Queens University Belfast; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	El-Agnaf, OMA (corresponding author), Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England.	o.el-agnaf@lancaster.ac.uk	Cookson, Mark/AAW-2516-2021; Allsop, David/B-9725-2008	Cookson, Mark/0000-0002-1058-3831; Allsop, David/0000-0002-0513-5575; Benson, Fiona Elizabeth/0000-0002-3918-7015; Fullwood, Nigel James/0000-0002-9405-8515; L Martin, Francis/0000-0001-8562-4944	NATIONAL INSTITUTE ON AGING [ZIAAG000953, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baba M, 1998, AM J PATHOL, V152, P879; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Kalantzi OI, 2004, CARCINOGENESIS, V25, P613, DOI 10.1093/carcin/bgh048; Kapurniotu A, 2002, J MOL BIOL, V315, P339, DOI 10.1006/jmbi.2001.5244; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Martin FL, 2003, J NEUROCHEM, V87, P620, DOI 10.1046/j.1471-4159.2003.02013.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Nagai Y, 2003, HUM MOL GENET, V12, P1253, DOI 10.1093/hmg/ddg144; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren H, 2001, BIOCHEM BIOPH RES CO, V288, P703, DOI 10.1006/bbrc.2001.5783; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yared E, 2002, MUTAGENESIS, V17, P345, DOI 10.1093/mutage/17.4.345	57	139	153	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1315	+		10.1096/fj.03-1346fje	http://dx.doi.org/10.1096/fj.03-1346fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180968				2022-12-25	WOS:000222327500026
J	Tepper, OM; Callaghan, MJ; Chang, EI; Galiano, RD; Bhatt, KA; Baharestani, S; Gan, J; Simon, B; Hopper, RA; Levine, JP; Gurtner, GC				Tepper, OM; Callaghan, MJ; Chang, EI; Galiano, RD; Bhatt, KA; Baharestani, S; Gan, J; Simon, B; Hopper, RA; Levine, JP; Gurtner, GC			Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2	FASEB JOURNAL			English	Article						therapeutic angiogenesis; growth factors	DOUBLE-BLIND TRIAL; GROWTH-FACTOR; GENE-THERAPY; EXPRESSION; VASCULOGENESIS; PROLIFERATION; MIGRATION; NONUNION; REPAIR; CELLS	Pulsed electromagnetic fields (PEMF) have been shown to be clinically beneficial, but their mechanism of action remains unclear. The present study examined the impact of PEMF on angiogenesis, a process critical for successful healing of various tissues. PEMF increased the degree of endothelial cell tubulization (sevenfold) and proliferation (threefold) in vitro. Media from PEMF cultures had a similar stimulatory effect, but heat denaturation ablated this activity. In addition, conditioned media was able to induce proliferative and chemotactic changes in both human umbilical vein endothelial cells and fibroblasts, but had no effect on osteoblasts. Angiogenic protein screening demonstrated a fivefold increase in fibroblast growth factor beta-2 (FGF-2), as well as smaller increases in other angiogenic growth factors (angiopoietin-2, thrombopoietin, and epidermal growth factor). Northern blot analysis demonstrated an increase in FGF-2 transcription, and FGF-2 neutralizing antibody inhibited the effects of PEMF. In vivo, PEMF exposure increased angiogenesis more than twofold. We conclude that PEMF augments angiogenesis primarily by stimulating endothelial release of FGF-2, inducing paracrine and autocrine changes in the surrounding tissue. These findings suggest a potential role for PEMF in therapeutic angiogenesis.	NYU, Sch Med, Microvasc Res & Vasc Tissue Engn Lab, New York, NY 10016 USA	New York University	Gurtner, GC (corresponding author), NYU, Med Ctr, Inst Reconstruct Plast Surg, TH-169,550 1st Ave, New York, NY 10016 USA.	geoffrey.gurtner@med.nyu.edu						Aaron RK, 2002, J ORTHOP RES, V20, P233, DOI 10.1016/S0736-0266(01)00084-5; BASSETT CAL, 1974, SCIENCE, V184, P575; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243; BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623-200110000-00009; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; DONSKI PK, 1979, PLAST RECONSTR SURG, V64, P239, DOI 10.1097/00006534-197908000-00017; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; Freshney R.I, 2000, CULTURE ANIMAL CELLS, P149; Guerkov HH, 2001, CLIN ORTHOP RELAT R, P265; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jasti A C, 2001, Biomed Sci Instrum, V37, P209; Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; RYABY JT, 1998, CLIN ORTHOP S, V355, P205; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; SCOTT G, 1994, J BONE JOINT SURG AM, V76A, P820, DOI 10.2106/00004623-199406000-00005; SHARRARD WJW, 1990, J BONE JOINT SURG BR, V72, P347, DOI 10.1302/0301-620X.72B3.2187877; Steinbrech DS, 2000, AM J PHYSIOL-CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853; Stix G, 1998, SCI AM, V278, P33, DOI 10.1038/scientificamerican0398-33; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; YENPATTON GPA, 1988, J CELL PHYSIOL, V134, P37, DOI 10.1002/jcp.1041340105	26	160	180	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1231	+		10.1096/fj.03-0847fje	http://dx.doi.org/10.1096/fj.03-0847fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208265				2022-12-25	WOS:000222327500023
J	Weihofen, WA; Liu, JG; Reutter, W; Saenger, W; Fan, H				Weihofen, WA; Liu, JG; Reutter, W; Saenger, W; Fan, H			Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; ATOMIC-STRUCTURE; T-CELLS; BINDING; PROTEIN; CD26; IV/CD26; PROGRAM; INACTIVATION; ASSOCIATION	Dipeptidyl-peptidase IV (DPPIV or CD26) is a homodimeric type II membrane glycoprotein in which the two monomers are subdivided into a beta-propeller domain and an alpha/beta-hydrolase domain. As dipeptidase, DPPIV modulates the activity of various biologically important peptides and, in addition, DPPIV acts as a receptor for adenosine deaminase (ADA), thereby mediating co-stimulatory signals in T-lymphocytes. The 3.0-Angstrom resolution crystal structure of the complex formed between human DPPIV and bovine ADA presented here shows that each beta-propeller domain of the DPPIV dimer binds one ADA. At the binding interface, two hydrophobic loops protruding from the beta-propeller domain of DPPIV interact with two hydrophilic and heavily charged alpha-helices of ADA, giving rise to the highest percentage of charged residues involved in a protein-protein contact reported thus far. Additionally, four glycosides linked to Asn(229) of DPPIV bind to ADA. In the crystal structure of porcine DPPIV, the observed tetramer formation was suggested to mediate epithelial and lymphocyte cell-cell adhesion. ADA binding to DPPIV could regulate this adhesion, as it would abolish tetramerization.	Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany; Charite Univ Med Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Saenger, W (corresponding author), Free Univ Berlin, Inst Chem Kristallog, Takustr 6, D-14195 Berlin, Germany.	saenger@chemie.fu-berlin.de; hua.fan@charite.de						Abbott CA, 1999, EUR J BIOCHEM, V266, P798, DOI 10.1046/j.1432-1327.1999.00902.x; Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; DEMEESTER I, 1994, EUR J IMMUNOL, V24, P566, DOI 10.1002/eji.1830240311; Dobers J, 2002, PROTEIN EXPRES PURIF, V25, P527, DOI 10.1016/S1046-5928(02)00043-8; Dong RP, 1997, J IMMUNOL, V159, P6070; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Gines S, 2002, BIOCHEM J, V361, P203, DOI 10.1042/0264-6021:3610203; Gorrell MD, 2001, SCAND J IMMUNOL, V54, P249, DOI 10.1046/j.1365-3083.2001.00984.x; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Ludwig K, 2004, BIOCHEM BIOPH RES CO, V313, P223, DOI 10.1016/j.bbrc.2003.11.112; MARTIN M, 1995, J IMMUNOL, V155, P4630; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Richard E, 2002, J BIOL CHEM, V277, P19720, DOI 10.1074/jbc.M111901200; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Valenzuela A, 1997, J IMMUNOL, V158, P3721; von Bonin A, 1998, IMMUNOL REV, V161, P43; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	35	82	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43330	43335		10.1074/jbc.M405001200	http://dx.doi.org/10.1074/jbc.M405001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15213224	hybrid			2022-12-25	WOS:000224226400117
J	Popovici, C; Conchonaud, F; Birnbaum, D; Roubin, R				Popovici, C; Conchonaud, F; Birnbaum, D; Roubin, R			Functional phylogeny relates LET-756 to fibroblast growth factor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR FGF; C-ELEGANS; CAENORHABDITIS-ELEGANS; SKELETAL DISORDERS; HOMOLOGOUS FACTORS; SIGNAL SEQUENCE; RECEPTOR; SECRETION; GENE; EXPRESSION	Fibroblast growth factors (FGFs) are secreted regulatory proteins involved in various developmental processes. In vertebrates, the FGF superfamily comprises 22 members. In non-vertebrates, six FGF genes have been identified in Ciona intestinalis, three in Drosophila melanogaster, and two (let-756 and egl-17) in Caenorhabditis elegans. The core of LET-756 shares a 30-50% sequence identity with the various members of the superfamily. The relationships between vertebrate and non-vertebrate FGFs are not clear. We made chimeric FGFs by replacing the core region of LET-756 by the cores of various mammalian, fly, and worm FGFs. LET-756 deleted in its core region was no longer able to rescue the lethal phenotype of a let-756 null mutant, and only chimeras containing the cores of FGFs 9, 16, and 20 showed rescue capacity. This core contains an internal motif of six amino acid residues (EFISIA) whose deletion or mutation abolished both the rescue activity and FGF secretion in the supernatant of transfected COS-1 cells. Chimera containing the core of C. intestinalis FGF9/16/20, a potential ortholog of FGF9 lacking the complete EFISIA motif, was not able to rescue the lethal phenotype or be secreted. However, the introduction of the EFISIA motif restored both activities. The data show that the EFISIA motif in the core of LET-756 is essential for its biological activity and that FGFs 9, 16, and 20, which contain that motif, are functionally close to LET-756 and may be evolutionary related. This non-classical mode of secretion using an internal motif is conserved throughout evolution.	Marseille Canc Res Inst, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Mol Oncol Lab, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Roubin, R (corresponding author), Marseille Canc Res Inst, UMR599, INSERM, 27 Bd Lei Roure, F-13009 Marseille, France.	roubin@marseille.inserm.fr	POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127; Birnbaum, Daniel/0000-0001-7920-9883				Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; Bulow HE, 2004, NEURON, V42, P367, DOI 10.1016/S0896-6273(04)00246-6; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; Colvin JS, 1999, DEV DYNAM, V216, P72; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Garces A, 2000, J NEUROSCI RES, V60, P1, DOI 10.1002/(SICI)1097-4547(20000401)60:1<1::AID-JNR1>3.0.CO;2-P; GOLDFARB M, 2001, SCI STKE; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Goodman SJ, 2003, DEVELOPMENT, V130, P3757, DOI 10.1242/dev.00604; Huang P, 2004, DEVELOPMENT, V131, P2595, DOI 10.1242/dev.01135; Kim HS, 2001, CYTOGENET CELL GENET, V93, P131, DOI 10.1159/000056965; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Miyakawa K, 2003, J BIOL CHEM, V278, P35718, DOI 10.1074/jbc.M300690200; Ohmachi S, 2000, BIOCHEM BIOPH RES CO, V277, P355, DOI 10.1006/bbrc.2000.3675; Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200; Ornitz DM, 2001, GENOME BIOL, V2; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; Roubin R, 1999, ONCOGENE, V18, P6741, DOI 10.1038/sj.onc.1203074; Satou Y, 2002, DEV GENES EVOL, V212, P432, DOI 10.1007/s00427-002-0266-8; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Stathopoulos A, 2004, GENE DEV, V18, P687, DOI 10.1101/gad.1166404; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wood WB, 1998, NEMATODE CAENORHABDI	31	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40146	40152		10.1074/jbc.M405795200	http://dx.doi.org/10.1074/jbc.M405795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15199049	hybrid			2022-12-25	WOS:000223791500113
J	Expert-Bezancon, A; Sureau, A; Durosay, P; Salesse, R; Groeneveld, H; Lecaer, JP; Marie, J				Expert-Bezancon, A; Sureau, A; Durosay, P; Salesse, R; Groeneveld, H; Lecaer, JP; Marie, J			hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MUSCLE-SPECIFIC EXON; SECONDARY STRUCTURE; ALTERNATIVE EXON; BINDING-SITES; A/B PROTEINS; HIV-1 TAT; 5'-SPLICE-SITE SELECTION; COOPERATIVE BINDING; SILENCER ELEMENT/	Mutually exclusive splicing of exons 6A and 6B from the chicken beta-tropomyosin gene involves numerous regulatory sequences. Previously, we identified a G-rich intronic sequence (S3) downstream of exon 6B. This element consists of six G-rich motifs, mutations of which abolish splicing of exon 6B. In this paper, we investigated the cellular factors that bind to this G-rich element. By using RNA affinity chromatography, we identified heterogeneous nuclear ribonucleoprotein (hnRNP) A1, the SR proteins ASF/SF2 and SC35, and hnRNP F/H as specific components that are assembled onto the G-rich element. By using hnRNP A1-depleted HeLa nuclear extract and add-back experiments, we show that hnRNP A1 has a negative effect on splicing of exon 6B. In agreement with in vitro data, artificial recruitment of hnRNP A1, as a fusion with the MS2 coat protein, also represses splicing of exon 6B ex vivo. In contrast, ASF/SF2 and SC35 activate splicing of exon 6B. As observed with other systems, hnRNP A1 counteracts the stimulating effect of the SR proteins. Moreover, cross-linking experiments show that both ASF/SF2 and SC35 are able to displace binding of hnRNP A1 to the G-rich element, suggesting that the binding sites for these proteins are overlapping. These data indicate that the G-rich sequence is a composite element that acts as an enhancer or as a silencer, depending on which proteins bind to them.	Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, CNRS,UPR 2167, F-91198 Gif Sur Yvette, France; INRA, Unite Recepteur & Commun, F-78352 Jouy En Josas, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Marie, J (corresponding author), Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, CNRS,UPR 2167, F-91198 Gif Sur Yvette, France.	marie@cgm.cnrs-gif.fr	Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BLACK DL, 1995, RNA, V1, P763; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carlo T, 1996, RNA, V2, P342; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domsic JK, 2003, MOL CELL BIOL, V23, P8762, DOI 10.1128/MCB.23.23.8762-8772.2003; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGELBRECHT J, 1992, J MOL BIOL, V227, P108, DOI 10.1016/0022-2836(92)90685-D; Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Miriami E, 2003, NUCLEIC ACIDS RES, V31, P1974, DOI 10.1093/nar/gkg279; MOORE MJ, 1993, RNA WORLD, V13, P303; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Rooke N, 2003, MOL CELL BIOL, V23, P1874, DOI 10.1128/MCB.23.6.1874-1884.2003; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIRANDPUGNET P, 1995, J MOL BIOL, V251, P591, DOI 10.1006/jmbi.1995.0458; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Tange TO, 2001, EMBO J, V20, P5748; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	61	67	69	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38249	38259		10.1074/jbc.M405377200	http://dx.doi.org/10.1074/jbc.M405377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208309	hybrid			2022-12-25	WOS:000223684100024
J	Morgan-Kiss, RM; Cronan, JE				Morgan-Kiss, RM; Cronan, JE			The Escherichia coli fadK (ydiD) gene encodes an anerobically regulated short chain acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; FATTY ACID DEGRADATION; TRANSMEMBRANE MOVEMENT; ACTIVATION; BIOSYNTHESIS; INITIATION; EXPRESSION; MECHANISM; ADENYLATE; ISOFORMS	We recently reported a new metabolic competency for Escherichia coli, the ability to degrade and utilize fatty acids of various chain lengths as sole carbon and energy sources (Campbell, J. W., Morgan- Kiss, R. M., and Cronan J. E. ( 2003) Mol. Microbiol. 47, 793 - 805). This beta-oxidation pathway is distinct from the previously described aerobic fatty acid degradation pathway and requires enzymes encoded by two operons, yfcYX and ydiQRSTD. The yfcYX operon ( renamed fadIJ) encodes enzymes required for hydration, oxidation, and thiolytic cleavage of the acyl chain. The ydiQRSTD operon encodes a putative acyl-CoA synthetase, ydiD ( renamed fadK), as well as putative electron transport chain components. We report that FadK is as an acyl-CoA synthetase that has a preference for short chain length fatty acid substrates (< 10 C atoms). The enzymatic mechanism of FadK is similar to other acyl-CoA synthetases in that it forms an acyl-AMP intermediate prior to the formation of the final acyl-CoA product. Expression of FadK is repressed during aerobic growth and is maximally expressed under anaerobic conditions in the presence of the terminal electron acceptor, fumarate.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019	Morgan-kiss, Rachael/0000-0003-4783-5358				BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BORGSTROM B, 1958, ACTA CHEM SCAND, V12, P1533, DOI 10.3891/acta.chem.scand.12-1533; Buchet A, 1998, J BACTERIOL, V180, P2599, DOI 10.1128/JB.180.10.2599-2608.1998; Campbell JW, 2003, MOL MICROBIOL, V47, P793, DOI 10.1046/j.1365-2958.2003.03341.x; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Farewell A, 1996, J BACTERIOL, V178, P6443, DOI 10.1128/jb.178.22.6443-6450.1996; Fujino T, 1997, J BIOCHEM-TOKYO, V122, P212; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMEDA K, 1985, BIOCHIM BIOPHYS ACTA, V832, P343, DOI 10.1016/0167-4838(85)90269-9; Keating TA, 1999, CURR OPIN CHEM BIOL, V3, P598, DOI 10.1016/S1367-5931(99)00015-0; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Morsczeck C, 2001, BBA-GENE STRUCT EXPR, V1521, P59, DOI 10.1016/S0167-4781(01)00287-1; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; REED LJ, 1958, J BIOL CHEM, V232, P123; SAMUEL D, 1970, European Journal of Biochemistry, V12, P576, DOI 10.1111/j.1432-1033.1970.tb00889.x; Sawers G, 2001, MOL MICROBIOL, V39, P1285, DOI 10.1046/j.1365-2958.2001.02316.x; Subrahmanyam S, 1998, J BACTERIOL, V180, P4596, DOI 10.1128/JB.180.17.4596-4602.1998; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; Upson RH, 1996, ANAL BIOCHEM, V243, P41, DOI 10.1006/abio.1996.0479; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Yoo JH, 2001, BIOCHEM J, V360, P699, DOI 10.1042/0264-6021:3600699	35	43	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37324	37333		10.1074/jbc.M405233200	http://dx.doi.org/10.1074/jbc.M405233200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15213221	hybrid			2022-12-25	WOS:000223554600018
J	Datta, A; Nag, A; Pan, W; Hay, N; Gartel, AL; Colamonici, O; Mori, Y; Raychaudhuri, P				Datta, A; Nag, A; Pan, W; Hay, N; Gartel, AL; Colamonici, O; Mori, Y; Raychaudhuri, P			Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CELL-CYCLE PROGRESSION; C-MYC; ORNITHINE-DECARBOXYLASE; EMBRYO FIBROBLASTS; GROWTH ARREST; ONCOGENIC RAS; MDM2; P19(ARF); P14(ARF)	The tumor suppressor protein ARF (alternate reading frame) inhibits MDM2 to stabilize and activate the functions of p53. Here we provide evidence for an additional activity of ARF that attenuates cell cycle progression independently of p53 activation. We show that ARF interacts with c-Myc independently of MDM2 or p53. Consequently, ARF relocalizes c-Myc from the nucleoplasm to the nucleolus. Binding and relocalization by ARF correlate with an inhibition of the c-Myc-activated transcription in both p53-positive and -negative cells. Using inducible cell lines, we show that the wild type ARF, but not a mutant, inhibits expression of the c-Myc-induced genes before inhibiting S phase. Moreover, ARF inhibits Myc-induced progression into S phase in cells lacking p53 or expressing a defective p53, indicating that ARF inhibits the S phase stimulatory function of c-Myc independently of p53. Our results strongly suggest that c-Myc is a bona fide target of ARF and that ARF attenuates c-Myc independently of the ARF-p53 axis.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Rheumatol Sect, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	Pradip@uic.edu			NCI NIH HHS [CA 55079, CA 88863, CA 100035] Funding Source: Medline; NIGMS NIH HHS [GM 54709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100035, R01CA088863, R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 2000, CANCER RES, V60, P129; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Groth A, 2000, J BIOL CHEM, V275, P27473; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENGYUN F, 2000, J BIOL CHEM, V275, P8945; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	103	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36698	36707		10.1074/jbc.M312305200	http://dx.doi.org/10.1074/jbc.M312305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199070	hybrid			2022-12-25	WOS:000223453600069
J	Gellhaus, A; Dong, XS; Propson, S; Maass, K; Klein-Hitpass, L; Kibschull, M; Traub, O; Willecke, K; Perbal, B; Lye, SJ; Winterhager, E				Gellhaus, A; Dong, XS; Propson, S; Maass, K; Klein-Hitpass, L; Kibschull, M; Traub, O; Willecke, K; Perbal, B; Lye, SJ; Winterhager, E			Connexin43 interacts with NOV - A possible mechanism for negative regulation of cell growth in choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; CCN FAMILY; INTERCELLULAR COMMUNICATION; INDUCIBLE EXPRESSION; POTENTIAL ROLE; GLIOMA-CELLS; GENE; MOUSE; DIFFERENTIATION; TRANSFECTION	The gap junction protein connexin43 (Cx43) is thought to be involved in growth control in several tissues. Using the doxycycline inducible tet-on system, we generated human malignant trophoblast Jeg3 cells transfected with either Cx40, Cx43, or C-terminal truncated Cx43 (trCx43). Cx43, but not Cx40 or trCx43, displayed a reduced cell growth of Jeg3 cells in vitro and tumor growth in nude mice, suggesting a role of the C terminus of Cx43 in growth regulation. Using gene array analysis, the growth regulator NOV (CCN3), a member of the CCN gene family, was found to be up-regulated only in the Cx43-transfected cells. Validation by reverse transcriptase-PCR confirmed an up-regulation of the NOV transcript exclusively upon Cx43 induction. In contrast to Cx40 or trCx43, induction of Cx43 led to a switch in localization of NOV from the nucleus to the cell membrane, where it is colocalized with Cx43. Coimmunoprecipitation showed a binding of NOV to the C terminus of Cx43 in vitro as well as in transfected cells. Jeg3 cells transfected only with NOV revealed that NOV itself acts as a growth regulator. We suggest that Cx43 is able to regulate cell growth via an up-regulation of NOV transcription, a change in localization of the NOV protein and a binding of NOV to the C terminus of Cx43.	Univ Hosp Essen, Inst Anat, D-45122 Essen, Germany; Univ Hosp Essen, Inst Cell Biol, D-45122 Essen, Germany; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Paris, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France	University of Duisburg Essen; University of Duisburg Essen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Bonn; UDICE-French Research Universities; Universite Paris Cite	Winterhager, E (corresponding author), Univ Hosp Essen, Inst Anat, 55 Hufelandstr, D-45122 Essen, Germany.	e.winterhager@uni-essen.de	Lye, Stephen J/E-7269-2013	Lye, Stephen J/0000-0002-3305-4406; Maass, Karen/0000-0001-9815-841X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042558] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01 HD 42558-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; Chevalier G, 1998, AM J PATHOL, V152, P1563; Cronier L, 2003, BIOL REPROD, V69, P1472, DOI 10.1095/biolreprod.103.016360; Cronier L, 2002, MOL HUM REPROD, V8, P1005, DOI 10.1093/molehr/8.11.1005; Czyz J, 2000, EXP CELL RES, V255, P40, DOI 10.1006/excr.1999.4760; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Durig J, 2003, BLOOD, V101, P2748, DOI 10.1182/blood-2002-09-2683; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Ellis PD, 2003, J VASC RES, V40, P234, DOI 10.1159/000071887; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Frendo JL, 2003, J CELL SCI, V116, P3413, DOI 10.1242/jcs.00648; Gabriel HD, 2001, EUR J BIOCHEM, V268, P1749, DOI 10.1046/j.1432-1327.2001.02040.x; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gramsch B, 2001, EXP CELL RES, V264, P397, DOI 10.1006/excr.2000.5145; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; Hellmann P, 1996, PFLUG ARCH EUR J PHY, V432, P501, DOI 10.1007/s004240050162; Hellmann P, 1999, EXP CELL RES, V246, P480, DOI 10.1006/excr.1998.4332; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2002, MOL CARCINOGEN, V35, P29, DOI 10.1002/mc.10071; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; McLeod TL, 2001, CELL COMMUN ADHES, V8, P441, DOI 10.3109/15419060109080767; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Olbina G, 2003, MOL CANCER RES, V1, P690; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; PATTILLO RA, 1968, SCIENCE, V159, P1467, DOI 10.1126/science.159.3822.1467; Peebles KA, 2003, CARCINOGENESIS, V24, P651, DOI 10.1093/carcin/bgg008; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 1999, J CLIN PATHOL-MOL PA, V52, P84, DOI 10.1136/mp.52.2.84; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; Winterhager E, 1999, PLACENTA, V20, P627, DOI 10.1053/plac.1999.0434; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yamasaki H, 1999, NOVART FDN SYMP, V219, P241; YAMASAKI H, 1991, ENVIRON HEALTH PERSP, V93, P191, DOI 10.2307/3431188; YUE H, 2001, NUCLEIC ACIDS RES, V29, P1; Zhang YW, 2003, J BIOL CHEM, V278, P44852, DOI 10.1074/jbc.M305072200; Zhang YW, 2003, CANCER RES, V63, P1623; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	64	124	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36931	36942		10.1074/jbc.M404073200	http://dx.doi.org/10.1074/jbc.M404073200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15181016	hybrid			2022-12-25	WOS:000223453600096
J	Schwarzer, C; Machen, TE; Illek, B; Fischer, H				Schwarzer, C; Machen, TE; Illek, B; Fischer, H			NADPH oxidase-dependent acid production in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRACHEAL EPITHELIUM; SURFACE LIQUID PH; INTRACELLULAR PH; PROTON CHANNELS; H+ CHANNEL; CONDUCTANCE; INHIBITION; DIFFERENTIATION; NEUTROPHILS; ACTIVATION	The purpose of this study was to determine the role of NADPH oxidase in H+ secretion by airway epithelia. In whole cell patch clamp recordings primary human tracheal epithelial cells (hTE) and the human serous gland cell line Calu-3 expressed a functionally similar zinc-blockable plasma membrane H+ conductance. However, the rate of H+ secretion of confluent epithelial monolayers measured in Ussing chambers was 9-fold larger in hTE compared with Calu-3. In hTE H+ secretion was blocked by mucosal ZnCl2 and the NADPH oxidase blockers acetovanillone and 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), whereas these same blockers had no effect in Calu-3. We determined levels of transcripts for the NADPH oxidase transmembrane isoforms (Nox1 through -5, Duox1 and -2, and p22(phox)) and found Duox1, -2, and p22(phox) to be highly expressed in hTE, as well as the intracellular subunits p40(phox), p47(phox), and p67(phox). In contrast, Calu-3 lacked transcripts for Duox1, p40(phox), and p47(phox). Anti-Duox antibody staining resulted in prominent apical staining in hTE but no significant staining in Calu-3. When treated with amiloride to block the Na+/H+ exchanger, intracellular pH in hTE acidified at significantly higher rates than in Calu-3, and treatment with AEBSF blocked acidification. These data suggest a role for an apically located Duox-based NADPH oxidase during intracellular H+ production and H+ secretion, but not in H+ conduction.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley	Fischer, H (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	hfischer@chori.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071829, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051799] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 071829, 1P50 HL 60288] Funding Source: Medline; NIDDK NIH HHS [DK 51799] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bowler RP, 2002, AM J RESP CRIT CARE, V166, pS38, DOI 10.1164/rccm.2206014; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; CHERNY VV, 1995, J GEN PHYSIOL, V105, P861, DOI 10.1085/jgp.105.6.861; Clary-Meinesz C, 1998, EUR RESPIR J, V11, P330, DOI 10.1183/09031936.98.11020330; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DeCoursey TE, 2002, J GEN PHYSIOL, V120, P773, DOI 10.1085/jgp.20028704; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; GIDDENS WE, 1972, ARCH ENVIRON HEALTH, V25, P166, DOI 10.1080/00039896.1972.10666156; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Illek B, 1998, AM J PHYSIOL-LUNG C, V275, pL902, DOI 10.1152/ajplung.1998.275.5.L902; Inglis SK, 2003, AM J PHYSIOL-LUNG C, V284, pL855, DOI 10.1152/ajplung.00348.2002; Jayaraman S, 2001, AM J PHYSIOL-CELL PH, V281, pC1504, DOI 10.1152/ajpcell.2001.281.5.C1504; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; KYLE H, 1990, J APPL PHYSIOL, V68, P135, DOI 10.1152/jappl.1990.68.1.135; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; LUK CK, 1983, CLIN SCI, V64, P449, DOI 10.1042/cs0640449; Maturana A, 2001, J BIOL CHEM, V276, P30277, DOI 10.1074/jbc.M010438200; Morgan D, 2002, J GEN PHYSIOL, V119, P571, DOI 10.1085/jgp.20018544; Paradiso AM, 1997, AM J PHYSIOL-LUNG C, V273, pL148, DOI 10.1152/ajplung.1997.273.1.L148; Reeves EP, 2003, J MED MICROBIOL, V52, P643, DOI 10.1099/jmm.0.05181-0; Sachs LA, 2003, IN VITRO CELL DEV-AN, V39, P56; Shatwell KP, 1996, INT J BIOCHEM CELL B, V28, P1191, DOI 10.1016/S1357-2725(96)00084-2; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Tamada T, 2001, JOP, V2, P219; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WILLUMSEN NJ, 1992, J PHYSIOL-LONDON, V455, P247, DOI 10.1113/jphysiol.1992.sp019300; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713	50	123	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36454	36461		10.1074/jbc.M404983200	http://dx.doi.org/10.1074/jbc.M404983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210697	hybrid			2022-12-25	WOS:000223453600038
J	Standfuss, J; Kuhlbrandt, W				Standfuss, J; Kuhlbrandt, W			The three isoforms of the light-harvesting complex II - Spectroscopic features, trimer formation, and functional roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEIN; PHOTOSYSTEM-II; LHC-II; CHLOROPHYLL-A; PHOSPHORYLATION; RECONSTITUTION; TRIMERIZATION; POLYPEPTIDES; ORGANIZATION; PLANTS	The major light-harvesting complex (LHC-II) of higher plants plays a crucial role in capturing light energy for photosynthesis and in regulating the flow of energy within the photosynthetic apparatus. Native LHC-II isolated from plant tissue consists of three isoforms, Lhcb1, Lhcb2, and Lhcb3, which form homo- and heterotrimers. All three isoforms are highly conserved among different species, suggesting distinct functional roles. We produced the three LHC-II isoforms by heterologous expression of the polypeptide in Escherichia coli and in vitro refolding with purified pigments. Although Lhcb1 and Lhcb2 are very similar in polypeptide sequence and pigment content, Lhcb3 is clearly different because it lacks an N-terminal phosphorylation site and has a higher chlorophyll a/b ratio, suggesting the absence of one chlorophyll b. Low temperature absorption and fluorescence emission spectra of the pure isoforms revealed small but significant differences in pigment organization. The oligomeric state of the pure isoforms and of their permutations was investigated by native gel electrophoresis, sucrose density gradient centrifugation, and SDS-PAGE. Lhcb1 and Lhcb2 formed trimeric complexes by themselves and with one another, but Lhcb3 was able to do so only in combination with one or both of the other isoforms. We conclude that the main role of Lhcb1 and Lhcb2 is in the adaptation of photosynthesis to different light regimes. The most likely role of Lhcb3 is as an intermediary in light energy transfer from the main Lhcb1/Lhcb2 antenna to the photosystem II core.	Max Planck Inst Biophys, Dept Biol Struct, D-60439 Frankfurt, Germany	Max Planck Society	Standfuss, J (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Marie Curie Str 13-15, D-60439 Frankfurt, Germany.	joerg.standfuss@mpibp-frankfurt.mpg.de	Standfuss, Joerg/G-5126-2011	Kuhlbrandt, Werner/0000-0002-2013-4810				Andersson J, 2003, PLANT J, V35, P350, DOI 10.1046/j.1365-313X.2003.01811.x; Barber J, 1999, CURR OPIN STRUC BIOL, V9, P469, DOI 10.1016/S0959-440X(99)80066-9; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; Fleming GR, 1997, CURR OPIN STRUC BIOL, V7, P738, DOI 10.1016/S0959-440X(97)80086-3; HOBE S, 1995, BIOCHEMISTRY-US, V34, P10224, DOI 10.1021/bi00032a016; Hobe S, 2003, J BIOL CHEM, V278, P5912, DOI 10.1074/jbc.M211145200; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; IDE JP, 1986, ULTRAFAST PHENOMENA, V5, P406; ISLAM K, 1987, BIOCHIM BIOPHYS ACTA, V893, P333, DOI 10.1016/0005-2728(87)90054-5; Jackowski G, 2001, BBA-BIOENERGETICS, V1504, P340, DOI 10.1016/S0005-2728(00)00262-0; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JANSSON S, 1990, BIOCHIM BIOPHYS ACTA, V1019, P110, DOI 10.1016/0005-2728(90)90130-V; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Kuttkat A, 1996, EUR J BIOCHEM, V242, P288, DOI 10.1111/j.1432-1033.1996.0288r.x; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P59, DOI 10.1016/0005-2728(87)90212-X; LARSSON UK, 1985, BIOCHIM BIOPHYS ACTA, V809, P396, DOI 10.1016/0005-2728(85)90190-2; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; MORISHIGE DT, 1991, FEBS LETT, V293, P183, DOI 10.1016/0014-5793(91)81182-8; MORRISSEY PJ, 1989, PLANT CELL PHYSIOL, V30, P335; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PAULSEN H, 1995, PHOTOCHEM PHOTOBIOL, V62, P367, DOI 10.1111/j.1751-1097.1995.tb02357.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; Peterman EJG, 1997, CHEM PHYS LETT, V264, P279, DOI 10.1016/S0009-2614(96)01334-6; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rogl H, 1999, BIOCHEMISTRY-US, V38, P16214, DOI 10.1021/bi990739p; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Rogl H, 2002, BIOCHEMISTRY-US, V41, P2281, DOI 10.1021/bi015875k; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMPSON DJ, 1996, ADV PHOTOSYNTHESIS, P493; STANDFUSS J, 2000, M PLANCK I BIOPHYSIC; Walters RG, 1999, PHOTOSYNTH RES, V61, P77, DOI 10.1023/A:1006243005318; Yang CH, 1999, BIOCHEMISTRY-US, V38, P16205, DOI 10.1021/bi990738x	44	66	73	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36884	36891		10.1074/jbc.M402348200	http://dx.doi.org/10.1074/jbc.M402348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208324	hybrid			2022-12-25	WOS:000223453600090
J	van Vugt, MATM; van de Weerdt, BCM; Vader, G; Janssen, H; Calafat, J; Klompmaker, R; Wolthuis, RMF; Medema, RH				van Vugt, MATM; van de Weerdt, BCM; Vader, G; Janssen, H; Calafat, J; Klompmaker, R; Wolthuis, RMF; Medema, RH			Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; CELL-CYCLE; MITOTIC SPINDLE; SCHIZOSACCHAROMYCES-POMBE; CHROMATID SEPARATION; CHECKPOINT ARREST; MAMMALIAN-CELLS; M-PHASE; MITOSIS; PHOSPHORYLATION	Polo-like kinase-1 (Plk1) performs multiple essential functions during the cell cycle. Here we show that human Plk1-deficient cells are unable to separate their centrosomes, fail to form a bipolar spindle, and undergo a Mad2/BubR1-dependent prometaphase arrest. However, electron microscopy demonstrates that kinetochoremicrotubule interactions can be established in cells lacking Plk1. In addition, co-depletion of Plk1 and survivin allows mitotic exit. This indicates that Plk1 depletion does not prevent microtubule attachment, but specifically interferes with the generation of tension, as a consequence of a failure to form a bipolar spindle. Moreover, we find that after silencing of the spindle assembly checkpoint, degradation of cyclin B1 is unaffected in cells lacking Plk1. These data indicate that activation of the anaphase promoting complex or cyclosome (APC/C)-Cdc20 complex that is under control of the spindle assembly checkpoint does not require Plk1 activity. Finally, we find that translocation of chromosome passengers and initiation of cleavage furrow ingression is unaffected in cells depleted of Plk1. Thus, our data confirm an important role of Plk1 in bipolar spindle formation, and also demonstrate that Plk1 is dispensable for APC/C-Cdc20 activation and the initiation of cytokinesis.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Medema, RH (corresponding author), Netherlands Canc Inst, Div Mol Biol, H8,Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.medema@nki.nl	Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381; Wolthuis, Rob/0000-0002-3109-1588; Vader, Gerben/0000-0001-5729-0991				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lens SMA, 2003, CELL CYCLE, V2, P507, DOI 10.4161/cc.2.6.559; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Taylor SS, 2001, J CELL SCI, V114, P4385; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	61	154	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36841	36854		10.1074/jbc.M313681200	http://dx.doi.org/10.1074/jbc.M313681200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210710	hybrid			2022-12-25	WOS:000223453600086
J	Yoshiba, S; Ooga, T; Nakagawa, N; Shibata, T; Inoue, Y; Yokoyama, S; Kuramitsu, S; Masui, R				Yoshiba, S; Ooga, T; Nakagawa, N; Shibata, T; Inoue, Y; Yokoyama, S; Kuramitsu, S; Masui, R			Structural insights into the Thermus thermophilus ADP-ribose pyrophosphatase mechanism via crystal structures with the bound substrate and metal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUDIX HYDROLASES; DIFFRACTION DATA; IDENTIFICATION; MOLSCRIPT; PROGRAM; FAMILY	ADP-ribose pyrophosphatase (ADPRase) catalyzes the divalent metal ion-dependent hydrolysis of ADP-ribose to ribose 5'-phosphate and AMP. This enzyme plays a key role in regulating the intracellular ADP-ribose levels, and prevents nonenzymatic ADP-ribosylation. To elucidate the pyrophosphatase hydrolysis mechanism employed by this enzyme, structural changes occurring on binding of substrate, metal and product were investigated using crystal structures of ADPRase from an extreme thermophile, Thermus thermophilus HB8. Seven structures were determined, including that of the free enzyme, the Zn2+-bound enzyme, the binary complex with ADP-ribose, the ternary complexes with ADPribose and Zn2+ or Gd3+, and the product complexes with AMP and Mg2+ or with ribose 5'-phosphate and Zn2+. The structural and functional studies suggested that the ADP-ribose hydrolysis pathway consists of four reaction states: bound with metal (I), metal and substrate (II), metal and substrate in the transition state (III), and products (IV). In reaction state II, Glu-82 and Glu-70 abstract a proton from a water molecule. This water molecule is situated at an ideal position to carry out nucleophilic attack on the adenosyl phosphate, as it is 3.6 Angstrom away from the target phosphorus and almost in line with the scissile bond.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; RIKEN, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; RIKEN, Gen Sci Ctr, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN, Harima Inst SPring 8, Mikazuki, Hyogo 6795148, Japan	Osaka University; RIKEN; RIKEN; RIKEN	Masui, R (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	rmasui@bio.sci.osaka-u.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; AMES BN, 1960, J BIOL CHEM, V235, P769; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dean J.A., 1999, LANGES HDB CHEM; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gabelli SB, 2002, BIOCHEMISTRY-US, V41, P9279, DOI 10.1021/bi0259296; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUST I, 1994, EUR J BIOCHEM, V221, P1047, DOI 10.1111/j.1432-1033.1994.tb18823.x; Kang LW, 2003, STRUCTURE, V11, P1015, DOI 10.1016/S0969-2126(03)00154-0; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rafty LA, 2002, J BIOL CHEM, V277, P47114, DOI 10.1074/jbc.M208997200; Ribeiro JM, 1999, J BIOCHEM MOL TOXIC, V13, P171, DOI 10.1002/(SICI)1099-0461(1999)13:3/4<171::AID-JBT7>3.3.CO;2-M; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vieille C, 1996, Biotechnol Annu Rev, V2, P1, DOI 10.1016/S1387-2656(08)70006-1; YAMAMOTO M, 2001, SPRING 8 INF, V6, P202; Yokoyama S, 2000, PROG BIOPHYS MOL BIO, V73, P363, DOI 10.1016/S0079-6107(00)00012-2; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Yoshiba S, 2003, ACTA CRYSTALLOGR D, V59, P1840, DOI 10.1107/S090744490301713X	33	26	27	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37163	37174		10.1074/jbc.M403817200	http://dx.doi.org/10.1074/jbc.M403817200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210687	hybrid			2022-12-25	WOS:000223453600120
J	Aihara, K; Azuma, H; Akaike, M; Ikeda, Y; Yamashita, M; Sudo, T; Hayashi, H; Yamada, Y; Endoh, F; Fujimura, M; Yoshida, T; Yamaguchi, H; Hashizume, S; Kato, M; Yoshimura, K; Yamamoto, Y; Kato, S; Matsumoto, T				Aihara, K; Azuma, H; Akaike, M; Ikeda, Y; Yamashita, M; Sudo, T; Hayashi, H; Yamada, Y; Endoh, F; Fujimura, M; Yoshida, T; Yamaguchi, H; Hashizume, S; Kato, M; Yoshimura, K; Yamamoto, Y; Kato, S; Matsumoto, T			Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-FACTOR; 1,25-DIHYDROXYVITAMIN D-3; ANTITHROMBIN DEFICIENCY; WHOLE-BLOOD; EXPRESSION; CELLS; AGGREGATION; RICKETS	Vitamin D metabolites influence the expression of various genes involved in calcium homeostasis, cell differentiation, and regulation of the immune system. Expression of these genes is mediated by the activation of the nuclear vitamin D receptor (VDR). Previous studies have shown that a hormonally active form of vitamin D, 1alpha,25-dihydroxyvitamin D3, exerts anticoagulant effects in cultured monocytic cells. To clarify whether activation of VDR plays any antithrombotic actions in vivo, hemostatic/thrombogenic systems were examined in normocalcemic VDR knock-out (KO) mice on a high calcium diet and compared with wild type and hypocalcemic VDRKO mice that were fed a regular diet. Platelet aggregation was enhanced significantly in normocalcemic VDRKO mice compared with wild type and hypocalcemic VDRKO mice. Aortic endothelial nitric-oxide (NO) synthase expression and urinary NOx excretions were reduced in hypocalcemic VDRKO mice, but not in normocalcemic VDRKO mice. Northern blot and RT-PCR analyses revealed that the gene expression of antithrombin in the liver as well as that of thrombomodulin in the aorta, liver and kidney was down-regulated in hypo- and normocalcemic VDRKO mice. Whereas tissue factor mRNA expression in the liver and kidney was up-regulated in VDRKO mice regardless of plasma calcium level. Furthermore, VDRKO mice manifested an exacerbated multi-organ thrombus formation after exogenous lipopolysaccharide injection regardless of the calcemic conditions. These results demonstrate that activation of nuclear VDR elicits antithrombotic effects in vivo, and suggest that the VDR system may play a physiological role in the maintenance of antithrombotic homeostasis.	Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan; Univ Tokushima, Grad Sch Med, Dept Pathol, Tokushima 7708503, Japan; Otsuka Pharmaceut Co Ltd, Inst New Drug Discovery 1, Tokushima 7710192, Japan; TSL Inc, Higashimatuyama Lab, Anat & Mol Div, Higashimatsuyama, Saitama, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Tokushima University; Tokushima University; Otsuka Pharmaceutical; University of Tokyo	Aihara, K (corresponding author), Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	aihara@clin.med.tokushima-u.ac.jp	Aihara, Ken-ichi/AEE-8245-2022	Aihara, Ken-ichi/0000-0001-8906-0920; Ikeda, Yasumasa/0000-0003-4318-7349				ABRAMS C, 1991, THROMB HAEMOSTASIS, V65, P467; Asakura H, 2001, THROMB HAEMOSTASIS, V85, P287; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Endo I, 2003, ENDOCRINOLOGY, V144, P5138, DOI 10.1210/en.2003-0502; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Koyama T, 1998, BLOOD, V92, P160, DOI 10.1182/blood.V92.1.160.413k16_160_167; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Loscalzo J, 2000, Trans Am Clin Climatol Assoc, V111, P158; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mathieu C, 2001, J BONE MINER RES, V16, P2057, DOI 10.1359/jbmr.2001.16.11.2057; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; NIELSEN HK, 1991, SEMIN THROMB HEMOST, V17, P250; Niessen RWLM, 1996, BIOCHEM J, V318, P263, DOI 10.1042/bj3180263; Ohsawa M, 2000, CIRCULATION, V102, P2867; Ozeki Y, 2001, THROMB RES, V101, P65, DOI 10.1016/S0049-3848(00)00377-7; POLLER L, 1988, THROMB HAEMOSTASIS, V60, P18; Sudo T, 2003, PLATELETS, V14, P239, DOI 10.1080/0953710031000118885; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Verhagen AMG, 1998, J AM SOC NEPHROL, V9, P755; Yamada K, 1997, J NEUROCHEM, V68, P1234; Yanada M, 2002, BLOOD, V99, P2455, DOI 10.1182/blood.V99.7.2455; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	27	189	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35798	35802		10.1074/jbc.M404865200	http://dx.doi.org/10.1074/jbc.M404865200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205460	hybrid			2022-12-25	WOS:000223303400080
J	Bohme, I; Rabe, H; Luddens, H				Bohme, I; Rabe, H; Luddens, H			Four amino acids in the alpha subunits determine the gamma-aminobutyric acid sensitivities of GABA(A) receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTORS; BINDING; PHARMACOLOGY; CELLS; HIPPOCAMPAL; AFFINITY; CHANNELS; DOMAIN; SITES	GABA(A) receptors, mediators of fast inhibitory neurotransmission, are heteropentameric assemblies from a large array of subunits. Differences in the sensitivity of receptor subtypes to endogenous GABA may permit subunit-dependent finely tuned responsiveness to the same GABAergic inputs. Using both radioligand binding and electrophysiology combined with mutagenesis, we identified a domain of four amino acids within the alpha subunits that mediates the distinct sensitivities to GABA allowing their selective switch between alphabeta3gamma2 combinations. Replacing this domain in alpha3 by the corresponding segments of alpha1-alpha5 resulted in mutant receptors displaying the GABA EC50 values of the respective wild-type receptors. Vice versa, the alpha3 motif forced the low sensitivity to GABA of alpha3 upon alpha1beta3gamma2, alpha4beta3gamma2, and alpha5beta3gamma2. Binding of the GABA agonist [H-3] muscimol was not affected by the exchange of the motif between alpha1 and alpha3 subunits. Thus, the equilibrium binding pocket is maintained upon replacement of the four amino acids. Taken together our data suggest that the identified motifs contribute to a structure involved in the transduction of the binding signal rather than to the binding itself.	Univ Mainz, Dept Psychiat, Mol Biol Lab, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Luddens, H (corresponding author), Univ Mainz, Dept Psychiat, Mol Biol Lab, Untere Zahlbacher Str 8, D-55131 Mainz, Germany.	lueddens@uni-mainz.de						Barnard EA, 1998, PHARMACOL REV, V50, P291; Baur R, 2003, J NEUROCHEM, V87, P325, DOI 10.1046/j.1471-4159.2003.01982.x; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brickley SG, 1999, J NEUROSCI, V19, P2960; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; DUCIC I, 1995, J PHARMACOL EXP THER, V272, P438; EBERT B, 1994, MOL PHARMACOL, V46, P957; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Fritschy JM, 1998, NEUROSCI LETT, V249, P99, DOI 10.1016/S0304-3940(98)00397-8; Gingrich KJ, 1995, J PHYSIOL-LONDON, V489, P529, DOI 10.1113/jphysiol.1995.sp021070; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartvig L, 2000, J NEUROCHEM, V75, P1746, DOI 10.1046/j.1471-4159.2000.0751746.x; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; KORPI ER, 1993, MOL PHARMACOL, V44, P87; KORPI ER, 1992, EUR J PHARMACOL, V211, P427, DOI 10.1016/0014-2999(92)90402-P; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LUDDENS H, 1995, J NEUROSCI, V15, P6957; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Nusser Z, 1998, J NEUROSCI, V18, P1693; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; Saxena NC, 1996, MOL PHARMACOL, V49, P567; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8	36	43	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35193	35200		10.1074/jbc.M405653200	http://dx.doi.org/10.1074/jbc.M405653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199051	hybrid			2022-12-25	WOS:000223303400009
J	Chen, ZJ; Rogge, G; Hague, C; Alewood, D; Colless, B; Lewis, RJ; Minneman, KP				Chen, ZJ; Rogge, G; Hague, C; Alewood, D; Colless, B; Lewis, RJ; Minneman, KP			Subtype-selective noncompetitive or competitive inhibition of human alpha(1)-adrenergic receptors by rho-TIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1D)-ADRENERGIC RECEPTOR; CELL-SURFACE EXPRESSION; ARTERIAL BLOOD-PRESSURE; PHASE PEPTIDE-SYNTHESIS; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; CARDIAC-HYPERTROPHY; MOLECULAR-CLONING; RAT-BRAIN; ALPHA(1A)-ADRENERGIC RECEPTOR	The 19-amino acid conopeptide (rho-TIA) was shown previously to antagonize noncompetitively alpha(1B)-adrenergic receptors (ARs). Because this is the first peptide ligand for these receptors, we compared its interactions with the three recombinant human alpha(1)-AR subtypes (alpha(1A), alpha(1B), and alpha(1D)). Radioligand binding assays showed that rho-TIA was 10-fold selective for human alpha(1B)- over alpha(1A)- and alpha(1D)-ARs. As observed with hamster alpha(1B)-ARs, rho-TIA decreased the number of binding sites (B-max) for human alpha(1B)-ARs without changing affinity (K-D), and this inhibition was unaffected by the length of incubation but was reversed by washing. However, rho-TIA had opposite effects at human alpha(1A)-ARs and alpha(1D)-ARs, decreasing KD without changing Bmax, suggesting it acts competitively at these subtypes. rho-TIA reduced maximal NE-stimulated [H-3] inositol phosphate formation in HEK293 cells expressing human alpha(1B)-ARs but competitively inhibited responses in cells expressing alpha(1A)- or alpha(1D)-ARs. Truncation mutants showed that the amino-terminal domains of alpha(1B)- or alpha(1D)-ARs are not involved in interaction with rho-TIA. Alanine-scanning mutagenesis of rho-TIA showed F18A had an increased selectivity for alpha(1B)-ARs, and F18N also increased subtype selectivity. I8A had a slightly reduced potency at alpha(1B)-ARs and was found to be a competitive, rather than noncompetitive, inhibitor in both radioligand and functional assays. Thus rho-TIA noncompetitively inhibits alpha(1B)-ARs but competitively inhibits the other two subtypes, and this selectivity can be increased by mutation. These differential interactions do not involve the receptor amino termini and are not because of the charged nature of the peptide, and isoleucine 8 is critical for its noncompetitive inhibition at alpha(1B)-ARs.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Xenome Ltd, Indooroopilly, Qld 4068, Australia	Emory University	Minneman, KP (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	kminneman@pharm.emory.edu	Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X				ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; Burcelin R, 2004, J BIOL CHEM, V279, P1108, DOI 10.1074/jbc.M307788200; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Drouin C, 2002, J NEUROSCI, V22, P2873, DOI 10.1523/JNEUROSCI.22-07-02873.2002; ESBENSHADE TA, 1995, MOL PHARMACOL, V47, P977; FOGLAR R, 1995, EUR J PHARM-MOLEC PH, V288, P201, DOI 10.1016/0922-4106(95)90195-7; GOETZ AS, 1995, EUR J PHARMACOL, V272, pR5, DOI 10.1016/0014-2999(94)00751-R; Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104; GREENGRASS P, 1979, EUR J PHARMACOL, V55, P323, DOI 10.1016/0014-2999(79)90202-4; GROSS G, 1988, EUR J PHARMACOL, V151, P333, DOI 10.1016/0014-2999(88)90819-9; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; HAN C, 1987, MOL PHARMACOL, V32, P505; Hancock AA, 1996, DRUG DEVELOP RES, V39, P54; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; HENRY JA, 1993, BIOORG MED CHEM LETT, V3, P949, DOI 10.1016/S0960-894X(00)80698-8; HIRASAWA A, 1993, BIOCHEM BIOPH RES CO, V195, P902, DOI 10.1006/bbrc.1993.2130; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Hruby VJ, 2003, LIFE SCI, V73, P699, DOI 10.1016/S0024-3205(03)00390-4; Hruby VJ, 2002, NAT REV DRUG DISCOV, V1, P847, DOI 10.1038/nrd939; Leppik RA, 2000, MOL PHARMACOL, V57, P436, DOI 10.1124/mol.57.3.436; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MINNEMAN KP, 1983, MOL PHARMACOL, V23, P359; MORROW AL, 1985, EUR J PHARMACOL, V109, P285, DOI 10.1016/0014-2999(85)90432-7; MORROW AL, 1986, MOL PHARMACOL, V29, P321; O'Connell TD, 2003, J CLIN INVEST, V111, P1783, DOI 10.1172/JCI200316100; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Pupo AS, 2003, EUR J PHARMACOL, V462, P1, DOI 10.1016/S0014-2999(03)01292-5; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Rokosh DG, 2002, P NATL ACAD SCI USA, V99, P9474, DOI 10.1073/pnas.132552699; Romeo G, 2003, J MED CHEM, V46, P2877, DOI 10.1021/jm0307741; Saha S, 1998, J PEPT RES, V52, P112; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; Sharpe IA, 2003, J BIOL CHEM, V278, P34451, DOI 10.1074/jbc.M305410200; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Tanoue A, 2002, J CLIN INVEST, V109, P765, DOI 10.1172/JCI200214001; Tanoue A, 2002, LIFE SCI, V71, P2207, DOI 10.1016/S0024-3205(02)02012-X; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; WALKER P, 1994, J BIOL CHEM, V269, P2863; Waugh DJJ, 1999, J PHARMACOL EXP THER, V291, P1164; XIE YB, 1990, J BIOL CHEM, V265, P21411; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8; Zuscik MJ, 2001, J BIOL CHEM, V276, P13738, DOI 10.1074/jbc.M008693200; Zuscik MJ, 2000, NAT MED, V6, P1388, DOI 10.1038/82207	60	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35326	35333		10.1074/jbc.M403703200	http://dx.doi.org/10.1074/jbc.M403703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194691	hybrid			2022-12-25	WOS:000223303400025
J	Hu, HZ; Gu, QH; Wang, CB; Colton, CK; Tang, JS; Kinoshita-Kawada, M; Lee, LY; Wood, JD; Zhu, MX				Hu, HZ; Gu, QH; Wang, CB; Colton, CK; Tang, JS; Kinoshita-Kawada, M; Lee, LY; Wood, JD; Zhu, MX			2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; CAPSAICIN-RECEPTOR; CA2+ RELEASE; ION-CHANNEL; VANILLOID RECEPTOR-1; TRPC3 CHANNELS; ENTRY; 2-APB; HEAT; SENSITIVITY	The transient receptor potential (TRP) superfamily contains a large number of proteins encoding cation permeable channels that are further divided into TRPC (canonical), TRPM (melastatin), and TRPV (vanilloid) subfamilies. Among the six TRPV members, TRPV1, TRPV2, TRPV3, and TRPV4 form heat-activated cation channels, which serve diverse functions ranging from nociception to osmolality regulation. Although chemical activators for TRPV1 and TRPV4 are well documented, those for TRPV2 and TRPV3 are lacking. Here we show that in the absence of other stimuli, 2-aminoethoxydiphenyl borate (2APB) activates TRPV1, TRPV2, and TRPV3, but not TRPV4, TRPV5, and TRPV6 expressed in HEK293 cells. In contrast, 2APB inhibits the activity of TRPC6 and TRPM8 evoked by 1-oleolyl-2-acetyl-sn-glycerol and menthol, respectively. In addition, low levels of 2APB strongly potentiate the effect of capsaicin, protons, and heat on TRPV1 as well as that of heat on TRPV3 expressed in Xenopus oocytes. In dorsal root ganglia neurons, supra-additive stimulations were evoked by 2APB and capsaicin or 2APB and acid. Our data suggest the existence of a common activation mechanism for TRPV1, TRPV2, and TRPV3 that may serve as a therapeutic target for pain management and treatment for diseases caused by hypersensitivity and temperature misregulation.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University of Kentucky; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Wood, JD (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	wood.13@osu.edu; zhu.55@osu.edu		Hu, Hongzhen/0000-0002-8967-7522; Lee, Lu-Yuan/0000-0001-8306-2845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL067379, R01HL067379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67379] Funding Source: Medline; NIDDK NIH HHS [DK057075] Funding Source: Medline; NINDS NIH HHS [NS42183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lemonnier L, 2004, FEBS LETT, V556, P121, DOI 10.1016/S0014-5793(03)01387-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Tsuzuki K, 2004, J NEUROSCI, V24, P762, DOI 10.1523/JNEUROSCI.4658-03.2004; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	52	372	410	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35741	35748		10.1074/jbc.M404164200	http://dx.doi.org/10.1074/jbc.M404164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194687	hybrid			2022-12-25	WOS:000223303400073
J	Jonsson, S; Ricagno, S; Lindqvist, Y; Richards, NGJ				Jonsson, S; Ricagno, S; Lindqvist, Y; Richards, NGJ			Kinetic and mechanistic characterization of the formyl-CoA transferase from Oxalobacter formigenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A TRANSFERASE; PSEUDOMONAS OXALATICUS OX1; ESCHERICHIA-COLI; OXALYL-COENZYME; CARBON ASSIMILATION; EXCHANGE PROTEIN; ACYL-TRANSFER; THIOL ESTERS; FORMATE; GENE	Oxalobacter formigenes is an obligate anaerobe that colonizes the human gastrointestinal tract and employs oxalate breakdown to generate ATP in a novel process involving the interplay of two coupled enzymes and a membrane-bound oxalate: formate antiporter. Formyl-CoA transferase is a critical enzyme in oxalate-dependent ATP synthesis and is the first Class III CoA-transferase for which a high resolution, three-dimensional structure has been determined (Ricagno, S., Jonsson, S., Richards, N., and Lindqvist, Y. (2003) EMBO J. 22, 3210-3219). We now report the first detailed kinetic characterizations of recombinant, wild type formyl-CoA transferase and a number of site-specific mutants, which suggest that catalysis proceeds via a series of anhydride intermediates. Further evidence for this mechanistic proposal is provided by the x-ray crystallographic observation of an acylenzyme intermediate that is formed when formyl-CoA transferase is incubated with oxalyl-CoA. The catalytic mechanism of formyl-CoA transferase is therefore established and is almost certainly employed by all other members of the Class III CoA-transferase family.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	Karolinska Institutet; State University System of Florida; University of Florida	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	ylva.lindqvist@mbb.ki.se; richards@qtp.ufl.edu	Lindqvist, Ylva/F-9009-2010; Ricagno, Stefano/AAH-9763-2020; Ricagno, Stefano/G-1456-2015	Ricagno, Stefano/0000-0001-6678-5873; Ricagno, Stefano/0000-0001-6678-5873; Lindqvist, Ylva/0000-0003-3162-8661	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061666, R56DK061666, R01DK053556] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53556, DK61666] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ALLISON MJ, 1986, J NUTR, V116, P455, DOI 10.1093/jn/116.3.455; ANATHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1990, J BACTERIOL, V172, P3537, DOI 10.1128/jb.172.7.3537-3540.1990; BAETZ AL, 1992, SYST APPL MICROBIOL, V15, P167, DOI 10.1016/S0723-2020(11)80087-1; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAX PC, 1970, RECL TRAV CHIM PAY-B, V89, P265; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cornick NA, 1996, APPL ENVIRON MICROB, V62, P3011, DOI 10.1128/AEM.62.8.3011-3013.1996; Cornick NA, 1996, CAN J MICROBIOL, V42, P1081, DOI 10.1139/m96-138; DAWSON KA, 1980, APPL ENVIRON MICROB, V40, P833, DOI 10.1128/AEM.40.4.833-839.1980; DEMOZ A, 1995, J CHROMATOGR B, V667, P148, DOI 10.1016/0378-4347(94)00595-V; Dickert S, 2000, EUR J BIOCHEM, V267, P3874, DOI 10.1046/j.1432-1327.2000.01427.x; Elssner T, 2001, BIOCHEMISTRY-US, V40, P11140, DOI 10.1021/bi0108812; EMSLEY P, 2004, IN PRESS ACTA CRYS D, V60; Gogos A, 2004, ACTA CRYSTALLOGR D, V60, P507, DOI 10.1107/S0907444904000034; Gruez A, 2003, J BIOL CHEM, V278, P34582, DOI 10.1074/jbc.C300282200; Heider J, 2001, FEBS LETT, V509, P345, DOI 10.1016/S0014-5793(01)03178-7; HERSH LB, 1967, J BIOL CHEM, V242, P3468; Hess RA, 1998, J AM CHEM SOC, V120, P2703, DOI 10.1021/ja973413h; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAKOBY WB, 1956, J BIOL CHEM, V222, P435; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LESLIE AGW, 1997, MOSFLM VERSION 5 40; Leutwein C, 2002, ARCH MICROBIOL, V178, P517, DOI 10.1007/s00203-002-0484-5; Leutwein C, 2001, J BACTERIOL, V183, P4288, DOI 10.1128/JB.183.14.4288-4295.2001; Lloyd AJ, 2001, BIOCHEMISTRY-US, V40, P2455, DOI 10.1021/bi002169v; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; LUNG HY, 1994, J BACTERIOL, V176, P2468, DOI 10.1128/JB.176.8.2468-2472.1994; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOORE SA, 1982, J BIOL CHEM, V257, P893; MOORE SA, 1982, J BIOL CHEM, V257, P882; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; QUAYLE JR, 1959, BIOCHEM J, V72, P631, DOI 10.1042/bj0720631; QUAYLE JR, 1963, BIOCHEM J, V89, P492, DOI 10.1042/bj0890492; QUAYLE JR, 1963, BIOCHEM J, V87, P368, DOI 10.1042/bj0870368; Ricagno S, 2003, EMBO J, V22, P3210, DOI 10.1093/emboj/cdg333; Ricagno S, 2003, ACTA CRYSTALLOGR D, V59, P1276, DOI 10.1107/S0907444903009545; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Segel I. H., 1975, ENZYME KINETICS, P273; Selmer T, 1999, J BIOL CHEM, V274, P20772, DOI 10.1074/jbc.274.30.20772; Sidhu H, 1998, LANCET, V352, P1026, DOI 10.1016/S0140-6736(98)03038-4; Sidhu H, 1997, J BACTERIOL, V179, P3378, DOI 10.1128/jb.179.10.3378-3381.1997; Sidhu H, 1999, J AM SOC NEPHROL, V10, pS334; SLY WS, 1963, J BIOL CHEM, V238, P2632; SRAMEK SJ, 1977, ARCH BIOCHEM BIOPHYS, V181, P525, DOI 10.1016/0003-9861(77)90259-4; STEVENS W, 1964, RECL TRAV CHIM PAY B, V83, P863; WHITE H, 1976, J BIOL CHEM, V251, P1688; Yang W, 2001, J AM CHEM SOC, V123, P11004, DOI 10.1021/ja010726a; Ye HQ, 1999, J LIPID RES, V40, P17; ZAITSEV GM, 1993, MICROBIOLOGY+, V62, P378	60	45	50	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36003	36012		10.1074/jbc.M404873200	http://dx.doi.org/10.1074/jbc.M404873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15213226	hybrid			2022-12-25	WOS:000223303400102
J	Kovacs, M; Toth, J; Hetenyi, C; Malnasi-Csizmadia, A; Sellers, JR				Kovacs, M; Toth, J; Hetenyi, C; Malnasi-Csizmadia, A; Sellers, JR			Mechanism of blebbistatin inhibition of myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; RABBIT SKELETAL-MUSCLE; TRYPTOPHAN RESIDUE; NEURITE OUTGROWTH; MOTOR DOMAIN; BINDING; ACTIN; CONTRACTION; TRANSITION; RESOLUTION	Blebbistatin is a recently discovered small molecule inhibitor showing high affinity and selectivity toward myosin II. Here we report a detailed investigation of its mechanism of inhibition. Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. Blebbistatin interferes neither with binding of myosin to actin nor with ATP-induced actomyosin dissociation. Instead, it blocks the myosin heads in a products complex with low actin affinity. Blind docking molecular simulations indicate that the productive blebbistatin-binding site of the myosin head is within the aqueous cavity between the nucleotide pocket and the cleft of the actin-binding interface. The property that blebbistatin blocks myosin II in an actin-detached state makes the compound useful both in muscle physiology and in exploring the cellular function of cytoplasmic myosin II isoforms, whereas the stabilization of a specific myosin intermediate confers a great potential in structural studies.	NIH, Mol Cardiol Lab, NHLBI, Bethesda, MD 20892 USA; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Eotvos Lorand University	Sellers, JR (corresponding author), NIH, Mol Cardiol Lab, NHLBI, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Csizmadia, András Málnási/K-7632-2018; Kovacs, Mihaly/A-6841-2011; Hetenyi, Csaba/G-5249-2010	Csizmadia, András Málnási/0000-0002-2430-8398; Hetenyi, Csaba/0000-0002-8013-971X; Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004234, ZIAHL004234] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Brown J, 2003, J HISTOCHEM CYTOCHEM, V51, P421, DOI 10.1177/002215540305100403; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LIMOUZE J, 2004, IN PRESS J MUSCLE RE; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Onishi H, 2000, P NATL ACAD SCI USA, V97, P11203, DOI 10.1073/pnas.200362897; Ostap EM, 2002, J MUSCLE RES CELL M, V23, P305, DOI 10.1023/A:1022047102064; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Sellers J. R., 1999, MYOSINS; Shaw MA, 2003, BIOCHEMISTRY-US, V42, P6128, DOI 10.1021/bi026964f; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wylie SR, 2003, MOL BIOL CELL, V14, P4654, DOI 10.1091/mbc.E03-03-0187; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yumura S, 2003, INT REV CYTOL, V224, P173, DOI 10.1016/S0074-7696(05)24005-6	31	692	703	5	79	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35557	35563		10.1074/jbc.M405319200	http://dx.doi.org/10.1074/jbc.M405319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205456	hybrid			2022-12-25	WOS:000223303400051
J	Patenge, N; Elkin, SK; Oettinger, MA				Patenge, N; Elkin, SK; Oettinger, MA			ATP-dependent remodeling by SWI/SNF and ISWI proteins stimulates V(D)J cleavage of 5 S arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; CHROMATIN-STRUCTURE; NUCLEOSOMAL DNA; TRANSCRIPTION FACTORS; PHD FINGER; GENE; RECOMBINATION; RAG2; ACCESSIBILITY; CELL	Control of V(D)J recombination is critical for the generation of a fully developed immune repertoire. The molecular mechanisms underlying the regulation of antigen receptor gene assembly are beginning to be revealed. Here we studied the influence of chromatin modifications on V(D)J cleavage of a polynucleosomal substrate, in which V(D)J cleavage is greatly reduced compared with naked DNA. ATP-dependent remodeling by human SWI/SNF (hSWI/SNF) in the presence of HMG1 led to a substantial increase of cleavage by the recombination activation gene (RAG) proteins. Either BRG1, the ATPase subunit of hSWI/SNF, or SNF2h, the ATPase of human ISWI complexes, was capable of stimulating V(D)J cleavage of the array, although these remodelers act by different mechanisms. No effect of histone hyperacetylation was detectable in this system. As is observed on naked DNA, in the presence of core RAG1, the full-length RAG2 protein proved to be more active than core RAG2 on these polynucleosomal arrays, reinforcing the importance of the RAG2 C-terminal domain for efficient recombination. Comparison of 5 S array cleavage by the RAG proteins or by the restriction enzyme HhaI after remodeling by hSWI/SNF suggested that RAG proteins and HhaI might have different requirements for maximal accessibility of the substrate.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Oettinger, MA (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Wellman 10,50 Blossom St, Boston, MA 02114 USA.	oettinger@frodo.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Angelin-Duclos C, 1998, MOL CELL BIOL, V18, P6253, DOI 10.1128/MCB.18.11.6253; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann M, 2003, EMBO J, V22, P5197, DOI 10.1093/emboj/cdg487; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Cherry SR, 1999, P NATL ACAD SCI USA, V96, P10788, DOI 10.1073/pnas.96.19.10788; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; COTE J, 1995, METHODS MOL GEN, V6, P102; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Langst G, 2001, J CELL SCI, V114, P2561; LEWIS SM, 1994, ADV IMMUNOL, V56, P127; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Maes J, 2001, J IMMUNOL, V167, P866, DOI 10.4049/jimmunol.167.2.866; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; McBlane F, 2000, CURR BIOL, V10, P483, DOI 10.1016/S0960-9822(00)00449-8; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Morshead KB, 2003, P NATL ACAD SCI USA, V100, P11577, DOI 10.1073/pnas.1932643100; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OwenHughes T, 1996, EMBO J, V15, P4702, DOI 10.1002/j.1460-2075.1996.tb00847.x; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tripathi R, 2002, J IMMUNOL, V168, P2316, DOI 10.4049/jimmunol.168.5.2316; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VanGent DC, 1996, CURR TOP MICROBIOL, V217, P1; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8	70	41	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35360	35367		10.1074/jbc.M405790200	http://dx.doi.org/10.1074/jbc.M405790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201272	hybrid			2022-12-25	WOS:000223303400029
J	Payan, F; Leone, P; Porciero, S; Furniss, C; Tahir, T; Williamson, G; Durand, A; Manzanares, P; Gilbert, HJ; Juge, N; Roussel, A				Payan, F; Leone, P; Porciero, S; Furniss, C; Tahir, T; Williamson, G; Durand, A; Manzanares, P; Gilbert, HJ; Juge, N; Roussel, A			The dual nature of the wheat xylanase protein inhibitor XIP-I - Structural basis for the inhibition of family 10 and family 11 xylanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-ENZYME INTERMEDIATE; TRITICUM-AESTIVUM; 3-DIMENSIONAL STRUCTURE; ALPHA-AMYLASE; SPECIFICITY; SUBSTRATE; BINDING; IDENTIFICATION; SEQUENCE	The xylanase inhibitor protein I (XIP-I) from wheat Triticum aestivum is the prototype of a novel class of cereal protein inhibitors that inhibit fungal xylanases belonging to glycoside hydrolase families 10 (GH10) and 11 (GH11). The crystal structures of XIP-I in complex with Aspergillus nidulans (GH10) and Penicillium funiculosum (GH11) xylanases have been solved at 1.7 and 2.5 Angstrom resolution, respectively. The inhibition strategy is novel because XIP-I possesses two independent enzyme-binding sites, allowing binding to two glycoside hydrolases that display a different fold. Inhibition of the GH11 xylanase is mediated by the insertion of an XIP-I Pi-shaped loop (Lalpha(4)beta(5)) into the enzyme active site, whereas residues in the helix alpha7 of XIP-I, pointing into the four central active site subsites, are mainly responsible for the reversible inactivation of GH10 xylanases. The XIP-I strategy for inhibition of xylanases involves substrate-mimetic contacts and interactions occluding the active site. The structural determinants of XIP-I specificity demonstrate that the inhibitor is able to interact with GH10 and GH11 xylanases of both fungal and bacterial origin. The biological role of the xylanase inhibitors is discussed in light of the present structural data.	Inst Food Res, Inst Food Res, Norwich NR4 7UA, Norfolk, England; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CSIC, Inst Agroquim & Tecnol Alimentos, Valencia 46100, Spain; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Fac Sci & Tech St Jerome, INRA, UMR 1111, Inst Mediterraneen Rech Nutr, F-13397 Marseille, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Newcastle University - UK; INRAE; UDICE-French Research Universities; Aix-Marseille Universite	Juge, N (corresponding author), Inst Food Res, Inst Food Res, Colney Lane, Norwich NR4 7UA, Norfolk, England.	nathalie.juge@bbsrc.ac.uk	Williamson, Gary/AAE-9665-2019; Manzanares, Paloma/H-2873-2012	Williamson, Gary/0000-0002-5624-6267; Manzanares, Paloma/0000-0001-5036-9787; Juge, Nathalie/0000-0001-8515-1315; Tahir, Tariq/0000-0002-3992-6877				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Belshaw NJ, 2002, APPL MICROBIOL BIOT, V60, P455, DOI 10.1007/s00253-002-1141-2; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; Bishop JG, 2000, P NATL ACAD SCI USA, V97, P5322, DOI 10.1073/pnas.97.10.5322; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coutinho PM, 1999, ROY SOC CH, P3; De Lorenzo G, 2002, CURR OPIN PLANT BIOL, V5, P295, DOI 10.1016/S1369-5266(02)00271-6; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Elliott GO, 2003, J CEREAL SCI, V37, P187, DOI 10.1006/jcrs.2002.0493; Fierens K, 2003, FEBS LETT, V540, P259, DOI 10.1016/S0014-5793(03)00276-X; Flatman R, 2002, BIOCHEM J, V365, P773, DOI 10.1042/BJ20020168; Furniss CSM, 2002, BBA-PROTEINS PROTEOM, V1598, P24, DOI 10.1016/S0167-4838(02)00366-7; Garcia-Vallve S, 2000, MOL BIOL EVOL, V17, P352, DOI 10.1093/oxfordjournals.molbev.a026315; Gebruers K, 2004, BBA-PROTEINS PROTEOM, V1696, P213, DOI 10.1016/j.bbapap.2003.08.013; Gebruers K, 2001, BIOCHEM J, V353, P239, DOI 10.1042/0264-6021:3530239; Jeffries TW, 1996, CURR OPIN BIOTECH, V7, P337, DOI 10.1016/S0958-1669(96)80041-3; Juge N, 2004, BBA-PROTEINS PROTEOM, V1696, P203, DOI 10.1016/j.bbapap.2003.08.014; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; Kulkarni N, 1999, FEMS MICROBIOL REV, V23, P411, DOI 10.1111/j.1574-6976.1999.tb00407.x; MacCabe AP, 1996, GENE, V175, P29, DOI 10.1016/0378-1119(96)00116-3; McLauchlan WR, 1999, BIOCHEM J, V338, P441, DOI 10.1042/0264-6021:3380441; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payan F, 2003, BIOCHEM J, V372, P399, DOI 10.1042/BJ20021802; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sabini E, 2001, ACTA CRYSTALLOGR D, V57, P1344, DOI 10.1107/S0907444901010873; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Sansen S, 2004, J BIOL CHEM, V279, P36022, DOI 10.1074/jbc.M404212200; Sapag A, 2002, J BIOTECHNOL, V95, P109, DOI 10.1016/S0168-1656(02)00002-0; Sato Y, 1999, GENE, V238, P93, DOI 10.1016/S0378-1119(99)00321-2; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; Tahir TA, 2002, J BIOL CHEM, V277, P44035, DOI 10.1074/jbc.M205657200; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; [No title captured]	38	101	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36029	36037		10.1074/jbc.M404225200	http://dx.doi.org/10.1074/jbc.M404225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181003	Green Published, hybrid			2022-12-25	WOS:000223303400105
J	Singh, P; Salih, M; Leddy, JJ; Tuana, BS				Singh, P; Salih, M; Leddy, JJ; Tuana, BS			The muscle-specific calmodulin-dependent protein kinase assembles with the glycolytic enzyme complex at the sarcoplasmic reticulum and modulates the activity of glyceraldehyde-3-phosphate dehydrogenase in a Ca2+/calmodulin-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; 3-PHOSPHOGLYCERATE KINASE; ANCHORING PROTEIN; ALPHA-KAP; CA2+; PHOSPHORYLATION; RECEPTOR; BINDING; FORM	The skeletal muscle specific Ca2+/calmodulin-dependent protein kinase (CaMKIIbeta(M)) is localized to the sarcoplasmic reticulum (SR) by an anchoring protein, alphaKAP, but its function remains to be defined. Protein interactions of CaMKIIbeta(M) indicated that it exists in complex with enzymes involved in glycolysis at the SR membrane. The kinase was found to complex with glycogen phosphorylase, glycogen debranching enzyme, glyceraldehyde-3- phosphate dehydrogenase (GAPDH), and creatine kinase in the SR membrane. CaMKIIbeta(M) was also found to assemble with aldolase A, GAPDH, enolase, lactate dehydrogenase, creatine kinase, pyruvate kinase, and phosphorylase b kinase from the cytosolic fraction. The interacting proteins were substrates of CaMKIIbeta(M), and their phosphorylation was enhanced in a Ca2+- and calmodulin (CaM)-dependent manner. The CaMKIIbeta(M) could directly phosphorylate GAPDH and markedly increase (similar to3.4-fold) its activity in a Ca2+/CaM-dependent manner. These data suggest that the muscle CaMKIIbeta(M) isoform may serve to assemble the glycogen-mobilizing and glycolytic enzymes at the SR membrane and specifically modulate the activity of GAPDH in response to calcium signaling. Thus, the activation of CaMKIIbeta(M) in response to calcium signaling would serve to modulate GAPDH and thereby ATP and NADH levels at the SR membrane, which in turn will regulate calcium transport processes.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	btuana@uottawa.ca						Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Benfenati F, 1996, MOL BRAIN RES, V40, P297, DOI 10.1016/0169-328X(96)00053-8; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; CONNELLY PA, 1987, J BIOL CHEM, V262, P10154; CUENDA A, 1993, BIOCHEM BIOPH RES CO, V196, P1127, DOI 10.1006/bbrc.1993.2368; CUENDA A, 1995, J BIOL CHEM, V270, P11998, DOI 10.1074/jbc.270.20.11998; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HEILMEYER LMG, 1990, MOL CELL BIOCHEM, V99, P111; HELMREICH E, 1964, P NATL ACAD SCI USA, V52, P647, DOI 10.1073/pnas.52.3.647; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Ikemoto A, 2003, J BIOL CHEM, V278, P5929, DOI 10.1074/jbc.M211617200; IMAMURA K, 1982, BIOCHEM J, V131, P223; Jona I, 2001, PFLUG ARCH EUR J PHY, V441, P729, DOI 10.1007/s004240000484; Laver DR, 2001, J PHYSIOL-LONDON, V537, P763; LEDDY JJ, 1993, BIOCHEM J, V295, P849, DOI 10.1042/bj2950849; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LORCA T, 1994, BBA-MOL CELL RES, V1223, P325, DOI 10.1016/0167-4889(94)90091-4; MACLENNAN DH, 1984, ADV CYCLIC NUCL PROT, V17, P393; MALHOTRA OP, 1995, EUR J BIOCHEM, V227, P556, DOI 10.1111/j.1432-1033.1995.tb20424.x; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; Nadeau OW, 1997, J BIOL CHEM, V272, P26202, DOI 10.1074/jbc.272.42.26202; NARANG S, 1974, COMP BIOCHEM PHYSIOL, V49, P477, DOI 10.1016/0305-0491(74)90183-7; Nori A, 2003, BIOCHEM J, V370, P873, DOI 10.1042/BJ20021624; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; SUKHODOLETS MV, 1988, FEBS LETT, V238, P161, DOI 10.1016/0014-5793(88)80248-5; TOMPA P, 1990, BIOCHEM INT, V20, P487; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; WEBER JP, 1982, BIOCHEMISTRY-US, V21, P4189, DOI 10.1021/bi00260a042; Xu KY, 1998, J HISTOCHEM CYTOCHEM, V46, P419, DOI 10.1177/002215549804600401; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Yasykova MY, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1192; Zhu XS, 2004, CELL CALCIUM, V35, P165, DOI 10.1016/j.ceca.2003.09.002; Zima AV, 2004, J PHYSIOL-LONDON, V555, P727, DOI 10.1113/jphysiol.2003.055848; Zima AV, 2003, FEBS LETT, V547, P32, DOI 10.1016/S0014-5793(03)00664-1	47	63	63	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35176	35182		10.1074/jbc.M402282200	http://dx.doi.org/10.1074/jbc.M402282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199064	hybrid			2022-12-25	WOS:000223303400007
J	Tikunova, SB; Davis, JP				Tikunova, SB; Davis, JP			Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM BINDING-SITES; CA2+ BINDING; EF-HAND; STRUCTURAL TRANSITION; CONFORMATIONAL CHANGE; TARGET RECOGNITION; N-DOMAIN; EXCHANGE; AFFINITY; MG2+	Cardiac troponin C belongs to the EF-hand superfamily of calcium-binding proteins and plays an essential role in the regulation of muscle contraction and relaxation. To follow calcium binding and exchange with the regulatory N-terminal domain (N-domain) of human cardiac troponin C, we substituted Phe at position 27 with Trp, making a fluorescent cardiac troponin C-F27W. Trp(27) accurately reported the kinetics of calcium association and dissociation of the N-domain of cardiac troponin C-F27W. To sensitize the N-domain of cardiac troponin C-F27W to calcium, we individually substituted the hydrophobic residues Phe(20), Val(44), Met(45), Leu(48), and Met(81) with polar Gln. These mutations were designed to increase the calcium affinity of the N-domain of cardiac troponin C by facilitating the movement of helices B and C (BC unit) away from helices N, A, and D (NAD unit). As anticipated, these selected hydrophobic residue substitutions increased the calcium affinity of the regulatory domain of cardiac troponin C-F27W similar to2.1-15.2-fold. Surprisingly, the increased calcium affinity caused by the hydrophobic residue substitutions was largely due to faster calcium association rates (2.6-8.7-fold faster) rather than to slower calcium dissociation rates (1.2-2.9-fold slower). The regulatory N-domains of cardiac troponin C-F27W and its mutants were also able to bind magnesium competitively and with physiologically relevant affinities (1.2-2.7 mM). The design of calcium-sensitizing cardiac troponin C mutants presented in this work enhances the understanding of how to control cation binding properties of EF-hand proteins and ultimately their structure and physiological function.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Tikunova, SB (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 209 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	tikunova1@hotmail.com			NHLBI NIH HHS [HL073600] Funding Source: Medline; NIAMS NIH HHS [AR20792] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020792] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ababou A, 2001, BIOCHEMISTRY-US, V40, P12719, DOI 10.1021/bi010405b; Ababou A, 2001, PROTEIN SCI, V10, P301, DOI 10.1110/ps.33601; Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Arteaga GM, 2002, ANN MED, V34, P248, DOI 10.1080/078538902320322510; BEST PM, 1977, J PHYSIOL-LONDON, V265, P1; Black DJ, 2000, BIOCHEMISTRY-US, V39, P13831, DOI 10.1021/bi001106+; BLACK DJ, 2001, BIOPHYS J, V80, P408; Browne JP, 1997, BIOCHEMISTRY-US, V36, P9550, DOI 10.1021/bi970460d; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; Davis JP, 2004, J BIOL CHEM, V279, P17348, DOI 10.1074/jbc.M314095200; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; Davis JP, 1999, BIOCHEMISTRY-US, V38, P4235, DOI 10.1021/bi982495z; de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7; DONALDSON SKB, 1978, J GEN PHYSIOL, V71, P645, DOI 10.1085/jgp.71.6.645; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; Erhardt Leif R, 2003, Ital Heart J, V4 Suppl 2, p27S; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Gillis TE, 2003, BIOCHEMISTRY-US, V42, P6418, DOI 10.1021/bi0340494; Gillis TE, 2003, AM J PHYSIOL-CELL PH, V284, pC1176, DOI 10.1152/ajpcell.00339.2002; Gillis TE, 2000, AM J PHYSIOL-REG I, V279, pR1707, DOI 10.1152/ajpregu.2000.279.5.R1707; Gomes AV, 2002, IUBMB LIFE, V54, P323, DOI 10.1080/15216540216037; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; Hazard AL, 1998, PROTEIN SCI, V7, P2451, DOI 10.1002/pro.5560071123; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; HONGO K, 1994, JPN J PHYSIOL, V44, P357, DOI 10.2170/jjphysiol.44.357; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kragelund BB, 1998, BIOCHEMISTRY-US, V37, P8926, DOI 10.1021/bi9726436; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Malmendal A, 1998, J BIOL CHEM, V273, P28994, DOI 10.1074/jbc.273.44.28994; Moyes CD, 1996, BIOCHEMISTRY-US, V35, P11756, DOI 10.1021/bi9607057; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Rupp H, 1982, Adv Myocardiol, V3, P455; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SOLARO RJ, 1976, CIRC RES, V39, P8, DOI 10.1161/01.RES.39.1.8; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tikunova SB, 2004, BIOPHYS J, V86, p394A; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tikunova SB, 2001, BIOCHEMISTRY-US, V40, P3348, DOI 10.1021/bi0021333; Wang ST, 1998, BIOCHEMISTRY-US, V37, P14539, DOI 10.1021/bi9814641	61	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35341	35352		10.1074/jbc.M405413200	http://dx.doi.org/10.1074/jbc.M405413200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205455	hybrid			2022-12-25	WOS:000223303400027
J	Zhu, PP; Patterson, A; Stadler, J; Seeburg, DP; Sheng, M; Blackstone, C				Zhu, PP; Patterson, A; Stadler, J; Seeburg, DP; Sheng, M; Blackstone, C			Intra- and intermolecular domain interactions of the C-terminal GTPase effector domain of the multimeric dynamin-like GTPase Drp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-LIMITING STEP; MITOCHONDRIAL DIVISION; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; MEDIATED ENDOCYTOSIS; OUTER-MEMBRANE; PROTEIN DLP1; MXA GTPASE; FISSION; YEAST	Mammalian Drp1 is a dynamin-like GTPase required for mitochondrial fission. Although it exists primarily as a cytosolic homo-tetramer in vivo, it can also self-assemble into higher order structures on the mitochondrial outer membrane, where it is required for proper mitochondrial division. Functional studies and sequence comparisons have revealed four different structural domains in Drp1, comprising N-terminal GTP-binding, middle, insert B, and C-terminal GTPase effector (GED) domains. Here we describe an intramolecular interaction within Drp1 between the GED and the N-terminal GTP-binding and middle domains. A point mutation (K679A) within the C-terminal GED domain inhibits this intramolecular association, without affecting the formation of Drp1 tetramers or the intermolecular associations among isolated C-terminal domains. Mutant Drp1 K679A exhibits impaired GTPase activity, and when overexpressed in mammalian cells it decreases mitochondrial division. Sedimentation experiments indicate that the K679A mutation either increases Drp1 complex formation or, more likely, decreases complex disassembly as compared with wild-type Drp1. Taken together, these data suggest that the C-terminal GED domain is important for stimulation of GTPase activity, formation and stability of higher order complexes, and efficient mitochondrial division.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; NIH, NIH George Washington Univ Grad Partnerships Prog, Bethesda, MD 20892 USA; MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bldg 35,Rm 2C-913,9000 Rockville Pike, Bethesda, MD 20892 USA.	blackstc@ninds.nih.gov	Patterson, Andrew/G-3852-2012; Patterson, Andrew/ABF-1575-2020	Patterson, Andrew/0000-0003-2073-0070; Patterson, Andrew/0000-0003-2073-0070				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howng SL, 2004, BIOCHEM BIOPH RES CO, V314, P766, DOI 10.1016/j.bbrc.2003.12.172; Imoto M, 1998, J CELL SCI, V111, P1341; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Klockow B, 2002, EMBO J, V21, P240, DOI 10.1093/emboj/21.3.240; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Muhlberg AB, 2000, METHODS, V20, P475, DOI 10.1006/meth.2000.0960; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; van der Bliek AM, 2000, J CELL BIOL, V151, pF1, DOI 10.1083/jcb.151.2.F1; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	47	157	161	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35967	35974		10.1074/jbc.M404105200	http://dx.doi.org/10.1074/jbc.M404105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208300	hybrid			2022-12-25	WOS:000223303400098
J	Carvalho, AL; Goyal, A; Prates, JAM; Bolam, DN; Gilbert, HJ; Pires, VMR; Ferreira, LMA; Planas, A; Romao, MJ; Fontes, CMGA				Carvalho, AL; Goyal, A; Prates, JAM; Bolam, DN; Gilbert, HJ; Pires, VMR; Ferreira, LMA; Planas, A; Romao, MJ; Fontes, CMGA			The family 11 carbohydrate-binding module of Clostridium thermocellum Lic26A-Cel5E accommodates beta-1,4- and beta-1,3-1,4-mixed linked glucans at a single binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGAND-BINDING; AFFINITY ELECTROPHORESIS; SEQUENCE; COMPLEX; RECOGNITION; DOMAINS; OLIGOSACCHARIDES; IDENTIFICATION; SPECIFICITY	Modular glycoside hydrolases that attack recalcitrant polymers generally contain noncatalytic carbohydrate-binding modules (CBMs), which play a critical role in the action of these enzymes by localizing the appended catalytic domains onto the surface of insoluble polysaccharide substrates. Type B CBMs, which recognize single polysaccharide chains, display ligand specificities that are consistent with the substrates hydrolyzed by the associated catalytic domains. In enzymes that contain multiple catalytic domains with distinct substrate specificities, it is unclear how these different activities influence the evolution of the ligand recognition profile of the appended CBM. To address this issue, we have characterized the properties of a family 11 CBM (CtCBM11) in Clostridium thermocellum Lic26A-Cel5E, an enzyme that contains GH5 and GH26 catalytic domains that display beta-1,4- and beta-1,3 -1,4-mixed linked endoglucanase activity, respectively. Here we show that CtCBM11 binds to both beta-1,4- and beta-1,3-1,4-mixed linked glucans, displaying K-a values of 1.9 x 10(5), 4.4 x 10(4), and 2 x 10(3) M-1 for Glc-beta1,4-Glc-beta1,4-Glc- beta1,3-Glc, Glc-beta1,4-Glc-beta1,4-Glc-beta1,4-Glc, and Glc-beta1,3-Glc- beta1,4-Glc-beta1,3-Glc, respectively, demonstrating that CBMs can display a preference for mixed linked glucans. To determine whether these ligands are accommodated in the same or diverse sites in CtCBM11, the crystal structure of the protein was solved to a resolution of 1.98 Angstrom. The protein displays a beta-sandwich with a concave side that forms a potential binding cleft. Site-directed mutagenesis revealed that Tyr(22), Tyr(53), and Tyr(129), located in the putative binding cleft, play a central role in the recognition of all the ligands recognized by the protein. We propose, therefore, that CtCBM11 contains a single ligand-binding site that displays affinity for both beta-1,4- and beta-1,3 - 1,4-mixed linked glucans.	Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Univ Tecn Lisboa, Ctr Interdisciplinar Invest Sanidade Anim, Fac Med Vet, P-1300744 Lisbon, Portugal; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Ramon Llull, Biochem Lab, Inst Quim Sarria, Barcelona 08017, Spain	Universidade Nova de Lisboa; Universidade de Lisboa; Newcastle University - UK; Universitat Ramon Llull; Institut Quimic de Sarria	Romao, MJ (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal.	mromao@dq.fct.unl.pt; cafontes@fmv.utl.pt	Pires, Virginia/J-4799-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017; Prates, José A M/K-9934-2013; Carvalho, Ana Luísa/G-5638-2011; PLANAS, ANTONI/I-4803-2015; Romao, Maria J/A-4115-2013	Pires, Virginia/0000-0003-1307-3797; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Prates, José A M/0000-0003-1032-5987; Carvalho, Ana Luísa/0000-0002-3824-0240; PLANAS, ANTONI/0000-0001-7073-3320; Romao, Maria J/0000-0002-3004-0543; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753; Bolam, David/0000-0003-0314-3122				Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Coutinho PM, 1999, ROY SOC CH, P3; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V31; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Faijes M, 2003, BIOCHEMISTRY-US, V42, P13304, DOI 10.1021/bi030131n; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAMAL S, 2004, IN PRESS STRUCTURE; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Malburg SRC, 1997, APPL ENVIRON MICROB, V63, P2449, DOI 10.1128/AEM.63.6.2449-2453.1997; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearson WR, 1998, J MOL BIOL, V276, P71, DOI 10.1006/jmbi.1997.1525; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; ROUSSEL A, 1991, TURBO FRODO SILICON, P86; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Sunna A, 2001, BIOCHEM J, V356, P791, DOI 10.1042/0264-6021:3560791; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; YAGUE E, 1990, GENE, V89, P61, DOI 10.1016/0378-1119(90)90206-7	43	84	91	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34785	34793		10.1074/jbc.M405867200	http://dx.doi.org/10.1074/jbc.M405867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192099	hybrid			2022-12-25	WOS:000223134800086
J	Hormann, F; Kuchler, M; Sveshnikov, D; Oppermann, U; Li, Y; Soll, J				Hormann, F; Kuchler, M; Sveshnikov, D; Oppermann, U; Li, Y; Soll, J			Tic32, an essential component in chloroplast biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; PROTEIN IMPORT MACHINERY; 11-CIS RETINOL DEHYDROGENASE; ARABIDOPSIS-THALIANA; PRECURSOR PROTEINS; REVERSE GENETICS; BINDING PROTEIN; REDOX STATE; TRANSLOCATION	Chloroplast protein import across the inner envelope is facilitated by the translocon of the inner envelope of chloroplasts (Tic). Here we have identified Tic32 as a novel subunit of the Tic complex. Tic32 can be purified from solubilized inner envelope membranes by chromatography on Tic110 containing affinity matrix. Co-immunoprecipitation experiments using either Tic32 or Tic110 antisera indicated a tight association between these polypeptides as well as with other Tic subunits, e. g. Tic40, Tic22, or Tic62, whereas the outer envelope protein Toc75 was not found in this complex. Chemical cross-linking suggests that Tic32 is involved late in the overall translocation process, because both the precursor form as well as the mature form of Rubisco small subunit can be detected. We were unable to isolate Arabidopsis null mutants of the attic32 gene, indicating that Tic32 is essential for viability. Deletion of the attic32 gene resulted in early seed abortion because the embryo was unable to differentiate from the heart stage to the torpedo stage. The homology of Tic32 to short-chain dehydrogenases suggests a dual role of Tic32 in import, one as a regulatory component and one as an important subunit in the assembly of the entire complex.	Univ Munich, Dept Biol & Plant Biochem, D-80638 Munich, Germany; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Max Planck Inst Plant Breeding, D-50829 Cologne, Germany	University of Munich; Karolinska Institutet; Max Planck Society	Soll, J (corresponding author), Univ Munich, Dept Biol & Plant Biochem, Menzinger Str 67, D-80638 Munich, Germany.	soll@uni-muenchen.de	Li, Yong/A-6283-2011	Li, Yong/0000-0003-2651-8791				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Chou ML, 2003, EMBO J, V22, P2970, DOI 10.1093/emboj/cdg281; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; Heins L, 2002, EMBO J, V21, P2616, DOI 10.1093/emboj/21.11.2616; Hiltbrunner A, 2001, BIOCHEM CELL BIOL, V79, P629, DOI 10.1139/bcb-79-5-629; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Hirohashi T, 2001, PLANT PHYSIOL, V125, P2154, DOI 10.1104/pp.125.4.2154; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Inaba T, 2003, J BIOL CHEM, V278, P38617, DOI 10.1074/jbc.M306367200; Jelic M, 2002, BIOL CHEM, V383, P1875, DOI 10.1515/BC.2002.211; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim J, 2003, PLANT CELL PHYSIOL, V44, P85, DOI 10.1093/pcp/pcg013; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; Liu CM, 1998, PLANT J, V16, P21, DOI 10.1046/j.1365-313x.1998.00268.x; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NADA A, 2004, IN PRESS J CELL SCI; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Rylott EL, 2003, J BIOL CHEM, V278, P21370, DOI 10.1074/jbc.M300826200; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Soll J, 2002, CURR OPIN PLANT BIOL, V5, P529, DOI 10.1016/S1369-5266(02)00296-0; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; THEG SM, 1989, J BIOL CHEM, V264, P6730; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	61	78	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34756	34762		10.1074/jbc.M402817200	http://dx.doi.org/10.1074/jbc.M402817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180984	hybrid, Green Published			2022-12-25	WOS:000223134800082
J	Wang, HH; Cronan, JE				Wang, HH; Cronan, JE			Functional replacement of the FabA and FabB proteins of Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF homologues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; HYDROXYDECANOYL THIOESTER DEHYDRASE; MEMBRANE-LIPID-COMPOSITION; CRYSTAL-STRUCTURE; SYNTHASE-I; STREPTOCOCCUS-PNEUMONIAE; CONDENSING ENZYMES; BIOSYNTHESIS; GENE; TRANSCRIPTION	The anaerobic unsaturated fatty acid synthetic pathway of Escherichia coli requires two specialized proteins, FabA and FabB. However, the fabA and fabB genes are found only in the Gram-negative alpha- and gamma-proteobacteria, and thus other anaerobic bacteria must synthesize these acids using different enzymes. We report that the Gram-positive bacterium Enterococcus faecalis encodes a protein, annotated as FabZ1, that functionally replaces the E. coli FabA protein, although the sequence of this protein aligns much more closely with E. coli FabZ, a protein that plays no specific role in unsaturated fatty acid synthesis. Therefore E. faecalis FabZ1 is a bifunctional dehydratase/isomerase, an enzyme activity heretofore confined to a group of Gram-negative bacteria. The FabZ2 protein is unable to replace the function of E. coli FabZ, although FabZ2, a second E. faecalis FabZ homologue, has this ability. Moreover, an E. faecalis FabF homologue (FabF1) was found to replace the function of E. coli FabB, whereas a second FabF homologue was inactive. From these data it is clear that bacterial fatty acid biosynthetic pathways cannot be deduced solely by sequence comparisons.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI 15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Altabe SG, 2003, J BACTERIOL, V185, P3228, DOI 10.1128/JB.185.10.3228-3231.2003; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BLOCH K, 1971, ENZYMES, P441; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chang YY, 1999, MOL MICROBIOL, V33, P249, DOI 10.1046/j.1365-2958.1999.01456.x; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; CRONAN JE, 1974, P NATL ACAD SCI USA, V71, P3758, DOI 10.1073/pnas.71.9.3758; CRONAN JE, 1972, J BACTERIOL, V112, P206, DOI 10.1128/JB.112.1.206-211.1972; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1969, J BACTERIOL, V100, P601, DOI 10.1128/JB.100.2.601-604.1969; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GUERRA DJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P336, DOI 10.1016/0003-9861(90)90339-Z; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; Hoang TT, 1997, J BACTERIOL, V179, P5326, DOI 10.1128/jb.179.17.5326-5332.1997; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; KASS LR, 1968, J BIOL CHEM, V243, P3223; Lai CY, 2003, J BIOL CHEM, V278, P51494, DOI 10.1074/jbc.M308638200; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Marrakchi H, 2002, J BIOL CHEM, V277, P44809, DOI 10.1074/jbc.M208920200; Moche M, 2001, J MOL BIOL, V305, P491, DOI 10.1006/jmbi.2000.4272; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MONTGOMERIE JZ, 1973, J BACTERIOL, V115, P73, DOI 10.1128/JB.115.1.73-75.1973; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; Price AC, 2003, J BACTERIOL, V185, P4136, DOI 10.1128/JB.185.14.4136-4143.2003; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rock C O, 1981, Methods Enzymol, V72, P397; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; SILBERT DF, 1967, P NATL ACAD SCI USA, V58, P1579, DOI 10.1073/pnas.58.4.1579; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; von Wettstein-Knowles P, 2000, BIOCHEM SOC T, V28, P601, DOI 10.1042/BST0280601; Wang HH, 2003, J BACTERIOL, V185, P4930, DOI 10.1128/JB.185.16.4930-4937.2003; WILKINS PO, 1982, ARCH MICROBIOL, V132, P211, DOI 10.1007/BF00508733	48	82	94	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34489	34495		10.1074/jbc.M403874200	http://dx.doi.org/10.1074/jbc.M403874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194690	hybrid			2022-12-25	WOS:000223134800051
J	Drummelsmith, J; Girard, I; Trudel, N; Ouellette, M				Drummelsmith, J; Girard, I; Trudel, N; Ouellette, M			Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; TRYPANOSOMA-BRUCEI; DRUG-RESISTANCE; VISCERAL LEISHMANIASIS; 3'-UNTRANSLATED REGION; GENE AMPLIFICATION; ACID-METABOLISM; REDUCTASE; MECHANISMS; TARENTOLAE	Leishmania is a trypanosomatid parasite causing serious disease and displaying resistance to various drugs. Here, we present comparative proteomic analyses of Leishmania major parasites that have been either shocked with or selected in vitro for high level resistance to the model antifolate drug methotrexate. Numerous differentially expressed proteins were identified by these experiments. Some were associated with the stress response, whereas others were found to be overexpressed due to genetic linkage to primary resistance mediators present on DNA amplicons. Several proteins not previously associated with resistance were also identified. The role of one of these, methionine adenosyltransferase, was confirmed by gene transfection and metabolite analysis. After a single exposure to low levels of methotrexate, L. major methionine adenosyltransferase transfectants could grow at high concentrations of the drug. Methotrexate resistance was also correlated to increased cellular S-adenosylmethionine levels. The folate and S-adenosylmethionine regeneration pathways are intimately connected, which may provide a basis for this novel resistance phenotype. This thorough comparative proteomic analysis highlights the variety of responses required for drug resistance to be achieved.	Univ Laval, Infect Dis Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Ouellette, M (corresponding author), CHUQ, Infect Dis Res Ctr, Pavillon CHUL,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	marc.ouellette@crchul.ulaval.ca	Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				BARAK AJ, 1984, J AM COLL NUTR, V3, P93; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; BROCHU C, 2004, IN RPESS CELL STRESS; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Cash P, 1999, ELECTROPHORESIS, V20, P2259, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2259::AID-ELPS2259>3.0.CO;2-F; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Drummelsmith J, 2003, MOL CELL PROTEOMICS, V2, P146, DOI 10.1074/mcp.M200085-MCP200; El Fadili A, 2004, J BIOL CHEM, V279, P18575, DOI 10.1074/jbc.M400652200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORSTHOEFEL NR, 1995, PLANT PHYSIOL, V108, P1185, DOI 10.1104/pp.108.3.1185; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gaskin AA, 2002, J VET INTERN MED, V16, P34, DOI 10.1892/0891-6640(2002)016&lt;0034:VLIANY&gt;2.3.CO;2; Goldberg B, 1999, ARCH BIOCHEM BIOPHYS, V364, P13, DOI 10.1006/abbi.1999.1098; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; Haimeur A, 1999, MOL MICROBIOL, V34, P726, DOI 10.1046/j.1365-2958.1999.01634.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Kabututu Z, 2003, INT J PARASITOL, V33, P219, DOI 10.1016/S0020-7519(02)00253-9; Kashiwagi H, 2000, Hum Cell, V13, P135; Kishi T, 2000, CANCER-AM CANCER SOC, V89, P925, DOI 10.1002/1097-0142(20000815)89:4<925::AID-CNCR28>3.0.CO;2-W; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Kundig C, 1999, NUCLEIC ACIDS RES, V27, P3653, DOI 10.1093/nar/27.18.3653; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MAGI B, 2004, IN PRESS CELL DEATH; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; MATTHEWS RG, 1982, ADV ENZYME REGUL, V20, P123, DOI 10.1016/0065-2571(82)90012-7; McAtee CP, 2001, PROTEOMICS, V1, P516, DOI 10.1002/1615-9861(200104)1:4<516::AID-PROT516>3.3.CO;2-F; Ouellette M, 1998, ADV EXP MED BIOL, V456, P99; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; PAJARES MA, 1994, BIOCHEM J, V303, P949, DOI 10.1042/bj3030949; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PHELOUZAT MA, 1995, BIOCHEM J, V305, P133, DOI 10.1042/bj3050133; Prasad J, 2003, APPL ENVIRON MICROB, V69, P917, DOI 10.1128/AEM.69.2.917-925.2003; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; REFSUM H, 1989, CLIN PHARMACOL THER, V46, P510, DOI 10.1038/clpt.1989.179; Reguera RM, 2002, J BIOL CHEM, V277, P3158, DOI 10.1074/jbc.M105512200; RHEE MS, 1992, MOL PHARMACOL, V42, P909; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; Soto M, 2003, PARASITOLOGY, V127, P95, DOI 10.1017/S0031182003003445; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Wang JY, 1997, ARCH BIOCHEM BIOPHYS, V342, P197, DOI 10.1006/abbi.1997.0126; Wang W, 2001, J CHROMATOGR B, V762, P59, DOI 10.1016/S0378-4347(01)00341-3; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	54	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33273	33280		10.1074/jbc.M405183200	http://dx.doi.org/10.1074/jbc.M405183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190060	hybrid			2022-12-25	WOS:000223039700033
J	Ivetic, A; Florey, O; Deka, J; Haskard, DO; Ager, A; Ridley, AJ				Ivetic, A; Florey, O; Deka, J; Haskard, DO; Ager, A; Ridley, AJ			Mutagenesis of the ezrin-radixin-moesin binding domain of L-selectin tail affects shedding, microvillar positioning, and leukocyte tethering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INTERCELLULAR-ADHESION MOLECULE-3; CYTOPLASMIC DOMAIN; HUMAN NEUTROPHILS; DOWN-REGULATION; SUBCELLULAR-LOCALIZATION; GLYCOPROTEIN LIGAND-1; T-LYMPHOCYTES; ERM PROTEINS; IN-VIVO	L-selectin is a cell adhesion molecule that mediates the initial capture ( tethering) and subsequent rolling of leukocytes along ligands expressed on endothelial cells. We have previously identified ezrin and moesin as novel binding partners of the 17-amino acid L-selectin tail, but the biological role of this interaction is not known. Here we identify two basic amino acid residues within the L-selectin tail that are required for binding to ezrin-radixin-moesin (ERM) proteins: arginine 357 and lysine 362. L-selectin mutants defective for ERM binding show reduced localization to microvilli and decreased phorbol 12-myristate 13-acetate-induced shedding of the L-selectin ectodomain. Cells expressing these L-selectin mutants have reduced tethering to the L-selectin ligand P-selectin glycoprotein ligand-1, but rolling velocity on P-selectin glycoprotein ligand-1 is not affected. These results suggest that ERM proteins are required for microvillar positioning of L-selectin and that this is important both for leukocyte tethering and L-selectin shedding.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England; Hammersmith Hosp, BHF Cardiovasc Med Unit, Imperial Coll, London W12 0NN, England; Natl Inst Med Res, Div Prot Structure, London NW7 1AA, England; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; Imperial College London; MRC National Institute for Medical Research; MRC National Institute for Medical Research; University of London; University College London	Ivetic, A (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	aleks@ludwig.ucl.ac.uk		Ridley, Anne/0000-0001-8186-5708; Florey, Oliver/0000-0002-1075-7424; Ager, Ann/0000-0002-5763-8908; Ivetic, Aleksandar/0000-0001-9844-6518				Alexander SR, 2000, J LEUKOCYTE BIOL, V67, P415, DOI 10.1002/jlb.67.3.415; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BORREGAARD N, 1994, J LEUKOCYTE BIOL, V56, P80, DOI 10.1002/jlb.56.1.80; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Brenner B, 1998, EXP CELL RES, V243, P123, DOI 10.1006/excr.1998.4146; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; Fors BP, 2001, J IMMUNOL, V167, P3642, DOI 10.4049/jimmunol.167.7.3642; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; Gamulescu MA, 2003, PLATELETS, V14, P211, DOI 10.1080/0953710031000118830; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x; Ivetic A, 2002, J BIOL CHEM, V277, P2321, DOI 10.1074/jbc.M109460200; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; Khan AI, 2003, INFLAMMATION, V27, P265, DOI 10.1023/A:1026056525755; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; LEY K, 1993, BLOOD, V82, P1632; Malhotra R, 1996, BIOCHEM J, V320, P589, DOI 10.1042/bj3200589; Malhotra R, 1997, BIOESSAYS, V19, P919, DOI 10.1002/bies.950191012; Malhotra R, 1997, CHEM BIOL, V4, P543, DOI 10.1016/S1074-5521(97)90240-4; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Serrador JM, 2002, J BIOL CHEM, V277, P10400, DOI 10.1074/jbc.M110694200; Serrador JM, 2002, EUR J IMMUNOL, V32, P1560, DOI 10.1002/1521-4141(200206)32:6<1560::AID-IMMU1560>3.0.CO;2-U; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Turutin DV, 2003, FEBS LETT, V536, P241, DOI 10.1016/S0014-5793(03)00061-9; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228; Zhao L C, 2001, Dev Immunol, V8, P267, DOI 10.1155/2001/91831; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	55	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33263	33272		10.1074/jbc.M312212200	http://dx.doi.org/10.1074/jbc.M312212200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178693	hybrid			2022-12-25	WOS:000223039700032
J	Kalin, N; Fernandes, J; Hrafnsdottir, S; van Meer, G				Kalin, N; Fernandes, J; Hrafnsdottir, S; van Meer, G			Natural phosphatidylcholine is actively translocated across the plasma membrane to the surface of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; MDR3 P-GLYCOPROTEIN; INTACT HUMAN-ERYTHROCYTES; RED-BLOOD-CELLS; TRANSBILAYER MOVEMENT; FLIP-FLOP; MULTIDRUG TRANSPORTER; LIPID ASYMMETRY; CARNITINE PALMITOYLTRANSFERASE; INTRACELLULAR-TRANSPORT	The cell surface of eukaryotic cells is enriched in choline phospholipids, whereas the aminophospholipids are concentrated at the cytosolic side of the plasma membrane by the activity of one or more P-type ATPases. Lipid translocation has been investigated mostly by using short chain lipid analogs because assays for endogenous lipids are inherently complicated. In the present paper, we optimized two independent assays for the translocation of natural phosphatidylcholine (PC) to the cell surface based on the hydrolysis of outer leaflet phosphoglycerolipids by exogenous phospholipase A(2) and the exchange of outer leaflet PC by a transfer protein. We report that PC reached the cell surface in the absence of vesicular traffic by a pathway that involved translocation across the plasma membrane. In erythrocytes, PC that was labeled at the inside of the plasma membrane was translocated to the cell surface with a half-time of 30 min. This translocation was probably mediated by an ATPase, because it required ATP and was vanadate-sensitive. The inhibition of PC translocation by glibenclamide, an inhibitor of various ATP binding cassette transporters, and its reduction in erythrocytes from both Abcb1a/1b and Abcb4 knockout mice, suggest the involvement of ATP binding cassette transporters in natural PC cell surface translocation. The relative importance of the outward translocation of PC as compared with the well characterized fast inward translocation of phosphatidylserine for the overall asymmetric phospholipid organization in plasma membranes remains to be established.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Kalin, N (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Membrane Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	nanette.kaelin@dlr.de	van Meer, Gerrit/AAH-1560-2021	van Meer, Gerrit/0000-0002-5976-6436				Allen JD, 2000, CANCER RES, V60, P5761; Allen JD, 2002, MOL CANCER THER, V1, P417; ANDRICK C, 1991, BIOCHIM BIOPHYS ACTA, V1064, P235, DOI 10.1016/0005-2736(91)90307-T; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; BERR F, 1993, J BIOL CHEM, V268, P3976; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; CLASSEN J, 1989, J MEMBRANE BIOL, V111, P169, DOI 10.1007/BF01871780; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1992, J BIOL CHEM, V267, P19412; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; CRAIN RC, 1980, BIOCHIM BIOPHYS ACTA, V620, P37, DOI 10.1016/0005-2760(80)90182-4; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Devaux PF, 2000, BIOCHIMIE, V82, P497, DOI 10.1016/S0300-9084(00)00209-1; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Ernest S, 1999, J AM SOC NEPHROL, V10, P2306; Farge E, 1999, AM J PHYSIOL-CELL PH, V276, pC725, DOI 10.1152/ajpcell.1999.276.3.C725; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; Farge E, 1995, BIOPHYS J, V69, P2501, DOI 10.1016/S0006-3495(95)80120-7; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fuchs M, 1997, AM J PHYSIOL-GASTR L, V273, pG1312, DOI 10.1152/ajpgi.1997.273.6.G1312; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Haest CWM, 1997, BBA-BIOMEMBRANES, V1325, P17, DOI 10.1016/S0005-2736(96)00239-8; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Huang ZH, 2004, BBA-BIOMEMBRANES, V1660, P155, DOI 10.1016/j.bbamem.2003.11.010; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; Kamp H H, 1974, Methods Enzymol, V32, P140; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; MIDDELKOOP E, 1986, BIOCHIM BIOPHYS ACTA, V855, P421, DOI 10.1016/0005-2736(86)90087-8; MORROT G, 1986, P NATL ACAD SCI USA, V83, P6863, DOI 10.1073/pnas.83.18.6863; MYHER JJ, 1989, LIPIDS, V24, P396, DOI 10.1007/BF02535147; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLAGEMANN PGW, 1985, BIOCHIM BIOPHYS ACTA, V817, P51, DOI 10.1016/0005-2736(85)90067-7; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; RAMSAY RR, 1991, BIOCHEM J, V275, P685, DOI 10.1042/bj2750685; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; RAWYLER A, 1985, BIOCHEMISTRY-US, V24, P1777, DOI 10.1021/bi00328a031; RENOOIJ W, 1977, BIOCHIM BIOPHYS ACTA, V470, P465, DOI 10.1016/0005-2736(77)90137-7; RENOOIJ W, 1976, EUR J BIOCHEM, V61, P53, DOI 10.1111/j.1432-1033.1976.tb09996.x; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHWICHTENHOVEL C, 1992, BIOCHIM BIOPHYS ACTA, V1111, P35, DOI 10.1016/0005-2736(92)90271-M; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SLEIGHT RG, 1989, J CELL SCI, V93, P363; SMIT JJM, 1994, LAB INVEST, V71, P638; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; van Helvoort A, 1997, J CELL SCI, V110, P75; VAN MEER G, 1980, EUR J BIOCHEM, V103, P283; VAN MEER G, 1982, J CELL BIOCHEM, V19, P193, DOI 10.1002/jcb.240190209; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; VERMEULEN WP, 1996, THESIS U UTRECHT UTR; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	76	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33228	33236		10.1074/jbc.M401751200	http://dx.doi.org/10.1074/jbc.M401751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175345	Green Published, hybrid			2022-12-25	WOS:000223039700028
J	Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H				Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H			Gene expression profiling and subgroup identification of oligodendrogliomas	ONCOGENE			English	Article						oligodendroglioma; low-grade astrocytoma; cDNA array; LOH 1p; LOH 19q; TP53 mutations	CELL-CYCLE; MICROARRAY; SURVIVAL; RECEPTOR; GLIOMAS; MARKER; GRADE; OLIG2; JUND; 19Q	The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-beta, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the inummoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial least-squares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P = 0.0305; survival to 5-years, 80 vs 0%, P = 0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Victor Segalen Univ, Dept Neuropathol, F-33076 Bordeaux, France; Neurol & Neurosurg Hosp, Dept Neuropathol, F-69394 Lyon, France; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; UDICE-French Research Universities; Universite de Bordeaux; CHU Lyon; University of Zurich; University Zurich Hospital	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohgaki@iarc.fr	Heppner, Frank/ABH-8393-2020	Heppner, Frank/0000-0001-9816-8917				Azzarelli BN, 2003, J NEUROPATH EXP NEUR, V62, P544; Blumcke I, 2001, J NEUROPATH EXP NEUR, V60, P984; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; DURAND JF, 2001, GUIDE UTILISATION RE; Fuller GN, 1999, CANCER RES, V59, P4228; Grifa A, 1998, BIOCHEM BIOPH RES CO, V250, P240, DOI 10.1006/bbrc.1998.9296; Gunthert AR, 2002, BIOCHEM BIOPH RES CO, V294, P11, DOI 10.1016/S0006-291X(02)00427-8; Gutmann DH, 2002, CANCER RES, V62, P2085; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huang HT, 2000, CANCER RES, V60, P6868; Ino Y, 2001, CLIN CANCER RES, V7, P839; KLEIHUES P, 2000, DIFFUSE ASTROCYTOMA, P22; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; Ligon KL, 2003, J NEUROPATH EXP NEUR, V62, P544; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Marie Y, 2001, LANCET, V358, P298, DOI 10.1016/S0140-6736(01)05499-X; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Miettinen HE, 2001, J NEURO-ONCOL, V55, P29, DOI 10.1023/A:1012961918848; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Nutt CL, 2003, CANCER RES, V63, P1602; OBATA S, 1995, J CELL SCI, V108, P3765; Ohnishi A, 2003, J NEUROPATH EXP NEUR, V62, P1052, DOI 10.1093/jnen/62.10.1052; Perry JR, 2001, CURR OPIN NEUROL, V14, P705, DOI 10.1097/00019052-200112000-00005; Peters HC, 1998, NEUROGENETICS, V2, P47, DOI 10.1007/s100480050051; REIFENBERGER G, 2000, OLIGODENDROGLIOMA PA, P56; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schafer JL, 1997, ANAL INCOMPLETE MULT, V1st, DOI 10.1201/9781439821862; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Tanwar MK, 2002, CANCER RES, V62, P4364; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Watanabe T, 2002, ACTA NEUROPATHOL, V103, P267, DOI 10.1007/s004010100464; Watson MA, 2001, CANCER RES, V61, P1825; Zerbini LF, 2003, CANCER RES, V63, P2206	40	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6012	6022		10.1038/sj.onc.1207781	http://dx.doi.org/10.1038/sj.onc.1207781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208679	Bronze			2022-12-25	WOS:000222941100017
J	Graham, ME; Barclay, JW; Burgoyne, RD				Graham, ME; Barclay, JW; Burgoyne, RD			Syntaxin/Munc18 interactions in the late events during vesicle fusion and release in exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NSF ATPASE ACTIVITY; PROTEIN-KINASE-C; SNARE COMPLEX; MEMBRANE-FUSION; NSEC-1 MUNC-18; ALPHA-SNAP; LATE STEPS; CHROMAFFIN; DOCKING; 1A	The SNARE proteins, syntaxin, SNAP-25, and VAMP, form part of the core machinery for membrane fusion during regulated exocytosis. Additional proteins are required to account for the speed, spatial restriction, and tight control of exocytosis and a key role is played by members of the Sec1/Munc18 family of proteins that have been implicated either in vesicle docking or fusion itself through their interactions with the corresponding syntaxin. Using amperometry to assay the kinetics of single vesicle fusion/release events in adrenal chromaffin cells, the effect of expression of syntaxin 1A mutants was examined. Overexpression of wild-type syntaxin or its cytoplasmic domain had no effect on the kinetics of release during single exocytotic events although the cytoplasmic domain reduced the frequency of exocytosis. In contrast, expression of either an open syntaxin 1A or the I233A mutant resulted in increased quantal size and a slowing of the kinetics of release. The wild-type and mutant syntaxins were overexpressed to a similar extent and the only common defect shown by the syntaxin 1A mutants was reduced binding to Munc18-1. These results are consistent with a role for Munc18-1 in controlling the late stages of exocytosis by binding to and limiting the availability of syntaxin in its open conformation. Modification of the Munc18-1/syntaxin 1A interaction would therefore be a key mechanism for the regulation of quantal size.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Barclay, Jeff W/0000-0003-4320-2094				Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BRENNER S, 1974, GENETICS, V77, P71; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Craig TJ, 2003, J NEUROCHEM, V86, P1450, DOI 10.1046/j.1471-4159.2003.01955.x; CRAIG TJ, 2004, IN PRESS J BIOCH BIO; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2001, J CELL SCI, V114, P4397; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Graham ME, 1997, J NEUROCHEM, V69, P2369; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2002, J BIOL CHEM, V277, P9375, DOI 10.1074/jbc.M111729200; Munson M, 2000, NAT STRUCT BIOL, V7, P894; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pothos EN, 2002, J PHYSIOL-LONDON, V542, P453, DOI 10.1113/jphysiol.2002.018630; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rowe J, 2001, J CELL SCI, V114, P3323; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sombers LA, 2004, J NEUROSCI, V24, P303, DOI 10.1523/JNEUROSCI.1119-03.2004; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang CT, 2003, NATURE, V424, P943, DOI 10.1038/nature01857; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Wu MN, 2001, EUR J CELL BIOL, V80, P196, DOI 10.1078/0171-9335-00143; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	56	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32751	32760		10.1074/jbc.M400827200	http://dx.doi.org/10.1074/jbc.M400827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175344	hybrid			2022-12-25	WOS:000222849700094
J	Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K				Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K			Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression	ONCOGENE			English	Article						marker; metastasis; invasion; methylation	PROTEIN; DIFFERENTIATION; EXPRESSION; MOTILITY; GROWTH; CAP43	The differentiation-related gene-1 (Drg-1) was first identified as a gene strongly upregulated by induction of differentiation in colon carcinoma cells in vitro, and later the same gene was shown to suppress tumorigenicity of human bladder cancer cells in vivo. On the other hand, we and others have demonstrated that the Drg-1 gene suppresses prostate and colon cancer metastases in mouse models. In the context of such potential organ-specific differential function of the Drg-1 gene, the present study was designed to clarify the expression status, regulation and function of Drg-1 in the case of human breast cancer. We found that the expression of the Drg-1 protein was significantly reduced in breast tumor cells, particularly in patients with lymph node or bone metastasis as compared to those with localized breast cancer. Drg-1 expression also exhibited significant inverse correlation with the disease-free survival rate of patients and emerged as an independent prognostic factor. The downregulation of the Drg-1 gene appeared to be largely at the RNA level, and the DNA methylation inhibitor, 5-Azacytidine, significantly elevated the Drg-1 gene expression in various breast tumor cell lines. Furthermore, we found that overexpression of the Drg-1 gene suppresses the invasiveness of breast cancer cells in vitro, and this suppression was also achieved by treatment of cells with 5-Azacytidine. Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Akita, Japan; Univ Montpellier II, Montpellier, France	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Universite de Montpellier	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu		Piquemal, David/0000-0002-5870-4276; commes, therese/0000-0002-7918-0176	NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Davol PA, 2003, CANCER RES, V63, P6772; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Guang RJ, 2000, CANCER RES, V60, P749; Hartsough MT, 2001, CANCER RES, V61, P2320; Kim HL, 2001, CANCER RES, V61, P2833; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Masuda K, 2003, INT J CANCER, V105, P803, DOI 10.1002/ijc.11152; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; vanBelzen N, 1997, LAB INVEST, V77, P85; Yamada SD, 2002, CANCER RES, V62, P6717; Zhou DJ, 1998, CANCER RES, V58, P2182	18	148	158	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5675	5681		10.1038/sj.onc.1207734	http://dx.doi.org/10.1038/sj.onc.1207734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184886				2022-12-25	WOS:000222629500012
J	Tou, JS; Smith, BC; Bojanowski, CM; Meleth, AD; Gery, I; Csaky, KG; Chew, EY; Chan, CC				Tou, JS; Smith, BC; Bojanowski, CM; Meleth, AD; Gery, I; Csaky, KG; Chew, EY; Chan, CC			The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration	FASEB JOURNAL			English	Article						chemoattractant; single nucleotide polymorphism; archived paraffin-embedded slide; gene expression; risk factor	APOLIPOPROTEIN-E; RECEPTOR CX3CR1; GENETIC RISK; FRACTALKINE; CX(3)CR1; DRUSEN; INFLAMMATION; POLYMORPHISM; ASSOCIATION; MACULOPATHY	This study examined the association between the sequence variation/expression of CX3CR1, a chemokine receptor, and age-related macular degeneration (AMD). Peripheral blood from 85 AMD patients and 105 subjects without AMD (controls), as well as ocular tissue from 40 pathological sections with AMD and two normal eye sections, were screened for V249I and T280M, two single nucleotide polymorphisms (SNPs) in CX3CR1. An increased prevalence, with the highest odds ratio of 3.57, of the I249 and M280 carriers was found among the AMD cases as compared with the controls. When comparing CX3CR1 expression in the archived eye sections, CX3CR1 transcripts were not detectable in the maculae of AMD eyes bearing T/M280; however, transcripts were detected in the maculae of normal eyes bearing T/T280 or T/M280 as well as in the AMD maculae bearing T/T280. Furthermore, lower CX3CR1 protein expression was observed in the maculae of AMD eyes bearing T/M280 compared with the controls bearing T/T280. The I249 and M280 alleles result in a lowered number of receptor binding sites and a decreased ligand affinity. Our data suggest that a decrease, caused by sequence variation and/or lower CX3CR1 expression, in CX3CR1-induced cellular activities could contribute to AMD development.	NEI, Immunol Lab, Bethesda, MD 20892 USA; NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA; NEI, HHMI, Bethesda, MD 20892 USA; NEI, Sect Gene Therapy, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Chan, CC (corresponding author), NEI, Immunol Lab, Bldg 10,10 Ctr Dr,Rm 10N103, Bethesda, MD 20892 USA.	chanc@nei.nih.gov			Intramural NIH HHS [Z99 EY999999, Z01 EY000222-22, Z01 EY000418-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000069, Z01EY000222, Z01EY000418] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5; Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613; DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483; Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1; Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8; Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646; la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003; Lutty G, 1999, MOL VIS, V5; Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500; Schmidt S, 2000, MOL VIS, V6, P287; Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191; Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558; Sunnemark D, 2003, BRAIN PATHOL, V13, P617; Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001	40	156	164	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1297	+		10.1096/fj.04-1862fje	http://dx.doi.org/10.1096/fj.04-1862fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208270	Green Accepted			2022-12-25	WOS:000222327500016
J	Sirikantaramas, S; Morimoto, S; Shoyama, Y; Ishikawa, Y; Wada, Y; Shoyama, Y; Taura, F				Sirikantaramas, S; Morimoto, S; Shoyama, Y; Ishikawa, Y; Wada, Y; Shoyama, Y; Taura, F			The gene controlling marijuana psychoactivity - Molecular cloning and heterologous expression of Delta(1)-tetrahydrocannabinolic acid synthase from Cannabis sativa L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERBERINE BRIDGE ENZYME; COVALENTLY BOUND FLAVIN; FIR ABIES-GRANDIS; FUNCTIONAL EXPRESSION; 6-HYDROXY-D-NICOTINE OXIDASE; CDNA ISOLATION; TETRAHYDROCANNABINOLIC ACID; ALKALOID BIOSYNTHESIS; MONOTERPENE SYNTHASES; ARTHROBACTER-OXIDANS	Delta(1)-Tetrahydrocannabinolic acid ( THCA) synthase is the enzyme that catalyzes oxidative cyclization of cannabigerolic acid into THCA, the precursor of Delta(1)-tetrahydrocannabinol. We cloned a novel cDNA (GenBank(TM) accession number AB057805) encoding THCA synthase by reverse transcription and polymerase chain reactions from rapidly expanding leaves of Cannabis sativa. This gene consists of a 1635-nucleotide open reading frame, encoding a 545-amino acid polypeptide of which the first 28 amino acid residues constitute the signal peptide. The predicted molecular weight of the 517-amino acid mature polypeptide is 58,597 Da. Interestingly, the deduced amino acid sequence exhibited high homology to berberine bridge enzyme from Eschscholtzia californica, which is involved in alkaloid biosynthesis. The liquid culture of transgenic tobacco hairy roots harboring the cDNA produced THCA upon feeding of cannabigerolic acid, demonstrating unequivocally that this gene encodes an active THCA synthase. Overexpression of the recombinant THCA synthase was achieved using a baculovirus-insect expression system. The purified recombinant enzyme contained covalently attached FAD cofactor at a molar ratio of FAD to protein of 1: 1. The mutant enzyme constructed by changing His-114 of the wild-type enzyme to Ala-114 exhibited neither absorption characteristics of flavoproteins nor THCA synthase activity. Thus, we concluded that the FAD binding residue is His-114 and that the THCA synthase reaction is FAD-dependent. This is the first report on molecular characterization of an enzyme specific to cannabinoid biosynthesis.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan	Kyushu University	Taura, F (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.	taura@phar.kyushu-u.ac.jp	Sirikantaramas, Supaart/E-3239-2010; Sirikantaramas, Supaart/AAF-7376-2020	Sirikantaramas, Supaart/0000-0003-0330-0845				Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Bird DA, 2001, PLANTA, V213, P888, DOI 10.1007/s004250100582; Bohlmann J, 1997, J BIOL CHEM, V272, P21784, DOI 10.1074/jbc.272.35.21784; Bohlmann J, 1999, ARCH BIOCHEM BIOPHYS, V368, P232, DOI 10.1006/abbi.1999.1332; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; BRUHMULLER M, 1972, EUR J BIOCHEM, V29, P143, DOI 10.1111/j.1432-1033.1972.tb01968.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; FABIAN J, 1965, J BACTERIOL, V89, P921; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoelscher DJ, 2003, PHYTOCHEMISTRY, V62, P1081, DOI 10.1016/S0031-9422(02)00674-X; KIMURA M, 1970, EXPERIENTIA, V26, P819, DOI 10.1007/BF02114192; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; KUTCHAN TM, 1995, J BIOL CHEM, V270, P24475, DOI 10.1074/jbc.270.41.24475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUCH L, 1990, J BIOL CHEM, V265, P12761; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; Mechoulam R, 2000, CURR PHARM DESIGN, V6, P1313, DOI 10.2174/1381612003399509; MECHOULAM R, 1970, SCIENCE, V168, P1159, DOI 10.1126/science.168.3936.1159; MECHOULAM R, 1969, J CHEM SOC CHEM COMM, P343, DOI 10.1039/c29690000343; MECHOULAM R, 1969, TETRAHEDRON LETT, V10, P5349; Phillips MA, 2003, ARCH BIOCHEM BIOPHYS, V411, P267, DOI 10.1016/S0003-9861(02)00746-4; SHOYAMA Y, 1975, PHYTOCHEMISTRY, V14, P2189, DOI 10.1016/S0031-9422(00)91096-3; Singer T P, 1978, Methods Enzymol, V53, P397; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEFFENS P, 1985, PHYTOCHEMISTRY, V24, P2577, DOI 10.1016/S0031-9422(00)80672-X; TAURA F, 1995, PHYTOCHEMISTRY, V39, P457, DOI 10.1016/0031-9422(94)00887-Y; TAURA F, 1995, J AM CHEM SOC, V117, P9766, DOI 10.1021/ja00143a024; Taura F, 1996, J BIOL CHEM, V271, P17411, DOI 10.1074/jbc.271.29.17411; TURNER CE, 1980, J NAT PROD, V43, P169, DOI 10.1021/np50008a001; VANHAUTE E, 1983, EMBO J, V2, P411, DOI 10.1002/j.1460-2075.1983.tb01438.x; WHITE FF, 1980, J BACTERIOL, V141, P1134, DOI 10.1128/JB.141.3.1134-1141.1980; Wise ML, 1998, J BIOL CHEM, V273, P14891, DOI 10.1074/jbc.273.24.14891; YAMAUCHI T, 1967, CHEM PHARM BULL, V15, P1075; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343	46	182	207	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39767	39774		10.1074/jbc.M403693200	http://dx.doi.org/10.1074/jbc.M403693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15190053	hybrid			2022-12-25	WOS:000223791500070
J	Laughery, M; Todd, M; Kaplan, JH				Laughery, M; Todd, M; Kaplan, JH			Oligomerization of the Na,K-ATPase in cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA-UNITS; CROSS-LINKING; NA+/K+-ATPASE; SUBUNIT INTERACTIONS; ORTHO-PHENANTHROLINE; SARCOPLASMIC-RETICULUM; HIGH-AFFINITY; NA+,K+-ATPASE; CA2+-ATPASE; ASSOCIATION	The higher order oligomeric state of the Na,K-ATPase alphabeta heterodimer in cell membranes is the subject of controversy. We have utilized the baculovirus-infected insect cell system to express Na,K-ATPase with alpha-subunits bearing either His(6) or FLAG epitopes at the carboxyl terminus. Each of these constructs produced functional Na,K-ATPase alphabeta heterodimers that were delivered to the plasma membrane (PM). Cells were simultaneously co-infected with viruses encoding alpha-His/beta and alpha-FLAG/beta Na,K-ATPases. Co-immunoprecipitation of the His-tagged alpha-subunit in the endoplasmic reticulum (ER) and PM fractions of co-infected cells by the anti-FLAG antibody demonstrates that protein-protein associations exist between these heterodimers. This suggests the Na,K-ATPase is present in cell membranes in an oligomeric state of at least (alphabeta)(2) composition. Deletion of 256 amino acid residues from the central cytoplasmic loop of the alpha-subunit results in the deletion alpha-4,5-loop-less (alpha-4,5LL), which associates with beta but is confined to the ER. Co-immunoprecipitation demonstrates that when this inactive alpha-4,5LL/beta heterodimer is co-expressed with wild-type alphabeta, oligomers of wild-type alphabeta and alpha-4,5LL/beta form in the ER, but the alpha-4,5LL mutant remains retained in the ER, and the wild-type protein is still delivered to the PM. We conclude that the Na,K-ATPase is present as oligomers of the monomeric alphabeta heterodimer in native cell membranes.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.			Kaplan, Jack/0000-0002-7048-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30315] Funding Source: Medline; NIGMS NIH HHS [GM 39500] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; Askari A, 2000, INT CONGR SER, V1207, P17; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Costa CJ, 2003, J BIOL CHEM, V278, P9176, DOI 10.1074/jbc.M212351200; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Froehlich JP, 1997, ANN NY ACAD SCI, V834, P280, DOI 10.1111/j.1749-6632.1997.tb52259.x; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 2000, INT CONGR SER, V1207, P357; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; HUANG W, 1978, BIOCHEM BIOPH RES CO, V82, P1314, DOI 10.1016/0006-291X(78)90331-5; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; HUANG WH, 1979, FEBS LETT, V101, P67, DOI 10.1016/0014-5793(79)81297-1; HUANG WH, 1988, METHOD ENZYMOL, V156, P345; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; JORDAN C, 1995, J BIOL CHEM, V270, P29971; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kaya S, 2003, ANN NY ACAD SCI, V986, P278, DOI 10.1111/j.1749-6632.2003.tb07185.x; Koster JC, 1997, ANN NY ACAD SCI, V834, P135, DOI 10.1111/j.1749-6632.1997.tb52240.x; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; Laughery MD, 2003, J BIOL CHEM, V278, P34794, DOI 10.1074/jbc.M302899200; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1992, ANN NY ACAD SCI, V671, P147, DOI 10.1111/j.1749-6632.1992.tb43792.x; MARTIN DW, 1992, J BIOL CHEM, V267, P23922; Martin DW, 2000, P NATL ACAD SCI USA, V97, P3195, DOI 10.1073/pnas.050558397; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; Palladino MJ, 2003, J NEUROSCI, V23, P1276, DOI 10.1523/JNEUROSCI.23-04-01276.2003; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Scheiner-Bobis G, 1988, Prog Clin Biol Res, V268A, P219; SCHONER W, 1994, SODIUM PUMP, P332; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Taniguchi K, 1999, Nihon Yakurigaku Zasshi, V114, P179; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2003, ANN NY ACAD SCI, V986, P1, DOI 10.1111/j.1749-6632.2003.tb07131.x; VILSEN B, 1987, J BIOL CHEM, V262, P10511	46	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36339	36348		10.1074/jbc.M402778200	http://dx.doi.org/10.1074/jbc.M402778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208327	hybrid			2022-12-25	WOS:000223453600023
J	Carstens, MJ; Krempler, A; Triplett, AA; van Lohuizen, M; Wagner, KU				Carstens, MJ; Krempler, A; Triplett, AA; van Lohuizen, M; Wagner, KU			Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUSCEPTIBILITY GENE; TSG101 PROTEIN; TRANSCRIPTIONAL ACTIVATION; ENDOSOMAL TRAFFICKING; EMBRYONIC LETHALITY; BREAST-CANCER; MICE; MOUSE; P53; PROLIFERATION	Our previous studies have shown that cells conditionally deficient in Tsg101 arrested at the G(1)/S cell cycle checkpoint and died. We created a series of Tsg101 conditional knock-out cell lines that lack p53, p21(Cip1), or p19(Arf) to determine the involvement of the Mdm2-p53 circuit as a regulator for G(1)/S progression and cell death. In this new report we show that the cell cycle arrest in Tsg101-deficient cells is p53-dependent, but a null mutation of the p53 gene is unable to maintain cell survival. The deletion of the Cdkn1a gene in Tsg101 conditional knock-out cells resulted in G(1)/S progression, suggesting that the p53-dependent G(1) arrest in the Tsg101 knock-out is mediated by p21(Cip1). The Cre-mediated excision of Tsg101 in immortalized fibroblasts that lack p19(Arf) seemed not to alter the ability of Mdm2 to sequester p53, and the p21-mediated G(1) arrest was not restored. Based on these findings, we propose that the p21-dependent cell cycle arrest in Tsg101-deficient cells is an indirect consequence of cellular stress and not caused by a direct effect of Tsg101 on Mdm2 function as previously suggested. Finally, the deletion of Tsg101 from primary tumor cells that express mutant p53 and that lack p21(Cip1) expression results in cell death, suggesting that additional transforming mutations during tumorigenesis do not affect the important role of Tsg101 for cell survival.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA; Netherlands Canc Inst, Dept Mol Genet, NL-1066 CX Amsterdam, Netherlands	University of Nebraska System; University of Nebraska Medical Center; Netherlands Cancer Institute	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Rm 8009, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [R01CA093797] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093797, CA93797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DEOCALUNA R, 1995, NATURE, V0378; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EL DW, 1993, CELL, V75, P817; Feng GH, 2000, CANCER RES, V60, P1736; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HENRY MDH, 2004, IN PRESS ONCOGENE; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Wagner KU, 1999, CYTOGENET CELL GENET, V84, P87, DOI 10.1159/000015221; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhong Q, 1998, CANCER RES, V58, P2699	40	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35984	35994		10.1074/jbc.M400408200	http://dx.doi.org/10.1074/jbc.M400408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210712	hybrid, Green Accepted			2022-12-25	WOS:000223303400100
J	Izawa, S; Takemura, R; Inoue, Y				Izawa, S; Takemura, R; Inoue, Y			Gle2p is essential to induce adaptation of the export of bulk poly(A)(+) mRNA to heat shock in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; MEMBRANE-FLUIDITY; COUPLING TRANSCRIPTION; HYDROGEN-PEROXIDE; NUCLEOPORIN RIP1P; LIPID-COMPOSITION; 3'-END FORMATION; COMPLEX; PROTEIN; ETHANOL	The export of bulk poly(A)(+) mRNA is blocked under heat-shocked (42degreesC) conditions in Saccharomyces cerevisiae. We found that an mRNA export factor Gle2p rapidly dissociated from the nuclear envelope and diffused into the cytoplasm at 42degreesC. However, in exponential phase cells pretreated with mild heat stress (37degreesC for 1 h), Gle2p did not dissociate at 42degreesC, and the export of bulk poly(A)(+) mRNA continued. Cells in stationary phase also continued with the export of bulk poly(A)(+) mRNA at 42degreesC without the dissociation of Gle2p from the nuclear envelope. The dissociation of Gle2p was caused by increased membrane fluidity and correlated closely with blocking of the export of bulk poly(A)(+) mRNA. Furthermore, the mutants gle2Delta and rip1Delta could not induce such an adaptation of the export of bulk poly(A)(+) mRNA to heat shock. Our findings indicate that Gle2p plays a crucial role in mRNA export especially under heat-shocked conditions. Our findings also indicate that the nuclear pore complexes that Gle2p constitutes need to be stabilized for the adaptation and that the increased membrane integrity caused by treatment with mild heat stress or by survival in stationary phase is likely to contribute to the stabilization of the association between Gle2p and the nuclear pore complexes.	Kyoto Univ, Grad Sch Agr, Mol Microbiol Lab, Kyoto 6110011, Japan	Kyoto University	Izawa, S (corresponding author), Kyoto Univ, Grad Sch Agr, Mol Microbiol Lab, Kyoto 6110011, Japan.	izawa@kais.kais.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450				ALEXANDRE H, 1994, FEMS MICROBIOL LETT, V124, P17, DOI 10.1016/0378-1097(94)90326-3; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bisson LF, 1999, AM J ENOL VITICULT, V50, P107; Blomberg A, 2002, METHOD ENZYMOL, V350, P559, DOI 10.1016/S0076-6879(02)50985-X; Brodsky AS, 2000, RNA, V6, P1737, DOI 10.1017/S1355838200001059; Bucci M, 1998, MOL BIOL CELL, V9, P2439, DOI 10.1091/mbc.9.9.2439; Cole CN, 2000, FR MOLEC B, V33, P276; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; Hammell CM, 2002, MOL CELL BIOL, V22, P6441, DOI 10.1128/MCB.22.18.6441-6457.2002; Henry MF, 2003, MOL BIOL CELL, V14, P3929, DOI 10.1091/mbc.E03-01-0854; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Hilleren P, 2001, RNA, V7, P753, DOI 10.1017/S1355838201010147; Hurt E, 2000, J BIOL CHEM, V275, P8361, DOI 10.1074/jbc.275.12.8361; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; KUNKEE RE, 1993, YEAST, P39; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Long RM, 1995, RNA, V1, P1071; MILLER MJ, 1982, J BACTERIOL, V151, P311, DOI 10.1128/JB.151.1.311-327.1982; Mizoguchi H, 1997, J FERMENT BIOENG, V83, P12, DOI 10.1016/S0922-338X(97)87319-9; Mizoguchi H, 1996, J FERMENT BIOENG, V81, P406, DOI 10.1016/0922-338X(96)85141-5; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Orvar BL, 2000, PLANT J, V23, P785, DOI 10.1046/j.1365-313x.2000.00845.x; PIPER P, 1997, YEAST STRESS RESPONS, P75; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; PIPER PW, 1994, MICROBIOL-SGM, V140, P3031, DOI 10.1099/13500872-140-11-3031; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Sangwan V, 2002, PLANT J, V31, P629, DOI 10.1046/j.1365-313X.2002.01384.x; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Shulga N, 2003, MOL CELL BIOL, V23, P534, DOI 10.1128/MCB.23.2.534-542.2003; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Sugiyama K, 2000, BIOCHEM J, V352, P71, DOI 10.1042/0264-6021:3520071; Swan TM, 1999, CAN J MICROBIOL, V45, P472, DOI 10.1139/cjm-45-6-472; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Vainberg IE, 2000, MOL CELL BIOL, V20, P3996, DOI 10.1128/MCB.20.11.3996-4005.2000; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Yasumiba S, 2001, BIOCHEM J, V354, P591, DOI 10.1042/0264-6021:3540591; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6; Zhang GJ, 2000, J MEMBRANE BIOL, V175, P53, DOI 10.1007/s002320001054	61	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35469	35478		10.1074/jbc.M403692200	http://dx.doi.org/10.1074/jbc.M403692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210706	hybrid			2022-12-25	WOS:000223303400040
J	Xu, JF; Liao, K				Xu, JF; Liao, K			Protein kinase B/AKT 1 plays a pivotal role in insulin-like growth factor-1 receptor signaling induced 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; MITOTIC CLONAL EXPANSION; B C-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; CELL-SURVIVAL; NEGATIVE REGULATION; FACTOR FKHR; ADIPOGENESIS; PREADIPOCYTES	During 3T3-L1 preadipocyte differentiation induction, the insulin-stimulated insulin-like growth factor-1 (IGF-1) receptor signal is responsible for the induction of adipocyte differentiation. Treatment with inhibitors of phosphatidylinositol 3-kinase, LY294002 or wortmannin, leads to the complete blockade of adipocyte differentiation in 3T3-L1 preadipocytes. Of the three factors (1-methyl-3-isobutylxanthine, dexamethasone, and insulin) inducing 3T3-L1 preadipocyte differentiation, only insulin was able to activate the phosphatidylinositol 3-kinase-protein kinase B/Akt signal cascade. In 3T3-L1 preadipocytes, protein kinase B/Akt 1 RNA interference not only suppressed the expression of protein kinase B/Akt 1 but also blocked hormone-induced adipocyte differentiation. In these protein kinase B/Akt 1 RNA interference cells, the signal molecules upstream of protein kinase B/Akt 1, such as IGF-1 receptor and insulin receptor substrate-1, were normally activated by insulin stimulation, whereas insulin-stimulated phosphorylation of forkhead transcription factor (FKHR), which is a downstream molecule of PKB/Akt 1, was blocked. Thus, protein kinase B/Akt 1 is an important signal mediator in IGF-1 receptor signal cascade for inducing adipocyte differentiation.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Liao, K (corresponding author), Shanghai Inst Biochem & Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	kliao@sibs.ac.cn						Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Blair LAC, 1999, J NEUROSCI, V19, P1940; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cho KJ, 2003, J BIOL CHEM, V278, P34823, DOI 10.1074/jbc.M210747200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FONT DE, 1997, MOL CELL BIOL, V17, P6068; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LeRoith D, 1997, ENDOCRINE, V7, P103, DOI 10.1007/BF02778074; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sorisky A, 1996, OBES RES, V4, P9, DOI 10.1002/j.1550-8528.1996.tb00507.x; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	49	166	174	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35914	35922		10.1074/jbc.M402297200	http://dx.doi.org/10.1074/jbc.M402297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192111	hybrid			2022-12-25	WOS:000223303400092
J	Yang, F; Bleich, D				Yang, F; Bleich, D			Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA STABILITY; INSULIN-SECRETION; BINDING PROTEIN; 3'-UNTRANSLATED REGION; CARCINOMA-CELLS; EXPRESSION; INHIBITION; ACTIVATION; INDUCTION	Prostaglandin E-2 (PGE(2)) has been shown to negatively affect pancreatic beta-cell function, and its inducible synthesis is mediated in part by cycloxygenase-2 (COX-2). Regulation of basal and inducible COX-2 gene expression in pancreatic beta-cells is not fully understood. In this report, we used pancreatic beta-cells (RINm5F) to explore the molecular mechanisms regulating COX-2 promoter activity. Through deletion analysis of a -907/+70-bp 5' upstream region of the mouse COX-2 gene, we identified an inhibition domain (-804/-371) and an activation domain (-371/+70). The highest promoter activity was seen when the promoter was reduced to -371 bp. Several cis-acting elements were selected for site-directed mutations in the activation domain. We identified three sites that were essential for basal COX-2 promoter activity: 1) CCAAT/enhancer-binding protein (C/EBP), 2) aryl hydrocarbon receptor (AhR), and 3) cAMP response element-binding protein (CREB). Single mutation of each individual site inhibited 70-80% of basal COX-2 promoter activity. Double mutation of the AhR and CREB-binding sites showed synergy in repressing COX-2 promoter activity as did mutation of all three sites. We demonstrated that the transcription factors from RINm5F nuclear extracts specifically bound to oligonucleotides containing C/EBP, AhR, or CREB consensus sites. Forskolin, an activator of adenyl cyclase, increased COX-2 promoter activity via the CREB site. COX-2 promoter activity was also increased by 2,3,7,8-tetrachlorodibenzo-p-dioxin, an AhR activator, through the AhR site. Both forskolin and 2,3,7,8-tetrachlorodibenzo-p-dioxin increased COX-2 mRNA in a dose-dependent manner. We consider these three transcriptional regulators of COX-2 expression to be potential targets for the prevention of beta-cell damage mediated by PGE(2).	City Hope Natl Med Ctr, Dept Diabet Endocrinol & Metab, Susan & Leslie Gonda Goldschmied Diabet & Genet R, Duarte, CA 91010 USA	City of Hope	Bleich, D (corresponding author), City Hope Natl Med Ctr, Dept Diabet Endocrinol & Metab, Susan & Leslie Gonda Goldschmied Diabet & Genet R, 1500 E Duarte Rd, Duarte, CA 91010 USA.	dbleich@coh.org						Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481; Bishop-Bailey D, 1999, INT J MOL MED, V3, P41; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006/bbrc.1998.8966; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Guan ZH, 1998, AM J PHYSIOL-RENAL, V274, pF673, DOI 10.1152/ajprenal.1998.274.4.F673; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; Han X, 2002, MOL ENDOCRINOL, V16, P2145, DOI 10.1210/me.2001-0300; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Luo C, 2002, CELL TISSUE RES, V310, P169, DOI 10.1007/s00441-002-0628-6; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Persaud SJ, 2004, DIABETES, V53, pS190, DOI 10.2337/diabetes.53.2007.S190; Puga A, 1997, BIOCHEM PHARMACOL, V54, P1287, DOI 10.1016/S0006-2952(97)00417-6; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Richards JA, 2002, J STEROID BIOCHEM, V80, P203, DOI 10.1016/S0960-0760(01)00187-X; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; ROBERTSON RP, 1974, J CLIN INVEST, V54, P310, DOI 10.1172/JCI107766; ROBERTSON RP, 1987, DIABETES, V36, P1047, DOI 10.2337/diabetes.36.9.1047; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Steer SA, 2003, VIRAL IMMUNOL, V16, P447, DOI 10.1089/088282403771926283; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Wolfle D, 2000, CARCINOGENESIS, V21, P15, DOI 10.1093/carcin/21.1.15	45	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35403	35411		10.1074/jbc.M404055200	http://dx.doi.org/10.1074/jbc.M404055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15213229	hybrid			2022-12-25	WOS:000223303400034
J	Karasarides, M; Chiloeches, A; Hayward, R; Niculescu-Duvaz, D; Scanlon, I; Friedlos, F; Ogilvie, L; Hedley, D; Martin, J; Marshall, CJ; Springer, CJ; Marais, R				Karasarides, M; Chiloeches, A; Hayward, R; Niculescu-Duvaz, D; Scanlon, I; Friedlos, F; Ogilvie, L; Hedley, D; Martin, J; Marshall, CJ; Springer, CJ; Marais, R			B-RAF is a therapeutic target in melanoma	ONCOGENE			English	Article						B-RAF; melanoma; RNA interference; proliferation; apoptosis; BAY43-9006	SIGNALING PATHWAY; BRAF MUTATIONS; APOPTOSIS; CANCER; ACTIVATION; GENE; INHIBITOR; NEOPLASIA; CARCINOMA; CELLS	B-RAF is a serine/threonine-specific protein kinase that is mutated in approximately 70% of human melanomas. However, the role of this signalling molecule in cancer is unclear. Here, we show that ERK is constitutively activated in melanoma cells expressing oncogenic B-RAF and that this activity is required for proliferation. B-RAF depletion by siRNA blocks ERK activity, whereas A-RAF and C-RAF depletion do not affect ERK signalling. B-RAF depletion inhibits DNA synthesis and induces apoptosis in three melanoma cell lines and we show that the RAF inhibitor BAY43-9006 also blocks ERK activity, inhibits DNA synthesis and induces cell death in these cells. BAY43-9006 targets B-RAF signalling in vivo and induces a substantial growth delay in melanoma tumour xenografts. Our data demonstrate that oncogenic B-RAF activates ERK signalling, induces proliferation and protects cells from apoptosis, demonstrating that it is an important therapeutic target and thus provides novel strategies for clinical management of melanoma and other cancers.	Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Signal Transduct Team, London SW3 6JB, England; Inst Canc Res, Gene & Oncogene Targeting Team, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Oncogene Team, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marais, R (corresponding author), Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, Signal Transduct Team, 237 Fulham Rd, London SW3 6JB, England.	richard.marais@icr.ac.uk	Chiloeches, Antonio/Z-5993-2019	Antonio, Chiloeches Galvez/0000-0001-7162-330X; Marais, Richard/0000-0001-7484-4183; Springer, Caroline/0000-0002-0650-4002				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Brose MS, 2002, CANCER RES, V62, P6997; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Hingorani SR, 2003, CANCER RES, V63, P5198; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kimura ET, 2003, CANCER RES, V63, P1454; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; LEEVERS SJ, 1993, THESIS U LONDON LOND; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; Marais R, 1996, CANCER RES, V56, P4735; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Workman P, 1998, BRIT J CANCER, V77, P1; Yuen ST, 2002, CANCER RES, V62, P6451	29	354	378	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6292	6298		10.1038/sj.onc.1207785	http://dx.doi.org/10.1038/sj.onc.1207785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208680				2022-12-25	WOS:000223399000013
J	Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN				Zhang, H; Herbert, BS; Pan, KH; Shay, JW; Cohen, SN			Disparate effects of telomere attrition on gene expression during replicative senescence of human mammary epithelial cells cultured under different conditions	ONCOGENE			English	Article						replicative senescence; telomere shortening; microarray; mammary epithelial cells; culture conditions	LIFE-SPAN; REVERSE-TRANSCRIPTASE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; DNA MICROARRAYS; MITOTIC CLOCK; P16(INK4A); EXTENSION; IMMORTALIZATION	Telomere shortening in populations of human mammary epithelial cells (HMECs) that survive early replicative arrest (M0) by the inactivation of p16(INK4A) during cell culture on plastic dishes leads to a state of permanent replicative arrest termed senescence. While culture of HMECs on feeder layers abrogates M0 and p16(INK4A) inactivation, progressive telomere attrition in these cells also eventually results in permanent replicative arrest. Expression of telomerase prevents both senescence on plastic (S-P) and senescence on feeder layers (S-FL) in HMECs, as it does also in cultured primary human fibroblasts. We report here that the gene expression profiles of senescence in HMECs of the same lineage maintained under different culture conditions showed surprisingly little commonality. Moreover, neither of these senescence-associated profiles in HMECs resembles the pro. le for senescence in human fibroblasts. These results indicate that senescence-associated alterations in gene expression resulting from telomere attrition are affected by culture conditions as well as by cell origins, and argue that replicative senescence at the molecular level is a diverse rather than unique cellular process.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Stanford Univ, Sch Med, Program Biomed Informat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	sncohen@stanford.edu	Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA70907] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yaswen P, 2001, J MAMMARY GLAND BIOL, V6, P223, DOI 10.1023/A:1011364925259; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	40	19	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6193	6198		10.1038/sj.onc.1207834	http://dx.doi.org/10.1038/sj.onc.1207834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195144				2022-12-25	WOS:000223399000003
J	Alonso, AD; Mederlyova, A; Novak, M; Grundke-Iqbal, I; Iqbal, K				Alonso, AD; Mederlyova, A; Novak, M; Grundke-Iqbal, I; Iqbal, K			Promotion of hyperphosphorylation by frontotemporal dementia tau mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ABNORMALLY PHOSPHORYLATED-TAU; R406W HUMAN TAU; V337M HUMAN TAU; PROTEIN-TAU; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEUROBLASTOMA-CELLS; FTDP-17 MUTATIONS; P301L TAU	Mutations in the tau gene are known to cosegregate with the disease in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). However, the molecular mechanism by which these mutations might lead to the disease is not understood. Here, we show that four of the FTDP-17 tau mutations, R406W, V337M, G272V, and P301L, result in tau proteins that are more favorable substrates for phosphorylation by brain protein kinases than the wild-type, largest four-repeat protein tau4L and tau4L more than tau3L. In general, at all the sites studied, mutant tau proteins were phosphorylated faster and to a higher extent than tau4L and tau4L > tau3L. The most dramatic difference found was in the rate and level of phosphorylation of tau4L(R406W) at positions Ser-396, Ser-400, Thr-403, and Ser-404. Phosphorylation of this mutant tau was 12 times faster and 400% greater at Ser-396 and less than 30% at Ser-400, Thr-403, and Ser-404 than phosphorylation of tau4L. The mutated tau proteins polymerized into filaments when 4-6 mol of phosphate per mol of tau were incorporated, whereas wild-type tau required similar to10 mol of phosphate per mol of protein to self-assemble. Mutated and wild-type tau proteins were able to sequester normal tau upon incorporation of similar to4 mol of phosphate per mol of protein, which was achieved at as early as 30 min of phosphorylation in the case of mutant tau proteins. These findings taken together suggest that the mutations in tau might cause neurodegeneration by making the protein a more favorable substrate for hyperphosphorylation.	New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; Slovak Acad Sci, Inst Neuroimmunol, Bratislava 84246, Slovakia	Institute for Basic Research in Developmental Disabilities; Slovak Academy of Sciences	Iqbal, K (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	iqbalk@worldnet.att.net			FIC NIH HHS [TW 00507] Funding Source: Medline; NIA NIH HHS [AG 19158] Funding Source: Medline; NINDS NIH HHS [MN/NS 31862] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; ALONSO AD, 1995, MOL BRAIN RES, V31, P194, DOI 10.1016/0169-328X(95)00051-S; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, J BIOL CHEM, V276, P37967; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bird TD, 1999, BRAIN, V122, P741, DOI 10.1093/brain/122.4.741; Crowther RA, 2000, J STRUCT BIOL, V130, P271, DOI 10.1006/jsbi.2000.4270; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Fath T, 2002, J NEUROSCI, V22, P9733; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldbaum O, 2003, J NEUROSCI, V23, P8872; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1998, BRAIN RES, V464, P43; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; Ho L, 2001, NEUROSCI LETT, V310, P1, DOI 10.1016/S0304-3940(01)02044-4; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Janssen JC, 2002, NEUROLOGY, V58, P1161, DOI 10.1212/WNL.58.8.1161; Jicha GA, 1999, NEUROSCI LETT, V260, P153, DOI 10.1016/S0304-3940(98)00980-X; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KREMER L, 1988, ANAL BIOCHEM, V175, P91, DOI 10.1016/0003-2697(88)90365-X; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Perez M, 2001, BIOCHEMISTRY-US, V40, P5983, DOI 10.1021/bi002961w; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SINGH TJ, 1995, FEBS LETT, V358, P267, DOI 10.1016/0014-5793(94)01445-7; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tanemura K, 2001, NEUROBIOL DIS, V8, P1036, DOI 10.1006/nbdi.2001.0439; Tanemura K, 2002, J NEUROSCI, V22, P133, DOI 10.1523/JNEUROSCI.22-01-00133.2002; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yoshida H, 2002, J NEUROCHEM, V80, P548, DOI 10.1046/j.0022-3042.2001.00729.x	62	231	246	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34873	34881		10.1074/jbc.M405131200	http://dx.doi.org/10.1074/jbc.M405131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190058	hybrid			2022-12-25	WOS:000223134800097
J	Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS				Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS			Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome	ONCOGENE			English	Article						E2F3 gene; prostate cancer; EZH2 gene	RENAL-CELL CARCINOMA; BLADDER-CANCER; BREAST-CANCER; GENE; PROLIFERATION; EXPRESSION; TFE3; P53; EZH2; ADENOCARCINOMAS	E2F transcription factors, including EM, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P=0.0022) and cause-specific survival (P=0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of EM-positive nuclei identified within their prostate cancers (up to 20, 21-40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P=0.0014) and for cause-specific survival (P=0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P=0.0103, stratified P=0.0086) and cause-specific survival (unstratified P=0.0288, stratified P=0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.	Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England; Univ Liverpool, Dept Pathol & Mol Genet, Liverpool, Merseyside, England; Canc Res Inst, Sect Canc Genet, Male Urol Canc Res Ctr, Sutton, Surrey, England; Royal Marsden NHS Trust, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of Liverpool; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Cooper, CS (corresponding author), Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England.	colin.cooper@icr.ac.uk	Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; Eeles, Rosalind/0000-0002-3698-6241; Feber, Andrew/0000-0001-5282-0498				Bostwick D G, 1999, Semin Urol Oncol, V17, P222; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; CORDONCARDO C, 1994, CANCER RES, V54, P794; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Cox D. R., 1984, ANAL SURVIVAL DATA; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2000, PROSTATE, P4; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; FOSTER CS, 2001, CURR DIAGN PATHOL, V7, P4; GAO X, 1995, ONCOGENE, V11, P1395; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Greene FL, 2002, AJCC CANC STAGING HD; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Humbert PO, 2000, GENE DEV, V14, P690; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kibel AS, 2000, UROLOGY, V55, P316, DOI 10.1016/S0090-4295(99)00478-1; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Konishi N, 2002, JPN J CANCER RES, V93, P767, DOI 10.1111/j.1349-7006.2002.tb01318.x; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Osman I, 1999, CLIN CANCER RES, V5, P2082; Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Sobin LH, 1997, TNM CLASSIFICATION M, P170; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tomovska S, 2001, INT J ONCOL, V18, P1239; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	36	134	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5871	5879		10.1038/sj.onc.1207800	http://dx.doi.org/10.1038/sj.onc.1207800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184867				2022-12-25	WOS:000222941100001
J	Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ				Armes, JE; Hammet, F; de Silva, M; Ciciulla, J; Ramus, SJ; Soo, WK; Mahoney, A; Yarovaya, N; Henderson, MA; Gish, K; Hutchins, AM; Price, GR; Venter, DJ			Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers	ONCOGENE			English	Article						breast cancer; comparative genomic hybridization; expression microarrays; tumor-suppressor genes; chromosome 8	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED PROTEIN-KINASE; YOUNG-WOMEN; CARCINOMA; REGION; PCM-1; RISK; POLYMORPHISMS; ABERRATIONS; APOPTOSIS	Loss of genetic material from chromosome arm 8p occurs commonly in breast carcinomas, suggesting that this region is the site of one or more tumor-suppressor genes (TSGs). Comparative genomic hybridization analysis showed that 8p loss is more common in breast cancers from pre-menopausal compared with post-menopausal patients, as well as in high-grade breast cancers, regardless of the menopausal status. Subsequent high-resolution gene expression profiling of genes mapped to chromosome arm 8p, on an extended cohort of clinical tumor samples, indicated a similar dichotomy of breast cancer clinicopathologic types. Some of these genes showed differential downregulation in early-onset and later-onset, high-grade cancers compared with lower-grade, later-onset cancers. Three such genes were analysed further by in situ technologies, performed on tissue microarrays representing breast tumor and normal tissue samples. PCM1, which encodes a centrosomal protein, and DUSP4/MKP-2, which encodes a MAP kinase phosphatase, both showed frequent gene and protein loss in carcinomas. In contrast, there was an excess of cases showing loss of expression in the absence of reduced gene copy number of SFRP1, which encodes a dominant-negative receptor for Wnt-family ligands. These candidate TSGs may constitute some of the molecular drivers of chromosome arm 8p loss in breast carcinogenesis.	St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia; Victorian Breast Canc Res Consortium, Mol Pathol Lab, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Canc Genom Lab, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Peter MacCallum Canc Inst, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia; Prot Design Labs, Fremont, CA 94555 USA; Womens & Childrens Hlth, Melbourne, Vic 3053, Australia	St Vincent's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Armes, JE (corresponding author), St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia.	jane.armes@svhm.org.au	Susan, Ramus/C-1607-2008; Armes, Jane/D-6396-2012; Ramus, Susan/AAG-8352-2019; Price, Gareth/A-4832-2017	Armes, Jane/0000-0002-2215-0347; Ramus, Susan/0000-0003-0005-7798; Soo, Wee Kheng/0000-0002-5774-9800; Price, Gareth/0000-0003-2439-8650				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Bouras T, 2002, CANCER RES, V62, P1289; Charafe-Jauffret E, 2002, INT J ONCOL, V21, P989; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Ishibe N, 1998, CANCER RES, V58, P667; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Konig JJ, 1999, UROL RES, V27, P3, DOI 10.1007/s002400050082; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lai H, 2002, CANCER BIOL THER, V1, P31, DOI 10.4161/cbt.1.1.37; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Liu QQ, 2001, J CELL SCI, V114, P797; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; RADFORD DM, 1995, CANCER RES, V55, P3399; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sigbjornsdottir BI, 2000, J MED GENET, V37, P342, DOI 10.1136/jmg.37.5.342; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Venables W., 2002, MODERN APPL STAT S, VFourth; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Willis S, 2003, GENE CHROMOSOME CANC, V36, P382, DOI 10.1002/gcc.10138; Xiong P, 2001, CANCER RES, V61, P8465; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	35	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5697	5702		10.1038/sj.onc.1207740	http://dx.doi.org/10.1038/sj.onc.1207740			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184884				2022-12-25	WOS:000222629500016
J	Chiarini, R; Moran, O; Revoltella, RP				Chiarini, R; Moran, O; Revoltella, RP			Identification of an antigenic domain near the C terminus of human granulocyte-macrophage colony-stimulating factor and its spatial localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GM-CSF; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PULMONARY ALVEOLAR PROTEINOSIS; GROWTH-FACTORS; ALPHA-CHAIN; BETA-CHAIN; SYNTHETIC PEPTIDES; MOLECULAR-DYNAMICS; IL-5 RECEPTORS; ANTIBODIES	The goal of this study was to map an epitope on the human granulocyte-macrophage colony-stimulating factor (hGM-CSF) at its C terminus, a region whose integrity is fundamental in maintaining the normal function of this molecule. Residues including the fourth alpha-helix (D, 103 - 116) were analyzed for their role in the interaction with antibodies (Abs) raised against the protein. Five peptides homologous to different segments of the C terminus of hGM-CSF were synthesized. Peptide-(102 121) included the same residues of the alpha-helix D and the next five amino acids toward the C terminus; peptide[ E108A]-( 102 - 121) introduced the mutation E108A in order to verify the role of acidic residues; peptide-[C96A]( 93 - 110) encompassed the beta-sheet 2 and half of the alpha-helix D; peptide-[C121A]-( 110 - 127) included the second half of the alpha-helix D and the C terminus of hGM-CSF; peptide-( 13 - 31)- Gly-Pro-Gly-(103 - 116) included both the alpha-helices A and D connected by the tripeptide Gly-Pro-Gly, which allows the original antiparallel orientation of the two alpha-helices to be maintained. Both anti-protein and anti-peptide-( 102 - 121) antibodies, capable of neutralizing the stimulatory activity of hGM-CSF in the bone marrow colony-forming assays, recognized a specific epitope in the C terminus of hGM-CSF. Molecular modeling estimated the surface accessibility of hGM-CSF and the stability of the synthetic peptides in aqueous solution. Altogether, our results showed that the immunogenic region includes part of the alpha-helix D and the residues 116 - 120, which are external to this helix and particularly exposed on the protein surface, confirming the feasible participation of this region in antibody binding.	CNR, Ist Tecnol Biomed, I-56100 Pisa, Italy; CNR, Ist Biofis, I-16149 Genoa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Revoltella, RP (corresponding author), CNR, Ist Tecnol Biomed, Via G Moruzzi 1, I-56100 Pisa, Italy.	r.revoltella@imd.pi.cnr.it	Moran, Oscar/W-4277-2019					ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; BALDWIN GC, 1988, P NATL ACAD SCI USA, V85, P2763, DOI 10.1073/pnas.85.8.2763; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BEFFY P, 1994, HYBRIDOMA, V13, P457, DOI 10.1089/hyb.1994.13.457; BEFFY P, 1994, FUND CLIN IMMUNOL, V2, P53; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Case D. A., 2002, AMBER 7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CORTI A, 1992, MOL IMMUNOL, V29, P471, DOI 10.1016/0161-5890(92)90004-H; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; GRIBBEN JG, 1990, LANCET, V335, P434, DOI 10.1016/0140-6736(90)90665-R; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; Hubbard S. J., 1993, NACESS COMPUTER PROG; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; Khanjari F, 2003, THORAX, V58, P645, DOI 10.1136/thorax.58.7.645; Kitamura T, 1999, J EXP MED, V190, P875, DOI 10.1084/jem.190.6.875; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; Kontsek P, 1997, CYTOKINE, V9, P550, DOI 10.1006/cyto.1997.0200; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; MELLSTEDT H, 1994, J INTERFERON RES, V14, P179, DOI 10.1089/jir.1994.14.179; MEROPOL NJ, 1991, HYBRIDOMA, V10, P433, DOI 10.1089/hyb.1991.10.433; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; METCALF D, 1984, HAEMOPOIETIC COLONY; Modrowski D, 1997, J CELL PHYSIOL, V170, P35; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; Mueller MM, 1999, AM J PATHOL, V155, P1557, DOI 10.1016/S0002-9440(10)65472-7; NICOLA NA, 1992, CANCER RES, V52, P2012; Noli N, 1997, J PEPT SCI, V3, P323, DOI 10.1002/(SICI)1099-1387(199709)3:5<323::AID-PSC108>3.0.CO;2-5; RAGNHAMMAR P, 1994, BLOOD, V84, P4078, DOI 10.1182/blood.V84.12.4078.bloodjournal84124078; REVOLTELLA R P, 1992, Pharmacological Research, V26, P192, DOI 10.1016/1043-6618(92)90660-4; Revoltella RP, 1997, LEUKEMIA LYMPHOMA, V26, P29, DOI 10.3109/10428199709058597; Revoltella RP, 1998, BIOTHERAPY, V10, P321, DOI 10.1007/BF02678552; Revoltella RP, 1999, BIOSENS BIOELECTRON, V14, P555, DOI 10.1016/S0956-5663(99)00034-2; Revoltella RP, 2000, CELL IMMUNOL, V204, P114, DOI 10.1006/cimm.2000.1704; REVOLTELLA RP, 1995, AR SER S PUBL, P463; SUE JM, 1983, P NATL ACAD SCI-BIOL, V80, P3651, DOI 10.1073/pnas.80.12.3651; Svenson M, 1998, BLOOD, V91, P2054, DOI 10.1182/blood.V91.6.2054.2054_2054_2061; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Uchida K, 2004, BLOOD, V103, P1089, DOI 10.1182/blood-2003-05-1565; VARSHNEY A, 1994, IEEE COMPUT GRAPH, V14, P19, DOI 10.1109/38.310720; Vispo NS, 1999, HYBRIDOMA, V18, P251, DOI 10.1089/027245799315907; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WEGMANN TG, 1989, TRANSPLANT P, V21, P566; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	63	0	0	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37908	37917		10.1074/jbc.M404663200	http://dx.doi.org/10.1074/jbc.M404663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201279	hybrid			2022-12-25	WOS:000223554600084
J	Quinn, SJ; Bai, M; Brown, EM				Quinn, SJ; Bai, M; Brown, EM			pH sensing by the calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; EXTRACELLULAR CALCIUM; CA2+-SENSING RECEPTOR; PARATHYROID-HORMONE; PROTONATION SITE; NMDA RECEPTOR; CA2+ CHANNELS; RAT; EXPRESSION; POLYAMINES	The calcium-sensing receptor (CaR) is activated by small changes in the ionic extracellular calcium concentration (Ca-o) within the physiological range, allowing the parathyroid gland to regulate serum Cao; however, the CaR is also distributed in a number of other tissues where it may sense other endogenous agonists and modulators. CaR agonists are polycationic molecules, and our previous studies suggest that charged residues in the extracellular domain of the CaR are critical for receptor activation through electrostatic interactions. Therefore, pH could also potentially modulate CaR activation by its polycationic agonists. Changes in the concentration of extracellular H+ substantially altered the activation of the CaR by Ca-o and other CaR agonists. The effects of external pH on the CaR's sensitivity to its agonists were observed for both acidic and basic deviations from physiological pH of 7.4, with increases in pH rendering the receptor more sensitive to activation by Cao and decreases in pH producing the converse effect. At pH values more acidic than 5.5, CaR sensitivity to its agonists showed some recovery. Changes in the intracellular pH could not account for the effects of external pH on CaR sensitivity to its agonists. Other G-protein-coupled receptors, which are endogenously expressed in human embryonic kidney 293 cells, showed little change in activity with alterations in external pH or effects opposite those found for the CaR. Extracellular pH directly alters the CaR in the case of Ca-o and Mg-o activation; however, the charges on many organic and inorganic agonists are pH-dependent. Activating CaR mutations show reduced pH(o) modulation, suggesting a molecular mechanism for increased CaR activity at physiological pHo. Several CaR-expressing tissues, including regions of the stomach, the kidney, bone, and the brain, could potentially use the CaR as a sensor for pH and acid-base status.	Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Quinn, SJ (corresponding author), Brigham & Womens Hosp, Div Endocrine, 221 Longwood Ave, Boston, MA 02115 USA.	squinn@rics.bwh.harvard.edu	Centeno, Patricia Pacios/O-8368-2016		NIDDK NIH HHS [DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BICHARA M, 1990, J CLIN INVEST, V86, P430, DOI 10.1172/JCI114729; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Burgess J., 1999, IONS SOLUTION BASIC, P62; Chen XH, 1997, J BIOL CHEM, V272, P30002, DOI 10.1074/jbc.272.48.30002; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Cima RR, 1997, AM J PHYSIOL-GASTR L, V273, pG1051, DOI 10.1152/ajpgi.1997.273.5.G1051; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; Houillier P, 1996, KIDNEY INT, V50, P987, DOI 10.1038/ki.1996.400; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006-291X(02)02133-2; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray JM, 1997, J CLIN INVEST, V99, P2328, DOI 10.1172/JCI119413; Reector FC., 1986, KIDNEY, P551; REYNOLDS IJ, 1988, EUR J PHARMACOL, V151, P103, DOI 10.1016/0014-2999(88)90697-8; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; ROCK DM, 1995, ANNU REV PHARMACOL, V35, P463; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SANDS JM, 1997, J CLIN INVEST, V99, P1917; SHEPHERD RM, 1992, AM J PHYSIOL, V262, pC182, DOI 10.1152/ajpcell.1992.262.1.C182; STIM JA, 1994, MINER ELECTROL METAB, V20, P60; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Valtin H, 1983, RENAL FUNCTION	34	114	118	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37241	37249		10.1074/jbc.M404520200	http://dx.doi.org/10.1074/jbc.M404520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201280	hybrid			2022-12-25	WOS:000223554600008
J	Yakunin, AF; Proudfoot, M; Kuznetsova, E; Savchenko, A; Brown, G; Arrowsmith, CH; Edwards, AM				Yakunin, AF; Proudfoot, M; Kuznetsova, E; Savchenko, A; Brown, G; Arrowsmith, CH; Edwards, AM			The HD domain of the Escherichia coli tRNA nucleotidyltransferase has 2 ',3 '-cyclic phosphodiesterase, 2 '-nucleotidase, and phosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCA-ADDING ENZYME; CYCLIC PHOSPHODIESTERASE; PURIFICATION; BINDING; GENE; IDENTIFICATION; POLYMERASES; SUPERFAMILY; SUBSTRATE; CLEAVAGE	In all mature tRNAs, the 3'-terminal CCA sequence is synthesized or repaired by a template-independent nucleotidyltransferase (ATP(CTP):tRNA nucleotidyltransferase; EC 2.7.7.25). The Escherichia coli enzyme comprises two domains: an N-terminal domain containing the nucleotidyltransferase activity and an uncharacterized C-terminal HD domain. The HD motif defines a superfamily of metal-dependent phosphohydrolases that includes a variety of uncharacterized proteins and domains associated with nucleotidyltransferases and helicases from bacteria, archaea, and eukaryotes. The C-terminal HD domain in E. coli tRNA nucleotidyltransferase demonstrated Ni2+-dependent phosphatase activity toward pyrophosphate, canonical 5'-nucleoside tri- and diphosphates, NADP, and 2'-AMP. Assays with phosphodiesterase substrates revealed surprising metal-independent phosphodiesterase activity toward 2',3'-cAMP, -cGMP, and -cCMP. Without metal or in the presence of Mg2+, the tRNA nucleotidyltransferase hydrolyzed 2',3'-cyclic substrates with the formation of 2'-nucleotides, whereas in the presence of Ni2+, the protein also produced some 3'-nucleotides. Mutations at the conserved His-255 and Asp-256 residues comprising the C-terminal HD domain of this protein inactivated both phosphodiesterase and phosphatase activities, indicating that these activities are associated with the HD domain. Low concentrations of the E. coli tRNA (10 nM) had a strong inhibiting effect on both phosphatase and phosphodiesterase activities. The competitive character of inhibition by tRNA suggests that it might be a natural substrate for these activities. This inhibition was completely abolished by the addition of Mg2+, Mn2+, or Ca2+, but not Ni2+. The data suggest that the phosphohydrolase activities of the HD domain of the E. coli tRNA nucleotidyltransferase are involved in the repair of the 3'-CCA end of tRNA.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C4, Canada; Ontario Canc Inst, Ontario Ctr Struct Proteom, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; Structural Genomics Consortium; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Yakunin, AF (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	a.iakounine@utoronto.ca	Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490; Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250	NIGMS NIH HHS [GM 62413, GM 62414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413, P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; AN G, 1979, J BACTERIOL, V137, P1100, DOI 10.1128/JB.137.3.1100-1110.1979; ANRAKU Y, 1964, J BIOL CHEM, V239, P3412; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BEST AN, 1971, ARCH BIOCHEM BIOPHYS, V142, P527, DOI 10.1016/0003-9861(71)90516-9; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CENTER MS, 1968, J BIOL CHEM, V243, P138; Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200; CUCHILLO CM, 1993, FEBS LETT, V333, P207, DOI 10.1016/0014-5793(93)80654-D; CUDNY H, 1986, J BIOL CHEM, V261, P6450; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P459; DEUTSCHER MP, 1990, METHOD ENZYMOL, V181, P434; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; Giege R, 1996, P NATL ACAD SCI USA, V93, P12078, DOI 10.1073/pnas.93.22.12078; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HEINEMEYER EA, 1977, FEBS LETT, V84, P357, DOI 10.1016/0014-5793(77)80724-2; Hofmann A, 2000, EMBO J, V19, P6207, DOI 10.1093/emboj/19.22.6207; Hogg T, 2004, CELL, V117, P57, DOI 10.1016/S0092-8674(04)00260-0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; KELLEY RL, 1988, METHOD ENZYMOL, V161, P307; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; LI ZW, 1994, J BIOL CHEM, V269, P6064; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; Mechold U, 1996, J BACTERIOL, V178, P1401, DOI 10.1128/jb.178.5.1401-1411.1996; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; Okorokov AL, 1997, PROTEIN ENG, V10, P273, DOI 10.1093/protein/10.3.273; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SETO D, 1988, J BIOL CHEM, V263, P1494; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Yue DX, 1996, RNA, V2, P895; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	47	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36819	36827		10.1074/jbc.M405120200	http://dx.doi.org/10.1074/jbc.M405120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210699	hybrid			2022-12-25	WOS:000223453600084
J	Horng, YC; Cobine, PA; Maxfield, AB; Carr, HS; Winge, DR				Horng, YC; Cobine, PA; Maxfield, AB; Carr, HS; Winge, DR			Specific copper transfer from the Cox17 metallochaperone to both Sco1 and Cox11 in the assembly of yeast cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; PROTEIN; CHAPERONE; GENE; PURIFICATION; TRAFFICKING; SITES; CCS	The assembly of the copper sites in cytochrome c oxidase involves a series of accessory proteins, including Cox11, Cox17, and Sco1. The two mitochondrial inner membrane proteins Cox11 and Sco1 are thought to be copper donors to the Cu-B and Cu-A sites of cytochrome oxidase, respectively, whereas Cox17 is believed to be the copper donor to Sco1 within the intermembrane space. In this report we show Cox17 is a specific copper donor to both Sco1 and Cox11. Using in vitro studies with purified proteins, we demonstrate direct copper transfer from CuCox17 to Sco1 or Cox11. The transfer is specific because no transfer occurs to heterologous proteins, including bovine serum albumin and carbonic anhydrase. In addition, a C57Y mutant of Cox17 fails to transfer copper to Sco1 but is competent for copper transfer to Cox11. The in vitro transfer studies were corroborated by a yeast cytoplasm expression system. Soluble domains of Sco1 and Cox11, lacking the mitochondrial targeting sequence and transmembrane domains, were expressed in the yeast cytoplasm. Metallation of these domains was strictly dependent on the co-expression of Cox17. Thus, Cox17 represents a novel copper chaperone that delivers copper to two proteins.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; Cobine, Paul A/G-3107-2011; Horng, Yih-Chern/I-6682-2018	Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189	NCI NIH HHS [5P30-CA-42014] Funding Source: Medline; NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cobine PA, 2004, J BIOL CHEM, V279, P14447, DOI 10.1074/jbc.M312693200; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; GELLER BL, 1982, ARCH BIOCHEM BIOPHYS, V213, P109, DOI 10.1016/0003-9861(82)90445-3; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990	31	210	220	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35334	35340		10.1074/jbc.M404747200	http://dx.doi.org/10.1074/jbc.M404747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199057	hybrid			2022-12-25	WOS:000223303400026
J	Ruiz, PA; Kim, SC; Sartor, RB; Haller, D				Ruiz, PA; Kim, SC; Sartor, RB; Haller, D			15-deoxy-Delta(12,14)-prostaglandin J(2)-mediated ERK signaling inhibits gram-negative bacteria-induced RelA phosphorylation and interleukin-6 gene expression in intestinal epithelial cells through modulation of protein phosphatase 2A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; LUMINAL BACTERIA; P65 SUBUNIT; KINASE; COLITIS; J(2); INFLAMMATION; ALPHA	We have previously shown that non-pathogenic Gram-negative Bacteroides vulgatus induces transient RelA phosphorylation (Ser-536), NF-kappaB activity, and proinflammatory gene expression in native and intestinal epithelial cell (IEC) lines. We now demonstrate that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) but not prostaglandin E-2 inhibits lipopolysaccharide (LPS) (B. vulgatus)/LPS (Escherichia coli)-induced RelA phosphorylation and interleukin-6 gene expression in the colonic epithelial cell line CMT-93. This inhibitory effect of 15d-PGJ(2) was mediated independently of LPS-induced IkappaBalpha phosphorylation/degradation and RelA nuclear translocation as well as RelA DNA binding activity. Interestingly, although B. vulgatus induced nuclear expression of peroxisome proliferator-activated receptor gamma(PPARgamma) in native epithelium of monoassociated Fisher rats, PPARgamma-specific knock-down in CMT-93 cells using small interference RNA failed to reverse the inhibitory effects of PPARgamma agonist 15d-PGJ(2), suggesting PPARgamma-independent mechanisms. In addition, 15dPGJ(2) but not the synthetic high affinity PPARgamma ligand rosiglitazone triggered ERK1/2 phosphorylation in IEC, and most importantly, MEK1 inhibitor PD98059 reversed the inhibitory effect of 15dPGJ(2) on LPS-induced RelA phosphorylation and interleukin-6 gene expression. Calyculin A, a specific phosphoserine/phosphothreonine phosphatase inhibitor increased the basal phosphorylation of RelA and reversed the inhibitory effect of 15d-PGJ(2) on LPS-induced RelA phosphorylation. We further demonstrated in co-immunoprecipitation experiments that 15d-PGJ(2) triggered protein phosphatase 2A activity, which directly dephosphorylated RelA in LPS-stimulated CMT-93 cells. We concluded that 15d-PGJ(2) may help to control NF-kappaB signaling and normal intestinal homeostasis to the enteric microflora by modulating RelA phosphorylation in IEC through altered protein phosphatase 2A activity.	Tech Univ Munich, Ctr Nutr & Food Res Immunobiol Nutr, D-35350 Freising Weihenstephan, Germany; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	Technical University of Munich; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Haller, D (corresponding author), Tech Univ Munich, Ctr Nutr & Food Res Immunobiol Nutr, D-35350 Freising Weihenstephan, Germany.	haller@wzw.tum.de		Ruiz-Castro, Pedro Antonio/0000-0001-7528-1474; Haller, Dirk/0000-0002-6977-4085	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK053347] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987, R01 DK53347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ardite E, 1998, BRIT J PHARMACOL, V124, P431, DOI 10.1038/sj.bjp.0701887; Auwerx J, 2002, AM J PHYSIOL-GASTR L, V282, pG581, DOI 10.1152/ajpgi.00508.2001; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gordon JI, 1997, AM J PHYSIOL-GASTR L, V273, pG565, DOI 10.1152/ajpgi.1997.273.3.G565; Guyton K, 2001, J LEUKOCYTE BIOL, V69, P631; Haller D, 2004, J PEDIATR GASTR NUTR, V38, P123, DOI 10.1097/00005176-200402000-00004; Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hinz B, 2003, BIOCHEM BIOPH RES CO, V302, P415, DOI 10.1016/S0006-291X(03)00195-5; Huang WC, 2002, EXP CELL RES, V277, P192, DOI 10.1006/excr.2002.5546; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Katayama K, 2003, GASTROENTEROLOGY, V124, P1315, DOI 10.1016/S0016-5085(03)00262-2; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saubermann LJ, 2002, INFLAMM BOWEL DIS, V8, P330, DOI 10.1097/00054725-200209000-00004; SAVAGE DC, 1968, J EXP MED, V127, P67, DOI 10.1084/jem.127.1.67; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Shkoda A, 2004, GASTROENTEROLOGY, V126, pA8; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Tanaka T, 2001, CANCER RES, V61, P2424; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	59	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36103	36111		10.1074/jbc.M405032200	http://dx.doi.org/10.1074/jbc.M405032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199053	Green Published, hybrid			2022-12-25	WOS:000223303400112
J	Van Dyck, F; Delvaux, ELD; Van de Ven, WJM; Chavez, MV				Van Dyck, F; Delvaux, ELD; Van de Ven, WJM; Chavez, MV			Repression of the transactivating capacity of the oncoprotein PLAG1 by SUMOylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; PLEOMORPHIC ADENOMA; SUMO MODIFICATION; NUCLEAR-BODIES/; GENE-EXPRESSION; SALIVARY-GLAND; E3 LIGASE; TRANSCRIPTION; ACTIVATION; FAMILY	Human pleomorphic adenoma gene 1 (PLAG1), a developmentally regulated proto-oncogene, is consistently rearranged and overexpressed in pleomorphic salivary gland adenomas and lipoblastomas with 8q12 translocations. Together with PLAGL1 and PLAGL2, PLAG1 belongs to a subfamily of C2H2 zinc finger transcription factors that activate transcription through binding to the bipartite consensus sequence GRGGC(N)(6-8)GGG. Ectopic expression of PLAG1 deregulates target genes and presumably results in uncontrolled cell proliferation. To gain insight into molecular mechanisms regulating PLAG transcriptional capacity, we searched for interaction partners using the yeast two-hybrid system and confirmed these by glutathione S-transferase pull-down. Ubiquitin-conjugating enzyme 9 (UBC9) and protein inhibitor of activated STAT (PIAS) proteins were first identified as genuine interacting partners of mouse PlagL2. Because UBC9 and PIAS are components of the small ubiquitin-related modifier (SUMO) modification pathway, we hypothesized that PLAG proteins could be SUMOylated. Here, we report results obtained for founding family member PLAG1. Its endogenous SUMOylation was demonstrated, and SUMOylation of PLAG1 was further investigated in cells co-transfected with PLAG1 and SUMO-1 DNA or a SUMO-1 mutant form and similarly examined in the presence or absence of DNA encoding the various PIAS proteins. Using anti-PLAG1 antibodies, we discovered single and double SUMO-1-modified forms of PLAG1. By mutating predicted SUMO consensus sites, we defined two important target lysines for SUMOylation in PLAG1, Lys-244 and Lys-263. Moreover, mutation of both SUMO consensus sequences, resulting in inhibition of SUMOylation, led to a significant increase of the transactivation capacity of PLAG1. Nuclear distribution of PLAG1 was not measurably influenced. Our results suggest a direct repression of the transactivating capacity of the oncoprotein PLAG1 by SUMOylation.	Univ Leuven, Dept Human Genet, Oncol Mol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	KU Leuven	Van de Ven, WJM (corresponding author), Univ Leuven, Dept Human Genet, Oncol Mol Lab, Herestr 49, B-3000 Louvain, Belgium.	wim.vandeven@med.kuleuven.ac.be	Chavez Casarejos, Viviana Marcela Marcela Chavez/AAX-1755-2021	Chavez Casarejos, Viviana Marcela Marcela Chavez/0000-0001-6260-1547				Astrom AK, 1999, CANCER RES, V59, P918; Astrom AK, 2000, INT J ONCOL, V16, P1107; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Hensen K, 2002, CANCER RES, V62, P1510; Hibbard MK, 2000, CANCER RES, V60, P4869; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; Sternsdorf T, 2003, CURR BIOL, V13, pR258, DOI 10.1016/S0960-9822(03)00193-3; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Voz ML, 2004, ONCOGENE, V23, P179, DOI 10.1038/sj.onc.1207013; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	38	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36121	36131		10.1074/jbc.M401753200	http://dx.doi.org/10.1074/jbc.M401753200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208321	hybrid			2022-12-25	WOS:000223303400114
J	Wu, YL; Hooks, SB; Harden, TK; Dohlman, HG				Wu, YL; Hooks, SB; Harden, TK; Dohlman, HG			Dominant-negative inhibition of pheromone receptor signaling by a single point mutation in the G protein alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; NUCLEOTIDE SPECIFICITY; ADENYLYL-CYCLASE; RGS PROTEINS; YEAST; MUTANT; BINDING; RAS; MECHANISM; GENE	In yeast, two different constitutive mutants of the G protein alpha subunit have been reported. Gpa1(Q323L) cannot hydrolyze GTP and permanently activates the pheromone response pathway. Gpa1(N388D) was also proposed to lack GTPase activity, yet it has an inhibitory effect on pheromone responsiveness. We have characterized this inhibitory mutant (designated Galpha(ND)) and found that it binds GTP, interacts with G protein betagamma subunits, and exhibits full GTPase activity in vitro. Although pheromone leads to dissociation of the receptor from wild-type G protein, the same treatment promotes stable association of the receptor with Galpha(ND). We conclude that agonist binding to the receptor promotes the formation of a nondissociable complex with Galpha(ND), and in this manner prevents activation of the endogenous wild-type G protein. Dominant-negative mutants may be useful in matching specific receptors and their cognate G proteins and in determining mechanisms of G protein signaling specificity.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	hdohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [P01-GM65533, F32-GM66561, P01 GM065533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, F32GM066561] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Cismowski MJ, 2001, BIOCHEM BIOPH RES CO, V284, P247, DOI 10.1006/bbrc.2001.4959; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Grishina G, 2000, MOL PHARMACOL, V57, P1081; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KURJAN J, 1991, GENE DEV, V5, P475, DOI 10.1101/gad.5.3.475; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Metodiev MV, 2002, SCIENCE, V296, P1483, DOI 10.1126/science.1070540; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PARKER EM, 1991, J BIOL CHEM, V266, P519; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SIKORSKI RS, 1989, GENETICS, V122, P19; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71; Yun CW, 1997, BIOCHEM BIOPH RES CO, V240, P287, DOI 10.1006/bbrc.1997.7649; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002; Zhou Jianlong, 1999, Cell Biochemistry and Biophysics, V30, P193, DOI 10.1007/BF02738067	61	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35287	35297		10.1074/jbc.M404896200	http://dx.doi.org/10.1074/jbc.M404896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197187	Green Published, hybrid			2022-12-25	WOS:000223303400020
J	Xin, CY; Ren, SY; Kleuser, B; Shabahang, S; Eberhardt, W; Radeke, H; Schafer-Korting, M; Pfeilschifter, J; Huwiler, A				Xin, CY; Ren, SY; Kleuser, B; Shabahang, S; Eberhardt, W; Radeke, H; Schafer-Korting, M; Pfeilschifter, J; Huwiler, A			Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; PROTEIN-COUPLED RECEPTORS; NITRIC-OXIDE SYNTHASE; TGF-BETA; EXPERIMENTAL GLOMERULONEPHRITIS; KINASE CASCADE; PROSTAGLANDIN SYNTHESIS; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; EXPRESSION	Exposure of renal mesangial cells to sphingosine 1-phosphate (S1P) leads to a rapid and transient activation of the mitogen- and stress-activated protein kinases but also the protein kinase B. Here, we show that S1P also induces phosphorylation of Smad proteins, which are members of the transforming growth factor-beta (TGF-beta) signaling device. However, Smad phosphorylation occurred more slowly with a maximal effect after 20-30 min of S1P stimulation when compared with the rapid activation of the MAPKs. Interestingly, Smad phosphorylation is increased by pertussis toxin, which is in contrast to the complete inhibition of S1P-induced MAPK phosphorylation by pertussis toxin. TGF-beta is a potent anti-inflammatory cytokine, which in mesangial cells attenuates the expression of (i) inducible nitric-oxide synthase (iNOS) caused by interleukin (IL)-1beta, (ii) secreted phospholipase A(2) (sPLA(2)), and (iii) matrix metalloproteinase-9 (MMP-9). These gene products are also down-regulated by S1P in a concentration-dependent manner. Furthermore, the expression of connective tissue growth factor is enhanced by both TGF-beta(2) and S1P. These effects of S1P are not mediated by the MAPK cascade as neither pertussis toxin nor the MAPK cascade inhibitor U0126 are able to reverse this inhibition. Overexpression of the inhibitory Smad-7 or down-regulation of co-Smad-4 lead to a reversal of the blocking effect of S1P on IL-1beta-induced NO release. Moreover, down-regulating the TGF-beta receptor type II by the siRNA technique or antagonizing the S1P(3) receptor subtype with suramin abrogates S1P-stimulated Smad phosphorylation. In summary, our data show that S1P trans-activates the TGF-beta receptor and triggers activation of Smads followed by activation of connective tissue growth factor gene transcription and inhibition of IL-1 1beta-induced expression of iNOS, sPLA2, and MMP-9.	Univ Frankfurt Klinikum, Pharmazentrum, D-60590 Frankfurt, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Free University of Berlin	Huwiler, A (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Huwiler@em.uni-frankfurt.de	Radeke, Heinfried H/E-3772-2013	Radeke, Heinfried H/0000-0002-4499-2510; Kleuser, Burkhard/0000-0002-1888-9595				Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Cheng JF, 2002, EXP BIOL MED, V227, P943, DOI 10.1177/153537020222701102; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; DING A, 1990, J IMMUNOL, V145, P940; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Franitza S, 2002, EUR J IMMUNOL, V32, P193, DOI 10.1002/1521-4141(200201)32:1<193::AID-IMMU193>3.0.CO;2-H; Frey RS, 1997, CANCER RES, V57, P628; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hartner A, 2003, J MOL MED-JMM, V81, P32, DOI 10.1007/s00109-002-0403-x; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Im DS, 2003, TRENDS PHARMACOL SCI, V24, P2, DOI 10.1016/S0165-6147(02)00012-3; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Madry H, 2001, J MOL MED-JMM, V79, P184, DOI 10.1007/s001090000186; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Manggau M, 2001, J INVEST DERMATOL, V117, P1241, DOI 10.1046/j.0022-202x.2001.01496.x; MARTI HP, 1994, AM J PATHOL, V144, P82; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; MUHL H, 1992, FEBS LETT, V301, P190, DOI 10.1016/0014-5793(92)81245-H; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PFEILSCHIFTER J, 1989, EUR J CLIN INVEST, V19, P347, DOI 10.1111/j.1365-2362.1989.tb00241.x; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1990, BIOCHEM J, V270, P269, DOI 10.1042/bj2700269; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1986, BIOCHEM J, V234, P125, DOI 10.1042/bj2340125; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Schiffer M, 2000, KIDNEY INT, V58, pS45, DOI 10.1046/j.1523-1755.2000.07708.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Vogler R, 2003, J INVEST DERMATOL, V120, P693, DOI 10.1046/j.1523-1747.2003.12096.x; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	66	160	165	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35255	35262		10.1074/jbc.M312091200	http://dx.doi.org/10.1074/jbc.M312091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192102	hybrid			2022-12-25	WOS:000223303400016
J	Joers, A; Jaks, V; Kase, J; Maimets, T				Joers, A; Jaks, V; Kase, J; Maimets, T			p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress	ONCOGENE			English	Article						p53; transcription; DNA damage; GFP; flow cytometry	P53 PROTEIN; GENE-EXPRESSION; ACTIVATION; APOPTOSIS; MDM-2; TRANSACTIVATION; PARTICIPATION; ACCUMULATION; DEFICIENT; MEDIATOR	The p53 protein is a central player in cellular response to DNA damage. Induction of p53 by DNA-damaging agents involves elevation of its steady-state level and activation of its potency as a transcription factor. In the cell population, these responses can occur either homogeneously (where every single cell responds simultaneously and similarly to its neighbor) or heterogeneously (where only some cells of a population respond and the number of these increases with increasing dose of inducer). We have studied here the p53 response to DNA-damaging agents (camptothecin, mitomycin C) in individual cells. We show that the level of p53 protein is increased in every single cell of the population homogeneously, while the p53-dependent transcription can be subject to an on/off-type response. Depending on the structure of the target promoter, p53-dependent transcription can be regulated according to the binary or graded model. The on/off-type transcriptional activation pattern of p53 defines two distinct subpopulations of cells after DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia	University of Tartu; Estonian Biocentre	Joers, A (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.	ajoers@ebc.ee	Maimets, Toivo/E-9268-2017; Jaks, Viljar/H-2467-2012	Maimets, Toivo/0000-0001-6461-3365; Jaks, Viljar/0000-0002-2221-6262; Roostalu, Johanna/0000-0002-6757-0468; Joers, Arvi/0000-0003-2083-3977				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Graubert TA, 1998, NUCLEIC ACIDS RES, V26, P2849, DOI 10.1093/nar/26.12.2849; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	40	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6175	6185		10.1038/sj.onc.1207864	http://dx.doi.org/10.1038/sj.onc.1207864			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208667				2022-12-25	WOS:000223399000001
J	Butchbach, MER; Tian, GL; Guo, H; Lin, CLG				Butchbach, MER; Tian, GL; Guo, H; Lin, CLG			Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains - Importance for excitatory amino acid transporter localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NICOTINIC ACETYLCHOLINE-RECEPTOR; AFFINITY GLUTAMATE TRANSPORTER; INTERACTING PROTEIN GTRAP3-18; KINASE-C-ALPHA; HIPPOCAMPAL-NEURONS; RAT-BRAIN; EAAC1; MEMBRANE; SUBTYPE	In the present study, we investigated the role of membrane cholesterol in the function of glutamate transporters. Depletion of membrane cholesterol by methyl-beta-cyclodextrin resulted in reduced Na+-dependent glutamate uptake in primary cortical cultures. Glial glutamate transporter EAAT2-mediated uptake was more sensitive to this effect. Cell surface biotinylation and immunostaining experiments revealed that the loss of cholesterol significantly altered the trafficking of EAAT2 to the plasma membrane as well as their membrane distribution. These effects were also observed in neuronal glutamate transporter EAAT3 but to a lesser extent. Furthermore, the treatment of mouse brain plasma membrane vesicles with methyl-beta-cyclodextrin resulted in a significant reduction in glutamate uptake, suggesting that cholesterol depletion has a direct effect on the function of the glutamate transporters. Plasma membrane cholesterol is localized within discreet microdomains known as lipid rafts. Analyses of purified lipid raft microdomains revealed that a large portion of total EAAT2 and a minor portion of total EAAT1, EAAT3, and EAAT4 were associated with lipid rafts. Artificial aggregation of lipid rafts in vivo resulted in the formation of larger EAAT2-immunoreactive clusters on the cell surface. The purified lipid raft-associated fractions were capable of Na+-dependent glutamate uptake. Our data suggest that the glutamate transporters, especially EAAT2, are associated with cholesterol-rich lipid raft microdomains of the plasma membrane and that the association with these cholesterol-rich microdomains is important for excitatory amino acid transporter localization and function.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Neurosci Grad Studies Program, Columbus, OH 43210 USA; Ohio State Univ, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	Lin, Chien-liang G/E-3513-2011	Butchbach, Matthew/0000-0003-2912-6400	NIMH NIH HHS [MH 598005] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; Butchbach MER, 2002, GENE, V292, P81, DOI 10.1016/S0378-1119(02)00669-8; Butchbach MER, 2003, J NEUROCHEM, V84, P891, DOI 10.1046/j.1471-4159.2003.01588.x; Canolle B, 2004, J NEUROCHEM, V88, P1521, DOI 10.1046/j.1471-4159.2003.02301.x; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Cheng CL, 2002, J NEUROSCI, V22, P10643; Coco S, 1997, EUR J NEUROSCI, V9, P1902, DOI 10.1111/j.1460-9568.1997.tb00757.x; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Daniels KK, 1998, NEUROCHEM RES, V23, P103, DOI 10.1023/A:1022413823183; Davis KE, 1998, J NEUROSCI, V18, P2475; Duan SM, 1999, J NEUROSCI, V19, P10193; Eckert GP, 2003, BRAIN RES, V962, P144, DOI 10.1016/S0006-8993(02)03986-0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; Gonzalez MI, 2003, J NEUROSCI, V23, P5589; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; Hering H, 2003, J NEUROSCI, V23, P3262; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Maekawa S, 2003, BBA-BIOMEMBRANES, V1610, P261, DOI 10.1016/S0005-2736(03)00023-3; Marchand S, 2002, J NEUROSCI, V22, P8891; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023, DOI 10.1152/ajprenal.1997.273.6.F1023; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Swanson RA, 1997, J NEUROSCI, V17, P932; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4	48	132	133	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34388	34396		10.1074/jbc.M403938200	http://dx.doi.org/10.1074/jbc.M403938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187084	hybrid			2022-12-25	WOS:000223134800039
J	Choudhary, S; Sommers, JA; Brosh, RM				Choudhary, S; Sommers, JA; Brosh, RM			Biochemical and kinetic characterization of the DNA helicase and exonuclease activities of Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECQ HELICASE; SYNDROME CELLS; S-PHASE; HOMOLOGOUS RECOMBINATION; REPLICATION ARREST; REPAIR PROCESSES; SYNDROME GENE; POLYMERASE-I; WRN HELICASE; INVITRO	The WRN gene, defective in the premature aging and genome instability disorder Werner syndrome, encodes a protein with DNA helicase and exonuclease activities. In this report, cofactor requirements for WRN catalytic activities were examined. WRN helicase performed optimally at an equimolar concentration ( 1 mM) of Mg2+ and ATP with a K-m of 140 muM for the ATP-Mg2+ complex. The initial rate of WRN helicase activity displayed a hyperbolic dependence on ATP-Mg2+ concentration. Mn2+ and Ni2+ substituted for Mg2+ as a cofactor for WRN helicase, whereas Fe2+ or Cu2+ ( 10 muM) profoundly inhibited WRN unwinding in the presence of Mg2+. Zn2+ ( 100 muM) was preferred over Mg2+ as a metal cofactor for WRN exonuclease activity and acts as a molecular switch, converting WRN from a helicase to an exonuclease. Zn2+ strongly stimulated the exonuclease activity of a WRN exonuclease domain fragment, suggesting a Zn2+ binding site in the WRN exonuclease domain. A fluorometric assay was used to study WRN helicase kinetics. The initial rate of unwinding increased with WRN concentration, indicating that excess enzyme over DNA substrate improved the ability of WRN to unwind the DNA substrate. Under presteady state conditions, the burst amplitude revealed a 1: 1 ratio between WRN and DNA substrate, suggesting an active monomeric form of the helicase. These are the first reported kinetic parameters of a human RecQ unwinding reaction based on real time measurements, and they provide mechanistic insights into WRN-catalyzed DNA unwinding.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Harrigan JA, 2003, BIOCHIMIE, V85, P1185, DOI 10.1016/j.biochi.2003.10.006; Hartwig A, 2002, ENVIRON HEALTH PERSP, V110, P797, DOI 10.1289/ehp.02110s5797; Hartwig A, 2002, TOXICOL LETT, V127, P47, DOI 10.1016/S0378-4274(01)00482-9; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1986, J BIOL CHEM, V261, P169; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; Tanaka Y, 2004, FEBS LETT, V556, P167, DOI 10.1016/S0014-5793(03)01402-9; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	56	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34603	34613		10.1074/jbc.M401901200	http://dx.doi.org/10.1074/jbc.M401901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187093	hybrid			2022-12-25	WOS:000223134800065
J	Jeong, HG; Youn, CK; Cho, HJ; Kim, SH; Kim, MH; Kim, HB; Chang, IY; Lee, YS; Chung, MH; You, HJ				Jeong, HG; Youn, CK; Cho, HJ; Kim, SH; Kim, MH; Kim, HB; Chang, IY; Lee, YS; Chung, MH; You, HJ			Metallothionein-III prevents gamma-ray-induced 8-oxoguanine accumulation in normal and hOGG1-depleted cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-INHIBITORY FACTOR; ALZHEIMERS-DISEASE BRAIN; OXIDATIVE DNA-DAMAGE; MESSENGER-RNA; ZINC-METALLOTHIONEIN; FREE-RADICALS; IONIZING-RADIATION; NEURITE FORMATION; CORTICAL-NEURONS; STRAND BREAKS	Metallothioneins (MT) play an important biological role in preventing oxidative damage to cells. We have previously demonstrated that the efficiency of the protective effect of MT-III against the DNA degradation from oxidative damage was much higher than that of MT-I/II. As an extension of the latter investigation, this study aimed to assess the ability of MT-III to suppress 8-oxoguanine (8-oxoG), which is one of the major base lesions formed after an oxidative attack to DNA and the mutant frequency of the HPRT gene in human fibroblast GM00637 cells upon exposure to gamma-rays. We found that human MT-III expression decreased the level of 8-oxoG and mutation frequency in the gamma-irradiated cells. Using an 8-oxoguanine DNA glycosylase (OGG1)-specific siRNAs, we also found that MT-III expression resulted in the suppression of the gamma-radiation-induced 8-oxoG accumulation and mutation in the OGG1-depleted cells. Moreover, the down-regulation of MT in human neuroblastoma SKNSH cells induced by MT-specific siRNA led to a significant increase in the 8-oxoG level, after exposure to gamma-irradiation. These results suggest that under the conditions of gamma-ray oxidative stress, MT-III prevents the gamma-radiation-induced 8-oxoG accumulation and mutation in normal and hOGG1-depleted cells, and this suppression might, at least in part, contribute to the anti-carcinogenic and neuroprotective role of MT-III.	Chosun Univ, Res Ctr Prot MAt, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul 139706, South Korea; Seoul Natl Univ, Sch Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; National Cancer Center - Korea (NCC); Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Res Ctr Prot MAt, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@chosun.ac.kr		Chang, In-Youb/0000-0002-8911-7541; KIM, HONGBEUM/0000-0001-9434-0708; You, Ho Jin/0000-0002-0530-4017				ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; Aschner M, 1998, NEUROTOXICOLOGY, V19, P653; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Brooks PJ, 2000, NEUROCHEM INT, V37, P403, DOI 10.1016/S0197-0186(00)00051-6; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; BURKITT MJ, 1990, FREE RADICAL RES COM, V10, P265, DOI 10.3109/10715769009149895; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cai L, 1998, CHEM-BIOL INTERACT, V115, P141, DOI 10.1016/S0009-2797(98)00069-6; Cai L, 1999, TOXICOLOGY, V132, P85, DOI 10.1016/S0300-483X(98)00150-4; Cai L, 2003, TOXICOL LETT, V136, P193, DOI 10.1016/S0378-4274(02)00359-4; Cai L, 1996, MUTAT RES-GENET TOX, V369, P233, DOI 10.1016/S0165-1218(96)90028-2; Carrasco J, 2003, NEUROBIOL DIS, V13, P22, DOI 10.1016/S0969-9961(03)00015-9; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Ceballos D, 2003, CELL MOL LIFE SCI, V60, P1209, DOI 10.1007/s00018-003-3047-2; CHAPMAN JD, 1973, RADIAT RES, V56, P291, DOI 10.2307/3573667; Chen HN, 2001, DIABETES, V50, P2040, DOI 10.2337/diabetes.50.9.2040; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; CHENG KC, 1992, J BIOL CHEM, V267, P166; Cherian MG, 2000, CELL MOL BIOL, V46, P347; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Durnam D M, 1987, Experientia Suppl, V52, P457; EICHHOLTZWIRTH H, 1993, BRIT J CANCER, V67, P1001, DOI 10.1038/bjc.1993.183; Erickson JC, 1997, J NEUROSCI, V17, P1271; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Glaab WE, 1999, MUTAT RES-FUND MOL M, V427, P67, DOI 10.1016/S0027-5107(99)00091-3; Greenstock C L, 1987, Free Radic Res Commun, V2, P233, DOI 10.3109/10715768709065288; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hogg N, 1998, SEMIN REPROD ENDOCR, V16, P241, DOI 10.1055/s-2007-1016284; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Iida T, 2002, ACTA NEUROPATHOL, V103, P20, DOI 10.1007/s004010100418; Irie Y, 2003, BRAIN RES, V960, P228, DOI 10.1016/S0006-8993(02)03891-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81; Jourdan E, 2002, ARCH BIOCHEM BIOPHYS, V405, P170, DOI 10.1016/S0003-9861(02)00401-0; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; KAGIMOTO O, 1991, J RADIAT RES, V32, P417, DOI 10.1269/jrr.32.417; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kondo Y, 1999, CARCINOGENESIS, V20, P1625, DOI 10.1093/carcin/20.8.1625; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; Kramer KK, 1996, TOXICOL APPL PHARM, V141, P1; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; Levadoux M, 1999, J BIOL CHEM, V274, P34961, DOI 10.1074/jbc.274.49.34961; Liu Philip K., 2001, Current Topics in Medicinal Chemistry, V1, P483, DOI 10.2174/1568026013394688; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lyras L, 1997, J NEUROCHEM, V68, P2061; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mei N, 2003, ENVIRON MOL MUTAGEN, V41, P332, DOI 10.1002/em.10165; MELLOFILHO AC, 1988, BIOCHEM J, V256, P475, DOI 10.1042/bj2560475; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; Miura T, 1997, LIFE SCI, V60, pPL301; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Nagano T, 2000, J CELL PHYSIOL, V185, P440, DOI 10.1002/1097-4652(200012)185:3<440::AID-JCP15>3.0.CO;2-N; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2003, CELL MOL LIFE SCI, V60, P185, DOI 10.1007/s000180300013; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RENAN MJ, 1989, RADIAT RES, V120, P442, DOI 10.2307/3577795; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rossman TG, 1998, MUTAT RES-FUND MOL M, V402, P103, DOI 10.1016/S0027-5107(97)00287-X; Rossman TG, 1997, MUTAT RES-FUND MOL M, V373, P75, DOI 10.1016/S0027-5107(96)00192-3; Sakamoto T, 2003, NEUROREPORT, V14, P2147, DOI 10.1097/00001756-200312020-00003; SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SATOH M, 1993, CANCER RES, V53, P4767; SHIRAISHI N, 1986, TOXICOL APPL PHARM, V85, P128, DOI 10.1016/0041-008X(86)90106-7; Sogawa CA, 2000, BRAIN RES, V853, P310, DOI 10.1016/S0006-8993(99)02284-2; Suzuki JS, 2003, CARCINOGENESIS, V24, P1123, DOI 10.1093/carcin/bgg052; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1989, BRAIN RES, V481, P190, DOI 10.1016/0006-8993(89)90503-9; UCHIDA Y, 1988, BIOCHEM BIOPH RES CO, V150, P1263, DOI 10.1016/0006-291X(88)90765-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Uchida Yoko, 1994, Biological Signals, V3, P211; Vukovic V, 2000, INT J RADIAT BIOL, V76, P757, DOI 10.1080/09553000050028904; WAALKES MP, 1985, FUND APPL TOXICOL, V5, P473, DOI 10.1016/0272-0590(85)90094-6; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamada M, 1996, BRAIN RES, V735, P257, DOI 10.1016/0006-8993(96)00586-0; You HJ, 2002, FEBS LETT, V521, P175, DOI 10.1016/S0014-5793(02)02870-3; You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6	103	27	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34138	34149		10.1074/jbc.M402530200	http://dx.doi.org/10.1074/jbc.M402530200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190073	hybrid			2022-12-25	WOS:000223134800011
J	Nomura, K; Kato, J; Takiguchi, N; Ohtake, H; Kuroda, A				Nomura, K; Kato, J; Takiguchi, N; Ohtake, H; Kuroda, A			Effects of inorganic polyphosphate on the proteolytic and DNA-binding activities of Lon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; PROTEIN-DEGRADATION; ION PROTEASE; SITE; LA; PURIFICATION; SYSTEM; OVERPRODUCTION; BACTERIAL; DOMAIN	Lon belongs to a unique group of proteases that bind to DNA and is involved in the regulation of several important cellular functions, including adaptation to nutritional downshift. Previously, we revealed that inorganic polyphosphate ( polyP) increases in Escherichia coli in response to amino acid starvation and that it stimulates the degradation of free ribosomal proteins by Lon. In this work, we examined the effects of polyP on the proteolytic and DNA-binding activities of Lon. An order-of-addition experiment suggested that polyP first binds to Lon, which stimulates Lon-mediated degradation of ribosomal proteins. A polyP-binding assay using Lon deletion mutants showed that the polyP-binding site of Lon is localized in the ATPase domain. Because the same ATPase domain also contains the DNA-binding site, polyP can compete with DNA for binding to Lon. In fact, an equimolar amount of polyP almost completely inhibited DNA-Lon complex formation, suggesting that Lon binds to polyP with a higher affinity than it binds to DNA. Collectively, our results showed that polyP may control the cellular activity of Lon not only as a protease but also as a DNA-binding protein.	Hiroshima Univ, Dept Mol Biotechnol, Hiroshima 7398530, Japan; Osaka Univ, Dept Biotechnol, Osaka 5650871, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	Hiroshima University; Osaka University; Japan Science & Technology Agency (JST)	Kuroda, A (corresponding author), Hiroshima Univ, Dept Mol Biotechnol, Hiroshima 7398530, Japan.	akuroda@hiroshima-u.ac.jp	Takiguchi, Noboru/F-3419-2014; Kato, Junichi/S-1469-2018	Takiguchi, Noboru/0000-0001-7266-0276; Kato, Junichi/0000-0003-0279-8813				AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; CACHIA C, 1991, J CHROMATOGR, V539, P343, DOI 10.1016/S0021-9673(01)83943-1; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHIN DT, 1988, J BIOL CHEM, V263, P11718; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Ebel W, 1999, J BACTERIOL, V181, P2236, DOI 10.1128/JB.181.7.2236-2243.1999; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUA SS, 1975, J BACTERIOL, V122, P510, DOI 10.1128/JB.122.2.510-517.1975; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kuroda A, 1997, J BIOL CHEM, V272, P21240, DOI 10.1074/jbc.272.34.21240; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Rotanova TV, 2002, VOP MED KHIM, V48, P541; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SONEZAKI S, 1994, APPL MICROBIOL BIOT, V42, P313; SONEZAKI S, 1995, APPL MICROBIOL BIOT, V43, P304; Sonezaki S, 1995, APPL MICROBIOL BIOT, V44, P484; WICKSTROM E, 1988, METHOD ENZYMOL, V164, P238; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	30	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34406	34410		10.1074/jbc.M404725200	http://dx.doi.org/10.1074/jbc.M404725200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187082	Green Submitted, hybrid			2022-12-25	WOS:000223134800041
J	Tominaga, K; Kondo, C; Kagata, T; Hishida, T; Nishizuka, M; Imagawa, M				Tominaga, K; Kondo, C; Kagata, T; Hishida, T; Nishizuka, M; Imagawa, M			The novel gene fad158, having a transmembrane domain and leucine-rich repeat, stimulates adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE 3T3-L1 CELLS; PPAR-GAMMA; INSULIN-RESISTANCE; EARLY-STAGE; ADIPOGENESIS; EXPRESSION; OBESITY; PROTEIN; REGULATOR; PROMOTES	Adipocyte differentiation is known to be regulated by a complex array of genes known as master regulators. Using a subtraction method, we previously isolated 102 genes that are expressed in the early stage of adipocyte differentiation. One of these genes named fad158 (factor for adipocyte differentiation 158) seems to be a novel gene, since there is no significantly similar gene listed in databases. Both mouse and human fad158 encode 803 amino acids and contain 4 transmembrane regions and 8 leucine-rich repeat motifs. Expression of fad158 was induced at an early stage in differentiating 3T3-L1 cells and was observed in the skeletal muscle. When the expression was knocked down with an antisense method in 3T3-L1 cells, the accumulation of oil droplets was reduced. Moreover, on overexpression of fad158 in NIH-3T3 cells, which are fibroblasts and do not usually differentiate into adipocytes, stable transformants accumulated oil droplets and showed an elevated expression of adipocyte marker genes, indicating that these cells had differentiated into mature adipocytes. fad158 has the ability to regulate adipocyte differentiation positively, especially at an early stage.	Nissui Pharmaceut Co Ltd, Div Res, Ibaraki 3070036, Japan		Imagawa, M (corresponding author), Nagoya City Univ, Dept Biol Mol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Aichi 4678603, Japan.	imagawa@phar.nagoya-cu.ac.jp						Check E, 2002, NATURE, V417, P106, DOI 10.1038/417106a; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVID V, 1993, J BIOL CHEM, V268, P9585; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kitamura A, 2001, BIOCHEM BIOPH RES CO, V287, P435, DOI 10.1006/bbrc.2001.5577; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishizuka M, 2002, BIOCHEM J, V361, P629, DOI 10.1042/0264-6021:3610629; Nishizuka M, 2003, J BIOL CHEM, V278, P15279, DOI 10.1074/jbc.M211479200; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Shimba S, 2003, BIOL PHARM BULL, V26, P1266; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Ward CW, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-4; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	36	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34840	34848		10.1074/jbc.M312927200	http://dx.doi.org/10.1074/jbc.M312927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184384	hybrid			2022-12-25	WOS:000223134800093
J	Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA				Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA			Brca1 inactivation induces p27Kip1-dependent cell cycle arrest and delayed development in the mouse mammary gland	ONCOGENE			English	Article						p27; BRCA1; mammary development; mouse model; cell cycle	DEPENDENT KINASE INHIBITOR; HEREDITARY BREAST-CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; DNA-REPAIR; P27(KIP1); EXPRESSION; P27; MUTATIONS; LINE	One common characteristic of breast cancers arising in carriers of the predisposition gene BRCA1 is a loss of expression of the CDK inhibitor p27(Kip1) (p27), suggesting that p27 interacts epistatically with BRCA1. To investigate this relationship, we examined expression of p27 in mice expressing a dominant negative allele of Brca1 (MMTV-trBr) in the mammary gland. While these mice rarely develop tumors, they showed a 50% increase in p27 protein and a delay in mammary gland development associated with reduced proliferation. In contrast, on a p27 heterozygote background, MMTV-trBrca1 mice showed an increase in S phase cells, and normal mammary development. p27 was the only protein in the cyclin cyclin-dependent kinase network to show altered expression, suggesting that it may be a central mediator of cell cycle arrest in response to loss of function of BRCA1. Furthermore, in human mammary epithelial MCF7 cells expressing BRCA1-specific RNAi and in the BRCA1-deficient human tumor cell line HCC1937, p27 is elevated at the mRNA level compared to cells expressing wild-type BRCA1. We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1.	Peter MacCallum Canc Ctr, Trescowthick Res Labs, Mol Oncol Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Med St Vincents, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Peter MacCallum Canc Ctr, Dept Pathol, Melbourne 3002, Australia; Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne 3002, Australia	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; University of Queensland; Peter Maccallum Cancer Center	McArthur, GA (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	grant.mcarthur@petermac.org	Deans, Andrew/U-3515-2019; Brown, Melissa A/F-1451-2010; Deans, Andrew J/E-5817-2011	Deans, Andrew/0000-0002-5271-4422; Deans, Andrew J/0000-0002-5271-4422; Simpson, Kaylene/0000-0001-9136-1781				Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davison EA, 2003, MOL ENDOCRINOL, V17, P2436, DOI 10.1210/me.2003-0199; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Eisinger F, 1996, CANCER RES, V56, P471; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujieda S, 1999, INT J CANCER, V84, P315, DOI 10.1002/(SICI)1097-0215(19990621)84:3<315::AID-IJC20>3.0.CO;2-U; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Humphreys RC, 1997, MOL ENDOCRINOL, V11, P801, DOI 10.1210/me.11.6.801; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kauraniemi P, 2000, CANCER RES, V60, P5323; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x; Pharoah PDP, 1999, CANCER RES, V59, P868; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Stoppa-Lyonnet D, 2000, J CLIN ONCOL, V18, P4053, DOI 10.1200/JCO.2000.18.24.4053; Sylvain V, 2002, INT J ONCOL, V20, P845; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	52	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6136	6145		10.1038/sj.onc.1207805	http://dx.doi.org/10.1038/sj.onc.1207805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208652				2022-12-25	WOS:000223261000013
J	Seo, T; Park, J; Lim, C; Choe, J				Seo, T; Park, J; Lim, C; Choe, J			Inhibition of nuclear factor kappa B activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						KSHV; VIRF3; NF-kappa B; IKK	IKK-ALPHA; INDUCED APOPTOSIS; DNA-SEQUENCES; TUMOR-SUPPRESSOR; MICE LACKING; BETA; ACTIVATION; SUBUNIT; PROTEIN; TNF	Nuclear factor-kappaB (NF-kappaB) is a transcription factor that plays an important role in the immune system and cell death. Many viral proteins modulate NF-kappaB to escape host immune surveillance, promote cell survival, and enhance viral replication. In the present study, we show that NF-kappaB activity is downmodulated by viral interferon regulatory factor 3 (vIRF3), which is encoded by Kaposi's sarcoma-associated herpesvirus open-reading frame K10.5. vIRF3 repressed NF-kappaB-dependent transcription in a dose-dependent manner and inhibited the activation of NF-kappaB induced by tumor necrosis factor (TNF)-alpha. In vivo studies showed vIRF3 inhibited IkappaB kinase beta (IKKbeta) activity, but not IKKalpha activity, resulting in reduced IkappaB phosphorylation. Immunofluorescence assays showed that vIRF3 interfered with nuclear translocation of NF-kappaB. In addition, consistent with the inhibition of NF-kappaB activity, vIRF3 sensitized cells to TNF-alpha-induced apoptosis. While vIRF3 interacts with IKKbeta in vitro and in 293T cells, we were unable to demonstrate vIRF3-IKKbeta interaction in BCBL-1 cells. Our results indicate that vIRF3 can regulate the host immune system and apoptosis via inhibition of NF-kappaB activity.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Lim, Chunghun/AAB-1253-2020; Choe, Joonho/F-3066-2011	Lim, Chunghun/0000-0001-8473-9272; 				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bakker TR, 1999, INT J CANCER, V80, P320; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lubyova B, 2004, J BIOL CHEM, V279, P7643, DOI 10.1074/jbc.M309485200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Seo T, 2000, BIOCHEM BIOPH RES CO, V270, P23, DOI 10.1006/bbrc.2000.2393; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	55	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6146	6155		10.1038/sj.onc.1207807	http://dx.doi.org/10.1038/sj.onc.1207807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208654				2022-12-25	WOS:000223261000014
J	Okunande, GW; Miller, ML; Pyne, GJ; Sutliff, RL; O'Connor, KT; Neumann, JC; Andringa, A; Miller, DA; Prasad, V; Doetschman, T; Paul, RJ; Shull, GE				Okunande, GW; Miller, ML; Pyne, GJ; Sutliff, RL; O'Connor, KT; Neumann, JC; Andringa, A; Miller, DA; Prasad, V; Doetschman, T; Paul, RJ; Shull, GE			Targeted ablation of plasma membrane Ca2+-ATPase (PMCA) 1 and 4 indicates a major housekeeping function for PMCA1 and a critical role in hyperactivated sperm motility and male fertility for PMCA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CALCIUM-PUMP; ISOFORM 2; CA-2+-TRANSPORTING ATPASE; NULL MUTATION; MOUSE SPERM; CA2+ PUMP; GENE; MICE; APOPTOSIS	The relative importance of plasma membrane Ca2+-ATPase (PMCA) 1 and PMCA4 was assessed in mice carrying null mutations in their genes (Atp2b1 and Atp2b4). Loss of both copies of the gene encoding PMCA1 caused embryolethality, whereas heterozygous mutants had no overt disease phenotype. Despite widespread and abundant expression of PMCA4, PMCA4 null (Pmca4(-/-)) mutants exhibited no embryolethality and appeared outwardly normal. Loss of PMCA4 impaired phasic contractions and caused apoptosis in portal vein smooth muscle in vitro; however, this phenotype was dependent on the mouse strain being employed. Pmca4(-/-) mice on a Black Swiss background did not exhibit the phenotype unless they also carried a null mutation in one copy of the Pmca1 gene. Pmca4(-/-) male mice were infertile but had normal spermatogenesis and mating behavior. Pmca4(-/-) sperm that had not undergone capacitation exhibited normal motility but could not achieve hyperactivated motility needed to traverse the female genital tract. Ultrastructure of the motility apparatus in Pmca4(-/-) sperm tails was normal, but an increased incidence of mitochondrial condensation indicated Ca2+ overload. Immunoblotting and immuno- histochemistry showed that PMCA4 is the most abundant isoform in testis and sperm and that it is localized to the principle piece of the sperm tail, which is also the location of the major Ca2+ channel (CatSper) required for sperm motility. These results are consistent with an essential housekeeping or developmental function for PMCA1, but not PMCA4, and show that PMCA4 expression in the principle piece of the sperm tail is essential for hyperactivated motility and male fertility.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61974, TGHL07382] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Eddy E. M., 1994, P29; GARCIA ML, 1999, FRONT BIOSCI, V4, P869; GREEB J, 1989, J BIOL CHEM, V264, P18569; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; Meyer JW, 2002, AM J PHYSIOL-HEART C, V283, pH1846, DOI 10.1152/ajpheart.00083.2002; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SCHUH K, 2004, J BIOL CHEM; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; SUAREZ SS, 1987, J EXP ZOOL, V244, P331, DOI 10.1002/jez.1402440218; Sutliff RL, 1999, ENDOCRINOLOGY, V140, P2077, DOI 10.1210/en.140.5.2077; Takahashi K, 1999, BIOCHEM BIOPH RES CO, V261, P773, DOI 10.1006/bbrc.1999.1102; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; YANAGIMACHI R, 1994, PHYSL REPROD, V0002, P00189; Zacharias DA, 1999, BBA-GEN SUBJECTS, V1428, P397, DOI 10.1016/S0304-4165(99)00058-6	29	244	256	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33742	33750		10.1074/jbc.M404628200	http://dx.doi.org/10.1074/jbc.M404628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178683	hybrid			2022-12-25	WOS:000223039700083
J	Stenovec, M; Kreft, M; Poberaj, I; Betz, WJ; Zorec, R				Stenovec, M; Kreft, M; Poberaj, I; Betz, WJ; Zorec, R			Slow spontaneous secretion from single large dense-core vesicles monitored in neuroendocrine cells	FASEB JOURNAL			English	Article						lactotrophs; fusion pore; membrane capacitance; atrial natriuretic peptide; FM 4-64	MEMBRANE-FUSION; EXOCYTOSIS; RELEASE; GRANULES; PORES; ENDOCYTOSIS; DYNAMICS	Hormones are released from cells by passing through an exocytotic pore that forms after vesicle and plasma membrane fusion. In stimulated exocytosis vesicle content is discharged swiftly. Although rapid vesicle discharge has also been proposed to mediate basal secretion, this has not been studied directly. We investigated basal hormone release by preloading fluorescent peptides into single vesicles. The hormone discharge, monitored with confocal microscopy, was compared with the simultaneous loading of vesicle by FM styryl dye. In stimulated vesicles FM 4-64 (4 muM), loading and hormone discharge occurs within seconds. In contrast, in approximate to 50% of spontaneously releasing vesicles, the vesicle content discharge and the FM 4-64 loading were slow (approximate to 3 min). These results show that in peptide secreting neuroendocrine cells the elementary vesicle content discharge differs in basal and in stimulated exocytosis. It is proposed that the view dating back for some decades, which is that, at rest, the vesicle discharge of hormones and neurotransmitters is similar to that occurring after stimulation, needs to be extended. In addition to the classical paradigm that secretory capacity of a cell is determined by controlling the probability of occurrence of elementary exocytotic events, one will have to consider activity modulation of elementary exocytotic events as well.	Celica Biomed Sci Ctr, Ljubljana 1000, Slovenia; Univ Ljubljana, Sch Med, Neuroendocrinol Mol Cell Physiol Lab, Ljubljana 1000, Slovenia; Fac Math & Phys Ljubljana, Dept Phys, Ljubljana, Slovenia; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA	University of Ljubljana; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Zorec, R (corresponding author), Celica Biomed Sci Ctr, Stegne 21, Ljubljana 1000, Slovenia.	robert.zorec@mf.uni.lj.si	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Zorec, Robert/0000-0002-7478-3875	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036665] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36665-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; BENTABOU S, 1994, J PHYSIOL-LONDON, V476, P29; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Burgoyne RD, 2001, BIOCHEM SOC T, V29, P467, DOI 10.1042/BST0290467; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dietl P, 2000, CELL BIOL INT, V24, P803, DOI 10.1006/cbir.2000.0630; DOUGLAS WW, 1985, ELECTROPHYSIOL SECRE; Duncan RR, 2003, NATURE, V422, P176, DOI 10.1038/nature01389; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Henkel AW, 2000, EMBO J, V19, P84, DOI 10.1093/emboj/19.1.84; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Katz B., 1966, NERVE MUSCLE SYNAPSE; Kreft M, 2004, COMPUT METH PROG BIO, V74, P63, DOI 10.1016/S0169-2607(03)00071-3; Kreft M, 1997, PFLUG ARCH EUR J PHY, V434, P212, DOI 10.1007/s004240050387; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Lollike K, 1998, BIOPHYS J, V75, P53, DOI 10.1016/S0006-3495(98)77494-6; LONGSWORTH LG, 1953, J AM CHEM SOC, V75, P5705, DOI 10.1021/ja01118a065; LONGSWORTH LG, 1952, J AM CHEM SOC, V74, P4155, DOI 10.1021/ja01136a059; Marty A., 1983, SINGLE CHANNEL RECOR; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Tani T, 2002, CELL BIOL INT, V26, P853, DOI 10.1006/cbir.2002.0937; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; WALKER AM, 1980, ENDOCRINOLOGY, V107, P1095, DOI 10.1210/endo-107-4-1095; Weise R, 2000, J MEMBRANE BIOL, V174, P15, DOI 10.1007/s002320001027; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473; ZUPANCIC G, 1994, J PHYSIOL-LONDON, V480, P539, DOI 10.1113/jphysiol.1994.sp020382	41	58	58	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1270	+		10.1096/fj.03-1397fje	http://dx.doi.org/10.1096/fj.03-1397fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180959				2022-12-25	WOS:000222327500031
J	Damdimopoulos, AE; Miranda-Vizuete, A; Treuter, E; Gustafsson, JA; Spyrou, G				Damdimopoulos, AE; Miranda-Vizuete, A; Treuter, E; Gustafsson, JA; Spyrou, G			An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTORS ER-ALPHA; INDUCED CELL-DEATH; NF-KAPPA-B; GENE-EXPRESSION; RETINOIC ACID; TRANSCRIPTION FACTORS; OXIDOREDUCTASE KDRF; HISTONE ACETYLATION; NUCLEAR RECEPTORS; REDOX REGULATION	The selenoprotein thioredoxin reductase (TrxR1) is an integral part of the thioredoxin system. It serves to transfer electrons from NADPH to thioredoxin leading to its reduction. Interestingly, recent work has indicated that thioredoxin reductase can regulate the activity of transcription factors such as p53, hypoxia-inducible factor, and AP-1. Here, we describe that an alternative splicing variant of thioredoxin reductase (TrxR1b) containing an LXXLL peptide motif, is implicated in direct binding to nuclear receptors. In vitro interaction studies revealed direct interaction of the TrxR1b with the estrogen receptors alpha and beta. Confocal microscopy analysis showed nuclear colocalization of the TrxR1b with both estrogen receptor alpha and beta in estradiol-17beta-treated cells. Transcriptional studies demonstrated that TrxR1b can affect estrogen-dependent gene activation differentially at classical estrogen response elements as compared with AP-1 response elements. Based on these results, we propose a model where thioredoxin reductase directly influences the estrogen receptor-coactivator complex assembly on non-classical estrogen response elements such as AP-1. In summary, our results suggest that TrxR1b is an important modulator of estrogen signaling.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Acad Athens, Inst Biomed Res, Dept Biochem, Soranou Cfesiou 4, Athens 11527, Greece.	giannis.spyrou@cbt.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189; Treuter, Eckardt/0000-0002-4147-8989				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akiyama TE, 2002, MOL ENDOCRINOL, V16, P707, DOI 10.1210/me.16.4.707; Arteel GE, 1999, CHEM RES TOXICOL, V12, P264, DOI 10.1021/tx980223r; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; Bjornstrom L, 2002, J BIOL CHEM, V277, P48479, DOI 10.1074/jbc.C200570200; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Glass CK, 2000, GENE DEV, V14, P121; HAINAUT P, 1993, CANCER RES, V53, P4469; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koishi R, 1997, J BIOL CHEM, V272, P2570; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; MirandaVizuete A, 1997, BIOCHEM J, V325, P287, DOI 10.1042/bj3250287; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Osborne S A, 2001, BMC Genomics, V2, P10, DOI 10.1186/1471-2164-2-10; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200	55	44	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38721	38729		10.1074/jbc.M402753200	http://dx.doi.org/10.1074/jbc.M402753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15199063	hybrid			2022-12-25	WOS:000223684100082
J	Tsubery, H; Mironchik, M; Fridkin, M; Shechter, Y				Tsubery, H; Mironchik, M; Fridkin, M; Shechter, Y			Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS; HEPATITIS-C; HALF-LIFE; EXENDIN-4; DELIVERY; RECEPTOR; PEGYLATION; INSULIN; DESIGN; 1,6-ELIMINATION	Polyethylene glycol (PEG)-conjugated therapeutic peptides/proteins have been shown to exhibit clinical properties superior to those of their corresponding unmodified parent molecules. However, the desirable pharmacological features gained by protein PEGylation become irrelevant if conjugates are inactivated or cannot reach their target tissues. Here we describe the design and synthesis of MAL-FMS-OSU. This bifunctional agent enables PEG chains to be linked to peptides and proteins through a slowly hydrolysable chemical bond. PEG-FMS-peptide/protein conjugates thus formed undergo spontaneous hydrolysis at a slow rate upon incubation at pH 8.5, 37 degreesC with a t(1/2) value of 8 - 14 +/- 2 h, generating the unmodified parent molecule. The validity of this approach was studied with exendin-4 and human growth hormone. A single subcutaneous administration of PEG(40,000)-FMS- exendin-4 facilitated a prolonged and stable reduction in glucose levels in mice (t(1/2) = 30 +/- 2 h) and exceeded the effect obtained by the same dose of the native hormone by 7 - 8 times.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Fridkin, M (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.	mati.fridkin@weizmann.ac.il; y.shechter@weizmann.ac.il						Albericio F, 2001, SYNTHETIC COMMUN, V31, P225, DOI 10.1081/SCC-100000203; Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Benet L., 1990, PHARMACOL BASIS THER, P3; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1994, PEPTIDES, V15, P453, DOI 10.1016/0196-9781(94)90204-6; FUERTGES F, 1990, J CONTROL RELEASE, V11, P139, DOI 10.1016/0168-3659(90)90127-F; Fung W.-J., 1997, POLYM PREPRINT, V38, P565; GERMAN AJ, 1987, FEBS LETT, V223, P361; Gershonov E, 1999, DIABETES, V48, P1437, DOI 10.2337/diabetes.48.7.1437; Gershonov E, 2000, J MED CHEM, V43, P2530, DOI 10.1021/jm990533m; GOKE R, 1993, J BIOL CHEM, V268, P19650; Greenwald RB, 2000, J MED CHEM, V43, P475, DOI 10.1021/jm990498j; Greenwald RB, 1999, J MED CHEM, V42, P3657, DOI 10.1021/jm990166e; KATRE NV, 1993, ADV DRUG DELIVER REV, V10, P91, DOI 10.1016/0169-409X(93)90005-O; Lee S, 2001, BIOCONJUGATE CHEM, V12, P163, DOI 10.1021/bc000064z; NUCCI ML, 1991, ADV DRUG DELIVER REV, V6, P133, DOI 10.1016/0169-409X(91)90037-D; Reddy KR, 2002, ADV DRUG DELIVER REV, V54, P571, DOI 10.1016/S0169-409X(02)00028-5; Reddy KR, 2000, ANN PHARMACOTHER, V34, P915, DOI 10.1345/aph.10054; Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; Shechter Y, 2003, BIOCHEM BIOPH RES CO, V305, P386, DOI 10.1016/S0006-291X(03)00715-0; Shechter Y, 2001, DRUG FUTURE, V26, P669, DOI 10.1358/dof.2001.026.07.858711; Shechter Y, 2001, P NATL ACAD SCI USA, V98, P1212, DOI 10.1073/pnas.98.3.1212; TSUSHIMA T, 1980, BIOCHEM J, V187, P479, DOI 10.1042/bj1870479; Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9; Working PK, 1997, ACS SYM SER, V680, P45; Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n	29	70	135	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38118	38124		10.1074/jbc.M405155200	http://dx.doi.org/10.1074/jbc.M405155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15190059	hybrid			2022-12-25	WOS:000223684100009
J	Lazarowski, ER; Tarran, R; Grubb, BR; van Heusden, CA; Okada, S; Boucher, RC				Lazarowski, ER; Tarran, R; Grubb, BR; van Heusden, CA; Okada, S; Boucher, RC			Nucleotide release provides a mechanism for airway surface liquid homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS AIRWAYS; INDEPENDENT ATP RELEASE; EPITHELIAL-CELLS; ADENOSINE RECEPTORS; CHLORIDE SECRETION; ADENYLYL-CYCLASE; CALU-3 CELLS; CFTR; CHANNELS	Nucleotides within the airway surface liquid (ASL) regulate airway epithelial ion transport rates by Ca2+- and protein kinase C-dependent mechanisms via activation of specific P2Y receptors. Extracellular adenine nucleotides also serve as precursors for adenosine, which promotes cyclic AMP-mediated activation of the cystic fibrosis transmembrane regulator chloride channel via A(2b) adenosine receptors. A biological role for extracellular ATP in ASL volume homeostasis has been suggested by the demonstration of regulated ATP release from airway epithelia. However, nucleotide hydrolysis at the airway surface makes it difficult to assess the magnitude of ATP release and the relative abundance of adenyl purines and, hence, to define their biological functions. We have combined ASL microsampling and high performance liquid chromatography analysis of fluorescent 1,N-6-ethenoadenine derivatives to measure adenyl purines in ASL. We found that adenosine, AMP, and ADP accumulated in high concentrations relative to ATP within the ASL covering polarized primary human normal or cystic fibrosis airway epithelial cells. By using immortalized epithelial cell monolayers that endogenously express a luminal A(2b) adenosine receptor, we found that basal as well as forskolin-promoted cyclic AMP production was reduced by exogenous adenosine deaminase, suggesting that A(2b) receptors sense endogenous adenosine within the ASL. The physiological role of adenosine was further established by illustrating that adenosine removal or inhibition of adenosine receptors in primary cultures impaired ASL volume regulation. Our data reveal a complex pattern of nucleotides/nucleosides in ASL under resting conditions and suggest that adenosine may play a key role in regulating ASL volume homeostasis.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lazarowski, ER (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, 7017 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	Eduardo_Lazarowski@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034322, HL 34322, P01 HL034322-18, P01 HL034322-189008] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Boucher RC, 2002, ADV DRUG DELIVER REV, V54, P1359, DOI 10.1016/S0169-409X(02)00144-8; Boudreault F, 2002, AM J PHYSIOL-CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Cobb BR, 2003, AM J RESP CELL MOL, V29, P410, DOI 10.1165/rcmb.2002-0247OC; Cobb BR, 2002, AM J PHYSIOL-LUNG C, V282, pL12, DOI 10.1152/ajplung.2002.282.1.L12; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Gabriel SE, 2002, CURR TOP MEMBR, V53, P193; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Grygorczyk R, 1996, J MEMBRANE BIOL, V151, P139, DOI 10.1007/s002329900065; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lazarowski ER, 2001, DRUG DEVELOP RES, V53, P66, DOI 10.1002/ddr.1172; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LAZAROWSKI ER, 2000, ECTO ATPASES RELATED, P283; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; LEVITT B, 1984, ANAL BIOCHEM, V137, P93, DOI 10.1016/0003-2697(84)90352-X; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; PARADISO AM, 2001, PEDIATR PULM, V22, P210; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; Picher M, 2004, J BIOL CHEM, V279, P20234, DOI 10.1074/jbc.M400305200; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; PICHER M, 2001, DRUG DEVELOP RES, V52, P52; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Roman RM, 2001, J MEMBRANE BIOL, V183, P165, DOI 10.1007/s00232-001-0064-7; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Szkotak AJ, 2003, J MEMBRANE BIOL, V192, P169, DOI 10.1007/s00232-002-1073-x; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tarran Robert, 2002, Methods Mol Med, V70, P479; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053	50	188	193	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36855	36864		10.1074/jbc.M405367200	http://dx.doi.org/10.1074/jbc.M405367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210701	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000223453600087
J	Ravid, T; Heidinger, JM; Gee, P; Khan, EM; Goldkorn, T				Ravid, T; Heidinger, JM; Gee, P; Khan, EM; Goldkorn, T			c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED UBIQUITINATION; CLATHRIN-COATED PITS; EGF-RECEPTOR; TYROSINE KINASES; DOWN-REGULATION; RING FINGER; ENDOCYTOSIS; PHOSPHORYLATION; INTERNALIZATION; ACTIVATION	Epidermal growth factor receptor (EGFR) controls cell growth and has a key role in tumorigenic processes. The extent of EGFR signaling is tightly regulated by post-transcriptional modifications leading to down-regulation of the levels of the receptor. Previous studies from our laboratory demonstrated that the reactive oxidant hydrogen peroxide activates the EGFR, yet, without down-regulation of the receptor levels, which results in prolonged receptor signaling. In the present study we examined the role of the E3 ligase c-Cbl, as a possible link between oxidative stress, EGFR signaling, and tumorigenic responses. First, we ectopically expressed a mutant EGFR (Tyr-1045 --> Phe) in cells lacking endogenous receptor, to determine whether the lack of phosphorylation at this site is the cause for EGFR retention at the membrane under oxidative stress, as we have previously suggested. Our findings suggest that abrogation of tyrosine 1045 phosphorylation alone is not enough to retain the EGFR at the plasma membrane under oxidative stress. Second, through the use of the Src inhibitor PP1, our findings establish EGFR movement out of the early endosomes as the exact location where c-Cbl-mediated ubiquitinylation is essential for EGFR trafficking. Finally, our studies substantiate the findings that c-Cbl-mediated ubiquitinylation is needed for degradation, but not for internalization of the EGFR in both transfection-dependent Chinese hamster ovary cells and transfection-independent A549 lung epithelial cells. These findings only begin to explain the features seen under oxidative stress, but they yield a greater understanding of the role of c-Cbl in EGFR trafficking.	Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA	University of California System; University of California Davis	Goldkorn, T (corresponding author), Univ Calif Davis, Sch Med, Dept Signal Transduct, TB 149,Davis Campus, Davis, CA 95616 USA.	ttgoldkorn@ucdavis.edu	Gee, Peter/H-5681-2013		NHLBI NIH HHS [HL 66189, HL 71871] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071871, R01HL066189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; ECCLES SA, 1994, INVAS METAST, V14, P337; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; VanWinkle LS, 1997, AM J PATHOL, V151, P443; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	31	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37153	37162		10.1074/jbc.M403210200	http://dx.doi.org/10.1074/jbc.M403210200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210722	hybrid			2022-12-25	WOS:000223453600119
J	Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM				Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM			Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin	ONCOGENE			English	Article						UbcH10; gene expression; DNA amplification; RNA interference; TRAIL/DR5; apoptosis	ANAPHASE-PROMOTING COMPLEX; INDUCED APOPTOSIS; CANCER-TREATMENT; PROSTATE-CANCER; EXPRESSION; PROTEOLYSIS; CELLS; MITOSIS; TARGETS; MARKERS	Gene expression pro. ling of anatomically diverse carcinomas and their corresponding normal tissues was used to identify genes with cancer-associated expression. We show here that the ubiquitin conjugase, UbcH10, is significantly overexpressed in many different types of cancers and is associated with the degree of tumor differentiation in carcinomas of the breast, lung, ovary and bladder, as well as in glioblastomas. We also show that UbcH10 overexpression in gastro-esophageal, and probably other carcinomas may be a direct consequence of chromosomal amplification at the UbcH10 locus, 20q13.1, a region known to be amplified in diverse tumors. To evaluate whether inhibition of UbcH10 function may be therapeutically relevant in cancer, we used small interfering RNAs (siRNAs) to silence UbcH10 transcription selectively. Diminution of UbcH10 expression significantly inhibited both tumor and normal cell proliferation without inducing cell death. However, when combined with agonists of the DR5/TRAIL receptor, siRNAs directed against the UbcH10 transcript dramatically enhanced killing of cancer cells, but not of proliferating primary human epithelial cells or fibroblasts. Together, these data demonstrate that UbcH10 plays an important role in tumor development and that its inhibition in combination with agonists of the TRAIL receptor may provide an enhanced therapeutic index.	Novartis Res Fdn, Gen Inst, San Diego, CA 92121 USA; Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA USA; Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland	Novartis; University of Virginia; University of Virginia; Novartis	Hampton, GM (corresponding author), Novartis Res Fdn, Gen Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org						Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Boye J, 2003, ANN ONCOL, V14, P520, DOI 10.1093/annonc/mdg175; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; LaTulippe E, 2002, CANCER RES, V62, P4499; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Mayer RJ, 2000, NAT REV MOL CELL BIO, V1, P145; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Okamoto Y, 2003, CANCER RES, V63, P4167; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Stennicke H R, 2000, Symp Soc Exp Biol, V52, P13; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Watanabe T, 2002, JPN J CANCER RES, V93, P1114, DOI 10.1111/j.1349-7006.2002.tb01213.x; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamanaka A, 2000, MOL BIOL CELL, V11, P2821, DOI 10.1091/mbc.11.8.2821	30	110	124	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6621	6629		10.1038/sj.onc.1207861	http://dx.doi.org/10.1038/sj.onc.1207861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208666				2022-12-25	WOS:000223530800009
J	Aseeva, E; Ossenbuhl, F; Eichacker, LA; Wanner, G; Soll, J; Vothknecht, UC				Aseeva, E; Ossenbuhl, F; Eichacker, LA; Wanner, G; Soll, J; Vothknecht, UC			Complex formation of Vipp1 depends on its alpha-helical PspA-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEIN PSPA; ESCHERICHIA-COLI; PHAGE-SHOCK; THYLAKOID MEMBRANES; GENE; SYNECHOCYSTIS; TRANSCRIPTION; BIOGENESIS; ENVELOPE; MUTANT	Vipp1 ((v) under bar esicle- (i) under bar nducing (p) under bar rotein in (p) under bar lastids (1) under bar) is found in Cyanobacteria and chloroplasts of photosynthetic eukaryotes where it is essential for the formation of the thylakoid membrane. Vipp1 is closely related to the (p) under bar hage (s) under bar hock (p) under bar rotein (A) under bar (PspA), a bacterial protein induced under diverse stress conditions. Vipp1 proteins differ from PspA by an additional C-terminal domain that is required for Vipp1 function in thylakoid biogenesis. We show here that in Cyanobacteria, green algae, and vascular plants, Vipp1 is part of a high molecular mass complex. The complex is formed by multiple copies of Vipp1, and complex formation involves interaction of the central alpha-helical domain that is common to Vipp1 as well as to PspA proteins. In chloroplasts of vascular plants, the Vipp1 complex can be visualized by green fluorescent protein fusion in discrete locations at the inner envelope. Green fluorescent protein fusion analysis furthermore revealed that complex formation is important for proper positioning of Vipp1 at the inner envelope of chloroplasts.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Munich	Vothknecht, UC (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	vothknecht@lrz.uni-muenchen.de	Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127				Adams H, 2003, J BACTERIOL, V185, P1174, DOI 10.1128/JB.185.4.1174-1180.2003; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BERGLER H, 1994, MICROBIOL-SGM, V140, P1937, DOI 10.1099/13500872-140-8-1937; BRISSETTE JL, 1991, J MOL BIOL, V220, P35, DOI 10.1016/0022-2836(91)90379-K; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; GAMBORG OL, 1976, IN VITRO CELL DEV B, V12, P473; Hankamer BD, 2004, J BIOL CHEM, V279, P8862, DOI 10.1074/jbc.M307889200; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; LI HM, 1994, PLANT MOL BIOL, V25, P619, DOI 10.1007/BF00029601; Mollier P, 2002, CURR GENET, V40, P405, DOI 10.1007/s00294-002-0271-5; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Vothknecht UC, 2001, BBA-MOL CELL RES, V1541, P91, DOI 10.1016/S0167-4889(01)00153-7; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; Westphal S, 2001, FEBS LETT, V506, P257, DOI 10.1016/S0014-5793(01)02931-3; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198	21	73	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35535	35541		10.1074/jbc.M401750200	http://dx.doi.org/10.1074/jbc.M401750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210715	hybrid			2022-12-25	WOS:000223303400048
J	Dai, Y; Rahmani, M; Corey, SJ; Dent, P; Grant, S				Dai, Y; Rahmani, M; Corey, SJ; Dent, P; Grant, S			A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; T(14/18) LYMPHOMA-CELLS; BCR-ABL ONCOGENE; KINASE INHIBITOR PD180970; COLONY-STIMULATING FACTOR; CYTOCHROME-C RELEASE; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; BLAST CRISIS; PHOSPHATIDYLINOSITOL 3-KINASE	The relationship between the Src kinase Lyn and Bcl-2 expression was examined in chronic myelogenous leukemia cells (K562 and LAMA84) displaying a Bcr/Abl-independent form of imatinib mesylate resistance. K562-R and LAMA-R cells that were markedly resistant to induction of mitochondrial dysfunction ( e. g. loss of mitochondrial membrane potential, Bax translocation, cytochrome c, and apoptosis-inducing factor release) and apoptosis by imatinib mesylate exhibited a pronounced reduction in expression of Bcr/ Abl, Bcl-x(L), and STAT5 but a striking increase in levels of activated Lyn. Whereas basal expression of Bcl-2 protein was very low in parental cells, imatinib-resistant cells displayed a marked increase in Bcl-2 mRNA and/or protein levels. Treatment of LAMA-R cells with the Src kinase inhibitor PP2 significantly reduced Lyn activation as well as Bcl-2 mRNA and protein levels. Transient or stable transfection of LAMA84 or K562 cells with a constitutively active Lyn (Y508F), but not with a kinase-dead mutant (K275D), significantly increased Bcl-2 protein expression and protected cells from lethality of imatinib mesylate. Ectopic expression of Bcl-2 protected K562 and LAMA84 cells from imatinib mesylate- and PP2-mediated lethality. Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells. In marked contrast, these interventions had little effect in parental LAMA84 cells that display low basal levels of Bcl-2. Together, these findings indicate that activation of Lyn in leukemia cells displaying a Bcr/ Abl-independent form of imatinib mesylate resistance plays a functional role in Bcl-2 up-regulation and provide a theoretical basis for the development of therapeutic strategies targeting Bcl-2 in such a setting.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu	Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753, R01CA100866, R01CA088906, P01CA072955] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100866, CA 63753, CA 72955, CA 93738, CA 88906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bates RC, 2001, CANCER RES, V61, P5275; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Canitrot Y, 2003, BLOOD, V102, P2632, DOI 10.1182/blood-2002-10-3207; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cirinna M, 2000, BLOOD, V96, P3915, DOI 10.1182/blood.V96.12.3915.h8003915_3915_3921; Dai Y, 2001, CANCER RES, V61, P5106; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; La Rosee P, 2002, CANCER RES, V62, P7149; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nieborowska-Skorska M, 2000, ONCOGENE, V19, P4117, DOI 10.1038/sj.onc.1203754; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Nimmanapalli R, 2002, CANCER RES, V62, P5761; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shangary S, 2003, EXP CELL RES, V289, P67, DOI 10.1016/S0014-4827(03)00234-9; Sinha S, 2001, EXP HEMATOL, V29, P746, DOI 10.1016/S0301-472X(01)00647-6; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; Tauchi T, 2003, CLIN CANCER RES, V9, P4267; von Bubnoff N, 2003, CANCER RES, V63, P6395; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wei S, 1996, J IMMUNOL, V157, P5155; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Yamaguchi H, 2002, CANCER RES, V62, P466; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yu CR, 2002, CLIN CANCER RES, V8, P2976	60	213	219	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34227	34239		10.1074/jbc.M402290200	http://dx.doi.org/10.1074/jbc.M402290200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175350	hybrid			2022-12-25	WOS:000223134800021
J	Korber, P; Horz, W				Korber, P; Horz, W			In vitro assembly of the characteristic chromatin organization at the yeast PHO5 promoter by a replication-independent extract system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; POSITIONED NUCLEOSOMES; TRANSCRIPTIONAL ACTIVATION; DNA-REPLICATION; MMTV PROMOTER; MINICHROMOSOMES; RECONSTITUTION; MAINTENANCE; REPRESSION; DISRUPTION	An extensive set of analyses of the yeast PHO5 gene, mostly performed in vivo, has made this gene a model for the role of chromatin structure in gene regulation. In the repressed state, the PHO5 promoter shows a characteristic chromatin organization with four positioned nucleosomes and a short hypersensitive site. So far the basis for this nucleosome positioning has remained unresolved. We have therefore decided to complement the in vivo studies by an in vitro approach. As a first step, we have asked whether the characteristic PHO5 promoter chromatin structure depends on the cellular context including replication or higher order nuclear chromatin organization or whether it can be reconstituted in vitro in a cell-free system. To this end we have established an in vitro chromatin assembly system based on yeast extracts. It is capable of generating extensive regular nucleosomal arrays with physiological spacing. Assembly requires supplementation with exogenous histones and is dependent on energy leading to chromatin with dynamic properties due to ATP-dependent activities of the extract. Using the PHO5 promoter sequence as template in this replication independent system, we obtain a nucleosomal pattern over the PHO5 promoter region that is very similar to the in vivo pattern of the repressed state. This shows that the chromatin structure at the PHO5 promoter represents a self-organizing system in cell-free yeast extracts and provides a promising substrate for in vitro studies with a direct in vivo correlate.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Horz, W (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	hoerz@bio.med.unimuenchen.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Belikov S, 2001, EMBO J, V20, P2802, DOI 10.1093/emboj/20.11.2802; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gregory PD, 1999, METH MOL B, V119, P417; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HORZ W, 1980, J MOL BIOL, V144, P305, DOI 10.1016/0022-2836(80)90093-5; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Robinson KM, 2003, MOL CELL BIOL, V23, P7937, DOI 10.1128/MCB.23.22.7937-7946.2003; Schultz MC, 1999, METHODS, V17, P161, DOI 10.1006/meth.1998.0727; Schultz MC, 1997, P NATL ACAD SCI USA, V94, P9034, DOI 10.1073/pnas.94.17.9034; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Terrell AR, 2002, J BIOL CHEM, V277, P31038, DOI 10.1074/jbc.M204662200; THOMA F, 1988, CELL, V55, P945, DOI 10.1016/0092-8674(88)90240-1; TOH EA, 1974, J BACTERIOL, V120, P608; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x	41	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35113	35120		10.1074/jbc.M405446200	http://dx.doi.org/10.1074/jbc.M405446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192097	hybrid			2022-12-25	WOS:000223134800124
J	Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C				Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C			Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); anaplastic large-cell lymphoma; X-ALK variants	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; GROWTH-FACTOR; TYROSINE KINASE; TROPOMYOSIN SYNTHESIS; ATIC-ALK; GENE; NPM; TRANSLOCATIONS; SUPPRESSION	Majority of anaplastic large-cell lymphomas (ALCLs) are associated with the t(2;5)(p23; q35) translocation, fusing the NPM ( nucleophosmin) and ALK (anaplastic lymphoma kinase) genes (NPM-ALK). Recent studies demonstrated that ALK may also be involved in variant translocations, namely, t(1;2)(q25;p23), t(2;3)(p23;q21), t(2;17)(p23;q23) and inv(2)(p23q35), which create the TPM3-ALK, TFG-ALK5, CLTC-ALK, and ATIC-ALK fusion genes, respectively. Although overexpression of NPM-ALK has previously been shown to transform fibroblasts, the transforming potential of variant X-ALK proteins has not been precisely investigated. We stably transfected the cDNAs coding for NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK or ATIC-ALK into nonmalignant NIH3T3 cells. All X-ALK variants are tyrosine phosphorylated and their subcellular distribution was in agreement with that observed in tumors. Moreover, our results show that the in vitro transforming capacity of NIH3T3-transfected cells are in relation to the level of X-ALK fusion proteins excepted for TPM3-ALK for which there is an inverse correlation. The differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion, migration through the endothelial barrier and tumorigenicity seem to be due to differential activation of various signaling pathways such as PI3-kinase/AKT. These findings may have clinical implications in the pathogenesis and prognosis of ALK-positive ALCLs.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Oncogenesis & Signaling Hematopoiet Cells, Toulouse, France; CHU Rangueil, INSERM, U589, F-31054 Toulouse, France; Univ Barcelona, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona	Delsol, G (corresponding author), CHU Purpan, Anat Pathol Lab, Pl Dr Baylac, F-31059 Toulouse, France.	delsol.g@chu-toulouse.fr	Campo, Elias/AAC-5593-2019; TOURIOL, Christian/O-8949-2014; Hieblot, Corinne/O-4734-2019; Espinos, Estelle/A-4661-2015; Allouche, Michele/P-4865-2019	Campo, Elias/0000-0001-9850-9793; TOURIOL, Christian/0000-0003-1219-4693; Espinos, Estelle/0000-0002-5693-8941; Racaud-Sultan, Claire/0000-0002-6549-1088				Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CHIARLE R, 2002, BLOOD, V7, P7; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hernandez L, 1999, BLOOD, V94, P3265; JOOSS KU, 1995, ONCOGENE, V10, P603; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232; Lamant L, 1999, BLOOD, V93, P3088; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; Miething C, 2003, ONCOGENE, V22, P4642, DOI 10.1038/sj.onc.1206575; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prasad SC, 1997, ELECTROPHORESIS, V18, P629, DOI 10.1002/elps.1150180348; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schweitzer KM, 1997, LAB INVEST, V76, P25; Slupianek A, 2001, CANCER RES, V61, P2194; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; URBANCIKOVA M, 1982, NEOPLASMA, V29, P655; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAJI H, 1992, APPL MICROBIOL BIOT, V37, P244; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	54	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6071	6082		10.1038/sj.onc.1207813	http://dx.doi.org/10.1038/sj.onc.1207813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208656				2022-12-25	WOS:000223261000007
J	Spitkovsky, D; Sasse, P; Kolossov, E; Bottinger, C; Fleischmann, BK; Hescheler, J; Wiesner, RJ				Spitkovsky, D; Sasse, P; Kolossov, E; Bottinger, C; Fleischmann, BK; Hescheler, J; Wiesner, RJ			Activity of complex III of the mitochondrial electron transport chain is essential for early heart muscle cell differentiation	FASEB JOURNAL			English	Article						cardiomyocyte; development; embryonic stem cells; embryoid bodies; respiratory chain	EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; RAT-TISSUES; DNA; CARDIOMYOCYTES; DEPOLARIZATION; CARDIOMYOPATHY; MAINTENANCE; SURVIVAL	During development of the heart, mitochondria proliferate within cardiomyocytes. It is unclear whether this is a response to the increasing energy demand or whether it is part of the developmental program. To investigate the role of the electron transport chain (ETC) in this process, we used transgenic murine embryonic stem (ES) cells in which the green fluorescent protein gene is under control of the alpha-myosin heavy chain promoter (alpha-MHC), allowing easy monitoring of cardiomyocyte differentiation. Spontaneous contraction of these cells within embryoid bodies (EBs) was not affected by inhibition of the ETC, suggesting that early heart cell function is sufficiently supported by anaerobic ATP production. However, heart cell development was completely blocked when adding antimycin A, an inhibitor of ETC complex III, before initiation of differentiation, whereas KCN did not block differentiation, strongly suggesting that specifically complex III function rather than mitochondrial ATP production is necessary for early heart cell development. When the underlying mechanism was examined, we noticed that antimycin A but not KCN lead to inhibition of spontaneous intracellular Ca++ oscillations, whereas both substances decreased mitochondrial membrane potential, as expected. We postulate that mitochondrial complex III activity is necessary for these Ca++ oscillations, which in turn are a prerequisite for cardiomyocyte differentiation.	Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany; Univ Cologne, Inst Neurophysiol, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany; Axiogenesis AG, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Bonn	Wiesner, RJ (corresponding author), Univ Cologne, Inst Vegetat Physiol, Robert Koch Str 39, D-50931 Cologne, Germany.	Rudolf.Wiesner@uni-koeln.de	Spitkovsky, Dimitry/ABA-1605-2020; Sasse, Philipp/G-9866-2013	Sasse, Philipp/0000-0002-8502-9472				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Finck BN, 2002, COLD SPRING HARB SYM, V67, P371, DOI 10.1101/sqb.2002.67.371; GAGNON J, 1991, MOL CELL BIOCHEM, V107, P21, DOI 10.1007/BF02424572; Garstka HL, 2003, NUCLEIC ACIDS RES, V31, P5039, DOI 10.1093/nar/gkg717; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; HOHL C, 1987, ARCH BIOCHEM BIOPHYS, V259, P527, DOI 10.1016/0003-9861(87)90519-4; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; Li JA, 2002, J CELL BIOL, V158, P103, DOI 10.1083/jcb.200204092; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Marin-Garcia J, 2000, MOL CELL BIOCHEM, V210, P47, DOI 10.1023/A:1007031919298; MARINGARCIA J, 1994, J MOL CELL CARDIOL, V26, P1029, DOI 10.1006/jmcc.1994.1123; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x	31	59	61	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1300	+		10.1096/fj.03-0520fje	http://dx.doi.org/10.1096/fj.03-0520fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180963				2022-12-25	WOS:000222327500029
J	Shi, YX; Latifi, T; Cromie, MJ; Groisman, EA				Shi, YX; Latifi, T; Cromie, MJ; Groisman, EA			Transcriptional control of the antimicrobial peptide resistance ugtL gene by the Salmonella PhoP and SlyA regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI; 2-COMPONENT SYSTEM; MOLECULAR CHARACTERIZATION; POLYMYXIN RESISTANCE; VIRULENCE; REGULON; IDENTIFICATION; ACTIVATOR; EXPRESSION	The PhoP/PhoQ two-component system is a master regulator that governs the ability of Salmonella to cause a lethal infection in mice, the adaptation to low Mg2+ environments, and resistance to a variety of antimicrobial peptides. We have recently established that the PhoP-activated ugtL gene is required for resistance to the antimicrobial peptides magainin 2 and polymyxin B. Here we report that ugtL transcription requires not only the PhoP protein but also the virulence regulatory protein SlyA. The PhoP protein footprinted two regions of the ugtL promoter, mutation of either one of which was sufficient to abolish ugtL transcription. Although the SlyA protein is a transcriptional activator of the ugtL gene, it footprinted the ugtL promoter at a region located downstream of the transcription start site. The PhoP protein footprinted the slyA promoter, indicating that it controls slyA transcription directly. The slyA mutant was hypersensitive to magainin 2 and polymyxin B, suggesting that the virulence attenuation exhibited by slyA mutants may be caused by hypersensitivity to antimicrobial peptides. We propose that the PhoP and SlyA proteins control ugtL transcription using a feed-forward loop design.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu			NIAID NIH HHS [AI49561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Castelli ME, 2003, J BIOL CHEM, V278, P23579, DOI 10.1074/jbc.M303042200; Chamnongpol S, 2003, J MOL BIOL, V325, P795, DOI 10.1016/S0022-2836(02)01268-8; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; Eguchi Y, 2004, J BACTERIOL, V186, P3006, DOI 10.1128/JB.186.10.3006-3014.2004; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GALAN JE, 1989, MICROB PATHOGENESIS, V6, P433, DOI 10.1016/0882-4010(89)90085-5; Garmendia J, 2003, MICROBIOL-SGM, V149, P2385, DOI 10.1099/mic.0.26397-0; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hilbert F, 1999, J BACTERIOL, V181, P2158, DOI 10.1128/JB.181.7.2158-2165.1999; Kato A, 2003, P NATL ACAD SCI USA, V100, P4706, DOI 10.1073/pnas.0836837100; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; Mangan S, 2003, J MOL BIOL, V334, P197, DOI 10.1016/j.jmb.2003.09.049; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; Munson GP, 2000, MOL MICROBIOL, V36, P1391, DOI 10.1046/j.1365-2958.2000.01957.x; Norte VA, 2003, J BACTERIOL, V185, P3508, DOI 10.1128/JB.185.12.3508-3514.2003; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Qi Y, 1998, MOL MICROBIOL, V28, P1187, DOI 10.1046/j.1365-2958.1998.00882.x; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Shi YX, 2004, MOL MICROBIOL, V53, P229, DOI 10.1111/j.1365-2958.2004.04107.x; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x	40	89	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38618	38625		10.1074/jbc.M406149200	http://dx.doi.org/10.1074/jbc.M406149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208313	hybrid			2022-12-25	WOS:000223684100069
J	Ben-Zvi, A; De los Rios, P; Dietler, G; Goloubinoff, P				Ben-Zvi, A; De los Rios, P; Dietler, G; Goloubinoff, P			Active solubilization and refolding of stable protein aggregates by cooperative unfolding action of individual Hsp70 chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; SUBSTRATE-BINDING; ESCHERICHIA-COLI; COMMON MECHANISM; DNAK; DISAGGREGATION; IMPLIES; FORM	Hsp70 is a central molecular chaperone that passively prevents protein aggregation and uses the energy of ATP hydrolysis to solubilize, translocate, and mediate the proper refolding of proteins in the cell. Yet, the molecular mechanism by which the active Hsp70 chaperone functions are achieved remains unclear. Here, we show that the bacterial Hsp70 ( DnaK) can actively unfold misfolded structures in aggregated polypeptides, leading to gradual disaggregation. We found that the specific unfolding and disaggregation activities of individual DnaK molecules were optimal for large aggregates but dramatically decreased for small aggregates. The active unfolding of the smallest aggregates, leading to proper global refolding, required the cooperative action of several DnaK molecules per misfolded polypeptide. This finding suggests that the unique ATP-fueled locking/unlocking mechanism of the Hsp70 chaperones can recruit random chaperone motions to locally unfold misfolded structures and gradually disentangle stable aggregates into refoldable proteins.	Univ Lausanne, Dept Biol Mol Vegetale, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, ITPSB, Lab Biophys Stat, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, IPMCSB, Lab Phys Mat Vivante, CH-1015 Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Goloubinoff, P (corresponding author), Univ Lausanne, Dept Biol Mol Vegetale, CH-1015 Lausanne, Switzerland.	Pierre.Goloubinoff@ie-bpv.unil.ch	De Los Rios, Paolo/B-2456-2010; EPFL, LBS/B-3567-2010; BEN-ZVI, ANAT/F-1674-2012	De Los Rios, Paolo/0000-0002-5394-5062; BEN-ZVI, ANAT/0000-0003-2477-6519; Goloubinoff, Pierre/0000-0002-4802-0807				Ben-Zvi AP, 2002, J BIOL CHEM, V277, P49422, DOI 10.1074/jbc.M209163200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	26	79	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37298	37303		10.1074/jbc.M405627200	http://dx.doi.org/10.1074/jbc.M405627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201275	hybrid			2022-12-25	WOS:000223554600014
J	Humphries, LA; Dangelmaier, C; Sommer, K; Kipp, K; Kato, RM; Griffith, N; Bakman, I; Turk, CW; Daniel, JL; Rawlings, DJ				Humphries, LA; Dangelmaier, C; Sommer, K; Kipp, K; Kato, RM; Griffith, N; Bakman, I; Turk, CW; Daniel, JL; Rawlings, DJ			Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase C gamma Src homology 2-Src homology 3 linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL RECEPTOR; ANTIGEN RECEPTOR; CA2+ MOBILIZATION; ACTIVATION; RESIDUES; BTK; C-GAMMA-2; SYK; LYMPHOCYTES; EXPRESSION	Tyrosine phosphorylation of phospholipase Cgamma2 (PLCgamma2) is a crucial activation switch that initiates and maintains intracellular calcium mobilization in response to B cell antigen receptor (BCR) engagement. Although members from three distinct families of nonreceptor tyrosine kinases can phosphorylate PLCgamma in vitro, the specific kinase(s) controlling BCR-dependent PLCgamma activation in vivo remains unknown. Bruton's tyrosine kinase (Btk)-deficient human B cells exhibit diminished inositol 1,4,5-trisphosphate production and calcium signaling despite a normal inducible level of total PLCgamma2 tyrosine phosphorylation. This suggested that Btk might modify a critical subset of residues essential for PLCgamma2 activity. To evaluate this hypothesis, we generated site-specific phosphotyrosine antibodies recognizing four putative regulatory residues within PLCgamma2. Whereas all four sites were rapidly modified in response to BCR engagement in normal B cells, Btk-deficient B cells exhibited a marked reduction in phosphorylation of the Src homology 2 (SH2)-SH3 linker region sites, Tyr(753) and Tyr(759). Phosphorylation of both sites was restored by expression of Tec, but not Syk, family kinases. In contrast, phosphorylation of the PLCgamma2 carboxyl- terminal sites, Tyr(1197) and Tyr(1217), was unaffected by the absence of functional Btk. Together, these data support a model whereby Btk/Tec kinases control sustained calcium signaling via site-specific phosphorylation of key residues within the PLCgamma2 SH2-SH3 linker.	Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19122 USA; Max Planck Inst Psychiat Mol Cellular & Clin Prot, D-80804 Munich, Germany	University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Max Planck Society	Rawlings, DJ (corresponding author), Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.	drawling@u.washington.edu	Rawlings, David/CAI-4751-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037091] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA081140] Funding Source: NIH RePORTER; NCI NIH HHS [CA81140] Funding Source: Medline; NICHD NIH HHS [HD37091] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Forssell J, 2000, SCAND J IMMUNOL, V52, P30; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Genevier HC, 1997, CLIN EXP IMMUNOL, V110, P386, DOI 10.1046/j.1365-2249.1997.4581478.x; Hashimoto A, 2000, J IMMUNOL, V165, P1738, DOI 10.4049/jimmunol.165.4.1738; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HEMPEL WM, 1991, J IMMUNOL, V146, P3713; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kouro T, 2001, INT IMMUNOL, V13, P485, DOI 10.1093/intimm/13.4.485; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Law CL, 1996, MOL CELL BIOL, V16, P1305; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Perez-Villar JJ, 1999, J IMMUNOL, V163, P6435; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Rodriguez R, 2003, BIOCHEM J, V374, P269, DOI 10.1042/BJ20021778; Rodriguez R, 2001, J BIOL CHEM, V276, P47982, DOI 10.1074/jbc.M107577200; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Setoguchi R, 1998, IMMUNOL LETT, V64, P109, DOI 10.1016/S0165-2478(98)00086-8; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Watanabe D, 2001, J BIOL CHEM, V276, P38595, DOI 10.1074/jbc.M103675200; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7	59	84	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37651	37661		10.1074/jbc.M311985200	http://dx.doi.org/10.1074/jbc.M311985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15184383	hybrid			2022-12-25	WOS:000223554600056
J	Takahashi, H; Tran, POT; LeRoy, E; Harmon, JS; Tanaka, Y; Robertson, RP				Takahashi, H; Tran, POT; LeRoy, E; Harmon, JS; Tanaka, Y; Robertson, RP			D-Glyceraldehyde causes production of intracellular peroxide in pancreatic islets, oxidative stress, and defective beta cell function via non-mitochondrial pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE-CONCENTRATIONS; INSULIN GENE-TRANSCRIPTION; CHRONIC EXPOSURE; AUTOXIDATIVE GLYCOSYLATION; DEHYDROGENASE-ACTIVITY; HYPERGLYCEMIC DAMAGE; HEXOSAMINE PATHWAY; KONINGIC ACID; HIT CELLS; TOXICITY	D-Glyceraldehyde (D-GLYC) is usually considered to be a stimulator of insulin secretion but theoretically can also form reactive oxygen species (ROS), which can inhibit beta cell function. We examined the time- and concentration-dependent effects of D-GLYC on insulin secretion, insulin content, and formation of ROS. We observed that a 2-h exposure to 0.05-2 mM D-GLYC potentiated glucose-stimulated insulin secretion (GSIS) in isolated Wistar rat islets but that higher concentrations inhibited GSIS. A 24-h exposure to 2 mM D-GLYC inhibited GSIS, decreased insulin content, and increased intracellular peroxide levels (2.14 +/- 0.31-fold increase, n = 4, p < 0.05). N-Acetylcysteine ( 10 mM) prevented the increase in intracellular peroxides and the adverse effects of D-GLYC on GSIS. In the presence of 11.1 but not 3.0 mM glucose, koningic acid ( 10 mu M), a specific glyceraldehyde-3- phosphate dehydrogenase inhibitor, increased intracellular peroxide levels (1.88 +/- 0.30-fold increase, n = 9, p < 0.01) and inhibited GSIS ( control GSIS = p < 0.001; koningic acid GSIS, not significant). To determine whether oxidative phosphorylation was the source of ROS formation, we cultured rat islets with mitochondrial inhibitors. Neither rotenone or myxothiazol prevented D-GLYC-induced increases in islet ROS. Adenoviral overexpression of manganese superoxide dismutase also failed to prevent the effect of D-GLYC to increase ROS levels. These observations indicate that exposure to excess D-GLYC increases reactive oxygen species in the islet via non-mitochondrial pathways and suggest the hypothesis that the oxidative stress associated with elevated D-GLYC levels could be a mechanism for glucose toxicity in beta cells exposed chronically to high glucose concentrations.	Pacific NW Res Inst, Seattle, WA 98122 USA; Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Gunma 3718511, Japan; Univ Washington, Dept Med, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	Gunma University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	rpr@pnri.org	Roberston, R Paul/AAX-5613-2021		NIDDK NIH HHS [DK 38325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038325, R56DK038325] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCAZAR O, 1995, BIOCHEM J, V310, P215, DOI 10.1042/bj3100215; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Beisswenger PJ, 2003, BBA-MOL BASIS DIS, V1637, P98, DOI 10.1016/S09254439(02)00219-3; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; HELLMAN B, 1974, ARCH BIOCHEM BIOPHYS, V162, P448, DOI 10.1016/0003-9861(74)90204-5; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Laychock SG, 1996, BIOCHEM PHARMACOL, V52, P793, DOI 10.1016/0006-2952(96)00391-7; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P194, DOI 10.1016/0003-9861(89)90100-8; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2; SAKAI K, 1988, BIOCHIM BIOPHYS ACTA, V952, P297, DOI 10.1016/0167-4838(88)90130-6; SAKAI K, 1991, BIOCHIM BIOPHYS ACTA, V1077, P192, DOI 10.1016/0167-4838(91)90058-8; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Taniguchi S, 2000, J BIOCHEM-TOKYO, V127, P289, DOI 10.1093/oxfordjournals.jbchem.a022606; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415	25	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37316	37323		10.1074/jbc.M403070200	http://dx.doi.org/10.1074/jbc.M403070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15213233	hybrid			2022-12-25	WOS:000223554600017
J	Young, GD; Murphy-Ullrich, JE				Young, GD; Murphy-Ullrich, JE			Molecular interactions that confer latency to transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ACTIVATION; THROMBOSPONDIN-1; SUPPRESSION; MECHANISMS; FIBROSIS; PEPTIDE	A major point of regulation of transforming growth factor-beta (TGF-beta) function is through control of activation of the latent TGF-beta complex, which consists of the latency associated peptide (LAP) secreted in non-covalent association with mature TGF-beta. Activation involves proteolysis, dissociation, or altered binding of LAP. However, the mechanism by which LAP confers latency to TGF-beta is poorly understood. Previously, we identified a conserved sequence near the N terminus of LAP as a site of thrombospondin-1 (TSP1) binding to the latent complex. Now we show that expression of the TGF-beta1-latent complex deleted in the TSP1 binding site ((LSKL)-L-54) of LAP (DeltaLSKL LAP) results in secretion of LAP, but not of mature TGF- beta. DeltaLSKL LAP also fails to bind soluble or immobilized TGF-beta1. Consistent with an inability to bind the mature domain, DeltaLSKL LAP is unable to confer latency to TGF-beta, suggesting that the LSKL sequence is important, not only for TSP1 binding and activation, but also for binding to the mature domain. We identified the sequence (RKPK)-R-94 in the receptor-binding region of mature TGF-beta1 as the binding site for LAP. Peptides of the RKPK sequence bind LAP and inhibit LAP/TGF-beta association. RKPK peptides also activate latent TGF-beta, presumably by disrupting LAP-mature TGF-beta interactions. These studies provide a molecular basis for both latency and activation by TSP1 through the LSKL sequence of LAP binding to the RKPK sequence of mature TGF-beta.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Cell Adhes & Matrix Res Ctr, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama, Dept Pathol, Volker Hall 668,1670 Univ Blvd, Birmingham, AL 35294 USA.	murphy@path.uab.edu			NCRR NIH HHS [C06 RR15490] Funding Source: Medline; NHLBI NIH HHS [R01 HL050061, HL50061] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumont N, 2002, DIFFERENTIATION, V70, P574, DOI 10.1046/j.1432-0436.2002.700910.x; Gressner AM, 2003, J HEPATOL, V39, P856, DOI 10.1016/S0168-8278(03)00432-X; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; Wolfraim LA, 2002, J IMMUNOL METHODS, V266, P7, DOI 10.1016/S0022-1759(02)00090-X; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x	20	82	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38032	38039		10.1074/jbc.M405658200	http://dx.doi.org/10.1074/jbc.M405658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208302	hybrid			2022-12-25	WOS:000223554600097
J	Agapova, LS; Volodina, JL; Chumakov, PM; Kopnin, BP				Agapova, LS; Volodina, JL; Chumakov, PM; Kopnin, BP			Activation of Ras-Ral pathway attenuates p53-independent DNA damage G(2) checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; SIGNALING PATHWAYS; GENE AMPLIFICATION; CROSS-LINKING; KINASE; CANCER; PROTEIN; ONCOGENE; GTPASES; PHOSPHORYLATION	Earlier we have found that in p53-deficient cells the expression of activated Ras attenuates the DNA damage-induced arrest in G(1) and G(2). In the present work we studied Ras-mediated effects on the G(2) checkpoint in two human cell lines, MDAH041 immortalized fibroblasts and Saos-2 osteosarcoma cells. The transduction of the H-Ras mutants that retain certain functions (V12S35, V12G37, and V12C40 retain the ability to activate Raf or RalGDS or phosphatidylinositol 3-kinase, respectively) as well as the activated or dominant-negative mutants of RalA (V23 and N28, respectively) has revealed that the activation of Ras-RalGEFs-Ral pathway was responsible for the attenuation of the G(2) arrest induced by ethyl metanesulfonate or doxorubicin. Noteworthy, the activated RalA V23N49 mutant, which cannot interact with RLIP76/RalBP1 protein, one of the best studied Ral effectors, retained the ability to attenuate the DNA damage-induced G(2) arrest. Activation of the Ras-Ral signaling affected neither the level nor the intracellular localization of cyclin B1 and CDC2 but interfered with the CDC2 inhibitory phosporylation at Tyr(15) and the decrease in the cyclin B/CDC2 kinase activity in damaged cells. The revealed function of the Ras-Ral pathway may contribute to the development of genetic instability in neoplastic cells.	Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Cleveland Clinic Foundation; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kopnin, BP (corresponding author), Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	bkopnin@yahoo.com	Kopnin, Boris/R-8240-2019; Volodina, Yulia L/AGE-9354-2022	Kopnin, Boris/0000-0003-3100-2212; Volodina, Yulia L/0000-0003-4388-3344; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Archer Herbert, 2002, Methods Mol Biol, V189, P67; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boettner B, 2002, GENE DEV, V16, P2033, DOI 10.1101/gad.1020602; BOS JL, 1989, CANCER RES, V49, P4682; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; ICHIKAWA T, 1990, CANCER RES, V50, P6349; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kellogg DR, 2003, J CELL SCI, V116, P4883, DOI 10.1242/jcs.00908; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimura ET, 2003, CANCER RES, V63, P1454; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Luce RA, 2001, METHOD ENZYMOL, V340, P396; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; Peitl P, 2002, MUTAGENESIS, V17, P67, DOI 10.1093/mutage/17.1.67; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Poon RYC, 2002, ENCY CANC, P393; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; RAK J, 1995, CANCER RES, V55, P4575; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosse C, 2003, J BIOL CHEM, V278, P30597, DOI 10.1074/jbc.M302191200; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; WANI MA, 1994, CANCER RES, V54, P2504; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamazaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P868, DOI 10.1006/bbrc.2000.4233; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	73	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36382	36389		10.1074/jbc.M405007200	http://dx.doi.org/10.1074/jbc.M405007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208305	hybrid			2022-12-25	WOS:000223453600028
J	Amado, M; Yan, Q; Comelli, EM; Collins, BE; Paulson, JC				Amado, M; Yan, Q; Comelli, EM; Collins, BE; Paulson, JC			Peanut agglutinin high phenotype of activated CD8(+) T cells results from de novo synthesis of CD45 glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; GANGLIOSIDE SIALIDASE; MURINE THYMOCYTES; PLASMA-MEMBRANE; POINT MUTATION; EXPRESSION; MOUSE; BINDING; IDENTIFICATION; NEURAMINIDASE	Following activation in the periphery, murine CD8(+) T cells exhibit a characteristic increased binding of peanut agglutinin (PNA), reflecting an increased expression of hyposialylated O-linked glycans (Galbeta1-3GalNAcalpha-O-Thr/Ser) on the cell surface. In this report, we show that the majority of the PNA receptors expressed on activated CD8(+) T cells are carried by CD45. Other glycoproteins (e.g. CD8) and the glycolipid asialo-GM1 also carry PNA receptors, although to a much lesser extent. Analysis of enzymes involved in the sialylation/de-sialylation pathways showed that generation of PNA receptors in activated CD8(+) T cells is not due to up-regulation of endogenous sialidases. Instead, our results indicate that the PNA(high) phenotype results from de novo synthesis of CD45 carrying reduced sialylated core 1 O-glycans.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Paulson, JC (corresponding author), Scripps Res Inst, Dept Mol Biol & Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-L71, La Jolla, CA 92037 USA.	jpaulson@scripps.edu	Paulson, James/AAG-3565-2019	Comelli, Elena/0000-0002-5201-5437	NIAID NIH HHS [R01 AI050143, AI 050143] Funding Source: Medline; NIGMS NIH HHS [GM 25042] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050143] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN WRA, 1982, IMMUNOLOGY, V46, P713; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; CHERVENAK R, 1982, THYMUS, V4, P61; Comelli EM, 2003, GENE, V321, P155, DOI 10.1016/j.gene.2003.08.005; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; DEMAIO A, 1986, CELL IMMUNOL, V99, P345, DOI 10.1016/0008-8749(86)90243-1; DEPETRIS S, 1983, EUR J IMMUNOL, V13, P831, DOI 10.1002/eji.1830131010; DESPONT JP, 1975, CELL IMMUNOL, V17, P487, DOI 10.1016/S0008-8749(75)80052-9; FAVERO J, 1984, CELL IMMUNOL, V86, P439, DOI 10.1016/0008-8749(84)90399-X; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Galvan M, 1998, J IMMUNOL, V161, P641; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Grabie N, 2002, EUR J IMMUNOL, V32, P2766, DOI 10.1002/1521-4141(2002010)32:10<2766::AID-IMMU2766>3.0.CO;2-0; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; Liu YJ, 1997, P NATL ACAD SCI USA, V94, P8138, DOI 10.1073/pnas.94.15.8138; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Moody AM, 2003, J BIOL CHEM, V278, P7240, DOI 10.1074/jbc.M210468200; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; OKA T, 2004, MOL BIOL CELL; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; PILLER F, 1988, J BIOL CHEM, V263, P15146; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; ROSE ML, 1981, IMMUNOLOGY, V42, P583; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; Slifka MK, 2000, J IMMUNOL, V164, P2009, DOI 10.4049/jimmunol.164.4.2009; Starr TK, 2003, J IMMUNOL, V171, P4512, DOI 10.4049/jimmunol.171.9.4512; TAIRA S, 1988, J IMMUNOL, V141, P440; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; WOMACK JE, 1981, SCIENCE, V212, P63, DOI 10.1126/science.7209520; Wu WY, 1997, GLYCOBIOLOGY, V7, P349, DOI 10.1093/glycob/7.3.349; Wu WY, 1996, J EXP MED, V184, P759, DOI 10.1084/jem.184.2.759; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	44	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36689	36697		10.1074/jbc.M405629200	http://dx.doi.org/10.1074/jbc.M405629200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210702	hybrid			2022-12-25	WOS:000223453600068
J	Clarke, TA; Im, SC; Bidwai, A; Waskell, L				Clarke, TA; Im, SC; Bidwai, A; Waskell, L			The role of the length and sequence of the linker domain of cytochrome b(5) in stimulating cytochrome P4502B4 catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; ENDOPLASMIC-RETICULUM; SUBSTRATE-BINDING; ESCHERICHIA-COLI; MEMBRANE; PROTEIN; EXPRESSION; METABOLISM; ALIGNMENT; REDUCTASE	Cytochrome b(5) (cyt b(5)) is a 15-kDa amphipathic protein with a cytosolic amino-terminal catalytic heme domain, which is anchored to the microsomal membrane by a hydrophobic transmembrane alpha-helix at its carboxyl terminus. These two domains are connected by an similar to15-amino acid linker domain, Ser(90)-Asp(104), which has been modified by site-directed mutagenesis to investigate whether the length or sequence of the linker influences the ability of cyt b(5) to bind ferric cytochrome P450 2B4 and donate an electron to oxyferrous (cyt P450 2B4), thereby stimulating catalysis. Because shortening the linker by 8 or more amino acids markedly inhibited the ability of cyt b(5) to bind cyt P450 2B4 and stimulate catalysis by this isozyme, it is postulated 7 amino acids are sufficient to allow a productive interaction. All mutant cyts b(5) except the protein lacking the entire 15-amino acid linker inserted normally into the microsomal membrane. Alternatively, lengthening the linker by 16 amino acids, reversing the sequence of the amino acids in the linker, and mutating conserved linker residues did not significantly alter the ability of cyt b(5) to interact with cyt P450 2B4. A model for the membrane-bound cyt b(5)-cyt P450 complex is presented.	Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48105 USA; Vet Affairs Med Res Ctr, Ann Arbor, MI 48105 USA; Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University of Michigan System; University of Michigan; University of East Anglia	Waskell, L (corresponding author), Univ Michigan, Dept Anesthesiol, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.	waskell@umich.edu	clarke, tom/D-1837-2009	clarke, tom/0000-0002-6234-1914	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Altuve A, 2001, BIOCHEMISTRY-US, V40, P9469, DOI 10.1021/bi010636i; Arnesano F, 1998, BIOCHEMISTRY-US, V37, P173, DOI 10.1021/bi971896w; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Banci L, 2000, EUR J BIOCHEM, V267, P755, DOI 10.1046/j.1432-1327.2000.01054.x; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Creighton T. E., 1993, PROTEINS STRUCTURES; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Estabrook R W, 1978, Methods Enzymol, V52, P212; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIORDANO SJ, 1993, BIOCHIM BIOPHYS ACTA, V1172, P95, DOI 10.1016/0167-4781(93)90274-H; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; Jayasinghe S, 2001, J MOL BIOL, V312, P927, DOI 10.1006/jmbi.2001.5008; Mathews K., 1990, BIOCHEMISTRY; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mulrooney SB, 2000, PROTEIN EXPRES PURIF, V19, P173, DOI 10.1006/prep.2000.1228; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; Park JY, 2003, J MED CHEM, V46, P1645, DOI 10.1021/jm020538a; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; RodriguezMaranon MJ, 1996, BIOCHEMISTRY-US, V35, P16378, DOI 10.1021/bi961895o; Schenkman JB, 2003, PHARMACOL THERAPEUT, V97, P139, DOI 10.1016/S0163-7258(02)00327-3; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STRITTMATTER P, J BIOL CHEM, V247, P7188; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2000, J INORG BIOCHEM, V81, P183, DOI 10.1016/S0162-0134(00)00102-1; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	40	34	35	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36809	36818		10.1074/jbc.M406055200	http://dx.doi.org/10.1074/jbc.M406055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194706	hybrid			2022-12-25	WOS:000223453600083
J	Lima, WF; Nichols, JG; Wu, HJ; Prakash, TP; Migawa, MT; Wyrzykiewicz, TK; Bhat, B; Crooke, ST				Lima, WF; Nichols, JG; Wu, HJ; Prakash, TP; Migawa, MT; Wyrzykiewicz, TK; Bhat, B; Crooke, ST			Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; WOBBLE POSITION; DNA; OLIGONUCLEOTIDES; SPECIFICITY; BINDING; DUPLEX; ENZYME	Human RNase H1 cleaves RNA exclusively in an RNA/DNA duplex; neither double-strand DNA nor double-strand RNA is a viable substrate. Previous studies suggest that the helical geometry and sugar conformation of the DNA and RNA may play a role in the selective recognition of the heteroduplex substrate by the enzyme. We systematically evaluated the influence of sugar conformation, minor groove bulk, and conformational flexibility of the heteroduplex on enzyme efficiency. Modified nucleotides were introduced into the oligodeoxyribonucleotide at the catalytic site of the heteroduplex and consisted of southern, northern, and eastern biased sugars with and without 2'-substituents, non-hydrogen bonding base modifications, abasic de-oxyribonucleotides, intranucleotide hydrocarbon linkers, and a ganciclovir-modified deoxyribonucleotide. Heteroduplexes containing modifications exhibiting strong northern or southern conformational biases with and without a bulky 2'-substituent were cleaved at a significantly slower rate than the unmodified substrate. Modifications imparting the greatest degree of conformational flexibility were the poorest substrates, resulting in dramatically slower cleavage rates for the ribonucleotide opposing the modification and the surrounding ribonucleotides. Finally, modified heteroduplexes containing modifications predicted to mimic the sugar pucker and conformational flexibility of the deoxyribonucleotide exhibited cleavage rates comparable with those of the unmodified substrate. These data suggest that sugar conformation, minor groove width, and the relative positions of the intra- and internucleotide phosphates are the crucial determinants in the selective recognition of the heteroduplex substrate by human RNase H1 and offer immediate steps to improve the performance of DNA-like antisense oligonucleotides.	ISIS Pharmaceut, Dept Biol Mol & Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Biol Mol & Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						AGRIS PF, 1992, J AM CHEM SOC, V114, P2652, DOI 10.1021/ja00033a044; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CERRITELLI SM, 1995, RNA, V1, P246; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; CONNOLLY BA, 1989, NUCLEIC ACIDS RES, V17, P4957, DOI 10.1093/nar/17.13.4957; Crouch R. J., 1982, NUCLEASES, P211; Denisov AY, 2001, NUCLEIC ACIDS RES, V29, P4284, DOI 10.1093/nar/29.21.4284; Detmer K, 2003, EUR J ORG CHEM, V2003, P1837, DOI 10.1002/ejoc.200200641; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; Egli M, 1996, BIOCHEMISTRY-US, V35, P8489, DOI 10.1021/bi9607214; Evans SP, 1999, J MOL BIOL, V291, P661, DOI 10.1006/jmbi.1999.2971; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FRASER A, 1993, J HETEROCYCLIC CHEM, V30, P1277, DOI 10.1002/jhet.5570300518; HALL KB, 1991, BIOCHEMISTRY-US, V30, P1795, DOI 10.1021/bi00221a010; Ikeda H, 1998, NUCLEIC ACIDS RES, V26, P2237, DOI 10.1093/nar/26.9.2237; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; Kanazaki M, 2000, J AM CHEM SOC, V122, P2422, DOI 10.1021/ja9934706; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 2003, J BIOL CHEM, V278, P49860, DOI 10.1074/jbc.M306543200; Lima WF, 2003, J BIOL CHEM, V278, P14906, DOI 10.1074/jbc.M211279200; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Saenger W., 1984, PRINCIPLES NUCL ACID; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; SCHMIT C, 1994, BIOORG MED CHEM LETT, V4, P1969, DOI 10.1016/S0960-894X(01)80545-X; SIERZPUTOWSKAGRACZ H, 1987, J AM CHEM SOC, V109, P7171, DOI 10.1021/ja00257a044; SPROAT BS, 1985, OLIGONUCLEOTIDE SYNT, P83; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TRAPANE TL, 1994, J AM CHEM SOC, V116, P8412, DOI 10.1021/ja00097a077; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Waga T, 1996, NUCLEOS NUCLEOT, V15, P287, DOI 10.1080/07328319608002385; Wilds CJ, 2000, NUCLEIC ACIDS RES, V28, P3625, DOI 10.1093/nar/28.18.3625; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YONEDA N, 1991, TETRAHEDRON, V47, P5329, DOI 10.1016/S0040-4020(01)80970-4; ZHU LM, 1995, BIOCHEMISTRY-US, V34, P2372, DOI 10.1021/bi00007a033	52	65	69	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36317	36326		10.1074/jbc.M405035200	http://dx.doi.org/10.1074/jbc.M405035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205459	hybrid			2022-12-25	WOS:000223453600021
J	Ro, HA; Carson, JH				Ro, HA; Carson, JH			pH microdomains in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-II; FLUORESCENCE CORRELATION SPECTROSCOPY; RENAL PROXIMAL TUBULE; H+ ION MOBILITY; NA+/H+ EXCHANGER; EXTRACELLULAR PH; EPITHELIAL-CELL; CYTOPLASMIC PH; TRANSPORT; COTRANSPORTER	Oligodendrocytes (OLs) are cells that produce myelin in the central nervous system. Here we use ratiometric pH indicator dye to analyze intracellular pH in OLs in culture. The results reveal alkaline microdomains, which predominate in the perikaryon and proximal dendrites, and acidic microdomains, which predominate in distal dendrites. Spatial nonuniformity of pH is generated by differential subcellular distribution of Na+/H+ exchanger (NHE), which is localized in a punctate distribution in the perikaryon and proximal processes, Na+/HCO3- cotransporter (NBC), which is localized in a punctate distribution in distal dendrites, and carbonic anhydrase isotype II (CAII), which is colocalized with either NHE or NBC. Inhibition of NHE activity by amiloride inhibits regeneration of alkaline microdomains after cytoplasmic acidification, whereas the inhibition of CAII activity with ethoxyzolamide inhibits acidification of dendrites. Fluorescence correlation spectroscopy analysis of CAII microinjected into OLs reveals freely diffusing protein throughout the cell as well as protein associated predominantly with NHE in the perikaryon and predominantly with NBC in the dendrites. Alkaline and acidic microdomains could be generated by transport metabolons consisting of CAII associated with NHE or NBC, respectively. This study provides the first evidence for pH microdomains in cells and describes a mechanism for how they are generated.	Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA	University of Connecticut	Carson, JH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA.	jcarson@nso2.uchc.edu			NCRR NIH HHS [RR 13186] Funding Source: Medline; NINDS NIH HHS [NS 15190] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR013186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015190, R56NS015190] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; Boussouf A, 2000, J NEUROSCI RES, V59, P731, DOI 10.1002/(SICI)1097-4547(20000315)59:6<731::AID-JNR5>3.0.CO;2-G; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; Cammer W, 1996, J NEUROIMMUNOL, V67, P131; CAMMER W, 1995, J NEUROSCI RES, V40, P451, DOI 10.1002/jnr.490400404; Cammer WB, 2000, EXS, V90, P475; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1988, NEUROSCIENCE, V27, P941, DOI 10.1016/0306-4522(88)90197-2; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; IVES HE, 1983, J BIOL CHEM, V258, P3513; Joseph D, 2002, AM J PHYSIOL-LUNG C, V282, pL675, DOI 10.1152/ajplung.00330.2001; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Levin MK, 2004, DIFFERENTIATION, V72, P1, DOI 10.1111/j.1432-0436.2004.07201002.x; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; MOODY W, 1984, ANNU REV NEUROSCI, V7, P257; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; Ridderstrale Y, 2000, J NEUROCYTOL, V29, P263, DOI 10.1023/A:1026571704422; ROBELLO M, 1994, NEUROSCIENCE, V61, P833, DOI 10.1016/0306-4522(94)90406-5; SMART SC, 1995, J AM COLL CARDIOL, V26, P1365, DOI 10.1016/0735-1097(95)00326-6; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2001, JOP, V2, P165; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, AM J PHYSIOL-CELL PH, V283, pC1522, DOI 10.1152/ajpcell.00115.2002; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Vaughan-Jones RD, 2002, J PHYSIOL-LONDON, V541, P139, DOI 10.1113/jphysiol.2001.013267; VERKMAN AS, 1987, BIOPHYS J, V51, P533, DOI 10.1016/S0006-3495(87)83379-9; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; VOET D, 1995, BIOCHEMISTRY-US, P353; WALZ W, 1989, CAN J PHYSIOL PHARM, V67, P577, DOI 10.1139/y89-092; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	39	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37115	37123		10.1074/jbc.M403099200	http://dx.doi.org/10.1074/jbc.M403099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192115	hybrid			2022-12-25	WOS:000223453600115
J	Bichsel, SJ; Tamaskovic, R; Stegert, MR; Hemmings, BA				Bichsel, SJ; Tamaskovic, R; Stegert, MR; Hemmings, BA			Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase by the hMOB1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; MITOTIC EXIT-NETWORK; CELL-CYCLE; GENE ENCODES; YEAST; MORPHOGENESIS; DROSOPHILA; MOB1; DBF2; PHOSPHORYLATION	NDR (nuclear Dbf2-related) kinase belongs to a family of kinases that is highly conserved throughout the eukaryotic world. We showed previously that NDR is regulated by phosphorylation and by the Ca2+-binding protein, S100B. The budding yeast relatives of Homo sapiens NDR, Cbk1, and Dbf2, were shown to interact with Mob2 (Mps one binder 2) and Mob1, respectively. This interaction is required for the activity and biological function of these kinases. In this study, we show that hMOB1, the closest relative of yeast Mob1 and Mob2, stimulates NDR kinase activity and interacts with NDR both in vivo and in vitro. The point mutations of highly conserved residues within the N-terminal domain of NDR reduced NDR kinase activity as well as human MOB1 binding. A novel feature of NDR kinases is an insert within the catalytic domain between subdomains VII and VIII. The amino acid sequence within this insert shows a high basic amino acid content in all of the kinases of the NDR family known to interact with MOB proteins. We show that this sequence is autoinhibitory, and our data indicate that the binding of human MOB1 to the N-terminal domain of NDR induces the release of this autoinhibition.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	Brian.Hemmings@fmi.ch						Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; Balasubramanian MK, 1998, GENETICS, V149, P1265; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Cong JL, 2001, DEVELOPMENT, V128, P2793; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Du LL, 2002, MOL BIOL CELL, V13, P503, DOI 10.1091/mbc.01-07-0365; Durrenberger F, 1999, MOL GEN GENET, V261, P281, DOI 10.1007/s004380050968; Geng W, 2000, GENETICS, V156, P1817; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hirata D, 2002, EMBO J, V21, P4863, DOI 10.1093/emboj/cdf495; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; Ponchon L, 2004, J MOL BIOL, V337, P167, DOI 10.1016/j.jmb.2004.01.010; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2004, J BIOL CHEM, V279, P23806, DOI 10.1074/jbc.M402472200; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	38	109	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35228	35235		10.1074/jbc.M404542200	http://dx.doi.org/10.1074/jbc.M404542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197186	hybrid			2022-12-25	WOS:000223303400013
J	Suntharalingam, M; Alcazar-Roman, A; Wente, SR				Suntharalingam, M; Alcazar-Roman, A; Wente, SR			Nuclear export of the yeast mRNA-binding protein Nab2 is linked to a direct interaction with Gfd1 and to Gle1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX STRUCTURE; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC FIBRILS; PROTEOMIC ANALYSIS; NUCLEOPORIN RIP1P; DOCKING SITE; GENE; TRANSCRIPTION; NUP116P	Nuclear export of mRNA is mediated by interactions between soluble factors and nuclear pore complex (NPC) proteins. In Saccharomyces cerevisiae, Nab2 is an essential RNA-binding protein that shuttles between the nucleus and cytoplasm. The mechanism for trafficking of Nab2-bound mRNA through the NPC has not been defined. Gle1 is also required for mRNA export, and Gle1 interactions with NPC proteins, the RNA helicase Dbp5, and Gfd1 have been reported. Here we report that Nab2, Gfd1, and Gle1 associate in a complex. By using immobilized recombinant Gfd1, Nab2 was isolated from total yeast lysate. A similar biochemical assay with immobilized recombinant Nab2 resulted in coisolation of Gfd1 and Gle1. A Nab2-Gfd1 complex was also identified by coimmunoprecipitation from yeast lysates. In vitro binding assays with recombinant proteins revealed a direct association between Nab2 and Gfd1, and two-hybrid assays delineated Gfd1 binding to the N-terminal Nab2 domain. This N-terminal Nab2 domain is distinct from its RNA binding domains suggesting Nab2 could bind Gfd1 and RNA simultaneously. As Nab2 export was blocked in a gle1 mutant at the restrictive temperature, we propose a model wherein Gfd1 serves as a bridging factor between Gle1 and Nab2-bound mRNA during export.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Wente, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, 3120 MRBIII,465 21st Ave S, Nashville, TN 37232 USA.	susan.wente@vanderbilt.edu		Alcazar-Roman, Abel R./0000-0003-1668-1886	NIGMS NIH HHS [GM51219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051219, R01GM051219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Blevins MB, 2003, J BIOL CHEM, V278, P20979, DOI 10.1074/jbc.M302061200; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hector RE, 2002, EMBO J, V21, P1800, DOI 10.1093/emboj/21.7.1800; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; James P, 1996, GENETICS, V144, P1425; Kendirgi F, 2003, J CELL BIOL, V160, P1029, DOI 10.1083/jcb.200211081; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Marfatia KA, 2003, J BIOL CHEM, V278, P6731, DOI 10.1074/jbc.M207571200; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Rayala HJ, 2004, MOL CELL PROTEOMICS, V3, P145, DOI 10.1074/mcp.M300106-MCP200; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strawn LA, 2004, NAT CELL BIOL, V6, P197, DOI 10.1038/ncb1097; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhao J, 2002, EMBO J, V21, P1177, DOI 10.1093/emboj/21.5.1177	61	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35384	35391		10.1074/jbc.M402044200	http://dx.doi.org/10.1074/jbc.M402044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208322	hybrid			2022-12-25	WOS:000223303400032
J	Geoffroy, K; Wiernsperger, N; Lagarde, M; El Bawab, S				Geoffroy, K; Wiernsperger, N; Lagarde, M; El Bawab, S			Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SPHINGOSINE 1-PHOSPHATE; INDUCE APOPTOSIS; GROWTH-FACTOR; STRESS; METABOLISM; ACTIVATION; ALBUMIN; SPHINGOSINE-1-PHOSPHATE; INTERLEUKIN-1-BETA	Advanced glycation end-products ( AGE) are generated by chronic hyperglycaemia and may cause diabetic microvascular complications such as diabetic nephropathy. Many factors influence the development of diabetic nephropathy; however, dysregulation of mesangial cell ( MC) proliferation appears to play an early and crucial role. In this study, we investigated the effects of AGE on rat MC proliferation and the involvement of sphingolipids in the AGE response. Results show a bimodal effect of AGE on MC proliferation. Thus, low AGE concentrations (< 1 mu M) induced a significant increase (+26%) of MC proliferation, whereas higher concentrations (10 mu M) markedly reduced it (-24%). In parallel, AGE exerted biphasic effects on neutral ceramidase expression and activity. Low AGE concentrations increased neutral ceramidase activity and expression, whereas high AGE concentrations showed opposite effects. Surprisingly, neutral ceramidase modulation did not result in changes of ceramide levels. However, the AGE (10 mu M)-inhibitory effect on MC proliferation was associated with accumulation of sphingosine and was specifically prevented by blocking glucosylceramide synthesis, suggesting that the high AGE concentration effects are mediated by sphingosine and/or glycolipids. On the other hand, treatment of cells with low AGE concentrations led to an increase of sphingosine kinase activity and sphingosine-1-phosphate production that drove the increase of MC proliferation. Interestingly, in glomeruli isolated from streptozotocin-diabetic rats, a time-dependent modulation of ceramidase activity was observed as compared with controls. These results suggest that AGE regulate MC growth by modulating neutral ceramidase and endogenous sphingolipids.	Inst Natl Sci Appl, INSERM, UMR 585, MERCK Sante,Diabet Microangiopathy Res Unit, F-69621 Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon	El Bawab, S (corresponding author), Inst Natl Sci Appl, INSERM, UMR 585, MERCK Sante,Diabet Microangiopathy Res Unit, Bldg L Pasteur,20 Ave A Einstein, F-69621 Villeurbanne, France.	samer.elbawab@merck.fr						Bendayan M, 1998, KIDNEY INT, V54, P438, DOI 10.1046/j.1523-1755.1998.00030.x; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; CHAO R, 1992, J BIOL CHEM, V267, P23459; Chen S, 2001, KIDNEY INT, V59, P673, DOI 10.1046/j.1523-1755.2001.059002673.x; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; DANZE PM, 1987, CLIN CHIM ACTA, V166, P143, DOI 10.1016/0009-8981(87)90416-5; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Feliers D, 2002, DIABETES, V51, P3290, DOI 10.2337/diabetes.51.11.3290; Forbes JM, 2003, J AM SOC NEPHROL, V14, pS254, DOI 10.1097/01.ASN.0000077413.41276.17; Franzen R, 2002, FEBS LETT, V532, P441, DOI 10.1016/S0014-5793(02)03727-4; Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; Hanafusa N, 2002, NEPHROL DIAL TRANSPL, V17, P580, DOI 10.1093/ndt/17.4.580; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; KENNEDY L, 1981, DIABETOLOGIA, V21, P94; Kim YS, 2001, J LAB CLIN MED, V138, P59, DOI 10.1067/mlc.2001.115494; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Ling X, 2001, LAB INVEST, V81, P845, DOI 10.1038/labinvest.3780294; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mene P, 2001, J NEPHROL, V14, P198; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Natalizio A, 2001, BIOCHEM BIOPH RES CO, V281, P78, DOI 10.1006/bbrc.2001.4295; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Perry DK, 2000, METHOD ENZYMOL, V312, P22; RASCH R, 1983, DIABETOLOGIA, V25, P280, DOI 10.1007/BF00279944; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Sakurai S, 2003, J AM SOC NEPHROL, V14, pS259, DOI 10.1097/01.ASN.0000077414.59717.74; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sugiyama S, 1996, NEPHROL DIAL TRANSPL, V11, P91; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; Tettamanti G, 2003, BIOCHIMIE, V85, P423, DOI 10.1016/S0300-9084(03)00047-6; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; WU VY, 1995, BIOCHEM BIOPH RES CO, V207, P521, DOI 10.1006/bbrc.1995.1219; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139	58	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34343	34352		10.1074/jbc.M403273200	http://dx.doi.org/10.1074/jbc.M403273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184394	hybrid			2022-12-25	WOS:000223134800034
J	Dimcheff, DE; Faasse, MA; McAtee, FJ; Portis, JL				Dimcheff, DE; Faasse, MA; McAtee, FJ; Portis, JL			Endoplasmic reticulum (ER) stress induced by a neurovirulent mouse retrovirus is associated with prolonged BiP binding and retention of a viral protein in the ER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; INDUCED SPONGIFORM NEURODEGENERATION; C RNA VIRUS; CELL-DEATH; ECOTROPIC RETROVIRUS; OXIDATIVE STRESS; GENE-EXPRESSION; PRION PROTEIN; WILD MICE; DISEASE	Some murine retroviruses cause a spongiform neurodegenerative disease exhibiting pathology resembling that observed in transmissible spongiform encephalopathies. The neurovirulence of these "spongiogenic retroviruses" is determined by the sequence of their respective envelope proteins, although the mechanisms of neurotoxicity are not understood. We have studied a highly neurovirulent virus called FrCas(E) that causes a rapidly progressive form of this disease. Recently, transcriptional markers of endoplasmic reticulum ( ER) stress were detected during the early preclinical period in the brains of FrCas(E)-infected mice. In contrast, ER stress was not observed in mice infected with an avirulent virus, F43, which carries a different envelope gene, suggesting a role for ER stress in disease pathogenesis. Here we have examined in NIH 3T3 cells the cause of this cellular stress response. The envelope protein of F43 bound BiP, a major ER chaperone, transiently and was processed normally through the secretory pathway. In contrast, the envelope protein of FrCasE bound to BiP for a prolonged period, was retained in the ER, and was degraded by the proteasome. Furthermore, engagement of the FrCasE envelope protein by ER quality control pathways resulted in decreased steady-state levels of this protein, relative to that of F43, both in NIH 3T3 cells and in the brains of infected mice. Thus, the ER stress induced by FrCasE appears to be initiated by inefficient folding of its viral envelope protein, suggesting that the neurodegenerative disease caused by this virus represents a protein misfolding disorder.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Portis, JL (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	jportis@nih.gov	Faasse, Mark/AAD-4049-2019	Faasse, Mark/0000-0002-1524-7239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000086, Z01AI000086] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ANDREWS JM, 1974, J NEUROPATH EXP NEUR, V33, P285, DOI 10.1097/00005072-197404000-00007; Askovic S, 2000, J VIROL, V74, P465, DOI 10.1128/JVI.74.1.465-473.2000; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CZUB S, 1994, LAB INVEST, V70, P711; DESGROSEILLERS L, 1984, J VIROL, V52, P356, DOI 10.1128/JVI.52.2.356-363.1984; Dimcheff DE, 2003, J VIROL, V77, P12617, DOI 10.1128/JVI.77.23.12617-12629.2003; Fujisawa R, 1998, J VIROL, V72, P5619, DOI 10.1128/JVI.72.7.5619-5625.1998; GARDNER MB, 1973, JNCI-J NATL CANCER I, V51, P1243, DOI 10.1093/jnci/51.4.1243; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim HT, 2004, LAB INVEST, V84, P816, DOI 10.1038/labinvest.3700104; KLEMENT V, 1976, J NATL CANCER I, V57, P1169, DOI 10.1093/jnci/57.5.1169; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Liu N, 2002, J NEUROVIROL, V8, P318, DOI 10.1080/13550280290100699; Lobigs M, 2003, IMMUNOL CELL BIOL, V81, P217, DOI 10.1046/j.1440-1711.2003.01161.x; LUI N, 2004, J NEUROVIROL, V10, P189; LYNCH WP, 1991, NEURON, V7, P365, DOI 10.1016/0896-6273(91)90289-C; Lynch WP, 1996, J VIROL, V70, P8896, DOI 10.1128/JVI.70.12.8896-8907.1996; LYNCH WP, 1995, J VIROL, V69, P1408, DOI 10.1128/JVI.69.3.1408-1419.1995; Lynch WP, 2000, J VIROL, V74, P1558, DOI 10.1128/JVI.74.3.1558-1565.2000; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MASUDA M, 1992, J VIROL, V66, P2798, DOI 10.1128/JVI.66.5.2798-2806.1992; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mollace V, 2001, TRENDS NEUROSCI, V24, P411, DOI 10.1016/S0166-2236(00)01819-1; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; PORTIS JL, 1990, J VIROL, V64, P1648, DOI 10.1128/JVI.64.4.1648-1656.1990; Portis JL, 2001, ADV VIRUS RES, V56, P3, DOI 10.1016/S0065-3527(01)56003-0; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SHIKOVA E, 1993, J VIROL, V67, P1137, DOI 10.1128/JVI.67.3.1137-1147.1993; Swanstrom R., 1997, P263; SWARZ JR, 1981, NEUROPATH APPL NEURO, V7, P365, DOI 10.1111/j.1365-2990.1981.tb00239.x; SZUREK PF, 1990, J VIROL, V64, P467, DOI 10.1128/JVI.64.2.467-475.1990; Terro F, 2002, J NEUROSCI RES, V69, P530, DOI 10.1002/jnr.10312; Tobisawa S, 2003, BIOCHEM BIOPH RES CO, V303, P496, DOI 10.1016/S0006-291X(03)00353-X; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wilt SG, 2000, J NEUROSCI RES, V62, P440, DOI 10.1002/1097-4547(20001101)62:3<440::AID-JNR14>3.3.CO;2-D; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	57	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33782	33790		10.1074/jbc.M403304200	http://dx.doi.org/10.1074/jbc.M403304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178688	hybrid			2022-12-25	WOS:000223039700087
J	Khurana, B; Kristie, TM				Khurana, B; Kristie, TM			A protein sequestering system reveals control of cellular programs by the transcriptional coactivator HCF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; LEUCINE-ZIPPER PROTEIN; DNA-DAMAGE; C1 HCF; VP16-INDUCED COMPLEX; ATF3 INDUCTION; HOMEO DOMAIN; VP16; PROLIFERATION; FAMILY	The mammalian transcriptional coactivator HCF-1 is a critical component of the multiprotein herpes simplex virus immediate early gene enhancer core complex. The protein has also been implicated in basic cellular processes such as cell-cycle progression, transcriptional coactivation, and mRNA processing. Functions have been attributed to HCF-1 primarily from analyses of protein-protein interactions and from the cell-cycle-arrested phenotype of an HCF-1 temperature-sensitive mutant. However, neither the mechanisms involved nor specific cellular transcriptional targets have been identified. As the protein is essential for cell viability and proliferation, a genetic system was developed to specifically sequester the nuclear factor in the cell cytoplasm in a regulated manner. This approach exhibits no significant cell toxicity yet clearly demonstrates the requirement of available nuclear HCF-1 for herpes simplex virus immediate early gene expression during productive infection. Additionally, cellular transcriptional events were identified that contribute to understanding the functions ascribed to the protein and implicate the protein in events that impact the regulation of critical cellular processes.	NIH, Viral Dis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kristie, TM (corresponding author), NIH, Viral Dis Lab, Bldg 4,Rm 131,4 Ctr Dr, Bethesda, MD 20892 USA.	thomas_Kristie@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000711, Z01AI000711] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe T, 2003, BIOCHEM BIOPH RES CO, V310, P1168, DOI 10.1016/j.bbrc.2003.09.143; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Beverdam A, 2002, GENESIS, V34, P221, DOI 10.1002/gene.10156; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Finch JS, 2002, J CANCER RES CLIN, V128, P3, DOI 10.1007/s00432-001-0298-x; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nicolas M, 2003, BIOCHEM J, V371, P265, DOI 10.1042/BJ20021166; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; Roizman Bernard, 1996, P1043; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Scarr RB, 2002, ONCOGENE, V21, P5245, DOI 10.1038/sj.onc.1205647; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; SYVAOJA JE, 1990, BIOESSAYS, V12, P533, DOI 10.1002/bies.950121106; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; VOGEL JL, 2001, ENCY MOL MED, V1, P732; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	59	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33673	33683		10.1074/jbc.M401255200	http://dx.doi.org/10.1074/jbc.M401255200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190068	hybrid			2022-12-25	WOS:000223039700077
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; RNA INTERFERENCE; C ISOFORMS; ACTIVATION; PHOSPHORYLATION; BINDING; RAF; IDENTIFICATION; MEK; INHIBITION	The phosphatidylinositide-3-OH kinase/3-phosphoinositide-dependent protein kinase-1 (PDK1)/Akt and the Raf/mitogen-activated protein kinase (MAPK/ERK) kinase (MEK)/mitogen-activated protein kinase ( MAPK) pathways have central roles in the regulation of cell survival and proliferation. Despite their importance, however, the cross-talk between these two pathways has not been fully understood. Here we report that PDK1 promotes MAPK activation in a MEK-dependent manner. In vitro kinase assay revealed that the direct targets of PDK1 in the MAPK pathway were the upstream MAPK kinases MEK1 and MEK2. The identified PDK1 phosphorylation sites in MEK1 and MEK2 are Ser(222) and Ser(226), respectively, and are known to be essential for full activation. To date, these sites are thought to be phosphorylated by Raf kinases. However, PDK1 gene silencing using small interference RNA demonstrates that PDK1 is associated with maintaining the steady-state phosphorylated MEK level and cell growth. The small interference RNA-mediated down-regulation of PDK1 attenuated maximum MEK and MAPK activities but could not prolong MAPK signaling duration. Stable and transient expression of constitutively active MEK1 overcame these effects. Our results suggest a novel cross-talk between the phosphatidylinositide-3-OH kinase/PDK1/Akt pathway and the Raf/MEK/MAPK pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33759	33767		10.1074/jbc.M402055200	http://dx.doi.org/10.1074/jbc.M402055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175348	hybrid			2022-12-25	WOS:000223039700085
J	Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E				Li, JF; Wang, FL; Protopopov, A; Malyukova, A; Kashuba, V; Minna, JD; Lerman, MI; Klein, G; Zabarovsky, E			Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene	ONCOGENE			English	Article						tumor suppressor gene; human chromosome 3p; gene mutation; lung cancer; renal carcinoma; prostate cancer	HUMAN-CHROMOSOME 3P21.3; HOMOZYGOUS DELETION REGION; EPIGENETIC INACTIVATION; CELL-GROWTH; LUNG; CANCER; SEARCH; BREAST; CONSTRUCTION; INHIBITION	RASSF1A, a major member of the RASSF1 gene family, is silenced by promoter methylation at a high frequency in a large number of human solid tumors. Controlled expression of RASSF1A reverts the tumorigenic phenotype of several human cancer cell lines. Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. In the small-cell lung cancer (SCLC) line U2020, only RASSF1A has shown growth inhibitory activity in vitro, while in the prostate cell line LNCaP and renal cell carcinoma (RCC) line KRC/Y both RASSF1A and RASSF1C showed similar (approximately 90%) suppressing activity in vitro. Both RASSF1C and RASSF1A suppressed the tumorigenicity of the KRC/Y RCC cell line in SCID mice. Mutations, deletions and loss of expression of RASSF1A and RASSF1C transgenes were identified in all 15 grown SCID tumors. In contrast, the mutant RASSF1A containing Cys65Arg and Val211Ala had reduced growth suppression activity both in vitro and in vivo and did not show any further changes in four grown SCID tumors. In addition, RASSF1C was shown to induce cell cycle arrest in KRC/Y cells. These results strongly imply that like RASSF1A the RASSF1C gene could serve a tumor suppressor function.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-03143 Kiev, Ukraine; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX 75390 USA; Natl Canc Inst, Canc Causing Genes Sect, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden	Karolinska Institutet; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Karolinska Institutet	Li, JF (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden.	jinli@ki.se; eugzab@ki.se	Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Vladimir I/0000-0001-9416-8282; 	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA 70907, N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Ji L, 2002, CANCER RES, V62, P2715; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li JF, 1999, FEBS LETT, V451, P289, DOI 10.1016/S0014-5793(99)00598-0; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Protopopov A, 2003, CANCER RES, V63, P404; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rubins JB, 2001, J LAB CLIN MED, V138, P101, DOI 10.1067/mlc.2001.116591; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; SENCHENKO VN, 2004, IN PRESS ONCOGENE; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tse C, 2002, CANCER RES, V62, P542; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wei MH, 1996, CANCER RES, V56, P1487; Xiang RH, 2002, CANCER RES, V62, P2637; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P6319, DOI 10.1093/nar/18.21.6319; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	31	43	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5941	5949		10.1038/sj.onc.1207789	http://dx.doi.org/10.1038/sj.onc.1207789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208682				2022-12-25	WOS:000222941100008
J	Wang, L; Lin, HK; Hu, YC; Xie, SZ; Yang, L; Chang, CS				Wang, L; Lin, HK; Hu, YC; Xie, SZ; Yang, L; Chang, CS			Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; KINASE 3-BETA; CANCER CELLS; CYCLIN D1; C-MYC; NUCLEAR EXPORT; HEAT-SHOCK; PHOSPHORYLATION; INSULIN; INHIBITION	Androgens play important roles in the growth of normal prostate and prostate cancer via binding to the androgen receptor (AR). In addition to androgens, AR activity can also be modulated by selective growth factors and/or kinases. Here we report a new kinase signaling pathway by showing that AR transactivation was repressed by wild type glycogen synthase kinase 3beta (GSK3beta) or constitutively active S9A-GSK3beta in a dose-dependent manner. In contrast, the catalytically inactive kinase mutant GSK3beta showed little effect on the AR transactivation. The suppression of AR transactivation by GSK3beta was abolished by the GSK3beta inhibitor lithium chloride. The in vitro kinase assay showed that GSK3beta prefers to phosphorylate the amino terminus of AR that may lead to the suppression of activation function 1 activity located in the NH2-terminal region of AR. GSK3beta interrupted the interaction between the NH2 and COOH termini of AR, and overexpression of the constitutively active form of GSK3beta, S9A-GSK3beta, reduced the androgen-induced prostate cancer cell growth in stably transfected CWR22R cells. Together, our data demonstrated that GSK3beta may function as a repressor to suppress AR-mediated transactivation and cell growth, which may provide a new strategy to modulate the AR-mediated prostate cancer growth.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Hu, Yueh-Chiang/0000-0002-7992-0525; Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Balaji KC, 1997, UROLOGY, V50, P1007, DOI 10.1016/S0090-4295(97)00390-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Cohen P, 1978, Biochem Soc Symp, P69; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; CULIG Z, 1995, EUR UROL, V27, P45; CULIG Z, 1994, CANCER RES, V54, P5474; DEGROOT RP, 1993, ONCOGENE, V8, P841; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; KOKONTIS J, 1994, CANCER RES, V54, P1566; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Truica CI, 2000, CANCER RES, V60, P4709; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wen Y, 2000, CANCER RES, V60, P6841; WOODGETT JR, 2001, SCI STKE; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	57	78	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32444	32452		10.1074/jbc.M313963200	http://dx.doi.org/10.1074/jbc.M313963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15178691	hybrid			2022-12-25	WOS:000222849700058
J	Baron, RM; Carvajal, IM; Fredenburgh, LE; Liu, XL; Porrata, Y; Cullivan, ML; Haley, KJ; Sonna, LA; De Sanctis, GT; Ingenito, EP; Perrella, MA				Baron, RM; Carvajal, IM; Fredenburgh, LE; Liu, XL; Porrata, Y; Cullivan, ML; Haley, KJ; Sonna, LA; De Sanctis, GT; Ingenito, EP; Perrella, MA			Nitric oxide synthase-2 down-regulates surfactant protein-B expression and enhances endotoxin-induced lung injury in mice	FASEB JOURNAL			English	Article						acute respiratory distress syndrome; inflammation; cytokines; gene transcription; LPS	RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR MACROPHAGES; EPITHELIAL-CELLS; GENE-EXPRESSION; MOUSE; DYSFUNCTION; SEPSIS; ARDS	Acute respiratory distress syndrome ( ARDS) is a life-threatening ailment characterized by severe lung injury involving inflammatory cell recruitment to the lung, cytokine production, surfactant dysfunction, and up-regulation of nitric oxide synthase 2 (NOS2) resulting in nitric oxide ( NO) production. We hypothesized that NO production from NOS2 expressed in lung parenchymal cells in a murine model of ARDS would correlate with abnormal surfactant function and reduced surfactant protein-B (SP-B) expression. Pulmonary responses to nebulized endotoxin (lipopolysaccharide, LPS) were evaluated in wild-type (WT) mice, NOS2 null (-/-) mice, and NOS2-chimeric animals derived from bone marrow transplantation. NOS2(-/-) animals exhibited significantly less physiologic lung dysfunction and loss of SP-B expression than did WT animals. However, lung neutrophil recruitment and bronchoalveolar lavage cytokine levels did not significantly differ between NOS2(-/-) and WT animals. Chimeric animals for NOS2 exhibited the phenotype of the recipient and therefore demonstrated that parenchymal production of NOS2 is critical for the development of LPS-induced lung injury. Furthermore, administration of NO donors, independent of cytokine stimulation, decreased SP-B promoter activity and mRNA expression in mouse lung epithelial cells. This study demonstrates that expression of NOS2 in lung epithelial cells is critical for the development of lung injury and mediates surfactant dysfunction independent of NOS2 inflammatory cell expression and cytokine production.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; USA, Environm Med Res Inst, Thermal & Mt Med Div, Natick, MA 01760 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Liu, Xiaoli/0000-0003-2904-4413	NHLBI NIH HHS [HL60788] Funding Source: Medline; NIAID NIH HHS [AI054465] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI054465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRKHANIAN JD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P315, DOI 10.1016/0005-2760(93)90188-F; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bhandari V, 2003, FRONT BIOSCI-LANDMRK, V8, pE361, DOI 10.2741/1086; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; CIFUENTES J, 1995, J APPL PHYSIOL, V78, P1800, DOI 10.1152/jappl.1995.78.5.1800; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Frank JA, 2003, CRIT CARE, V7, P233, DOI 10.1186/cc1829; GODLESKI JJ, 1972, J EXP MED, V136, P630, DOI 10.1084/jem.136.3.630; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; Hallman M, 1996, SEMIN PERINATOL, V20, P173, DOI 10.1016/S0146-0005(96)80046-2; Hallman M, 1996, J APPL PHYSIOL, V80, P2035, DOI 10.1152/jappl.1996.80.6.2035; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531, DOI 10.1164/ajrccm/140.2.531; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Ingenito EP, 1999, J APPL PHYSIOL, V86, P1702, DOI 10.1152/jappl.1999.86.5.1702; Ingenito EP, 2001, AM J RESP CELL MOL, V25, P35, DOI 10.1165/ajrcmb.25.1.4021; Kobayashi A, 1998, CHEST, V113, P1632, DOI 10.1378/chest.113.6.1632; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kristof AS, 1998, AM J RESP CRIT CARE, V158, P1883, DOI 10.1164/ajrccm.158.6.9802100; Layne MD, 2001, FASEB J, V15, P2733, DOI 10.1096/fj.01-0374fje; LUTCHEN KR, 1993, J APPL PHYSIOL, V75, P478, DOI 10.1152/jappl.1993.75.1.478; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mark L, 1999, AM J PHYSIOL-LUNG C, V276, pL491, DOI 10.1152/ajplung.1999.276.3.L491; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; POSSMAYER F, 1990, AM REV RESPIR DIS, V142, P749, DOI 10.1164/ajrccm/142.4.749; Pryhuber GS, 1996, AM J PHYSIOL-LUNG C, V270, pL714, DOI 10.1152/ajplung.1996.270.5.L714; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; Salinas D, 2003, AM J PHYSIOL-LUNG C, V285, pL1153, DOI 10.1152/ajplung.00084.2003; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Shanley TP, 2002, CRIT CARE MED, V30, P1960, DOI 10.1097/00003246-200209000-00003; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; VASANTHI VR, 2002, AM J PHYSIOL-LUNG C, V282, pL872; Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017; Wang LF, 2001, BIOCHEM BIOPH RES CO, V283, P694, DOI 10.1006/bbrc.2001.4842; Wang ZD, 1998, AM J RESP CRIT CARE, V158, P28, DOI 10.1164/ajrccm.158.1.9709041; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029	40	25	29	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1276	+		10.1096/fj.04-1518fje	http://dx.doi.org/10.1096/fj.04-1518fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208261				2022-12-25	WOS:000222327500003
J	Phillips, JD; Whitby, FG; Warby, CA; Labbe, P; Yang, C; Pflugrath, JW; Ferrara, JD; Robinson, H; Kushner, JP; Hill, CP				Phillips, JD; Whitby, FG; Warby, CA; Labbe, P; Yang, C; Pflugrath, JW; Ferrara, JD; Robinson, H; Kushner, JP; Hill, CP			Crystal structure of the oxygen-dependant coproporphyrinogen oxidase (Hem13p) of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III OXIDASE; HEREDITARY COPROPORPHYRIA; ESCHERICHIA-COLI; ACTIVE-SITE; IN-HOUSE; CHOLESTEROL OXIDASE; RADICAL SAM; T-FOLD; SEQUENCE; PROTEIN	Coproporphyrinogen oxidase (CPO) is an essential enzyme that catalyzes the sixth step of the heme biosynthetic pathway. Unusually for heme biosynthetic enzymes, CPO exists in two evolutionarily and mechanistically distinct families, with eukaryotes and some prokaryotes employing members of the highly conserved oxygen-dependent CPO family. Here, we report the crystal structure of the oxygen-dependent CPO from Saccharomyces cerevisiae (Hem13p), which was determined by optimized sulfur anomalous scattering and refined to a resolution of 2.0 Angstrom. The protein adopts a novel structure that is quite different from predicted models and features a central flat seven-stranded antiparallel sheet that is flanked by helices. The dimeric assembly, which is seen in different crystal forms, is formed by packing of helices and a short isolated strand that forms a beta-ladder with its counterpart in the partner subunit. The deep active-site cleft is lined by conserved residues and has been captured in open and closed conformations in two different crystal forms. A substratesized cavity is completely buried in the closed conformation by the similar to8-Angstrom movement of a helix that forms a lid over the active site. The structure therefore suggests residues that likely play critical roles in catalysis and explains the deleterious effect of many of the mutations associated with the disease hereditary coproporphyria.	Univ Utah, Sch Med, Dept Med, Div Hematol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Paris 07, CNRS, Inst Jacques Monod, Lab Biochim Porphyrines, F-75251 Paris 5, France; Rigaku Mol Struct Corp, The Woodlands, TX 77381 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; United States Department of Energy (DOE); Brookhaven National Laboratory	Hill, CP (corresponding author), Univ Utah, Sch Med, Dept Med, Div Hematol, 4C416 SOM,50 N 1900 E, Salt Lake City, UT 84132 USA.	chris@biochem.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020503, R37DK020503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056775] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20503, R01 DK020503] Funding Source: Medline; NIGMS NIH HHS [GM56775, R01 GM056775] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGARD M, 1989, EUR J BIOCHEM, V181, P417, DOI 10.1111/j.1432-1033.1989.tb14741.x; Breckau D, 2003, J BIOL CHEM, V278, P46625, DOI 10.1074/jbc.M308553200; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; Colloc'h N, 2002, FEBS LETT, V526, P5, DOI 10.1016/S0014-5793(02)03123-X; Colloc'h N, 2000, PROTEINS, V39, P142, DOI 10.1002/(SICI)1097-0134(20000501)39:2<142::AID-PROT4>3.0.CO;2-X; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Daimon M, 1997, HUM GENET, V99, P199, DOI 10.1007/s004390050338; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P2125, DOI 10.1107/S0907444903018973; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P393, DOI 10.1107/S0907444902020917; ELDER GH, 1978, BIOCHEM J, V169, P205, DOI 10.1042/bj1690205; ELDER GH, 1978, BIOCHEM J, V172, P345, DOI 10.1042/bj1720345; ELDER GH, 1978, BIOCHEM J, V169, P215, DOI 10.1042/bj1690215; FUJITA H, 1994, HUM MOL GENET, V3, P1807, DOI 10.1093/hmg/3.10.1807; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Jones MA, 2002, J BIOCHEM, V131, P201, DOI 10.1093/oxfordjournals.jbchem.a003088; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohno H, 1996, BBA-PROTEIN STRUCT M, V1292, P156, DOI 10.1016/0167-4838(95)00188-3; KRUSE E, 1995, PLANTA, V196, P796, DOI 10.1007/BF01106776; Labbe P, 1997, METHOD ENZYMOL, V281, P367; LAMORIL J, 1995, HUM MOL GENET, V4, P275, DOI 10.1093/hmg/4.2.275; Lamoril J, 2001, AM J HUM GENET, V68, P1130, DOI 10.1086/320118; Lamoril J, 1997, HUM MUTAT, V9, P78; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; Lash TD, 2002, BIOORG MED CHEM LETT, V12, P451, DOI 10.1016/S0960-894X(01)00774-0; Lash TD, 2001, J ORG CHEM, V66, P3753, DOI 10.1021/jo001697+; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Martasek P, 1998, SEMIN LIVER DIS, V18, P25, DOI 10.1055/s-2007-1007137; MARTASEK P, 1994, HUM MOL GENET, V3, P477, DOI 10.1093/hmg/3.3.477; Martasek P, 1997, CELL MOL BIOL, V43, P47; Medlock AE, 1996, J BIOL CHEM, V271, P32507, DOI 10.1074/jbc.271.51.32507; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsen JG, 2004, ACTA CRYSTALLOGR D, V60, P618, DOI 10.1107/S0907444904002598; Olsen JG, 2004, ACTA CRYSTALLOGR D, V60, P250, DOI 10.1107/S0907444903025927; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phillips JD, 2003, EMBO J, V22, P6225, DOI 10.1093/emboj/cdg606; Ramagopal UA, 2003, ACTA CRYSTALLOGR D, V59, P868, DOI 10.1107/S0907444903005663; Rosipal R, 1999, HUM MUTAT, V13, P44, DOI 10.1002/(SICI)1098-1004(1999)13:1<44::AID-HUMU5>3.0.CO;2-Q; SANO S, 1966, J BIOL CHEM, V241, P5276; SANO S, 1961, J BIOL CHEM, V236, P1173; Schreiber WE, 1997, HUM MUTAT, V10, P196; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wiman A, 2002, J HUM GENET, V47, P407, DOI 10.1007/s100380200059; Yang C, 2003, ACTA CRYSTALLOGR D, V59, P1943, DOI 10.1107/S0907444903018547; Yoshinaga T, 1997, METHOD ENZYMOL, V281, P355; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	55	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38960	38968		10.1074/jbc.M406050200	http://dx.doi.org/10.1074/jbc.M406050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15194705	hybrid			2022-12-25	WOS:000223684100110
J	Bassett, MH; Suzuki, T; Sasano, H; de Vries, CJM; Jimenez, PT; Carr, BR; Rainey, WE				Bassett, MH; Suzuki, T; Sasano, H; de Vries, CJM; Jimenez, PT; Carr, BR; Rainey, WE			The orphan nuclear receptor NGFIB regulates transcription of 3 beta-hydroxysteroid dehydrogenase - Implications for the control of adrenal functional zonation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN-FETAL; STEROID 21-HYDROXYLASE; FACTOR-I; EXPRESSION; CELLS; GENE; ISOMERASE; CORTEX; STEROIDOGENESIS	3beta-Hydroxysteroid dehydrogenase type 2 (HSD3B2) is a steroid-metabolizing enzyme that is essential for adrenal production of mineralocorticoids and glucocorticoids. Thus, HSD3B2 is expressed at high levels in the glomerulosa and fasciculata, where these steroids are produced. In contrast, the production of dehydroepiandrosterone ( DHEA) and DHEA sulfate in the adrenal reticularis is inversely correlated with the expression of HSD3B2. The reasons for the zonal expression of HSD3B2 are not known but represent an important aspect in the biochemical zonation of the adrenal. Using microarray, real time reverse transcriptase- PCR, immunohistochemistry, and HSD3B2 promoter analysis, we demonstrate that the NGFIB family of nuclear hormone receptors plays a critical part in the regulation of HSD3B2 transcription and may play an important role in the functional zonation of the adrenal gland. Microarray analysis of cortisol-versus DHEA sulfate-producing adrenal tissue demonstrated that NGIFB paralleled expression of HSD3B2 with expression much higher in cortisol-producing adrenal tissue; this observation was also demonstrated using real time reverse transcriptase-PCR analysis. In addition, immunohistochemistry confirmed that within adult and fetal adrenal gland NGFIB expression paralleled expression of HSD3B2. Transient transfections into H295R adrenal cells demonstrated that NGFIB family members enhanced HSD3B2 reporter activity but had no effect on a 17alpha-hydroxylase (CYP17) promoter construct. Deletion and mutational analyses of the 5'-flanking region of the HSD3B2 gene identified a consensus NGFIB response element that bound NGFIB in mobility shift assays. Infection of cultured human adrenal cells with adenovirus-containing NGFIB increased cortisol production by 8-fold and increased expression of HSD3B2 mRNA 26-fold over that observed in mock-infected cells. In primary cultures of adrenal cells, ACTH, an activator of HSD3B2, rapidly induced expression of NGFIB. These results suggest that NGFIB plays a crucial role in adrenal zonation by regulating HSD3B2 gene transcription.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, Dallas, TX 75390 USA; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808575, Japan; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tohoku University; University of Amsterdam; Academic Medical Center Amsterdam	Rainey, WE (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	braine@mednet.swmed.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007190, P50HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043140, R01DK069950, R29DK043140] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11149, T32-HD07190] Funding Source: Medline; NIDDK NIH HHS [DK069950, DK43140] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Bandoh S, 1997, J NEUROENDOCRINOL, V9, P3, DOI 10.1046/j.1365-2826.1997.00571.x; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; Bassett MH, 2002, J MOL ENDOCRINOL, V28, P125, DOI 10.1677/jme.0.0280125; Bird IM, 1998, ENDOCR RES, V24, P345, DOI 10.3109/07435809809032614; BYRNE GC, 1986, J CLIN ENDOCR METAB, V62, P413, DOI 10.1210/jcem-62-2-413; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DOODY KM, 1990, ENDOCRINOLOGY, V126, P2487, DOI 10.1210/endo-126-5-2487; Endoh A, 1996, J CLIN ENDOCR METAB, V81, P3558, DOI 10.1210/jc.81.10.3558; FUJIEDA K, 1982, J CLIN ENDOCR METAB, V54, P89, DOI 10.1210/jcem-54-1-89; Gell JS, 1998, J CLIN ENDOCR METAB, V83, P3695, DOI 10.1210/jc.83.10.3695; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Jimenez P, 2003, ENDOCRINOLOGY, V144, P4285, DOI 10.1210/en.2003-0472; LACK EE, 1990, PATHOLOGY ADRENAL GL, P1; Le Roy C, 2000, ENDOCRINOLOGY, V141, P1599, DOI 10.1210/en.141.5.1599; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; LU L, 2004, IN PRESS J CLIN ENDO; Maruyama K, 1998, INT J ONCOL, V12, P1237; MASON JI, 1993, J STEROID BIOCHEM, V47, P151, DOI 10.1016/0960-0760(93)90069-9; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Narasaka T, 2001, MOL CELL ENDOCRINOL, V174, P111, DOI 10.1016/S0303-7207(00)00445-7; PARKER CR, 1995, ENDOCR RES, V21, P69, DOI 10.3109/07435809509030422; Rainey WE, 2001, J ENDOCRINOL, V171, P209, DOI 10.1677/joe.0.1710209; SASANO H, 1990, ENDOCR PATHOL, V1, P739; Sasano Hironobu, 1990, Endocr Pathol, V1, P94, DOI 10.1007/BF02915624; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SIMONIAN MH, 1984, J CLIN ENDOCR METAB, V59, P643, DOI 10.1210/jcem-59-4-643; STANKOVIC AK, 1994, MOL CELL ENDOCRINOL, V99, P145, DOI 10.1016/0303-7207(94)90002-7; Suzuki T, 2000, CLIN ENDOCRINOL, V53, P739, DOI 10.1046/j.1365-2265.2000.01144.x; Wang WY, 2001, MOL CELL ENDOCRINOL, V173, P127, DOI 10.1016/S0303-7207(00)00404-4; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	39	106	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37622	37630		10.1074/jbc.M405431200	http://dx.doi.org/10.1074/jbc.M405431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208301	hybrid			2022-12-25	WOS:000223554600053
J	Hu, WH; Mo, XM; Walters, WM; Brambilla, R; Bethea, JR				Hu, WH; Mo, XM; Walters, WM; Brambilla, R; Bethea, JR			TNAP, a novel repressor of NF-kappa B-inducing kinase, suppresses NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; GENE-EXPRESSION; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; TRANSACTIVATION DOMAIN; MEDIATED DELIVERY; NF-KAPPA-B2 P100; CELL ACTIVATION; BINDING-SITE	NF-kappaB- inducing kinase (NIK) has been implicated as an essential component of NF-kappaB activation. However, the regulatory mechanism of NIK signaling remains elusive. We have identified a novel NIK interacting protein, TNAP ( for (T) under bar RAFs and (N) under bar IK- (a) under bar ssociated (p) under bar rotein). In mammalian cells, TNAP physically interacts with NIK, TRAF2, and TRAF3 but not IKK1 or IKK2. TNAP specifically inhibits NF-kappaB activation induced by tumor necrosis factor (TNF)-alpha, TNF receptor 1, TRADD, RIP, TRAF2, and NIK but does not affect IKK1- and IKK2-mediated NF-kappaB activation. Knockdown of TNAP by lentiviral-mediated small interference RNA potentiates TNF-alpha-induced NF-kappaB activation. TNAP suppresses NIK kinase activity and subsequently reduces p100 processing, p65 phosphorylation, and IkappaBalpha degradation. These data suggest that TNAP is a repressor of NIK activity and regulates both the classical and alternative NF-kappaB signaling pathways.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Max Delbrueck Ctr Mol Med, D-13122 Berlin, Germany	University of Miami; University of Miami; University of Miami; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bethea, JR (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terr, Miami, FL 33136 USA.	jbethea@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037130] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37130] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Bethea JR, 1997, J IMMUNOL, V158, P5815; Bethea JR, 1998, J NEUROSCI, V18, P3251; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; ERMEULEN L, 2003, EMBO J, V22, P1313; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Haxhinasto SA, 2004, J BIOL CHEM, V279, P2575, DOI 10.1074/jbc.M310628200; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x; Hu WH, 1999, J NEUROTRAUM, V16, P85, DOI 10.1089/neu.1999.16.85; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li XG, 2001, BIOCHEM BIOPH RES CO, V286, P587, DOI 10.1006/bbrc.2001.5442; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsumoto M, 2002, J IMMUNOL, V169, P1151, DOI 10.4049/jimmunol.169.3.1151; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Miyamoto S, 2004, MOL CELL, V13, P763, DOI 10.1016/S1097-2765(04)00158-3; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nho CW, 2004, J BIOL CHEM, V279, P26019, DOI 10.1074/jbc.M309022200; Nishitsuji H, 2004, MICROBES INFECT, V6, P76, DOI 10.1016/j.micinf.2003.10.009; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Perkins ND, 2003, ONCOGENE, V22, P7553, DOI 10.1038/sj.onc.1207139; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; TAKADA Y, 2004, J BIOL CHEM; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van den Haute C, 2003, HUM GENE THER, V14, P1799, DOI 10.1089/104303403322611809; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xie P, 2004, J EXP MED, V199, P661, DOI 10.1084/jem.20031255; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	96	29	31	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35975	35983		10.1074/jbc.M405699200	http://dx.doi.org/10.1074/jbc.M405699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208311	hybrid			2022-12-25	WOS:000223303400099
J	Stojanovic, A; Stitham, J; Hwa, J				Stojanovic, A; Stitham, J; Hwa, J			Critical role of transmembrane segment zinc binding in the structure and function of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; CRYSTAL-STRUCTURE; THERMAL-STABILITY; WATER-MOLECULES; DISULFIDE BOND; METHYL-GROUP; GLYCINE 121; HELICES 3; A-BETA; AGGREGATION	Zinc deficiency and retinitis pigmentosa are both important factors resulting in retinal dysfunction and night blindness. In this study, we address the critical biochemical and structural relevance of zinc ions in rhodopsin and examine whether zinc deficiency can lead to rhodopsin dysfunction. We report the identification of a high-affinity zinc coordination site within the transmembrane domain of rhodopsin, coordinated by the side chains of two highly conserved residues, Glu(122) in transmembrane helix III and His(211) in transmembrane helix V. We also demonstrate that this zinc coordination is critical for rhodopsin folding, 11-cis-retinal binding, and the stability of the chromophore-receptor interaction, defects of which are observed in retinitis pigmentosa. Furthermore, a cluster of retinitis pigmentosa mutations is localized within and around this zinc binding site. Based on these studies, we believe that improvement in zinc binding to rhodopsin at this site within the transmembrane domain may be a pharmacological approach for the treatment of select retinitis pigmentosa mutations. Transmembrane coordination of zinc may also be an important common principle across G-protein-coupled receptors.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Cardiol Sect, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Hwa, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	John.Hwa@Dartmouth.edu						Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Crow JP, 1997, J NEUROCHEM, V69, P1936; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Finefrock AE, 2003, J AM GERIATR SOC, V51, P1143, DOI 10.1046/j.1532-5415.2003.51368.x; Furutani Y, 2003, BIOCHEMISTRY-US, V42, P9619, DOI 10.1021/bi034592k; Gerlach LO, 2003, BIOCHEMISTRY-US, V42, P710, DOI 10.1021/bi0264770; Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han M, 1996, J BIOL CHEM, V271, P32330, DOI 10.1074/jbc.271.50.32330; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; Han M, 1998, BIOCHEMISTRY-US, V37, P538, DOI 10.1021/bi972060w; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Lynch T, 2000, EXP GERONTOL, V35, P445, DOI 10.1016/S0531-5565(00)00112-1; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Schetz JA, 1997, J NEUROCHEM, V68, P1990; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHUSTER TA, 1992, BIOCHEM J, V282, P123, DOI 10.1042/bj2820123; Stojanovic A, 2003, J BIOL CHEM, V278, P39020, DOI 10.1074/jbc.M303625200; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; Swaminath G, 2002, MOL PHARMACOL, V61, P65, DOI 10.1124/mol.61.1.65; TAM SW, 1976, BIOCHEM BIOPH RES CO, V72, P302, DOI 10.1016/0006-291X(76)90994-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H	46	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35932	35941		10.1074/jbc.M403821200	http://dx.doi.org/10.1074/jbc.M403821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194703	hybrid			2022-12-25	WOS:000223303400094
J	Borras, C; Esteve, JM; Vina, JR; Sastre, J; Vina, J; Pallardo, FV				Borras, C; Esteve, JM; Vina, JR; Sastre, J; Vina, J; Pallardo, FV			Glutathione regulates telomerase activity in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; MITOCHONDRIAL-DNA; OXIDATIVE DAMAGE; CANCER-CELLS; IN-VITRO; PROTEINS	Changes in telomerase activity have been associated either with cancer, when activity is increased, or with cell cycle arrest when it is decreased. We report that glutathione, a physiological antioxidant present at high intracellular concentrations, regulates telomerase activity in cells in culture. Telomerase activity increases in 3T3 fibroblasts before exponential cell growth. The peak of telomerase activity takes place 24 h after plating and coincides with the maximum levels of glutathione in the cells. When cells are treated with buthionine sulfoximine, which decreases glutathione levels in cells, telomerase activity decreases by 60%, and cell growth is delayed. Glutathione depletion inhibits expression of E2F4 and Id2, which regulate the cell cycle. When glutathione levels are restored after incubation with glutathione monoethylester, telomerase activity and the cell cycle-related proteins return to control values. To discover the effect of glutathione redox status on the telomerase multicomplex structure, we incubated protein extracts from fibroblasts with different glutathione redox buffers. Telomerase activity is maximal under reduced conditions i.e. when the reduced/oxidized glutathione ratio is high. Consequently glutathione concentration parallels telomerase activity. These results underscore the main role of glutathione in the control of telomerase activity and of the cell cycle.	Univ Valencia, Dept Physiol, Sch Med, Valencia 46010, Spain; Univ Valencia, Sch Med, Dept Biochem, Valencia 46010, Spain	University of Valencia; University of Valencia	Pallardo, FV (corresponding author), Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain.	pallardo@uv.es	Pallardo, Federico V./T-1156-2017; Vina, Jose/AAB-3069-2021; Viña, Juan R/ABE-5698-2021; borras, consuelo/Y-3407-2019	Pallardo, Federico V./0000-0003-3715-1980; Vina, Jose/0000-0001-9709-0089; Viña, Juan R/0000-0002-4035-3615; borras, consuelo/0000-0003-4606-1792				BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2526; Coppe JP, 2003, EXP CELL RES, V285, P131, DOI 10.1016/S0014-4827(03)00014-4; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hayakawa N, 1999, BIOCHEMISTRY-US, V38, P11501, DOI 10.1021/bi982829k; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KORNBERG A, 1969, SCIENCE, V163, P1410, DOI 10.1126/science.163.3874.1410; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; VINA J, 1978, BIOCHEM J, V170, P711, DOI 10.1042/bj1700711; Xiao XD, 2003, EXP MOL PATHOL, V75, P238, DOI 10.1016/S0014-4800(03)00092-3	21	61	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34332	34335		10.1074/jbc.M402425200	http://dx.doi.org/10.1074/jbc.M402425200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184392	hybrid			2022-12-25	WOS:000223134800032
J	Ji, CY; Wang, Y; Guo, XP; Hartson, S; Jiang, HB				Ji, CY; Wang, Y; Guo, XP; Hartson, S; Jiang, HB			A pattern recognition serine proteinase triggers the prophenoloxidase activation cascade in the tobacco hornworm, Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO ACTIVATION; PRO-PHENOL-OXIDASE; INSECT; HEMOLYMPH; EXPRESSION; PROTEASE; DEFENSE; TOLL; MELANIZATION; COLEOPTERAN	A serine proteinase cascade in insect hemolymph mediates prophenoloxidase activation, a defense mechanism against pathogen or parasite infection. Little is known regarding its initiating proteinase or how this enzyme is activated in response to invading microorganisms. We have isolated from the tobacco hornworm, Manduca sexta, a cDNA encoding a modular protein designated hemolymph proteinase 14 ( HP14). It contains five low density lipoprotein receptor class A repeats, a Sushi domain, a unique Cys-rich region, and a proteinase-catalytic domain. The HP14 mRNA exists in fat body and hemocytes of the naive larvae, and its level increases significantly at 24 h after a bacterial challenge. We expressed proHP14 with a carboxyl-terminal hexahistidine tag in a baculovirus/insect cell system and detected the recombinant protein in two forms. The 87-kDa protein was primarily intracellular, whereas the 75-kDa form was present in the medium. Interaction with peptidoglycan resulted in proteolytic processing of the purified zymogen and generation of an amidase activity. Supplementation of hemolymph with proHP14 greatly enhanced prophenoloxidase activation in response to Micrococcus luteus. These data suggest that proHP14 is a pattern recognition protein that binds to bacteria and autoactivates and triggers the prophenoloxidase activation system in the hemolymph of M. sexta.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Oklahoma State University System; Oklahoma State University - Stillwater	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA.	haobo@okstate.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashida Masaaki, 1998, P135; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Chou KC, 1997, J PROTEIN CHEM, V16, P765, DOI 10.1023/A:1026363816730; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Danielli A, 2000, P NATL ACAD SCI USA, V97, P7136, DOI 10.1073/pnas.97.13.7136; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gorman MJ, 2000, GENE, V251, P9, DOI 10.1016/S0378-1119(00)00181-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Iwanaga S, 1998, J BIOCHEM, V123, P1; Ji CY, 2003, PROTEIN EXPRES PURIF, V29, P235, DOI 10.1016/S1046-5928(03)00020-2; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; Yau YH, 2001, ANTIMICROB AGENTS CH, V45, P2820, DOI 10.1128/AAC.45.10.2820-2825.2001; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7	37	64	70	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34101	34106		10.1074/jbc.M404584200	http://dx.doi.org/10.1074/jbc.M404584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190055	hybrid			2022-12-25	WOS:000223134800006
J	Nishimura, H; Kim, E; Nakanishi, T; Baba, T				Nishimura, H; Kim, E; Nakanishi, T; Baba, T			Possible function of the ADAM1a/ADAM2 fertilin complex in the appearance of ADAM3 on the sperm surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; POLY(A) POLYMERASE; EGG FUSION; 2 ISOFORMS; PROTEIN; CYRITESTIN; FAMILY; GENE; SPERMATOGENESIS; LOCALIZATION	In mouse, two different isoforms of ADAM1 (fertilin alpha), ADAM1a and ADAM1b, are produced in the testis. ADAM1a is localized within the endoplasmic reticulum of testicular germ cells, whereas epididymal sperm contain only ADAM1b on the plasma membrane. In this study, we show that the loss of ADAM1a results in the male infertility because of the severely impaired ability of sperm to migrate from the uterus into the oviduct through the uterotubal junction. However, epididymal sperm of ADAM1a-deficient mice were capable of fertilizing cumulus-intact, zona pellucida-intact eggs in vitro despite the delayed dispersal of cumulus cells and the reduced adhesion/binding to the zona pellucida. Among testis (sperm)-specific proteins examined, only the level of ADAM3 (cyritestin) was strongly reduced in ADAM1a-deficient mouse sperm. Moreover, the appearance of ADAM3 on the sperm surface was dependent on the formation of a fertilin protein complex between ADAM1a and ADAM2 (fertilin beta) in testicular germ cells, although no direct interaction between the fertilin complex and ADAM3 was found. These results suggest that ADAM1a/ADAM2 fertilin may be implicated in the selective transport of specific sperm proteins including ADAM3 from the endoplasmic reticulum of testicular germ cells onto the cell surface. These proteins then can participate in sperm migration into the oviduct, the dispersal of cumulus cells, and sperm binding to the zona pellucida.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.	acroman@sakura.cc.tsukuba.ac.jp						Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; BABA T, 1994, J BIOL CHEM, V269, P10133; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kim E, 2003, BIOCHEM BIOPH RES CO, V304, P313, DOI 10.1016/S0006-291X(03)00588-6; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Nishimura H, 2002, GENE, V291, P67, DOI 10.1016/S0378-1119(02)00540-1; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; SUAREZ SS, 1987, BIOL REPROD, V36, P203, DOI 10.1095/biolreprod36.1.203; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Waters SI, 1997, BIOL REPROD, V56, P1245, DOI 10.1095/biolreprod56.5.1245; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	35	144	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34957	34962		10.1074/jbc.M314249200	http://dx.doi.org/10.1074/jbc.M314249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194697	hybrid			2022-12-25	WOS:000223134800107
J	Reszko, AE; Kasumov, T; David, F; Thomas, KR; Jobbins, KA; Cheng, JF; Lopaschuk, GD; Dyck, JRB; Diaz, M; Des Rosiers, C; Stanley, WC; Brunengraber, H				Reszko, AE; Kasumov, T; David, F; Thomas, KR; Jobbins, KA; Cheng, JF; Lopaschuk, GD; Dyck, JRB; Diaz, M; Des Rosiers, C; Stanley, WC; Brunengraber, H			Regulation of Malonyl-CoA concentration and turnover in the normal heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ISCHEMIC-HEART; COENZYME-A; PYRUVATE; MUSCLE; ASSAY	The goal of this study was to test the relationship between malonyl-CoA concentration and its turnover measured in isolated rat hearts perfused with (NaHCO3)-C-13. This turnover is a direct measurement of the flux of acetyl-CoA carboxylation in the intact heart. It also reflects the rate of malonyl-CoA decarboxylation, i.e. the only known fate of malonyl-CoA in the heart. Conditions were selected to result in stable malonyl-CoA concentrations ranging from 1.5 to 5 nmol.g wet weight(-1). The malonyl-CoA concentration was directly correlated with the turnover of malonyl-CoA, ranging from 0.7 to 4.2 nmol.min(-1).g wet weight(-1) (slope = 0.98, r(2) = 0.94). The V-max activities of acetyl-CoA carboxylase and of malonyl-CoA decarboxylase exceeded the rate of malonyl-CoA turnover by 2 orders of magnitude and did not correlate with either concentration or turnover of malonyl-CoA. However, conditions of perfusion that increased acetylCoA supply resulted in higher turnover and concentration, demonstrating that malonyl-CoA turnover is regulated by the supply of acetyl-CoA. The only condition where the activity of malonyl-CoA decarboxylase regulated malonyl-CoA kinetics was when the enzyme was pharmacologically inhibited, resulting in increased malonyl-CoA concentration and decreased turnover. Our data show that, in the absence of enzyme inhibitors, the rate of acetyl-CoA carboxylation is the main determinant of the malonyl-CoA concentration in the heart.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Chugai Pharma USA LLC, San Diego, CA 92121 USA; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Alberta; University of Alberta; Universite de Montreal	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu	Rosiers, Christine Des/O-6285-2014	Cheng, Jie-Fei/0000-0002-5902-0490; Dyck, Jason/0000-0002-7045-2884	NHLBI NIH HHS [P01 HL 74237] Funding Source: Medline; NIDDK NIH HHS [DK 07319, R01 DK 35543] Funding Source: Medline; NIGMS NIH HHS [P50 GM 66309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM066309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; DANIEL WW, 1999, BIOSTATISTICS FDN AN, P633; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; HOLM S, 1979, SCAND J STAT, V6, P65; Kerner J, 2002, ANAL BIOCHEM, V306, P283, DOI 10.1006/abio.2002.5696; Longnus SL, 2001, AM J PHYSIOL-HEART C, V281, pH1561, DOI 10.1152/ajpheart.2001.281.4.H1561; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Panchal AR, 2000, AM J PHYSIOL-HEART C, V279, pH2390, DOI 10.1152/ajpheart.2000.279.5.H2390; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Stanley WC, 1996, J MOL CELL CARDIOL, V28, P905, DOI 10.1006/jmcc.1996.0085; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	18	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34298	34301		10.1074/jbc.M405488200	http://dx.doi.org/10.1074/jbc.M405488200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181001	hybrid			2022-12-25	WOS:000223134800028
J	Santiveri, CM; Perez-Canadillas, JM; Vadivelu, MK; Allen, MD; Rutherford, TJ; Watkins, NA; Bycroft, M				Santiveri, CM; Perez-Canadillas, JM; Vadivelu, MK; Allen, MD; Rutherford, TJ; Watkins, NA; Bycroft, M			NMR structure of the alpha-hemoglobin stabilizing protein - Insights into conformational heterogeneity and binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME RECYCLING FACTOR; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; ALIGNMENT; ISOMERIZATION; DOMAIN; ITK; MACROMOLECULES; PREDICTION; PROGRAM	The structure of alpha-hemoglobin stabilizing protein (AHSP), a molecular chaperone for free alpha-hemoglobin, has been determined using NMR spectroscopy. The protein native state shows conformational heterogeneity attributable to the isomerization of the peptide bond preceding a conserved proline residue. The two equally populated cis and trans forms both adopt an elongated antiparallel three alpha-helix bundle fold but display major differences in the loop between the first two helices and at the C terminus of helix 3. Proline to alanine single point mutation of the residue Pro-30 prevents the cis/trans isomerization. The structure of the P30A mutant is similar to the structure of the trans form of AHSP in the loop 1 region. Both the wild-type AHSP and the P30A mutant bind to alpha-hemoglobin, and the wild-type conformational heterogeneity is quenched upon complex formation, suggesting that just one conformation is the active form. Changes in chemical shift observed upon complex formation identify a binding interface comprising the C terminus of helix 1, the loop 1, and the N terminus of helix 2, with the exposed residues Phe-47 and Tyr-51 being attractive targets for molecular recognition. The characteristics of this interface suggest that AHSP binds at the intradimer alpha(1)beta(1) interface in tetrameric HbA.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, Dept Hematol, Div Transfus Med, Cambridge CB2 2PT, England	University of Cambridge; University of Cambridge	Bycroft, M (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	mb10031@cus.cam.ac.uk	Pérez-Cañadillas, Jose Manuel/AAN-1864-2020; Bycroft, Mark/D-9446-2017; Perez-Canadillas, Jose M/J-5748-2013	Perez-Canadillas, Jose M/0000-0002-8266-5502; Bycroft, Mark/0000-0002-0673-2216; Santiveri, Clara M./0000-0001-6095-7224				Andreotti AH, 2003, BIOCHEMISTRY-US, V42, P9515, DOI 10.1021/bi0350710; Antonini E, 1971, FRONT BIOL, V21, P1; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Breheny PJ, 2003, J AM CHEM SOC, V125, P15706, DOI 10.1021/ja0375380; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kim KK, 2000, EMBO J, V19, P2362, DOI 10.1093/emboj/19.10.2362; Kong Y, 2003, BLOOD, V102, p46A; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lerche MH, 1999, J MAGN RESON, V140, P259, DOI 10.1006/jmre.1999.1820; Luzzatto L, 2002, NATURE, V417, P703, DOI 10.1038/417703a; Mallis RJ, 2002, NAT STRUCT BIOL, V9, P900, DOI 10.1038/nsb864; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nakano H, 2003, J BIOL CHEM, V278, P3427, DOI 10.1074/jbc.M208098200; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERUTZ MF, 1982, NATURE, V295, P535, DOI 10.1038/295535a0; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Song JK, 2003, BIOCHEMISTRY-US, V42, P6380, DOI 10.1021/bi034053f; Toyoda T, 2000, RNA, V6, P1432, DOI 10.1017/S1355838200001060; Viprakasit V, 2004, BLOOD, V103, P3296, DOI 10.1182/blood-2003-11-3957; WUTHRICH K, 1986, NMR PROTEIN NUCL ACI, P263; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g; Yuan XM, 1998, PROTEIN SCI, V7, P2127, DOI 10.1002/pro.5560071009; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	38	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34963	34970		10.1074/jbc.M405016200	http://dx.doi.org/10.1074/jbc.M405016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178680	hybrid			2022-12-25	WOS:000223134800108
J	Voss, AA; Lango, J; Ernest-Russell, M; Morin, D; Pessah, IN				Voss, AA; Lango, J; Ernest-Russell, M; Morin, D; Pessah, IN			Identification of hyperreactive cysteines within ryanodine receptor type 1 by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MALIGNANT HYPERTHERMIA FAMILIES; CENTRAL CORE DISEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; NITRIC-OXIDE; REDOX SENSOR; SULFHYDRYL-REAGENTS; POLYACRYLAMIDE-GELS	The skeletal-type ryanodine receptor (RyR1) undergoes covalent adduction by nitric oxide (NO), redox-induced shifts in cation regulation, and non-covalent interactions driven by the transmembrane redox potential that enable redox sensing. Tight redox regulation of RyR1 is thought to be primarily mediated through highly reactive (hyperreactive) cysteines. Of the 100 cysteines per subunit of RyR1, similar to25-50 are reduced, with 6 - 8 considered hyperreactive. Thus far, only Cys-3635, which undergoes selective adduction by NO, has been identified. In this report, RyR1-enriched junctional sarcoplasmic reticulum is labeled with 7-diethylamino-3(4'-maleimidylphenyl)-4-methylcoumarin (CPM, 1 pmol/mug of protein) in the presence of 10 mM Mg2+, conditions previously shown to selectively label hyperreactive sulfhydryls and eliminate redox sensing. The CPM-adducted RyR1 is separated by gel electrophoresis and subjected to in-gel tryptic digestion. Isolation of CPM-adducted peptides is achieved by analytical and microbore high-performance liquid chromatography utilizing fluorescence and UV detection. Subsequent analysis using two direct and one tandem mass spectrometry methods results in peptide masses and sequence data that, compared with the known primary sequence of RyR1, enable unequivocal identification of CPM-adducted cysteines. This work is the first to directly identify seven hyperreactive cysteines: 1040, 1303, 2436, 2565, 2606, 2611, and 3635 of RyR1. In addition to Cys-3635, the nitrosylation site, six additional cysteines may contribute toward redox regulation of the RyR1 complex.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Pessah, IN (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [2R01 AR 43140] Funding Source: Medline; NIEHS NIH HHS [2P42 ES 04699, 1P01 ES 11269, ES 07059, T32 ES007059] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059, P01ES011269, P42ES004699] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; ALEMAN M, 2004, IN PRESS MUSCLE NERV; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Barone V, 1999, J MED GENET, V36, P115; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brandt A, 1999, HUM MOL GENET, V8, P2055, DOI 10.1093/hmg/8.11.2055; Bull R, 2003, AM J PHYSIOL-CELL PH, V285, pC119, DOI 10.1152/ajpcell.00296.2002; Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4; Donoso P, 2000, BIOPHYS J, V79, P279, DOI 10.1016/S0006-3495(00)76290-4; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Eager KR, 1997, AM J PHYSIOL-CELL PH, V272, pC1908, DOI 10.1152/ajpcell.1997.272.6.C1908; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feng W, 1999, MOL PHARMACOL, V55, P821; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Floyd RA, 1992, ANN NEUROL, V32, P22; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; Ignarro LJ, 2002, J CARDIAC SURG, V17, P301; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; KEATING KE, 1994, HUM MOL GENET, V3, P1855, DOI 10.1093/hmg/3.10.1855; Koesling D, 1999, METHODS, V19, P485, DOI 10.1006/meth.1999.0891; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manning BM, 1998, HUM MUTAT, V11, P45, DOI 10.1002/(SICI)1098-1004(1998)11:1<45::AID-HUMU7>3.0.CO;2-K; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; Ruffert H, 2002, ANAESTHESIST, V51, P904, DOI 10.1007/s00101-002-0390-x; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIGAL E, 1994, ANN NY ACAD SCI, V714, P211, DOI 10.1111/j.1749-6632.1994.tb12046.x; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46	49	66	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34514	34520		10.1074/jbc.M404290200	http://dx.doi.org/10.1074/jbc.M404290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197184	hybrid			2022-12-25	WOS:000223134800054
J	You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM				You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM			Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells	ONCOGENE			English	Article						Wnt signaling; apoptosis; lung cancer	HUMAN COLORECTAL-CANCER; BETA-CATENIN; SURVIVIN EXPRESSION; INDUCED APOPTOSIS; COLON-CARCINOMA; UP-REGULATION; C-MYC; PATHWAY; WNT-2; GENE	In this report, we have demonstrated that Wnt-2 protein is overexpressed in freshly resected human non-small-cell lung cancer (NSCLC) tissues. We have also developed a monoclonal antibody against the N-terminus of human Wnt-2 protein. This monoclonal antibody induces apoptosis in human NSCLC cell lines that overexpress Wnt-2 protein. Incubation of this antibody with normal human airway cells lacking Wnt-2 expression does not induce apoptosis. Wnt-2 signaling blockade by the anti-Wnt-2 antibody is confirmed by downregulation of cytosolic beta-catenin and reduction in TCF-dependent transcriptional activity (TOPFLASH assay). In addition, Wnt-2-specific small interfering RNA (siRNA) treatment in the NSCLC cell line A549 also downregulated cytosolic beta-catenin and induced apoptosis. Moreover, downregulation of an inhibitor of apoptosis family protein, Survivin, was noticed both in the Wnt-2 antibody- and siRNA-treated NSCLC cells, suggesting that inhibition of Wnt-2-mediated signaling induces apoptosis through inactivating Survinin.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; NCI, Off Director, Ctr Canc Res, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet & Gynecol, New York, NY 10032 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1996, CANCER RES, V56, P4320; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; HUGUET EL, 1994, CANCER RES, V54, P2615; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Katoh M, 2001, INT J ONCOL, V19, P1003; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olie RA, 2000, CANCER RES, V60, P2805; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uematsu K, 2003, CANCER RES, V63, P4547; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vider BZ, 1996, ONCOGENE, V12, P153; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang T, 2001, CANCER RES, V61, P8664	38	213	234	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6170	6174		10.1038/sj.onc.1207844	http://dx.doi.org/10.1038/sj.onc.1207844			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208662				2022-12-25	WOS:000223261000017
J	Kakizaki, I; Kojima, K; Takagaki, K; Endo, M; Kannagi, R; Ito, M; Maruo, Y; Sato, H; Yasuda, T; Mita, S; Kimata, K; Itano, N				Kakizaki, I; Kojima, K; Takagaki, K; Endo, M; Kannagi, R; Ito, M; Maruo, Y; Sato, H; Yasuda, T; Mita, S; Kimata, K; Itano, N			A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSIDE; UDP-GLUCURONOSYLTRANSFERASE UGT1A6; MOLECULAR-CLONING; IN-VITRO; PERICELLULAR MATRIX; ACID; EXPRESSION; SULFATE; GROWTH; CELLS	Specific inhibitors of hyaluronan (HA) biosynthesis can be valuable therapeutic agents to prevent cancer invasion and metastasis. We have found previously that 4-methylumbelliferone (MU) inhibits HA synthesis in human skin fibroblasts and in group C Streptococcus. In this paper, the inhibition mechanism in mammalian cells was investigated using rat 3Y1 fibroblasts stably expressing HA synthase (HAS) 2. Exposure of the transfectants to the inhibitor resulted in significant reduction of HA biosynthesis and matrix formation. The evaluation of HAS transcripts and analysis of cell-free HA synthesis demonstrated the post-transcriptional suppression of HAS activity by MU. Most interesting, the post-transcriptional suppression of HAS activity was also observed using p-nitrophenol, a well known substrate for UDP-glucuronyltransferases (UGT). We investigated whether the inhibition was exerted by the glucuronidation of MU using both high pressure liquid chromatography and TLC analyses. The production of MU-glucuronic acid (GlcUA) was consistent with the inhibition of HA synthesis in HAS transfectants. MU-GlcUA was also detected at a similar level in control cells, suggesting that the glucuronidation was mediated by an endogenous UGT. Elevated levels of UGT significantly enhanced the inhibitory effects of MU. In contrast, the inhibition by MU was diminished to the control level when an excess of UDP-GlcUA was added to the cell-free HA synthesis system. We propose a novel mechanism for the MU-mediated inhibition of HA synthesis involving the glucuronidation of MU by endogenous UGT resulting in a depletion of UDP-GlcUA.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Shiga Univ Med Sci, Core Res Evolut Sci & Technol, Japan Sci & Technol Agcy, Shiga, Japan; Shiga Univ Med Sci, Dept Internal Med 2, Shiga, Japan; Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; Shiga Univ Med Sci, Dept Biol, Shiga, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	Hirosaki University; Aichi Cancer Center; Japan Science & Technology Agency (JST); Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Osaka University; Aichi Medical University	Itano, N (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	itano@amugw.aichi-med-u.ac.jp	Kakizaki, Ikuko/AAO-5489-2020; Kannagi, Reiji/Q-6459-2018	Kakizaki, Ikuko/0000-0002-6702-5830; Kannagi, Reiji/0000-0003-4202-2921				AUGUST EM, 1993, ONCOL RES, V5, P415; Bock-Hennig BS, 2002, BIOCHEM PHARMACOL, V63, P123, DOI 10.1016/S0006-2952(01)00833-4; CHICHIBU K, 1989, CLIN CHIM ACTA, V181, P317, DOI 10.1016/0009-8981(89)90237-4; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; ElMaradny E, 1997, HUM REPROD, V12, P1080; ENDO Y, 2000, PROGR TRANSPLANTATIO, P1; GOLDBERG RL, 1983, J BIOL CHEM, V258, P7041; GRESSNER AM, 1991, BIOCHEM PHARMACOL, V42, P1987, DOI 10.1016/0006-2952(91)90599-Z; GRESSNER AM, 1991, EXP MOL PATHOL, V55, P143, DOI 10.1016/0014-4800(91)90049-4; Hanioka N, 2001, J PHARMACEUT BIOMED, V25, P65, DOI 10.1016/S0731-7085(00)00491-X; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Itano N, 1999, CANCER RES, V59, P2499; Ito M, 2002, EUR J CLIN PHARMACOL, V58, P11, DOI 10.1007/s00228-001-0417-2; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; Kakizaki I, 2002, EUR J BIOCHEM, V269, P5066, DOI 10.1046/j.1432-1033.2002.03217.x; Kamst E, 1999, BIOCHEMISTRY-US, V38, P4045, DOI 10.1021/bi982531u; Kanou M, 2002, FUND CLIN PHARMACOL, V16, P513, DOI 10.1046/j.1472-8206.2002.00097.x; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1991, J CELL SCI, V99, P227; Kosaki R, 1999, CANCER RES, V59, P1141; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LEVESQUE H, 1994, ATHEROSCLEROSIS, V105, P51, DOI 10.1016/0021-9150(94)90007-8; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Liu NF, 2001, CANCER RES, V61, P5207; MATUOKA K, 1985, CELL BIOL INT REP, V9, P577, DOI 10.1016/0309-1651(85)90023-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Nakamura T, 1997, BIOCHEM MOL BIOL INT, V43, P263; NAKAMURA T, 1995, BIOCHEM BIOPH RES CO, V208, P470, DOI 10.1006/bbrc.1995.1362; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; PLEBANI M, 1991, CLIN BIOCHEM, V24, P219, DOI 10.1016/0009-9120(91)80013-S; Radominska-Pandya A, 2002, ARCH BIOCHEM BIOPHYS, V399, P37, DOI 10.1006/abbi.2001.2743; Satoh T, 2000, J GASTROEN HEPATOL, V15, P402, DOI 10.1046/j.1440-1746.2000.02164.x; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; SMITH TJ, 1990, J CLIN ENDOCR METAB, V70, P655, DOI 10.1210/jcem-70-3-655; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKEDA S, 1981, J PHARMACOBIO-DYNAM, V4, P724, DOI 10.1248/bpb1978.4.724; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Ueki N, 2000, BBA-MOL CELL RES, V1495, P160, DOI 10.1016/S0167-4889(99)00161-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; ZAHAREVITZ DW, 1993, BIOCHEM MOL BIOL INT, V31, P627; ZIMMERMAN CL, 1991, J CHROMATOGR-BIOMED, V563, P83, DOI 10.1016/0378-4347(91)80279-L	54	202	206	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33281	33289		10.1074/jbc.M405918200	http://dx.doi.org/10.1074/jbc.M405918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190064	hybrid			2022-12-25	WOS:000223039700034
J	Turner, LJ; Nicholls, S; Hall, A				Turner, LJ; Nicholls, S; Hall, A			The activity of the Plexin-A1 receptor is regulated by Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; INHIBITORY GUIDANCE CUE; BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; AXON GUIDANCE; SEMAPHORIN RECEPTOR; ACTIVATING RHO; GTPASES; CDC42; AUTOINHIBITION	Plexins constitute a large family of transmembrane proteins that act as receptors for the semaphorin family of ligands. They are best known for their role in growth cone guidance, although they also are widely expressed outside the nervous system. Plexins are thought to control axon guidance by modifying the growth cone cytoskeleton, and Rho GTPases have been strongly implicated in this response. However, the exact contribution of Rho proteins is unclear. Sema3A/Plexin-A1-induced growth cone collapse, for example, requires Rac activity, which is a surprising result given that this GTPase is usually associated with membrane protrusions. We show here that Sema3A-induced collapse of COS-7 cells expressing Plexin-A1 also requires Rac but not Rho activity and that the cytoplasmic tail of Plexin-A1 interacts directly with activated Rac. However, collapse induced by a constitutively activated version of Plexin-A1 does not require Rac. We propose a novel function for Rac, namely that it acts upstream of Plexin-A1 during semaphoring-induced collapse, to regulate the activity of the receptor.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, Cell Biol Unit, Canc Res UK,Oncogene & Signal Transduct Grp, London WC1E 6BT, England	University of London; University College London; Cancer Research UK; University of London; University College London	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk						Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Challacombe JF, 1996, J CELL SCI, V109, P2031; Challacombe JF, 1997, J NEUROSCI, V17, P3085; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eickholt BJ, 1997, MOL CELL NEUROSCI, V9, P358, DOI 10.1006/mcne.1997.0636; Fan XP, 2003, NEURON, V40, P113, DOI 10.1016/S0896-6273(03)00591-9; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jin Z, 1997, J NEUROSCI, V17, P6256; Jurney WM, 2002, J NEUROSCI, V22, P6019; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TANAKA E, 1995, J CELL BIOL, V128, P127, DOI 10.1083/jcb.128.1.127; Tu H, 1999, MOL CELL BIOL, V19, P602; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Williamson T, 1996, P NATL ACAD SCI USA, V93, P15221, DOI 10.1073/pnas.93.26.15221; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng JQ, 1996, J NEUROSCI, V16, P1140	51	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33199	33205		10.1074/jbc.M402943200	http://dx.doi.org/10.1074/jbc.M402943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15187088	hybrid			2022-12-25	WOS:000223039700024
J	Duvvuri, M; Gong, YP; Chatterji, D; Krise, JP				Duvvuri, M; Gong, YP; Chatterji, D; Krise, JP			Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMES; DRUGS; LIPOPHILICITY; MITOCHONDRIA; DISPOSITION; DOXORUBICIN	A number of organelles contained within mammalian cells have been implicated in the selective sequestration of chemical entities including drug molecules. Specifically, weakly basic molecules have been shown to selectively associate with either the mitochondrial compartment or lysosomes; however, the structural basis for this differentiation has not been understood. To investigate this, we have identified a series of seven weakly basic compounds, all with pK(alpha) near neutrality, which have different sequestration sites within the multidrug-resistant HL-60 human leukemic cell line. Three of the compounds were selectively sequestered into the mitochondria of the cells, whereas the remainder were predominantly localized within lysosomes. Using specific chemical inhibitors to disrupt either mitochondrial or lysosomal accumulation capacity, we demonstrated that accumulation of these compounds into respective organelles are not competitive processes. Comparison of the permeability characteristics of these compounds as a function of pH revealed striking differences that correlate with the intracellular sequestration site. Only those compounds with significantly reduced permeability in the ionized state relative to the un-ionized state had the capacity to accumulate within lysosomes. Alternatively, those compounds with relatively pH-insensitive permeability selectively accumulated into mitochondria. Using novel quantitative assays for assaying drug accumulation into subcellular organelles, we demonstrated a correlation between these permeability characteristics and the lysosomal versus mitochondrial accumulation capacity of these compounds. Together, these results suggest that the selective accumulations of weakly basic compounds in either lysosomes and mitochondria occur via exclusive pathways governed by a unique permeability parameter.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Krise, JP (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.	krise@ku.edu						Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Binaschi M., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P113, DOI 10.2174/1568011013354723; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Diettrich O, 1998, FEBS LETT, V441, P369, DOI 10.1016/S0014-5793(98)01578-6; Duvvuri M, 2004, PHARM RES-DORDR, V21, P26, DOI 10.1023/B:PHAM.0000012148.12516.3f; FORD T, 1994, ANAL BIOCHEM, V220, P360, DOI 10.1006/abio.1994.1350; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P483; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Moriyama Y, 1996, J EXP BIOL, V199, P1447; Reymond F, 1999, CHEM-EUR J, V5, P39, DOI 10.1002/(SICI)1521-3765(19990104)5:1<39::AID-CHEM39>3.3.CO;2-V; Rivory LP, 1996, CANCER CHEMOTH PHARM, V38, P439, DOI 10.1007/s002800050508; Rottenberg H, 1979, Methods Enzymol, V55, P547; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; SKOVSGAARD T, 1990, TRANSPORT MULTIDRUG, P209; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100	19	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32367	32372		10.1074/jbc.M400735200	http://dx.doi.org/10.1074/jbc.M400735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15181006	Green Published, hybrid			2022-12-25	WOS:000222849700049
J	Darash-Yahana, M; Pikarsky, E; Abramovitch, R; Zeira, E; Pal, B; Karplus, R; Beider, K; Avniel, S; Kasem, S; Galun, E; Peled, A				Darash-Yahana, M; Pikarsky, E; Abramovitch, R; Zeira, E; Pal, B; Karplus, R; Beider, K; Avniel, S; Kasem, S; Galun, E; Peled, A			Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis	FASEB JOURNAL			English	Article						chemokine receptor; prostate tumors	CHEMOKINE RECEPTOR CXCR4; CELL-DERIVED FACTOR-1-ALPHA; PROSTATE-CANCER METASTASIS; NOD/SCID MICE; BONE-MARROW; FACTOR-I; ENDOTHELIAL-CELLS; MOLECULAR-BASIS; OVARIAN-CANCER; T-CELLS	Hormone refractory metastatic prostate cancer remains an incurable disease. We found that high expression levels of the chemokine receptor CXCR4 correlated with the presence of metastatic disease in prostate cancer patients. Positive staining for CXCL12, the ligand for CXCR4, was mainly present in the tumor-associated blood vessels and basal cell hyperplasia. Subcutaneous xenografts of PC3 and 22Rv1 prostate tumors that overexpressed CXCR4 in NOD/SCID mice were two- to threefold larger in volume and weight vs. controls. Moreover, blood vessel density, functionality, invasiveness of tumors into the surrounding tissues, and metastasis to the lymph node and lung were significantly increased in these tumors. Neutralizing the interactions of CXCL12/CXCR4 in vivo with CXCR4 specific antibodies inhibited the CXCR4-dependent tumor growth and vascularization. In vitro, CXCL12 induced the proliferation and VEGF secretion but not migration of PC3 and 22Rv1 cells overexpressing CXCR4. Similar effects of CXCR4 overexpression on tumor growth in vivo were also noted in two breast cancer lines, suggesting that the observed effect of CXCR4 is not unique to prostate tumor cells. Thus high levels of the chemokine receptor CXCR4 induce a more aggressive phenotype in prostate cancer cells and identify CXCR4 as a potential therapeutic target in advanced cases of metastatic prostate cancer.	Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, MRI Lab, HBRC, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Peled, A (corresponding author), Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.	peled@hadassah.org.il	pikarsky, eli/GXV-7099-2022; Galun, Eithan/AAD-9117-2022	Galun, Eithan/0000-0002-6243-6702; pikarsky, eli/0000-0003-4186-7105				Abramovitch R, 1998, MAGN RESON MED, V39, P813, DOI 10.1002/mrm.1910390519; Abramovitch R, 1999, CANCER RES, V59, P5012; Bachelder RE, 2002, CANCER RES, V62, P7203; Barbero S, 2003, CANCER RES, V63, P1969; Beider K, 2003, BLOOD, V102, P1951, DOI 10.1182/blood-2002-10-3293; Bernards R, 2003, NATURE, V425, P247, DOI 10.1038/425247a; Cashman J, 2002, BLOOD, V99, P792, DOI 10.1182/blood.V99.3.792; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Foster CS, 1999, BJU INT, V83, P171; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Kijowski J, 2001, STEM CELLS, V19, P453, DOI 10.1634/stemcells.19-5-453; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Lapidot T, 2001, ANN NY ACAD SCI, V938, P83, DOI 10.1111/j.1749-6632.2001.tb03577.x; Milliken D, 2002, CLIN CANCER RES, V8, P1108; Minamiguchi H, 2001, BRIT J HAEMATOL, V115, P175, DOI 10.1046/j.1365-2141.2001.03068.x; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nemeth JA, 1999, CANCER RES, V59, P1987; Neuhaus T, 2003, CELL PROLIFERAT, V36, P75, DOI 10.1046/j.1365-2184.2003.00262.x; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Sehgal A, 1998, J SURG ONCOL, V69, P99, DOI 10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.0.CO;2-M; Shen W, 2001, EXP HEMATOL, V29, P1439, DOI 10.1016/S0301-472X(01)00741-X; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Taichman RS, 2002, CANCER RES, V62, P1832; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	43	317	354	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1240	+		10.1096/fj.03-0935fje	http://dx.doi.org/10.1096/fj.03-0935fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180966				2022-12-25	WOS:000222327500037
J	Barabas, O; Pongracz, V; Kovari, J; Wilmanns, M; Vertessy, BG				Barabas, O; Pongracz, V; Kovari, J; Wilmanns, M; Vertessy, BG			Structural insights into the catalytic mechanism of phosphate ester hydrolysis by dUTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DUTPASE; CRYSTAL-STRUCTURE; SUBSTRATE-ANALOG; KINETIC CHARACTERIZATION; METAL-BINDING; PROTEIN; PYROPHOSPHATASE; EXPRESSION; VIRUS; SITE	dUTPase is essential to keep uracil out of DNA. Crystal structures of substrate (dUTP and alpha,beta-imino-dUTP) and product complexes of wild type and mutant dUTPases were determined to reveal how an enzyme responsible for DNA integrity functions. A kinetic analysis of wild type and mutant dUTPases was performed to obtain relevant mechanistic information in solution. Substrate hydrolysis is shown to be initiated via in-line nucleophile attack of a water molecule oriented by an activating conserved aspartate residue. Substrate binding in a catalytically competent conformation is achieved by (i) multiple interactions of the triphosphate moiety with catalysis-assisting Mg2+, (ii) a concerted motion of residues from three conserved enzyme motifs as compared with the apoenzyme, and (iii) an intricate hydrogen-bonding network that includes several water molecules in the active site. Results provide an understanding for the catalytic role of conserved residues in dUTPases.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1117 Budapest, Hungary; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; European Molecular Biology Laboratory (EMBL)	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, Karolina Ut 29-31, H-1113 Budapest, Hungary.	vertessy@enzim.hu	Vertessy, Beata G/H-6202-2012; Barabas, Orsolya/F-3961-2012	Barabas, Orsolya/0000-0002-2873-5872; Wilmanns, Matthias/0000-0002-4643-5435; Vertessy, Beata G./0000-0002-1288-2982				Aherne G.W., 1999, ANTICANCER DRUG DEV, P409; [Anonymous], 1978, TRANSITION STATES BI; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barabas O, 2003, J BIOL CHEM, V278, P38803, DOI 10.1074/jbc.M306967200; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; CANMAN CE, 1994, CANCER RES, V54, P2296; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Flachner B, 2004, BIOCHEMISTRY-US, V43, P3436, DOI 10.1021/bi035022n; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P108; Gonzalez A, 2001, ACTA CRYSTALLOGR D, V57, P767, DOI 10.1107/S0907444901004255; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Kovari J, 2004, J BIOL CHEM, V279, P17932, DOI 10.1074/jbc.M313643200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Mustafi D, 2003, P NATL ACAD SCI USA, V100, P5670, DOI 10.1073/pnas.1031504100; Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Persson T, 1996, BIOORGAN MED CHEM, V4, P553, DOI 10.1016/0968-0896(96)00044-2; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TAYLOR JS, 1981, J BIOL CHEM, V256, P9793; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vertessy BG, 1998, FEBS LETT, V421, P83, DOI 10.1016/S0014-5793(97)01545-7; Williams NH, 2004, BBA-PROTEINS PROTEOM, V1697, P279, DOI 10.1016/j.bbapap.2003.11.031; Wolfenden R, 1998, J AM CHEM SOC, V120, P833, DOI 10.1021/ja9733604; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	48	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42907	42915		10.1074/jbc.M406135200	http://dx.doi.org/10.1074/jbc.M406135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15208312	hybrid			2022-12-25	WOS:000224226400069
J	Zamurovic, N; Cappellen, D; Rohner, D; Susa, M				Zamurovic, N; Cappellen, D; Rohner, D; Susa, M			Coordinated activation of Notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis Notch - Target gene Hey1 inhibits mineralization and Runx2 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELL-DIFFERENTIATION; MC3T3-E1 CELLS; ARRAY ANALYSIS; STEM-CELLS; PROTEIN; EXPRESSION; DEFECTS; PHENOTYPE; MUTATIONS; SKELETAL	To examine early events in osteoblast differentiation, we analyzed the expression of about 9,400 genes in the murine MC3T3 cell line, whose robust differentiation was documented cytochemically and molecularly. The cells were stimulated for 1 and 3 days with the osteogenic stimulus containing bone morphogenic protein 2. Total RNA was extracted and analyzed by Affymetrix GeneChip oligonucleotide arrays. A regulated expression of 394 known genes and 295 expressed sequence tags was detected. The sensitivity and reliability of detection by microarrays was shown by confirming the expression pattern for 20 genes by radioactive quantitative reverse transcription-PCR. Functional classification of regulated genes was performed, defining the groups of regulated growth factors, receptors, and transcription factors. The most interesting finding was concomitant activation of transforming growth factor-beta, Wnt, and Notch signaling pathways, confirmed by strong up-regulation of their target genes by PCR. The transforming growth factor-beta pathway is activated by stimulated production of the growth factor itself, while the exact mechanism of Wnt and Notch activation remains elusive. We showed that bone morphogenic protein 2 stimulated expression of Hey1, a direct Notch target gene, in mouse MC3T3 and C2C12 cells, in human mesenchymal cells, and in mouse calvaria. Small interfering RNA-mediated inhibition of Hey1 induction led to an increase in osteoblast matrix mineralization, suggesting that Hey1 is a negative regulator of osteoblast maturation. This negative regulation is apparently achieved via interaction with Runx2: Hey1 completely abrogated Runx2 transcriptional activity. These findings identify the Notch-Hey1 pathway as a negative regulator of osteoblast differentiation/maturation, which is a completely novel aspect of osteogenesis and could point to possible new targets for bone anabolic agents.	Novartis Inst Biomed Res, Arthrit & Bone Metab Gastrointestinal Dis Area, CH-4002 Basel, Switzerland	Novartis	Susa, M (corresponding author), Novartis Inst Biomed Res, Arthrit & Bone Metab Gastrointestinal Dis Area, WKL-125-9-12, CH-4002 Basel, Switzerland.	mira.susa_spring@pharma.novartis.com						ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Baron R., 2003, PRIMER METABOLIC BON, P1; Beck GR, 2001, CELL GROWTH DIFFER, V12, P61; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Canalis Ernesto, 1996, P619; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Chambers TJ, 2000, J PATHOL, V192, P4; Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X; Chua CC, 2002, BBA-MOL CELL RES, V1593, P1, DOI 10.1016/S0167-4889(02)00257-4; Conover Cheryl A., 1996, P607; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Doi M, 2002, BIOCHEM BIOPH RES CO, V290, P381, DOI 10.1006/bbrc.2001.6196; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gordeladze JO, 2001, CURR PHARM DESIGN, V7, P275, DOI 10.2174/1381612013398167; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hagiwara H, 1998, J ENDOCRINOL, V156, P543, DOI 10.1677/joe.0.1560543; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hurley Marja M., 1996, P627; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Jumlongras D, 2001, AM J HUM GENET, V69, P67, DOI 10.1086/321271; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; KIM SJ, 1993, CELLULAR MOL BIOL BO, P98; Korchynskyi O, 2003, J BONE MINER RES, V18, P1177, DOI 10.1359/jbmr.2003.18.7.1177; Kraus P, 1999, J CELL BIOCHEM, P133; KRAUS P, 1999, J CELL BIOCH S, V75, P32; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Leis HJ, 1997, J BONE MINER RES, V12, P541, DOI 10.1359/jbmr.1997.12.4.541; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Mackie EJ, 1998, BONE, V22, P301, DOI 10.1016/S8756-3282(97)00297-4; MAILLARD C, 1993, ENDOCRINOLOGY, V133, P668, DOI 10.1210/en.133.2.668; Malaval L, 2001, J CELL BIOCHEM, P63; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Pilbeam Carol C., 1996, P715; Puente E, 2001, J BIOL CHEM, V276, P13461, DOI 10.1074/jbc.M010981200; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647	67	178	191	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37704	37715		10.1074/jbc.M403813200	http://dx.doi.org/10.1074/jbc.M403813200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15178686	hybrid			2022-12-25	WOS:000223554600062
J	Grunnet, M; Kaufmann, WA				Grunnet, M; Kaufmann, WA			Coassembly of big conductance Ca(2+)activated K+ channels and L-type voltage-gated Ca2+ channels in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CALCIUM-CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; SMOOTH-MUSCLE; CELLS; MODULATION; RECEPTORS; REPOLARIZATION	Based on electrophysiological studies, Ca2+-activated K+ channels and voltage-gated Ca2+ channels appear to be located in close proximity in neurons. Such colocalization would ensure selective and rapid activation of K+ channels by local increases in the cytosolic calcium concentration. The nature of the apparent coupling is not known. In the present study we report a direct coassembly of big conductance Ca2+-activated K+ channels (BK) and L-type voltage-gated Ca2+ channels in rat brain. Saturation immunoprecipitation studies were performed on membranes labeled for BK channels and precipitated with antibodies against alpha(1C) and alpha(1D) L-type Ca2+ channels. To confirm the specificity of the interaction, precipitation experiments were carried out also in reverse order. Also, additive precipitation was performed because alpha(1C) and alpha(1D) L-type Ca2+ channels always refer to separate ion channel complexes. Finally, immunochemical studies showed a distinct but overlapping expression pattern of the two types of ion channels investigated. BK and L-type Ca2+ channels were colocalized in various compartments throughout the rat brain. Taken together, these results demonstrate a direct coassembly of BK channels and L-type Ca2+ channels in certain areas of the brain.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark; Neurosearch AS, DK-2750 Ballerup, Denmark; Univ Oslo, Ctr Mol Biol & Neurosci, Dept Physiol, N-0317 Oslo, Norway	University of Copenhagen; University of Oslo	Grunnet, M (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, 12-6-26,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	mgrunnet@mfi.ku.dk		Kaufmann, Walter Anton/0000-0001-9735-5315				ASHCROFT FM, 2000, ION CHANNELS DIS, P125; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; CATTERALL WA, 1993, ANN NY ACAD SCI, V707, P1, DOI 10.1111/j.1749-6632.1993.tb38038.x; Chavis P, 1998, EUR J NEUROSCI, V10, P2322, DOI 10.1046/j.1460-9568.1998.00243.x; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; GOLA M, 1993, NEURON, V10, P689, DOI 10.1016/0896-6273(93)90170-V; Grunnet M, 1999, AM J PHYSIOL-GASTR L, V277, pG22, DOI 10.1152/ajpgi.1999.277.1.G22; Herrera GM, 2001, AM J PHYSIOL-CELL PH, V280, pC481, DOI 10.1152/ajpcell.2001.280.3.C481; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Isaacson JS, 2001, NEURON, V31, P1027, DOI 10.1016/S0896-6273(01)00428-7; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Koschak A, 1997, BIOCHEMISTRY-US, V36, P1943, DOI 10.1021/bi962074m; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Lesage F, 2004, P NATL ACAD SCI USA, V101, P671, DOI 10.1073/pnas.0307681100; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC267, DOI 10.1152/ajpcell.1995.269.1.C267; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Prakriya M, 1999, J NEUROPHYSIOL, V81, P2267, DOI 10.1152/jn.1999.81.5.2267; Runden-Pran E, 2002, NEUROSCIENCE, V112, P277, DOI 10.1016/S0306-4522(02)00092-1; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Sailer CA, 2002, J NEUROSCI, V22, P9698; Sorensen JB, 2001, PFLUG ARCH EUR J PHY, V442, P1, DOI 10.1007/s004240000493; STORM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; Sun XL, 2003, J NEUROSCI, V23, P3639; TWITCHELL WA, 1994, MOL PHARMACOL, V46, P793; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wu SN, 2001, CHINESE J PHYSIOL, V44, P161; Xia XM, 2000, J NEUROSCI, V20, P4890	34	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36445	36453		10.1074/jbc.M402254200	http://dx.doi.org/10.1074/jbc.M402254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210719	hybrid			2022-12-25	WOS:000223453600037
J	Lau, P; Nixon, SJ; Parton, RG; Muscat, GEO				Lau, P; Nixon, SJ; Parton, RG; Muscat, GEO			ROR alpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells - Caveolin-3 and CPT-1 are direct targets of ROR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; DOMINANT-NEGATIVE MUTANT; AMINO-TERMINAL DOMAINS; REV-ERBA-ALPHA; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; TRANSGENIC MICE; CARDIAC MYOCYTES; STAGGERER MOUSE; ACTIN GENE	The staggerer mice carry a deletion in the RORalpha gene and have a prolonged humoral response, overproduce inflammatory cytokines, and are immunodeficient. Furthermore, the staggerer mice display lowered plasma apoA-I/-II, decreased plasma high density lipoprotein cholesterol and triglycerides, and develop hypo-alpha-lipoproteinemia and atherosclerosis. However, relatively little is known about RORalpha in the context of target tissues, target genes, and lipid homeostasis. For example, RORalpha is abundantly expressed in skeletal muscle, a major mass peripheral tissue that accounts for similar to40% of total body weight and 50% of energy expenditure. This lean tissue is a primary site of glucose disposal and fatty acid oxidation. Consequently, muscle has a significant role in insulin sensitivity, obesity, and the blood-lipid profile. In particular, the role of RORalpha in skeletal muscle metabolism has not been investigated, and the contribution of skeletal muscle to the ROR-/- phenotype has not been resolved. We utilize ectopic dominant negative RORalpha expression in skeletal muscle cells to understand the regulatory role of RORs in this major mass peripheral tissue. Exogenous dominant negative RORalpha expression in skeletal muscle cells represses the endogenous levels of RORalpha and -gamma mRNAs and ROR-dependent gene expression. Moreover, we observed attenuated expression of many genes involved in lipid homeostasis. Furthermore, we show that the muscle carnitine palmitoyltransferase-1 and caveolin-3 promoters are directly regulated by ROR and coactivated by p300 and PGC-1. This study implicates RORs in the control of lipid homeostasis in skeletal muscle. In conclusion, we speculate that ROR agonists would increase fatty acid catabolism in muscle and suggest selective activators of ROR may have therapeutic utility in the treatment of obesity and atherosclerosis.	Univ Queensland, Sch Biomed Sci, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Ctr Microscopy & Microanal, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Muscat, GEO (corresponding author), Univ Queensland, Sch Biomed Sci, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	g.muscat@imb.uq.edu.au	Parton, Robert G/C-5673-2009; Nixon, Susan/D-4588-2017; Muscat, George/A-6401-2017	Parton, Robert G/0000-0002-7494-5248; Nixon, Susan/0000-0003-0346-9683; Muscat, George/0000-0002-5829-5695; Lau, Patrick/0000-0002-9693-390X				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; Chen SL, 2000, GENE DEV, V14, P1209; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Curlewis JD, 2002, ENDOCRINOLOGY, V143, P3984, DOI 10.1210/en.2002-220344; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; DUNWOODIE SL, 1994, J BIOL CHEM, V269, P12212; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hailstones D, 1998, J LIPID RES, V39, P369; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; Lopez IP, 2004, BIOCHEM BIOPH RES CO, V318, P234, DOI 10.1016/j.bbrc.2004.04.018; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; Matsui T, 1997, GENES CELLS, V2, P263, DOI 10.1111/j.1365-2443.1997.119gc0317.x; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; Medvedev A, 1996, GENE, V181, P199, DOI 10.1016/S0378-1119(96)00504-5; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Vosper H, 2002, PHARMACOL THERAPEUT, V95, P47, DOI 10.1016/S0163-7258(02)00232-2; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705	56	126	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36828	36840		10.1074/jbc.M404927200	http://dx.doi.org/10.1074/jbc.M404927200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199055	hybrid			2022-12-25	WOS:000223453600085
J	Maliekal, TT; Anto, RJ; Karunagaran, D				Maliekal, TT; Anto, RJ; Karunagaran, D			Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; CANCER-CELLS; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; CROSS-TALK; MAP KINASE; II GENE	We assessed the responsiveness of six human cervical cancer cell lines to transforming growth factor (TGF)-beta with p3TP-lux reporter assay and found that HeLa and SiHa cells were highly responsive to TGF-beta. However, when pSBE4-BV/Luc reporter with four Smad binding elements was used, only the SiHa, not the HeLa, cells showed Smad activation. Smad DNA binding activity was relatively more in SiHa than in HeLa cells upon TGF-beta treatment, and the active complex contained Smad 2 and Smad 4. In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, HeLa cells treated with 5 ng/ml of TGF-beta for 24 h showed proliferation, whereas SiHa cells showed growth inhibition under the same conditions. TGF-beta treatment resulted in G(0)/G(1) arrest with a reduction in S-phase only in SiHa cells. A chemical inhibitor of Smad activation (SB203580) blocked the growth inhibitory effect of TGF-beta in SiHa, whereas the proliferative response in HeLa was unaffected. TGF-beta-induced translocation of phospho-Smad 2 was relatively less in HeLa than in SiHa cells. MAPK activation occurred within 5 min and persisted up to 15 min upon TGF-beta treatment in HeLa but was negligible in SiHa cells. TGF-beta activated JNK in HeLa, but SiHa cells showed a down-regulation of its activity. When an inhibitor of MAPK (U0126) was used, the TGF-beta-mediated proliferative response in HeLa cells was completely abolished. SB203580 did not affect MAPK activation induced by TGF-beta in HeLa cells. We report for the first time an activation, presumably independent of Smad activation, of TGF-beta-dependent MAPK within 5 min of treatment that resulted in cell cycle progression in a cervical adenocarcinoma cell line.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Apati A, 2003, J BIOL CHEM, V278, P9235, DOI 10.1074/jbc.M205528200; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; BRAUN L, 1990, CANCER RES, V50, P7324; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fink SP, 2001, CANCER RES, V61, P256; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Fu YX, 2003, BIOCHEM BIOPH RES CO, V310, P391, DOI 10.1016/j.bbrc.2003.09.021; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin NE, 1999, MOL CELL ENDOCRINOL, V153, P79, DOI 10.1016/S0303-7207(99)00086-6; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; Jonson T, 2001, INT J ONCOL, V19, P71; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Osawa H, 2000, INT J ONCOL, V17, P723; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Rich JN, 2001, MICROSC RES TECHNIQ, V52, P363, DOI 10.1002/1097-0029(20010215)52:4<363::AID-JEMT1021>3.3.CO;2-6; Riggins GJ, 1997, CANCER RES, V57, P2578; Simeone DM, 2001, AM J PHYSIOL-CELL PH, V281, pC311, DOI 10.1152/ajpcell.2001.281.1.C311; Tanaka S, 2000, BRIT J CANCER, V82, P1557; Terada Y, 1999, NEPHROL DIAL TRANSPL, V14, P45, DOI 10.1093/ndt/14.suppl_1.45; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	49	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36287	36292		10.1074/jbc.M404568200	http://dx.doi.org/10.1074/jbc.M404568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192088	hybrid			2022-12-25	WOS:000223453600017
J	Schillo, S; Belusic, G; Hartmann, K; Franz, C; Kuhl, B; Brenner-Weiss, G; Paulsen, R; Huber, A				Schillo, S; Belusic, G; Hartmann, K; Franz, C; Kuhl, B; Brenner-Weiss, G; Paulsen, R; Huber, A			Targeted mutagenesis of the farnesylation site of Drosophila G gamma e disrupts membrane association of the G protein beta gamma complex and affects the light sensitivity of the visual system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-BETA; PDZ-DOMAIN PROTEIN; SIGNALING COMPLEX; CARBOXYL METHYLATION; SUBUNIT GENE; CA2+ CHANNEL; COMPOUND EYE; TRANSDUCTION; PHOTORECEPTORS; INAD	Activation of phototransduction in the compound eye of Drosophila is mediated by a heterotrimeric G protein that couples to the effector enzyme phospholipase Cbeta. The gamma subunit of this G protein (Ggammae) as well as gamma subunits of vertebrate transducins contain a carboxyl-terminal CAAX motif (C, cysteine; A, aliphatic amino acid; X, any amino acid) with a consensus sequence for protein farnesylation. To examine the function of Ggammae farnesylation, we mutated the farnesylation site and overexpressed the mutated Ggammae in Drosophila. Mass spectrometry of overexpressed Ggammae subunits revealed that nonmutated Ggammae is modified by farnesylation, whereas the mutated Ggammae is not farnesylated. In the transgenic flies, mutated Ggammae forms a dimeric complex with Gbetae, with the consequence that the fraction of non-membrane-bound Gbetagamma is increased. Thus, farnesylation of Ggammae facilitates the membrane attachment of the Gbetagamma complex. We also expressed human Ggammarod in Drosophila photoreceptors. Despite similarities in the primary structure between the transducin gamma subunit and Drosophila Ggammae, we observed no interaction of human Ggammarod with Drosophila Ggammae. This finding indicates that human Ggammarod and Drosophila Ggammae provide different interfaces for the interaction with Gbeta subunits. Electroretinogram recordings revealed a significant loss of light sensitivity in eyes of transgenic flies that express mutated Ggammae. This loss in light sensitivity reveals that post-translational farnesylation is a critical step for the formation of membrane-associated Galphabetagamma required for transmitting light activation from rhodopsin to phospholipase Cbeta.	Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, D-76131 Karlsruhe, Germany; Univ Ljubljana, Dept Biol, Biotech Facil, Ljubljana 1000, Slovenia; Forschungszentrum Karlsruhe, Inst Tech Chem Wasser & Geotechnol, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; University of Ljubljana; Helmholtz Association; Karlsruhe Institute of Technology	Huber, A (corresponding author), Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, Haid & Neu Str 9, D-76131 Karlsruhe, Germany.	Armin.Huber@bio.uka.de	Brenner-Weiss, Gerald/H-2868-2013; Huber, Armin/GYU-6322-2022; Kuehl, Boris/I-2630-2014	Brenner-Weiss, Gerald/0000-0002-6728-5907; Belusic, Gregor/0000-0003-3571-1948; Huber, Armin/0000-0003-3977-089X				Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; BIGAY J, 1994, METHOD ENZYMOL, V237, P449; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Dietrich A, 2003, BIOCHEM J, V376, P449, DOI 10.1042/BJ20030578; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Fogg VC, 2001, J BIOL CHEM, V276, P41797, DOI 10.1074/jbc.M107661200; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; McCarthy NEM, 2000, BIOCHEM J, V347, P163, DOI 10.1042/0264-6021:3470163; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MISMER D, 1987, GENETICS, V116, P565; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; OTOUSA JE, 1992, VISUAL NEUROSCI, V8, P385, DOI 10.1017/S0952523800004910; PARISH CA, 1994, BIOCHEMISTRY-US, V33, P9986, DOI 10.1021/bi00199a023; Parish CA, 1996, BIOCHEMISTRY-US, V35, P7499, DOI 10.1021/bi960271f; PAULSEN R, 2000, SERIES BIOPHYSICS BI, P41; PAULSEN R, 2000, SERIES BIOPHYSICS BI, P60; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; RAY K, 1992, J BIOL CHEM, V267, P6086; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; Schulz S, 1999, J BIOL CHEM, V274, P37605, DOI 10.1074/jbc.274.53.37605; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAO L, 1993, EXP EYE RES, V56, P497, DOI 10.1006/exer.1993.1063; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	49	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36309	36316		10.1074/jbc.M404611200	http://dx.doi.org/10.1074/jbc.M404611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205461	hybrid			2022-12-25	WOS:000223453600020
J	Demoulin, JB; Ericsson, J; Kallin, A; Rorsman, C; Ronnstrand, L; Heldin, CH				Demoulin, JB; Ericsson, J; Kallin, A; Rorsman, C; Ronnstrand, L; Heldin, CH			Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; FATTY-ACID SYNTHESIS; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; MESSENGER-RNA; CELL-SIZE; RECEPTOR; GENES; CHOLESTEROL; EXPRESSION	We analyzed the transcriptional program elicited by stimulation of normal human fibroblasts with platelet-derived growth factor (PDGF) using cDNA microarrays. 103 significantly regulated transcripts that had not been previously linked to PDGF signaling were identified. Among them, a cluster of genes involved in fatty acid and cholesterol biosynthesis, including stearoyl-CoA desaturase (SCD), fatty acid synthase, and hydroxymethylglutaryl-CoA synthase (HMGCS), was up-regulated by PDGF after 24 h of treatment, and their expression correlated with increased membrane lipid production. These genes are known to be controlled by sterol regulatory element-binding proteins (SREBP). PDGF increased the amount of mature SREBP-1 and regulated the promoters of SCD and HMGCS in an SREBP-dependent manner. In line with these results, blocking SREBP processing by addition of 25-hydroxycholesterol blunted the effects of PDGF on lipogenic enzymes. SREBP activation was dependent on the phosphatidylinositol 3-kinase (PI3K) pathway, as judged from the effects of the inhibitor LY294002 and mutation of the PDGFbeta receptor tyrosines that bind the PI3K adaptor subunit p85. Fibroblast growth factors (FGF-2 and FGF-4) and other growth factors mimicked the effects of PDGF on NIH3T3 and human fibroblasts. In conclusion, our results suggest that growth factors induce membrane lipid synthesis via the activation SREBP and PI3K.	Ludwig Inst Canc Res, Ctr Biomed, Uppsala Branch, SE-75124 Uppsala, Sweden; Univ Catholique Louvain, Christian de Duve Inst Cell Pathol, Expt Med Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain	Demoulin, JB (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Uppsala Branch, Box 595, SE-75124 Uppsala, Sweden.	jean-baptiste.demoulin@mexp.ucl.ac.be	Ronnstrand, Lars/A-2429-2011; Demoulin, Jean-Baptiste/E-5847-2010; Ericsson, Johan/AAA-6664-2020	Ronnstrand, Lars/0000-0003-1275-5809; Ericsson, Johan/0000-0003-1186-6574; Demoulin, Jean-Baptiste/0000-0002-8016-6689				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; DOBSON G, 1995, J CHROMATOGR B, V671, P197, DOI 10.1016/0378-4347(95)00157-E; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; HOLMSEN H, 1989, BIOCHEM J, V260, P589, DOI 10.1042/bj2600589; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jones SM, 2001, CHEM REV, V101, P2413, DOI 10.1021/cr000101f; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KHOO DE, 1991, BRIT J CANCER, V63, P97, DOI 10.1038/bjc.1991.20; Kotzka J, 2000, J LIPID RES, V41, P99; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; ROTH M, 1991, P NATL ACAD SCI USA, V88, P1888, DOI 10.1073/pnas.88.5.1888; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TOUCHSTONE JC, 1995, J CHROMATOGR B, V671, P169, DOI 10.1016/0378-4347(95)00232-8; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100	43	98	103	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35392	35402		10.1074/jbc.M405924200	http://dx.doi.org/10.1074/jbc.M405924200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15213220	Green Published, hybrid			2022-12-25	WOS:000223303400033
J	Sato, K; Yamasaki, K; Daiho, T; Miyauchi, Y; Takahashi, H; Ishida-Yamamoto, A; Nakamura, S; Iizuka, H; Suzuki, H				Sato, K; Yamasaki, K; Daiho, T; Miyauchi, Y; Takahashi, H; Ishida-Yamamoto, A; Nakamura, S; Iizuka, H; Suzuki, H			Distinct types of abnormality in kinetic properties of three Darier disease-causing sarco(endo)plasmic reticulum Ca2+-ATPase mutants that exhibit normal expression and high Ca2+ transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; MUSCLE SARCOPLASMIC-RETICULUM; ATP2A2 MUTATIONS; ADENOSINE-TRIPHOSPHATASE; CALCIUM-PUMP; PHOSPHORYLATED INTERMEDIATE; CONFORMATIONAL TRANSITION; CRYSTAL-STRUCTURE; DIVALENT-CATION; CATALYTIC SITE	The possible functional abnormalities in three different Darier disease-causing Ca2+-ATPase (SERCA2b) mutants, Ile(274) --> Val at the lumenal end of M3, Leu(321) --> Phe on the cytoplasmic part of M4, and Met(719) --> Ile in P domain, were explored, because they exhibited nearly normal expression and localization in COS-1 cells and the high ATPase and coupled Ca2+ transport activities that were essentially identical (L321F) or slightly lower (I274V by similar to35% and M719I by similar to30%) as compared with those of the wild type. These mutations happened to be in Japanese patients found previously by us. Kinetic analyses revealed that each of the mutants possesses distinct types of abnormalities; M719I and L321F possess the 2-3-fold reduced affinity for cytoplasmic Ca2+, whereas I274V possesses the normal high affinity. L321F exhibited also the remarkably reduced sensitivity to the feedback inhibition of the transport cycle by accumulated lumenal Ca2+, as demonstrated with the effect of Ca2+ ionophore on ATPase activity and more specifically with the effects of Ca2+ (up to 50 mM) on the decay of phosphoenzyme intermediates. The results on I274V and M719I suggest that the physiological requirement for Ca2+ homeostasis in keratinocytes to avoid haploinsufficiency is very strict, probably much more than considered previously. The insensitivity to lumenal Ca2+ in L321F likely brings the lumenal Ca2+ to an abnormally elevated level. The three mutants with their distinctively altered kinetic properties will thus likely cause different types of perturbation of intracellular Ca2+ homeostasis, but nevertheless all types of perturbation result in Darier disease. It might be possible that the observed unique feature of L321F could possibly be associated with the specific symptoms in the pedigree with this mutation, neuropsychiatric disorder, and behavior problems. The results also provided further insight into the global nature of conformational changes of SERCAs for ATP-driven Ca2+ transport.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; Chao SC, 2002, BRIT J DERMATOL, V146, P958, DOI 10.1046/j.1365-2133.2002.04786.x; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Daiho T, 2001, J BIOL CHEM, V276, P32771, DOI 10.1074/jbc.M101229200; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ikeda S, 2003, J INVEST DERMATOL, V121, P475, DOI 10.1046/j.1523-1747.2003.12400.x; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; OGURUSU T, 1991, J BIOCHEM-TOKYO, V109, P472, DOI 10.1093/oxfordjournals.jbchem.a123406; Onozuka T, 2004, BRIT J DERMATOL, V150, P652, DOI 10.1111/j.0007-0963.2004.05868.x; PICK U, 1982, J BIOL CHEM, V257, P6120; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 2000, J INVEST DERMATOL, V115, P1144, DOI 10.1046/j.1523-1747.2000.00182.x; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1989, J BIOL CHEM, V264, P920; Takahashi H, 2001, J DERMATOL SCI, V26, P169, DOI 10.1016/S0923-1811(00)00173-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wada T, 2003, BRIT J DERMATOL, V149, P185, DOI 10.1046/j.1365-2133.2003.05412.x; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Yang Y, 2001, J INVEST DERMATOL, V116, P482, DOI 10.1046/j.1523-1747.2001.127910.x; Youngburg GE, 1930, J LAB CLIN MED, V16, P158; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	68	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35595	35603		10.1074/jbc.M404887200	http://dx.doi.org/10.1074/jbc.M404887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208303	hybrid, Green Submitted			2022-12-25	WOS:000223303400055
J	Yu, YM; Zeng, H; Vijay-Kumar, M; Neish, AS; Merlin, D; Sitaraman, SV; Gewirtz, AT				Yu, YM; Zeng, H; Vijay-Kumar, M; Neish, AS; Merlin, D; Sitaraman, SV; Gewirtz, AT			STAT signaling underlies difference between flagellin-induced and tumor necrosis factor-alpha-induced epithelial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL FLAGELLIN; INTERLEUKIN-6 GENE; P38 MAPK; SALMONELLA; CELLS; SECRETION; CROSSTALK; ANALOGS	Both bacterial flagellin and the cytokine tumor necrosis factor-alpha (TNFalpha) are potent activators of intestinal epithelial cell pro-inflammatory gene expression in general; nonetheless, there seem to be distinct differences in the specific patterns of gene expression induced by these agonists. The goal of this study was to define one such difference and elucidate the signaling mechanism responsible for such differential gene induction by these agonists. We observed that expression of inducible nitric-oxide synthase is substantially induced by flagellin but only minimally expressed in response to TNFalpha. This difference seemed to be underlain by differential induction of signal transducers and activators of transcription (STAT) activation in that, whereas flagellin and TNFalpha seemed to be equipotent activators of p38 mitogen-activated protein kinase and nuclear factor-kappaB, flagellin induced substantially higher levels of STAT-1 and -3 tyrosine phosphorylation. Such flagellin-induced STAT activation exhibited delayed kinetics and was ablated by treatment with cycloheximide. Flagellin-induced activation of STAT-3 was abolished via neutralizing antibodies to interleukin (IL)-6, but not interferon (IFN)beta nor IFNgamma; none of these neutralizing antibodies had any effect on flagellin-induced STAT-1 tyrosine phosphorylation. Flagellin induced substantially more IL-6 expression than did TNFalpha, but neither agonist elicited detectable levels of IFN expression. Flagellin-induced expression of inducible nitric-oxide synthase but not IL-6, was abolished by blocking STAT activation with AG490, and was reduced by blocking STAT-3 activation with anti-IL-6. Together, these results indicate that epithelial cell induction of flagellin-specific gene expression is mediated, in part, by STAT activation that results from autocrine activation via IL-6.	Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Gewirtz, AT (corresponding author), Emory Univ, Dept Pathol & Lab Med, Pathol WRB 105H,615 Michael St, Atlanta, GA 30322 USA.	agewirt@emory.edu	Neish, Andrew/B-3895-2009; Vijay-Kumar, Matam/Q-8988-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061417, R24DK064399, R01DK061941] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061417, R01 DK002802, R24-DK064399, R01 DK061941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gewirtz AT, 2002, BEST PRACT RES CL GA, V16, P851, DOI 10.1053/bega.2002.0339; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Gewirtz AT, 2002, METHOD MICROBIOL, V31, P377, DOI 10.1016/S0580-9517(02)31022-5; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; McCormick B, 1998, CURR OPIN GASTROEN, V14, P492, DOI 10.1097/00001574-199811010-00013; McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Schmitt CK, 1996, J BACTERIOL, V178, P2911, DOI 10.1128/jb.178.10.2911-2915.1996; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wang LH, 1999, J IMMUNOL, V162, P3897; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668	21	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35210	35218		10.1074/jbc.M404064200	http://dx.doi.org/10.1074/jbc.M404064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199060	hybrid			2022-12-25	WOS:000223303400011
J	Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H				Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H			Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas	ONCOGENE			English	Article						colorectal carcinomas; microsatellite instability; oligonucleotide microarray; gene expression profile; molecular classification	COLON-CANCER; OLIGONUCLEOTIDE ARRAYS; TARGET GENES; BETA-CATENIN; SEQUENCES; MUTATIONS; PATHWAY; CARCINOGENESIS; IDENTIFICATION; MICROARRAYS	Recent molecular genetic studies have revealed that two major types of genomic instabilities, chromosomal instability (CIN) and microsatellite instability (MSI), exist in colorectal carcinomas. In order to clarify the molecular signature related to the CIN and MSI in colorectal carcinomas, we performed transcriptomic expression analysis on eight microsatellite instability-high (MSI-H) colorectal carcinomas and compared the results obtained with that of nine microsatellite stable (MSS) colorectal carcinomas using oligonucleotide microarrays containing 17 334 known genes and 1331 unknown genes or expression sequence tags ( ESTs). Unsupervised two-way hierarchical clustering with 5724 genes successfully classified tumors from normal mucosa, and displayed a distinctive MSI-H carcinomas subgroup. Based on intensive filtering, 57 known genes and eight ESTs were found to be highly relevant to the differentiation of MSI-H and MSS colorectal carcinomas. These genes successfully distinguish the new test set of six MSI-H and five MSS colorectal carcinomas. Many up- and downregulated genes in MSI-H colorectal carcinomas were related to the previously reported phenotypic characteristics; increased mucin production and intense peritumoral immune response in MSI-H carcinomas. Some of these differences were confirmed by semiquantitative reverse transcription-PCR and immunohistochemical analysis. Our findings indicate that there are many different genetic and transcriptomic characteristics between MSI-H and MSS colorectal carcinomas, and some of these differently expressed genes can be used as diagnostic or prognostic markers.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Dept Genet Engn, Suwon 440746, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Catholic University of Korea; Sungkyunkwan University (SKKU)	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008	Kim, Nam-Kyu/0000-0003-0639-5632; Kim, Hyunki/0000-0003-2292-5584				Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Biemer-Huttmann AE, 2000, CLIN CANCER RES, V6, P1909; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Duval A, 2002, CANCER RES, V62, P2447; Guidoboni M, 2001, AM J PATHOL, V159, P297, DOI 10.1016/S0002-9440(10)61695-1; Hiraga Y, 1998, ONCOLOGY-BASEL, V55, P307, DOI 10.1159/000011868; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mori Y, 2003, CANCER RES, V63, P4577; Notterman DA, 2001, CANCER RES, V61, P3124; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821	26	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6218	6225		10.1038/sj.onc.1207853	http://dx.doi.org/10.1038/sj.onc.1207853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208663				2022-12-25	WOS:000223399000006
J	Agarwalla, S; Stroud, RM; Gaffney, BJ				Agarwalla, S; Stroud, RM; Gaffney, BJ			Redox reactions of the iron-sulfur cluster in a ribosomal RNA methyltransferase, RumA - Optical and EPR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINELANDII FERREDOXIN-I; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ENDONUCLEASE-III; 4FE-4S CLUSTER; NITRIC-OXIDE; MOSSBAUER-SPECTROSCOPY; FERRICYANIDE OXIDATION; DNA-REPAIR; PROTEIN	An unprecedented [4Fe-4S] iron-sulfur cluster was found in RumA, the enzyme that methylates U1939 in Escherichia coli 23 S ribosomal RNA ( Agarwalla, S., Kealey, J. T., Santi, D. V., and Stroud, R. M. ( 2002) J. Biol. Chem. 277, 8835 - 8840; Lee, T. T., Agarwalla, S., and Stroud, R. M. ( 2004) Structure 12, 397 - 407). Methyltransferase reactions do not involve a redox step. To understand the structural and functional roles of the cluster in RumA, we have characterized redox reactions of the iron-sulfur cluster. As isolated aerobically, RumA exhibits a visible absorbance maximum at 390 nm and is EPR silent. It cannot be reduced by anaerobic additions of dithionite. Photoreduction by deazariboflavin/EDTA gives EPR spectra, the quantity (56% of S = 1/2 species) and details (g(av) similar to 1.96 - 1.93) of which indicate a [4Fe-4S](1+) cluster in the reduced RumA. Oxidation of RumA by ferricyanide leads to loss of the 390-nm band and appearance of lower intensity bands at 444 and 520 nm. EPR spectra of ferricyanide-oxidized RumA show a fraction (< 8%) of the FeS cluster trapped in the [3Fe-4S](1+) form (g(av) similar to 2.011) together with unusual radical-like spectrum (g' values 2.015, 2.00, and 1.95). RumA also reacts with nitric oxide to give EPR spectra characteristic of the protein-bound iron dinitrosyl species. Oxidation of the cluster leads to its decomposition and that could be a mechanism for regulating the activity of RumA under conditions of oxidative stress in the cell. Sequence data base searches revealed that RumA homologs are widespread in various kingdoms of life and contain a conserved and unique iron-sulfur cluster binding motif, CX(5)CGGC.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94107 USA	State University System of Florida; Florida State University; University of California System; University of California San Francisco	Gaffney, BJ (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.	gaffney@bio.fsu.edu	Stroud, Rhonda/GQZ-0151-2022; Gaffney, Betty J/C-9666-2015	Stroud, Rhonda/0000-0001-5242-8015; 	NIGMS NIH HHS [GM 51232, R01 GM065268, R01 GM051232, GM 65268] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051232, R01GM065268] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwalla S, 2002, J BIOL CHEM, V277, P8835, DOI 10.1074/jbc.M111825200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bentrop D, 2001, HANDBOOK ON METALLOPROTEINS, P357; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BERTINI I, 1993, BIOCHEMISTRY-US, V32, P12887, DOI 10.1021/bi00210a042; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; Boon EM, 2003, P NATL ACAD SCI USA, V100, P12543, DOI 10.1073/pnas.2035257100; Chen KS, 2002, J BIOL CHEM, V277, P5603, DOI 10.1074/jbc.M108916200; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DUNHAM WR, 1991, BIOCHIM BIOPHYS ACTA, V1079, P253, DOI 10.1016/0167-4838(91)90066-9; Foster HW, 1999, J AM CHEM SOC, V121, P4093; Glaser T, 2001, J AM CHEM SOC, V123, P442, DOI 10.1021/ja002183v; Glaser T, 2001, J AM CHEM SOC, V123, P4859, DOI 10.1021/ja0155940; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Griffin M., 1999, Molecular Physics Reports, V26, P60; GU XG, 1992, BIOCHEMISTRY-US, V31, P10295, DOI 10.1021/bi00157a017; HADLEY JH, 1974, P NATL ACAD SCI USA, V71, P4409, DOI 10.1073/pnas.71.11.4409; Hinks JA, 2002, J BIOL CHEM, V277, P16936, DOI 10.1074/jbc.M200668200; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; Iwasaki T, 2002, J BIOL CHEM, V277, P39642, DOI 10.1074/jbc.M207312200; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Jung YS, 2000, J BIOL CHEM, V275, P36974, DOI 10.1074/jbc.M004947200; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Knappe W R, 1978, Biochemistry, V17, P16; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Lee TT, 2004, STRUCTURE, V12, P397, DOI 10.1016/j.str.2004.02.009; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Lu AL, 2003, BIOCHEMISTRY-US, V42, P3742, DOI 10.1021/bi0269198; Madsen CT, 2003, NUCLEIC ACIDS RES, V31, P4738, DOI 10.1093/nar/gkg657; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; Rogers PA, 2003, DNA REPAIR, V2, P809, DOI 10.1016/S1568-7864(03)00065-X; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; Sridhar V, 1998, J BIOL INORG CHEM, V3, P140; SURERUS KK, 1989, P NATL ACAD SCI USA, V86, P9846, DOI 10.1073/pnas.86.24.9846; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; WANG TF, 1995, WELDING, V1, P8; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843	53	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34123	34129		10.1074/jbc.M405702200	http://dx.doi.org/10.1074/jbc.M405702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181002	hybrid, Green Accepted			2022-12-25	WOS:000223134800009
J	Napoli, A; Valenti, A; Salerno, V; Nadal, M; Garnier, F; Rossi, M; Ciaramella, M				Napoli, A; Valenti, A; Salerno, V; Nadal, M; Garnier, F; Rossi, M; Ciaramella, M			Reverse gyrase recruitment to DNA after UV light irradiation in Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON-SULFOLOBUS; TOPOISOMERASE-I; RECQ HELICASE; BINDING-PROTEIN; ACTINOMYCIN-D; REPAIR; DAMAGE; MECHANISM; TOPOLOGY; RECOMBINATION	Induction of DNA damage triggers a complex biological response concerning not only repair systems but also virtually every cell function. DNA topoisomerases regulate the level of DNA supercoiling in all DNA transactions. Reverse gyrase is a peculiar DNA topoisomerase, specific to hyperthermophilic microorganisms, which contains a helicase and a topoisomerase IA domain that has the unique ability to introduce positive supercoiling into DNA molecules. We show here that reverse gyrase of the archaean Sulfolobus solfataricus is mobilized to DNA in vivo after UV irradiation. The enzyme, either purified or in cell extracts, forms stable covalent complexes with UV-damaged DNA in vitro. We also show that the reverse gyrase translocation to DNA in vivo and the stabilization of covalent complexes in vitro are specific effects of UV light irradiation and do not occur with the intercalating agent actinomycin D. Our results suggest that reverse gyrase might participate, directly or indirectly, in the cell response to UV light-induced DNA damage. This is the first direct evidence of the recruitment of a topoisomerase IA enzyme to DNA after the induction of DNA damage. The interaction between helicase and topoisomerase activities has been previously proposed to facilitate aspects of DNA replication or recombination in both Bacteria and Eukarya. Our results suggest a general role of the association of such activities in maintaining genome integrity and a mutual effect of DNA topology and repair.	CNR, Inst Prot Biochem, I-80131 Naples, Italy; Univ Versailles, Lab Genet & Biol Cellulaire, Equipe Microbiol, CNRS FRE 2445, F-78035 Versailles, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); UDICE-French Research Universities; Universite Paris Saclay	Ciaramella, M (corresponding author), CNR, Inst Prot Biochem, Via P Castellino 111, I-80131 Naples, Italy.	m.ciaramella@ibp.cnr.it	Ciaramella, Maria/O-1152-2015	Ciaramella, Maria/0000-0003-1583-1694; Valenti, Anna/0000-0002-5278-3524; Garnier, Florence/0000-0002-6299-6531; NADAL, Marc/0000-0001-9637-7694				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Chakraverty RK, 2001, MOL CELL BIOL, V21, P7150, DOI 10.1128/MCB.21.21.7150-7162.2001; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Ciaramella M, 2002, ANTON LEEUW INT J G, V81, P85, DOI 10.1023/A:1020577510469; Dai PG, 2003, J BACTERIOL, V185, P5500, DOI 10.1128/JB.185.18.5500-5507.2003; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Duguet M, 1997, J CELL SCI, V110, P1345; Dutertre S, 2002, J BIOL CHEM, V277, P6280, DOI 10.1074/jbc.M105735200; Eckardt-Schupp F, 1999, BIOCHIMIE, V81, P161, DOI 10.1016/S0300-9084(99)80049-2; Forterre P, 1996, FEMS MICROBIOL REV, V18, P237; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 2003, J BIOL CHEM, V278, P42668, DOI 10.1074/jbc.M302994200; Hjort K, 2001, MOL MICROBIOL, V40, P225, DOI 10.1046/j.1365-2958.2001.02377.x; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; Laursen LV, 2003, MOL CELL BIOL, V23, P3692, DOI 10.1128/MCB.23.10.3692-3705.2003; Lilley DMJ., 1995, NUCL ACIDS MOL BIOL, P84; LopezGarcia P, 1997, MOL MICROBIOL, V23, P1267, DOI 10.1046/j.1365-2958.1997.3051668.x; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2003, DNA REPAIR, V2, P1115, DOI 10.1016/S1568-7864(03)00122-8; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NADAL M, 1994, J BIOL CHEM, V269, P5255; Napoli A, 2002, NUCLEIC ACIDS RES, V30, P2656, DOI 10.1093/nar/gkf377; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; Park JY, 2000, FEBS LETT, V476, P174, DOI 10.1016/S0014-5793(00)01718-X; PEDRINI AM, 1983, P NATL ACAD SCI-BIOL, V80, P1787, DOI 10.1073/pnas.80.7.1787; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Rodriguez AC, 2003, BIOCHEMISTRY-US, V42, P5993, DOI 10.1021/bi034188l; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; Salerno V, 2003, NUCLEIC ACIDS RES, V31, P6127, DOI 10.1093/nar/gkg831; Subramanian D, 1998, CANCER RES, V58, P976; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WASSERMANN K, 1990, MOL PHARMACOL, V38, P38; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; White MF, 2003, BIOCHEM SOC T, V31, P690, DOI 10.1042/BST0310690.; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X	44	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33192	33198		10.1074/jbc.M402619200	http://dx.doi.org/10.1074/jbc.M402619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15190074	hybrid			2022-12-25	WOS:000223039700023
J	Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M				Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M			Characterization of a new cytogenetic subtype of ductal breast carcinomas	ONCOGENE			English	Article						comparative genomic hybridization; ductal breast carcinomas; chromosome aberrations; TP53; chromosome gain	COMPARATIVE GENOMIC HYBRIDIZATION; REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CHROMOSOMAL EVOLUTION; GENETIC ALTERATIONS; SOLID TUMORS; DNA; PATHWAYS; CARCINOGENESIS	About 50% of ductal breast carcinomas do not yield analysable karyotypes after short-term culturing. Comparison of the cytogenetic subset to the whole data set of tumors revealed that slightly hyperdiploid tumors, that is, with DNA index between 1.05 and 1.3, were under-represented in tumors for which cytogenetic analysis was successful. The purpose of this study was to determine whether the pattern of chromosome imbalances in this subset differs from that generally reported. Comparative genomic hybridization (CGH) was used on 43 primary ductal breast carcinomas selected for slight hyperdiploidy. Microsatellite instability (MSI), TP53 mutation and expression were also investigated. All tumors were MSI negative. In all, 18 tumors (42%) presented mostly unbalanced chromosome rearrangements and DNA amplifications, with only few or no whole chromosome gains (WCG). This pattern of chromosome imbalances corresponds to that described in most breast tumors by previous cytogenetic and CGH analyses. It was associated with TP53 mutation in 17% of tumors. Another subset of 17 tumors (39%) displayed different and new features, characterized by recurrent gains of whole chromosomes 5, 7 and 8 with few chromosome rearrangements, rare DNA amplifications and no TP53 mutation. Eight tumors with as many rearrangements as WCG were left unclassified. We propose that, beside a major pathway characterized by multiple chromosome rearrangements, there is a minor pathway mainly characterized by WCG.	Inst Curie, CNRS, FRE 2584, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Muleris, M (corresponding author), Inst Curie, CNRS, FRE 2584, 26 Rue Ulm, F-75248 Paris, France.	martme.muleris@curie.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Anbazhagan R, 1999, CLIN CANCER RES, V5, P839; Bernardino J, 1997, GENE CHROMOSOME CANC, V19, P195; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875; Courjal F, 1997, CANCER RES, V57, P4368; DELATTRE O, 1989, LANCET, V2, P353; Dellas A, 2002, CLIN CANCER RES, V8, P1210; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; DUTRILLAUX B, 2000, CHROMOSOME GENE ALTE; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Haydon AMM, 2002, LANCET ONCOL, V3, P83, DOI 10.1016/S1470-2045(02)00649-6; Hoang JM, 1997, CANCER RES, V57, P300; Hoglund M, 2002, CANCER RES, V62, P2675; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lesec G, 1997, INT J ONCOL, V10, P747; LOTHE RA, 1993, CANCER RES, V53, P5849; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; Paulson TG, 1996, CANCER RES, V56, P4021; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; RIED T, 1995, CANCER RES, V55, P5415; Roylance R, 1999, CANCER RES, V59, P1433; Sandberg AA, 2000, CANCER GENET CYTOGEN, V123, P1, DOI 10.1016/S0165-4608(00)00295-8; Shackney SE, 1997, CYTOMETRY, V29, P1; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Soulie P, 1999, ONCOGENE, V18, P775, DOI 10.1038/sj.onc.1202336; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5986	5993		10.1038/sj.onc.1207799	http://dx.doi.org/10.1038/sj.onc.1207799			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208688				2022-12-25	WOS:000222941100013
J	Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A				Miyoshi, K; Wakioka, T; Nishinakamura, H; Kamio, M; Yang, L; Inoue, M; Hasegawa, M; Yonemitsu, Y; Komiya, S; Yoshimura, A			The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization	ONCOGENE			English	Article						migration; ERK; Sprouty; metastasis; Rho; signal transduction	SERUM RESPONSE FACTOR; ERK ACTIVATION; SENDAI-VIRUS; DROSOPHILA-SPROUTY; FOCAL ADHESIONS; STRESS FIBERS; ONCOGENIC RAS; KINASE; BINDING; EXPRESSION	Sprouty and the Sprouty-related protein, Spred (Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology-1 (EVH1) domain-containing protein), inhibit Ras-dependent extracellular signal-regulated kinase (ERK) signaling induced by a variety of growth factors. Since Sprouty proteins have been shown to inhibit not only ERK activation but also cell migration, we postulated that Spreds also inhibit cellular migration. Using stably highly metastatic LM8 cells infected with the Spred1-Sendai virus vector, we demonstrated that Spred1 inhibits the metastasis of LM8 cells in nude mice. Spred1 overexpression also inhibited migration of cells in vitro in response to chemokines, CCL19 and CCL21. We also found that Spred1 overexpression dissolved actin-stress fibers. Both EVH1 domain and C-terminal Sprouty-related domain were required for actin reassembly. Spred1 and Spred2 suppressed constitutively activated RhoA (V14RhoA)-induced stress fiber formation and serum response factor activation. Spred1 bound to activated RhoA, but not cdc42 and Rac. Spred1 also inhibited chemokine-induced RhoA activation and active RhoA-induced Rho-kinase activation. These data suggest that Spreds are key regulators of RhoA-mediated cell motility and signal transduction. Furthermore, our study suggests that the induction of Spreds could be a novel strategy for preventing cancer cell metastasis.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Orthoped Surg, Kagoshima 8908520, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Inoue, Makoto/0000-0003-0804-7439				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hashimoto S, 2002, MECH DEVELOP, V119, pS303, DOI 10.1016/S0925-4773(03)00132-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kranenburg O, 1997, J CELL SCI, V110, P2417; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Minowada G, 1999, DEVELOPMENT, V126, P4465; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	43	73	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5567	5576		10.1038/sj.onc.1207759	http://dx.doi.org/10.1038/sj.onc.1207759			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184877				2022-12-25	WOS:000222629500001
J	Chai, JY; Jones, MK; Tarnawski, AS				Chai, JY; Jones, MK; Tarnawski, AS			Serum response factor is a critical requirment for VEGF signaling in endothelial cells and VEGF-induced angiogenesis	FASEB JOURNAL			English	Article						SRF; vascular endothelial growth factor; actin dynamics	GROWTH-FACTOR; GASTRIC-ULCERS; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION; MECHANISMS; MIGRATION; INHIBITION; PROMOTER	Angiogenesis, new capillary blood vessel formation, is essential for embryonic development, wound healing, and cancer growth. Vascular endothelial growth factor (VEGF) induces angiogenesis by activating endothelial cell migration and proliferation. Serum response factor (SRF) is a transcription factor important for embryonic development and activation of immediate early gene expression. The roles of SRF in endothelial cell biology and angiogenesis have not been explored. Here we demonstrate that SRF is a downstream mediator of VEGF signaling in endothelial cells and a critical requirement for VEGF-induced angiogenesis. Knockdown of SRF protein levels in human and rat endothelial cells abolished VEGF-induced in vitro angiogenesis, impaired endothelial cell migration and proliferation, and inhibited VEGF-induced actin polymerization and immediate early gene expression. Injection of SRF antisense expression plasmid into gastric ulcers in rats significantly inhibited in vivo angiogenesis in granulation tissue. Mechanistically, this study also revealed that VEGF promotes SRF expression and nuclear translocation and increases SRF binding activity to DNA in endothelial cells through both Rho-actin and MEK-ERK dependent signaling pathways. These findings have potential therapeutic implications, e.g., local anti-SRF treatment may inhibit angiogenesis crucial for tumor growth.	Vet Affairs Med Ctr, Dept Med Gastroenterol, Gastroenterol Sect 111G, Long Beach, CA 90822 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, Dept Med Gastroenterol, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.	atarnawski@yahoo.com	Chai, Jianyuan/A-8300-2009; Chai, Jianyuan/AAJ-5892-2020	Chai, Jianyuan/0000-0001-6975-6867				Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Breslin JW, 2003, AM J PHYSIOL-HEART C, V284, pH92, DOI 10.1152/ajpheart.00330.2002; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; Ehring GR, 2000, J PHYSIOL PHARMACOL, V51, P799; Fahmy RG, 2002, J CELL BIOCHEM, V84, P575, DOI 10.1002/jcb.10057.abs; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Jones MK, 2000, J PHYSIOL PHARMACOL, V51, P813; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Pai Rama, 2000, Molecular Cell Biology Research Communications, V4, P111, DOI 10.1006/mcbr.2000.0260; Ponce ML, 2001, METH MOLEC MED, V46, P205, DOI 10.1385/1-59259-143-4:205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schor AM, 2001, METH MOLEC MED, V46, P145, DOI 10.1385/1-59259-143-4:145; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Settleman J, 2003, MOL CELL, V11, P1121, DOI 10.1016/S1097-2765(03)00189-8; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Strowski MZ, 2004, FASEB J, V18, P218, DOI 10.1096/fj.03-0055fje; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; TARNAWSKI A, 1990, J CLIN GASTROENTEROL, V12, pS148, DOI 10.1097/00004836-199001001-00025; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835	38	74	76	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1264	+		10.1096/fj.03-1232fje	http://dx.doi.org/10.1096/fj.03-1232fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180964				2022-12-25	WOS:000222327500032
J	Nilsen, N; Nonstad, U; Khan, N; Knetter, CF; Akira, S; Sundan, A; Espevik, T; Lien, E				Nilsen, N; Nonstad, U; Khan, N; Knetter, CF; Akira, S; Sundan, A; Espevik, T; Lien, E			Lipopolysaccharide and double-stranded RNA up-regulate toll-like receptor 2 independently of myeloid differentiation factor 88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMANIZED ANTI-CD4 ANTIBODY; INNATE IMMUNE-SYSTEM; BETA-GLUCAN RECEPTOR; CUTTING EDGE; PATTERN-RECOGNITION; GENE EXPRESSIONS; CELL ACTIVATION; DOWN-REGULATION; T-CELLS	Toll-like receptor 2 (TLR2) is a signaling receptor for a variety of microbial products, including bacterial lipoproteins and peptidoglycan, and is central in initiating immune responses toward Gram-positive bacteria, spirochetes, and mycobacteria. The mechanisms behind regulation of TLR2 protein expression are still not well understood. By using a newly developed monoclonal antibody against mouse TLR2, we detected TLR2 protein expression on macrophages, neutrophils, and dendritic cells. Endogenous macrophage TLR2 localized mostly to the cell membrane, with particular accumulation around phagosomes containing zymosan. Treatment of macrophages with the TLR2 antibody diminished cellular response to lipoproteins and down-regulated membrane TLR2. Marked up-regulation of surface TLR2 was observed on macrophages in response to whole bacteria, lipoproteins, lipopolysaccharide, poly(I-C) (double-stranded RNA), R848, and CpG DNA, and this up-regulation appeared to be a very sensitive marker for the presence of microbial products. Up-regulation of TLR2 in response to stimuli correlated with an increased response to secondary lipoprotein exposure following a low concentration of primary lipoprotein challenge. By comparison, exposure to a larger primary challenge induced a hyporeactive state. Most interestingly, lipopolysaccharide- and double-stranded RNA-induced upregulation of surface TLR2 in macrophages was found to be MyD88-independent, whereas the up-regulation in response to lipoproteins, R848, and CpG DNA was absent in MyD88-deficient cells. We conclude that complex mechanisms regulate expression and signaling via TLR2. Up-regulation of TLR2 in the presence of low, yet clinically relevant amounts of microbial products may be an important mechanism by which the immune system boosts its response to a beginning infection.	Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Dept Med, Worcester, MA 01605 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7489 Trondheim, Norway; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	University of Massachusetts System; University of Massachusetts Worcester; Norwegian University of Science & Technology (NTNU); Osaka University	Lien, E (corresponding author), Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Dept Med, 364 Plantat St,Lazare Res Bldg 311, Worcester, MA 01605 USA.	Egil.Lien@umassmed.edu	Akira, Shizuo/C-3134-2009; Nilsen, Nadra/G-5592-2017	Nilsen, Nadra/0000-0003-0407-1060	NIAID NIH HHS [R01 AI57588] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; BARTHOLOMEW M, 1995, IMMUNOLOGY, V85, P41; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brett SJ, 1997, IMMUNOLOGY, V91, P346, DOI 10.1046/j.1365-2567.1997.00265.x; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Delude RL, 1998, J IMMUNOL, V161, P3001; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heine H, 1999, J IMMUNOL, V162, P6971; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; HOEE K, 2003, NATURE, V424, P743; HOGAN MM, 1987, J IMMUNOL, V139, P3697; Hoshino K, 1999, J IMMUNOL, V162, P3749; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lien E, 2003, NAT IMMUNOL, V4, P1162, DOI 10.1038/ni1203-1162; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Liu T, 2002, INFECT IMMUN, V70, P6638, DOI 10.1128/IAI.70.12.6638-6645.2002; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Min R, 2002, BRIT J HAEMATOL, V118, P495, DOI 10.1046/j.1365-2141.2002.03635.x; MOREL P, 1992, CELL IMMUNOL, V145, P287, DOI 10.1016/0008-8749(92)90332-J; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Okada T, 2003, EUR J IMMUNOL, V33, P1012, DOI 10.1002/eji.200323616; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Schjetne KW, 2003, J IMMUNOL, V171, P32, DOI 10.4049/jimmunol.171.1.32; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Weighardt H, 2004, EUR J IMMUNOL, V34, P558, DOI 10.1002/eji.200324714; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511	70	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39727	39735		10.1074/jbc.M405027200	http://dx.doi.org/10.1074/jbc.M405027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15190057	hybrid			2022-12-25	WOS:000223791500065
J	Yang, YH; Ma, J; Chen, YJ; Wu, MA				Yang, YH; Ma, J; Chen, YJ; Wu, MA			Nucleocytoplasmic shuttling of receptor-interacting protein 3 (RIP3) - Identification of novel nuclear export and import signals in RIP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEATH DOMAIN; APOPTOSIS; KINASE; TRANSLOCATION; LOCALIZATION; CLEAVAGE; FAMILY; MEMBER	Receptor- interacting protein 3 (RIP3), a member of the RIP Ser/Thr kinase family, has been characterized as a pro-apoptotic protein involved in the tumor necrosis factor receptor-1 signaling pathway. In this study, we have mapped a minimal region of RIP3 sufficient for apoptosis induction to a fragment of 31 amino acids in length. This minimal region also functions as an unconventional nuclear localization signal sufficient to confer the import of full-length RIP3 to the nucleus to trigger apoptosis, suggesting that RIP3 is able to play an apoptosis-inducing role in the nucleus. In addition, we have characterized two novel leucine-rich nuclear export signals (NESs) that are responsible for the nuclear export of RIP3 to the cytoplasm via a chromosome region maintenance 1 (CRM1)-dependent pathway and an extra leucine-rich NES in the N terminus of RIP3 that contributes to the cytoplasmic distribution in a CRM1-independent manner. Thus, we provide the first evidence that RIP3 acts a nucleocytoplasmic shuttling protein, which presents a possible link between death receptor signaling and nuclear apoptosis.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, MA (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.	wumian88@yahoo.com	Chen, Youjun/G-4066-2015; Chen, Youjun/N-2571-2014; Ma, Jan/A-2241-2011; Wu, Mian/H-2494-2018	Chen, Youjun/0000-0003-4162-6897; Chen, Youjun/0000-0003-4162-6897; Wu, Mian/0000-0002-2714-0500				Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giannini A, 2004, EXP CELL RES, V295, P150, DOI 10.1016/j.yexcr.2003.12.012; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Ke N, 2001, J BIOL CHEM, V276, P12481, DOI 10.1074/jbc.C000871200; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Yang YH, 2002, FEBS LETT, V532, P36, DOI 10.1016/S0014-5793(02)03624-4; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5	26	44	48	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38820	38829		10.1074/jbc.M401663200	http://dx.doi.org/10.1074/jbc.M401663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208320	hybrid			2022-12-25	WOS:000223684100094
J	Garcin, ED; Bruns, CM; Lloyd, SJ; Hosfield, DJ; Tiso, M; Gachhui, R; Stuehr, DJ; Tainer, JA; Getzoff, ED				Garcin, ED; Bruns, CM; Lloyd, SJ; Hosfield, DJ; Tiso, M; Gachhui, R; Stuehr, DJ; Tainer, JA; Getzoff, ED			Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; REDUCTASE DOMAIN; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURES; OXYGENASE DOMAIN; TRANSFER COMPLEX; NO SYNTHASE; CALMODULIN; BINDING; ISOFORMS	Three nitric-oxide synthase (NOS) isozymes play crucial, but distinct, roles in neurotransmission, vascular homeostasis, and host defense, by catalyzing Ca2+/calmodulin-triggered NO synthesis. Here, we address current questions regarding NOS activity and regulation by combining mutagenesis and biochemistry with crystal structure determination of a fully assembled, electron-supplying, neuronal NOS reductase dimer. By integrating these results, we structurally elucidate the unique mechanisms for isozyme-specific regulation of electron transfer in NOS. Our discovery of the autoinhibitory helix, its placement between domains, and striking similarities with canonical calmodulin-binding motifs, support new mechanisms for NOS inhibition. NADPH, isozyme-specific residue Arg(1400), and the C-terminal tail synergistically repress NOS activity by locking the FMN binding domain in an electron-accepting position. Our analyses suggest that calmodulin binding or C-terminal tail phosphorylation frees a large scale swinging motion of the entire FMN domain to deliver electrons to the catalytic module in the holoenzyme.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Syrrx Inc, San Diego, CA 92121 USA; Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Scripps Research Institute; Scripps Research Institute; Cleveland Clinic Foundation	Getzoff, ED (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB4, La Jolla, CA 92037 USA.	edg@scripps.edu	Tainer, John/GWQ-4878-2022; Garcin, Elsa D/C-1556-2013	Tainer, John/0000-0003-1659-2429; Garcin, Elsa D/0000-0003-0501-8421	NHLBI NIH HHS [R01HL58883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Brunner K, 1998, BIOCHEMISTRY-US, V37, P17545, DOI 10.1021/bi981138l; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Kobayashi K, 2001, J BIOL CHEM, V276, P39864, DOI 10.1074/jbc.M102537200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rosenfeld RJ, 2002, BIOCHEMISTRY-US, V41, P13915, DOI 10.1021/bi026313j; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	56	233	237	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37918	37927		10.1074/jbc.M406204200	http://dx.doi.org/10.1074/jbc.M406204200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208315	hybrid			2022-12-25	WOS:000223554600085
J	Bianchi, C; Genova, ML; Castelli, GP; Lenaz, G				Bianchi, C; Genova, ML; Castelli, GP; Lenaz, G			The mitochondrial respiratory chain is partially organized in a supercomplex assembly - Kinetic evidence using flux control analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; CYTOCHROME-C OXIDOREDUCTASE; BOVINE HEART-MITOCHONDRIA; COENZYME-Q REDUCTASE; COMPLEX-I; ELECTRON-TRANSPORT; OXIDATIVE-PHOSPHORYLATION; PARACOCCUS-DENITRIFICANS; SUBMITOCHONDRIAL PARTICLES; OXIDASE SUPERCOMPLEX	The model of the respiratory chain in which the enzyme complexes are independently embedded in the lipid bilayer of the inner mitochondrial membrane and connected by randomly diffusing coenzyme Q and cytochrome c is mostly favored. However, multicomplex units can be isolated from mammalian mitochondria, suggesting a model based on direct electron channeling between complexes. Kinetic testing using metabolic flux control analysis can discriminate between the two models: the former model implies that each enzyme may be rate-controlling to a different extent, whereas in the latter, the whole metabolic pathway would behave as a single supercomplex and inhibition of any one of its components would elicit the same flux control. In particular, in the absence of other components of the oxidative phosphorylation apparatus (i.e. ATP synthase, membrane potential, carriers), the existence of a supercomplex would elicit a flux control coefficient near unity for each respiratory complex, and the sum of all coefficients would be well above unity. Using bovine heart mitochondria and submitochondrial particles devoid of substrate permeability barriers, we investigated the flux control coefficients of the complexes involved in aerobic NADH oxidation (I, III, IV) and in succinate oxidation (II, III, IV). Both Complexes I and III were found to be highly rate-controlling over NADH oxidation, a strong kinetic evidence suggesting the existence of functionally relevant association between the two complexes, whereas Complex IV appears randomly distributed. Moreover, we show that Complex II is fully rate-limiting for succinate oxidation, clearly indicating the absence of substrate channeling toward Complexes III and IV.	Univ Bologna, Dipartimento Biochim G Moruzzi, I-40126 Bologna, Italy	University of Bologna	Lenaz, G (corresponding author), Univ Bologna, Dipartimento Biochim G Moruzzi, Via Irnerio 48, I-40126 Bologna, Italy.	lenaz@biocfarm.unibo.it	Genova, Maria Luisa/H-6921-2012; Lenaz, Giorgio/B-5751-2013	Genova, Maria Luisa/0000-0002-9176-3630; 				BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Bianchi C, 2003, BIOFACTORS, V18, P3, DOI 10.1002/biof.5520180202; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BRAND MD, 1994, EUR J BIOCHEM, V226, P819, DOI 10.1111/j.1432-1033.1994.00819.x; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; EUBEL H, 2003, PLANT PHYSIOL, V133, P1; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105; Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1; Gutman M, 1985, COENZYME Q, P215; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hatefi Y, 1978, Methods Enzymol, V53, P21; Hatefi Y, 1978, Methods Enzymol, V53, P48; HATEFI Y, 1961, BIOCHIM BIOPHYS ACTA, V52, P106, DOI 10.1016/0006-3002(61)90908-8; Hatefi Y, 1978, Methods Enzymol, V53, P3; HATEFI Y, 1962, J BIOL CHEM, V237, P1676; HERON C, 1978, BIOCHEM J, V174, P791, DOI 10.1042/bj1740791; HOCHLI M, 1976, P NATL ACAD SCI USA, V73, P1636, DOI 10.1073/pnas.73.5.1636; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; *JAND SCI SOFTW, 1995, SIGM PLOT SCI GRAPH; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; LENAZ G, 1986, J BIOENERG BIOMEMBR, V18, P369, DOI 10.1007/BF00743011; Lenaz G, 2001, FEBS LETT, V509, P151, DOI 10.1016/S0014-5793(01)03172-6; Matsson M, 2001, J BIOENERG BIOMEMBR, V33, P99, DOI 10.1023/A:1010744330092; Moreno-Sanchez R, 1999, EUR J BIOCHEM, V264, P427, DOI 10.1046/j.1432-1327.1999.00621.x; Niebisch A, 2003, J BIOL CHEM, V278, P4339, DOI 10.1074/jbc.M210499200; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; Singer T P, 1979, Methods Enzymol, V55, P454; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SONE N, 1987, J BIOL CHEM, V262, P15386; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; Vanderkooi G, 1978, MOL BIOL MEMBRANES, P25; Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8; VONJAGOW G, 1986, BIOCHEMISTRY-US, V25, P775, DOI 10.1021/bi00352a006; YU L, 1982, J BIOL CHEM, V257, P2016; zawa T, 1987, BIOENERGETICS STRUCT, P101	52	197	202	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36562	36569		10.1074/jbc.M405135200	http://dx.doi.org/10.1074/jbc.M405135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205457	hybrid			2022-12-25	WOS:000223453600052
J	Jiang, HL; McGiff, JC; Quilley, J; Sacerdoti, D; Reddy, LM; Falck, JR; Zhang, F; Lerea, KM; Wong, PYK				Jiang, HL; McGiff, JC; Quilley, J; Sacerdoti, D; Reddy, LM; Falck, JR; Zhang, F; Lerea, KM; Wong, PYK			Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; 5,6-EPOXYEICOSATRIENOIC ACID; EPOXYGENASE METABOLITES; RAT-KIDNEY; HYPERPOLARIZING FACTOR; ANGIOTENSIN-II; CYCLOOXYGENASE; VASODILATION; INHIBITION	A novel eicosanoid, 5,6-trans-epoxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-trans-EET), was identified in rat red blood cells. Characterization of 5,6-trans-EET in the sn-2 position of the phospholipids was accomplished by hydrolysis with phospholipase A(2) followed by gas chromatography/mass spectrometry as well as electrospray ionization-tandem mass spectrometry analyses. The electron ionization spectrum of 5,6-erythro-dihydroxyeicosatrienoic acid (5,6-erythro-DHET), converted from 5,6-trans-EET in the samples, matches that of the authentic standard. Hydrogenation of the extracted 5,6-erythro-DHET with platinum(IV) oxide/hydrogen resulted in an increase of the molecular mass by 6 daltons and the same retention time shift as an authentic standard in gas chromatography, suggesting the existence of three olefins as well as the 5,6-erythro-dihydroxyl structure in the metabolite. Match of retention times by chromatography indicated identity of the stereochemistry of the red blood cell 5,6-erythro-DHET vis a vis the synthetic standard. High pressure liquid chromatography-electrospray ionization-tandem mass spectrometry analysis of the phospholipase A(2)-hydrolyzed lipid extracts from red blood cells revealed match of the mass spectrum and retention time of the compound with the authentic 5,6-trans-EET standard, providing direct evidence of the existence of 5,6-trans-EET in red blood cells. The presence of other trans-EETs was also demonstrated. The ability of both 5,6-trans-EET and its product 5,6-erythro-DHET to relax preconstricted renal interlobar arteries was significantly greater than that of 5,6-cis-EET. In contrast, 5,6-cis-EET and 5,6-trans-EET were equipotent in their capacity to inhibit collagen-induced rat platelet aggregation, whereas 5,6-erythro-DHET was without effect. We propose that the red blood cells serve as a reservoir for epoxides which on release may act in a vasoregulatory capacity.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Univ Padua, Dept Med, I-35128 Padua, Italy; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	New York Medical College; New York Medical College; University of Padua; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jiang, HL (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	houli_jiang@nymc.edu	; Sacerdoti, David/G-3997-2012	Falck, John/0000-0002-9219-7845; Sacerdoti, David/0000-0002-4933-7718	NHLBI NIH HHS [P01 HL034300, HL 25394, HL 34300] Funding Source: Medline; NIGMS NIH HHS [GM 31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300, R01HL025394, R37HL025394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTROM K, 1992, J BIOL CHEM, V267, P3686; BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CARLIN G, 1985, Journal of Free Radicals in Biology and Medicine, V1, P255, DOI 10.1016/0748-5514(85)90129-1; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; CASHMAN JR, 1987, NEUROENDOCRINOLOGY, V46, P246, DOI 10.1159/000124827; Chang WC, 2003, J BIOMED SCI, V10, P599, DOI 10.1159/000073525; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen YJ, 2003, J PHARMACOL EXP THER, V304, P1292, DOI 10.1124/jpet.102.042671; Cheng MK, 2004, BRIT J PHARMACOL, V141, P441, DOI 10.1038/sj.bjp.0705640; COREY EJ, 1980, TETRAHEDRON LETT, V21, P4243, DOI 10.1016/S0040-4039(00)92873-9; DAIKH BE, 1994, J PHARMACOL EXP THER, V269, P1130; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; Falck JR, 2003, AM J PHYSIOL-HEART C, V284, pH337, DOI 10.1152/ajpheart.00831.2001; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; Fulton D, 1998, J LIPID RES, V39, P1713; Fulton D, 1998, J PHARMACOL EXP THER, V287, P497; FULTON D, 1992, BRIT J PHARMACOL, V107, P722, DOI 10.1111/j.1476-5381.1992.tb14513.x; Fulton D, 1996, J PHARMACOL EXP THER, V277, P1195; Han HJ, 2000, KIDNEY INT, V57, P2457, DOI 10.1046/j.1523-1755.2000.00104.x; Hoebel BG, 1998, CLIN EXP PHARMACOL P, V25, P826, DOI 10.1111/j.1440-1681.1998.tb02162.x; Imig JD, 1996, J AM SOC NEPHROL, V7, P2364; Imig JD, 2000, AM J PHYSIOL-RENAL, V279, pF965, DOI 10.1152/ajprenal.2000.279.6.F965; Imig JD, 2001, J VASC RES, V38, P247, DOI 10.1159/000051053; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; JUNIER MP, 1990, ENDOCRINOLOGY, V126, P1534, DOI 10.1210/endo-126-3-1534; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; Medhora M, 1998, INT J MOL MED, V2, P661; Nakamura T, 1997, J MASS SPECTROM, V32, P888, DOI 10.1002/(SICI)1096-9888(199708)32:8<888::AID-JMS548>3.0.CO;2-W; Natarajan R, 2003, CURR OPIN PHARMACOL, V3, P198, DOI 10.1016/S1471-4892(03)00015-8; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; OHISHI N, 1990, METHOD ENZYMOL, V187, P286; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pomposiello SI, 2001, HYPERTENSION, V37, P887, DOI 10.1161/01.HYP.37.3.887; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Quilley J, 2000, TRENDS PHARMACOL SCI, V21, P121, DOI 10.1016/S0165-6147(00)01445-0; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; ROSE HG, 1965, J LIPID RES, V6, P428; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Sprague RS, 1996, AM J PHYSIOL-HEART C, V271, pH2717, DOI 10.1152/ajpheart.1996.271.6.H2717; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Thengchaisri N, 2003, AM J PHYSIOL-HEART C, V285, pH2255, DOI 10.1152/ajpheart.00487.2003; TschirretGuth RA, 1996, ARCH BIOCHEM BIOPHYS, V335, P93, DOI 10.1006/abbi.1996.0485; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; Widstrom RL, 2001, BIOCHEMISTRY-US, V40, P1070, DOI 10.1021/bi001602y; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhang F, 2001, HYPERTENSION, V38, P1311, DOI 10.1161/hy1201.096116	55	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36412	36418		10.1074/jbc.M403962200	http://dx.doi.org/10.1074/jbc.M403962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213230	hybrid			2022-12-25	WOS:000223453600032
J	Dreuw, A; Radtke, S; Pflanz, S; Lippok, BE; Heinrich, PC; Hermanns, HM				Dreuw, A; Radtke, S; Pflanz, S; Lippok, BE; Heinrich, PC; Hermanns, HM			Characterization of the signaling capacities of the novel gp130-like cytokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN-M RECEPTOR; TYROSINE KINASE JAK1; TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; PROTEIN-KINASE; ACTIVATION; INTERLEUKIN-6	The gp130-like receptor (GPL) is a recently cloned member of the family of type I cytokine receptors. The name reflects its close relationship to gp130, the common receptor subunit of the interleukin (IL)-6-type cytokines. Indeed, the recently proposed ligand for GPL, IL-31, is closely related to the IL-6-type cytokines oncostatin M, leukemia inhibitory factor, and cardiotrophin-1. The second signal transducing receptor for IL-31 seems to be the oncostatin M receptor beta (OSMRbeta). The present study characterizes in depth the molecular mechanisms underlying GPL-mediated signal transduction. GPL is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. We identify tyrosine residues 652 and 721 in the cytoplasmic region of the longest isoform of GPL (GPL745) as the major STAT5- and STAT3-activating sites, respectively. Additionally, we demonstrate Jak1 binding to GPL and its activation in heteromeric complexes with the OSMRbeta but also in a homomeric receptor complex. Most interesting, unlike OSMRbeta and gp130, GPL is insufficient to mediate ERK1/2 phosphorylation. We propose that this is due to a lack of recruitment of the tyrosine phosphatase SHP-2 or the adaptor protein Shc to the cytoplasmic domain of GPL.	Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Hermanns, HM (corresponding author), Rhein Westfal TH Aachen, Univ Klinikum, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	heinrich@rwth-aachen.de						AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; DILLON S, 2003, EUR CYTOKINE NETW, V14, P223; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; Gross Jane A., 2003, European Cytokine Network, V14, P109; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Szalai C, 2000, GENE, V243, P161, DOI 10.1016/S0378-1119(99)00536-3; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wiederkehr-Adam M, 2003, J BIOL CHEM, V278, P16117, DOI 10.1074/jbc.M300261200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	66	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36112	36120		10.1074/jbc.M401122200	http://dx.doi.org/10.1074/jbc.M401122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194700	hybrid			2022-12-25	WOS:000223303400113
J	Kinoshita, Y; Johnson, EM				Kinoshita, Y; Johnson, EM			Site-specific loading of an MCM protein complex in a DNA replication initiation zone upstream of the c-MYC gene in the HeLa cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MINICHROMOSOME MAINTENANCE PROTEINS; MCM4,6,7 HELICASE ACTIVITY; PUR-ALPHA; S-PHASE; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN; HUMAN ORC; BINDING; PHOSPHORYLATION	The MCM proteins participate in an orderly association, beginning with the origin recognition complex, that culminates in the initiation of chromosomal DNA replication. Among these, MCM proteins 4, 6, and 7 constitute a subcomplex that reportedly possesses DNA helicase activity. Little is known about DNA sequences initially bound by these MCM proteins or about their cell cycle distribution in the chromatin. We have determined the locations of certain MCM and associated proteins by chromatin immunoprecipitation (ChIP) in a zone of initiation of DNA replication upstream of the c-MYC gene in the HeLa cell cycle. MCM7 and its clamp-loading partner Cdc6 are highly specifically colocalized by ChIP and re-ChIP in G(1) and early S on a 198-bp segment located near the center of the initiation zone. ChIP and Re-ChIP colocalizes MCM7 and ORC1 to the same segment specifically in late G(1). MCM proteins 6 and 7 can be coimmunoprecipitated throughout the cell cycle, whereas MCM4 is reduced in the complex in late S and G(2), reappearing upon mitosis. MCM7 is not visualized by immunohistochemistry on metaphase chromosomes. MCM7 is recruited to multiple sites in chromatin in S and G(2), at which time it is not detected with ORC1. The rate of dissemination is surprisingly slow and is unlikely to be simply attributed to progression with replication forks. Results indicate sequence-specific loading of MCM proteins onto DNA in late G(1) followed by a recruitment to multiple sites in chromatin subsequent to replication.	CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, DH Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Johnson, EM (corresponding author), CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, Box 1194 Pathol, New York, NY 10029 USA.	edward.johnson@mssm.edu			NCI NIH HHS [R01-CA55219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 2002, J BIOL CHEM, V277, P2702, DOI 10.1074/jbc.M108118200; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; Daniel DC, 2001, J GEN VIROL, V82, P1543, DOI 10.1099/0022-1317-82-7-1543; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Dziak R, 2003, J BIOL CHEM, V278, P27372, DOI 10.1074/jbc.M301110200; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; ISHIMI Y, 1994, MOL CELL BIOL, V14, P6489, DOI 10.1128/MCB.14.10.6489; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Johnson EM, 2003, NUCLEIC ACIDS RES, V31, P2915, DOI 10.1093/nar/gkg395; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KARN J, 1974, J BIOL CHEM, V249, P667; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; KORNBERG A, 1992, DNA REPLICATION, P206; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Liu GQ, 2003, MOL CELL BIOL, V23, P1832, DOI 10.1128/MCB.23.5.1832-1842.2003; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schaarschmidt D, 2002, NUCLEIC ACIDS RES, V30, P4176, DOI 10.1093/nar/gkf532; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	51	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35879	35889		10.1074/jbc.M401640200	http://dx.doi.org/10.1074/jbc.M401640200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190069	hybrid			2022-12-25	WOS:000223303400089
J	Kohyama-Koganeya, A; Sasamura, T; Oshima, E; Suzuki, E; Nishihara, S; Ueda, R; Hirabayashi, Y				Kohyama-Koganeya, A; Sasamura, T; Oshima, E; Suzuki, E; Nishihara, S; Ueda, R; Hirabayashi, Y			Drosophila glucosylceramide synthase - A negative regulator of cell death mediated by proapoptotic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSPHINGOLIPID SYNTHESIS; GENETIC INTERFERENCE; BRAINIAC ENCODES; UDP-GLUCOSE; CERAMIDE; PROTEIN; EXPRESSION; APOPTOSIS; TOPOLOGY; SURVIVAL	Glucosylceramide synthase (GlcT-1) catalyzes the formation of glucosylceramide (GlcCer), the core structure of major glycosphingolipids (GSLs), from ceramide and UDP-glucose. Ceramide and its metabolites, such as sphingosine-1-phosphate, are now known to be important mediators of apoptosis and cell survival. Recently, we have shown that GlcT-1 functions to regulate intracellular ceramide levels via glycosylation of ceramide. In this study, we employ the fruit fly Drosophila melanogaster as a model system for understanding the in vivo roles of GlcT-1. We isolated and characterized a GlcT-1 homologue (DGlcT-1) from Drosophila. When DGlcT-1 was expressed in GM-95 cells deficient in GSLs (because of the absence of GlcT-1 activity), these cells regained the ability to synthesize GSLs. Northern blot and in situ hybridization analyses revealed that the expression of DGlcT-1 mRNA was ubiquitous throughout development, suggesting that DGlcT-1 is important for development and differentiation. Indeed, RNA interference experiments demonstrated that the loss of GlcT-1 function enhances apoptotic cell death. Conversely, targeted expression of GlcT-1 partially rescued cell death caused by the proapoptotic factors Reaper and Grim, suggesting that ceramide generation might be one signal pathway that executes the cell death program. We also found that GlcT-1 localized not only in the Golgi apparatus but also in the perinuclear endoplasmic reticulum, providing the first visual evidence of GlcT-1 in membranes. These results indicate that GlcT-1 might down-regulate ceramide generated in these membranes.	RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan; Tokyo Univ Sci, Dept Biol Sci & Technol, Minato Ku, Tokyo 108, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 108, Japan; Soka Univ, Fac Engn, Dept Bioinformat, Cell Biol Lab, Tokyo 1928577, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	RIKEN; Tokyo University of Science; University of Tokyo; Soka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST)	Hirabayashi, Y (corresponding author), RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hirabaya@postman.riken.jp	香山, 綾子/ABF-4396-2021	香山, 綾子/0000-0002-7632-7953; Suzuki, Emiko/0000-0002-4005-0542; Nishihara, Shoko/0000-0002-1668-2603; Hirabayashi, Yoshio/0000-0002-5774-7354				Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P7276; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DE MR, 1997, SCIENCE, V277, P1652; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Goode S, 1996, DEVELOPMENT, V122, P3863; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P12654, DOI 10.1073/pnas.93.10.4638; Ichikawa S, 1998, BIOCHEM BIOPH RES CO, V253, P707, DOI 10.1006/bbrc.1998.9855; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Komori H, 1999, J BIOL CHEM, V274, P8981, DOI 10.1074/jbc.274.13.8981; Komori H, 2000, FEBS LETT, V475, P247, DOI 10.1016/S0014-5793(00)01696-3; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Memon RA, 1999, J BIOL CHEM, V274, P19707, DOI 10.1074/jbc.274.28.19707; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Schwarz A, 1997, J NEUROSCI, V17, P2929; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; SUZUKI E, 1994, J ELECTRON MICROSC, V43, P183; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; van Meer G, 2001, P NATL ACAD SCI USA, V98, P1321, DOI 10.1073/pnas.98.4.1321; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wandall HH, 2003, J BIOL CHEM, V278, P1411, DOI 10.1074/jbc.C200619200; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	54	64	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35995	36002		10.1074/jbc.M400444200	http://dx.doi.org/10.1074/jbc.M400444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210713	hybrid			2022-12-25	WOS:000223303400101
J	Shah, R; Coleman, CS; Mir, K; Baldwin, J; Van Etten, JL; Grishin, NV; Pegg, AE; Stanley, BA; Phillips, MA				Shah, R; Coleman, CS; Mir, K; Baldwin, J; Van Etten, JL; Grishin, NV; Pegg, AE; Stanley, BA; Phillips, MA			Paramecium bursaria chlorella virus-1 encodes an unusual arginine decarboxylase that is a close homolog of eukaryotic ornithine decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; CATALYTIC IRREVERSIBLE INHIBITION; AMINO-ACID DECARBOXYLASES; ACTIVE-SITE RESIDUES; X-RAY-STRUCTURE; TRYPANOSOMA-BRUCEI; ALPHA-DIFLUOROMETHYLORNITHINE; MOLECULAR-MECHANISMS; ANGSTROM RESOLUTION; LEISHMANIA-DONOVANI	Paramecium bursaria chlorella virus (PBCV-1) is a large double-stranded DNA virus that infects chlorella-like green algae. The virus encodes a homolog of eukaryotic ornithine decarboxylase (ODC) that was previously demonstrated to be capable of decarboxylating L-ornithine. However, the active site of this enzyme contains a key amino acid substitution (Glu for Asp) of a residue that interacts with the delta-amino group of ornithine analogs in the x-ray structures of ODC. To determine whether this active-site change affects substrate specificity, kinetic analysis of the PBCV-1 decarboxylase (PBCV-1 DC) on three basic amino acids was undertaken. The k(cat)/K-m for L-arginine is 550-fold higher than for either L-ornithine or L-lysine, which were decarboxylated with similar efficiency. In addition, alpha-difluoromethylarginine was a more potent inhibitor of the enzyme than alpha-difluoromethylornithine. Mass spectrometric analysis demonstrated that inactivation was consistent with the formation of a covalent adduct at Cys(347). These data demonstrate that PBCV-1 DC should be reclassified as an arginine decarboxylase. The eukaryotic ODCs, as well as PBCV-1 DC, are only distantly related to the bacterial and plant arginine decarboxylases from their common beta/alpha-fold class; thus, the finding that PBCV-1 DC prefers L-arginine to L-ornithine was unexpected based on evolutionary analysis. Mutational analysis was carried out to determine whether the Asp-to-Glu substitution at position 296 (position 332 in Trypanosoma brucei ODC) conferred the change in substrate specificity. This residue was found to be an important determinant of substrate binding for both L-arginine and L-ornithine, but it is not sufficient to encode the change in substrate preference.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu	Stanley, Bruce/R-9856-2019	Stanley, Bruce/0000-0003-1338-2928	NCI NIH HHS [R37 CA18138] Funding Source: Medline; NCRR NIH HHS [P20RR15635] Funding Source: Medline; NIAID NIH HHS [R01 AI34432] Funding Source: Medline; NIGMS NIH HHS [GM32441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018138] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BITONTI AJ, 1987, BIOCHEM J, V242, P69, DOI 10.1042/bj2420069; BROWN MR, 1992, J EXP MAR BIOL ECOL, V161, P91, DOI 10.1016/0022-0981(92)90192-D; Coleman CS, 2004, BIOCHEM J, V379, P849, DOI 10.1042/BJ20040035; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; COLIGAN JE, 1996, CURRENT PROTOCOLS PR, V2; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hanfrey C, 2002, J BIOL CHEM, V277, P44131, DOI 10.1074/jbc.M206161200; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jackson LK, 2003, J BIOL CHEM, V278, P22037, DOI 10.1074/jbc.M300188200; Jeffrey CJ, 2000, PROTEIN ENG, V13, P105; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Kaiser A, 1999, VIROLOGY, V263, P254, DOI 10.1006/viro.1999.9972; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Li F, 1998, EXP PARASITOL, V88, P255, DOI 10.1006/expr.1998.4237; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MOMANY C, 1995, PROTEIN SCI, V4, P849; Morehead TA, 2002, VIROLOGY, V301, P165, DOI 10.1006/viro.2002.1573; Morgan DML, 1999, MOL BIOTECHNOL, V11, P229, DOI 10.1007/BF02788682; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; OBrien TG, 1997, CANCER RES, V57, P2630; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; Osterman AL, 1997, BIOCHEMISTRY-US, V36, P4558, DOI 10.1021/bi962916h; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; PEGG AE, 1994, BIOCHEM SOC T, V22, P846, DOI 10.1042/bst0220846; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; PEGG AE, 1995, J CELL BIOCHEM, P132; Pei JM, 2003, BIOINFORMATICS, V19, P427, DOI 10.1093/bioinformatics/btg008; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; POULIN R, 1992, J BIOL CHEM, V267, P150; Rajagopalan PTR, 2002, BIOCHEMISTRY-US, V41, P12618, DOI 10.1021/bi026369d; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; Roberts SC, 2002, J BIOL CHEM, V277, P5902, DOI 10.1074/jbc.M110118200; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tome ME, 1997, BIOL SIGNAL, V6, P150; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200	53	28	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35760	35767		10.1074/jbc.M405366200	http://dx.doi.org/10.1074/jbc.M405366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190062	hybrid			2022-12-25	WOS:000223303400075
J	Werner, ED; Lee, JS; Hansen, L; Yuan, MS; Shoelson, SE				Werner, ED; Lee, JS; Hansen, L; Yuan, MS; Shoelson, SE			Insulin resistance due to phosphorylation of insulin receptor substrate-1 at Serine 302	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYROSINE PHOSPHORYLATION; SERINE/THREONINE PHOSPHORYLATION; FACTOR-ALPHA; METABOLIC SYNDROME; TARGETED DISRUPTION; DIABETES-MELLITUS; SIGNALING CASCADE	Inhibitory serine phosphorylation is a potential molecular mechanism for insulin resistance. We have developed a new variant of the yeast two-hybrid method, referred to as disruptive yeast tri-hybrid (Y3H), to identify inhibitory kinases and sites of phosphorylation in insulin receptors (IR) and IR substrates, IRS-1. Using IR and IRS-1 as bait and prey, respectively, and c-Jun NH2-terminal kinase (JNK1) as the disruptor, we now show that phosphorylation of IRS-1 Ser-307, a previously identified site, is necessary but not sufficient for JNK1-mediated disruption of IR/IRS-1 binding. We further identify a new phosphorylation site, Ser-302, and show that this too is necessary for JNK1-mediated disruption. Seven additional kinases potentially linked to insulin resistance similarly block IR/IRS-1 binding in the disruptive Y3H, but through distinct Ser-302- and Ser-307-independent mechanisms. Phosphospecific antibodies that recognize sequences surrounding Ser(P)-302 or Ser(P)-307 were used to determine whether the sites were phosphorylated under relevant conditions. Phosphorylation was promoted at both sites in Fao hepatoma cells by reagents known to promote Ser/Thr phosphorylation, including the phorbol ester phorbol 12-myristate 13-acetate, anisomycin, calyculin A, and insulin. The antibodies further showed that Ser(P)-302 and Ser(P)-307 are increased in animal models of obesity and insulin resistance, including genetically obese ob/ob mice, diet-induced obesity, and upon induction of hyperinsulinemia. These findings demonstrate that phosphorylation at both Ser-302 and Ser-307 is necessary for JNK1-mediated inhibition of the IR/IRS-1 interaction and that Ser-302 and Ser-307 are phosphorylated in parallel in cultured cells and in vivo under conditions that lead to insulin resistance.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Lee, JS (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	Jongsoon.Lee@joslin.harvard.edu; Steven.Shoelson@joslin.harvard.edu	Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045943, P30DK036836, R21DK063225, F32DK009393, R01DK043123] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45943, DK43123, DK63225, DK36836, DK09393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; DHEPAGANON S, 2004, IN PRESS NAT STRUCT; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Harlow E., 1988, ANTIBODIES LAB MANUA; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; LAM K, 1994, J BIOL CHEM, V269, P20648; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; *NAT DIAB DAT GROU, 1994, DIAB AM; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Radziuk J, 2000, J CLIN ENDOCR METAB, V85, P4426, DOI 10.1210/jc.85.12.4426; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	80	178	181	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35298	35305		10.1074/jbc.M405203200	http://dx.doi.org/10.1074/jbc.M405203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199052	hybrid, Green Published			2022-12-25	WOS:000223303400021
J	Comegys, MM; Lin, SH; Rand, D; Britt, D; Flanagan, D; Callanan, H; Brilliant, K; Hixson, DC				Comegys, MM; Lin, SH; Rand, D; Britt, D; Flanagan, D; Callanan, H; Brilliant, K; Hixson, DC			Two variable regions in carcinoembryonic antigen-related cell adhesion molecule1 N-terminal domains located in or next to monoclonal antibody and adhesion epitopes show evidence of recombination in rat but not in human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; BILIARY GLYCOPROTEIN ISOFORMS; C-CAM; PLASMA-MEMBRANE; GENE FAMILY; HEPATOCELLULAR CARCINOMAS; TUMOR-SUPPRESSOR; ECTO-ATPASE; CEA FAMILY; INTERCELLULAR-ADHESION	In this paper, we have characterized the structure, evolutionary origin, and function of rat and human carcinoembryonic antigen-related cell adhesion molecule1 (CEACAM1) multifunctional Ig-like cell adhesion proteins that are expressed by many epithelial tissues. Restriction enzyme digestion reverse transcriptase-PCR analysis identified three cDNAs encoding novel CEACAM1 N-domains. Comparative sequence analysis showed that human and rat CEACAM1 N-domains segregated into two groups differing in similarity to rat CEACAM1(a)-4L and human CEACAM1. Sequence variability analysis indicated that both human and rat N-domains possessed two variable regions, and one contained a major adhesive epitope. Recombination analysis showed that the group of rat but not human N-domains with high sequence similarity was derived at least in part by recombination. Binding assays revealed that three monoclonal antibodies with strong reactivity for the CEACAM1(a)-4L N-domain showed no reactivity with CEACAM1(b)-4S, an allele with a different N-domain sequence. CEACAM1(b)-4S displayed adhesive activity efficiently blocked by a synthetic peptide corresponding to the adhesive epitope in CEACAM1(a)-4L. Blocking analysis also showed that the adhesive epitope for rat CEACAM1 was located downstream from the equivalent human and mouse epitopes. Glycosylation analysis demonstrated O-linked sugars on rat CEACAM1(b)-4S from COS-1 cells. However, this was not the alteration responsible for the lack of monoclonal antibody reactivity. When considered together with previous studies, our findings suggest an inverse relationship between functionality and amino acid sequence similarity to CEACAM1. Like IgG, the N-domain of CEACAM1 appears to tolerate 10 - 15% sequence diversification without loss of function but begins to show either altered specificity or diminished functionality at higher levels.	Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol & Oncol, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center; Brown University	Hixson, DC (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol & Oncol, 593 Eddy St, Providence, RI 02903 USA.	dhixson@lifespan.org			NATIONAL CANCER INSTITUTE [R01CA042714] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42714] Funding Source: Medline; NCRR NIH HHS [1P20 RR 17695] Funding Source: Medline; NIMH NIH HHS [NIMH 64856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BAUM O, 1995, EUR J BIOCHEM, V228, P316; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; BECKER A, 1986, EUR J CELL BIOL, V39, P417; BLOCHBERGER TC, 1989, J BIOL CHEM, V264, P20718; Bos MP, 1999, J EXP MED, V190, P331, DOI 10.1084/jem.190.3.331; Bos MP, 2002, INFECT IMMUN, V70, P1715, DOI 10.1128/IAI.70.4.1715-1723.2002; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; Comegys MM, 1999, ONCOGENE, V18, P3261, DOI 10.1038/sj.onc.1202666; *CTR BIOL SEQ AN, NETOGLYC SOFTW; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DVEKSLER GS, 1995, J VIROL, V69, P543, DOI 10.1128/JVI.69.1.543-546.1995; EDLUND M, 1993, EUR J BIOCHEM, V213, P1109, DOI 10.1111/j.1432-1033.1993.tb17860.x; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FARIS RA, 1990, CANCER RES, V50, P4755; Finkenzeller D, 2000, MOL CELL BIOL, V20, P7140, DOI 10.1128/MCB.20.19.7140-7145.2000; Finkenzeller D, 2003, MOL CELL BIOL, V23, P272, DOI 10.1128/MCB.23.1.272-279.2003; GILBERT G, 1999, SEQPUP SOFTWARE VERS; Hammarstrom S, 1998, CELL ADHES COMMUN S, V5, P1; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1989, CANCER RES, V49, P6788; Hixson DC, 2000, EXP MOL PATHOL, V68, P152, DOI 10.1006/exmp.2000.2302; HIXSON DC, 1983, CANCER RES, V43, P3874; HIXSON DC, 1985, CANCER RES, V45, P5049; HSIEH JT, 1995, CANCER RES, V55, P190; Huang XL, 1997, BIOCHEMISTRY-US, V36, P10846, DOI 10.1021/bi9703655; Huang YQ, 1997, J CELL BIOL, V138, P143, DOI 10.1083/jcb.138.1.143; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Hughes AL, 1997, BIOESSAYS, V19, P777, DOI 10.1002/bies.950190907; *I MOL EV GEN, MEGA SOFTW; Kannicht C, 1999, GLYCOBIOLOGY, V9, P897, DOI 10.1093/glycob/9.9.897; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; Kleinerman DI, 1996, CANCER RES, V56, P3431; KODELJA V, 1989, J BIOL CHEM, V264, P6906; Kunath T, 1995, ONCOGENE, V11, P2375; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Liang TC, 1996, ARCH BIOCHEM BIOPHYS, V329, P208, DOI 10.1006/abbi.1996.0210; Lim YP, 1996, CANCER RES, V56, P3934; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; Lin SH, 1998, BIOCHEM BIOPH RES CO, V245, P472, DOI 10.1006/bbrc.1998.8381; McCaw SE, 2003, MOL MICROBIOL, V49, P623, DOI 10.1046/j.1365-2958.2003.03591.x; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCENTIRE KD, 1989, CANCER RES, V49, P6795; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOWERY J, 1991, HEPATOLOGY, V13, P47; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINTER A, 1988, J VIROL, V62, P1016, DOI 10.1128/JVI.62.3.1016-1021.1988; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; Popp A, 1999, CELL MICROBIOL, V1, P169, DOI 10.1046/j.1462-5822.1999.00017.x; Rao PV, 1997, VIROLOGY, V229, P336, DOI 10.1006/viro.1997.8446; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rozas J, 1997, COMPUT APPL BIOSCI, V13, P307; RUDERT F, 1989, J MOL EVOL, V29, P126, DOI 10.1007/BF02100111; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SIGAL SH, 1994, HEPATOLOGY, V19, P999; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Taheri M, 2000, J BIOL CHEM, V275, P26935; Tan KM, 2002, EMBO J, V21, P2076, DOI 10.1093/emboj/21.9.2076; TEIXEIRA AM, 1994, BLOOD, V84, P211; Turbide C, 1997, CANCER RES, V57, P2781; Virji M, 1999, MOL MICROBIOL, V34, P538, DOI 10.1046/j.1365-2958.1999.01620.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469; Wessner DR, 1998, J VIROL, V72, P1941, DOI 10.1128/JVI.72.3.1941-1948.1998; Wikstrom K, 1996, EXP CELL RES, V227, P360, DOI 10.1006/excr.1996.0285; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YANG L, 1993, HEPATOLOGY, V18, P357, DOI 10.1016/0270-9139(93)90019-J; Zimmermann W, 1998, CELL ADHES COMMUN S, V5, P31	82	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35063	35078		10.1074/jbc.M404431200	http://dx.doi.org/10.1074/jbc.M404431200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184366	hybrid			2022-12-25	WOS:000223134800119
J	Karacsonyi, C; Knorr, R; Fulbier, A; Lindner, R				Karacsonyi, C; Knorr, R; Fulbier, A; Lindner, R			Association of major histocompatibility complex II with cholesterol- and sphingolipid-rich membranes precedes peptide loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; T-CELL RESPONSES; LIPID RAFTS; INVARIANT CHAIN; ANTIGEN PRESENTATION; EARLY ENDOSOMES; IN-VIVO; HLA-DM; B-CELL; TETRASPAN MICRODOMAINS	Major histocompatibility complex class II protein (MHC II) molecules present antigenic peptides to CD4-positive T-cells. Efficient T cell stimulation requires association of MHC II with membrane microdomains organized by cholesterol and glycosphingolipids or by tetraspanins. Using detergent extraction at 37 degreesC combined with a modified flotation assay, we investigated the sequence of events leading to the association of MHC II with cholesterol- and glycosphingolipid-rich membranes (DRMs) that are distinct from tetraspanins. We find two stages of association of MHC II with DRMs. In stage one, complexes of MHC II and invariant chain, a chaperone involved in MHC II transport, enter DRMs in the Golgi stack. In early endosomes, these complexes are almost quantitatively associated with DRMs. Upon transport to late endocytic compartments, MHC II-bound invariant chain is stepwise proteolyzed to the MHC class II-associated invariant chain peptide ( CLIP) that remains MHC II-bound and retains a preference for DRMs. At the transition between the two stages, CLIP is exchanged against processed antigens, and the resulting MHC II-peptide complexes are transported to the cell surface. In the second stage, MHC II shows a lower overall association with DRMs. However, surface MHC II molecules occupied with peptides that induce resistance to denaturation by SDS are enriched in DRMs relative to SDS-sensitive MHC II-peptide complexes. Likewise, MHC II molecules loaded with long-lived processing products of hen-egg lysozyme containing the immunodominant epitope 48 - 61 show a very high preference for DRMs. Thus after an initial mainly intracellular stage of high DRM association, MHC II moves to a second stage in which its preference for DRMs is modulated by bound peptides.	Hannover Med Sch, Dept Cell Biol, Ctr Anat, D-30625 Hannover, Germany	Hannover Medical School	Lindner, R (corresponding author), Carl Neuberg Str 1, D-30625 Hannover, Germany.	rli@zellbiologie.mh-hannover.de	Lindner, Robert/AAO-9538-2020	Lindner, Robert/0000-0002-6421-5778				ADAMS TE, 1983, IMMUNOLOGY, V50, P613; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Becart S, 2003, J CELL SCI, V116, P2565, DOI 10.1242/jcs.00449; Bouillon M, 2003, J BIOL CHEM, V278, P7099, DOI 10.1074/jbc.M211566200; Brachet V, 1999, MOL BIOL CELL, V10, P2891, DOI 10.1091/mbc.10.9.2891; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; Busch R, 2000, CURR OPIN IMMUNOL, V12, P99, DOI 10.1016/S0952-7915(99)00057-6; Castellino F, 1998, J IMMUNOL, V161, P4048; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Denzer K, 2000, J CELL SCI, V113, P3365; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dolan BP, 2004, J IMMUNOL, V172, P907, DOI 10.4049/jimmunol.172.2.907; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GLIMCHER LH, 1985, J IMMUNOL, V135, P3542; Goebel J, 2002, HUM IMMUNOL, V63, P813, DOI 10.1016/S0198-8859(02)00458-5; Hammond C, 1998, J IMMUNOL, V161, P3282; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hiltbold EM, 2003, J IMMUNOL, V170, P1329, DOI 10.4049/jimmunol.170.3.1329; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; Lindner R, 2002, TRAFFIC, V3, P133, DOI 10.1034/j.1600-0854.2002.030206.x; Lindner R, 1996, EMBO J, V15, P6910, DOI 10.1002/j.1460-2075.1996.tb01083.x; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; NABAVI N, 1989, J IMMUNOL, V142, P1444; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; Pond L, 1999, J BIOL CHEM, V274, P18049, DOI 10.1074/jbc.274.25.18049; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SCHAFER PH, 1994, IMMUNITY, V1, P699, DOI 10.1016/1074-7613(94)90040-X; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Setterblad N, 2003, J LEUKOCYTE BIOL, V74, P40, DOI 10.1189/jlb.0103045; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Verreck FAW, 2001, EUR J IMMUNOL, V31, P1029, DOI 10.1002/1521-4141(200104)31:4<1029::AID-IMMU1029>3.0.CO;2-Q; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574	67	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34818	34826		10.1074/jbc.M404608200	http://dx.doi.org/10.1074/jbc.M404608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184367	hybrid			2022-12-25	WOS:000223134800090
J	Martin, CC; Oeser, JK; O'Brien, RM				Martin, CC; Oeser, JK; O'Brien, RM			Differential regulation of islet-specific glucose-6-phosphatase catalytic subunit-related protein gene transcription by Pax-6 and Pdx-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; GLUCAGON GENE; PAIRED-DOMAIN; IN-VIVO; GLUCOSE-METABOLISM; INSULIN PROMOTER; CONTROL ELEMENT; BETA-CELLS; T-CELLS; EXPRESSION	Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) is selectively expressed in islet beta cells and is a major autoantigen in a mouse model of type I diabetes. The analysis of IGRP-chloramphenicol acetyltransferase ( CAT) fusion gene expression through transient transfection of islet-derived betaTC-3 cells revealed that a promoter region, located between - 273 and - 254, is essential for high IGRP-CAT fusion gene expression. The sequence of this promoter region does not match that for any known islet-enriched transcription factor. However, data derived from gel retardation assays, a modified ligation-mediated polymerase chain reaction in situ footprinting technique and a SDS-polyacrylamide separation/renaturation procedure led to the hypothesis that this protein might be Pax-6, a conclusion that was confirmed by gel supershift assays. Additional experiments revealed a second non-consensus Pax-6 binding site in the - 306/ - 274 IGRP promoter region. Pax-6 binding to these elements is unusual in that it appears to require both its homeo and paired domains. Interestingly, loss of Pax-6 binding to the - 273/ - 246 element is compensated by Pax-6 binding to the - 306/ - 274 element and vice versa. Gel retardation assays revealed that another islet-enriched transcription factor, namely Pdx-1, binds four non-consensus elements in the IGRP promoter. However, mutation of these elements has little effect on IGRP fusion gene expression. Although chromatin immunoprecipitation assays show that both Pax-6 and Pdx-1 bind to the IGRP promoter within intact cells, in contrast to the critical role of these factors in beta cell-specific insulin gene expression, IGRP gene transcription appears to require Pax-6 but not Pdx-1.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 761 PRB MRB II, Nashville, TN 37232 USA.	richard.obrien@vanderbilt.edu			NCI NIH HHS [5T32 CA 09385-17] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20593, DK 61645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK061645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Bischof LJ, 2001, DIABETES, V50, P502, DOI 10.2337/diabetes.50.3.502; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Bramblett DE, 2000, ADV PHARMACOL, V47, P255; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Frigeri C, 2004, DIABETES, V53, P1754, DOI 10.2337/diabetes.53.7.1754; Gannon M, 2001, DEV BIOL, V238, P185, DOI 10.1006/dbio.2001.0359; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Hutton JC, 2003, P NATL ACAD SCI USA, V100, P8626, DOI 10.1073/pnas.1633447100; Jun HS, 2002, CELL MOL LIFE SCI, V59, P1892, DOI 10.1007/PL00012512; Jun S, 1996, DEVELOPMENT, V122, P2639; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Lieberman SM, 2003, P NATL ACAD SCI USA, V100, P8384, DOI 10.1073/pnas.0932778100; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Martin CC, 2003, BIOCHEM J, V371, P675, DOI 10.1042/BJ20021585; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Maxam A M, 1980, Methods Enzymol, V65, P499; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Notkins AL, 2002, J BIOL CHEM, V277, P43545, DOI 10.1074/jbc.R200012200; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petrolonis AJ, 2004, J BIOL CHEM, V279, P13976, DOI 10.1074/jbc.M307756200; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Winter William E, 2002, Diabetes Technol Ther, V4, P817, DOI 10.1089/152091502321118838; Yamaoka T, 1999, INT J MOL MED, V3, P247; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	59	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34277	34289		10.1074/jbc.M404830200	http://dx.doi.org/10.1074/jbc.M404830200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180990	hybrid			2022-12-25	WOS:000223134800026
J	Wu, SY; Tan, MJ; Hu, YY; Wang, JL; Scheuner, D; Kaufman, RJ				Wu, SY; Tan, MJ; Hu, YY; Wang, JL; Scheuner, D; Kaufman, RJ			Ultraviolet light activates NF kappa B through translational inhibition of I kappa B alpha synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION; UV-RADIATION; KINASE; INITIATION; TRANSCRIPTION; GCN2; PERK; RNA	UV light induces a delayed and prolonged (3-20 h) activation of NFkappaB when compared with the immediate and acute (10-90 min) activation of NFkappaB in response to tumor necrosis factor alpha treatment. In the early phase (3-12 h) of NFkappaB activation, UV light reduces inhibitor of NFkappaB (IkappaB) through an IkappaB kinase-independent, but polyubiquitin-dependent, pathway. However, the mechanism for the UV light-induced reduction of IkappaB and activation of NFkappaB is not known. In this report, we show that UV light down-regulates the total amount of IkappaB through decreasing IkappaB mRNA translation. Our data show that UV light inhibits translation of IkappaB in wildtype mouse embryo fibroblasts (MEFS/S) and that this inhibition is prevented in MEFA/A cells in which the phosphorylation site, Ser-51 in the eukaryotic translation initiation factor 2 alpha-subunit, is replaced with a non-phosphorylatable Ala (S51A). Our data also show that UV light-induced NFkappaB activation is delayed in MEFA/A cells and in an MCF-7 cell line that is stably transfected with a trans-dominant negative mutant protein kinase-like endoplasmic reticulum kinase (PERK). These results suggest that UV light-induced eukaryotic translation initiation factor 2 alpha-subunit phosphorylation translationally inhibits new IkappaB synthesis. Without a continuous supply of newly synthesized IkappaB, the existing IkappaB is degraded through a polyubiquitin-dependent proteasomal pathway leading to NFkappaB activation. Based upon our results, we propose a novel mechanism by which UV light regulates early phase NFkappaB activation by means of an ER-stress-induced translational inhibition pathway.	Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Wu, SY (corresponding author), Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA.	wus1@ohio.edu	Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 86926] Funding Source: Medline; NIDDK NIH HHS [R01 DK 42394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Faggioli L, 1997, BIOCHEM BIOPH RES CO, V233, P507, DOI 10.1006/bbrc.1997.6489; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PRICE NT, 1991, BIOCHEM BIOPH RES CO, V176, P993, DOI 10.1016/0006-291X(91)90380-P; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; RANU RS, 1979, BIOCHEM BIOPH RES CO, V91, P1437, DOI 10.1016/0006-291X(79)91227-0; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Sood R, 2000, GENETICS, V154, P787; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	28	113	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34898	34902		10.1074/jbc.M405616200	http://dx.doi.org/10.1074/jbc.M405616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184376	hybrid			2022-12-25	WOS:000223134800100
J	Xie, ZC; Romano, DM; Kovacs, DM; Tanzi, RE				Xie, ZC; Romano, DM; Kovacs, DM; Tanzi, RE			Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; CALCIUM HOMEOSTASIS; BETA-APP; PRESENILIN-1; NICASTRIN; CLEAVAGE; APH-1; MUTATIONS; PEN-2	Familial Alzheimer's disease mutations in the presenilin 1 gene (PSEN1) have been previously shown to potentiate caspase activation and apoptosis in transfected cells and transgenic mice. However, the mechanism underlying this effect is not known. We set out to determine whether cellular sensitivity to caspase activation could be affected by modulating presenilin 1 (PS1) processing. PS1 processing was altered using RNA interference (RNAi) aimed at silencing the expression of the genes encoding the four components of the gamma-secretase complex, PSEN1, APH-1, PEN-2, and nicastrin. RNAi for these genes was carried out in naive H4 human neuroglioma cells, as well as H4 cell lines overexpressing either wild-type PSEN1 or the Familial Alzheimer's disease mutant PSEN1-Delta9 (PS1-mutant), that were induced to undergo apoptosis. In wildtype PSEN1 cells, RNAi for PEN-2, as expected, increased levels of full-length PS1 (PS1-FL) and decreased PS1 endoproteolysis. This was accompanied by potentiated caspase-3 activation in response to an apoptotic stimulus. In contrast, nicastrin RNAi, which only decreased levels of PS1-amino-terminal fragment and did not affect PS1-FL levels, had no effect on caspase-3 activation during apoptosis. Surprisingly, in the PS1-mutant cells, RNAi for PEN-2 ( and APH-1) did not increase but instead reduced the levels of PS1-FL deleted for exon 9. In turn, this was accompanied by attenuated caspase-3 activation in response to an apoptotic stimulus. Finally, in naive H4 cells, PSEN1 RNAi also attenuated caspase-3 activation in response to an apoptotic stimulus. Collectively, these findings indicate that cellular sensitivity to caspase activation correlates with overall PS1 protein levels, particularly with levels of FL-PS1.	Massachusetts Gen Hosp, MassGen Inst Neurogenet Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Tanzi, RE (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Genet & Aging Res Unit, 114 16th St,C3009, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060009, R37MH060009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134, R01AG014713] Funding Source: NIH RePORTER; NIA NIH HHS [AG 00294-17, P50 AG 05134, AG 014713-07] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07592] Funding Source: Medline; NIMH NIH HHS [MH 60009-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Chan SL, 2002, NEUROBIOL DIS, V11, P2, DOI 10.1006/nbdi.2002.0542; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Holtzman DM, 1997, NAT MED, V3, P954, DOI 10.1038/nm0997-954; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Mattson MP, 2000, J NEUROSCI, V20, P1358; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Raina AK, 2003, PROG NEURO-PSYCHOPH, V27, P251, DOI 10.1016/S0278-5846(03)00020-4; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1998, NEUROBIOL AGING, V19, pS23, DOI 10.1016/S0197-4580(98)00041-4; Xie ZC, 2004, NEURODEGENER DIS, V1, P29, DOI 10.1159/000076667; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	47	26	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34130	34137		10.1074/jbc.M401094200	http://dx.doi.org/10.1074/jbc.M401094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184387	hybrid			2022-12-25	WOS:000223134800010
J	Revington, M; Holder, TM; Zuiderweg, ERP				Revington, M; Holder, TM; Zuiderweg, ERP			NMR study of nucleotide-induced changes in the nucleotide binding domain of Thermus thermophilus Hsp70 chaperone DnaK - Implications for the allosteric mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; SUBSTRATE-BINDING; SECONDARY STRUCTURE; EXCHANGE FACTOR; ATPASE DOMAIN; COMPLEX; CYCLE; TRANSITION; MUTATIONS	We present an NMR investigation of the nucleotide-dependent conformational properties of a 44-kDa nucleotide binding domain (NBD) of an Hsp70 protein. Conformational changes driven by ATP binding and hydrolysis in the N-terminal NBD are believed to allosterically regulate substrate affinity in the C-terminal substrate binding domain. Several crystal structures of Hsc70 NBDs in different nucleotide states have, however, not shown significant structural differences. We have previously reported the NMR assignments of the backbone resonances of the NBD of the bacterial Hsp70 homologue Thermus thermophilus DnaK in the ADP-bound state. In this study we show, by assigning the NBD with the ATP/transition state analogue, ADP.AlFx, bound, that it closely mimics the ATP-bound state. Chemical shift difference mapping of the two nucleotide states identified differences in a cluster of residues at the interface between subdomains 1A and 1B. Further analysis of the spectra revealed that the ATP state exhibited a single conformation, whereas the ADP state was in slow conformational exchange between a form similar to the ATP state and another state unique to the ADP-bound form. A model is proposed of the allosteric mechanism based on the nucleotide state altering the balance of a dynamic equilibrium between the open and closed states. The observed chemical shift perturbations were concentrated in an area close to a previously described J-domain binding channel, confirming the importance of that region in the allosteric mechanism.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zuiderweg, ERP (corresponding author), Univ Michigan, Div Biophys Res, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	zuiderwe@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063027] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63027] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harrison C, 2003, CELL STRESS CHAPERON, V8, P218, DOI 10.1379/1466-1268(2003)008<0218:GANEFF>2.0.CO;2; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Houry WA, 2001, CURR PROTEIN PEPT SC, V2, P227, DOI 10.2174/1389203013381134; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1998, BIOL CHEM, V379, P261; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Osipiuk J, 1997, BBA-GENE STRUCT EXPR, V1353, P253, DOI 10.1016/S0167-4781(97)00071-7; Reid KL, 1996, CELL STRESS CHAPERON, V1, P127, DOI 10.1379/1466-1268(1996)001<0127:PIBMOT>2.3.CO;2; REVINGTON M, 2004, IN PRESS J BIOLMOL N; *ROCH APPL SCI, 2003, BIOCH CAT, P303; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; Sitkoff D, 1997, J AM CHEM SOC, V119, P12262, DOI 10.1021/ja9721430; Slepenkov SV, 2003, FEBS LETT, V539, P100, DOI 10.1016/S0014-5793(03)00207-2; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	52	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33958	33967		10.1074/jbc.M313967200	http://dx.doi.org/10.1074/jbc.M313967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175340	hybrid			2022-12-25	WOS:000223039700106
J	Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK				Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK			Cre-mediated reversible immortalization of human renal proximal tubular epithelial cells	ONCOGENE			English	Article						immortalization; lentiviral vector; telomerase; T antigen; kidney	HUMAN-FIBROBLASTS; TELOMERASE ACTIVATION; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; HUMAN HEPATOCYTES; DOME FORMATION; IN-VIVO; EXPRESSION; ONCOGENE; TRANSFORMATION	Primary human renal proximal tubule epithelial cells (RPTECs) are of limited use for basic research and for clinical applications due to their limited lifespan in culture. Here we used two lentivirus vectors carrying the human telomerase (hTERT) and the SV40T antigen (Tag) flanked by loxP sites to reversibly immortalize RPTECs. Transduced RPTEC clones continued to proliferate while retaining biochemical and functional characteristics of primary cells. The clones exhibited contact-inhibited, anchorage- and growth factor-dependent growth and did not form tumors in nude mice, suggesting that the cells were not transformed. Transient Cre expression in these cells led to efficient proviral deletion, upregulation of some renal specific activities, and decreased growth rates. Ultimately, the cells underwent replicative senescence, indicating intact cell cycle control. Thus, reversible immortalization allows the expansion of human RPTECs, leading to large production of RPTECs that retain most tissue-specific properties.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Yee, JK (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Miller Bldg 110,1500 E Duarte Rd, Duarte, CA 91010 USA.	jyee@coh.org			NCI NIH HHS [R21 CA101629] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA101629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berghella L, 1999, HUM GENE THER, V10, P1607, DOI 10.1089/10430349950017617; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; Condon J, 2002, BIOL REPROD, V67, P506, DOI 10.1095/biolreprod67.2.506; DEYOUNG LM, 1978, CANCER RES, V38, P3697; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JOLY V, 1990, J PHARMACOL EXP THER, V255, P17; Kawano Y, 2003, BLOOD, V101, P532, DOI 10.1182/blood-2002-04-1268; Kim BH, 2000, EXP MOL MED, V32, P29, DOI 10.1038/emm.2000.6; Kim D, 2002, KIDNEY INT, V61, P464, DOI 10.1046/j.1523-1755.2002.00153.x; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kowolik CM, 2002, MOL THER, V5, P762, DOI 10.1006/mthe.2002.0603; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVER JE, 1979, P NATL ACAD SCI USA, V76, P1323, DOI 10.1073/pnas.76.3.1323; Montalto MC, 1999, J CELL PHYSIOL, V180, P46, DOI 10.1002/(SICI)1097-4652(199907)180:1<46::AID-JCP5>3.0.CO;2-K; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	40	24	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5950	5957		10.1038/sj.onc.1207801	http://dx.doi.org/10.1038/sj.onc.1207801			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208689				2022-12-25	WOS:000222941100009
J	Austenaa, LMI; Carlsen, H; Ertesvag, A; Alexander, G; Blomhoff, HK; Blomhoff, R				Austenaa, LMI; Carlsen, H; Ertesvag, A; Alexander, G; Blomhoff, HK; Blomhoff, R			Vitamin A status significantly alters nuclear factor-kappa B activity assessed by in vivo imaging	FASEB JOURNAL			English	Article						retinoic acid; AGN 194310; vitamin A deficiency; molecular imaging	TRANS-RETINOIC ACID; CYTOKINE PRODUCTION; X-RECEPTOR; ACTIVATION; TRANSCRIPTION; DEFICIENCY; INHIBITION; EXPRESSION; MICE; INFLAMMATION	Our study aimed to investigate, in vivo, the relationship between vitamin A status and NF-kappaB activity, a transcription factor central in regulating inflammatory and immune responses. We used a novel transgenic murine NF-kappaB-luciferase reporter model that enabled molecular imaging of NF-kappaB activity in live mice via an intensified image-capture apparatus. Whole-body luminescence, which reflects overall NF-kappaB activity, was elevated 2.2-fold in vitamin A-deficient (VAD) mice compared with control mice. Specifically, NF-kappaB activity in VAD mice was increased 1.8-fold in the lymph nodes and 1.4-fold in the thymus and, NF-kappaB induction in UVB radiation-exposed skin was also enhanced in VAD mice compared with control mice. The administration of all-trans retinoic acid to VAD mice resulted in a transient reduction in NF-kappaB activity and, conversely, a single dose of the RAR-pan-antagonist, AGN 194310, administered to control mice, led to a marked, transient induction of whole-body luminescence. Our results suggest that vitamin A status, and vitamin A itself, affects NF-kappaB activity in vivo and that the elevated NF-kappaB activity in VAD may be a mechanism underlying some of the features of VAD syndrome.	Univ Oslo, Fac Med, Dept Nutr, Oslo, Norway; Univ Oslo, Fac Med, Dept Biochem, Oslo, Norway	University of Oslo; University of Oslo	Blomhoff, R (corresponding author), Univ Oslo, Fac Med, Dept Nutr, Oslo, Norway.	rune.blomhoff@medisin.uio.no		Carlsen, Harald/0000-0001-5123-5756				Aronica MA, 1999, J IMMUNOL, V163, P5116; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Bellamy C., 1998, STATE WORLDS CHILDRE; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CANTORNA MT, 1995, EUR J IMMUNOL, V25, P1673, DOI 10.1002/eji.1830250629; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Chadwick CC, 1998, EXP CELL RES, V239, P423, DOI 10.1006/excr.1997.3913; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; Cui DM, 2000, J NUTR, V130, P1132, DOI 10.1093/jn/130.5.1132; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Ferreira V, 1999, J IMMUNOL, V162, P6442; Feuillard J, 2000, INT IMMUNOL, V12, P613, DOI 10.1093/intimm/12.5.613; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Hisada T, 1999, EUR J PHARMACOL, V377, P63, DOI 10.1016/S0014-2999(99)00405-7; Horton JW, 2001, J TRAUMA, V50, P397, DOI 10.1097/00005373-200103000-00002; Jolly CA, 2001, CELL IMMUNOL, V213, P122, DOI 10.1006/cimm.2001.1866; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; Livrea M. A., 1994, Retinoids: from basic science to clinical applications., P293; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Reifen R, 2002, J NUTR, V132, P2743, DOI 10.1093/jn/132.9.2743; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Stephensen CB, 2002, J IMMUNOL, V168, P4495, DOI 10.4049/jimmunol.168.9.4495; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Swamidas GP, 1999, J NUTR, V129, P1285, DOI 10.1093/jn/129.7.1285; *WHO, 2003, VIT A DEF; Wiedermann U, 1996, SCAND J IMMUNOL, V44, P578, DOI 10.1046/j.1365-3083.1996.d01-351.x	38	47	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1255	+		10.1096/fj.03-1098fje	http://dx.doi.org/10.1096/fj.03-1098fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180954				2022-12-25	WOS:000222327500033
J	Meyer, M; Belke, DD; Trost, SU; Swanson, E; Dieterle, T; Scott, B; Cary, SP; Ho, P; Bluhm, WF; McDonough, PM; Silverman, GJ; Dillmann, WH				Meyer, M; Belke, DD; Trost, SU; Swanson, E; Dieterle, T; Scott, B; Cary, SP; Ho, P; Bluhm, WF; McDonough, PM; Silverman, GJ; Dillmann, WH			A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation	FASEB JOURNAL			English	Article						FRET; SERCA; PLN-Ab	SARCOPLASMIC-RETICULUM CA2+-ATPASE; HEART-FAILURE; DILATED CARDIOMYOPATHY; MYOCARDIAL-CONTRACTILITY; VENTRICULAR MYOCYTES; MONOCLONAL-ANTIBODY; PROTEIN EXPRESSION; GENE-TRANSFER; MOUSE HEARTS; STIMULATION	Many cardiovascular disease states end in progressive heart failure. Changes in intracellular calcium handling, including a reduced activity of the sarcoplasmic reticulum calcium pump (SERCA), contribute to this contractile dysfunction. As the regulatory protein phospholamban can inhibit the calcium pump, we evaluated it as a potential target to improve cardiac function. In this study, we describe a recombinant antibody-based protein (PLN-Ab) that binds to the cytoplasmic domain of phospholamban. Fluorescence resonance energy transfer (FRET) studies suggest that PLN-Ab mimics the effects of phospholamban phosphorylation. PLN-Ab accelerated the decay of the calcium transient when expressed in neonatal rat and adult mouse ventricular cardiac myocytes. In addition, direct injection of adenovirus encoding PLN-Ab into the diabetic mouse heart enhanced contractility when measured in vivo by echo cardiography and in ex vivo Langendorff perfused hearts. The PLN-Ab provides a novel therapeutic approach to improving contractility through in vivo expression of an antibody inside cardiac myocytes.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dillmann, WH (corresponding author), Univ Calif San Diego, Dept Med, 5063 Basic Sci Bldg, La Jolla, CA 92192 USA.	wdillmann@ucsd.edu	Dieterle, Thomas/CAA-2532-2022; Dieterle, Thomas/AAG-3619-2019	Dieterle, Thomas/0000-0002-3740-1903; Meyer, Markus/0000-0002-4398-5642; Scott, Brian/0000-0002-1321-7204; Silverman, Gregg/0000-0001-9480-9457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052946, R01HL054030, R01HL066917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI046637, R01AI040305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770, P30AR047360] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54030, HL-66917, HL-52946] Funding Source: Medline; NIAID NIH HHS [AI-40305, AI-46637] Funding Source: Medline; NIAMS NIH HHS [AR-40770, P30 AR-47360] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Cary SP, 2000, J IMMUNOL, V164, P4730, DOI 10.4049/jimmunol.164.9.4730; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; Drago GA, 1998, ANN NY ACAD SCI, V853, P273, DOI 10.1111/j.1749-6632.1998.tb08278.x; Eizema K, 2000, CIRCULATION, V101, P2193, DOI 10.1161/01.CIR.101.18.2193; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; He HP, 1999, CIRCULATION, V100, P974, DOI 10.1161/01.CIR.100.9.974; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Kim HW, 2001, LIFE SCI, V70, P367, DOI 10.1016/S0024-3205(01)01483-7; Kiss E, 1998, CIRC RES, V83, P608, DOI 10.1161/01.RES.83.6.608; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MAHLER F, 1975, AM J CARDIOL, V35, P626, DOI 10.1016/0002-9149(75)90048-X; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOVSESIAN MA, 1990, J CLIN INVEST, V85, P1698, DOI 10.1172/JCI114623; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; PACKER M, 1993, J AM COLL CARDIOL, V22, pA119, DOI 10.1016/0735-1097(93)90474-F; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1974, J BIOL CHEM, V249, P6174; Trost SU, 2002, DIABETES, V51, P1166, DOI 10.2337/diabetes.51.4.1166; Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137, DOI 10.1152/ajpheart.2001.281.3.H1137	34	29	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1312	+		10.1096/fj.03-1231fje	http://dx.doi.org/10.1096/fj.03-1231fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180962				2022-12-25	WOS:000222327500027
J	Banninger, G; Reich, NC				Banninger, G; Reich, NC			STAT2 nuclear trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED TRANSCRIPTION FACTOR; INTERFERON REGULATORY FACTOR; DNA-BINDING DOMAIN; IMPORTIN-ALPHA; LOCALIZATION SIGNAL; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; PROTEIN; ACTIVATION; TRANSPORT	STAT2 is a transcription factor critical to the signal transduction pathway of type I interferons (e.g. IFNalpha). STAT2 resides primarily in the cytoplasm and is tyrosine-phosphorylated after IFNalpha binds to cell surface receptors. In response to tyrosine phosphorylation STAT2 rapidly localizes to the nucleus and acquires the ability to bind specific DNA targets in association with two other proteins, STAT1 and IFN regulatory factor-9 (IRF-9). To elucidate the mechanisms that regulate cellular localization of STAT2, we investigated STAT2 nuclear trafficking both prior to tyrosine phosphorylation and after phosphorylation. Prior to phosphorylation, STAT2 is primarily resident in the cytoplasm, however, we found that it dynamically shuttles between nuclear and cytoplasmic compartments. The nuclear translocation of latent unphosphorylated STAT2 was found to be dependent on its constitutive association with IRF-9, and the export of STAT2 from the nucleus was contingent upon the function of an intrinsic nuclear export signal within the carboxyl terminus of STAT2. STAT2 export could be inhibited with leptomycin B, indicating a nuclear export signal within STAT2 is recognized by the CRM1 exportin carrier. In contrast, following tyrosine phosphorylation, STAT2 dimerizes with phosphorylated STAT1 and accumulates in the nucleus. In the absence of STAT1, STAT2 does not accumulate in the nucleus. In addition, subsequent to nuclear import of phosphorylated STAT2, it redistributes to the cytoplasm within an hour coordinate with its dephosphorylation in the nucleus. The regulation of STAT2 nuclear trafficking is distinct from the previously characterized STAT1 factor.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Reich, NC (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA50773] Funding Source: Medline; OAPP OPHS HHS [PPGCA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OAPP OPHS HHS		Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kraus TA, 2003, J BIOL CHEM, V278, P13033, DOI 10.1074/jbc.M212972200; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; Reich NC, 2002, J INTERF CYTOK RES, V22, P103, DOI 10.1089/107999002753452719; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	42	95	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39199	39206		10.1074/jbc.M400815200	http://dx.doi.org/10.1074/jbc.M400815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15175343	hybrid			2022-12-25	WOS:000223791500003
J	Valadi, A; Granath, K; Gustafsson, L; Adler, L				Valadi, A; Granath, K; Gustafsson, L; Adler, L			Distinct intracellular localization of Gpd1p and Gpd2p, the two yeast isoforms of NAD(+)-dependent glycerol-3-phosphate dehydrogenase, explains their different contributions to redox-driven glycerol production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 3-PHOSPHATE DEHYDROGENASE; UBIQUINONE OXIDOREDUCTASE; SUBCELLULAR-LOCALIZATION; CELLULAR-RESPONSES; OSMOTIC-STRESS; MITOCHONDRIAL; NADH; GENE; METABOLISM	During anaerobiosis Saccharomyces cerevisiae strongly increases glycerol production to provide for non-respiratory oxidation of NADH to NAD(+). We here report that respiratory-deficient cells become strictly dependent on the Gpd2p isoform of the NAD(+)-linked glycerol-3-phosphate dehydrogenase (Gpd). The growth inhibition of respiratory incompetent cox18Delta cells lacking GPD2 is reversed by the addition of acetoin, an alternative sink for NADH oxidation. Growth is also restored by addition of lysine or glutamic acid/glutamine, the synthesis of which involves production of mitochondrial NADH. Lysine produced a stronger growth stimulating effect than glutamic acid consistent with an upregulated expression of the IDP3 gene for peroxisomal synthesis of the glutamate precursor alpha-ketoglutarate. Gpd2p is known to be a cytosolic protein but possesses a classical mitochondrial presequence, which we show is sufficient for mitochondrial targeting. A partial mitochondrial localization of Gpd2p will provide for establishment of intramitochondrial redox balance under non-respiratory conditions. Gpd1p, the other Gpd isoform, is partly cytosolic and partly peroxisomal and becomes more strictly peroxisomal in respiratory-deficient mutants. The different cellular distribution of Gpd1p and Gpd2p thus appears to be the main reason Gpd1p cannot substitute for Gpd2p in cox18Deltagpd2Delta cells, despite similar kinetic characteristics of the two iso-enzymes.	Dept Cell & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Dept Mol Biotechnol, SE-40530 Gothenburg, Sweden	Chalmers University of Technology	Adler, L (corresponding author), Dept Cell & Mol Biol Microbiol, Box 462, SE-40530 Gothenburg, Sweden.	Lennart.Adler@gmm.gu.se						ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; ANDRE L, 1991, FEBS LETT, V286, P13, DOI 10.1016/0014-5793(91)80930-2; ANDREASEN AA, 1954, J CELL COMPAR PHYSL, V43, P271, DOI 10.1002/jcp.1030430303; ANDREASEN AA, 1953, J CELL COMPAR PHYSL, V41, P23, DOI 10.1002/jcp.1030410103; Ansell R, 1999, FEBS LETT, V461, P173, DOI 10.1016/S0014-5793(99)01456-8; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bakker BM, 2000, J BACTERIOL, V182, P4730, DOI 10.1128/JB.182.17.4730-4737.2000; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Bjorkqvist S, 1997, APPL ENVIRON MICROB, V63, P128; Brown A D, 1978, Adv Microb Physiol, V17, P181, DOI 10.1016/S0065-2911(08)60058-2; Butow RA, 2002, CELL DEATH DIFFER, V9, P1043, DOI 10.1038/sj.cdd.4401083; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Costenoble R, 2000, YEAST, V16, P1483, DOI 10.1002/1097-0061(200012)16:16<1483::AID-YEA642>3.0.CO;2-K; Cronwright GR, 2002, APPL ENVIRON MICROB, V68, P4448, DOI 10.1128/AEM.68.9.4448-4456.2002; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; GEE R, 1974, ARCH BIOCHEM BIOPHYS, V161, P187, DOI 10.1016/0003-9861(74)90250-1; Gonzalez E, 2000, J BIOL CHEM, V275, P35876, DOI 10.1074/jbc.M003035200; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KAWAMOTO S, 1979, FEBS LETT, V97, P253, DOI 10.1016/0014-5793(79)80096-4; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nissen TL, 1997, MICROBIOL-UK, V143, P203, DOI 10.1099/00221287-143-1-203; Nissen TL, 2000, YEAST, V16, P463, DOI 10.1002/(SICI)1097-0061(20000330)16:5<463::AID-YEA535>3.0.CO;2-3; NORDSTROM K, 1968, J I BREWING, V74, P429, DOI 10.1002/j.2050-0416.1968.tb03154.x; OURA E, 1977, PROCESS BIOCHEM, V12, P19; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; Pronk JT, 2002, APPL ENVIRON MICROB, V68, P2095, DOI 10.1128/AEM.68.5.2095-2100.2002; RONNOW B, 1993, YEAST, V9, P1121, DOI 10.1002/yea.320091013; SAMBROOK J, 1989, MOL CLONIN LAB MANUA; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Sass E, 2003, J BIOL CHEM, V278, P45109, DOI 10.1074/jbc.M302344200; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Skoneczny M, 1996, BIOCHIMIE, V78, P95, DOI 10.1016/0300-9084(96)82639-3; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; Valadi H, 2004, CURR GENET, V45, P90, DOI 10.1007/s00294-003-0469-1; van Roermund CWT, 2003, CELL MOL LIFE SCI, V60, P1838, DOI 10.1007/s00018-003-3076-x; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; von Jagow G, 1970, Eur J Biochem, V12, P583; [No title captured]	54	64	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39677	39685		10.1074/jbc.M403310200	http://dx.doi.org/10.1074/jbc.M403310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15210723	hybrid			2022-12-25	WOS:000223791500059
J	Shabalina, IG; Jacobsson, A; Cannon, B; Nedergaard, J				Shabalina, IG; Jacobsson, A; Cannon, B; Nedergaard, J			Native UCP1 displays simple competitive kinetics between the regulators purine nucleotides and fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; ADAPTIVE NONSHIVERING THERMOGENESIS; UNCOUPLING PROTEIN UCP1; PROTON TRANSPORT; OXIDATIVE-PHOSPHORYLATION; BINDING PROTEIN; INNER MEMBRANE; MITOCHONDRIAL; CONDUCTANCE; MECHANISM	Elucidation of the regulation of uncoupling protein 1 (UCP1) activity in its native environment, i.e. the inner membrane of brown-fat mitochondria, has been hampered by the presence of UCP1-independent, quantitatively unresolved effects of investigated regulators on the brown-fat mitochondria themselves. Here we have utilized the availability of UCP1-ablated mice to dissect UCP1-dependent and UCP1-independent effects of regulators. Using a complex-I-linked substrate ( pyruvate), we found that UCP1 can mediate a 4-fold increase in thermogenesis when stimulated with the classical positive regulator fatty acids ( oleate). After demonstrating that the fatty acids act in their free form, we found that UCP1 increased fatty acid sensitivity similar to30-fold ( as compared with the 1.5-fold increase reported earlier based on nominal fatty acid values). By identifying the UCP1-mediated fraction of the response, we could conclude that the interaction between purine nucleotides (GDP) and fatty acids ( oleate) unexpectedly displayed simple competitive kinetics. In GDP-inhibited mitochondria, oleate apparently acted as an activator. However, only a model in which UCP1 is inherently active (i.e." activating" fatty acids cannot be included in the model), where GDP functions as an inhibitor with a K-m of 0.05 mM, and where oleate functions as a competitive antagonist for the GDP effect (with a K-i of 5 nM) can fit all of the experimental data. We conclude that, when examined in its native environment, UCP1 functions as a proton ( equivalent) carrier in the absence of exogenous or endogenous fatty acids.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Shabalina, Irina/AAC-3720-2019; Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Shabalina, Irina G/A-4225-2011; Cannon, Barbara/B-3089-2016	Shabalina, Irina/0000-0002-2915-6450; Shabalina, Irina G/0000-0002-2915-6450; Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUKOWIEC.LJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P115, DOI 10.1016/0005-2760(74)90097-6; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; CANNON B, 1977, FEBS LETT, V74, P43, DOI 10.1016/0014-5793(77)80748-5; Cannon B, 1979, Methods Enzymol, V55, P65; Cannon B., 1973, MECHANISMS BIOENERGE, P357; Daikoku T, 1997, FEBS LETT, V410, P383, DOI 10.1016/S0014-5793(97)00619-4; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Esteves TC, 2004, BIOCHEM J, V379, P309, DOI 10.1042/BJ20031682; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; HOHORST HJ, 1968, H-S Z PHYSIOL CHEM, V349, P268; HUANG SG, 1995, EUR J BIOCHEM, V229, P718, DOI 10.1111/j.1432-1033.1995.tb20519.x; Huang SG, 2003, ARCH BIOCHEM BIOPHYS, V412, P142, DOI 10.1016/S0003-9861(03)00031-6; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; Nedergaard J, 2001, BIOCHEM SOC T, V29, P756; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NEDERGAARD J, 1977, NATURE, V267, P518, DOI 10.1038/267518a0; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; NICHOLLS DG, 1974, EUR J BIOCHEM, V49, P585, DOI 10.1111/j.1432-1033.1974.tb03862.x; PRUSINER SB, 1968, EUR J BIOCHEM, V6, P15, DOI 10.1111/j.1432-1033.1968.tb00413.x; RAFAEL J, 1969, H-S Z PHYSIOL CHEM, V350, P1121, DOI 10.1515/bchm2.1969.350.2.1121; RAFAEL J, 1994, EUR J BIOCHEM, V223, P971, DOI 10.1111/j.1432-1033.1994.tb19075.x; RAUCHOVA H, 1993, BIOCHEM MOL BIOL INT, V30, P139; REED N, 1968, J BIOL CHEM, V243, P2843; Rial E, 2004, BBA-BIOENERGETICS, V1608, P122, DOI 10.1016/j.bbabio.2003.11.001; RIAL E, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P261; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 2000, BIOCHEMISTRY-US, V39, P7197, DOI 10.1021/bi000314z; SHINOHARA Y, 1995, BBA-BIOENERGETICS, V1228, P229, DOI 10.1016/0005-2728(94)00179-9; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1999, J BIOENERG BIOMEMBR, V31, P431, DOI 10.1023/A:1005492205984; STRIELEMAN PJ, 1985, AM J PHYSIOL, V248, pE699, DOI 10.1152/ajpendo.1985.248.6.E699; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; Urbankova E, 2003, J BIOL CHEM, V278, P32497, DOI 10.1074/jbc.M303721200; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Wojtczak L, 1999, J BIOENERG BIOMEMBR, V31, P447, DOI 10.1023/A:1005444322823; [No title captured]	55	134	137	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38236	38248		10.1074/jbc.M402375200	http://dx.doi.org/10.1074/jbc.M402375200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208325	hybrid			2022-12-25	WOS:000223684100023
J	Wendler, P; Lehmann, A; Janek, K; Baumgart, S; Enenkel, C				Wendler, P; Lehmann, A; Janek, K; Baumgart, S; Enenkel, C			The bipartite nuclear localization sequence of Rpn2 is required for nuclear import of proteasomal base complexes via karyopherin alpha beta and proteasome functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLE BODY DUPLICATION; 26S PROTEASOME; SACCHAROMYCES-CEREVISIAE; REGULATORY PARTICLE; PROTEIN-DEGRADATION; PORE COMPLEXES; FISSION YEAST; CELL-DIVISION; S PROTEASOME; IN-VIVO	26 S proteasomes fulfill final steps in the ubiquitin-dependent degradation pathway by recognizing and hydrolyzing ubiquitylated proteins. As the 26 S proteasome mainly localizes to the nucleus in yeast, we addressed the question how this 2-MDa multisubunit complex is imported into the nucleus. 26 S proteasomes consist of a 20 S proteolytically active core and 19 S regulatory particles, the latter composed of two subcomplexes, namely the base and lid complexes. We have shown that 20 S core particles are translocated into the nucleus as inactive precursor complexes via the classic karyopherin alphabeta import pathway. Here, we provide evidence that nuclear import of base and lid complexes also depends on karyopherin alphabeta. Potential classic nuclear localization sequences (NLSs) of base subunits were analyzed. Rpn2 and Rpt2, a non-ATPase subunit and an ATPase subunit of the base complex, harbor functional NLSs. The Rpt2 NLS deletion yielded wild type localization. However, the deletion of the Rpn2 NLS resulted in improper nuclear proteasome localization and impaired proteasome function. Our data support the model by which nuclear 26 S proteasomes are assembled from subcomplexes imported by karyopherin alphabeta.	Univ Med Berlin, Charite, Inst Biochem CCM, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Enenkel, C (corresponding author), Univ Med Berlin, Charite, Inst Biochem CCM, Monbijoustr 2, D-10117 Berlin, Germany.	cordula.enenkel@charite.de	Wendler, Petra/X-5799-2019; Wendler, Petra/C-9056-2014	Wendler, Petra/0000-0002-8285-2199				Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fehlker M, 2003, EMBO REP, V4, P959, DOI 10.1038/sj.embor.embor938; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Guthrie C, 1991, GUIDE YEAST GENETICS; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HILT W, 2000, PROTEASOMES WORLD RE; Kajava AV, 2002, J BIOL CHEM, V277, P49791, DOI 10.1074/jbc.M204982200; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lehmann A, 2002, J MOL BIOL, V317, P401, DOI 10.1006/jmbi.2002.5443; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; McDonald HB, 2002, GENETICS, V162, P705; McDonald HB, 1997, J CELL BIOL, V137, P539, DOI 10.1083/jcb.137.3.539; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Saeki Y, 2000, BIOCHEM BIOPH RES CO, V273, P509, DOI 10.1006/bbrc.2000.2980; Tabb MM, 2000, MOL CELL BIOL, V20, P6062, DOI 10.1128/MCB.20.16.6062-6073.2000; Tatebe H, 2001, MICRON, V32, P67, DOI 10.1016/S0968-4328(00)00023-8; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yen HCS, 2003, J BIOL CHEM, V278, P30669, DOI 10.1074/jbc.M302093200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6	42	51	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37751	37762		10.1074/jbc.M403551200	http://dx.doi.org/10.1074/jbc.M403551200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15210724	hybrid			2022-12-25	WOS:000223554600067
J	Adrain, C; Creagh, EM; Cullen, SP; Martin, SJ				Adrain, C; Creagh, EM; Cullen, SP; Martin, SJ			Caspase-dependent inactivation of proteasome function during programmed cell death in Drosophila and man	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INDUCED APOPTOSIS; UBIQUITINATED PROTEINS; ACTIVATION; PATHWAY; ACCUMULATION; ELEGANS; IDENTIFICATION; DEGRADATION; DESTRUCTION	The caspase family of cysteine proteases plays a conserved role in the coordinate demolition of cellular structures during programmed cell death from nematodes to man. Because cells undergoing programmed cell death in nematodes, flies, and mammals all share common features, this suggests that caspases target a common set of cellular structures in each of these organisms. However, although many substrates for mammalian caspases have been identified, few substrates for these proteases have been identified in invertebrates. To search for similarities between the repertoires of proteins targeted for proteolysis by caspases in flies and mammals, we have performed proteomics-based screens in Drosophila and human cell lines undergoing apoptosis. Here we show that several subunits of the proteasome undergo caspase-dependent proteolysis in both organisms and that this results in diminished activity of this multicatalytic protease complex. These data suggest that caspase-dependent proteolysis decreases protein turnover by the proteasome and that this is a conserved event in programmed cell death from Drosophila to mammals.	Univ Dublin Trinity Coll, Dept Genet, Smurfit Inst, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Dept Genet, Smurfit Inst, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Creagh, Emma/AAX-1064-2021; Adrain, Colin/I-6259-2013	Creagh, Emma/0000-0001-7631-4370; Adrain, Colin/0000-0001-7597-4393; Martin, Seamus/0000-0002-8539-3143				Beyette J, 1998, BIOCHEM J, V332, P315, DOI 10.1042/bj3320315; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; HADARI T, 1992, J BIOL CHEM, V267, P719; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Shaham S, 1999, GENETICS, V153, P1655; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Soldatenkov VA, 1997, CANCER RES, V57, P3881; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36923	36930		10.1074/jbc.M402638200	http://dx.doi.org/10.1074/jbc.M402638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210720	hybrid, Green Published			2022-12-25	WOS:000223453600095
J	Barr, RK; Boehm, I; Attwood, PV; Watt, PM; Bogoyevitch, MA				Barr, RK; Boehm, I; Attwood, PV; Watt, PM; Bogoyevitch, MA			The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASES; MAP KINASE; DOCKING SITES; TYROSINE KINASE; CELL-DEATH; IN-VITRO; PATHWAY; PHOSPHORYLATION; NEURONS	We previously reported that a small peptide based on amino acids 143-153 of the c-Jun N-terminal kinase (JNK)-binding domain of JIP-1 functioned as an in vitro inhibitor of JNK activity. This peptide (TI-JIP: RP-KRPTTLNLF) resembles the kinase-interaction motif (KIM = (K/R)(2-3)X1-6(L/I)X(L/I)), which is common to upstream activators, downstream substrates, phosphatases, and scaffold proteins present in MAPK cascades. In this study, we characterized the mechanism of JNK inhibition by this peptide and further investigated the biochemical features of this peptide resulting in potent JNK inhibition. We also tested various KIM-based peptides for their ability to inhibit JNK activity. TI-JIP was found to be competitive with respect to the phosphoacceptor substrate c-Jun (K-I = 0.39 +/- 0.08 muM), and exhibit mixed (non-competitive) inhibition with respect to ATP. All seven substitutions of Pro-5 we tested significantly reduced the JNK inhibition, as did altering the Pro-5 to Leu-8 spacing. When we independently tested eight substitutions of either Thr-6 or Thr-7, only one substitution in each position was well tolerated. Furthermore, peptides based on the KIMs from other proteins were significantly less potent JNK inhibitors than TI-JIP, including a peptide from the JNK interactor Sab that contained all critical inhibitory residues present in TI-JIP. Therefore, despite having previously identified Arg-4, Pro-5, Leu-8, and Leu-10 in TI-JIP as independently critical for mediating JNK inhibition, we find their presence in other 11-mer peptides is not sufficient for JNK inhibition. TI-JIP is therefore a unique KIM-based inhibitor of JNK activity.	Univ Western Australia, Dept Biochem & Mol Biol, Crawley, WA 6009, Australia; Univ Western Australia, Ctr Child Hlth Res, Crawley, WA 6009, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Fac Life & Phys Sci, Sch Biomed & Chem Sci, Cell Signalling Lab Biochem & Mol Biol M310, Perth, WA 6009, Australia.	marieb@cyllene.uwa.edu.au	Attwood, Paul V/I-8207-2012	Barr, Renae/0000-0003-1601-7299; Stacey, Ingrid/0000-0002-3032-6031; Bogoyevitch, Marie/0000-0001-9745-3716				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; CHENG HC, 1986, J BIOL CHEM, V261, P989; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dickinson DA, 2002, FREE RADICAL BIO MED, V33, P974, DOI 10.1016/S0891-5849(02)00991-7; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hayess K, 1997, BIOCHEM PHARMACOL, V53, P1239, DOI 10.1016/S0006-2952(96)00877-5; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Iles KE, 2002, FREE RADICAL BIO MED, V32, P1304, DOI 10.1016/S0891-5849(02)00840-7; Ishida A, 1998, FEBS LETT, V427, P115, DOI 10.1016/S0014-5793(98)00405-0; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kamath JR, 2003, J PEPT RES, V62, P260, DOI 10.1046/j.1399-3011.2003.00094.x; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Luo Y, 2004, BIOCHEMISTRY-US, V43, P1254, DOI 10.1021/bi034515p; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 1998, J NEUROSCI, V18, P104; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Wang J, 2003, J NEUROSCI, V23, P8596; Wiltshire C, 2002, BIOCHEM J, V367, P577, DOI 10.1042/BJ20020553	48	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36327	36338		10.1074/jbc.M402181200	http://dx.doi.org/10.1074/jbc.M402181200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208323	hybrid			2022-12-25	WOS:000223453600022
J	Shan, ZH; Parker, T; Wiest, JS				Shan, ZH; Parker, T; Wiest, JS			Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer	ONCOGENE			English	Article						homozygous deletion; chromosome 9; lung cancers; TUSC1; expression; tumor suppressor gene	HETEROZYGOSITY; MELANOMA; REGION; METHYLATION; EPIGENETICS; CARCINOMA; 9P21-22; P15	Loss of heterozygosity (LOH) studies indicate that genetic alterations of chromosome 9p occur in numerous tumor types, suggesting the presence of tumor suppressor genes (TSGs) on chromosome 9p critical in carcinogenesis. Our previous LOH analyses in primary lung tumors led us to propose that chromosome 9p harbors other TSGs important in lung tumorigenesis. In this study, 30 non-small-cell lung cancer and 12 small-cell lung cancer cell lines were screened with 55 markers to identify new regions of homozygous deletion (HD) on chromosome 9p. Three novel noncontiguous homozygously deleted regions were detected and ranged in size from 840 kb to 7.4 Mb. One gene identified in the deletion at D9S126, TUSC1 ( tumor suppressor candidate 1), is an intronless gene. Multiplex polymerase chain reaction and Southern blot confirmed the HD of TUSC1. Northern blot analysis of TUSC1 demonstrated two transcripts of approximately 2 and 1.5 kb that are likely generated by alternative polyadenylation signals. Both transcripts are expressed in several human tissues and share an open-reading frame encoding a peptide of 209 amino acids. Analysing cell line cDNAs by reverse transcriptase (RT)-PCR demonstrated downregulation of TUSC1 in cell lines with or without HDs, suggesting that TUSC1 may play a role in lung tumorigenesis.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wiest, JS (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bldg 37,Room 4008,37 Convent Dr MSC4258, Bethesda, MD 20892 USA.	wiestj@mail.nih.gov		Pritchett, Tracy/0000-0002-3336-9336	Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mead LJ, 1997, INT J CANCER, V71, P213; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oh JJ, 2002, CANCER RES, V62, P3207; Pollock PM, 2001, CANCER RES, V61, P1154; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shan ZH, 2003, GENE, V303, P55, DOI 10.1016/S0378-1119(02)01143-5; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Stranahan PL, 1996, GLYCOCONJUGATE J, V13, P741, DOI 10.1007/BF00702338; Takeuchi S, 1997, LEUKEMIA, V11, P1636, DOI 10.1038/sj.leu.2400817; Wiest JS, 1997, CANCER RES, V57, P1; XIAO S, 1995, CANCER RES, V55, P2968	26	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6612	6620		10.1038/sj.onc.1207857	http://dx.doi.org/10.1038/sj.onc.1207857			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208665	Green Accepted			2022-12-25	WOS:000223530800008
J	Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Shibata, T; Kurumizaka, H; Yokoyama, S				Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Shibata, T; Kurumizaka, H; Yokoyama, S			Positive role of the mammalian TBPIP/HOP2 protein in DMC1-mediated homologous pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; RECA PROTEIN; CHROMOSOME SYNAPSIS; MOLECULAR-CLONING; FISSION YEAST; HOP2 PROTEIN; RECOMBINATION; RAD51; MOUSE; DMC1	In meiosis, homologous recombination preferentially occurs between homologous chromosomes rather than between sister chromatids, which is opposite to the bias of mitotic recombinational repair. The TBPIP/HOP2 protein is a factor that ensures the proper pairing of homologous chromosomes during meiosis. In the present study, we found that the purified mouse TBPIP/HOP2 protein stimulated homologous pairing catalyzed by the meiotic DMC1 recombinase in vitro. In contrast, TBPIP/HOP2 did not stimulate homologous pairing by RAD51, which is another homologous pairing protein acting in both meiotic and mitotic recombination. The positive effect of TBPIP/HOP2 in the DMC1-mediated homologous pairing was only observed when TBPIP/HOP2 first binds to double-stranded DNA, not to single-stranded DNA, before the initiation of the homologous pairing reaction. Deletion analyses revealed that the C-terminal basic region of TBPIP/HOP2 is required for efficient DNA binding and is also essential for its homologous pairing stimulation activity. Therefore, these results suggest that TBPIP/HOP2 directly binds to DNA and functions as an activator for DMC1 during the homologous pairing step in meiosis.	RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Fukui, Fac Med Sci, Dept Morphol & Physiol Sci, Div Cell Biol & Neurosci, Fukui 9101193, Japan; JST, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan; RIKEN Discovery Res Inst, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN Harima Inst SPring8, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; RIKEN Harima Inst SPring8, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Fukui; Japan Science & Technology Agency (JST); RIKEN; Waseda University; RIKEN; RIKEN; University of Tokyo	Kurumizaka, H (corresponding author), RIKEN Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yagi, Hideshi/0000-0002-8506-8965; Kurumizaka, Hitoshi/0000-0001-7412-3722				Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Gerton JL, 2002, P NATL ACAD SCI USA, V99, P6895, DOI 10.1073/pnas.102167899; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Ijichi H, 2000, GENE, V248, P99, DOI 10.1016/S0378-1119(00)00141-4; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Schommer C, 2003, PLANT J, V36, P1, DOI 10.1046/j.1365-313X.2003.01850.x; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V239, P176, DOI 10.1006/bbrc.1997.7447; Tsubouchi H, 2003, DEV CELL, V5, P915, DOI 10.1016/S1534-5807(03)00357-5; Tsubouchi H, 2002, MOL CELL BIOL, V22, P3078, DOI 10.1128/MCB.22.9.3078-3088.2002; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	41	29	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35263	35272		10.1074/jbc.M402481200	http://dx.doi.org/10.1074/jbc.M402481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192114	hybrid			2022-12-25	WOS:000223303400017
J	Pinson, B; Merle, M; Franconi, JM; Daignan-Fornier, B				Pinson, B; Merle, M; Franconi, JM; Daignan-Fornier, B			Low affinity orthophosphate carriers regulate PHO gene expression independently of internal orthophosphate concentration in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; PHOSPHATE-TRANSPORTER; INHIBITOR PHO81; PROTEIN; POLYPHOSPHATE; PHO80-PHO85; RECEPTOR; SYSTEM; KINASE	Phosphate is an essential nutrient that must be taken up from the growth medium through specific transporters. In Saccharomyces cerevisiae, both high and low affinity orthophosphate carriers allow this micro-organism to cope with environmental variations. Intriguingly, in this study we found a tight correlation between selenite resistance and expression of the high affinity orthophosphate carrier Pho84p. Our work further revealed that mutations in the low affinity orthophosphate carrier genes (PHO87, PHO90, and PHO91) cause deregulation of phosphate-repressed genes. Strikingly, the deregulation due to pho87Delta, pho90Delta, or pho91Delta mutations was neither correlated to impaired orthophosphate uptake capacity nor to a decrease of the intracellular orthophosphate or polyphosphate pools, as shown by P-31 NMR spectroscopy. Thus, our data clearly establish that the low affinity orthophosphate carriers affect phosphate regulation independently of intracellular orthophosphate concentration through a new signaling pathway that was found to strictly require the cyclin-dependent kinase inhibitor Pho81p. We propose that phosphate-regulated gene expression is under the control of two different regulatory signals as follows: the sensing of internal orthophosphate by a yet unidentified protein and the sensing of external orthophosphate by low affinity orthophosphate transporters; the former would be required to maintain phosphate homeostasis, and the latter would keep the cell informed on the medium phosphate richness.	Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, Unite Resonance Magnet Syst Biol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pinson, B (corresponding author), Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	benoit.pinson@ibgc.u-bordeaux2.fr		Pinson, Benoit/0000-0003-2936-9058				Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200; Auesukaree C, 2003, BIOCHEM BIOPH RES CO, V306, P843, DOI 10.1016/S0006-291X(03)01068-4; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; BISSON LF, 1982, GENETICS, V102, P341; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; BunYa M, 1996, CURR GENET, V29, P344, DOI 10.1007/s002940050055; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Espie P, 1997, J BIOENERG BIOMEMBR, V29, P591, DOI 10.1023/A:1022487119390; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nishimura K, 1999, YEAST, V15, P1711, DOI 10.1002/(SICI)1097-0061(199912)15:16<1711::AID-YEA497>3.0.CO;2-8; Ogawa N, 1995, MOL GEN GENET, V249, P406, DOI 10.1007/BF00287102; Ogawa N, 2000, J BACTERIOL, V182, P6687, DOI 10.1128/JB.182.23.6687-6693.2000; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OGAWA N, 1995, MOL CELL BIOL, V15, P997; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Persson BL, 1998, BBA-BIOENERGETICS, V1365, P23, DOI 10.1016/S0005-2728(98)00037-1; Pinson B, 2000, MOL MICROBIOL, V36, P679, DOI 10.1046/j.1365-2958.2000.01890.x; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Sherman F., 1983, METHODS YEAST GENETI; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; SUMMER JB, 1944, SCIENCE, V100, P413; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Wykoff DD, 2001, GENETICS, V159, P1491	40	48	49	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35273	35280		10.1074/jbc.M405398200	http://dx.doi.org/10.1074/jbc.M405398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194704	hybrid			2022-12-25	WOS:000223303400018
J	Hengst, JA; Bond, AS				Hengst, JA; Bond, AS			Transport of meprin subunits through the secretory pathway - Role of the transmembrane and cytoplasmic domains and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TAIL; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNIT; BETA-SUBUNIT; RETENTION; MOTIF; GENE; IDENTIFICATION; EXPRESSION; PROTEINS	The meprin alpha subunit, a multidomain metalloproteinase, is synthesized as a type I membrane protein and proteolytically cleaved during biosynthesis in the endoplasmic reticulum (ER), consequently losing its membrane attachment and COOH-terminal domains. The meprin alpha subunit is secreted as a disulfide-linked dimer that forms higher oligomers. By contrast, the evolutionarily related meprin beta subunit retains the COOH-terminal domains during biosynthesis and travels to the plasma membrane as a disulfide-linked integral membrane dimer. Deletion of a unique 56-amino acid inserted domain (the I domain) of meprin alpha prevents COOH-terminal proteolytic processing and results in the retention of this subunit within the ER. To determine elements responsible for this retention versus transport to the cell surface, mutagenesis experiments were performed. Replacement of the meprin alpha transmembrane (alphaT) and cytoplasmic (alphaC) domains with their beta counterparts allowed rapid movement of the alpha subunit to the cell surface. The meprin alphaT and alphaC domains substituted into meprin beta delayed movement of this chimera through the secretory pathway. Replacement of glycines in the meprin alphaT domain GXXXG motif with leucine residues, alanine insertions in the meprin alphaT domain, and mutagenesis of basic residues within the meprin alphaC domain did not enhance the movement of the alpha subunit through the secretory pathway. By contrast, a mutant of meprin alpha (C320AalphaDeltaI) that did not form disulfide-linked dimers or higher order oligomers was transported through the secretory pathway, although more slowly than meprin beta. Taken together, the data indicate that the meprin alphaT and alphaC domains together contain a weak signal for retention within the ER/cis-Golgi compartments that is strengthened by oligomerization.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, AS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171,500 Univ Dr, Hershey, PA 17033 USA.	jbond@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691, R01DK054625] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691, DK 54625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Becker C, 2003, BIOL CHEM, V384, P825, DOI 10.1515/BC.2003.092; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; BERTENSHAW GP, 2004, HDB PROTEOLYTIC ENZY, P599; Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1997, ASTACINS, P45; Booth A G, 1974, Biochem J, V142, P575; Carmago S, 2002, KIDNEY INT, V61, P959, DOI 10.1046/j.1523-1755.2002.00209.x; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chevallier S, 1996, BIOCHEM J, V317, P731, DOI 10.1042/bj3170731; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; Crisman JM, 2004, J IMMUNOL, V172, P4510, DOI 10.4049/jimmunol.172.7.4510; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; Litovchick L, 2002, J BIOL CHEM, V277, P34413, DOI 10.1074/jbc.M203986200; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Norman LP, 2003, MOL CELL BIOL, V23, P1221, DOI 10.1128/MCB.23.4.1221-1230.2003; Plemper RK, 2001, J BIOL CHEM, V276, P44239, DOI 10.1074/jbc.M105967200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Tsukuba T, 2002, ARCH BIOCHEM BIOPHYS, V397, P191, DOI 10.1006/abbi.2001.2672; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Villa JP, 2003, BIOCHEM SOC SYMP, V70, P53, DOI 10.1042/bss0700053; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325	42	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34856	34864		10.1074/jbc.M405774200	http://dx.doi.org/10.1074/jbc.M405774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187079	hybrid			2022-12-25	WOS:000223134800095
J	Kao, YY; Lai, HL; Hwang, MJ; Chern, YJ				Kao, YY; Lai, HL; Hwang, MJ; Chern, YJ			An important functional role of the N terminus domain of type VI adenylyl cyclase in G alpha(i)-mediated inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHEOCHROMOCYTOMA PC12 CELLS; CENTRAL-NERVOUS-SYSTEM; CYTOSOLIC DOMAINS; RECEPTOR ISOFORMS; ESCHERICHIA-COLI; BETA-GAMMA; G(I-ALPHA); EXPRESSION; BINDING	We show herein that removal of the first 86 amino acids (aa) of the N terminus ( designated N) of type VI adenylyl cyclase (ACVI) caused the resultant ACVI mutant (ACVI-DeltaA87) to be more greatly inhibited by a Galpha(i)-coupled receptor or activated Galpha(i) protein. Moreover, in vitro binding of the full-length N and C1a domain ( designated C1a), which interacts with Galpha(i), was detected. A truncated N terminus ( aa 1 - 86) also interacted with C1a, suggesting that the C1a-interacting region is located within aa 1 - 86. Mutation analyses further revealed that N might interact with C1a in the region ( aa 434 - 505) where Galpha(i) is bound. Mutations of two residues (Leu-472 and Val-476) located in this N-binding region of C1a suppressed the interaction between recombinant N and C1a and markedly reduced Galpha(i)-mediated inhibition of ACVI-DeltaA87. Further biochemical analyses of the effect of internal mutations of Leu-472/Val-476 on Galpha(i)-mediated inhibition of wild-type ACVI and ACVI-DeltaA87 suggested that N modulates the Galpha(i)-mediated inhibition of ACVI via binding to C1a when the level of Galpha(i) is low (i.e. around the IC50 value) and that a more complicated interfering mode results when the level of Galpha(i) is high (i.e. similar to10- to 20-fold of the IC50 value). Collectively, data presented herein suggest a novel function of the N terminus of ACVI in Galpha(i)-mediated regulation.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	Hwang, Ming-jing/E-9210-2012; chern, yijuang/S-7013-2018	Hwang, Ming-jing/0000-0002-9657-5663; chern, yijuang/0000-0002-5842-5429				ANTONI FA, 1995, J BIOL CHEM, V270, P28055; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Dessauer CW, 2002, J BIOL CHEM, V277, P28823, DOI 10.1074/jbc.M203962200; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Drutel G, 2001, MOL PHARMACOL, V59, P1; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; HARAZONO A, 1994, BIOCHEM BIOPH RES CO, V201, P340, DOI 10.1006/bbrc.1994.1707; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hu BA, 2002, J BIOL CHEM, V277, P33139, DOI 10.1074/jbc.M112373200; Huang CL, 1999, J NEUROCHEM, V72, P2437, DOI 10.1046/j.1471-4159.1999.0722437.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Lin TH, 2002, J BIOL CHEM, V277, P15721, DOI 10.1074/jbc.M111537200; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Senogles SE, 2004, J BIOL CHEM, V279, P1601, DOI 10.1074/jbc.M309792200; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34440	34448		10.1074/jbc.M401952200	http://dx.doi.org/10.1074/jbc.M401952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192109	hybrid			2022-12-25	WOS:000223134800045
J	Miyake, T; Reese, J; Loch, CM; Auble, DT; Li, R				Miyake, T; Reese, J; Loch, CM; Auble, DT; Li, R			Genome-wide analysis of ARS (autonomously replicating sequence) binding factor 1 (Abf1p)-mediated transcriptional regulation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; DNA-REPLICATION; YEAST; ACTIVATION; ABF1P; PURIFICATION; EXPRESSION; IDENTIFICATION; PROMOTER; ELEMENTS	Autonomously replicating sequence-binding factor-1 (Abf1p) is an essential sequence-specific transcription factor in Saccharomyces cerevisiae that participates in multiple nuclear events including DNA replication, transcription activation, and gene silencing. Numerous gene-specific analyses have implicated Abf1p in the transcriptional control of genes involved in a diverse range of cellular functions, leading to the notion that Abf1p acts as a global transcriptional regulator. Here we report findings from a genome-wide comparison of the gene expression profiles in the wild-type and abf1-1 temperature-sensitive mutant. The study identifies a total of 86 Abf1p-regulated genes (1.4% of the genome) of which 50 are activated and 36 are repressed by Abf1p. Interestingly, Abf1p binds to its own promoter in vivo and strongly represses its own transcription, suggesting a potential negative regulatory loop in Abf1p-mediated gene regulation. A comparison of our microarray data with the available databases reveals a significant overlap of genes regulated by Abf1p and those by several general transcription factors such as Mot1p and TAFs (TATA-binding protein-associated factors). Different mutant alleles of abf1 affect Abf1p-mediated transcription in a gene-dependent manner. Furthermore, Abf1p in vivo is associated with the promoter region of most Abf1p-activated but not with that of most Abf1p-repressed genes. Taken together, these results strongly suggest distinct underlying mechanisms by which Abf1p regulates gene expression.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, POB 800733, Charlottesville, VA 22908 USA.	rl2t@virginia.edu			NIGMS NIH HHS [GM 55763, R01 GM055763, GM 57893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763, R01GM057893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHO GN, 1995, NUCLEIC ACIDS RES, V23, P2980, DOI 10.1093/nar/23.15.2980; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; FRANCESCONI SC, 1989, MOL CELL BIOL, V9, P2906, DOI 10.1128/MCB.9.7.2906; GALIUSDURNER V, 1996, MOL CELL BIOL, V16, P2777; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GONCALVES PM, 1995, NUCLEIC ACIDS RES, V23, P1475, DOI 10.1093/nar/23.9.1475; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNZLER M, 1995, MOL MICROBIOL, V15, P167, DOI 10.1111/j.1365-2958.1995.tb02231.x; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1995, GENETICS, V141, P889; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARTENS JA, 1994, J BIOL CHEM, V269, P15661; Miyake T, 2002, MOL CELL BIOL, V22, P505, DOI 10.1128/MCB.22.2.505-516.2002; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; OZSARAC N, 1995, GENE, V164, P157, DOI 10.1016/0378-1119(95)00438-C; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; RAMER SW, 1992, P NATL ACAD SCI USA, V89, P11589, DOI 10.1073/pnas.89.23.11589; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; Schroeder SC, 1998, J BIOL CHEM, V273, P19884, DOI 10.1074/jbc.273.31.19884; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wiltshire S, 1997, NUCLEIC ACIDS RES, V25, P4250, DOI 10.1093/nar/25.21.4250; YOO HY, 1995, CURR MICROBIOL, V31, P163, DOI 10.1007/BF00293548	39	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34865	34872		10.1074/jbc.M405156200	http://dx.doi.org/10.1074/jbc.M405156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192094	hybrid			2022-12-25	WOS:000223134800096
J	Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK				Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK			Functional role of MIA in melanocytes and early development of melanoma	ONCOGENE			English	Article						melanocytes; melanoma; migration; MIA; array	MATRIX-METALLOPROTEINASE MT1-MMP; INHIBITORY-ACTIVITY; MALIGNANT-MELANOMA; CELL-LINES; INTEGRIN ALPHA-V-BETA-3; PLASMINOGEN ACTIVATORS; IN-VITRO; EXPRESSION; PROGRESSION; PROTEIN	The protein MIA(melanoma inhibitory activity) is highly expressed in malignant melanomas but not in melanocytes. Furthermore, expression of MIA correlates with tumor progression in vivo. Here, MIA-dependent changes of gene expression after long-term inhibition of MIA expression in the human melanoma cell line HMB2 were investigated. Primarily, we observed characteristic changes in cell morphology, and also found re-established cell-cell contacts in MIA-deficient cell clones grown in monolayer culture. Real-time reverse transcription-polymerase chain reaction (RT-PCR) showed a downregulation of N-cadherin expression and a reinduction of E-cadherin expression in the MIA-deficient cell clones. Further, both cancer cDNA array and protein arrays verified a marked downregulation of several other melanoma-associated genes (e.g. membrane-type 1 matrix metalloproteinase tissue-type plasminogen activator integrin beta3, secreted protein acidic and rich in cysteins and fibronectin) in the MIA-deficient melanoma cells, confirmed by real-time RT-PCR and Western blotting. As all these molecules are associated with migration, the effect of MIA on migration of human primary melanocytes was analysed. In the presence of MIA, we observed enhanced migratory ability of melanocytic cells, induction of melanoma-associated genes as well as inhibition of apoptosis due to anoikis. These results suggest that expression of MIA promotes melanoma progression by inducing further melanoma-associated genes.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2002, HISTOL HISTOPATHOL, V17, P289, DOI 10.14670/HH-17.289; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Krengel S, 2004, J CUTAN PATHOL, V31, P1, DOI 10.1046/j.0303-6987.2004.0106.x; Krengel S, 2002, J CUTAN PATHOL, V29, P390, DOI 10.1034/j.1600-0560.2002.290702.x; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li G, 2001, CANCER RES, V61, P3819; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; NATALI PG, 1995, BRIT J CANCER, V71, P1243, DOI 10.1038/bjc.1995.240; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; PAGGI MG, 2003, PIGMENT CELL RES, V16, P589; SAKSELA O, 1984, INT J CANCER, V33, P609, DOI 10.1002/ijc.2910330510; Seftor REB, 2001, CANCER RES, V61, P6322; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Stahlecker J, 2000, ANTICANCER RES, V20, P5041; Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2000, J BIOMOL NMR, V17, P87, DOI 10.1023/A:1008306918293; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; VANGRONINGEN JJM, 1995, CANCER RES, V55, P6237; WOLLINA U, 1991, ANTICANCER RES, V11, P1405	42	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6115	6124		10.1038/sj.onc.1207797	http://dx.doi.org/10.1038/sj.onc.1207797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208686				2022-12-25	WOS:000223261000011
J	Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S				Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S			Genetic alterations of the NRP/B gene are associated with human brain tumors	ONCOGENE			English	Article						NRP/B; alteration; human brain tumor; nuclear matrix protein; Kelch repeat	NUCLEAR-MATRIX PROTEIN; ACTIN-BINDING PROTEIN; HUMAN BREAST-CANCER; MAP KINASE-KINASE; RETINOBLASTOMA PROTEIN; P53 PATHWAY; CELLS; APOPTOSIS; GROWTH; DIFFERENTIATION	Nearly all brain tumors develop following the progressive accumulation of genetic alterations of oncogenes and tumor suppressor genes (such as p53 and retinoblastoma protein). Furthermore, aberrations in the nuclear matrix often contribute to genomic instabilities and the development of cancer. We have previously shown that nuclear-restricted protein/brain (NRP/B), a member of the BTB/Kelch repeat family, is a nuclear matrix protein normally expressed in neurons but not in astrocytes, and that it is an early and specific marker of neurons during the development of the central nervous system. Here, we show aberrant expression of NRP/B in human brain tissues. NRP/B is expressed in the cytoplasm of human brain tumor cells (glioblastoma, GBM) arising from astrocytes. NRP/B mutations (13 mutations in the Kelch domains, two in the intervening sequence (IVS) domain and two in the BTB domain) were detected in brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH and U87-MG) and in primary human malignant GBM tissues (eight samples). More importantly, we found that NRP/B mutants, but not wild-type (wt) NRP/B, increased the activation of ERK and consequently promoted cell proliferation, attenuated caspase activation and suppressed the cellular apoptosis induced by the stressful stimulus cisplatin (10 mum). These events were observed to occur via a p53-mediated pathway. In addition, while wt NRP/B was associated with actin, mutations in the Kelch domains of NRP/B led to its reduced binding affinity to actin. Thus, alterations and gene mutations within the NRP/B gene may contribute to brain tumorigenesis by promoting cell proliferation, suppressing apoptosis and by affecting nuclear cytoskeleton dynamics.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02215 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1 R01 CA096805] Funding Source: Medline; NINDS NIH HHS [1 R01 NS046628-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberti I, 2000, J CELL BIOCHEM, V79, P471, DOI 10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.3.CO;2-F; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Back SA, 1998, J NEUROSCI, V18, P6241; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Biernat Wojciech, 1998, Polish Journal of Pathology, V49, P267; Bode J, 2000, J CELL BIOCHEM, P3; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brunagel G, 2002, CANCER RES, V62, P2437; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collins VP, 1998, CANCER SURV, V32, P37; DARDICK I, 1981, AM J PATHOL, V103, P10; Davido T, 2000, J CELL BIOCHEM, P136; Davie JR, 2001, PROG NUCLEIC ACID RE, V65, P299; Deppert W, 2000, J CELL BIOCHEM, P115; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fujita M, 2001, CANCER RES, V61, P7722; Getzenberg RH, 1996, CANCER RES, V56, P1690; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grim J, 1997, CLIN CANCER RES, V3, P2415; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Konety BR, 1999, J CELL BIOCHEM, P183; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIBERMANN TA, 1985, J CELL SCI, P161; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meyers S, 2000, J CELL BIOCHEM, P93; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Reilly KM, 2001, SEMIN CANCER BIOL, V11, P177, DOI 10.1006/scbi.2000.0375; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Sotolongo B, 2000, J CELL BIOCHEM, P23; Stein G, 2000, J CELL BIOCHEM, P1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Ueki K, 1996, CANCER RES, V56, P150; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhao L, 2000, J BIOL CHEM, V275, P16845, DOI 10.1074/jbc.275.22.16845	68	40	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5890	5900		10.1038/sj.onc.1207776	http://dx.doi.org/10.1038/sj.onc.1207776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208678				2022-12-25	WOS:000222941100003
J	Sato, K; Hayami, R; Wu, WW; Nishikawa, T; Nishikawa, H; Okuda, Y; Ogata, H; Fukuda, M; Ohta, T				Sato, K; Hayami, R; Wu, WW; Nishikawa, T; Nishikawa, H; Okuda, Y; Ogata, H; Fukuda, M; Ohta, T			Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRCA1/BARD1 HETERODIMER; POLYUBIQUITIN CHAINS; PROTEIN B23; BRCA1; CENTROSOME; MITOSIS; COMPLEX; BINDING; CELLS; RNA	The breast and ovarian tumor suppressor BRCA1 forms a heterodimeric RING-type ubiquitin ligase with BARD1 to catalyze untraditional Lys-6-linked polyubiquitin chains. It is not clear how the BRCA1-BARD1 ligase regulates various cellular processes such as DNA repair, cell-cycle progression, transcriptional regulation, and centrosome duplication. Here we report that BRCA1-BARD1 catalyzes the polyubiquitination of nucleolar phosphoprotein nucleophosmin/B23 (NPM). Two different mass spectrometry screens for protein ubiquitinated by BRCA1-BARD1 both identified NPM. NPM interacts with N-terminal fragments of BRCA1 and BARD1 in a manner dependent upon BRCA1-BARD1 heterodimer formation. NPM colocalizes with BRCA1 and BARD1 in mitotic cells suggesting the possibility of NPM regulation by BRCA1-BARD1 during mitosis. BRCA1-BARD1 catalyzes the ubiquitination of NPM in vitro and in vivo, and BRCA1-BARD1 co-expression in cells causes NPM stabilization rather than degradation. This is consistent with the notion that this ligase catalyzes untraditional polyubiquitin chains. Given the many overlapped functions between NPM and BRCA1, we propose that NPM is a strong candidate as a substrate of the BRCA1-BARD1 ubiquitin ligase.	St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan	Saint Marianna University	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp		Ohta, Tomohiko/0000-0002-9700-7342; WU, WENWEN/0000-0002-3654-585X				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zatsepina OV, 1999, J CELL SCI, V112, P455	22	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30919	30922		10.1074/jbc.C400169200	http://dx.doi.org/10.1074/jbc.C400169200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15184379	hybrid			2022-12-25	WOS:000222726800002
J	Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H				Leong, CTC; Ng, CY; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H			Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44	ONCOGENE			English	Article						estrogen regulated; membrane associated; CUB domains; zona-pellucida and HuUO-44	TUMOR-SUPPRESSOR GENE; LONG ARM; EXPRESSION; IDENTIFICATION; CHROMOSOME-10; TAMOXIFEN; UTERUS; DOMAIN; DMBT1; LOCALIZATION	We have previously reported the characterization of an estrogen-regulated rat uterine-ovarian-specific complementary DNA (UO-44). To understand the involvement of this protein in the initiation and progression of human ovarian and uterine cancers, we now report the cloning and characterization of the human ortholog (HuUO-44). HuUO-44 is mapped to chromosome 10q26.13 and contains nine exons. Multiple tissue Northern blot detected two HuU044 transcripts of approximately 2 and 3kb in the pancreas. RT-PCR demonstrated that HuU044 undergoes a complex series of alternative splicing events between exons 2 and 6 that yielded four novel splice variants, HuUO-44A, HuUO-44B, HuUO-44C and HuUO-44D. Putative functional motifs identified in HuU044 are two CUB domains and a zona-pellucida domain. Transfection studies demonstrated the membrane-associated nature of HuU044. By immunohistochemistry, HuU044 was located to the normal ovarian and ovarian tumor epithelial cells; in NIH-OVCAR3 ovarian cancer cells, HuU044 was detected only at the leading edge of the dividing cells. Most importantly, a marked loss in cell attachment and proliferation was observed in NIH-OVCAR3 cells cultured in the presence of a polyclonal HuU044 antiserum. These findings suggest the potential role of HuU044 in cell motility, cell-cell matrices.	Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Mol Endocrinol Lab, Div Cellular & Mol Res, Singapore 169610, Singapore.	cmrhth@nccs.com.sg	Nguyen, Hung/M-8118-2014	Nguyen, Hung/0000-0001-8378-555X; Ong, Choon Kiat/0000-0001-6402-4288				AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen DH, 1999, J BIOL CHEM, V274, P32215, DOI 10.1074/jbc.274.45.32215; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; EINSPANIER R, 1991, BIOCHEM BIOPH RES CO, V179, P1006, DOI 10.1016/0006-291X(91)91918-3; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; GRAY IC, 1995, CANCER RES, V55, P4800; Gregoire L, 2001, CLIN CANCER RES, V7, P4280; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; HUYNH HT, 1993, CANCER RES, V53, P5585; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Kasik JW, 1998, BIOCHEM J, V330, P947; KATZENELLENBOGE.BS, 1975, BIOCHEMICAL ACTION H, V3, P187; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; Kazandi M, 2002, EUR J GYNAECOL ONCOL, V23, P257; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 2000, CANCER RES, V60, P1704; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nielsen S, 1998, EUR EAT DISORD REV, V6, P4, DOI 10.1002/(SICI)1099-0968(199803)6:1<4::AID-ERV237>3.3.CO;2-G; Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WHITE MM, 1995, ENDOCR REV, V16, P739, DOI 10.1210/er.16.6.739; Wu WG, 1999, CANCER RES, V59, P1846; YOSHINAGA K, 1969, ENDOCRINOLOGY, V85, P103, DOI 10.1210/endo-85-1-103	37	19	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5707	5718		10.1038/sj.onc.1207754	http://dx.doi.org/10.1038/sj.onc.1207754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184879				2022-12-25	WOS:000222629500018
J	Sanvicens, N; Gomez-Vicente, V; Masip, I; Messeguer, A; Cotter, TG				Sanvicens, N; Gomez-Vicente, V; Masip, I; Messeguer, A; Cotter, TG			Oxidative stress-induced apoptosis in retinal photoreceptor cells is mediated by calpains and caspases and blocked by the oxygen radical scavenger CR-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURONAL DEATH; NITRIC-OXIDE; IN-VIVO; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; PHOTIC INJURY; CROSS-TALK; KAPPA-B; ACTIVATION; CALCIUM	A critical role for reactive oxygen species (ROS) in photoreceptor apoptosis has been established. However, the exact molecular mechanisms triggered by oxidative stress in photoreceptor cell death remain undefined. This study delineates the molecular events that occur after treatment of the photoreceptor cell line 661W with the nitric oxide donor sodium nitroprusside ( SNP). Cytosolic calcium levels increased during photoreceptor apoptosis, leading to activation of the calcium-dependent proteases calpains. Furthermore, caspase activation also occurred following SNP insult. However, although treatment with the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala- Asp fluoromethyl ketone inhibited caspase activity per se in SNP-treated 661W cells, it did not prevent apoptosis. On the other hand, CR-6 (3,4-dihydro- 6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran) acted as a scavenger of ROS and reduced 661W photoreceptor apoptosis induced by SNP by preventing the activation of a pathway in which calpains have a key role. In summary, we report for the first time that both caspases and calpains are involved in 661W photoreceptor apoptosis and that calpain activation can be prevented by the ROS scavenger CR-6.	Natl Univ Ireland Univ Coll Cork, Biosci Res Inst, Dept Biochem, Tumour Biol Lab, Cork, Ireland; CSIC, Inst Invest Auim & Ambientals Barcelona, Dept Biol Organ Chem, ES-08034 Barcelona, Spain	University College Cork; Consejo Superior de Investigaciones Cientificas (CSIC)	Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Biosci Res Inst, Dept Biochem, Tumour Biol Lab, Cork, Ireland.	t.cotter@ucc.ie	Gómez-Vicente, Violeta/A-6089-2013	Gómez-Vicente, Violeta/0000-0002-5696-8673; Messeguer, Angel/0000-0002-8358-9425; Cotter, Thomas/0000-0003-4626-5613				ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Carella G, 2003, EUR J OPHTHALMOL, V13, pS5; Carmody RJ, 1999, EXP CELL RES, V248, P520, DOI 10.1006/excr.1998.4421; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; CASAS J, 1992, J AGR FOOD CHEM, V40, P585, DOI 10.1021/jf00016a011; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Crawford MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1304, DOI 10.1006/bbrc.2001.4501; Donovan M, 2002, CELL DEATH DIFFER, V9, P1220, DOI 10.1038/sj.cdd.4401105; Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200; Doonan F, 2003, J NEUROSCI, V23, P5723; Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Irurre J Jr, 1993, Bioorg Med Chem, V1, P219, DOI 10.1016/S0968-0896(00)82124-0; Jomary C, 2001, MOL CELL NEUROSCI, V18, P335, DOI 10.1006/mcne.2001.1036; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim DH, 2002, OPHTHALMIC RES, V34, P150, DOI 10.1159/000063659; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; LAM S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1751, DOI 10.1001/archopht.1990.01070140105039; Li ZY, 1995, DEGENERATIVE DIS RET; Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X; Liu CD, 1999, J NEUROSCI, V19, P4778; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; McCollum AT, 2002, J NEUROCHEM, V82, P1208, DOI 10.1046/j.1471-4159.2002.01057.x; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Migliore L, 2002, MUTAT RES-REV MUTAT, V512, P135, DOI 10.1016/S1383-5742(02)00046-7; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Montoliu C, 1999, BIOCHEM PHARMACOL, V58, P255, DOI 10.1016/S0006-2952(99)00104-5; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicotera P, 2002, TOXICOL LETT, V127, P189, DOI 10.1016/S0378-4274(01)00500-8; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Ranchon I, 1999, INVEST OPHTH VIS SCI, V40, P1191; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X; ROSNER M, 1992, ARCH OPHTHALMOL-CHIC, V110, P857, DOI 10.1001/archopht.1992.01080180129040; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tuohy G, 2002, INVEST OPHTH VIS SCI, V43, P3583; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349; Yamazaki H, 2002, INVEST OPHTH VIS SCI, V43, P919; Yuyama K, 2003, J NEUROSCI RES, V73, P351, DOI 10.1002/jnr.10669; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	64	100	111	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39268	39278		10.1074/jbc.M402202200	http://dx.doi.org/10.1074/jbc.M402202200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15210718	hybrid			2022-12-25	WOS:000223791500011
J	Nemoto, T; Kojima, T; Oshima, A; Bito, H; Kasai, H				Nemoto, T; Kojima, T; Oshima, A; Bito, H; Kasai, H			Stabilization of exocytosis by dynamic F-actin coating of zymogen granules in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; RHO-GTPASES; RAT; CELL; CYTOSKELETON; PROTEIN; SECRETION; MEMBRANE; CALCIUM; VILLIN	Reorganization of F-actin in the apical region of mouse pancreatic acinar cells during Ca2+-dependent exocytosis of zymogen granules was investigated by two-photon excitation microscopy with intact acini. Granules were rapidly coated with F-actin in response to either agonist stimulation or photolysis of a caged-Ca2+ compound. Such F-actin coating occurred exclusively at the surface of granules undergoing exocytosis and was prevented either by latrunculin-A, which inhibits actin polymerization, or by Clostridium botulinum exoenzyme C3, which inhibits the small GTPase Rho. Latrunculin-A or exoenzyme C3 also triggered the formation of vacuoles in acinar cells, a characteristic of acute pancreatitis. Stimulation of acini with high concentrations of cholecystokinin, which cause acute pancreatitis in mice, also impaired the F-actin coating of granules and induced vacuole formation. Latrunculin-A reduced the latency to exocytosis but did not affect the total number of exocytic events, suggesting that F-actin slows and further stabilizes exocytosis by facilitating F-actin coating. Rho-dependent F-actin coating of granule membranes thus stabilizes exocytic structures and is necessary for physiological progression of sequetial compound exocytosis in the exocrine pancreas and for prevention of acute pancreatitis.	Natl Inst Physiol Sci, Dept Cell Physiol, Aichi 4448787, Japan; Grad Univ Adv Studies SOKENDAI, Aichi 4448787, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Kyoto Prefectural Univ Med, Dept Otolaryngol, Kamigyo Ku, Kyoto 6020841, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Tokyo 1130033, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo	Nemoto, T (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, 5-1 Higashiyama, Aichi 4448787, Japan.	tn@nips.ac.jp	Nemoto, Tomomi/B-4412-2012; Bito, Haruhiko/A-8635-2008	Nemoto, Tomomi/0000-0001-6102-1495; Bito, Haruhiko/0000-0001-6315-9594; Kasai, Haruo/0000-0003-2327-9027				Beil M, 2002, AM J PHYSIOL-GASTR L, V282, pG450, DOI 10.1152/ajpgi.00042.2001; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BURNHAM DB, 1982, CELL TISSUE RES, V222, P201; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; DECAMILLI P, 1976, J CELL BIOL, V70, P59, DOI 10.1083/jcb.70.1.59; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halpain S, 2000, TRENDS NEUROSCI, V23, P141, DOI 10.1016/S0166-2236(00)01576-9; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; ICHIKAWA A, 1965, J CELL BIOL, V24, P369, DOI 10.1083/jcb.24.3.369; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KLOPPEL G, 1994, ACUTE PANCREATITIS D, P35; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P97, DOI 10.1007/BF00432156; Leser J, 2000, AM J PHYSIOL-GASTR L, V278, pG486, DOI 10.1152/ajpgi.2000.278.3.G486; Miyake K, 2001, J CELL SCI, V114, P3487; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; OKONSKI MS, 1990, J CLIN INVEST, V86, P1649, DOI 10.1172/JCI114887; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Raraty M, 2000, P NATL ACAD SCI USA, V97, P13126, DOI 10.1073/pnas.97.24.13126; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; SAHARA N, 1990, CELL TISSUE RES, V261, P461, DOI 10.1007/BF00313524; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SCHEELE G, 1987, GASTROENTEROLOGY, V92, P345, DOI 10.1016/0016-5085(87)90127-2; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Torgerson RR, 2000, J CELL PHYSIOL, V182, P438, DOI 10.1002/(SICI)1097-4652(200003)182:3<438::AID-JCP15>3.0.CO;2-N; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140-6736(95)91695-4; WATANABE O, 1984, AM J PHYSIOL, V246, pG457, DOI 10.1152/ajpgi.1984.246.4.G457; Williams JA, 2002, PHARMACOL TOXICOL, V91, P297, DOI 10.1034/j.1600-0773.2002.910606.x; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	49	105	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37544	37550		10.1074/jbc.M403976200	http://dx.doi.org/10.1074/jbc.M403976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15184362	hybrid			2022-12-25	WOS:000223554600045
J	Scaffidi, AK; Petrovic, N; Moodley, YP; Fogel-Petrovic, M; Kroeger, KM; Seeber, RM; Eidne, KA; Thompson, PJ; Knight, DA				Scaffidi, AK; Petrovic, N; Moodley, YP; Fogel-Petrovic, M; Kroeger, KM; Seeber, RM; Eidne, KA; Thompson, PJ; Knight, DA			alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGF beta) type II receptor to potentiate the proliferative effects of TGF beta 1 in living human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; EPITHELIAL-CELLS; INSULIN-RECEPTOR; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; INTEGRIN EXPRESSION; CYTOPLASMIC DOMAIN; HORMONE-RECEPTOR; KINASE; ACTIVATION	The alpha(v)beta(3) integrin is known to cooperate with receptor tyrosine kinases to enhance cellular responses. To determine whether alpha(v)beta(3) regulates transforming growth factor beta (TGFbeta) 1-induced responses, we investigated the interaction between alpha(v)beta(3) and TGFbeta type II receptor (TGFbetaIIR) in primary human lung fibroblasts. We report that TGFbeta1 up-regulates cell surface and mRNA expression of alpha(v)beta(3) in a time- and dose-dependent manner. Co-immunoprecipitation and confocal microscopy showed that TGFbetaRII associates and clusters with alpha(v)beta(3), following TGFbeta1 exposure. This association was not observed with alpha(v)beta(5) or alpha(5)beta(1). We also used a novel molecular proximity assay, bioluminescence resonance energy transfer (BRET), to quantify this dynamic interaction in living cells. TGFbeta1 stimulation resulted in a BRET signal within 5 min, whereas tenascin, which binds alpha(v)beta(3), did not induce a substantial BRET signal. Co-exposure to tenascin and TGFbeta1 produced no further increases in BRET than TGFbeta1 alone. Cyclin D1 was rapidly induced in cells co-exposed to TGFbeta1 and tenascin, and as a consequence proliferation induced by TGFbeta1 was dramatically enhanced in cells co-exposed to tenascin or vitronectin. Cholesterol depletion inhibited the interaction between TGFbetaRII and alpha(v)beta(3) and abrogated the proliferative effect. The cyclic RGD peptide, GpenGRGDSPCA, which blocks alpha(v)beta(3), also abolished the synergistic proliferative effect seen. These results indicate a new interaction partner for the alpha(v)beta(3) integrin, the TGFbetaIIR, in which TGFbeta1-induced responses are potentiated in the presence alpha(v)beta(3) ligands. Our data provide a novel mechanism by which TGFbeta1 may contribute to abnormal wound healing and tissue fibrosis.	Univ Western Australia, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia; Univ Western Australia, Ctr Asthma Allergy & Resp Res, Nedlands, WA 6009, Australia; Western Australian Inst Med Res, Nedlands, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Knight, DA (corresponding author), Univ British Columbia, St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada.	dknight@mrl.ubc.ca	Seeber, Ruth/AAS-9411-2021	Seeber, Ruth/0000-0003-3265-7931				Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Boute N, 2003, EMBO REP, V4, P313, DOI 10.1038/sj.embor.embor767; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Clark RAF, 1996, AM J PATHOL, V148, P1407; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Graf K, 2000, HYPERTENSION, V35, P978, DOI 10.1161/01.HYP.35.4.978; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Issad T, 2002, ANN NY ACAD SCI, V973, P120, DOI 10.1111/j.1749-6632.2002.tb04619.x; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; JANAT MF, 1992, J CELL PHYSIOL, V151, P588, DOI 10.1002/jcp.1041510319; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; KUMAR NM, 1995, EXP CELL RES, V221, P385, DOI 10.1006/excr.1995.1389; Levinson H, 2002, J CELL PHYSIOL, V193, P219, DOI 10.1002/jcp.10164; LINNALA A, 1995, AM J RESP CELL MOL, V13, P578, DOI 10.1165/ajrcmb.13.5.7576694; McAnulty RJ, 1997, BIOCHEM J, V321, P639, DOI 10.1042/bj3210639; Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537-1891(02)00339-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moustakas A, 1999, J CELL SCI, V112, P1169; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; POHL WR, 1991, AM REV RESPIR DIS, V143, P1369, DOI 10.1164/ajrccm/143.6.1369; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Scaffidi AK, 2001, J CELL SCI, V114, P3507; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; TESCHLER H, 1993, AM REV RESPIR DIS, V147, P332, DOI 10.1164/ajrccm/147.2.332; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	47	83	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37726	37733		10.1074/jbc.M403010200	http://dx.doi.org/10.1074/jbc.M403010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15187087	hybrid			2022-12-25	WOS:000223554600064
J	Fischer, M; Romisch, W; Saller, S; Illarionov, B; Richter, G; Rohdich, F; Eisenreich, W; Bacher, A				Fischer, M; Romisch, W; Saller, S; Illarionov, B; Richter, G; Rohdich, F; Eisenreich, W; Bacher, A			Evolution of vitamin B-2 biosynthesis - Structural and functional similarity between pyrimidine deaminases of eubacterial and plant origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; GTP CYCLOHYDROLASE-II; LUMAZINE SYNTHASE; RIBOFLAVIN SYNTHASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; KINETIC-ANALYSIS	The Arabidopsis thaliana open reading frame At4g20960 predicts a protein whose N-terminal part is similar to the eubacterial 2,5-diamino-6-ribosylamino-4-(3H)-pyrimidinone 5'-phosphate deaminase domain. A synthetic open reading frame specifying a pseudomature form of the plant enzyme directed the synthesis of a recombinant protein which was purified to apparent homogeneity and was shown by NMR spectroscopy to convert 2,5-diamino-6-ribosylamino-4(3H)-pyrimidinone 5'-phosphate into 5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidinedione 5'-phosphate at a rate of 0.9 mumol mg(-1) min(-1). The substrate and product of the enzyme are both subject to spontaneous anomerization of the ribosyl side chain as shown by C-13 NMR spectroscopy. The protein contains 1 eq of Zn2+/subunit. The deaminase activity could be assigned to the N-terminal section of the plant protein. The deaminase domains of plants and eubacteria share a high degree of similarity, in contrast to deaminases from fungi. These data show that the riboflavin biosynthesis in plants proceeds by the same reaction steps as in eubacteria, whereas fungi use a different pathway.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Fischer, M (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	markus.fischer@ch.tum.de	Fischer, Markus J./G-9477-2012; Fischer, Markus/H-2870-2012; Richter, Gerald/F-3642-2011; Fischer, Markus/AFT-1856-2022; Eisenreich, Wolfgang/A-1258-2013	Fischer, Markus/0000-0001-7243-4199; Eisenreich, Wolfgang/0000-0002-9832-8279				Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Bacher A, 1997, METHOD ENZYMOL, V280, P382; Bacher A, 1997, METHOD ENZYMOL, V280, P389; BACHER A, 1970, J BIOL CHEM, V245, P4647; BACHER A, 1971, J BIOL CHEM, V246, P7018; BACHER A, 2001, Patent No. 11145; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Eberhardt S, 1996, EUR J BIOCHEM, V242, P712, DOI 10.1111/j.1432-1033.1996.0712r.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Fischer M, 2002, J BIOL CHEM, V277, P41410, DOI 10.1074/jbc.M206863200; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; Gerhardt S, 2002, STRUCTURE, V10, P1371, DOI 10.1016/S0969-2126(02)00864-X; Graupner M, 2002, J BACTERIOL, V184, P1952, DOI 10.1128/JB.184.7.1952-1957.2002; Haase I, 2003, J BIOL CHEM, V278, P37909, DOI 10.1074/jbc.M303090200; Haase I, 2003, EUR J BIOCHEM, V270, P1025, DOI 10.1046/j.1432-1033.2003.03478.x; Herz S, 2002, PHYTOCHEMISTRY, V60, P3, DOI 10.1016/S0031-9422(02)00056-0; Herz S, 2000, PHYTOCHEMISTRY, V53, P723, DOI 10.1016/S0031-9422(00)00013-3; HOLLANDER I, 1979, BIOCHEM BIOPH RES CO, V89, P759, DOI 10.1016/0006-291X(79)90694-6; Illarionov B, 2003, J BIOL CHEM, V278, P47700, DOI 10.1074/jbc.M305050200; Illarionov B, 2001, P NATL ACAD SCI USA, V98, P7224, DOI 10.1073/pnas.131610698; Illarionov B, 2001, J BIOL CHEM, V276, P11524, DOI 10.1074/jbc.M008931200; Ireton GC, 2003, STRUCTURE, V11, P961, DOI 10.1016/S0969-2126(03)00153-9; Jordan DB, 1999, J BIOL CHEM, V274, P22114, DOI 10.1074/jbc.274.31.22114; Kaiser J, 2002, EUR J BIOCHEM, V269, P5264, DOI 10.1046/j.1432-1033.2002.03239.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1992, EUR J BIOCHEM, V210, P711, DOI 10.1111/j.1432-1033.1992.tb17472.x; Lee J., 1985, CHEM BIOLUMINESCENCE, P401; LINGENS F, 1967, Z NATURFORSCH PT B, VB 22, P755; LOGVINENKO EM, 1993, GENETIKA+, V29, P922; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MEIGHEN EA, 1993, FASEB J, V7, P1016, DOI 10.1096/fasebj.7.11.8370470; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; MITSUDA H, 1970, J VITAMINOL, V16, P285, DOI 10.5925/jnsv1954.16.285; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; OLTMANNS O, 1972, J BACTERIOL, V110, P818, DOI 10.1128/JB.110.3.818-822.1972; Persson K, 1999, PROTEIN SCI, V8, P2355; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REVUELTA DJL, 1995, Patent No. 944420785; REVUELTA DJL, 1994, Patent No. 924238904; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Richter G, 1997, METHOD ENZYMOL, V280, P374; Ritz H, 2001, J BIOL CHEM, V276, P22273, DOI 10.1074/jbc.M100752200; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheuring J, 2001, J ORG CHEM, V66, P3811, DOI 10.1021/jo001739u; Schramek N, 2003, J AM CHEM SOC, V125, P4460, DOI 10.1021/ja028226k; SHAVLOVSKII G M, 1981, Mikrobiologiya, V50, P1008; Steinbacher S, 2003, J BIOL CHEM, V278, P42256, DOI 10.1074/jbc.M307301200; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435	61	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36299	36308		10.1074/jbc.M404406200	http://dx.doi.org/10.1074/jbc.M404406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208317	hybrid			2022-12-25	WOS:000223453600019
J	Jones, RJ; Smith, SME; Gao, YT; DeMay, BS; Mann, KJ; Salerno, KM; Salerno, JC				Jones, RJ; Smith, SME; Gao, YT; DeMay, BS; Mann, KJ; Salerno, KM; Salerno, JC			The function of the small insertion in the hinge subdomain in the control of constitutive mammalian nitric-oxide synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; ELECTRON-TRANSFER; RELAXING FACTOR; L-ARGININE; CALMODULIN-BINDING; MOLECULAR-CLONING; REDUCTASE DOMAIN; ESCHERICHIA-COLI; PROTEIN-KINASE; NO SYNTHASE	Control of nitric oxide (NO) synthesis in the constitutive nitric-oxide synthases (NOS) by calcium/calmodulin is exerted through the regulation of electron transfer from NADPH through the reductase domains. This process has been shown previously to involve the calmodulin binding site, the autoinhibitory insertion in the FMN binding domain, and the C-terminal tail. Smaller sequence elements also appear to correlate with control. Although some of these elements appear well positioned to function in control, they are poorly conserved; their role in control is neither well established nor defined by available information. In this study mutations have been induced in the small insertion of the hinge subdomain, which has been shown recently to form a beta hairpin in structural studies of the neuronal NOS reductase domains adjacent to the calmodulin site and the autoinhibitory element. Modification of the small insertion in neuronal NOS tends to increase cytochrome c reduction but not NO synthetic activity; some modifications or deletions in the corresponding region in endothelial NOS modestly increase activity under some conditions. Unexpectedly, some minor changes in the sequence introduce a loss in the content of heme relative to flavin cofactors. Taken together, these results suggest that the small insertion protects the calmodulin binding site and that it may be a modulator of NOS activity.	Rensselaer Polytech Inst, Dept Biol, JR Sci Ctr, Troy, NY 12180 USA	Rensselaer Polytechnic Institute	Salerno, JC (corresponding author), Rensselaer Polytech Inst, Dept Biol, JR Sci Ctr, 110 8th St, Troy, NY 12180 USA.	salerj@rpi.edu	salerno, john c/A-2595-2014	Bartlow, Kathleen/0000-0003-1181-5304				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; Fossetta JD, 1996, FEBS LETT, V379, P135, DOI 10.1016/0014-5793(95)01496-9; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Gross SS, 1996, METHOD ENZYMOL, V268, P159; HAINU M, 1989, BIOCHEMISTRY-US, V28, P8639; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JAUSSENS SP, 1992, J BIOL CHEM, V267, P14519; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishimura JS, 1999, J BIOL CHEM, V274, P5399, DOI 10.1074/jbc.274.9.5399; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SALERNO JC, 1996, Patent No. 6150500; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	44	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36876	36883		10.1074/jbc.M402808200	http://dx.doi.org/10.1074/jbc.M402808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210721	hybrid			2022-12-25	WOS:000223453600089
J	Uchida, T; Yamasaki, T; Eto, S; Sugawara, H; Kurisu, G; Nakagawa, A; Kusunoki, M; Hatakeyama, T				Uchida, T; Yamasaki, T; Eto, S; Sugawara, H; Kurisu, G; Nakagawa, A; Kusunoki, M; Hatakeyama, T			Crystal structure of the hemolytic lectin CEL-III isolated from the marine invertebrate Cucumaria echinata - Implications of domain structure for its membrane pore-formation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; RIBOSOME-INACTIVATING PROTEIN; AMINO-ACID-SEQUENCE; BINDING; RECOGNITION; HOLOTHUROIDEA; REFINEMENT; MOLSCRIPT; ALIGNMENT; CALCIUM	CEL-III is a Ca2+-dependent and galactose-specific lectin purified from the sea cucumber, Cucumaria echinata, which exhibits hemolytic and hemagglutinating activities. Six molecules of CEL-III are assumed to oligomerize to form an ion-permeable pore in the cell membrane. We have determined the crystal structure of CEL-III by using single isomorphous replacement aided by anomalous scattering in lead at 1.7 Angstrom resolution. CEL-III consists of three distinct domains as follows: the N-terminal two carbohydrate-binding domains (1 and 2), which adopt beta-trefoil folds such as the B-chain of ricin and are members of the (QXW) 3 motif family; and domain 3, which is a novel fold composed of two alpha-helices and one beta-sandwich. CEL-III is the first Ca2+-dependent lectin structure with two beta-trefoil folds. Despite sharing the structure of the B-chain of ricin, CEL-III binds five Ca2+ ions at five of the six subdomains in both domains 1 and 2. Considering the relatively high similarity among the five subdomains, they are putative binding sites for galactose-related carbohydrates, although it remains to be elucidated whether bound Ca2+ is directly involved in interaction with carbohydrates. The paucity of hydrophobic interactions in the interfaces between the domains and biochemical data suggest that these domains rearrange upon carbohydrate binding in the erythrocyte membrane. This conformational change may be responsible for oligomerization of CEL-III molecules and hemolysis in the erythrocyte membranes.	Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Prote, Osaka 5650871, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; RIKEN, Plant Sci Ctr, Lab Commun Mech, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Osaka University; Nagasaki University; RIKEN	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Prote, 3-2 Yamadaoka, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp; thata@net.nagasaki-u.ac.jp	KURISU, GENJI/ABA-5960-2020; Nakagawa, Atsushi/D-4329-2009; KURISU, GENJI/AAD-7109-2022; Nakagawa, Atsushi/M-5731-2019	KURISU, GENJI/0000-0002-5354-0807; Nakagawa, Atsushi/0000-0002-1700-7861; KURISU, GENJI/0000-0002-5354-0807; Nakagawa, Atsushi/0000-0002-1700-7861; Hatakeyama, Tomomitsu/0000-0002-9505-1980				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Cioci G, 2003, FEBS LETT, V555, P297, DOI 10.1016/S0014-5793(03)01249-3; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; HATAKEYAMA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1314, DOI 10.1271/bbb.59.1314; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; Hatakeyama T, 1999, J BIOCHEM, V125, P277, DOI 10.1093/oxfordjournals.jbchem.a022284; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; Hatakeyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P157, DOI 10.1271/bbb.66.157; Hatakeyama T, 2004, J BIOCHEM, V135, P65, DOI 10.1093/jb/mvh007; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; Kouzuma Y, 2003, J BIOCHEM, V134, P395, DOI 10.1093/jb/mvg157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mancheno JM, 2004, ACTA CRYSTALLOGR D, V60, P1139, DOI 10.1107/S0907444904007991; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell E, 2002, NAT STRUCT BIOL, V9, P918, DOI 10.1038/nsb865; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nakano M, 1999, BBA-PROTEIN STRUCT M, V1435, P167, DOI 10.1016/S0167-4838(99)00212-5; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Oda T, 1997, J BIOCHEM, V121, P560; Oda T, 1999, J BIOCHEM, V125, P713, DOI 10.1093/oxfordjournals.jbchem.a022341; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Sallay I, 1998, BIOSCI BIOTECH BIOCH, V62, P1757, DOI 10.1271/bbb.62.1757; Sallay I, 2001, BIOSCI BIOTECH BIOCH, V65, P1347, DOI 10.1271/bbb.65.1347; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	53	50	52	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37133	37141		10.1074/jbc.M404065200	http://dx.doi.org/10.1074/jbc.M404065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194688	Green Published, hybrid			2022-12-25	WOS:000223453600117
J	Winkler, DG; Yu, CP; Geoghegan, JC; Ojala, EW; Skonier, JE; Shpektor, D; Sutherland, MK; Latham, JA				Winkler, DG; Yu, CP; Geoghegan, JC; Ojala, EW; Skonier, JE; Shpektor, D; Sutherland, MK; Latham, JA			Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; BMP ANTAGONIST; DIFFERENTIATION; OVEREXPRESSION; OSTEOPOROSIS; EXPRESSION; INDUCTION; SKELETON; SOST; LIMB	Noggin and sclerostin are bone morphogenetic protein (BMP) antagonists that modulate mitogenic activity through sequestering BMPs. Little is known of the interactions among this class of proteins. We show that recombinant sclerostin and noggin bound to each other with high affinity (K-D = 2.92 nM). This observation has been extended to naturally expressed noggin and sclerostin from the rat osteosarcoma cell line, ROS 17/2.8, supporting a role for the complex in natural systems. The noggin-sclerostin complex was competitive with BMP binding and mutually attenuated the activity of each BMP antagonist. Collectively, the data demonstrate a novel and exquisite paradigm for the regulation of BMP activity through direct neutralization of the BMP and activation by co-localized BMP antagonist expression. The pleiotrophic nature of noggin and sclerostin represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis.	Celltech R&D Inc, Dept Gene Funct & Target Validat, Bothell, WA 98021 USA		Latham, JA (corresponding author), 2409 10th Ave W, Seattle, WA 98119 USA.	latham@alderbio.com						Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399-0004.2003.00036.x; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; Pizette S, 2001, DEVELOPMENT, V128, P4463; Pizette S, 1999, DEVELOPMENT, V126, P883; Sharov AA, 2003, EMBO J, V22, P2992, DOI 10.1093/emboj/cdg291; SUTHERLAND MK, 2004, IN PRESS BONE; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wu XB, 2002, J BONE MINER RES, V17, pS143; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Yu MK, 2002, NATURE, V420, P308, DOI 10.1038/nature01196; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	19	71	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36293	36298		10.1074/jbc.M400521200	http://dx.doi.org/10.1074/jbc.M400521200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15199066	hybrid			2022-12-25	WOS:000223453600018
J	Yang, XFF; Ji, YR; Schneider, BL; Reitzer, L				Yang, XFF; Ji, YR; Schneider, BL; Reitzer, L			Phosphorylation-independent dimer-dimer interactions by the enhancer-binding activator NtrC of Escherichia coli - A third function for the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN REGULATOR-I; PROTEIN NTRC; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; DNA INVERSION; SIGNAL-TRANSDUCTION; RESPONSE REGULATORS; RECEIVER DOMAIN; RNA-POLYMERASE; OPERON	The response regulator NtrC transcriptionally activates genes of the nitrogen-regulated (Ntr) response. Phosphorylation of its N-terminal receiver domain stimulates an essential oligomerization of the central domain. Deletion of the central domain reduces, but does not eliminate, intermolecular interactions as assessed by cooperative binding to DNA. To analyze the structural determinants and function of this central domain-independent as well as phosphorylation-independent oligomerization, we randomly mutagenized DNA coding for an NtrC without its central domain and isolated strains containing NtrC with defective phosphorylation-independent cooperative binding. The alterations were primarily localized to helix B of the C-terminal domain. Site-specific mutagenesis that altered surface residues of helix B confirmed this localization. The purified NtrC variants, with or without the central domain, were specifically defective in phosphorylation-independent cooperative DNA binding and had little defect, if any, on other functions, such as noncooperative DNA binding. We propose that this region forms an oligomerization interface. Full-length NtrC variants did not efficiently repress the glnA-ntrBC operon when NtrC was not phosphorylated, which suggests that phosphorylation-independent cooperative binding sets the basal level for glutamine synthetase and the regulators of the Ntr response. The NtrC variants in these cells generally, but not always, supported wild-type growth in nitrogen-limited media and wild-type activation of a variety of Ntr genes. We discuss the differences and similarities between the NtrC C-terminal domain and the homologous Fis, which is also capable of intermolecular interactions.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Reitzer, L (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.	reitzer@utdallas.edu	Yang, X. Frank/F-3266-2010; Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090	NIGMS NIH HHS [GM 47965] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047965] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Bantscheff M, 1999, BIOCHEMISTRY-US, V38, P11012, DOI 10.1021/bi990781k; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; Cho HS, 2001, CURR OPIN STRUC BIOL, V11, P679, DOI 10.1016/S0959-440X(01)00271-8; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; Haldimann A, 2001, J BACTERIOL, V183, P6384, DOI 10.1128/JB.183.21.6384-6393.2001; Harrod AC, 2004, J BIOL CHEM, V279, P2350, DOI 10.1074/jbc.M306181200; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kiupakis AK, 2002, J BACTERIOL, V184, P2940, DOI 10.1128/JB.184.11.2940-2950.2002; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Leung DW, 1989, TECHNIQUE, V1, P11; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; Lu CD, 1999, J BACTERIOL, V181, P1934, DOI 10.1128/JB.181.6.1934-1938.1999; McLeod SM, 1999, J MOL BIOL, V294, P333, DOI 10.1006/jmbi.1999.3262; Merickel SK, 1998, GENE DEV, V12, P2803, DOI 10.1101/gad.12.17.2803; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; Miller JH., 1972, EXPT MOL GENETICS; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; Morett E, 1998, FEBS LETT, V433, P108, DOI 10.1016/S0014-5793(98)00888-6; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; OSUNA R, 1991, EMBO J, V10, P1593, DOI 10.1002/j.1460-2075.1991.tb07680.x; Park S, 2002, FASEB J, V16, P1964, DOI 10.1096/fj.02-0395fje; Park S, 2002, BIOCHEMISTRY-US, V41, P10934, DOI 10.1021/bi0260031; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Pybus CA, 2002, THESIS U TEXAS DALLA; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; ROTHSTEIN DM, 1980, P NATL ACAD SCI-BIOL, V77, P7372, DOI 10.1073/pnas.77.12.7372; Safo MK, 1997, EMBO J, V16, P6860, DOI 10.1093/emboj/16.22.6860; Samsonova NN, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIAU SP, 1993, J BACTERIOL, V175, P190, DOI 10.1128/JB.175.1.190-199.1993; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	52	15	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36708	36714		10.1074/jbc.M405205200	http://dx.doi.org/10.1074/jbc.M405205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208307	hybrid			2022-12-25	WOS:000223453600070
J	Bulygin, VV; Duncan, TM; Cross, RL				Bulygin, VV; Duncan, TM; Cross, RL			Rotor/stator interactions of the epsilon subunit in Escherichia coli ATP synthase and implications for enzyme regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; F0F1-ATP SYNTHASE; BETA-SUBUNITS; GAMMA-SUBUNIT; ROTARY MOTOR; OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; TERMINAL DOMAIN; CROSS-LINKING	The H+-translocating F0F1-ATP synthase of Escherichia coli functions as a rotary motor, coupling the transmembrane movement of protons through F-0 to the synthesis of ATP by F-1. Although the epsilon subunit appears to be tightly associated with the gamma subunit in the central stalk region of the rotor assembly, several studies suggest that the C-terminal domain of epsilon can undergo significant conformational change as part of a regulatory process. Here we use disulfide cross-linking of substituted cysteines on functionally coupled ATP synthase to characterize interactions of epsilon with an F-0 component of the rotor (subunit c) and with an F-1 component of the stator (subunit beta). Oxidation of the engineered F0F1 causes formation of two disulfide bonds, betaD380C-epsilonS108C and epsilonE31C-cQ42C, to give a beta-epsilon-c cross-linked product in high yield. The results demonstrate the ability of epsilon to span the central stalk region from the surface of the membrane (epsilon-c) to the bottom of F1 (beta-epsilon) and suggest that the conformation detected here is distinct from both the "closed" state seen with isolated epsilon (Uhlin, U., Cox, G. B., and Guss, J. M. (1997) Structure 5, 1219-1230) and the "open" state seen in a complex with a truncated form of the gamma subunit (Rodgers, A. J., and Wilce, M. C. (2000) Nat. Struct. Biol. 7, 1051-1054). The kinetics of beta-epsilon and epsilon-c cross-linking were studied separately using F0F1 containing one or the other matched cysteine pair. The rate of cross-linking at the epsilon/c (rotor/rotor) interface is not influenced by the type of nucleotide added. In contrast, the rate of beta-epsilon cross-linking is fastest under ATP hydrolysis conditions, intermediate with MgADP, and slowest with MgAMP-PNP. This is consistent with a regulatory role for a reversible beta/epsilon (stator/rotor) interaction that blocks rotation and inhibits catalysis. Furthermore, the rate of beta-epsilon cross-linking is much faster than that indicated by previous studies, allowing for the possibility of a rapid response to regulatory signals.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cross, RL (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	crossr@upstate.edu		Duncan, Thomas/0000-0002-6432-4958	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023152, R01GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Borsch M, 2002, FEBS LETT, V527, P147, DOI 10.1016/S0014-5793(02)03198-8; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Duncan T. M., 2004, ENZYMES, VXXIII, P203; Duncan TM, 1995, BIOCHEM SOC T, V23, P736, DOI 10.1042/bst0230736; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Etzold C, 1997, EUR J BIOCHEM, V243, P336, DOI 10.1111/j.1432-1033.1997.0336a.x; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Johnson EA, 2002, BIOCHEMISTRY-US, V41, P2446, DOI 10.1021/bi011939f; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Ma JP, 2002, STRUCTURE, V10, P921, DOI 10.1016/S0969-2126(02)00789-X; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Peskova YB, 2000, BIOCHEMISTRY-US, V39, P11830, DOI 10.1021/bi0013694; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P267, DOI 10.1016/0167-4781(93)90213-W; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	63	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35616	35621		10.1074/jbc.M405012200	http://dx.doi.org/10.1074/jbc.M405012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199054	hybrid			2022-12-25	WOS:000223303400057
J	Choe, CU; Harrison, KD; Grant, W; Ehrlich, BE				Choe, CU; Harrison, KD; Grant, W; Ehrlich, BE			Functional coupling of chromogranin with the inositol 1,4,5-trisphosphate receptor shapes calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID CELL SECRETION; B-LIKE IMMUNOREACTIVITY; NEUROLOGICAL DISEASES; ALZHEIMERS-DISEASE; PROTEIN; CHANNEL; PEPTIDE; GRANULES; RELEASE; NEURONS	Chromogranins A and B are high capacity, low affinity calcium (Ca2+) storage proteins that bind to the inositol 1,4,5-trisphosphate-gated receptor (InsP(3)R). Although most commonly associated with secretory granules of neuroendocrine cells, chromogranins have also been found in the lumen of the endoplasmic reticulum (ER) of many cell types. To investigate the functional consequences of the interaction between the InsP(3)R and the chromogranins, we disrupted the interaction between the two proteins by adding a chromogranin fragment, which competed with chromogranin for its binding site on the InsP(3)R. Responses were monitored at the single channel level and in intact cells. When using InsP(3)R type I incorporated into planar lipid bilayers and activated by cytoplasmic InsP(3) and luminal chromogranin, the addition of the fragment reversed the enhancing effect of chromogranin. Moreover, the expression of the fragment in the ER of neuronally differentiated PC12 cells attenuated agonist-induced intracellular Ca2+ signaling. These results show that the InsP(3)R/chromogranin interaction amplifies Ca2+ release from the ER and that chromogranin is an essential component of this intracellular channel complex.	Yale Univ, Dept Pharmacol & Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Inst Neural Signal Transduct, D-20251 Hamburg, Germany	Yale University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63496] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; Eder U, 1998, J NEURAL TRANSM, V105, P39, DOI 10.1007/s007020050036; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FISCHERCOLBRIE R, 1985, NEUROSCIENCE, V16, P547, DOI 10.1016/0306-4522(85)90191-5; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HELLE KB, 1993, NEUROCHEM INT, V22, P353, DOI 10.1016/0197-0186(93)90017-Y; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Johenning FW, 2002, J NEUROSCI, V22, P5344; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LEWIS JJ, 1988, SURGERY, V104, P1031; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Marksteiner J, 2002, J MOL NEUROSCI, V18, P53, DOI 10.1385/JMN:18:1-2:53; Marksteiner J, 2000, ACTA NEUROPATHOL, V100, P205, DOI 10.1007/s004010000239; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; Nagase T, 2003, NEUROSCIENCE, V117, P821, DOI 10.1016/S0306-4522(02)00803-5; NISHIMURA M, 1994, BRAIN RES, V634, P339, DOI 10.1016/0006-8993(94)91940-2; Nowakowski C, 2002, SCHIZOPHR RES, V58, P43, DOI 10.1016/S0920-9964(01)00389-9; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; SIMON JP, 1989, BIOCHEM J, V262, P1; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; Steffl M, 2003, ANN ANAT, V185, P103, DOI 10.1016/S0940-9602(03)80070-5; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Thrower EC, 2003, J BIOL CHEM, V278, P49699, DOI 10.1074/jbc.M309307200; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Yoo SH, 2000, J BIOL CHEM, V275, P30293, DOI 10.1074/jbc.M001204200	42	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35551	35556		10.1074/jbc.M311261200	http://dx.doi.org/10.1074/jbc.M311261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194698	hybrid			2022-12-25	WOS:000223303400050
J	Saha, PK; Kojima, H; Martinez-Botas, J; Sunehag, AL; Chan, L				Saha, PK; Kojima, H; Martinez-Botas, J; Sunehag, AL; Chan, L			Metabolic adaptations in the absence of perilipin - Increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; HUMAN NEWBORN; MUSCLE; LIPOLYSIS; GENE; INTOLERANCE; PROTEIN; INACTIVATION; ADIPONECTIN	Targeted disruption of the lipid droplet protein, perilipin, in mice leads to constitutional lipolysis associated with marked reduction in white adipose tissue as a result of unbridled lipolysis. To investigate the metabolic adaptations in response to the constitutive lipolysis, we studied perilipin-null (plin(-/-)) mice in terms of their fatty acid oxidation and glycerol and glucose metabolism homeostasis by using dynamic biochemical testing and clamp and tracer infusion methods. plin(-/-) mice showed increased beta-oxidation in muscle, liver, and adipose tissue resulting from a coordinated regulation of the enzymes and proteins involved in beta-oxidation. The increased beta-oxidation helped remove the extra free fatty acids created by the constitutive lipolysis. An increase in the expression of the transcripts for uncoupling proteins-2 and -3 also accompanied this increase in fatty acid oxidation. Adult plin(-/-) mice had normal plasma glucose but a reduced basal hepatic glucose production (46% that of plin(+/+)). Insulin infusion during low dose hyperinsulinemic-euglycemic clamp further lowered the glucose production in plin(-/-) mice, but plin(-/-) mice also showed a 36% decrease (p < 0.007) in glucose disposal rate during the low dose insulin clamp, indicating peripheral insulin resistance. However, compared with plin(-/-) mice, 14-week-old plin(-/-) mice showed no significant difference in glucose disposal rate during the high dose hyperinsulinemic clamp, whereas 42-week-old plin(-/-) mice displayed significant insulin resistance on high dose hyperinsulinemic clamp. Despite increasing insulin resistance with age, plin(-/-) mice at different ages maintained a normal glucose response during an intraperitoneal glucose tolerance curve, being compensated by the increased beta-oxidation and reduced hepatic glucose production. These experiments uncover the metabolic adaptations associated with the constitutional lipolysis in plin(-/-) mice that allowed the mice to continue to exhibit normal glucose tolerance in the presence of peripheral insulin resistance.	Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; ARS, USDA, Childrens Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA)	Chan, L (corresponding author), Baylor Coll Med, Div Diabet Endocrinol & Metab, Dept Med, N520-10,1 Baylor Plaza, Houston, TX 77030 USA.	lchan@bcm.tmc.edu	Martinez-Botas, Javier/AAD-8733-2021	Martinez-Botas, Javier/0000-0002-5190-3619	NHLBI NIH HHS [HL-51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; BIER DM, 1977, DIABETES, V26, P1005, DOI 10.2337/diabetes.26.11.1005; BOUGNERES PF, 1987, BIOL NEONATE, V52, P87; BOUGNERES PF, 1982, J CLIN INVEST, V70, P262, DOI 10.1172/JCI110613; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; FJELD CR, 1992, PEDIATR RES, V32, P693, DOI 10.1203/00006450-199212000-00015; Fujita Y, 1998, DIABETOLOGIA, V41, P1459, DOI 10.1007/s001250051092; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ihlemann J, 1999, AM J PHYSIOL-ENDOC M, V277, pE208, DOI 10.1152/ajpendo.1999.277.2.E208; Jones JP, 1997, AM J PHYSIOL-ENDOC M, V273, pE682, DOI 10.1152/ajpendo.1997.273.4.E682; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, J CLIN INVEST, V108, P153, DOI 10.1172/JCI10294; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; PATEL D, 1992, PEDIATR RES, V31, P52, DOI 10.1203/00006450-199201000-00010; Reitman ML, 2002, ANNU REV NUTR, V22, P459, DOI 10.1146/annurev.nutr.22.010402.102849; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; SUNEHAG A, 1994, PEDIATR RES, V36, P550, DOI 10.1203/00006450-199410000-00024; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	44	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35150	35158		10.1074/jbc.M405499200	http://dx.doi.org/10.1074/jbc.M405499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197189	hybrid			2022-12-25	WOS:000223303400005
J	Svarovskaia, ES; Xu, HZ; Mbisa, JL; Barr, R; Gorelick, RJ; Ono, A; Freed, EO; Hu, WS; Pathak, VK				Svarovskaia, ES; Xu, HZ; Mbisa, JL; Barr, R; Gorelick, RJ; Ono, A; Freed, EO; Hu, WS; Pathak, VK			Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 Virions through interactions with viral and nonviral RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIF PROTEIN; ANTIVIRAL ACTIVITY; INFECTIVITY FACTOR; REPLICATION CYCLE; T-LYMPHOCYTES; IN-VIVO; DNA; HYPERMUTATION; DEGRADATION	Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is a host cytidine deaminase that is packaged into virions and confers resistance to retroviral infection. APOBEC3G deaminates deoxycytidines in minus strand DNA to deoxyuridines, resulting in G to A hypermutation and viral inactivation. Human immunodeficiency virus type 1 (HIV-1) virion infectivity factor counteracts the antiviral activity of APOBEC3G by inducing its proteosomal degradation and preventing virion incorporation. To elucidate the mechanism of viral suppression by APOBEC3G, we developed a sensitive cytidine deamination assay and analyzed APOBEC3G virion incorporation in a series of HIV-1 deletion mutants. Virus-like particles derived from constructs in which pol, env, and most of gag were deleted still contained high levels of cytidine deaminase activity; in addition, coimmunoprecipitation of APOBEC3G and HIV-1 Gag in the presence and absence of RNase A indicated that the two proteins do not interact directly but form an RNase-sensitive complex. Viral particles lacking HIV-1 genomic RNA which were generated from the gag-pol expression constructs pC-Help and pSYNGP packaged APOBEC3G at 30-40% of the wild-type level, indicating that interactions with viral RNA are not necessary for incorporation. In addition, viral particles produced from an nucleocapsid zinc finger mutant contained similar to1% of the viral genomic RNA but similar to30% of the cytidine deaminase activity. The reduction in APOBEC3G incorporation was equivalent to the reduction in the total RNA present in the nucleocapsid mutant virions. These results indicate that interactions with viral proteins or viral genomic RNA are not essential for APOBEC3G incorporation and suggest that APOBEC3G interactions with viral and nonviral RNAs that are packaged into viral particles are sufficient for APOBEC3G virion incorporation.	NCI, HIV Drug Resistance Program, Ctr Canc Res, Frederick, MD 21702 USA; NCI, AIDS Vaccine Program, Sci Appl Int Corp Inc, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Pathak, VK (corresponding author), NCI, HIV Drug Resistance Program, Ctr Canc Res, POB B,Bldg 535,Rm 334, Frederick, MD 21702 USA.	vpathak@ncifcrf.gov		Mbisa, Jean/0000-0002-0348-9679; Pathak, Vinay/0000-0003-2441-8412; Ono, Akira/0000-0001-7841-851X	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010595, Z01BC010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARONOFF R, 1991, J VIROL, V65, P71, DOI 10.1128/JVI.65.1.71-80.1991; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Fu W, 2003, J VIROL, V77, P754, DOI 10.1128/JVI.77.1.754-761.2003; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; Ono A, 2000, J VIROL, V74, P5142, DOI 10.1128/JVI.74.11.5142-5150.2000; Ono A, 2000, J VIROL, V74, P2855, DOI 10.1128/JVI.74.6.2855-2866.2000; Ott DE, 2003, J VIROL, V77, P5547, DOI 10.1128/JVI.77.10.5547-5556.2003; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	33	227	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35822	35828		10.1074/jbc.M405761200	http://dx.doi.org/10.1074/jbc.M405761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210704	hybrid			2022-12-25	WOS:000223303400083
J	Chan, Y; Fish, JE; D'Abreo, C; Lin, S; Robb, GB; Teichert, AM; Karantzoulis-Fegaras, F; Keightley, A; Steer, BM; Marsden, PA				Chan, Y; Fish, JE; D'Abreo, C; Lin, S; Robb, GB; Teichert, AM; Karantzoulis-Fegaras, F; Keightley, A; Steer, BM; Marsden, PA			The cell-specific expression of endothelial nitric-oxide synthase - A role for DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN MECP2; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; ERYTHROPOIETIN GENE; CPG ISLANDS; PROMOTER; CANCER; SITES; SP1	The basis for the endothelial cell-restricted expression of endothelial nitric-oxide synthase ( eNOS) is not known. While transgenic promoter/reporter mice demonstrated endothelium cell-specific eNOS expression, we found robust expression of episomal eNOS promoter/reporter constructs in cell types that do not express the native eNOS transcript. To explore the mechanism underlying this differential activity pattern of chromatin-versus episome-based eNOS promoters, we examined the methylation status of 5'-regulatory sequences of the human eNOS gene. DNA methylation differed dramatically between endothelial and nonendothelial cell types, including vascular smooth muscle cells. This same cell type-specific methylation pattern was observed in vivo in endothelial and vascular smooth muscle cells of the mouse aorta at the native murine eNOS promoter. We addressed the functional consequences of methylation on eNOS transcription using transient transfection of in vitro methylated promoter/reporter constructs and found that methylated constructs exhibited a marked decrease in the synergistic action of Sp1, Sp3, and Ets1 on eNOS promoter activity. The addition of methyl-CpG-binding protein 2 further reduced the transcriptional activity of methylated eNOS constructs. Importantly, chromatin immunoprecipitation demonstrated the presence of Sp1, Sp3, and Ets1 at the native eNOS promoter in endothelial cells but not in vascular smooth muscle cells. Finally, robust expression of eNOS mRNA was induced in nonendothelial cell types following inhibition of DNA methyltransferase activity with 5-azacytidine, demonstrating the importance of DNA methylation-mediated repression. This report is the first to show that promoter DNA methylation plays an important role in the cell-specific expression of a constitutively expressed gene in the vascular endothelium.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Teichert, Anouk-Martine/O-1462-2015; Lin, Steve/H-3723-2013; Marsden, Philip A/B-1441-2012	Teichert, Anouk-Martine/0000-0001-9648-8677; Lin, Steve/0000-0002-8644-9719; Robb, Gregory Brett/0000-0002-2382-2256; Fish, Jason/0000-0003-0640-7277				Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Clark S. J., 1997, P151; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; HALL AV, 1994, J BIOL CHEM, V269, P33082; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Kupper D, 1997, BIOTECHNIQUES, V23, P843, DOI 10.2144/97235bm17; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lin XH, 2003, CANCER RES, V63, P498; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; Minami T, 2002, BLOOD, V100, P4019, DOI 10.1182/blood-2002-03-0955; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Yin H, 2000, BLOOD, V95, P111, DOI 10.1182/blood.V95.1.111.001k20_111_119; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	59	186	197	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35087	35100		10.1074/jbc.M405063200	http://dx.doi.org/10.1074/jbc.M405063200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180995	hybrid			2022-12-25	WOS:000223134800121
J	Mayorga, M; Bahi, N; Ballester, M; Comella, JX; Sanchis, D				Mayorga, M; Bahi, N; Ballester, M; Comella, JX; Sanchis, D			Bcl-2 is a key factor for cardiac fibroblast resistance to programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS; FAMILY-MEMBERS; ACTIVATION; MITOCHONDRIAL; HYPOXIA; PATHWAY; PROTEIN	Cardiac fibroblasts play an essential role in the physiology of the heart. These produce extracellular matrix proteins and synthesize angiogenic and cardioprotective factors. Although fibroblasts of cardiac origin are known to be resistant to apoptosis and to remain metabolically active in situations compromising cell survival, the underlying mechanisms are unknown. Here, we report that cardiac fibroblasts were more resistant than dermal or pulmonary fibroblasts to mitochondria-dependent cell death. Cytochrome c release was blocked in cardiac fibroblasts but not in dermal fibroblasts treated with staurosporine, etoposide, serum deprivation, or simulated ischemia, precluding caspase-3 activation and DNA fragmentation. Resistance to apoptosis of cardiac fibroblasts correlated with the expression of the anti-apoptotic protein Bcl-2, whereas skin and lung fibroblasts did not express detectable levels of this protein. Bcl-xL, Bax, and Bak were expressed at similar levels in cardiac, dermal, and lung fibroblasts. In addition, the death of cardiac fibroblasts during hypoxia was not associated with the cleavage of Bid but rather with Bcl-2 disappearance, suggesting the requirement of the mitochondrial apoptotic machinery to execute death receptor-induced programmed cell death. Knockdown of bcl-2 expression by siRNA in cardiac fibroblasts increased their apoptotic response to staurosporine, serum, and glucose deprivation and to simulated ischemia. Moreover, dermal fibroblasts overexpressing Bcl-2 achieved a similar level of resistance to these stimuli as cardiac fibroblasts. Thus, our data demonstrate that Bcl-2 is an important effector of heart fibroblast resistance to apoptosis and highlight a probable mechanism for promoting survival advantage in fibroblasts of cardiac origin.	Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain; Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Med, Lleida 25008, Spain; Hosp Arnau Vilanova, Lab Recerca, Lleida 25198, Spain	Universitat de Lleida; Universitat de Lleida; University Hospital Arnau de Vilanova	Sanchis, D (corresponding author), Univ Lleida, Grp Cell Signaling & Apoptosis, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	daniel.sanchis@cmb.udl.es	Sanchis, Daniel/C-8077-2009; Sanchis, Daniel/B-5644-2009; Comella, Joan X/D-7333-2012; Bahi, Nuria/ABE-9680-2021; Pla, Nuria Bahi/B-8022-2009; Comella, Joan/GQA-4279-2022	Sanchis, Daniel/0000-0003-0047-8533; Comella, Joan X/0000-0002-6218-0786; Bahi, Nuria/0000-0003-2845-0313; Pla, Nuria Bahi/0000-0003-2845-0313; 				Abbate A, 2003, J AM COLL CARDIOL, V41, P753, DOI 10.1016/S0735-1097(02)02959-5; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Agocha A, 1997, J MOL CELL CARDIOL, V29, P2233, DOI 10.1006/jmcc.1997.0462; Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Aoyama T, 2002, CARDIOVASC RES, V55, P787, DOI 10.1016/S0008-6363(02)00493-5; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bouillet P, 2002, J CELL SCI, V115, P1567; Bruce MC, 1999, AM J RESP CELL MOL, V20, P228, DOI 10.1165/ajrcmb.20.2.3150; Chen DB, 2000, LIFE SCI, V67, P1683, DOI 10.1016/S0024-3205(00)00759-1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dammer S, 2002, CIRCULATION, V106, P309; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gardner LB, 2003, MOL CELL BIOL, V23, P9032, DOI 10.1128/MCB.23.24.9032-9045.2003; Gonzalez A, 2002, HYPERTENSION, V39, P75, DOI 10.1161/hy0102.100788; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Kang MJ, 1997, J MOL CELL CARDIOL, V29, P1767, DOI 10.1006/jmcc.1997.0450; Katz AM, 2000, HEART FAILURE; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; NOVACK DV, 1994, AM J PATHOL, V145, P61; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Pablos JL, 1997, J HISTOCHEM CYTOCHEM, V45, P711, DOI 10.1177/002215549704500509; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; SCHAPER J, 1992, BASIC RES CARDIOL, V87, P303; Scheubel RJ, 2002, J AM COLL CARDIOL, V39, P481, DOI 10.1016/S0735-1097(01)01769-7; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Soler RM, 1999, J NEUROSCI, V19, P9160; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Takemura G, 1998, CIRC RES, V82, P1130, DOI 10.1161/01.RES.82.11.1130; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; van den Hoff MJB, 2000, CARDIOVASC RES, V45, P603, DOI 10.1016/S0008-6363(99)00401-0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x; Zhang XM, 2001, J AM COLL CARDIOL, V38, P2055, DOI 10.1016/S0735-1097(01)01665-5	49	70	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34882	34889		10.1074/jbc.M404616200	http://dx.doi.org/10.1074/jbc.M404616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184368	hybrid			2022-12-25	WOS:000223134800098
J	Orth, JHC; Lang, S; Aktories, K				Orth, JHC; Lang, S; Aktories, K			Action of Pasteurella multocida toxin depends on the helical domain of G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL FRAGMENT; TYROSINE PHOSPHORYLATION; BACTERIAL TOXINS; MITOGENIC TOXIN; POTENT MITOGEN; PROTEIN; ALPHA; ACTIVATION; INCREASES; MECHANISM	Pasteurella multocida produces a 146-kDa protein toxin (PMT), which activates multiple cellular signal transduction pathways, resulting in the activation of phospholipase Cbeta, RhoA, Jun kinase, and extracellular signal-regulated kinase. Using Galpha(q)/Galpha(11)-deficient cells, it was shown that the PMT-induced pleiotropic effects are mediated by Galpha(q) but not by the highly related Galpha(11) protein (Zywietz, A., Gohla, A., Schmelz, M., Schultz, G., and Offermanns, S. ( 2001) J. Biol. Chem. 276, 3840 - 3845). Here we studied the molecular basis of the unique specificity of PMT to distinguish between Galpha(q) and/or Galpha(11). Infection of Galpha(q/11)-deficient cells with retrovirus-encoding Galpha(q) caused reconstitution of PMT-induced activation of phospholipase Cbeta, whereas Galpha(11)-encoding virus did not reconstitute PMT activity. Chimeras between Galpha(q) and/or Galpha(11) revealed that a peptide region of Galpha(q), covering amino acid residues 105 - 113, is essential for the action of PMT to activate phospholipase Cbeta. Exchange of glutamine 105 or asparagine 109 of Galpha(11), which are located in the all-helical domain of the Galpha subunit, with the equally positioned histidines of Galpha(q), renders Galpha(11) capable of transmission PMT-induced phospholipase Cbeta activation. The data indicate that the all-helical domain of Galpha(q) is essential for the action of PMT and suggest an essential functional role of this domain in signal transduction via G(q) proteins.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Baldwin MR, 2003, J BIOL CHEM, V278, P32719, DOI 10.1074/jbc.M303524200; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHANTER N, 1990, CAN J VET RES, V54, pS45; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; KAMP EM, 1988, AM J VET RES, V49, P1844; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Mullan PB, 1996, INFECT IMMUN, V64, P959, DOI 10.1128/IAI.64.3.959-965.1996; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Orth JHC, 2003, BIOCHEMISTRY-US, V42, P4971, DOI 10.1021/bi0272959; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PEDERSEN KB, 1981, NORD VET MED, V33, P513; Pullinger GD, 2001, INFECT IMMUN, V69, P7839, DOI 10.1128/IAI.69.12.7839-7850.2001; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; STADDON JM, 1991, J BIOL CHEM, V266, P4840; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	36	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34150	34155		10.1074/jbc.M405353200	http://dx.doi.org/10.1074/jbc.M405353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192096	hybrid			2022-12-25	WOS:000223134800012
J	Wang, SX; Skorczewski, J; Feng, X; Mei, L; Murphy-Ullrich, JE				Wang, SX; Skorczewski, J; Feng, X; Mei, L; Murphy-Ullrich, JE			Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; FACTOR USF; NITRIC-OXIDE; EXTRACELLULAR-MATRIX; MULTIPLE FORMS; MESSENGER-RNA; ACTIVATION; EXPRESSION; GMP	Thrombospondin 1 (TSP1) transcription is stimulated by glucose, resulting in increased TGF-beta activation and matrix protein synthesis. We previously showed that inducible expression of the catalytic domain of cGMP-dependent protein kinase (PKG) inhibits glucose-regulated TSP1 transcription and transforming growth factor (TGF)-beta activity in stably transfected rat mesangial cells (RMCs(tr/cd)). However, the molecular mechanisms by which PKG represses glucose-regulated TSP1 transcription are unknown. Using a luciferase-promoter deletion assay, we now identify a single region of the human TSP1 promoter (-1172 to -878, relative to the transcription start site) that is responsive to glucose. Further characterization of this region identified an 18-bp sequence that specifically binds nuclear proteins from mesangial cells. Moreover, binding is significantly enhanced by high glucose treatment and is reduced by increased PKG activity. Gel mobility shift and supershift assays show that the nuclear proteins binding to the 18-bp sequence are USF1 and -2. USF1 and USF2 bound to the endogenous TSP1 promoter using a chromatin immunoprecipitation assay. Glucose stimulates nuclear USF2 protein accumulation through protein kinase C, p38 MAPK, and extracellular signal-regulated kinase pathways. Increased PKG activity down-regulates USF2 protein levels and its DNA binding activity under high glucose conditions, resulting in inhibition of glucose-induced TSP1 transcription and TGF-beta activity. Overexpression of USF2 reversed the inhibitory effect of PKG on glucose-induced TSP1 gene transcription and TGF-beta activity. Taken together these data present the first evidence that USF2 mediates glucose-induced TSP1 expression and TSP1-dependent TGF-beta bioactivity in mesangial cells, suggesting that USF2 is an important transcriptional regulator of diabetic complications.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, SX (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Cell Adhes & Matrix Res Ctr, Volker Hall,668C,1670 Univ Blvd, Birmingham, AL 35294 USA.	swang@path.uab.edu	Mei, Lin/G-8755-2012		NCRR NIH HHS [C06 RR 15490] Funding Source: Medline; NIAMS NIH HHS [AR 47830] Funding Source: Medline; NIDDK NIH HHS [DK 54624] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BAYRAKTAR M, 1994, J INT MED RES, V22, P90, DOI 10.1177/030006059402200204; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; Dey NB, 1998, CIRC RES, V82, P139; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 1996, J BIOL CHEM, V271, P4597; Haneda M, 2001, AM J KIDNEY DIS, V38, pS178, DOI 10.1053/ajkd.2001.27438; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Hida K, 2000, J LIPID RES, V41, P1615; Holmes DIR, 1997, BIOCHEM BIOPH RES CO, V238, P179, DOI 10.1006/bbrc.1997.7265; HUGO C, 1995, KIDNEY INT, V48, P1846, DOI 10.1038/ki.1995.483; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Ingram AJ, 1999, KIDNEY INT, V56, P1721, DOI 10.1046/j.1523-1755.1999.00743.x; Iwano M, 1996, KIDNEY INT, V49, P1120, DOI 10.1038/ki.1996.162; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LIN Q, 1994, J BIOL CHEM, V269, P23894; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCGREGOR B, 1994, AM J PATHOL, V144, P1281; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Poczatek MH, 2000, AM J PATHOL, V157, P1353, DOI 10.1016/S0002-9440(10)64649-4; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; RIFKIN DB, 1993, THROMB HAEMOSTASIS, V70, P177; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Tada H, 2001, J DIABETES COMPLICAT, V15, P193, DOI 10.1016/S1056-8727(01)00147-7; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tsiani E, 2002, AM J PHYSIOL-ENDOC M, V282, pE161, DOI 10.1152/ajpendo.2002.282.1.E161; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wang SX, 2003, DIABETES, V52, P2144, DOI 10.2337/diabetes.52.8.2144; Wang SX, 2002, J BIOL CHEM, V277, P9880, DOI 10.1074/jbc.M108360200; Weigert C, 2004, J BIOL CHEM, V279, P15908, DOI 10.1074/jbc.M313524200; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Wilmer WA, 2001, KIDNEY INT, V60, P858, DOI 10.1046/j.1523-1755.2001.060003858.x; WOLF G, 1992, KIDNEY INT, V42, P647, DOI 10.1038/ki.1992.330; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	66	90	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34311	34322		10.1074/jbc.M401629200	http://dx.doi.org/10.1074/jbc.M401629200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184388	hybrid			2022-12-25	WOS:000223134800030
J	Wooldridge, AA; MacDonald, JA; Erdodi, F; Ma, CY; Borman, MA; Hartshorne, DJ; Haystead, TAJ				Wooldridge, AA; MacDonald, JA; Erdodi, F; Ma, CY; Borman, MA; Hartshorne, DJ; Haystead, TAJ			Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of serine 695 in response to cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN-PHOSPHATASE; DEPENDENT PROTEIN-KINASE; HORMONE-SENSITIVE LIPASE; MYOSIN-BINDING SUBUNIT; INTEGRIN-LINKED KINASE; CA2+ SENSITIZATION; CONTRACTION; INHIBITION; TELOKIN; RELAXATION	Regulation of smooth muscle myosin phosphatase (SMPP-1M) is thought to be a primary mechanism for explaining Ca2+ sensitization/desensitization in smooth muscle. Ca2+ sensitization induced by activation of G protein-coupled receptors acting through RhoA involves phosphorylation of Thr-696 ( of the human isoform) of the myosin targeting subunit (MYPT1) of SMPP-1M inhibiting activity. In contrast, agonists that elevate intracellular cGMP and cAMP promote Ca2+ desensitization in smooth muscle through apparent activation of SMPP-1M. We show that cGMP-dependent protein kinase (PKG)/cAMP-dependent protein kinase (PKA) efficiently phosphorylates MYPT1 in vitro at Ser-692, Ser-695, and Ser-852 ( numbering for human isoform). Although phosphorylation of MYPT1 by PKA/PKG has no direct effect on SMPP-1M activity, a primary site of phosphorylation is Ser-695, which is immediately adjacent to the inactivating Thr-696. In vitro, phosphorylation of Ser-695 by PKA/PKG appeared to prevent phosphorylation of Thr-696 by MYPT1K. In ileum smooth muscle, Ser-695 showed a 3-fold increase in phosphorylation in response to 8-bromo-cGMP. Addition of constitutively active recombinant MYPT1K to permeabilized smooth muscles caused phosphorylation of Thr-696 and Ca2+ sensitization; however, this phosphorylation was blocked by preincubation with 8-bromo-cGMP. These findings suggest a mechanism of Ca2+ desensitization in smooth muscle that involves mutual exclusion of phosphorylation, whereby phosphorylation of Ser-695 prevents phosphorylation of Thr-696 and therefore inhibition of SMPP-1M.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Calgary, Dept Biochem & Mol Biol, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, Debrecen, Hungary; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Duke University; University of Calgary; University of Debrecen; University of Arizona	Haystead, TAJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	hayst001@mc.duke.edu	Erdődi, Ferenc/B-3383-2011	MacDonald, Justin/0000-0002-9238-8473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL023615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 23615, HL 19242-24] Funding Source: Medline; NIDDK NIH HHS [DK 52378-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beall AC, 1997, J BIOL CHEM, V272, P11283; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Chiba Y, 2001, EUR J PHARMACOL, V427, P77, DOI 10.1016/S0014-2999(01)01225-0; Chiba Y, 2001, INFLAMM RES, V50, P333, DOI 10.1007/PL00000253; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Huang QQ, 2004, J BIOL CHEM, V279, P597, DOI 10.1074/jbc.M308496200; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Iizuka K, 2000, EUR J PHARMACOL, V406, P273, DOI 10.1016/S0014-2999(00)00504-5; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Komatsu S, 2002, AM J PHYSIOL-CELL PH, V283, pC752, DOI 10.1152/ajpcell.00501.2001; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; MADONALD JA, 2001, P NATL ACAD SCI USA, V98, P2419; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Woodrum DA, 2001, MOL CELL ENDOCRINOL, V177, P135, DOI 10.1016/S0303-7207(01)00407-5; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	37	165	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34496	34504		10.1074/jbc.M405957200	http://dx.doi.org/10.1074/jbc.M405957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194681	hybrid			2022-12-25	WOS:000223134800052
J	Droetto, S; Viale, A; Primo, L; Jordaney, N; Bruno, S; Pagano, M; Piacibello, W; Bussolino, F; Aglietta, M				Droetto, S; Viale, A; Primo, L; Jordaney, N; Bruno, S; Pagano, M; Piacibello, W; Bussolino, F; Aglietta, M			Vasculogenic potential of long term repopulating cord blood progenitors	FASEB JOURNAL			English	Article						endothelial progenitor cell (EPC); hematopoietic stem cell (HSC)	HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; EX-VIVO EXPANSION; BONE-MARROW; GENE-TRANSFER; TUMOR ANGIOGENESIS; LENTIVIRAL VECTORS; PERIPHERAL-BLOOD; IN-VIVO; NEOVASCULARIZATION	In the adult, involvement of bone marrow-derived circulating endothelial progenitor cells (EPCs) in tissue revascularization (vasculogenesis) and the cooperation of hematopoietic cell subsets in supporting this process have been described in different experimental animal models. However, the effective contribution of such cells in restoring organ vascularization in a clinical setting needs to be clarified. In this study, a mouse transplantation model was engrafted by human cord blood hematopoietic stem and progenitor cells to follow the behavior of donor-derived endothelial and hematopoietic cells in the presence of a localized source of an angiogenic inducer. Human endothelial markers (CD31(+)/CD45(-), VE-cadherin(+)) were always detectable in the bone marrow of transplanted mice, while they were only randomly detectable in peripheral neovascularization sites. To investigate the ability of human transplanted hematopoietic stem cells to support new vessel formation in response to altered homeostatic conditions, chimeric mice were further treated by systemic injection of human mononuclear cells (MNCs). Our data indicate that MNC administration in transplanted mice enhances vasculogenesis in the newly formed vessels. Taken together these results suggest that human-derived EPCs, long-term engrafting a xenotransplantation model, have hematopoietic and endothelial developmental potential, which can be modulated by altering the physiological conditions of host microenvironment.	Univ Turin, Sch Med, IRCC, Div Clin Oncol, I-10060 Candiolo, TO, Italy; Univ Turin, Sch Med, IRCC, Div Mol & Angiogensis, I-10060 Candiolo, TO, Italy; Univ Turin, Dept Oncol Sci, I-10060 Candiolo, TO, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10060 Candiolo, TO, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin	Droetto, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Clin Oncol, I-10060 Candiolo, TO, Italy.	sara.droetto@ircc.it	; Bussolino, Federico/K-2500-2016	AGLIETTA, Massimo/0000-0002-2255-7972; Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; BRUNO, Stefania/0000-0002-8879-9536				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crisa L, 1999, BLOOD, V94, P3928, DOI 10.1182/blood.V94.11.3928.423k02_3928_3940; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; DIPIETRO LA, 1993, AM J PATHOL, V143, P678; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hillebrands JL, 2003, ARTERIOSCL THROM VAS, V23, P380, DOI 10.1161/01.ATV.0000059337.60393.64; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lane WJ, 2000, BLOOD, V96, P4152; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Luttun A, 2002, TRENDS CARDIOVAS MED, V12, P88, DOI 10.1016/S1050-1738(01)00152-9; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; PASSANITI A, 1992, LAB INVEST, V67, P519; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; Piacibello W, 2002, BLOOD, V100, P4391, DOI 10.1182/blood.V100.13.4391; POLVERINI PJ, 1984, LAB INVEST, V51, P635; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Tordjman R, 2001, BLOOD, V97, P1968, DOI 10.1182/blood.V97.7.1968; Vigna E, 2000, J GENE MED, V2, P308; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158	50	17	23	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1273	+		10.1096/fj.03-1444fje	http://dx.doi.org/10.1096/fj.03-1444fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208264				2022-12-25	WOS:000222327500017
J	Johnson, GB; Riggs, BL; Platt, JL				Johnson, GB; Riggs, BL; Platt, JL			A genetic basis for the "Adonis" phenotype of low adiposity and strong bones	FASEB JOURNAL			English	Article						Toll-like receptor 4; osteoporosis; obesity; fat; CD14	TOLL-LIKE RECEPTOR-4; POSTMENOPAUSAL WOMEN; MURINE MACROPHAGES; CUTTING EDGE; LIPOPOLYSACCHARIDE; CD14; MICE; LPS; DIFFERENTIATION; MOUSE	Toll receptors in Drosophila contribute to host defense and establish the body plan. Mammalian homologues of Toll, the Toll-like receptors (TLRs), are thought to function only in host defense. Here, we report that mice harboring mutations in TLR4 or in CD14, a co-receptor for TLR4, have an "ideal" body plan consisting of increased bone mineral content, density, and size as well as decreased body fat. These mutant mice live long lives, have normal activity and fertility, and show no evidence of infection. Unlike many strains of caged wild-type mice, they do not become obese. Although all mice continue to gain body fat, bone content, and overall weight, the difference in bone content and body fat between mutant and wild- type mice increases with age. Thus, defects in TLR4/CD14 complex generate an "Adonis" phenotype, characterized by this ideal body type, and this function could potentially be exploited for the treatment of osteoporosis and obesity.	Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW,Med Sci Bldg 2-66, Rochester, MN 55905 USA.	platt.jeffrey@mayo.edu	Johnson, Geoffrey B/AAG-2729-2021; Platt, Jeffrey/AHB-0480-2022	Johnson, Geoffrey B/0000-0002-4866-1401; Platt, Jeffrey/0000-0002-4915-0419; Johnson, Geoffrey/0000-0002-9781-4072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053733] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46810] Funding Source: Medline; NIAID NIH HHS [AI53733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akhter MP, 2000, CALCIFIED TISSUE INT, V67, P337, DOI 10.1007/s002230001144; Amano S, 1997, J CELL PHYSIOL, V173, P301, DOI 10.1002/(SICI)1097-4652(199712)173:3<301::AID-JCP1>3.0.CO;2-R; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Brot C, 1997, J INTERN MED, V242, P505, DOI 10.1111/j.1365-2796.1997.tb00024.x; Chiang CY, 2003, J PERIODONTAL RES, V38, P36, DOI 10.1034/j.1600-0765.2003.01617.x; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Hou L, 2000, INFECT IMMUN, V68, P4681, DOI 10.1128/IAI.68.8.4681-4687.2000; Itoh K, 2003, J IMMUNOL, V170, P3688, DOI 10.4049/jimmunol.170.7.3688; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson GB, 2003, TRENDS IMMUNOL, V24, P19, DOI 10.1016/S1471-4906(02)00014-5; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Khosla S, 2002, ENDOCRINOLOGY, V143, P4161, DOI 10.1210/en.2002-220843; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406; McCauley LK, 2002, J PERIODONTOL, V73, P1377, DOI 10.1902/jop.2002.73.11.1377; Means TK, 1999, J IMMUNOL, V163, P6748; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Premer DM, 2002, INFLAMMATION, V26, P97, DOI 10.1023/A:1014840412552; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TRAYHURN P, 2003, SCI STKE, pPE7; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Wang W, 2002, VLSI DES, V14, P183, DOI 10.1080/10655140290010097; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	34	49	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1282	+		10.1096/fj.04-1572fje	http://dx.doi.org/10.1096/fj.04-1572fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208271				2022-12-25	WOS:000222327500005
J	Jin, ZH; Gao, FQ; Flagg, T; Deng, XM				Jin, ZH; Gao, FQ; Flagg, T; Deng, XM			Tobacco-specific nitrosamine 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY NEUROENDOCRINE CELLS; LUNG-CARCINOMA CELLS; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE NNK; MITOCHONDRIAL-MEMBRANE; NICOTINIC RECEPTOR; INTERPHASE NUCLEI; MAMMALIAN-CELLS; N-NITROSAMINES; RAT-BRAIN; APOPTOSIS	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is formed by nitrosation of nicotine and has been identified as the most potent carcinogen contained in cigarette smoke. NNK significantly contributes to smoking-related lung cancer, but the molecular mechanism remains enigmatic. Bcl2 and c-Myc are two major oncogenic proteins that cooperatively promote tumor development. We report here that NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser(70) and c-Myc at Thr(58) and Ser(62) through activation of both ERK1/2 and PKCalpha, which is required for NNK-induced survival and proliferation of human lung cancer cells. Treatment of cells with staurosporine or PD98059 blocks both Bcl2 and c-Myc phosphorylation and results in suppression of NNK-induced proliferation. Specific depletion of c-Myc expression by RNA interference retards G(1)/S cell cycle transition and blocks NNK-induced cell proliferation. Phosphorylation of Bcl2 at Ser(70) promotes a direct interaction between Bcl2 and c-Myc in the nucleus and on the outer mitochondrial membrane that significantly enhances the half-life of the c-Myc protein. Thus, NNK-induced functional cooperation of Bcl2 and c-Myc in promoting cell survival and proliferation may occur in a novel mechanism involving their phosphorylation, which may lead to development of human lung cancer and/or chemoresistance.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAI-5562-2020; Jin, Zhaohui/AAQ-2893-2021	Jin, Zhaohui/0000-0001-7844-5833; 				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BELINSKY SA, 1990, MUTAT RES, V233, P105, DOI 10.1016/0027-5107(90)90155-W; BEPLER G, 1989, ONCOGENE, V4, P45; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; COOK RM, 1993, CURR PROB CANCER, V17, P71; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hecht SS, 1996, CRIT REV TOXICOL, V26, P163, DOI 10.3109/10408449609017929; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Hoffmann D, 1996, CRIT REV TOXICOL, V26, P199, DOI 10.3109/10408449609017931; IKEGAKI N, 1994, CANCER RES, V54, P6; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Lopez MG, 1998, P NATL ACAD SCI USA, V95, P14184, DOI 10.1073/pnas.95.24.14184; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SALVATERRA PM, 1976, J BIOL CHEM, V251, P6327; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Stellman SD, 2001, CANCER EPIDEM BIOMAR, V10, P1193; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Viallet J, 1996, J CELL BIOCHEM, P228; WASEEM NH, 1990, J CELL SCI, V96, P121; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	57	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40209	40219		10.1074/jbc.M404056200	http://dx.doi.org/10.1074/jbc.M404056200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15210690	hybrid			2022-12-25	WOS:000223791500120
J	Hu, TH; Exton, JH				Hu, TH; Exton, JH			Protein kinase C alpha translocates to the perinuclear region to activate phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; SELECTIVE INHIBITORS; RAT-BRAIN; IN-VIVO; PHOSPHORYLATION; LOCALIZATION; CELLS; ASSOCIATION; CLONING	The inhibition of phorbol ester activation of phospholipase D1 (PLD1) by protein kinase C (PKC) inhibitors has been considered proof of phosphorylation-dependent activation of PLD1 by PKCalpha. We studied the effect of the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I on PLD1 activation and found that they inhibited the activation by interfering with PKCalpha binding to PLD1. Further studies showed that only unphosphorylated PKCalpha could bind to and activate PLD1 and that both inhibitors induced phosphorylation of PKCalpha. The phosphorylation status of either PLD1 or PKCalpha per se did not affect PLD1 activation in vitro. Immunofluorescence studies showed that PLD1 remained in the perinuclear region after phorbol ester treatment, whereas PKCalpha translocated from cytosol to both plasma membrane and perinuclear regions. Both Ro-31-8220 and bisindolylmaleimide I blocked the translocation of PKCalpha to the perinuclear region but not to the plasma membrane. Studies with okadaic acid suggested that phosphorylation regulated the relocation of PKCalpha from the plasma membrane to the perinuclear region. It is proposed that localization and interaction of PKCalpha with PLD1 in the perinuclear region is required for PLD1 activation and that PKC inhibitors inhibit this through phosphorylation of PKCalpha, which blocks its translocation.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Rm 831 Light Hall, Nashville, TN 37232 USA.	john.exton@vanderbilt.edu	Hu, T/G-3381-2010					Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Buchner K, 1997, FEBS LETT, V406, P61, DOI 10.1016/S0014-5793(97)00226-3; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Gatti A, 1996, J BIOL CHEM, V271, P31718, DOI 10.1074/jbc.271.49.31718; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Singer WD, 1996, J BIOL CHEM, V271, P4504; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	44	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35702	35708		10.1074/jbc.M402372200	http://dx.doi.org/10.1074/jbc.M402372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187091	hybrid			2022-12-25	WOS:000223303400068
J	Kadyrov, FA; Drake, JW				Kadyrov, FA; Drake, JW			UvsX recombinase and Dda helicase rescue stalled bacteriophage T4 DNA replication forks in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRRADIATED ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; DEPENDENT ATPASE; STRAND EXCHANGE; REPAIR; PROTEIN; PURIFICATION; DAMAGE; CELLS	The rescue of stalled replication forks via a series of steps that include fork regression, template switching, and fork restoration often has been proposed as a major mechanism for accurately bypassing non-coding DNA lesions. Bacteriophage T4 encodes almost all of the proteins required for its own DNA replication, recombination, and repair. Both recombination and recombination repair in T4 rely on UvsX, a RecA-like recombinase. We show here that UvsX plus the T4-encoded helicase Dda suffice to rescue stalled T4 replication forks in vitro. This rescue is based on two sequential template-switching reactions that allow DNA replication to bypass a non-coding DNA lesion in a non-mutagenic manner.	NIEHS, Lab Mol Genet E3 01, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Drake, JW (corresponding author), NIEHS, Lab Mol Genet E3 01, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	drake@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES061055, Z01ES061055] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARRY J, 1994, J BIOL CHEM, V269, P33049; BEHME MT, 1975, J VIROL, V15, P50, DOI 10.1128/JVI.15.1.50-54.1975; BERNSTEIN H, 1989, J BACTERIOL, V171, P2265, DOI 10.1128/jb.171.5.2265-2270.1989; Bierne H, 1997, MOL MICROBIOL, V26, P557, DOI 10.1046/j.1365-2958.1997.6011973.x; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; BROOMFIELD S, 2001, MUTAT RES, V486, P176; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; DEBRECENI N, 1970, BIOCHEM BIOPH RES CO, V41, P115, DOI 10.1016/0006-291X(70)90476-6; DEFAIS M, 1989, J BACTERIOL, V171, P4938, DOI 10.1128/jb.171.9.4938-4944.1989; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GANESAN AK, 1974, J MOL BIOL, V87, P103, DOI 10.1016/0022-2836(74)90563-4; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HINTON DM, 1985, J BIOL CHEM, V260, P2851; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; JIANG H, 1993, J BIOL CHEM, V268, P7904; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; Kadyrov FA, 2003, J BIOL CHEM, V278, P25247, DOI 10.1074/jbc.M302564200; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; RESNICK MA, 1983, GENETICS, V104, P583; RESNICK MA, 1981, J BACTERIOL, V146, P285, DOI 10.1128/JB.146.1.285-290.1981; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Sickmier EA, 2004, STRUCTURE, V12, P583, DOI 10.1016/j.str.2004.02.016; SMITH KC, 1970, J MOL BIOL, V51, P459, DOI 10.1016/0022-2836(70)90001-X; WACHSMAN JT, 1987, GENETICS, V115, P405; WEIGLE JJ, 1953, P NATL ACAD SCI USA, V39, P628, DOI 10.1073/pnas.39.7.628; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	49	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35735	35740		10.1074/jbc.M403942200	http://dx.doi.org/10.1074/jbc.M403942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194689	hybrid			2022-12-25	WOS:000223303400072
J	Travagli, J; Letourneur, M; Bertoglio, J; Pierre, J				Travagli, J; Letourneur, M; Bertoglio, J; Pierre, J			STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING SOCS; DNA-BINDING SPECIFICITY; NF-KAPPA-B; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL REPRESSION; SYNERGISTIC ACTIVATION; PROTEIN INTERACTIONS; NEGATIVE REGULATOR	Supressor of cytokine signaling (SOCS)-1 is selectively and rapidly induced by appropriate agonists and modulates cytokine responses by interfering with the Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway. On the basis of the observation that interleukin (IL)-4 up-regulates Socs-1 in the keratinocyte HaCaT cell line, we investigated which sequences of the 5'-Socs-1 gene are responsive to IL-4. We therefore have cloned the 5'-flanking region of this gene, and by promoter analysis we identified a functional IL-4-responsive element located at nucleotide (-684/-570) upstream from the transcription initiation site, whose presence and integrity are necessary to ensure IL-4 responsiveness. This element contains three STAT6 and one Ets consensus binding sequences of which specific mutations abolished IL-4 responsiveness either partially or totally. We also report that Ets-1 physically interacted with STAT6. Exogenous expression of Ets-1 in conjunction with STAT6 activation strongly inhibited expression of a Socs-1 promoter-luciferase reporter. Collectively, our data demonstrated the involvement of STAT6 and Ets, via a composite DNA element, in the IL-4 regulation of Socs-1 gene expression in keratinocytes.	Fac Pharm Chatenay Malabry, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U461, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	josiane.pierre@cep.u-psud.fr						Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Federici M, 2002, J IMMUNOL, V169, P434, DOI 10.4049/jimmunol.169.1.434; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Losman JA, 1999, J IMMUNOL, V162, P3770; Lu J, 2004, MOL CELL BIOL, V24, P428, DOI 10.1128/MCB.24.1.428-441.2004; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Pesu M, 2003, EUR J IMMUNOL, V33, P1727, DOI 10.1002/eji.200323680; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Woelfle J, 2004, AM J PHYSIOL-ENDOC M, V286, pE393, DOI 10.1152/ajpendo.00389.2003; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	52	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35183	35192		10.1074/jbc.M403223200	http://dx.doi.org/10.1074/jbc.M403223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199062	hybrid			2022-12-25	WOS:000223303400008
J	Weisshart, K; Pestryakov, P; Smith, RWP; Hartmann, H; Kremmer, E; Lavrik, O; Nasheuer, HP				Weisshart, K; Pestryakov, P; Smith, RWP; Hartmann, H; Kremmer, E; Lavrik, O; Nasheuer, HP			Coordinated regulation of replication protein A activities by its subunits p14 and p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-DNA-BINDING; POLYMERASE-ALPHA-PRIMASE; SV40 T-ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC CELLS; S-PHASE; RP-A	The heterotrimeric replication protein A (RPA) has multiple essential activities in eukaryotic DNA metabolism and in signaling pathways. Despite extensive analyses, the functions of the smallest RPA subunit p14 are still unknown. To solve this issue we produced and characterized a dimeric RPA complex lacking p14, RPADeltap14, consisting of p70 and p32. RPADeltap14 was able to bind single-stranded DNA, but its binding mode and affinity differed from those of the heterotrimeric complex. Moreover, in the RPADeltap14 complex p32 only minimally recognized the 3'-end of a primer in a primer-template junction. Partial proteolytic digests revealed that p14 and p32 together stabilize the C terminus of p70 against degradation. Although RPADeltap14 efficiently supported bidirectional unwinding of double-stranded DNA and interacted with both the simian virus 40 (SV40) large T antigen and cellular DNA polymerase alpha-primase, it did not support cell-free SV40 DNA replication. This inability manifested itself in a failure to support both the primer synthesis and primer elongation reactions. These data reveal that efficient binding and correct positioning of the RPA complex on single-stranded DNA requires all three subunits to support DNA replication.	Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland; Inst Mol Biotechnol, D-07745 Jena, Germany; Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Div, Novosibirsk 630090, Russia; GSF, Inst Immunol, D-81377 Munich, Germany	Ollscoil na Gaillimhe-University of Galway; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nasheuer, HP (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Univ Rd, Galway, Ireland.	h.nasheuer@nuigalway.ie	Pestryakov, Pavel/AAH-2022-2020; Lavrik, Olga I/G-4641-2013; Nasheuer, Heinz P./B-9025-2008; Smith, Richard/J-8117-2019	Pestryakov, Pavel/0000-0003-3277-5321; Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079; Hartmann, Hella/0000-0002-7133-7474				Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Daboussi F, 2002, CELL SIGNAL, V14, P969, DOI 10.1016/S0898-6568(02)00052-9; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Kautz AR, 2001, J VIROL, V75, P1751, DOI 10.1128/JVI.75.4.1751-1760.2001; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 1998, NUCLEIC ACIDS RES, V26, P602, DOI 10.1093/nar/26.2.602; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; Mass G, 2001, NUCLEIC ACIDS RES, V29, P3892, DOI 10.1093/nar/29.18.3892; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; Nuss JE, 2004, PROTEIN SCI, V13, P1365, DOI 10.1110/ps.04616304; Pestryakov PE, 2004, NUCLEIC ACIDS RES, V32, P1894, DOI 10.1093/nar/gkh346; Pestryakov PE, 2003, J BIOL CHEM, V278, P17515, DOI 10.1074/jbc.M301265200; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STRAUSFELD U, 1989, PREP BIOCHEM, V19, P37, DOI 10.1080/10826068908544895; Taneja P, 2002, J BIOL CHEM, V277, P40853, DOI 10.1074/jbc.M208067200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; WAGA S, 1994, J BIOL CHEM, V269, P10923; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang M, 2000, NUCLEIC ACIDS RES, V28, P4742, DOI 10.1093/nar/28.23.4742; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35368	35376		10.1074/jbc.M403825200	http://dx.doi.org/10.1074/jbc.M403825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205463	hybrid			2022-12-25	WOS:000223303400030
J	Rothnie, A; Storm, J; Campbell, J; Linton, KJ; Kerr, ID; Callaghan, R				Rothnie, A; Storm, J; Campbell, J; Linton, KJ; Kerr, ID; Callaghan, R			The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-BINDING SITE; CYSTEINE-SCANNING MUTAGENESIS; TERTIARY STRUCTURE CHANGES; CROSS-LINKING ANALYSIS; MULTIDRUG-RESISTANCE; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; SUBSTRATE-SPECIFICITY; ATPASE ACTIVITY; TRANSPORT	Structural evidence has demonstrated that P-glycoprotein (P-gp) undergoes considerable conformational changes during catalysis, and these alterations are important in drug interaction. Knowledge of which regions in P-gp undergo conformational alterations will provide vital information to elucidate the locations of drug binding sites and the mechanism of coupling. A number of investigations have implicated transmembrane segment six (TM6) in drug-P-gp interactions, and a cysteine-scanning mutagenesis approach was directed to this segment. Introduction of cysteine residues into TM6 did not disturb basal or drug-stimulated ATPase activity per se. Under basal conditions the hydrophobic probe coumarin maleimide readily labeled all introduced cysteine residues, whereas the hydrophilic fluorescein maleimide only labeled residue Cys-343. The amphiphilic BODIPY-maleimide displayed a more complex labeling profile. The extent of labeling with coumarin maleimide did not vary during the catalytic cycle, whereas fluorescein maleimide labeling of F343C was lost after nucleotide binding or hydrolysis. BODIPY-maleimide labeling was markedly altered during the catalytic cycle and indicated that the adenosine 5'-(beta, gamma-imino) triphosphate-bound and ADP/vanadate-trapped intermediates were conformationally distinct. Our data are reconciled with a recent atomic scale model of P-gp and are consistent with a tilting of TM6 in response to nucleotide binding and ATP hydrolysis.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ Oxford, Lab Mol Biophys, Oxford OX1 3QU, England; Hammersmith Hosp, Med Res Council Clin Sci Ctr, Imperial Coll Sch Med, London W12 0NN, England; Univ Nottingham, Ctr Biochem & Cell Biol, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England	University of Oxford; University of Oxford; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Nottingham	Callaghan, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.	richard.callaghan@ndcls.ox.ac.uk	Kerr, Ian D/B-3803-2015; Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020; Rothnie, Alice/F-1358-2011	Kerr, Ian D/0000-0002-7544-8454; Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Rothnie, Alice/0000-0002-4259-7015; Storm, Janet/0000-0001-7812-4220				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, J LIPID RES, V42, P1007; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Gabriel MP, 2003, BIOCHEMISTRY-US, V42, P7780, DOI 10.1021/bi0341049; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; KRUPKA RM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P114, DOI 10.1016/0005-2728(93)90010-D; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956	51	52	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34913	34921		10.1074/jbc.M405336200	http://dx.doi.org/10.1074/jbc.M405336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192095	Green Accepted, hybrid			2022-12-25	WOS:000223134800102
J	Besana, A; Barbuti, A; Tateyama, MA; Symes, AJ; Robinson, RB; Feinmark, SJ				Besana, A; Barbuti, A; Tateyama, MA; Symes, AJ; Robinson, RB; Feinmark, SJ			Activation of protein kinase C epsilon inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM LEAK; TRANSLOCATION; EXPRESSION; ARRHYTHMIAS; ISOZYME; TREK-1; HEART; BLOCK; ACID	Activation of the platelet-activating factor (PAF) receptor leads to a decrease in outward current in murine ventricular myocytes by inhibiting the TASK-1 channel. TASK-1 carries a background or "leak" current and is a member of the two-pore domain potassium channel family. Its inhibition is sufficient to delay repolarization, causing prolongation of the action potential duration, and in some cases, early after depolarizations. We set out to determine the cellular mechanisms that control regulation of TASK-1 by PAF. Inhibition of TASK-1 via activation of the PAF receptor is protein kinase C (PKC)dependent. Using isoform-specific PKC inhibitor or activator peptides in patch clamp experiments, we now demonstrate that activation of PKCepsilon is both necessary and sufficient to regulate murine TASK-1 current in a heterologous expression system and to induce repolarization abnormalities in isolated myocytes. Furthermore, site-directed mutagenesis studies have identified threonine 381, in the C-terminal tail of murine TASK-1, as a critical residue in this regulation.	Columbia Univ, Dept Pharmacol, Ctr Mol Therapeut, New York, NY 10032 USA	Columbia University	Feinmark, SJ (corresponding author), Columbia Univ, Dept Pharmacol, Ctr Mol Therapeut, 630 W 168th St, New York, NY 10032 USA.	sjf1@columbia.edu	Barbuti, Andrea/N-9805-2013; Symes, Aviva J/S-7471-2016	Barbuti, Andrea/0000-0002-4521-4913; Symes, Aviva J/0000-0003-2557-9939	NHLBI NIH HHS [HL70105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 2002, AM HEART J, V144, P769, DOI 10.1067/mhj.2002.125804; Armstrong SC, 2004, CARDIOVASC RES, V61, P427, DOI 10.1016/j.cardiores.2003.09.031; Barbuti A, 2002, AM J PHYSIOL-HEART C, V282, pH2024, DOI 10.1152/ajpheart.00956.2001; Bayliss Douglas A, 2003, Mol Interv, V3, P205, DOI 10.1124/mi.3.4.205; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Hoffman BF, 1996, J CARDIOVASC ELECTR, V7, P120, DOI 10.1111/j.1540-8167.1996.tb00507.x; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; Sariahmetoglu M, 1998, PHARMACOL RES, V38, P173, DOI 10.1006/phrs.1998.0348; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721	28	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33154	33160		10.1074/jbc.M403525200	http://dx.doi.org/10.1074/jbc.M403525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184378	hybrid			2022-12-25	WOS:000223039700018
J	Loong, SLE; Korzh, S; Price, A				Loong, SLE; Korzh, S; Price, A			Reduced DNA-dependent protein kinase activity in two cell lines derived from adult cancer patients with late radionecrosis	ONCOGENE			English	Article						DNA-dependent protein kinase; radiation injury; radiosensitivity	IN-VITRO RADIOSENSITIVITY; STRAND BREAK REPAIR; INTRINSIC RADIOSENSITIVITY; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; RADIOTHERAPY; CARCINOMA; EXPRESSION; ASSAY	Epstein-Barr virus-immortalized lymphoblastoid cell tines were derived from five patients with late radionecrosis. Two of these cell lines exhibited postradiation viability levels intermediate between normal cell fines and that from an individual with ataxia telangiectasia. Compared with controls, these two cell lines exhibited impaired ability to rejoin DNA double-strand breaks on pulsed-field gel electrophoresis and 6-10-fold reduced DNA-dependent protein kinase (DNA-PK) activity in vitro in cell-free extracts. Immunoblotting showed normal levels of Ku70, Ku80 and XRCC4 and the presence of DNA-PKcs in both cell lines. These findings suggest that DNA-PK might be an important factor affecting the predisposition of radiotherapy patients to late radionecrosis.	Univ Edinburgh, Western Gen Hosp, Div Oncogen, Edinburgh EH4 2XU, Midlothian, Scotland; Natl Canc Ctr, Dept Therapeut Radiol, Singapore, Singapore; Natl Canc Ctr, Div Med Sci, Singapore, Singapore	University of Edinburgh; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Price, A (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Oncogen, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	a.price@ed.ac.uk						Alapetite C, 1999, INT J CANCER, V83, P83, DOI 10.1002/(SICI)1097-0215(19990924)83:1<83::AID-IJC16>3.0.CO;2-8; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Alsbeih G, 2000, INT J RADIAT ONCOL, V46, P143, DOI 10.1016/S0360-3016(99)00409-5; Bjork-Eriksson T, 1998, BRIT J CANCER, V77, P2371, DOI 10.1038/bjc.1998.394; Dibiase SJ, 2000, CANCER RES, V60, P1245; GODSEN CM, 1986, HUMAN CYTOGENETICS P, P31; Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641; ILIAKIS G, 1991, BIOESSAYS, V13, P641; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Polischouk AG, 1999, INT J RADIAT ONCOL, V43, P191, DOI 10.1016/S0360-3016(98)00362-9; PRICE P, 1990, CANCER RES, V50, P1392; Safwat A, 2002, INT J RADIAT ONCOL, V52, P198, DOI 10.1016/S0360-3016(01)02690-6; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tucker SL, 1996, RADIOTHER ONCOL, V38, P103, DOI 10.1016/0167-8140(95)01669-4; West CML, 1997, BRIT J CANCER, V76, P1184, DOI 10.1038/bjc.1997.531; West CML, 1998, INT J RADIAT BIOL, V73, P409, DOI 10.1080/095530098142248; Woods T, 2002, NUCLEIC ACIDS RES, V30, P5120, DOI 10.1093/nar/gkf625; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	23	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5562	5566		10.1038/sj.onc.1207771	http://dx.doi.org/10.1038/sj.onc.1207771			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184871	Bronze			2022-12-25	WOS:000222588400017
J	Peelman, F; Van Beneden, K; Zabeau, L; Iserentant, H; Ulrichts, P; Defeau, D; Verhee, A; Catteeuw, D; Elewaut, D; Tavernier, J				Peelman, F; Van Beneden, K; Zabeau, L; Iserentant, H; Ulrichts, P; Defeau, D; Verhee, A; Catteeuw, D; Elewaut, D; Tavernier, J			Mapping of the leptin binding sites and design of a leptin antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IMMUNOGLOBULIN-LIKE DOMAIN; RECEPTOR-BINDING; EXTRACELLULAR DOMAIN; PROPOSED MECHANISM; IMMUNE-RESPONSES; ACTIVATION; INTERLEUKIN-6; CYTOKINE	The leptin/leptin receptor system shows strong similarities to the long-chain cytokine interleukin-6 (IL-6) and granulocyte colony-stimulating factor cytokine/receptor systems. The IL-6 family cytokines interact with their receptors through three different binding sites I-III. The leptin structure was superposed on the crystal structures of several long-chain cytokines, and a series of leptin mutants was generated focusing on binding sites I-III. The effect of the mutations on leptin receptor (LR) signaling and on binding to the membrane proximal cytokine receptor homology domain (CRH2) of the LR was determined. Mutations in binding site I at the C terminus of helix D show a modest effect on signaling and do not affect binding to CRH2. Binding site II is composed of residues at the surface of helices A and C. Mutations in this site impair binding to CRH2 but have only limited effect on signaling. Site III mutations around the N terminus of helix D impair receptor activation without affecting binding to CRH2. We identified an S120A/T121A mutant in binding site III, which lacks any signaling capacity, but which still binds to CRH2 with wild type affinity. This leptin mutant behaves as a potent leptin antagonist both in vitro and in vivo.	Ghent Univ VIB, Dept Med Prot Res, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; Univ Ghent, Fac Med & Hlth Sci, Dept Rheumatol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Tavernier, J (corresponding author), Ghent Univ VIB, Dept Med Prot Res, Fac Med & Hlth Sci, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.tavernier@UGent.be	Tavernier, Jan/AAG-3636-2019; Elewaut, Dirk/K-6831-2014					Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; Boulanger MJ, 2004, J MOL BIOL, V335, P641, DOI 10.1016/j.jmb.2003.10.070; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Broekaert D, 2002, EUR CYTOKINE NETW, V13, P78; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunner L, 1999, INT J OBESITY, V23, P463, DOI 10.1038/sj.ijo.0800842; Busso N, 2002, J IMMUNOL, V168, P875, DOI 10.4049/jimmunol.168.2.875; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Correia MLD, 2004, CURR OPIN NEPHROL HY, V13, P215, DOI 10.1097/01.mnh.0000119533.79618.b3; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; Demartis A, 1996, CANCER RES, V56, P4213; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Eyckerman S, 1999, EUR CYTOKINE NETW, V10, P549; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Guisez Y, 1998, PROTEIN EXPRES PURIF, V12, P249, DOI 10.1006/prep.1997.0836; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; INOUE M, 1995, P NATL ACAD SCI USA, V92, P8579, DOI 10.1073/pnas.92.19.8579; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Matarese G, 2002, TRENDS IMMUNOL, V23, P182, DOI 10.1016/S1471-4906(02)02188-9; Matarese G, 2002, DIABETES, V51, P1356, DOI 10.2337/diabetes.51.5.1356; Matarese G, 2001, J IMMUNOL, V166, P5909, DOI 10.4049/jimmunol.166.10.5909; Murad A, 2003, FASEB J, V17, P1895, DOI 10.1096/fj.03-0068fje; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Peelman F, 2004, PROG LIPID RES, V43, P283, DOI 10.1016/j.plipres.2004.03.001; PEELMAN F, 2004, IN PRESS CURR PHARM; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; Renne C, 1998, J BIOL CHEM, V273, P27213, DOI 10.1074/jbc.273.42.27213; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Sandowski Y, 2002, J BIOL CHEM, V277, P46304, DOI 10.1074/jbc.M207556200; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Siegmund B, 2002, GASTROENTEROLOGY, V122, P2011, DOI 10.1053/gast.2002.33631; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tarzi RM, 2004, AM J PATHOL, V164, P385, DOI 10.1016/S0002-9440(10)63128-8; Verploegen SABW, 1997, FEBS LETT, V405, P237, DOI 10.1016/S0014-5793(97)00192-0; White DW, 1999, J CELL BIOCHEM, V73, P278, DOI 10.1002/(SICI)1097-4644(19990501)73:2<278::AID-JCB13>3.0.CO;2-W; YEN TT, 1977, EXPERIENTIA, V33, P995, DOI 10.1007/BF01945927; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078; Zabeau L, 2003, FEBS LETT, V546, P45, DOI 10.1016/S0014-5793(03)00440-X; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	112	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41038	41046		10.1074/jbc.M404962200	http://dx.doi.org/10.1074/jbc.M404962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15213225	hybrid			2022-12-25	WOS:000223916800102
J	Risteli, M; Niemitalo, O; Lankinen, H; Juffer, AH; Myllyla, R				Risteli, M; Niemitalo, O; Lankinen, H; Juffer, AH; Myllyla, R			Characterization of collagenous peptides bound to lysyl hydroxylase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SYNDROME TYPE-VI; CIRCULAR-DICHROISM SPECTRA; CAENORHABDITIS-ELEGANS; TISSUE DISTRIBUTION; IN-VITRO; EXPRESSION; LYSINE; GENE; GLUCOSYLTRANSFERASE	Lysyl hydroxylase (LH, EC 1.14.11.4) is the enzyme catalyzing the formation of hydroxylysyl residues in collagens and other proteins with collagenous domains. Although lower species, such as Caenorhabditis elegans, have only one LH orthologue, LH activity in higher species, such as human, rat, and mouse, is present in three molecules, LH1, LH2, and LH3, encoded by three different genes. In addition, LH2 is present in two alternatively spliced forms (LH2a, LH2b). To understand the functions of the four molecular forms of LH in vertebrates, we analyzed differences in the binding and hydroxylation of various collagenous peptides by the LH isoforms. Nine-amino acid-long synthetic peptides on Pepspot were used for the binding analysis and an activity assay to measure hydroxylation. Our data with 727 collagenous peptides indicated that a positive charge on the peptide and specific amino acid residues in close proximity to the lysyl residues in the collagenous sequences are the key factors promoting peptide binding to the LH isoforms. The data suggest that the LH binding site is not a deep hydrophobic pocket but is open and hydrophilic where acidic amino acids play an important role in the binding. The data do not indicate strict sequence specificity for the LH isoforms, but the data indicated that there was a clear preference for some sequences to be bound and hydroxylated by a certain isoform.	Univ Oulu, Vioctr Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Cent Hosp, Haartman Inst, Diagnost Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, Peptide & Prot Lab, FIN-00014 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Myllyla, R (corresponding author), Univ Oulu, Vioctr Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	raili.myllyla@oulu.fi		Juffer, Andre/0000-0003-3533-0520				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Agrafiotis DK, 1997, PROTEIN SCI, V6, P287; ARMSTRONG LC, 1995, BBA-GENE STRUCT EXPR, V1264, P93, DOI 10.1016/0167-4781(95)00130-9; AYAD S, 1998, EXTRACELLULAR MATRIX, P43; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; BERRY DA, 1996, STAT BAYESIAN PERSPE, P518; DEB K, 2002, COMPUTATIONALLY EFFI; Eyre D, 2002, MOL GENET METAB, V76, P211, DOI 10.1016/S1096-7192(02)00036-7; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; JIANG P, 1991, J BIOL CHEM, V266, P22960; Johnstone IL, 2000, TRENDS GENET, V16, P21, DOI 10.1016/S0168-9525(99)01857-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADLER K, 1994, PROTEIN PROFILE, V1, P525; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1973, BIOCHEMISTRY-US, V12, P4966, DOI 10.1021/bi00748a023; KIVIRIKKO KI, 1972, BIOCHEMISTRY-US, V11, P122, DOI 10.1021/bi00751a021; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Mercer DK, 2003, BIOCHEM BIOPH RES CO, V307, P803, DOI 10.1016/S0006-291X(03)01262-2; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rautavuoma K, 2000, MATRIX BIOL, V19, P73, DOI 10.1016/S0945-053X(99)00058-X; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Ruotsalainen H, 2001, MATRIX BIOL, V20, P137, DOI 10.1016/S0945-053X(01)00130-5; RYHANEN L, 1975, BIOCHIM BIOPHYS ACTA, V397, P50; SAMMON JW, 1969, IEEE T COMPUT, VC 18, P401, DOI 10.1109/T-C.1969.222678; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Steinmann Beat, 1993, P351; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; VALTAVAARA M, 1999, ACTA U OULUENSIS; van der Slot AJ, 2003, J BIOL CHEM, V278, P40967, DOI 10.1074/jbc.M307380200; Wang CG, 2002, MATRIX BIOL, V21, P559, DOI 10.1016/S0945-053X(02)00071-9; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; Wang CG, 2002, J BIOL CHEM, V277, P18568, DOI 10.1074/jbc.M201389200; WEI L, 1997, USING RADIAL DISTRIB, P465; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	48	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37535	37543		10.1074/jbc.M405638200	http://dx.doi.org/10.1074/jbc.M405638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208310	hybrid			2022-12-25	WOS:000223554600044
J	Aronov, S; Gerst, JE				Aronov, S; Gerst, JE			Involvement of the late secretory pathway in actin regulation and mRNA transport in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS CELL POLARIZATION; UNCONVENTIONAL MYOSIN; BUDDING YEAST; LOCALIZATION; EXOCYTOSIS; PROTEIN; GROWTH; GENE; CYTOSKELETON; REQUIREMENT	Both the delivery of secretory vesicles and asymmetric distribution of mRNA to the bud are dependent upon the actin cytoskeleton in yeast. Here we examined whether components of the exocytic apparatus play a role in mRNA transport. By screening secretion mutants in situ and in vivo, we found that all had an altered pattern of ASH1 mRNA localization. These included alleles of CDC42 and RHO3 (cdc42-6 and rho3-V51) thought to regulate specifically the fusion of secretory vesicles but were found to affect strongly the cytoskeleton as well. Most interestingly, mutations in late secretion-related genes not directly involved in actin regulation also showed substantial alterations in ASH1 mRNA distribution. These included mutations in genes encoding components of the exocyst (SEC10 and SEC15), SNARE regulatory proteins (SEC1, SEC4, and SRO7), SNAREs (SEC9 and SSO1/2), and proteins involved in Golgi export (PIK1 and YPT31/32). Importantly, prominent defects in the actin cytoskeleton were observed in all of these strains, thus implicating a known causal relationship between the deregulation of actin and the inhibition of mRNA transport. Our novel observations suggest that vesicular transport regulates the actin cytoskeleton in yeast (and not just vice versa) leading to subsequent defects in mRNA transport and localization.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gerst, JE (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	jeffrey.gerst@weizmann.ac.il	Liberman-Aronov, Stella/H-6935-2019	Liberman-Aronov, Stella/0000-0001-6938-053X				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Beach DL, 1999, CURR BIOL, V9, P569, DOI 10.1016/S0960-9822(99)80260-7; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Bretscher A, 2003, J CELL BIOL, V160, P811, DOI 10.1083/jcb.200301035; Casamayor A, 2002, CURR OPIN MICROBIOL, V5, P179, DOI 10.1016/S1369-5274(02)00300-4; Chartrand P, 2001, ANNU REV CELL DEV BI, V17, P297, DOI 10.1146/annurev.cellbio.17.1.297; Dollar G, 2002, DEVELOPMENT, V129, P517; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Fehrenbacher KL, 2003, TRENDS CELL BIOL, V13, P472, DOI 10.1016/S0962-8924(03)00174-0; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Gao XD, 2003, J CELL BIOL, V162, P635, DOI 10.1083/jcb.200302038; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; HAARER BK, 1994, J CELL SCI, V107, P1055; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Ho J, 2001, MOL BIOL CELL, V12, P1541, DOI 10.1091/mbc.12.6.1541; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; LEW DJ, 1991, J MEMBRANE BIOL, V123, P261, DOI 10.1007/BF01870409; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Rose MD., 1990, METHODS YEAST GENETI; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; Shaw SL, 1996, DEVELOPMENT, V122, P2623; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Toi H, 2003, MOL BIOL CELL, V14, P2237, DOI 10.1091/mbc.E02-09-0616; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wedlich-Soldner R, 2003, NAT CELL BIOL, V5, P267, DOI 10.1038/ncb0403-267; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485	45	43	45	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36962	36971		10.1074/jbc.M402068200	http://dx.doi.org/10.1074/jbc.M402068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192110	hybrid			2022-12-25	WOS:000223453600099
J	Morgan, CT; Tsivkovskii, R; Kosinsky, YA; Efremov, RG; Lutsenko, S				Morgan, CT; Tsivkovskii, R; Kosinsky, YA; Efremov, RG; Lutsenko, S			The distinct functional properties of the nucleotide-binding domain of ATP7B, the human copper-transporting ATPase - Analysis of the Wilson disease mutations E1064A, H1069Q, R1151H, AND C1104F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; ADENOSINE-TRIPHOSPHATASE ATP7B; ESCHERICHIA-COLI; OVARIAN-CARCINOMA; CALCIUM-PUMP; PROTEIN; MOTIF; NA,K-ATPASE; DIVERSITY	Copper transport by the P-1-ATPase ATP7B, or Wilson disease protein (WNDP),(1) is essential for human metabolism. Perturbation of WNDP function causes intracellular copper accumulation and severe pathology, known as Wilson disease (WD). Several WD mutations are clustered within the WNDP nucleotide-binding domain (N-domain), where they are predicted to disrupt ATP binding. The mechanism by which the N-domain coordinates ATP is presently unknown, because residues important for nucleotide binding in the better characterized P-2-ATPases are not conserved within the P-1-ATPase subfamily. To gain insight into nucleotide binding under normal and disease conditions, we generated the recombinant WNDP N-domain and several WD mutants. Using isothermal titration calorimetry, we demonstrate that the N-domain binds ATP in a Mg2+-independent manner with a relatively high affinity of 75 muM, compared with millimolar affinities observed for the P-2-ATPase N-domains. The WNDP N-domain shows minimal discrimination between ATP, ADP, and AMP, yet discriminates well between ATP and GTP. Similar results were obtained for the N-domain of ATP7A, another P-1-ATPase. Mutations of the invariant WNDP residues E1064A and H1069Q drastically reduce nucleotide affinities, pointing to the likely role of these residues in nucleotide coordination. In contrast, the R1151H mutant exhibits only a 1.3-fold reduction in affinity for ATP. The C1104F mutation significantly alters protein folding, whereas C1104A does not affect the structure or function of the N-domain. Together, the results directly demonstrate the phenotypic diversity of WD mutations within the N-domain and indicate that the nucleotide-binding properties of the P-1-ATPases are distinct from those of the P-2-ATPases.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	Oregon Health & Science University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Morgan, Clinton/AAM-7410-2021; Roman, Efremov/A-7460-2014	Roman, Efremov/0000-0002-5474-4721	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55719] Funding Source: Medline; NIGMS NIH HHS [1P01 GM 67166-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Abed M, 2004, BIOCHEM J, V379, P235, DOI 10.1042/BJ20040168; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; EFREMOV RG, 2004, BIOCH J         0517; Fatemi N, 2002, J BIOENERG BIOMEMBR, V34, P339, DOI 10.1023/A:1021245902195; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Katano K, 2003, MOL PHARMACOL, V64, P466, DOI 10.1124/mol.64.2.466; Komatsu M, 2000, CANCER RES, V60, P1312; Loudianos G, 2000, SEMIN LIVER DIS, V20, P353, DOI 10.1055/s-2000-9389; Loudianos G, 1999, J MED GENET, V36, P833; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Okkeri J, 2004, BIOCHEM J, V377, P95, DOI 10.1042/BJ20030740; Okkeri J, 2002, EUR J BIOCHEM, V269, P1579, DOI 10.1046/j.1432-1033.2002.02810.x; Riordan SM, 2001, J HEPATOL, V34, P165, DOI 10.1016/S0168-8278(00)00028-3; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 2003, BIOCHEM BIOPH RES CO, V301, P488, DOI 10.1016/S0006-291X(03)00010-X	32	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36363	36371		10.1074/jbc.M404553200	http://dx.doi.org/10.1074/jbc.M404553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205462	hybrid			2022-12-25	WOS:000223453600026
J	Schagger, H; de Coo, R; Bauer, MF; Hofmann, S; Godinot, C; Brandt, U				Schagger, H; de Coo, R; Bauer, MF; Hofmann, S; Godinot, C; Brandt, U			Significance of respirasomes for the assembly/stability of human respiratory chain complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-B GENE; STOP-CODON MUTATION; III DEFICIENCY; MITOCHONDRIAL MYOPATHY; EXERCISE INTOLERANCE; OXIDASE; ELECTRON; SUPERCOMPLEXES; PATIENT; YEAST	We showed that the human respiratory chain is organized in supramolecular assemblies of respiratory chain complexes, the respirasomes. The mitochondrial complexes I (NADH dehydrogenase) and III (cytochrome c reductase) form a stable core respirasome to which complex IV (cytochrome c oxidase) can also bind. An analysis of the state of respirasomes in patients with an isolated deficiency of single complexes provided evidence that the formation of respirasomes is essential for the assembly/stability of complex I, the major entry point of respiratory chain substrates. Genetic alterations leading to a loss of complex III prevented respirasome formation and led to the secondary loss of complex I. Therefore, primary complex III assembly deficiencies presented as combined complex III/I defects. This dependence of complex I assembly/stability on respirasome formation has important implications for the diagnosis of mitochondrial respiratory chain disorders.	Goethe Univ Frankfurt, Fachbereich Med, Zentrum Biol Chem, Inst Biochem 1, D-60590 Frankfurt, Germany; Erasmus Univ, Med Ctr, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Acad Hosp Munich Schwabing, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, D-80804 Munich, Germany; Acad Hosp Munich Schwabing, Diabet Res Inst, D-80804 Munich, Germany; Ctr Mol & Cell Genet, CNRS, Unit 5534, F-69622 Villeurbanne, France; Univ Lyon 1, F-69622 Villeurbanne, France	Goethe University Frankfurt; Erasmus University Rotterdam; Erasmus MC; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Schagger, H (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25, D-60590 Frankfurt, Germany.	schagger@zbc.kgu.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811; de Coo, Irenaeus/0000-0003-0533-7422				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y; Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599; Bouzidi MF, 1996, BBA-MOL BASIS DIS, V1317, P199, DOI 10.1016/S0925-4439(96)00055-5; Bruno C, 2003, MUSCLE NERVE, V28, P508, DOI 10.1002/mus.10429; Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257; CHAZOTTE B, 1988, J BIOL CHEM, V263, P14359; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.3.CO;2-Q; de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706; De Meirleir L, 2003, AM J MED GENET A, V121A, P126, DOI 10.1002/ajmg.a.20171; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; Fellman V, 2002, BLOOD CELL MOL DIS, V29, P444, DOI 10.1006/bcmd.2002.0582; Genova Maria Luisa, 2003, Ital J Biochem, V52, P58; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900; Lamantea E, 2002, NEUROMUSCULAR DISORD, V12, P49, DOI 10.1016/S0960-8966(01)00244-9; Mancuso M, 2003, J NEUROL SCI, V209, P61, DOI 10.1016/S0022-510X(02)00462-8; Raza H, 2002, BIOCHEM J, V366, P45, DOI 10.1042/BJ20020533; REICHMANN H, 1986, ARCH NEUROL-CHICAGO, V43, P957, DOI 10.1001/archneur.1986.00520090081024; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002	31	240	244	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36349	36353		10.1074/jbc.M404033200	http://dx.doi.org/10.1074/jbc.M404033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208329	hybrid			2022-12-25	WOS:000223453600024
J	Yasuda, Y; Li, ZQ; Greenbaum, D; Bogyo, M; Weber, E; Bromme, D				Yasuda, Y; Li, ZQ; Greenbaum, D; Bogyo, M; Weber, E; Bromme, D			Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CYSTEINE PROTEASE; MATRIX METALLOPROTEINASES; MOLECULAR-CLONING; INVARIANT CHAIN; CLASS-II; ATHEROSCLEROSIS; LOCALIZATION; PROTEINASES; DEGRADATION	Atherosclerosis is characterized by a thickening and loss of elasticity of the arterial wall. Loss of elasticity has been attributed to the degradation of the arterial elastin matrix. Cathepsins K and S are papain-like cysteine proteases with known elastolytic activities, and both enzymes have been identified in macrophages present in plaque areas of diseased blood vessels. Here we demonstrate that macrophages express a third elastolytic cysteine protease, cathepsin V, which exhibits the most potent elastase activity yet described among human proteases and that cathepsin V is present in atherosclerotic plaque specimens. Approximately 60% of the total elastolytic activity of macrophages can be attributed to cysteine proteases with cathepsins V, K, and S contributing equally. From this 60%, two-thirds occur extracellularly and one-third intracellularly with the latter credited to cathepsin V. Ubiquitously expressed glycosaminoglycans (GAGs) such as chondroitin sulfate specifically inhibit the elastolytic activities of cathepsins V and K via the formation of specific cathepsin-GAG complexes. In contrast, cathepsin S, which does not form complexes with chondroitin sulfate is not inhibited; thus suggesting a specific regulation of elastolytic activities of cathepsins by GAGs. Because the GAG content is reduced in atherosclerotic plaques, an increase of cathepsins V and K activities may accelerate the destruction of the elastin matrix in diseased arteries.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Univ Halle Wittenberg, Inst Physiol Chem, D-06114 Halle An Der Saale, Saale, Germany	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Stanford University; Martin Luther University Halle Wittenberg	Bromme, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave 100th St, New York, NY 10029 USA.	dieter.bromme@mssm.edu		Bogyo, Matthew/0000-0003-3753-4412; Weber, Ekkehard/0000-0002-4014-4303	NIAMS NIH HHS [AR 46182, AR 48669] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669, R01AR046182] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Adachi W, 1998, INVEST OPHTH VIS SCI, V39, P1789; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 2004, METHODS, V32, P199, DOI 10.1016/S1046-2023(03)00212-3; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; Caballero AR, 2001, ANAL BIOCHEM, V290, P330, DOI 10.1006/abio.2001.4999; Cheng XW, 2004, AM J PATHOL, V164, P243, DOI 10.1016/S0002-9440(10)63114-8; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; Filippov S, 2003, J EXP MED, V198, P925, DOI 10.1084/jem.20030626; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Greenbaum DC, 2002, CHEM BIOL, V9, P1085, DOI 10.1016/S1074-5521(02)00238-7; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114; Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002-9440(10)63068-4; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Lijnen HR, 2002, BIOCHEM SOC T, V30, P163, DOI 10.1042/bst0300163; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; MURATA K, 1989, ATHEROSCLEROSIS, V78, P69, DOI 10.1016/0021-9150(89)90160-3; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Parkar AA, 2000, PROTEIN EXPRES PURIF, V20, P152, DOI 10.1006/prep.2000.1280; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3; RUST L, 1994, METHOD ENZYMOL, V235, P554; Santamaria I, 1998, CANCER RES, V58, P1624; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPERBER K, 1990, J IMMUNOL METHODS, V129, P31, DOI 10.1016/0022-1759(90)90417-T; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Tolosa E, 2003, J CLIN INVEST, V112, P517, DOI 10.1172/JCI200318028; Tournu C, 1998, ARCH BIOCHEM BIOPHYS, V360, P15, DOI 10.1006/abbi.1998.0916; Volpi N, 1997, CHEM-BIOL INTERACT, V105, P157, DOI 10.1016/S0009-2797(97)00045-8; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P477, DOI 10.1097/00041433-200110000-00002; Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084	53	150	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36761	36770		10.1074/jbc.M403986200	http://dx.doi.org/10.1074/jbc.M403986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192101	hybrid			2022-12-25	WOS:000223453600077
J	Konas, DW; Zhu, K; Sharma, M; Aulak, KS; Brudvig, GW; Stuehr, DJ				Konas, DW; Zhu, K; Sharma, M; Aulak, KS; Brudvig, GW; Stuehr, DJ			The FAD-shielding residue Phe(1395) regulates neuronal nitric-oxide synthase catalysis by controlling NADP(+) affinity and a conformational equilibrium within the flavoprotein domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 REDUCTASE; AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; FLAVIN DOMAIN; FERREDOXIN-NADP(+) REDUCTASE; COENZYME BINDING; P450 REDUCTASE; PHOTOSYSTEM-II; NO SYNTHASE; CALMODULIN	Phe(1395) stacks parallel to the FAD isoalloxazine ring in neuronal nitric-oxide synthase (nNOS) and is representative of conserved aromatic amino acids found in structurally related flavoproteins. This laboratory previously showed that Phe(1395) was required to obtain the electron transfer properties and calmodulin (CaM) response normally observed in wild-type nNOS. Here we characterized the F1395S mutant of the nNOS flavoprotein domain (nNOSr) regarding its physical properties, NADP(+) binding characteristics, flavin reduction kinetics, steady-state and pre-steady-state cytochrome c reduction kinetics, and ability to shield its FMN cofactor in response to CaM or NADP(H) binding. F1395S nNOSr bound NADP(+) with 65% more of the nicotinamide ring in a productive conformation with FAD for hydride transfer and had an 8-fold slower rate of NADP(+) dissociation. CaM stimulated the rates of NADPH-dependent flavin reduction in wild-type nNOSr but not in the F1395S mutant, which had flavin reduction kinetics similar to those of CaM-free wild-type nNOSr. CaM-free F1395S nNOSr lacked repression of cytochrome c reductase activity that is typically observed in nNOSr. The combined results from pre-steady-state and EPR experiments revealed that this was associated with a lesser degree of FMN shielding in the NADP(+)-bound state as compared with wild type. We conclude that Phe(1395) regulates nNOSr catalysis in two ways. It facilitates NADP(+) release to prevent this step from being rate-limiting, and it enables NADP(H) to properly regulate a conformational equilibrium involving the FMN subdomain that controls reactivity of the FMN cofactor in electron transfer.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Cleveland Clinic Foundation; Yale University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org			NIGMS NIH HHS [GM51491, GM36442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036442, R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CHEN X, 1990, CHEM PHARM BULL, V38, P612, DOI 10.1248/cpb.38.612; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furchgott RF, 1999, BIOSCIENCE REP, V19, P235, DOI 10.1023/A:1020537506008; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Guan ZW, 2003, J BIOL CHEM, V278, P30859, DOI 10.1074/jbc.M301929200; Guan ZW, 2003, ARCH BIOCHEM BIOPHYS, V412, P65, DOI 10.1016/S0003-9861(03)00009-2; Gutierrez A, 2003, BIOCHEM SOC T, V31, P497, DOI 10.1042/BST0310497; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; INNES JB, 1989, BIOCHEMISTRY-US, V28, P1116, DOI 10.1021/bi00429a028; ISOGAI Y, 1990, BIOCHIM BIOPHYS ACTA, V1017, P204, DOI 10.1016/0005-2728(90)90185-7; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JJP, 1997, FASEB J SS, V11, P63; KLATT P, 1992, J BIOL CHEM, V267, P11374; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Lane P, 2000, ACTA PHYSIOL SCAND, V168, P53; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MASSEY V, 1962, J BIOL CHEM, V237, P2347; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Mayer B., 2000, HDB EXPT PHARM, V143; MEINHARDT SW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P67, DOI 10.1016/0005-2728(92)90127-N; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; NAGAMATSU T, 1984, J CHEM SOC PERK T 1, P561, DOI 10.1039/p19840000561; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuart-Smith K, 2002, J CLIN PATHOL-MOL PA, V55, P360, DOI 10.1136/mp.55.6.360; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; STUEHR DJ, 2004, IN PRESS J BIOL CHEM; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WANG ZX, 1992, ANAL BIOCHEM, V206, P376, DOI 10.1016/0003-2697(92)90381-G; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	67	45	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35412	35425		10.1074/jbc.M400872200	http://dx.doi.org/10.1074/jbc.M400872200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15180983	hybrid			2022-12-25	WOS:000223303400035
J	Lemtiri-Chlieh, F; Berkowitz, GA				Lemtiri-Chlieh, F; Berkowitz, GA			Cyclic adenosine monophosphate regulates calcium channels in the plasma membrane of Arabidopsis leaf guard and mesophyll cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION-CHANNEL; ABSCISIC-ACID; CYCLASE ACTIVITY; CATION CHANNELS; NITRIC-OXIDE; K+ CHANNEL; HYPERPOLARIZATION; EXPRESSION; IDENTIFICATION; CALMODULIN	The effect of cAMP on Ca2+-permeable channels from Arabidopsis thaliana leaf guard cell and mesophyll cell protoplasts was studied using the patch clamp technique. In the whole cell configuration, dibutyryl cAMP was found to increase a hyperpolarization-activated Ba2+ conductance (I-Ba). The increase of IBa was blocked by the addition of GdCl3. In excised outside-out patches, the addition of dibutyryl cAMP consistently activated a channel with particularly fast gating kinetics. Current/voltage analyses indicated a single channel conductance of similar to13 picosiemens. In patches where we measured some channel activity prior to cAMP application, the data suggest that cAMP enhances channel activity without affecting the single channel conductance. The cAMP activation of these channels was reversible upon washout. The results obtained with excised patches indicate that the cAMP-activated IBa seen in the whole cell configuration could be explained by a direct effect of cAMP on the Ca2+ channel itself or a close entity to the channel. This work represents the first demonstration using patch clamp analysis of the presence in plant cell membranes of an ion channel directly activated by cAMP.	Univ Connecticut, Dept Plant Sci, Agr Biotechnol Lab, Storrs, CT 06269 USA	University of Connecticut	Berkowitz, GA (corresponding author), Univ Connecticut, Dept Plant Sci, Agr Biotechnol Lab, U-4067,Storrs Rd, Storrs, CT 06269 USA.	gerald.berkowitz@uconn.edu	Lemtiri-Chlieh, Fouad/S-3022-2019; Lemtiri-Chlieh, Fouad/B-5624-2008; Lemtiri-Chlieh, Fouad/Y-9683-2019; Lemtiri-Chlieh, Fouad/D-5201-2013	Lemtiri-Chlieh, Fouad/0000-0002-7418-2623				Arazi T, 2000, PLANT MOL BIOL, V42, P591, DOI 10.1023/A:1006345302589; ASSMANN SM, 1995, PLANT PHYSIOL, V108, P885, DOI 10.1104/pp.108.3.885; Balague C, 2003, PLANT CELL, V15, P365, DOI 10.1105/tpc.006999; Balasubramanian S, 1996, J MEMBRANE BIOL, V152, P13, DOI 10.1007/s002329900081; Chan CWM, 2003, PLANT PHYSIOL, V132, P728, DOI 10.1104/pp.102.019216; Clough SJ, 2000, P NATL ACAD SCI USA, V97, P9323, DOI 10.1073/pnas.150005697; Cousson A, 1998, PLANTA, V206, P308, DOI 10.1007/s004250050405; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gelli A, 1997, J MEMBRANE BIOL, V155, P35, DOI 10.1007/s002329900156; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamilton DWA, 2000, P NATL ACAD SCI USA, V97, P4967, DOI 10.1073/pnas.080068897; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Hua BG, 2003, PLANT PHYSIOL, V132, P1353, DOI 10.1104/pp.103.020560; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Johannes E, 1994, Symp Soc Exp Biol, V48, P113; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kiegle E, 2000, PLANT J, V21, P225, DOI 10.1046/j.1365-313x.2000.00659.x; Kohler C, 2001, PLANTA, V213, P327, DOI 10.1007/s004250000510; Kohler C, 2000, FEBS LETT, V471, P133, DOI 10.1016/S0014-5793(00)01383-1; KUROSAKI F, 1993, ARCH BIOCHEM BIOPHYS, V302, P144, DOI 10.1006/abbi.1993.1192; Lemtiri-Chlieh F, 2003, P NATL ACAD SCI USA, V100, P10091, DOI 10.1073/pnas.1133289100; LemtiriChlieh F, 1996, J MEMBRANE BIOL, V153, P105, DOI 10.1007/s002329900114; Leng Q, 1999, PLANT PHYSIOL, V121, P753, DOI 10.1104/pp.121.3.753; Leng Q, 2002, PLANT PHYSIOL, V128, P400, DOI 10.1104/pp.010832; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; Ludidi N, 2003, J BIOL CHEM, V278, P6490, DOI 10.1074/jbc.M210983200; Maathuis FJM, 2001, PLANT PHYSIOL, V127, P1617, DOI 10.1104/pp.010502; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Moutinho A, 2001, P NATL ACAD SCI USA, V98, P10481, DOI 10.1073/pnas.171104598; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pharmawati M, 2001, PLANT PHYSIOL BIOCH, V39, P385, DOI 10.1016/S0981-9428(01)01252-9; Richards H, 2002, PHYTOCHEMISTRY, V61, P531, DOI 10.1016/S0031-9422(02)00266-2; Seifert R, 1999, EMBO J, V18, P119, DOI 10.1093/emboj/18.1.119; Sunkar R, 2000, PLANT J, V24, P533, DOI 10.1046/j.1365-313x.2000.00901.x; Talke IN, 2003, TRENDS PLANT SCI, V8, P286, DOI 10.1016/S1360-1385(03)00099-2; Trewavas AJ, 2002, CURR OPIN PLANT BIOL, V5, P425, DOI 10.1016/S1369-5266(02)00281-9; Very AA, 2002, TRENDS PLANT SCI, V7, P168, DOI 10.1016/S1360-1385(02)02262-8; Very AA, 2000, P NATL ACAD SCI USA, V97, P9801, DOI 10.1073/pnas.160250397; Volotovski ID, 1998, PLANT PHYSIOL, V117, P1023, DOI 10.1104/pp.117.3.1023; Walden R, 1998, CURR OPIN PLANT BIOL, V1, P419, DOI 10.1016/S1369-5266(98)80266-5; White PJ, 2002, BBA-BIOMEMBRANES, V1564, P299, DOI 10.1016/S0005-2736(02)00509-6; Witters E, 2004, RAPID COMMUN MASS SP, V18, P499, DOI 10.1002/rcm.1365; Xu W, 1999, J MEMBRANE BIOL, V171, P117, DOI 10.1007/s002329900564; YAO XQ, 1995, P NATL ACAD SCI USA, V92, P11711, DOI 10.1073/pnas.92.25.11711	51	85	93	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35306	35312		10.1074/jbc.M400311200	http://dx.doi.org/10.1074/jbc.M400311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199067	hybrid			2022-12-25	WOS:000223303400022
J	Wang, S; Liu, Y; Adamson, CL; Valdez, G; Guo, W; Hsu, SC				Wang, S; Liu, Y; Adamson, CL; Valdez, G; Guo, W; Hsu, SC			The mammalian exocyst, a complex required for exocytosis, inhibits tubulin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC6/8 COMPLEX; COMPONENT SEC5; MEMBRANE; PURIFICATION; MICROTUBULES; PROTEINS; DYNAMICS	The exocyst is a 734-kDa complex essential for development. Perturbation of its function results in early embryonic lethality. Extensive investigation has revealed that this complex participates in multiple biological processes, including protein synthesis and vesicle/protein targeting to the plasma membrane. In this article we report that the exocyst may also play a role in modulating microtubule dynamics. Using monoclonal antibodies, we observed that endogenous exocyst subunits co-localized with microtubules and mitotic spindles in normal rat kidney cells. To test for a functional relationship between the exocyst complex and microtubules, we established an in vitro exocyst reconstitution assay and studied exocyst effect on microtubule dynamics. We found that the exocyst complex reconstituted from eight recombinant exocyst subunits inhibited tubulin polymerization in vitro. Deletion of exocyst subunit sec5, sec6, sec15, or exo70 diminished its tubulin polymerization inhibition activity. Surprisingly, exocyst subunit exo70 itself was also capable of inhibiting tubulin polymerization, although exocyst complex with exo70 deletion did not lose its activity completely. Overexpression of exo70 in NRK cells resulted in microtubule network disruption and the formation of filopodia-like plasma membrane protrusions. The formation of these membrane protrusions was greatly hampered by stabilizing microtubules with taxol. Overexpression of exo84, an exocyst subunit that did not show tubulin polymerization inhibition activity, did not cause this phenotype. Results shown in this article, along with a previous report that localized microtubule instability induces plasma membrane addition, implicates a novel role for the exocyst in modulating microtubule dynamics underlying exocytosis.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Piscataway, NJ 08854 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Brain & Spinal Cord Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, WM Keck Ctr Collaborat Neurosci, Stony Brook, NY 11794 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Rutgers State University New Brunswick; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania	Hsu, SC (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Rm D419,604 Allison Rd, Piscataway, NJ 08854 USA.	hsu@biology.rutgers.edu	wang, sheng/B-1969-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018218] Funding Source: NIH RePORTER; NINDS NIH HHS [NS388892, NS18218] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Friedrich GA, 1997, DEV BIOL, V192, P364, DOI 10.1006/dbio.1997.8727; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Murthy M, 2003, NEURON, V37, P433, DOI 10.1016/S0896-6273(03)00031-X; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Sjolinder M, 2002, FEBS LETT, V532, P211, DOI 10.1016/S0014-5793(02)03677-3; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Terbush DR, 2001, METHOD ENZYMOL, V329, P100; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; Zakharenko S, 1998, J CELL BIOL, V143, P1077, DOI 10.1083/jcb.143.4.1077; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	30	58	61	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35958	35966		10.1074/jbc.M313778200	http://dx.doi.org/10.1074/jbc.M313778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15205466	hybrid			2022-12-25	WOS:000223303400097
J	Lubelski, J; Mazurkiewicz, P; van Merkerk, R; Konings, WN; Driessen, AJM				Lubelski, J; Mazurkiewicz, P; van Merkerk, R; Konings, WN; Driessen, AJM			ydaG and ydbA of Lactococcus lactis encode a heterodimeric ATP-binding cassette-type multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DRUG EXTRUSION; ABC-TRANSPORTERS; ESCHERICHIA-COLI; RESISTANCE PROTEIN; EFFLUX PUMPS; SYSTEMS; RECONSTITUTION; MECHANISM; LMRA; MICROORGANISMS	Multidrug resistance (MDR)-type transporters mediate the active extrusion of structurally and functionally dissimilar compounds from the cells, thereby rendering cells resistant to a range of drugs. The ydaG and ydbA genes of Lactococcus lactis encode two ATP-binding cassette half-transporters, which both share homology with MDR proteins such as LmrA from L. lactis or the mammalian P-glycoprotein. The ydaG/ydbA genes were cloned and expressed separately and jointly in L. lactis using the nisin-inducible system. When both proteins are co-expressed, several structurally dissimilar drugs such as ethidium, daunomycin, and BCECF-AM are extruded from the cell. YdaG and YdbA could be co-purified as a stable heterodimer. ATPase activity was found to be associated with the YdaG/YdbA heterodimer only and not with the individual subunits. Both the ydaG and ydbA genes are up-regulated in multidrug-resistant L. lactis strains selected for growth in the presence of a variety of toxic compounds. This is the first demonstration of a functional heterodimeric ATP-binding cassette-type MDR transporter.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012; Lubelski, Jacek/D-8639-2013; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Blackmore CG, 2001, MOL MEMBR BIOL, V18, P97, DOI 10.1080/09687680010030200; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Borges-Walmsley MI, 2003, BIOCHEM J, V376, P313, DOI 10.1042/BJ20020957; Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; Gajic O, 2003, J BIOL CHEM, V278, P34291, DOI 10.1074/jbc.M211100200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Jenkinson HF, 1996, J DENT RES, V75, P736, DOI 10.1177/00220345960750020201; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Mazurkiewicz P, 2002, J BIOL CHEM, V277, P26081, DOI 10.1074/jbc.M203141200; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ozkan P, 2002, BBA-GEN SUBJECTS, V1572, P143, DOI 10.1016/S0304-4165(02)00303-3; Paulsen IT, 2003, CURR OPIN MICROBIOL, V6, P446, DOI 10.1016/j.mib.2003.08.005; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	48	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34449	34455		10.1074/jbc.M404072200	http://dx.doi.org/10.1074/jbc.M404072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192086	Green Published, hybrid			2022-12-25	WOS:000223134800046
J	Miyamoto, Y; Yamauchi, J; Mizuno, N; Itoh, H				Miyamoto, Y; Yamauchi, J; Mizuno, N; Itoh, H			The adaptor protein Nck1 mediates endothelin A receptor-regulated cell migration through the Cdc42-dependent c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK SIGNALING PATHWAY; RHO-GTPASES; SH3 DOMAINS; BETA-GAMMA; SRC KINASE; B RECEPTOR; ACTIVATION; MICE; GRB2; RAS	Cell migration plays key roles in physiological and pathological phenomena, such as development and oncogenesis. The adaptor proteins Grb2, CrkII, and Nck1 are composed of only a single Src homology 2 domain and some Src homology 3 domains, giving specificity to each signal transduction pathway. However, little is known about the relationships between their adaptor proteins and cell migration, which are regulated by the G protein-coupled receptor. Here we showed that Nck1, but not Grb2 or CrkII, mediated the inhibition of cell migration induced by the endothelin-1 and endothelin A receptor. The small interference RNA and dominant negative mutants of Nck1 diminished the endothelin-1-induced inhibition of cell migration. Although overexpression of wild-type Nck1 was detected in the cytosol and did not affect cell migration, expression of the myristoylation signal sequence-conjugated Nck1 was detected in the membrane and induced activation of Cdc42 and c-Jun N-terminal kinase, inhibiting cell migration. Taken together, these results suggest that the endothelin A receptor transduces the signal of inhibition of cell migration through Cdc42-dependent c-Jun N-terminal kinase activation by using Nck1.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Nara 6300192, Japan; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Nara Institute of Science & Technology; Stanford University	Itoh, H (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, 8916-5 Takayama, Nara 6300192, Japan.	hitoh@bs.naist.jp						Abe Y, 2000, J BIOL CHEM, V275, P8664, DOI 10.1074/jbc.275.12.8664; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Flynn DC, 2001, ONCOGENE, V20, P6270, DOI 10.1038/sj.onc.1204769; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GENARD C, 1994, ANNU REV IMMUNOL, V12, P775; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MAKMAN MH, 1995, J IMMUNOL, V154, P1323; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Ridley AJ, 2001, J CELL SCI, V114, P2713; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 2002, FEBS LETT, V527, P284, DOI 10.1016/S0014-5793(02)03231-3; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	42	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34336	34342		10.1074/jbc.M402767200	http://dx.doi.org/10.1074/jbc.M402767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187089	hybrid			2022-12-25	WOS:000223134800033
J	Onesto, C; Berra, E; Grepin, R; Pages, G				Onesto, C; Berra, E; Grepin, R; Pages, G			Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-TRANSCRIPTION; POLY(A) BINDING-PROTEIN; 3' UNTRANSLATED REGION; HYPOXIA; STABILIZATION; STABILITY; EXPRESSION; HUR; KINASE; IDENTIFICATION	Expression of vascular endothelial growth factor ( VEGF) is tightly regulated, particularly at the level of its mRNA stability, which is essentially mediated through the 3'-untranslated region (3'-UTR) of VEGF mRNA. To identify new protein partners regulating VEGF mRNA stability, we screened a cDNA expression library with an RNA probe corresponding to the entire VEGF mRNA 3'-UTR. We identified the "poly(A)-binding protein-interacting protein 2" (PAIP2) as a new VEGF mRNA 3'-UTR interacting protein. By RNA electromobility shift assays, we showed that PAIP2 binds to two distinct regions of a domain encompassing base 1 to 1280 of the VEGF 3'-UTR. Such in vitro interaction was confirmed using cell extracts in which PAIP2 expression is induced by tetracycline (Tet-on cells). Moreover, we demonstrated by RNA affinity purification as well as by ribonucleoprotein complexes immunoprecipitation, that PAIP2 interacts with VEGF mRNA in vivo. Using an in vitro RNA degradation assay, the half-life of VEGF 3'-UTR was found to be increased by overexpressing PAIP2. PAIP2 stabilizes endogenous VEGF mRNA in Tet-on cells, leading to increased VEGF secretion. Moreover, RNAi- mediated knock-down of PAIP2 significantly reduces the steady-state levels of endogenous VEGF mRNA. We also showed, by in vitro protein-protein interactions and co-immunoprecipitation experiments, that PAIP2 interacts with HuR, an already known VEGF mRNA-binding protein, suggesting cooperation of both proteins for VEGF mRNA stabilization. Hence, PAIP2 appears to be a crucial regulator of VEGF mRNA and as a consequence, any variation in its expression could modulate angiogenesis.	Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Pages, G (corresponding author), Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice 2, France.	gpages@unice.fr	Berra, Edurne/F-9692-2011; Pages, Gilles/N-7135-2017	Berra, Edurne/0000-0002-3820-5744; 				Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; Bonino F, 2001, BIOTECHNIQUES, V30, P1254, DOI 10.2144/01306st02; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Feral C, 2001, NUCLEIC ACIDS RES, V29, P1872, DOI 10.1093/nar/29.9.1872; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Gouyon F, 2003, BIOCHEM J, V375, P167, DOI 10.1042/BJ20030661; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Steger K, 1998, MOL HUM REPROD, V4, P939, DOI 10.1093/molehr/4.10.939; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Trawick JD, 1997, J BIOL CHEM, V272, P3099, DOI 10.1074/jbc.272.5.3099; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000	38	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34217	34226		10.1074/jbc.M400219200	http://dx.doi.org/10.1074/jbc.M400219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175342	hybrid			2022-12-25	WOS:000223134800020
J	Swingler, TE; Bess, KL; Yao, J; Stifani, S; Jayaraman, PS				Swingler, TE; Bess, KL; Yao, J; Stifani, S; Jayaraman, PS			The proline-rich homeodomain protein recruits members of the Groucho/transducin-like enhancer of split protein family to co-repress transcription in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-LIKE-ENHANCER; MESSENGER-RNA TRANSPORT; AMINO-TERMINAL ENHANCER; HOMEOBOX GENE; MEDIATED TRANSCRIPTION; DROSOPHILA GROUCHO; HEX; EXPRESSION; INTERACTS; DOMAIN	The proline-rich homeodomain protein (PRH/Hex) is important in the control of cell proliferation and differentiation and in the regulation of multiple processes in embryonic development. We have shown previously that PRH contains two domains that can independently bring about transcriptional repression. The PRH homeodomain represses transcription by binding to TATA box sequences, whereas the proline-rich N-terminal domain of PRH can repress transcription when attached to a heterologous DNA-binding domain. The Groucho/transducin-like enhancer of split (TLE) family of proteins are transcriptional co-repressors that interact with a number of DNA-bound transcription factors and play multiple roles in development. Here we demonstrate that the proline-rich N-terminal domain of PRH binds to TLE1 in vitro and in yeast two-hybrid assays. We show that PRH and TLE proteins are co-expressed in hematopoietic cells and interact in co-immunoprecipitation assays. We demonstrate that TLE1 increases repression by PRH in transient transfection assays and that titration of endogenous TLE proteins by co-expression of Grg5, a natural trans-dominant negative protein, alleviates transcriptional repression by PRH. Finally, we show that a mutation in the PRH N-terminal domain that blocks the PRH-TLE1 interaction in vitro eliminates co-repression. We discuss these results in terms of the roles of PRH and TLE in cell differentiation and development.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Bristol; McGill University	Jayaraman, PS (corresponding author), Univ Bristol, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	Sheela.Jayaraman@bristol.ac.uk		/0000-0002-6500-9095; Stifani, Stefano/0000-0002-2376-7701				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Bess KL, 2003, BIOCHEM J, V374, P667, DOI 10.1042/BJ20030769; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Brickman JM, 2000, DEVELOPMENT, V127, P2303; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Courey AJ, 2001, GENE DEV, V15, P2786; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Dasen JS, 2001, GENE DEV, V15, P3193, DOI 10.1101/gad.932601; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; Du ZW, 2001, BIOCHEM BIOPH RES CO, V282, P701, DOI 10.1006/bbrc.2001.4636; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; George A, 2003, ONCOGENE, V22, P6764, DOI 10.1038/sj.onc.1206822; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jayaraman PS, 2000, LEUKEMIA RES, V24, P1023, DOI 10.1016/S0145-2126(00)00072-2; Jimenez G, 1999, MOL CELL BIOL, V19, P2080; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KOEFFLER HP, 1980, BLOOD, V56, P344; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Obinata A, 2002, DEV GROWTH DIFFER, V44, P281; Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Puppin C, 2003, NUCLEIC ACIDS RES, V31, P1845, DOI 10.1093/nar/gkg295; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Smith ST, 1996, DEVELOPMENT, V122, P3141; STIFANI S, 1992, NAT GENET, V2, P343, DOI 10.1038/ng1292-343a; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang H, 2002, GENETICS, V160, P799	68	64	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34938	34947		10.1074/jbc.M404488200	http://dx.doi.org/10.1074/jbc.M404488200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187083	hybrid			2022-12-25	WOS:000223134800105
J	Lin, J; Yang, QY; Yan, Z; Markowitz, J; Wilder, PT; Carrier, F; Weber, DJ				Lin, J; Yang, QY; Yan, Z; Markowitz, J; Wilder, PT; Carrier, F; Weber, DJ			Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; REGULATORY DOMAIN; PROTEIN; PATHWAY; S100B(BETA-BETA); ACTIVATION; BINDING; FAMILY; GROWTH; GADD45	S100 calcium-binding proteins such as S100B are elevated in primary malignant melanoma and are used as markers for this and numerous other cancers. Wild-type p53 protein levels are relatively low in these cancer cells (i.e. when compared with cells without S100B) but are elevated when RNA antisense to S100B is introduced. This result implicates S100B in the down-regulation of p53 and is consistent with the large decreases in p53 protein levels observed previously in transient co-transfections of p53 and S100B (Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carrier, F. (2001) J. Biol. Chem. 276, 35037-35041). Down-regulation of p53 in primary malignant melanoma cells is likely the result of a direct interaction with S100B, which was observed by co-immunoprecipitation experiments. Furthermore, p53 binds regions of the S100B promoter, one of which matches the 20-nucleotide p53-binding consensus DNA sequence perfectly. Therefore, when p53 levels increase, it contributes to its own demise by up-regulating the transcription of S100B as part of a negative feedback loop. This is analogous to what is found for another protein that down-regulates p53, namely hdm2 (human double mutant 2).	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Weber, DJ (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dweber@umaryland.edu	Weber, David J/B-5349-2011; Markowitz, Joseph/AAS-1041-2021; Carrier, France/C-3063-2008	Weber, David J/0000-0002-8824-1110; Carrier, France/0000-0002-5517-5284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058888, GM58888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AMBURGEY JC, 1995, J BIOMOL NMR, V6, P171, DOI 10.1007/BF00211781; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; Carrier F., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P102; Castets F, 1997, MOL BRAIN RES, V46, P208, DOI 10.1016/S0169-328X(96)00298-7; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COCHRAN AJ, 1993, MELANOMA RES, V3, P325, DOI 10.1097/00008390-199310000-00004; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; MARKS A, 1990, EXP CELL RES, V187, P59, DOI 10.1016/0014-4827(90)90116-R; Meek DW, 1997, PATHOL BIOL, V45, P804; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; OConnor PM, 1997, CANCER RES, V57, P4285; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Rustandi RR, 1999, PROTEIN SCI, V8, P1743, DOI 10.1110/ps.8.9.1743; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber DJ, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P521; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	41	102	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34071	34077		10.1074/jbc.M405419200	http://dx.doi.org/10.1074/jbc.M405419200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178678	hybrid			2022-12-25	WOS:000223039700119
J	Mukhopadhyay, S; Munshi, HG; Kambhampati, S; Sassano, A; Platanias, LC; Stack, MS				Mukhopadhyay, S; Munshi, HG; Kambhampati, S; Sassano, A; Platanias, LC; Stack, MS			Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MATRIX-METALLOPROTEINASE; BASEMENT-MEMBRANE; STRUCTURAL PROTEINS; SIGNAL-TRANSDUCTION; MMP-9; HEAD; PHOSPHORYLATION; MIGRATION; CASCADE	Matrix metalloproteinases ( MMPs) play an important role in the invasive behavior of a number of cancers including oral squamous cell cancer (OSCC), and increased expression of MMP-9 is correlated with invasive and metastatic OSCC. Because calcium is an important regulator of keratinocyte function, the effect of modulating extracellular calcium on MMP-9 expression in OSCC cell lines was evaluated. Increasing extracellular calcium induced a dose-dependent increase in MMP-9 expression in immortalized normal and premalignant oral keratinocytes, but not in two highly invasive OSCC cell lines. Differential activation of MAPK signaling was also induced by calcium. p38 MAPK activity was downregulated, whereas ERK1/2 activity was enhanced. Pharmacologic inhibition of p38 MAPK activity or expression of a catalytically inactive mutant of the upstream kinase MAPK kinase 3 (MKK3) increased the calcium induced MMP-9 gene expression, demonstrating that p38 MAPK activity negatively regulated this process. Interestingly blocking p38 MAPK activity enhanced ERK1/2 phosphorylation, suggesting reciprocal regulation between the ERK1/2 and p38 MAPK pathways. Together these data support a model wherein calcium-induced MMP-9 expression is differentially regulated by the ERK1/2 and p38 MAPK pathways in oral keratinocytes, and the data suggest that a loss of this regulatory mechanism accompanies malignant transformation of the oral epithelium.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA077816, T32CA070085, K08CA094877, R01CA085870, R01CA094079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA94079, R01CA77816, R01CA85870, T32 CA70085, K08CA94877] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Corbetta S, 2002, J CLIN ENDOCR METAB, V87, P2201, DOI 10.1210/jc.87.5.2201; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Firth NA, 1996, AUST DENT J, V41, P83, DOI 10.1111/j.1834-7819.1996.tb05918.x; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hong SD, 2000, ORAL ONCOL, V36, P207, DOI 10.1016/S1368-8375(99)00088-3; Ikebe T, 1999, CLIN EXP METASTAS, V17, P315, DOI 10.1023/A:1006642428826; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jordan R C, 1997, J Can Dent Assoc, V63, P517; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; Kobayashi T, 1998, DERMATOLOGY, V197, P1, DOI 10.1159/000017967; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; KUMAGAI S, 1994, HEAD NECK-J SCI SPEC, V16, P51, DOI 10.1002/hed.2880160111; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Li SP, 2003, CANCER RES, V63, P3473; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MENON GK, 1994, J INVEST DERMATOL, V102, P789, DOI 10.1111/1523-1747.ep12377921; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RHEINWALD JG, 1981, CANCER RES, V41, P1657; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKR WA, 1987, HUM PATHOL, V18, P1043, DOI 10.1016/S0046-8177(87)80221-6; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Simon C, 1998, LARYNGOSCOPE, V108, P1686, DOI 10.1097/00005537-199811000-00018; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	47	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33139	33146		10.1074/jbc.M405194200	http://dx.doi.org/10.1074/jbc.M405194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180997	hybrid			2022-12-25	WOS:000223039700016
J	Yarmola, EG; Bubb, MR				Yarmola, EG; Bubb, MR			Effects of profilin and thymosin beta(4) on the critical concentration of actin demonstrated in vitro and in cell extracts with a novel direct assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BARBED-END; RATE CONSTANTS; ADP-ACTIN; QUANTITATIVE-ANALYSIS; ELECTRON-MICROSCOPY; PROTEIN FUNCTION; ATP-ACTIN; FILAMENTS; POLYMERIZATION	The free actin concentration at steady state, A(c), is a variable that determines how actin regulatory proteins influence the extent of actin polymerization. We describe a novel method employing fluorescence anisotropy to directly measure A(c) in any sample after the addition of a trace amount of labeled thymosin beta(4) or thymosin beta(4) peptide. Using this assay, we confirm earlier theoretical work on the helical polymerization of actin and confirm the effects of actin filament-stabilizing drugs and capping proteins on A(c), thereby validating the assay. We also confirm a controversial prior observation that profilin lowers the critical concentration of Mg2+-actin. A general mechanism is proposed to explain this effect, and the first quantitative dose-response curve for the effect of profilin on A(c) facilitates its evaluation. This mechanism also predicts the effect of profilin on critical concentration in the presence of the limited amount of capping protein, which is the condition often found in cells, and the effect of profilin on critical concentration in cell extracts is demonstrated for the first time. Additionally, nonlinear effects of thymosin beta(4) on the steady state amount of F-actin are explained by the observed changes in A(c). This assay has potential in vivo applications that complement those demonstrated in vitro.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Malcom Randall Dept Vet Affairs Med Ctr, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida	Bubb, MR (corresponding author), Univ Florida, Coll Med, Dept Med, Box 100221, Gainesville, FL 32610 USA.	bubbmr@medicine.ufl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K25AR048918] Funding Source: NIH RePORTER; NIAMS NIH HHS [5K25AR048918] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blanchoin L, 2002, BIOCHEMISTRY-US, V41, P597, DOI 10.1021/bi011214b; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; BONDER EM, 1983, CELL, V34, P491, DOI 10.1016/0092-8674(83)90382-3; Bubb MR, 2003, J BIOL CHEM, V278, P24629, DOI 10.1074/jbc.M302796200; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; Clayton AHA, 2002, BIOPHYS J, V83, P1631, DOI 10.1016/S0006-3495(02)73932-5; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CRAIG SW, 1980, CELL, V22, P739, DOI 10.1016/0092-8674(80)90550-4; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; DiNubile MJ, 1997, CELL MOTIL CYTOSKEL, V37, P211, DOI 10.1002/(SICI)1097-0169(1997)37:3<211::AID-CM3>3.0.CO;2-9; Geese M, 2000, J CELL SCI, V113, P1415; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; JANMEY PA, 1986, J BIOL CHEM, V261, P8357; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kinosian HJ, 2002, BIOCHEMISTRY-US, V41, P6734, DOI 10.1021/bi016083t; NISHIDA E, 1981, J BIOCHEM-TOKYO, V89, P1197; Nyman T, 2002, J BIOL CHEM, V277, P15828, DOI 10.1074/jbc.M112195200; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; TARDIF M, 1995, J BIOL CHEM, V270, P28075; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YIN HL, 1980, J BIOL CHEM, V255, P9494	41	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33519	33527		10.1074/jbc.M404392200	http://dx.doi.org/10.1074/jbc.M404392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184365	hybrid			2022-12-25	WOS:000223039700060
J	Nenquin, M; Szollosi, A; Aguilar-Bryan, L; Bryan, J; Henquin, JC				Nenquin, M; Szollosi, A; Aguilar-Bryan, L; Bryan, J; Henquin, JC			Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; CYTOPLASMIC CA2+; PROTEIN-KINASE; KNOCKOUT MICE; ELECTRICAL-ACTIVITY; INTRACELLULAR CA2+; MOUSE ISLETS; B-CELLS; GLUCOSE; ATP	In normal beta-cells glucose induces insulin secretion by activating both a triggering pathway (closure of K-ATP channels, depolarization, and rise in cytosolic [Ca2+](i)) and an amplifying pathway (augmentation of Ca2+ efficacy on exocytosis). It is unclear if and how nutrients can regulate insulin secretion by beta-cells lacking K-ATP channels (Sur1 knockout mice). We compared glucose- and amino acid-induced insulin secretion and [Ca2+](i) changes in control and Sur1KO islets. In 1 mM glucose (non-stimulatory for controls), the triggering signal [Ca2+](i) was high (loss of regulation) and insulin secretion was stimulated in Sur1KO islets. This "basal" secretion was decreased or increased by imposed changes in [Ca2+](i) and was dependent on ATP production, indicating that both triggering and amplifying signals are involved. High glucose stimulated insulin secretion in Sur1KO islets, by an unsuspected, transient increase in [Ca2+](i) and a sustained activation of the amplifying pathway. Unlike controls, Sur1KO islets were insensitive to diazoxide and tolbutamide, which rules out effects of either drug at sites other than K-ATP channels. Amino acids potently increased insulin secretion by Sur1KO islets through both a further electrogenic rise in [Ca2+](i) and a metabolism-dependent activation of the amplifying pathway. After sulfonylurea blockade of their K-ATP channels, control islets qualitatively behaved like Sur1KO islets, but their insulin secretion rate was consistently lower for a similar or even higher [Ca2+](i). In conclusion, fuel secretagogues can control insulin secretion in beta-cells without K-ATP channels, partly by an unsuspected influence on the triggering [Ca2+](i) signal and mainly by the modulation of a very effective amplifying pathway.	Univ Louvain, Fac Med UCL 55 30, Unite Endocrinol & Metab, B-1200 Brussels, Belgium; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Universite Catholique Louvain; Baylor College of Medicine; Baylor College of Medicine	Henquin, JC (corresponding author), Univ Louvain, Fac Med UCL 55 30, Unite Endocrinol & Metab, Ave Hippocrate 55, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be	Szollosi, Andras/J-5097-2013; Szollosi, Andras/P-4278-2019	Szollosi, Andras/0000-0002-5570-4609	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057671, R01DK052771] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57671, DK52771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; Ammala C, 2000, DIABETES, V49, pA62; Anello M, 1999, BRIT J PHARMACOL, V127, P1883, DOI 10.1038/sj.bjp.0702731; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; Bertrand G, 2002, J BIOL CHEM, V277, P32883, DOI 10.1074/jbc.M205326200; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; Doliba NM, 2004, AM J PHYSIOL-ENDOC M, V286, pE834, DOI 10.1152/ajpendo.00292.2003; Dufer M, 2004, DIABETOLOGIA, V47, P488, DOI 10.1007/s00125-004-1348-0; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 2002, DIABETES, V51, P87, DOI 10.2337/diabetes.51.1.87; GarciaBarrado MJ, 1996, EUR J PHARMACOL, V298, P279, DOI 10.1016/0014-2999(95)00806-3; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GILON P, 1992, J BIOL CHEM, V267, P20713; Harris TE, 2000, BIOCHEM BIOPH RES CO, V270, P1119, DOI 10.1006/bbrc.2000.2563; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1978, NATURE, V271, P271, DOI 10.1038/271271a0; Henquin JC, 2003, EUR J CLIN INVEST, V33, P742, DOI 10.1046/j.1365-2362.2003.01207.x; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HERMANS MP, 1987, DIABETOLOGIA, V30, P659; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Komatsu M, 2001, ENDOCR J, V48, P275, DOI 10.1507/endocrj.48.275; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Minami K, 2002, J BIOL CHEM, V277, P25277, DOI 10.1074/jbc.M203988200; Nakazaki M, 2002, DIABETES, V51, P3440, DOI 10.2337/diabetes.51.12.3440; Nichols CG, 2002, AM J PHYSIOL-ENDOC M, V283, pE403, DOI 10.1152/ajpendo.00168.2002; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; PANTEN U, 1984, BIOCHEM J, V219, P189, DOI 10.1042/bj2190189; PRENTKI M, 1983, J BIOL CHEM, V258, P4239; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Sato Y, 1999, ENDOCRINOLOGY, V140, P2252, DOI 10.1210/en.140.5.2252; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Sieg A, 2004, AM J PHYSIOL-ENDOC M, V286, pE463, DOI 10.1152/ajpendo.00365.2003; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37	56	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32316	32324		10.1074/jbc.M402076200	http://dx.doi.org/10.1074/jbc.M402076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175349	hybrid			2022-12-25	WOS:000222849700042
J	Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K				Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K			Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells	ONCOGENE			English	Article						small interfering RNAs; cyclin B1; G2/M arrest; proliferation; apoptosis	B1 OVEREXPRESSION; CANCER-CELLS; CARCINOMA; LOCALIZATION; ACTIVATION; PLK1	Cyclin B1 is the regulatory subunit of M-phase promoting factor, and proper regulation of cyclin B1 is essential for the initiation of mitosis. Increasing evidence indicates that the deregulation of cyclin B1 is involved in neoplastic transformation, suggesting the suppression of cyclin B1 could be an attractive strategy for antiproliferative therapy. In the present work, we analysed the impact of small interfering RNAs (siRNAs) targeted to cyclin B1 on different human tumor cell lines. Cyclin B1 siRNAs reduced the protein level of cyclin B1 in HeLa, MCF-7, BT-474 and MDA-MB-435 tumor cells and efficiently reduced the kinase activity of Cdc2/cyclin B1 in HeLa cells. siRNA-treated cells were arrested in G2/M phase in all tumor cell lines tested. Proliferation of tumor cells from different origins was suppressed by 50-80% 48 h after transfection and apoptosis was increased from 5 to 40-50%. Furthermore, tumor cells showed less colony-forming ability after siRNA treatment. In contrast, primary human umbilical vein endothelial cells exhibited only a slight change in cell cycle, and neither apoptosis nor clear inhibition of proliferation was observed after cyclin B1 siRNA treatment for 48 h. These results indicate that siRNAs against cyclin B1 could become a powerful antiproliferative tool in future antitumor therapy.	Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Davies TG, 2002, NAT STRUCT BIOL, V9, P745, DOI 10.1038/nsb842; Dong YY, 2002, CANCER LETT, V177, P13, DOI 10.1016/S0304-3835(01)00770-4; Hassan KA, 2002, CANCER RES, V62, P6414; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li JQ, 2003, INT J ONCOL, V22, P1101; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Park M, 2000, CANCER RES, V60, P542; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Yin XY, 2001, CANCER RES, V61, P6487; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	20	163	180	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5843	5852		10.1038/sj.onc.1207757	http://dx.doi.org/10.1038/sj.onc.1207757			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208674				2022-12-25	WOS:000222629800014
J	Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP				Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP			Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth	ONCOGENE			English	Article						TSLC1; lung cancer; adenovirus vector; apoptosis; tumorigenesis	SUPPRESSOR ACTIVITY; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; PROMOTER; PROTEIN; ADENOCARCINOMA; TUMORIGENICITY; ASSOCIATION	The TSLC1 tumor-suppressor gene is silenced in a number of human cancer tissues and cell lines, including lung, prostate, liver, stomach, pancreatic, and breast cancers. Expression of TSLC1 in a non-small-cell lung cancer (NSCLC) cell line A549 suppresses tumorigenicity in nude mice. However, the molecular mechanism of TSLC1 action is not yet elucidated. In the present study, we show that the expression of TSLC1 from a recombinant adenovirus vector (Ad-TSLC1) inhibited cell proliferation and induced apoptosis in the NSCLC cell line A549. We also demonstrated that subcutaneous tumor growth in nude mice induced by A549 cells was suppressed to the extent of 70-80% by intratumoral injection of Ad-TSLC1. Re-expression of TSLC1 also resulted in activation of the apoptotic protease caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP). The antiproliferative and proapoptotic activity of TSLC1 required the presence of the FERM-binding and PDZ-interacting motifs located in the cytoplasmic domain. Our results demonstrate the proapoptotic and oncosuppressive activity of TSLC1 protein, and suggest the potential of TSLC1 for gene therapy.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Ghosh, HP (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ghosh@mcmaster.ca	Seidlitz, Eric P/K-6765-2013; Singh, Gurmit/C-6744-2014	Seidlitz, Eric P/0000-0001-9760-1133; 				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; ASHE PC, 2003, BIOL PSYCHIAT, V27, P199; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Ji L, 1999, CANCER RES, V59, P3333; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Mao XL, 2003, CANCER RES, V63, P7979; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Ng Philip, 2002, Methods Mol Med, V69, P389; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Tran YK, 1999, CANCER RES, V59, P35; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; Yageta M, 2002, CANCER RES, V62, P5129	30	81	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5632	5642		10.1038/sj.onc.1207756	http://dx.doi.org/10.1038/sj.onc.1207756			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184878				2022-12-25	WOS:000222629500008
J	Brizzi, MF; Dentelli, P; Rosso, A; Calvi, C; Gambino, R; Cassader, M; Salvidio, G; Deferrari, G; Camussi, G; Pegoraro, L; Pagano, G; Cavallo-Perin, P				Brizzi, MF; Dentelli, P; Rosso, A; Calvi, C; Gambino, R; Cassader, M; Salvidio, G; Deferrari, G; Camussi, G; Pegoraro, L; Pagano, G; Cavallo-Perin, P			RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and P21(waf) to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy	FASEB JOURNAL			English	Article						MC; signal transduction and activators of transcription; AGE	GROWTH-FACTOR-BETA; GLYCATION END-PRODUCTS; MATRIX GENE-EXPRESSION; PROTEIN-KINASE-C; HIGH GLUCOSE; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; ACTIVATION; ALBUMIN; HYPERTROPHY	The molecular events associated with acute and chronic exposure of mesangial cells (MC) to hyperglycemia were evaluated. We found that, unlike high glucose (HG) and Amadori adducts, advanced glycation end products (AGE) and transforming growth factor-beta (TGF-beta) induced p21(waf) expression and accumulation of MC in G(0)/G(1). TGF-beta1 blockade inhibited AGE-mediated collagen production but only partially affected AGE-induced p21(waf) expression and cell-cycle events, indicating that AGE by binding to AGE receptor (RAGE) per se could control MC growth. Moreover, AGE and TGF-beta treatment led to the activation of the signal transduction and activators of transcription (STAT)5 and the formation of a STAT5/p21SIE2 complex. The role of STAT5 in AGE- and TGF-beta-mediated p21(Waf) expression and growth arrest, but not collagen production, was confirmed by the expression of the dominant negative STAT5 (DeltaSTAT5) or the constitutively activated STAT5 (1*6-STAT5) constructs. Finally, in p21(waf)-/- fibroblasts both AGE and TGF-beta failed to inhibit cell-cycle progression. A potential in vivo role of these mechanisms was sustained by the increasing immunoreactivity for the activated STAT5 and p21(waf) in kidney biopsies from early to advanced stage of diabetic nephropathy. Our data indicate that AGE- and TGF-beta-mediated signals, by converging on STAT5 activation and p21(waf) expression, may regulate MC growth.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Genoa, Dept Internal Med, Genoa, Italy	University of Turin; University of Genoa	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	GAMBINO, Roberto/AAC-7517-2022; Camussi, Giovanni/J-7624-2016; Brizzi, Maria Felice/J-7882-2016	GAMBINO, Roberto/0000-0003-1902-3627; Camussi, Giovanni/0000-0003-2795-232X; DEFERRARI, GIACOMO/0000-0001-8703-2416				Al-Douahji M, 1999, KIDNEY INT, V56, P1691, DOI 10.1046/j.1523-1755.1999.00728.x; Amiri F, 2002, KIDNEY INT, V61, P1605, DOI 10.1046/j.1523-1755.2002.00311.x; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; Brizzi MF, 2002, DIABETES, V51, P3311, DOI 10.2337/diabetes.51.11.3311; Brizzi MF, 2002, J CLIN INVEST, V109, P111, DOI 10.1172/JCI13617; Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; Bussolati B, 1999, AM J PATHOL, V154, P623, DOI 10.1016/S0002-9440(10)65307-2; Chen S, 2000, KIDNEY INT, V58, pS40, DOI 10.1046/j.1523-1755.2000.07707.x; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; COHEN MP, 1995, MOL CELL BIOCHEM, V151, P61, DOI 10.1007/BF01076897; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; Cohen MP, 1999, AM J PHYSIOL-RENAL, V276, pF684, DOI 10.1152/ajprenal.1999.276.5.F684; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Feliers D, 2002, DIABETES, V51, P3290, DOI 10.2337/diabetes.51.11.3290; Forbes JM, 2003, J AM SOC NEPHROL, V14, pS254, DOI 10.1097/01.ASN.0000077413.41276.17; Franch HA, 1996, AM J PHYSIOL-CELL PH, V270, pC932, DOI 10.1152/ajpcell.1996.270.3.C932; Griffin SV, 2003, SEMIN NEPHROL, V23, P569, DOI 10.1053/S0270-9295(03)00133-5; Guh JY, 2001, AM J KIDNEY DIS, V38, P1096, DOI 10.1053/ajkd.2001.28616; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Jerums G, 2003, ARCH BIOCHEM BIOPHYS, V419, P55, DOI 10.1016/j.abb.2003.08.017; Kim YS, 2001, J LAB CLIN MED, V138, P59, DOI 10.1067/mlc.2001.115494; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Lam S, 2003, DIABETES, V52, P2975, DOI 10.2337/diabetes.52.12.2975; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; Miele C, 2003, J BIOL CHEM, V278, P47376, DOI 10.1074/jbc.M301088200; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Preisig P, 1999, KIDNEY INT, V56, P1193, DOI 10.1046/j.1523-1755.1999.00708.x; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Takeuchi M, 2001, MOL MED, V7, P783, DOI 10.1007/BF03401969; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; Wang XD, 2002, DIABETES, V51, P3505, DOI 10.2337/diabetes.51.12.3505; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097; ZIYADEH FN, 1993, MOL CELL BIOCHEM, V125, P19, DOI 10.1007/BF00926830; ZIYADEH FN, 1997, KIDNEY INT S, V60, P7	50	45	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1249	+		10.1096/fj.03-1053fje	http://dx.doi.org/10.1096/fj.03-1053fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180953				2022-12-25	WOS:000222327500034
J	Jones, DP; Go, YM; Anderson, CL; Ziegler, TR; Kinkade, JM; Kirlin, WG				Jones, DP; Go, YM; Anderson, CL; Ziegler, TR; Kinkade, JM; Kirlin, WG			Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control	FASEB JOURNAL			English	Article						proliferation; differentiation; apoptosis; phase 2 enzymes; oxidative stress	DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; CACO-2 CELLS; HUMAN PLASMA; GLUTATHIONE; THIOREDOXIN; APOPTOSIS; THIOL; STATE	Redox mechanisms function in control of gene expression, cell proliferation, and apoptosis, but the circuitry for redox signaling remains unclear. Cysteine and methionine are the only amino acids in proteins that undergo reversible oxidation/reduction under biologic conditions and, as such, provide a means for control of protein activity, protein-protein interaction, protein trafficking, and protein-DNA interaction. Hydrogen peroxide and other reactive oxygen species (ROS) provide a mechanism to oxidize signaling proteins. However, oxidation of sulfur-containing side chains of cysteine and methionine by ROS can result in oxidation states of sulfur (e.g., sulfinate, sulfonate, sulfone) that are not reducible under biologic conditions. Thus, mechanisms for oxidation that protect against over-oxidation of these susceptible residues and prevent irreversible loss of activity would be advantageous. The present study shows that the steady-state redox potential of the cysteine/cystine couple (E-h = -145 mV) in cells is sufficiently oxidized (>90 mV) relative to the GSH/GSSG (-250 mV) and thioredoxin (Trx1, -280 mV) redox couples for the cysteine/cystine couple to function as an oxidant in redox switching. Consequently, the cysteine/cystine couple provides a means to oxidize proteins without direct involvement of more potent oxidants. A circuitry model incorporating cysteine as a redox node, along with Trx1 and GSH, reveals how selective interactions between the different thiol/disulfide couples and reactive protein thiols could differentially regulate metabolic functions. Moreover, inclusion of cysteine/cystine as a signaling node distinct from GSH and Trx1 significantly expands the redox range over which protein thiol/disulfide couples may operate to control physiologically relevant processes.	Emory Univ, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA; Emory Univ, Ctr Clin & Mol Nutr, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr Hlth Sci, Atlanta, GA 30322 USA; Morehouse Sch Med, Dept Pharmacol & Toxicol, Atlanta, GA 30310 USA	Emory University; Emory University; Emory University; Emory University; Emory University; Morehouse School of Medicine	Jones, DP (corresponding author), Emory Univ, Dept Med, 4131 Rollins Res Ctr, Atlanta, GA 30322 USA.	jpjones@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES009313, R01ES011195, R01ES009047] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55850] Funding Source: Medline; NIEHS NIH HHS [ES011195, ES09313, ES09047] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Fayos BE, 1997, ENDOTHELIUM-J ENDOTH, V5, P339, DOI 10.3109/10623329709052598; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Kwon YH, 2001, AM J PHYSIOL-ENDOC M, V280, pE804, DOI 10.1152/ajpendo.2001.280.5.E804; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; LASH LH, 1986, ARCH BIOCHEM BIOPHYS, V247, P120, DOI 10.1016/0003-9861(86)90540-0; Lawrence CL, 2002, FASEB J, V16, pA996; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MANNERVIK B, 1983, BIOCHEM J, V213, P519, DOI 10.1042/bj2130519; Miller LT, 2002, J NUTR, V132, P2303, DOI 10.1093/jn/132.8.2303; MILLER LT, 2001, THESIS EMORY U ATLAN; Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002; Noda T, 2002, CELL PROLIFERAT, V35, P117, DOI 10.1046/j.1365-2184.2002.00229.x; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; REED DJ, 1978, FUNCTIONS GLUTATHION, P13; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Sies H., 1982, METABOLIC COMPARTMEN, P205; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Watson WH, 2003, FEBS LETT, V543, P144, DOI 10.1016/S0014-5793(03)00430-7; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	38	226	245	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1246	+		10.1096/fj.03-0971fje	http://dx.doi.org/10.1096/fj.03-0971fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180957				2022-12-25	WOS:000222327500035
J	Jiang, HD; Liu, XY				Jiang, HD; Liu, XY			Principles of mimicking and engineering the self-organized structure of hard tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEATION; EPIPHYSEAL CARTILAGE; LIQUID NUCLEATION; HYDROXYAPATITE; MACROMOLECULES; CALCIFICATION; AGGREGATION; INDUCTION; CRYSTALS; MATRIX	The mechanism of the formation of a self-aligned hydroxyapatite (HAP) nanocrystallite structure was examined. It is found that the highly ordered HAP nanocrystallite assembly is attributed to the so-called self(homo)epitaxial nucleation and growth. On the other hand, according to this mechanism, a high supersaturation will give rise to a random assembly of HAP crystallites. The effects of ions, biosubstrate, and supersaturation on the micro/nanostructure correlation between substrate and biominerals as well as their implications in hard tissue formation were examined. Surprisingly, some biomolecules are found to be able to suppress the supersaturation-driven interfacial structure mismatch and hence promote the well aligned HAP pattern formation.	Natl Univ Singapore, Dept Phys, Singapore 117542, Singapore	National University of Singapore	Jiang, HD (corresponding author), Natl Univ Singapore, Dept Phys, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Zhou, Weiqian/B-8991-2011; Liu, XY/E-5090-2010; Li, Jingliang/A-6039-2011	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246; Liu, Xiang-Yang/0000-0002-5592-6885				ALI SY, 1973, BIOCHEM J, V134, P647, DOI 10.1042/bj1340647; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BERMAN A, 1993, SCIENCE, V259, P776, DOI 10.1126/science.259.5096.776; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; CHERNOV AA, 1984, MODERN CRYSTALLOGRAP, V3, P225; Elliott JC, 1994, STRUCTURE CHEM APATI, P111; EVERETT DH, 1994, BASIC PRINCIPLES COL, P185; Gebhardt M., 1972, CRYSTAL GROWTH INTRO, P105; GLIMCHER MJ, 1989, P 3 INT C CHEM BIOL, P617; HARRIS DC, 1999, QUANTITATIVE CHEM AN, P175; HUNTER GK, 1989, J THEOR BIOL, V138, P195, DOI 10.1016/S0022-5193(89)80139-0; KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi N, 2004, KEY ENG MATER, V254-2, P537, DOI 10.4028/www.scientific.net/KEM.254-256.537; KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306; LAAKSONEN A, 1995, ANNU REV PHYS CHEM, V46, P489, DOI 10.1146/annurev.pc.46.100195.002421; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 1999, J CHEM PHYS, V111, P1628, DOI 10.1063/1.479391; Liu XY, 2003, J AM CHEM SOC, V125, P888, DOI 10.1021/ja020355d; Liu XY, 2000, J CHEM PHYS, V112, P9949, DOI 10.1063/1.481644; Liu XY, 2000, LANGMUIR, V16, P7337, DOI 10.1021/la991333g; Liu XY, 2000, J CHEM PHYS, V113, P4408, DOI 10.1063/1.1288030; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MCDOWELL H, 1977, J RES NBS A PHYS CH, V81, P273, DOI 10.6028/jres.081A.017; McGraw R, 1996, PHYS REV LETT, V76, P2754, DOI 10.1103/PhysRevLett.76.2754; MOSS M, 1965, ORAL SURG ORAL MED O, V20, P795, DOI 10.1016/0030-4220(65)90143-X; Oxtoby DW, 2000, NATURE, V406, P464, DOI 10.1038/35020163; Rodriguez-Clemente R, 1998, J EUR CERAM SOC, V18, P1351, DOI 10.1016/S0955-2219(98)00064-8; Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756-3282(97)00149-X; Siesser, 1994, COCCOLITHOPHORES, P51; SOHNEL O, 1988, J COLLOID INTERF SCI, V123, P43, DOI 10.1016/0021-9797(88)90219-6; Ten Cate A.R., 1985, ORAL HISTOLOGY DEV S; WEAKLIEM CL, 1994, J CHEM PHYS, V101, P2398, DOI 10.1063/1.467680; WINTER WT, 1978, J MOL BIOL, V125, P1, DOI 10.1016/0022-2836(78)90251-6; ZENG XC, 1991, J CHEM PHYS, V94, P4472, DOI 10.1063/1.460603; Zettlemoyer A. C., 1969, NUCLEATION	37	40	40	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41286	41293		10.1074/jbc.M314027200	http://dx.doi.org/10.1074/jbc.M314027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15192103	hybrid			2022-12-25	WOS:000224075500007
J	Vo, TD; Greenberg, HJ; Palsson, BO				Vo, TD; Greenberg, HJ; Palsson, BO			Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-COMPOSITION; FLUX-BALANCE ANALYSIS; HEART-MITOCHONDRIA; ENERGY-METABOLISM; CARRIER; TRANSPORT; PHOSPHATIDYLSERINE; ORGANIZATION; BIOGENESIS; OXIDATION	Diverse datasets including genomic, proteomic, isotopomer, and DNA sequence variation are becoming available for human mitochondria. Thus there is a need to integrate these data within an in silico modeling framework where mitochondrial biology and related disorders can be studied and analyzed. This paper reports a reconstruction and characterization of the human mitochondrial metabolic network based on proteomic and biochemical data. The 189 reactions included in this reconstruction are both elementally and charge-balanced and are assigned to their respective cellular compartments (mitochondrial, cytosol, or extracellular). The capabilities of the reconstructed network to fulfill three metabolic functions (ATP production, heme synthesis, and mixed phospholipid synthesis) were determined. Network-based analysis of the mitochondrial energy conversion process showed that the overall ATP yield per glucose is 31.5. Network flexibility, characterized by allowable variation in reaction fluxes, was evaluated using flux variability analysis and analysis of all of the possible optimal flux distributions. Results showed that the network has high flexibility for the biosynthesis of heme and phospholipids but modest flexibility for maximal ATP production. A subset of all of the optimal network flux distributions, computed with respect to the three metabolic functions individually, was found to be highly correlated, suggesting that this set may contain physiological meaningful fluxes. Examinations of optimal flux distributions also identified correlated reaction sets that form functional modules in the network.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Colorado, Dept Math, Denver, CO 80217 USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Denver	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr,POB 0412, La Jolla, CA 92093 USA.	bpalsson@be-research.ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785				Aimar-Beurton M, 2002, MOL BIOL REP, V29, P227, DOI 10.1023/A:1020338115406; ANDERSON ED, 2002, MOSEK APS; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Antunes F, 2002, FREE RADICAL BIO MED, V33, P1260, DOI 10.1016/S0891-5849(02)01016-X; Atamna H, 2002, ARCH BIOCHEM BIOPHYS, V397, P345, DOI 10.1006/abbi.2001.2671; Avis D, 2000, DMV SEMINAR, V29, P177; AVIS D, 2003, IRS; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Brown G.C.N.D.G., 1999, MITOCHONDRIA CELL DE; BUNGER R, 1993, BIOCHIM BIOPHYS ACTA, V1151, P223, DOI 10.1016/0005-2736(93)90107-B; Burgard AP, 2004, GENOME RES, V14, P301, DOI 10.1101/gr.1926504; CAREW JS, 2002, MOL CANC; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Duarte NC, 2004, GENOME RES, V14, P1298, DOI 10.1101/gr.2250904; Edwards JS, 2000, BMC BIOINFORMATICS, V1, DOI 10.1186/1471-2105-1-1; Edwards JS, 2002, BIOTECHNOL BIOENG, V77, P27, DOI 10.1002/bit.10047; EDWARDS JS, 1999, METAB ENG, P13; Fiermonte G, 1999, BIOCHEM J, V344, P953, DOI 10.1042/0264-6021:3440953; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; *GAMS DEV CORP, 2003, GAMS; *GEN, 2003, SYMPHENY; GLOSTER J, 1969, CARDIOVASC RES, V3, P45, DOI 10.1093/cvr/3.1.45; GLOSTER J, 1970, Journal of Molecular and Cellular Cardiology, V1, P459, DOI 10.1016/0022-2828(70)90042-8; Grynberg A, 1996, J CARDIOVASC PHARM, V28, pS11; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; Kauffman KJ, 2003, CURR OPIN BIOTECH, V14, P491, DOI 10.1016/j.copbio.2003.08.001; Korzeniewski B, 1996, BIOCHEM J, V319, P143, DOI 10.1042/bj3190143; Lee S, 2000, COMPUT CHEM ENG, V24, P711, DOI 10.1016/S0098-1354(00)00323-9; Lehninger A., 1993, PRINCIPLES BIOCH; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; *MATHWORKS INC, 2003, MATLAB; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; Ozawa T, 2003, NAT BIOTECHNOL, V21, P287, DOI 10.1038/nbt791; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Papin JA, 2002, J THEOR BIOL, V215, P67, DOI 10.1006/jtbi.2001.2499; Papin JA, 2002, GENOME RES, V12, P1889, DOI 10.1101/gr.327702; Phalakornkule C, 2001, METAB ENG, V3, P124, DOI 10.1006/mben.2000.0165; Price ND, 2002, BIOPHYS J, V83, P2879, DOI 10.1016/S0006-3495(02)75297-1; Price ND, 2002, GENOME RES, V12, P760, DOI 10.1101/gr.218002; Ramakrishna R, 2001, AM J PHYSIOL-REG I, V280, pR695, DOI 10.1152/ajpregu.2001.280.3.R695; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; ROCQUELIN G, 1989, LIPIDS, V24, P775, DOI 10.1007/BF02544583; ROCQUELIN G, 1985, J MOL CELL CARDIOL, V17, P769, DOI 10.1016/S0022-2828(85)80038-9; Salway J.G., 2017, METABOLISM GLANCE; Santos DL, 2003, MOL CELL BIOCHEM, V246, P163, DOI 10.1023/A:1023475022025; Schilling CH, 2000, J THEOR BIOL, V203, P229, DOI 10.1006/jtbi.2000.1073; Searcy DG, 2003, CELL RES, V13, P229, DOI 10.1038/sj.cr.7290168; SEDMAN R, 1982, BIOCHEM PHARMACOL, V31, P761, DOI 10.1016/0006-2952(82)90460-9; Sherry AD, 2004, METAB ENG, V6, P12, DOI 10.1016/j.ymben.2003.10.007; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Verma M, 2003, NAT REV CANCER, V3, P789, DOI 10.1038/nrc1192; Voet D, 1999, FUNDAMENTALS BIOCH; Vu TH, 2002, NEUROL CLIN, V20, P809, DOI 10.1016/S0733-8619(01)00017-2; Westermann B, 2003, NAT BIOTECHNOL, V21, P239, DOI 10.1038/nbt0303-239; Williamson J R, 1980, Ann N Y Acad Sci, V341, P593, DOI 10.1111/j.1749-6632.1980.tb47201.x	65	110	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39532	39540		10.1074/jbc.M403782200	http://dx.doi.org/10.1074/jbc.M403782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15205464	hybrid			2022-12-25	WOS:000223791500043
J	Bhattacharya, A; Lakhman, SS; Singh, S				Bhattacharya, A; Lakhman, SS; Singh, S			Modulation of L-type calcium channels in Drosophila via a pituitary adenylyl cyclase-activating polypeptide (PACAP)-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARVAL MUSCLE-FIBERS; POTASSIUM CURRENTS; CA2+ CHANNEL; PACAP; RELEASE; CELLS; NEUROPEPTIDE; RECEPTORS; SECRETION; TRANSCRIPTION	Modulation of calcium channels plays an important role in many cellular processes. Previous studies have shown that the L-type Ca2+ channels in Drosophila larval muscles are modulated via a cAMP-protein kinase A (PKA)-mediated pathway. This raises questions on the identity of the steps prior to cAMP, particularly the endogenous signal that may initiate this modulatory cascade. We now present data suggesting the possible role of a neuropeptide, pituitary adenylyl cyclase-activating polypeptide ( PACAP), in this modulation. Mutations in the amnesiac (amn) gene, which encodes a polypeptide homologous to human PACAP-38, reduced the L-type current in larval muscles. Conditional expression of a wild-type copy of the amn gene rescued the current from this reduction. Bath application of human PACAP-38 also rescued the current. PACAP-38 did not rescue the mutant current in the presence of PACAP-6 38, an antagonist at type-I PACAP receptor. 2', 5'-dideoxyadenosine, an inhibitor of adenylyl cyclase, prevented PACAP-38 from rescuing the amn current. In addition, 2', 5'-dideoxyadenosine reduced the wild-type current to the level seen in amn, whereas it failed to further reduce the current observed in amn muscles. H-89, an inhibitor of PKA, suppressed the effect of PACAP-38 on the current. The above data suggest that PACAP, the type-I PACAP receptors, and adenylyl cyclase play a role in the modulation of L-type Ca2+ channels via cAMP-PKA pathway. The data also provide support for functional homology between human PACAP-38 and the amn gene product in Drosophila.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Singh, S (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, 102 Farber Hall, Buffalo, NY 14214 USA.	singhs@buffalo.edu			NIGMS NIH HHS [GM-50779] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050779] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIDLEY DJ, 1998, PHYSL EXCITABLE CELS; Akiyama M, 2001, J NEUROCHEM, V78, P499, DOI 10.1046/j.1471-4159.2001.00452.x; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Ashburner M., 1989, DROSOPHILA LAB HDB; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Bhattacharya A, 1999, J NEUROBIOL, V39, P491, DOI 10.1002/(SICI)1097-4695(19990615)39:4<491::AID-NEU3>3.0.CO;2-6; Chang CH, 1998, AM J PHYSIOL-GASTR L, V275, pG192, DOI 10.1152/ajpgi.1998.275.2.G192; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CHOPRA M, 1994, J NEUROBIOL, V25, P119, DOI 10.1002/neu.480250204; Cooper EC, 1999, P NATL ACAD SCI USA, V96, P4759, DOI 10.1073/pnas.96.9.4759; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; Davies NP, 2003, CURR OPIN NEUROL, V16, P559, DOI 10.1097/00019052-200310000-00001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DeZazzo J, 1999, J NEUROSCI, V19, P8740, DOI 10.1523/JNEUROSCI.19-20-08740.1999; Dubnau J, 1998, ANNU REV NEUROSCI, V21, P407, DOI 10.1146/annurev.neuro.21.1.407; Dziema H, 2002, J NEUROPHYSIOL, V88, P1374, DOI 10.1152/jn.2002.88.3.1374; EVANS PD, 1978, J EXP BIOL, V73, P235; EVANS PD, 1988, MOL BASIS DRUG PESTI; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Geng GJ, 1997, AM J PHYSIOL-REG I, V273, pR1339, DOI 10.1152/ajpregu.1997.273.4.R1339; GHO M, 1986, PFLUG ARCH EUR J PHY, V407, P526, DOI 10.1007/BF00657511; GIELOW ML, 1995, J NEUROSCI, V15, P6085; Gu GG, 1997, J NEUROBIOL, V33, P265, DOI 10.1002/(SICI)1097-4695(199709)33:3<265::AID-NEU5>3.0.CO;2-#; Hashimoto H, 2002, BIOCHEM BIOPH RES CO, V297, P427, DOI 10.1016/S0006-291X(02)02144-7; Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498; Hernandez M, 2004, BRIT J PHARMACOL, V141, P123, DOI 10.1038/sj.bjp.0705582; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Lindstrom E, 2001, J PHYSIOL-LONDON, V535, P663, DOI 10.1111/j.1469-7793.2001.00663.x; Martinez-Fuentes AJ, 1998, ENDOCRINOLOGY, V139, P5116, DOI 10.1210/en.139.12.5116; Maturana A, 2002, J BIOL CHEM, V277, P39713, DOI 10.1074/jbc.M200464200; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Miller RJ, 1997, TRENDS NEUROSCI, V20, P189, DOI 10.1016/S0166-2236(96)01037-5; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Shibuya I, 1998, J NEUROENDOCRINOL, V10, P31, DOI 10.1046/j.1365-2826.1998.00168.x; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Takeuchi T, 2004, REGUL PEPTIDES, V118, P1, DOI 10.1016/j.regpep.2003.10.033; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; Vaudry D, 2000, PHARMACOL REV, V52, P269; Waddell S, 2001, ANNU REV NEUROSCI, V24, P1283, DOI 10.1146/annurev.neuro.24.1.1283; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; WU CF, 1985, J NEUROSCI, V5, P2626; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Xiao D, 2002, NEUROENDOCRINOLOGY, V76, P325, DOI 10.1159/000066627; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7; Zhou CJ, 2002, CURR PROTEIN PEPT SC, V3, P423, DOI 10.2174/1389203023380576	60	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37291	37297		10.1074/jbc.M403819200	http://dx.doi.org/10.1074/jbc.M403819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201281	hybrid			2022-12-25	WOS:000223554600013
J	Li, DL; Xiao, YC; Xu, X; Xiong, XY; Lu, SY; Liu, ZH; Zhu, Q; Wang, MC; Gu, XC; Liang, SP				Li, DL; Xiao, YC; Xu, X; Xiong, XY; Lu, SY; Liu, ZH; Zhu, Q; Wang, MC; Gu, XC; Liang, SP			Structure-activity relationships of hainantoxin-IV and structure determination of active and inactive sodium channel Blockers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; MOLECULAR-MECHANISMS; SECONDARY STRUCTURE; CONUS-GEOGRAPHUS; CHEMICAL-SHIFT; MUSCLE; INHIBITOR; NMR; BINDING; SITE	Hainantoxin-IV (HNTX-IV) can specifically inhibit the neuronal tetrodotoxin-sensitive sodium channels and defines a new class of depressant spider toxin. The sequence of native HNTX-IV is ECLGFGKGCNPSNDQC-CKSSNLVCSRKHRWCKYEI-NH2. In the present study, to obtain further insight into the primary and tertiary structural requirements of neuronal sodium channel blockers, we determined the solution structure of HNTX-IV as a typical inhibitor cystine knot motif and synthesized four mutants designed based on the predicted sites followed by structural elucidation of two inactive mutants. Pharmacological studies indicated that the S12A and R26A mutants had activities near that of native HNTX-IV, while K27A and R29A demonstrated activities reduced by 2 orders of magnitude. H-1 MR analysis showed the similar molecular conformations for native HNTX-IV and four synthetic mutants. Furthermore, in the determined structures of K27A and R29A, the side chains of residues 27 and 29 were located in the identical spatial position to those of native HNTX-IV. These results suggested that residues Ser(12), Arg(26), Lys(27), and Arg(29) were not responsible for stabilizing the distinct conformation of HNTX-IV, but Lys(27) and Arg(29) were critical for the bioactivities. The potency reductions produced by Ala substitutions were primarily due to the direct interaction of the essential residues Lys27 and Arg29 with sodium channels rather than to a conformational change. After comparison of these structures and activities with correlated toxins, we hypothesized that residues Lys(27), Arg(29), His(28), Lys(32), Phe(5), and Trp(30) clustered on one face of HNTX-IV were responsible for ligand binding.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Hunan Normal University; Peking University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China.	liangsp@hunnu.edu.cn	Xiao, Yucheng/H-3600-2012					BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; FUHRMAN FA, 1967, SCI AM, V217, P61, DOI 10.1038/scientificamerican0867-60; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hu ZH, 1997, J PHYSIOL-LONDON, V501, P67, DOI 10.1111/j.1469-7793.1997.067bo.x; Hui KY, 2002, J GEN PHYSIOL, V119, P45, DOI 10.1085/jgp.119.1.45; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Li RA, 2002, FEBS LETT, V511, P159, DOI 10.1016/S0014-5793(01)03316-6; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; Liu Z, 2003, CELL MOL LIFE SCI, V60, P972, DOI 10.1007/s00018-003-2354-x; Liu ZH, 2002, ACTA BIOCH BIOPH SIN, V34, P516; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; Nakamura M, 2001, FEBS LETT, V503, P107, DOI 10.1016/S0014-5793(01)02714-4; Nielsen KJ, 2002, J BIOL CHEM, V277, P27247, DOI 10.1074/jbc.M201611200; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Safo P, 2000, J NEUROSCI, V20, P76, DOI 10.1523/JNEUROSCI.20-01-00076.2000; SATO K, 1991, J BIOL CHEM, V266, P16989; SCHANTZ EJ, 1986, ANN NY ACAD SCI, V479, P15, DOI 10.1111/j.1749-6632.1986.tb15557.x; Shon KJ, 1998, J NEUROSCI, V18, P4473; SZILAGYI L, 1989, J MAGN RESON, V83, P441, DOI 10.1016/0022-2364(89)90341-7; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Xiao YC, 2003, TOXICON, V41, P643, DOI 10.1016/S0041-0101(02)00280-5; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; YANAGAWA Y, 1987, J NEUROSCI, V7, P1498; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhu Q, 2002, BIOCHEMISTRY-US, V41, P11488, DOI 10.1021/bi026136m	42	55	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37734	37740		10.1074/jbc.M405765200	http://dx.doi.org/10.1074/jbc.M405765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201273	hybrid			2022-12-25	WOS:000223554600065
J	Anthony, TG; McDaniel, BJ; Byerley, RL; McGrath, BC; Cavener, DDR; McNurlan, MA; Wek, RC				Anthony, TG; McDaniel, BJ; Byerley, RL; McGrath, BC; Cavener, DDR; McNurlan, MA; Wek, RC			Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; TRANSLATIONAL CONTROL; EIF2-ALPHA KINASE; MAMMALIAN HOMOLOG; MESSENGER-RNA; ACTIVATION; STRESS; MTOR; PHOSPHORYLATION; AVAILABILITY	In eukaryotic cells, amino acid depletion reduces translation by a mechanism involving phosphorylation of eukaryotic initiation factor-2 (eIF2). Herein we describe that mice lacking the eIF2 kinase, general control nonderepressible 2 (GCN2) fail to alter the phosphorylation of this initiation factor in liver, and are moribund in response to dietary leucine restriction. Wild-type (GCN2(+/+)) and two strains of GCN2 null (GCN2(-/-)) mice were provided a nutritionally complete diet or a diet devoid of leucine or glycine for 1 h or 6 days. In wildtype mice, dietary leucine restriction resulted in loss of body weight and liver mass, yet mice remained healthy. In contrast, a significant proportion of GCN2(-/-) mice died within 6 days of the leucine-deficient diet. Protein synthesis in wild-type livers was decreased concomitant with increased phosphorylation of eIF2 and decreased phosphorylation of 4E-BP1 and S6K1, translation regulators controlled nutritionally by mammalian target of rapamycin. Whereas translation in the liver was decreased independent of GCN2 activity in mice fed a leucine-free diet for 1 h, protein synthesis in GCN2(-/-) mice at day 6 was enhanced to levels measured in mice fed the complete diet. Interestingly, in addition to a block in eIF2 phosphorylation, phosphorylation of 4E-BP1 and S6K1 was not decreased in GCN2(-/-) mice deprived of leucine for 6 days. This suggests that GCN2 activity can also contribute to nutritional regulation of the mammalian target of rapamycin pathway. As a result of the absence of these translation inhibitory signals, liver weights were preserved and instead, skeletal muscle mass was reduced in GCN2(-/-) mice fed a leucine-free diet. This study indicates that loss of GCN2 eIF2 kinase activity shifts the normal maintenance of protein mass away from skeletal muscle to provide substrate for continued hepatic translation.	Indiana Univ Sch Med, Dept Biochem & Mol Biol, Evansville, IN 47712 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; SUNY Stony Brook, Dept Surg, Stony Brook, NY 11794 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Indiana University System; Indiana University-Purdue University Indianapolis	Anthony, TG (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, 8600 Univ Blvd, Evansville, IN 47712 USA.	tganthon@iupui.edu	Cavener, Douglas R/E-3524-2010; Anthony, Tracy/K-7951-2017	Anthony, Tracy/0000-0002-8586-5884; Reinert, Rachel/0000-0001-7778-4219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017446] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG 17446] Funding Source: Medline; NIGMS NIH HHS [R01 GM 49164] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony TG, 2001, AM J PHYSIOL-ENDOC M, V281, pE430, DOI 10.1152/ajpendo.2001.281.3.E430; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; BEVERLY JL, 1990, AM J PHYSIOL, V259, pR716, DOI 10.1152/ajpregu.1990.259.4.R716; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; CASO G, 2002, PRESS, P1; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Gietzen DW, 2004, J NUTR, V134, P717, DOI 10.1093/jn/134.4.717; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jefferson LS, 2003, J NUTR, V133, p2046S, DOI 10.1093/jn/133.6.2046S; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kahn C Ronald, 2003, Exp Diabesity Res, V4, P169, DOI 10.1155/EDR.2003.169; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kimball Sr, 2004, TOP CURR GENET, V7, P113; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Kobayashi H, 2003, AM J PHYSIOL-ENDOC M, V284, pE488, DOI 10.1152/ajpendo.00094.2002; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; LUNDHOLM K, 1991, ACTA PHYSIOL SCAND, V141, P207, DOI 10.1111/j.1748-1716.1991.tb09069.x; McNurlan MA, 1997, J CLIN INVEST, V100, P2125, DOI 10.1172/JCI119747; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; MORTIMORE GE, 1990, INT J BIOCHEM, V22, P1075, DOI 10.1016/0020-711X(90)90104-B; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026; PRONCZUK AW, 1970, J NUTR, V100, P1249, DOI 10.1093/jn/100.11.1249; Proud C G, 2004, Curr Top Microbiol Immunol, V279, P215; Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015; SAID AK, 1970, J NUTR, V100, P1363, DOI 10.1093/jn/100.11.1363; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sood R, 2000, GENETICS, V154, P787; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Wek RC, 2004, TOP CURR GENET, V7, P171; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WOODWARD CN, 1988, BIOCHEM MED METAB B, V39, P199, DOI 10.1016/0885-4505(88)90077-1; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	43	166	172	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36553	36561		10.1074/jbc.M404559200	http://dx.doi.org/10.1074/jbc.M404559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213227	hybrid			2022-12-25	WOS:000223453600051
J	Ellis, PD; Smith, CWJ; Kemp, P				Ellis, PD; Smith, CWJ; Kemp, P			Regulated tissue-specific alternative splicing of enhanced green fluorescent protein transgenes conferred by alpha-tropomyosin regulatory elements in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; MUTUALLY EXCLUSIVE EXON; MESSENGER-RNA; SMOOTH; GENE; SELECTION; ISOFORMS; SITE; MECHANISMS; EXPRESSION	The mutually exclusive exons 2 and 3 of alpha-tropomyosin (alphaTM) have been used as a model system for strictly regulated alternative splicing. Exon 2 inclusion is only observed at high levels in smooth muscle (SM) tissues, whereas striated muscle and non-muscle cells use predominantly exon 3. Experiments in cell culture have shown that exon 2 selection results from repression of exon 3 and that this repression is mediated by regulatory elements flanking exon 3. We have now tested the cell culture-derived model in transgenic mice. We show that by harnessing the intronic splicing regulatory elements, expression of an enhanced green fluorescent protein transgene with a constitutively active promoter can be restricted to SM cells. Splicing of both endogenous alphaTM and a series of transgenes carrying regulatory element mutations was analyzed by reverse transcriptase-PCR. These studies indicated that although SM-rich tissues are equipped to regulate splicing of high levels of endogenous or transgene alphaTM RNA, other non-SM tissues such as spleen, which express lower amounts of alphaTM, also splice significant proportions of exon 2, and this splicing pattern can be recapitulated by transgenes expressed at low levels. We confirm the importance in vivo of the negatively acting regulatory elements for regulated skipping of exon 3. Moreover, we provide evidence that some of the regulatory factors responsible for exon 3 skipping appear to be titratable, with loss of regulated splicing sometimes being associated with high transgene expression levels.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Smith, CWJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	cwjs1@cam.ac.uk; pk@mole.bio.cam.ac.uk		Kemp, Paul/0000-0001-8975-7293				Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blanchard EM, 1997, CIRC RES, V81, P1005; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DiDonato CJ, 2001, HUM MOL GENET, V10, P2727, DOI 10.1093/hmg/10.23.2727; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Gooding C, 2003, J BIOL CHEM, V278, P15201, DOI 10.1074/jbc.M210131200; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Gromak N, 2002, NUCLEIC ACIDS RES, V30, P3548, DOI 10.1093/nar/gkf480; Ichida M, 2000, J BIOL CHEM, V275, P15992, DOI 10.1074/jbc.275.21.15992; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; OWENS GK, 1995, PHYSIOL REV, V75, P487; Perez I, 1997, RNA, V3, P764; Rethinasamy P, 1998, CIRC RES, V82, P116; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Seipelt RL, 1998, MOL CELL BIOL, V18, P1042, DOI 10.1128/MCB.18.2.1042; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; Wagner E, 2002, J CELL SCI, V115, P3033; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	39	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36660	36669		10.1074/jbc.M405380200	http://dx.doi.org/10.1074/jbc.M405380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194683	hybrid			2022-12-25	WOS:000223453600065
J	Fu, CT; Bechberger, JF; Ozog, MA; Perbal, B; Naus, CC				Fu, CT; Bechberger, JF; Ozog, MA; Perbal, B; Naus, CC			CCN3 (NOV) interacts with connexin43 in C6 glioma cells - Possible mechanism of connexin-mediated growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; TISSUE GROWTH; INTERCELLULAR COMMUNICATION; POTENTIAL ROLE; EXPRESSION; GENE; FAMILY; REGULATORS; TUMORIGENICITY; TRANSFECTION	Many tumor cells exhibit aberrant gap junctional intercellular communication, which can be restored by transfection with connexin genes. We have previously discovered that overexpression of connexin43 (Cx43) in C6 glioma cells not only reduces proliferation but also leads to production of soluble growth-inhibitory factors. We identified that several members of the CCN ((C) under bar yr61/(c) under bar onnective tissue growth factor/(n) under bar ephroblastoma-over-expressed) family are up-regulated following Cx43 expression, including CCN3 (NOV). We now report evidence for an association between CCN3 and Cx43. Western blot analysis demonstrated that the 48-kDa full-length CCN3 protein was present in the lysate and conditioned medium of growth-suppressed C6-Cx43 cells, as well as primary astrocytes, but not in C6 parental and human glioma cells. Immunocytochemical examination of CCN3 revealed diffuse localization in parental C6 cells, whereas transfection of C6 cells with Cx43 (C6-Cx43) or with a modified Cx43 tagged to green fluorescent protein on its C terminus (Cx43-GFP) resulted in punctate staining, suggesting that CCN3 co-localizes with Cx43 in plaques at the plasma membrane. In cells expressing a C-terminal truncation of Cx43 (Cx43Delta244-382), this co-localization was lost. Glutathione S-transferase pull-down assay and co-immunoprecipitation demonstrated that CCN3 was able to physically interact with Cx43. In contrast, CCN3 was not found to associate with Cx43Delta244-382. Similar experiments revealed that CCN3 did not co-localize or associate with other connexins, including Cx40 or Cx32. Taken together, these data support an interaction of CCN3 with the C terminus of Cx43, which could play an important role in mediating growth control induced by specific gap junction proteins.	Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V6T 1Z3, Canada; Univ Paris 07, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France	University of British Columbia; UDICE-French Research Universities; Universite Paris Cite	Naus, CC (corresponding author), Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V6T 1Z3, Canada.	christian.naus@ubc.ca						ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Chevalier G, 1998, AM J PATHOL, V152, P1563; DEFEIJTER AW, 1990, MOL CARCINOGEN, V3, P54, DOI 10.1002/mc.2940030203; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P5628, DOI 10.1073/pnas.78.9.5628; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goldberg Gary S., 1994, In Vivo (Attiki), V8, P745; Goldberg GS, 2000, CANCER RES, V60, P6018; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; Huang RP, 1998, CANCER RES, V58, P5089; HUANG Y, 1993, BIOTECHNIQUES, V15, P989; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KALIMI GH, 1992, MOL CARCINOGEN, V5, P301, DOI 10.1002/mc.2940050411; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; McLeod TL, 2001, CELL COMMUN ADHES, V8, P441, DOI 10.3109/15419060109080767; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; MESNIL M, 1995, CANCER RES, V55, P629; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; Naus CCG, 2000, BRAIN RES REV, V32, P259, DOI 10.1016/S0165-0173(99)00087-9; NAUS CCG, 1996, GAP JUNCTIONS NERVOU; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 1999, J CLIN PATHOL-MOL PA, V52, P84, DOI 10.1136/mp.52.2.84; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; SWIERENGA SHH, 1992, IARC SCI PUBL, V116, P165; Thibout H, 2003, J CLIN ENDOCR METAB, V88, P327, DOI 10.1210/jc.2002-020304; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371; VANELDIK LJ, 1985, BIOCHEM BIOPH RES CO, V126, P825, DOI 10.1016/0006-291X(85)90259-1; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang YW, 2003, J BIOL CHEM, V278, P44852, DOI 10.1074/jbc.M305072200; Zhang YW, 2003, CANCER RES, V63, P1623; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	60	130	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36943	36950		10.1074/jbc.M403952200	http://dx.doi.org/10.1074/jbc.M403952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213231	hybrid			2022-12-25	WOS:000223453600097
J	Kakunaga, S; Ikeda, W; Shingai, T; Fujito, T; Yamada, A; Minami, Y; Imai, T; Takai, Y				Kakunaga, S; Ikeda, W; Shingai, T; Fujito, T; Yamada, A; Minami, Y; Imai, T; Takai, Y			Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS RECEPTOR; CONTACT INHIBITION; IMMUNOGLOBULIN SUPERFAMILY; ACTIVATION; PROTEIN; MIGRATION; NECTIN; MEMBER; CD155; CYCLE	Necl-5/Tage4/poliovirus receptor/CD155 has been shown to be the poliovirus receptor and to be up-regulated in rodent and human carcinoma. We have found previously that mouse Necl-5 regulates cell motility. We show here that mouse Necl-5 is furthermore involved in the regulation of cell proliferation. Studies using a specific antibody against Necl-5 and a dominant negative mutant of Necl-5 revealed that Necl-5 enhanced the serum-induced proliferation of NIH3T3, Swiss3T3, and mouse embryonic fibroblast cells. Necl-5 enhanced the serum-induced activation of the Ras-Raf-MEK-ERK signaling, up-regulated cyclins D2 and E, and down-regulated p27(Kip1), eventually shortening the period of the G(0)/G(1) phase of the cell cycle in NIH3T3 cells. Necl-5 similarly enhanced the platelet-derived growth factor-induced activation of the Ras-Raf-MEK-ERK signaling and shortened the period of the G(0)/G(1) phase of the cell cycle in NIH3T3 cells. Necl-5 acted downstream of the platelet-derived growth factor receptor and upstream of Ras. Moreover, up-regulated Necl-5 was involved at least partly in the enhanced proliferation of transformed cells including NIH3T3 cells transformed by an oncogenic Ras or v-Src. These results indicate that Necl-5 plays roles not only in cell motility but also in cell proliferation.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; MARTZ E, 1972, J CELL PHYSIOL, V79, P189, DOI 10.1002/jcp.1040790205; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ravens I, 2003, BIOCHEM BIOPH RES CO, V312, P1364, DOI 10.1016/j.bbrc.2003.11.067; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669	35	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36419	36425		10.1074/jbc.M406340200	http://dx.doi.org/10.1074/jbc.M406340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213219	hybrid			2022-12-25	WOS:000223453600033
J	Schiffer, M; Mundel, P; Shaw, AS; Bottinger, EP				Schiffer, M; Mundel, P; Shaw, AS; Bottinger, EP			A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; TGF-BETA; PODOCYTE; KINASE; ERK; ACTIVATION; SURVIVAL; NEPHRIN; NUMBER; FAMILY	CD2-associated protein (CD2AP) is an adaptor molecule involved in T cell receptor signaling and podocyte homeostasis. CD2AP-deficient mice develop nephrotic syndrome and renal failure caused by glomerulosclerosis. Here we report that increased transforming growth factor-beta1 (TGF-beta1) expression and apoptosis were present in podocytes at the onset of albuminuria and were followed by depletion of podocytes associated with progressive focal-segmental glomerulosclerosis in CD2AP-/- mice. Conditionally immortalized podocytes derived from CD2AP-/- mice were more susceptible to TGF-beta-induced apoptosis compared with CD2AP+/+ podocytes. Reconstitution of CD2AP rescued CD2AP-/- podocytes from TGF-beta-induced apoptosis. CD2AP was required for early activation of anti-apoptotic phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase 1/2 by TGF-beta. In contrast, activation of pro-apoptotic p38 MAPK by TGF-beta was accelerated and enhanced in the absence of CD2AP. CD2AP was not required for PI3K/AKT activation by insulin and epidermal growth factor, indicating that CD2AP is a selective mediator of anti-apoptotic TGF-beta signaling. In summary, we identified CD2AP as a novel mediator for selective activation of survival pathways and repression of apoptosis signaling by TGF-beta in podocytes. Together, our in vitro and in vivo findings suggest that TGF-beta-induced podocyte apoptosis is an early pathomechanism in mice developing focal-segmental glomerulosclerosis associated with functional impairment of CD2AP.	Mt Sinai Sch Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL)	Bottinger, EP (corresponding author), Mt Sinai Sch Med, 1 Gystave L Levy Pl,Box 1118, New York, NY 10029 USA.	bottinger@mssm.edu	Schiffer, Mario/U-7050-2019	Schiffer, Mario/0000-0002-8414-1470	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056077, R01DK060043] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 60043, R01 DK 56077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevan P, 2001, J CELL SCI, V114, P1429; BOHLE A, 1992, PATHOL RES PRACT, V188, P908, DOI 10.1016/S0344-0338(11)80252-9; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies CC, 2004, J BIOL CHEM, V279, P1010, DOI 10.1074/jbc.M303820200; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Fine LOC, 1998, KIDNEY INT S65, V65, P74; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629; KESTILA M, 1994, KIDNEY INT, V45, P986, DOI 10.1038/ki.1994.133; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kretzler M, 2001, FASEB J, V15, P1843, DOI 10.1096/fj.00-0832fje; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Li C, 2000, AM J PHYSIOL-RENAL, V279, pF785, DOI 10.1152/ajprenal.2000.279.4.F785; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447; Moustakas A, 2001, J CELL SCI, V114, P4359; Mundel P, 1998, ANN ANAT, V180, P391; Mundel P, 2001, Adv Nephrol Necker Hosp, V31, P235; Mundel P, 1996, EXP NEPHROL, V4, P263; Petermann AT, 2002, KIDNEY INT, V61, P40, DOI 10.1046/j.1523-1755.2002.00102.x; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; RENNKE HG, 1994, RENAL PATHOLOGY, P116; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Saleem MA, 2002, AM J PATHOL, V161, P1459, DOI 10.1016/S0002-9440(10)64421-5; Schiffer M, 2002, J AM SOC NEPHROL, V13, P2657, DOI 10.1097/01.ASN.0000033276.06451.50; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Shankland SJ, 1997, KIDNEY INT, V52, P294, DOI 10.1038/ki.1997.335; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Steffes MW, 2001, KIDNEY INT, V59, P2104, DOI 10.1046/j.1523-1755.2001.0590062104.x; Vogelmann SU, 2003, AM J PHYSIOL-RENAL, V285, pF40, DOI 10.1152/ajprenal.00404.2002; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Xu DZ, 2003, J BIOL CHEM, V278, P39349, DOI 10.1074/jbc.M302771200	41	168	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37004	37012		10.1074/jbc.M403534200	http://dx.doi.org/10.1074/jbc.M403534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213232	hybrid			2022-12-25	WOS:000223453600103
J	Engel, M; Mazurek, S; Eigenbrodt, E; Welter, C				Engel, M; Mazurek, S; Eigenbrodt, E; Welter, C			Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HETEROTRIMERIC G-PROTEINS; ENERGY PHOSPHATE TRANSFER; PYRUVATE-KINASE; 2,3-BISPHOSPHOGLYCERATE PHOSPHATASE; TRANSCRIPTION FACTOR; EXTRACELLULAR AMP; ENOLASE ACTIVITY; CREATINE-KINASE; NDPK-B	The putative tumor metastasis suppressor protein Nm23-H1 is a nucleoside diphosphate kinase that exhibits a novel protein kinase activity when bound to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In this study we show that the glycolytic enzyme phosphoglycerate mutase B (PGM) becomes phosphorylated in the presence of the Nm23-H1.GAPDH complex in vitro. Mutation of His-10 in PGM abolishes the Nm23-H1.GAPDH complex-induced phosphorylation. Nm23-H1, GAPDH, and PGM are known to co-localize as shown by free flow isoelectric focusing. In association with Nm23-H1 and GAPDH, PGM could be activated by dCTP, which is a substrate of Nm23-H1, in addition to the well known PGM activator 2,3-bisphosphoglycerate. A synthetic cell-penetrating peptide (PGMtide) encompassing the phosphorylated histidine and several residues from PGM (LIR (H) under bar GE) promoted growth arrest of several tumor cell lines, whereas proliferation of tested non-tumor cells was not influenced. Analysis of metabolic activity of one of the tumor cell lines, MCF-7, indicated that PGMtide inhibited glycolytic flux, consistent with in vivo inhibition of PGM. The specificity of the observed effect was further determined experimentally by testing the effect of PGMtide on cells growing in the presence of pyruvate, which helps to compensate PGM inhibition in the glycolytic pathway. Thus, growth of MCF-7 cells was not arrested by PGMtide in the presence of pyruvate. The data presented here provide evidence that inhibition of PGM activity can be achieved by exogenous addition of a polypeptide, resulting in inhibition of glycolysis and cell growth arrest in cell culture.	Univ Saarland, Dept Human Genet, Sch Med, D-66421 Homburg, Germany; Univ Giessen, Inst Biochem & Endocrinol, D-35392 Giessen, Germany	Saarland University; Justus Liebig University Giessen	Engel, M (corresponding author), PhosphoSites GmbH, Universitatskliniken Geb 7, Starterzentrum 3, D-66421 Homburg, Germany.	m.engel@phosphosites.com	Mazurek, Sybille/ABH-2089-2020					BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Bergmeyer H. U., 1974, METHODEN ENZYMATISCH, VI; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, V2; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boren J, 2003, J BIOL CHEM, V278, P28395, DOI 10.1074/jbc.M302932200; Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3; Cuello F, 2003, J BIOL CHEM, V278, P7220, DOI 10.1074/jbc.M210304200; Durany N, 1997, BRIT J CANCER, V75, P969, DOI 10.1038/bjc.1997.168; Durany N, 1997, BRIT J CANCER, V76, P1139, DOI 10.1038/bjc.1997.525; Durany N, 2000, BRIT J CANCER, V82, P20; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Hegde P, 2001, CANCER RES, V61, P7792; Hippe HJ, 2003, J BIOL CHEM, V278, P7227, DOI 10.1074/jbc.M210305200; HUGO F, 1992, J CELL PHYSIOL, V153, P539, DOI 10.1002/jcp.1041530315; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Mazurek S, 1996, J CELL PHYSIOL, V167, P238, DOI 10.1002/(SICI)1097-4652(199605)167:2<238::AID-JCP7>3.0.CO;2-Q; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 1998, ANTICANCER RES, V18, P3275; Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MEDINA MA, 1988, BIOCHEM INT, V16, P339; Otero AD, 2000, J BIOENERG BIOMEMBR, V32, P269, DOI 10.1023/A:1005589029959; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860; RYLL T, 1992, BIOTECHNOL BIOENG, V40, P934, DOI 10.1002/bit.260400810; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; STANKIEWICZ PJ, 1987, BIOCHEMISTRY-US, V26, P1264, DOI 10.1021/bi00379a010; Steeg PS, 2003, CANCER LETT, V190, P1, DOI 10.1016/S0304-3835(02)00499-8; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WAGNER P, 2001, BIOCHEM J, V346, P623; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; YEOH GCT, 1980, NATURE, V285, P108, DOI 10.1038/285108a0; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	42	50	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35803	35812		10.1074/jbc.M402768200	http://dx.doi.org/10.1074/jbc.M402768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181008	hybrid			2022-12-25	WOS:000223303400081
J	Yoshida, K; Inoue, I				Yoshida, K; Inoue, I			Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor	ONCOGENE			English	Article						MCM10; TopBP1; DNA replication; UV irradiation; promoter; E2F	DNA-DAMAGE; S-PHASE; REPLICATION ORIGINS; CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MICROARRAY ANALYSIS; IN-VIVO; PROTEIN; PRB; ACTIVATION	MCM10 and TopBP1 function in the initiation of DNA replication, by regulating the chromatin binding of the DNA polymerase a loading factor, CDC45. TopBP1 is also known as a DNA damage response protein. In this study, we showed that the transcription of human MCM10 and TopBP1 is activated by transcription factors E2F1-3, but not by factors E2F4-7. Analysis of various MCM10 and TopBP1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the E2F1-induced activation of MCM10 and TopBP1 gene transcription, which is further suppressed by pRb. The promoter activities of human MCM10 and TopBP1 were demonstrated to be growth dependent via the E2F-responsive sequence. Although E2F1 was stabilized by ultraviolet (UV) irradiation, the mRNA expression level of TopBP1 was suppressed in HCT116 human diploid colon cancer cells. We showed, by performing chromatin immunoprecipitation that, in response to UV irradiation but not doxorubicin treatment, E2F4 accumulated on the MCM10 and TopBP1 promoters. Our data suggest a model in which UV irradiation-induced DNA damage depends, at least in part, on the accumulation of the E2F4 transcription factor on the MCM10 and TopBP1 promoters, which results in suppression of DNA replication.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yoshidak@ims.u-tokyo.ac.jp						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blattner C, 1999, MOL CELL BIOL, V19, P3704; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Homesley L, 2000, GENE DEV, V14, P913; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lei M, 2001, J CELL SCI, V114, P1447; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin WC, 2001, GENE DEV, V15, P1833; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Moberg K, 1996, MOL CELL BIOL, V16, P1436; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Potter T, 2000, RADIAT RES, V154, P151, DOI 10.1667/0033-7587(2000)154[0151:KETURR]2.0.CO;2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi Y, 2000, GENE DEV, V14, P804; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	50	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6250	6260		10.1038/sj.onc.1207829	http://dx.doi.org/10.1038/sj.onc.1207829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195143				2022-12-25	WOS:000223399000009
J	Bhatnagar, A; Sheffler, DJ; Kroeze, WK; Compton-Toth, B; Roth, BL				Bhatnagar, A; Sheffler, DJ; Kroeze, WK; Compton-Toth, B; Roth, BL			Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected G alpha(q)-coupled protein receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HYDROXYTRYPTAMINE(2A) RECEPTOR; IN-VITRO; INDEPENDENT INTERNALIZATION; COUPLED RECEPTORS; DOWN-REGULATION; SALVINORIN-A; CELL BIOLOGY; NULL MICE; AGONIST; TRANSDUCTION	5-Hydroxytryptamine 2A (5-HT2A) serotonin receptors are important for a variety of functions including vascular smooth muscle contraction, platelet aggregation, and the modulation of perception, cognition, and emotion. In a search for 5-HT2A receptor-interacting proteins, we discovered that caveolin-1 (Cav-1), a scaffolding protein enriched in caveolae, complexes with 5-HT2A receptors in a number of cell types including C6 glioma cells, transfected HEK-293 cells, and rat brain synaptic membrane preparations. To address the functional significance of this interaction, we performed RNA interference-mediated knockdown of Cav-1 in C6 glioma cells, a cell type that endogenously expresses both 5-HT2A receptors and Cav-1. We discovered that the in vitro knockdown of Cav-1 in C6 glioma cells nearly abolished 5-HT2A receptor-mediated signal transduction as measured by calcium flux assays. RNA interference-mediated knockdown of Cav-1 also greatly attenuated endogenous Galpha(q)-coupled P2Y purinergic receptor-mediated signaling without altering the signaling of PAR-1 thrombin receptors. Cav-1 appeared to modulate 5-HT2A signaling by facilitating the interaction of 5-HT2A receptors with Galpha(q). These studies provide compelling evidence for a prominent role of Cav-1 in regulating the functional activity of not only 5-HT2A serotonin receptors but also selected Galpha(q)-coupled receptors.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Rm W441,2109 Adelbert Rd, Cleveland, OH 44106 USA.	bryan.roth@case.edu	Roth, Bryan L/F-3928-2010		NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001366, R01MH061887, R01MH057635] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 43703] Funding Source: Medline; NIMH NIH HHS [R01 MH 57635, R01 MH 61887, K02 MH 01366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Berry SA, 1996, MOL PHARMACOL, V50, P306; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DOYLE VM, 1986, N-S ARCH PHARMACOL, V333, P98, DOI 10.1007/BF00506510; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dreja K, 2002, ARTERIOSCL THROM VAS, V22, P1267, DOI 10.1161/01.ATV.0000023438.32585.A1; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNON RA, 1984, LIFE SCI, V35, P2505, DOI 10.1016/0024-3205(84)90436-3; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Gray JA, 2002, SCIENCE, V297, P529, DOI 10.1126/science.1075453; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Park H, 2000, AM J PHYSIOL-HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285; Park WY, 2001, ANN NY ACAD SCI, V928, P79; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Raymond JR, 2001, PHARMACOL THERAPEUT, V92, P179, DOI 10.1016/S0163-7258(01)00169-3; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; ROTH BL, 1981, J BIOL CHEM, V256, P117; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rothman RB, 2003, J PHARMACOL EXP THER, V307, P138, DOI 10.1124/jpet.103.053975; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saucier C, 1997, J NEUROCHEM, V68, P1998; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200	44	136	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34614	34623		10.1074/jbc.M404673200	http://dx.doi.org/10.1074/jbc.M404673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190056	hybrid, Green Published			2022-12-25	WOS:000223134800066
J	Miyazaki, M; Dobrzyn, A; Sampath, H; Lee, SH; Man, WC; Chu, K; Peters, JM; Gonzalez, FJ; Ntambi, JM				Miyazaki, M; Dobrzyn, A; Sampath, H; Lee, SH; Man, WC; Chu, K; Peters, JM; Gonzalez, FJ; Ntambi, JM			Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; CAUSES INSULIN-RESISTANCE; MESSENGER-RNA LEVELS; GENE-EXPRESSION; PROTEIN-KINASE; PPAR-GAMMA; TARGETED DISRUPTION; TISSUE DISTRIBUTION; SKELETAL-MUSCLE; UP-REGULATION	Stearoyl-CoA desaturase catalyzes the rate-limiting step in the biosynthesis of monounsaturated fatty acids, which are required for normal rates of synthesis of triglycerides, cholesterol esters, and phospholipids. Mice with a targeted disruption of the stearoyl-CoA desaturase 1 (SCD1) isoform are protected against diet and leptin deficiency-induced adiposity, have increased energy expenditure, and have up-regulated expression of hepatic genes encoding enzymes of fatty acid beta-oxidation. Because peroxisome proliferator-activated receptor-alpha( PPARalpha) is a key transcription factor that induces the transcription of fatty acid beta-oxidation and thermogenic genes, we hypothesized that the increased fatty acid oxidation observed in SCD1 deficiency is dependent on activation of the PPARalpha pathway. Here we show that mice nullizygous for SCD1 and PPARalpha are still protected against adiposity, have increased energy expenditure, and maintain high expression of PPARalpha target genes in the liver and brown adipose tissue. The SCD1 deficiency rescued hepatic steatosis of the PPARalpha(-/-) mice. The SCD1 mutation increased the phosphorylation of both AMP-activated protein kinase and acetylCoA carboxylase, thereby increasing CPT activity and stimulating the oxidation of liver palmitoyl-CoA in the PPARalpha null mice. The findings indicate that the reduced adiposity, reduced liver steatosis, increased energy expenditure, and increased expression of PPARalpha target genes associated with SCD1 deficiency are independent of activation of the PPARalpha pathway.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Peters, Jeffrey/D-8847-2011; Dobrzyn, Agnieszka/R-4073-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460; Peters, Jeffrey/0000-0003-2782-2998	NIDDK NIH HHS [R01 DK 62388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Akiyama TE, 2001, J BIOL CHEM, V276, P39088, DOI 10.1074/jbc.M107073200; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Cabrero A, 2000, ARCH BIOCHEM BIOPHYS, V380, P353, DOI 10.1006/abbi.2000.1927; Chen HC, 2003, AM J PHYSIOL-ENDOC M, V284, pE213, DOI 10.1152/ajpendo.00248.2002; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crowley V, 2001, NUTR METAB CARDIOVAS, V11, P70; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEE S, 2004, IN PRESS J LIPID RES; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1978, BIOCHIM BIOPHYS ACTA, V529, P201, DOI 10.1016/0005-2760(78)90063-2; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Minokoshi Y, 2003, BIOCHEM SOC T, V31, P196, DOI 10.1042/bst0310196; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2001, J BIOL CHEM, V276, P39455, DOI 10.1074/jbc.M106442200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Teruel T, 1999, BIOCHEM BIOPH RES CO, V264, P311, DOI 10.1006/bbrc.1999.1526; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WOODS A, 1994, J BIOL CHEM, V269, P19509; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Zhang L, 2001, BIOCHEM J, V357, P183, DOI 10.1042/0264-6021:3570183; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	61	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35017	35024		10.1074/jbc.M405327200	http://dx.doi.org/10.1074/jbc.M405327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180999	hybrid			2022-12-25	WOS:000223134800114
J	Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K				Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K			Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells	ONCOGENE			English	Article						X inactivation; Klinefelter syndrome; female-derived cancer	SEX-CHROMOSOMES; XIST EXPRESSION; CHROMATIN; TUMORS; BREAST; GENE; STR; CARCINOMA; BRCA1; LINE	The increased risk of several types of cancer in Klinefelter syndrome (47XXY) suggests that the extra X chromosome may be involved in the tumorigenesis associated with this syndrome. Here, we show that cancer cells (PSK-1) derived from a patient with Klinefelter syndrome (47XXY) showing loss of an inactive X chromosome subsequently gained active X chromosomes. We found that this abnormal X chromosome composition in PSK-1 is caused by a loss of an inactive X chromosome followed by multiplication of identical active X chromosomes, not by reactivation of an inactive X chromosome. Furthermore, we extended the characterization of loss-of-inactive X in a series of 22 female-derived cancer cell lines (eight breast cancer cell lines, seven ovarian cancer cell lines, and seven cervical cancer cell lines). The data demonstrate that loss-of-inactive X in the female-derived cancer cells is mainly achieved by loss of an inactive X chromosomes followed by multiplication of an identical active X chromosomes. However, distinctive pathways, including reactivation of an inactive X chromosome, are also involved in the mechanisms for loss-of-inactive X and gain-of-active X in female-derived cancer cells. The biological significance of the loss-of-inactive X and gain-of-active X in the oncogenesis of Klinefelter syndrome and female-derived cancer cells are discussed.	Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan; Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan; Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan; Univ Otago, Dept Biochem, Dunedin, New Zealand; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan	Shiga University of Medical Science; Asahikawa Medical College; Shiga University of Medical Science; University of Otago; Kyoto University	Okamoto, K (corresponding author), Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan.	keisei@belle.shiga-med.ac.jp						Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Edelmann J, 2002, FORENSIC SCI INT, V125, P217, DOI 10.1016/S0379-0738(02)00005-1; Edelmann J, 2001, INT J LEGAL MED, V114, P301, DOI 10.1007/s004140000188; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Giordano SH, 2002, ANN INTERN MED, V137, P678, DOI 10.7326/0003-4819-137-8-200210150-00013; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HOPMAN AHN, 1989, AM J PATHOL, V135, P1105; Huang DX, 2003, FORENSIC SCI INT, V133, P246, DOI 10.1016/S0379-0738(03)00077-X; Huang KC, 2002, MOL CANCER THER, V1, P769; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kawakami T, 2003, GENE CHROMOSOME CANC, V38, P97, DOI 10.1002/gcc.10234; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Kim CJ, 2000, PROSTATE, V42, P287; KIRCHGESSNER CU, 1995, J MED GENET, V32, P925, DOI 10.1136/jmg.32.12.925; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Melki JR, 1999, CANCER RES, V59, P3730; MULERIS M, 1990, GENE CHROMOSOME CANC, V1, P221, DOI 10.1002/gcc.2870010306; PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912; SAVINO A, 1971, ACTA CYTOL, V15, P372; Smyth CM, 1998, ARCH INTERN MED, V158, P1309, DOI 10.1001/archinte.158.12.1309; Son JY, 2002, INT J LEGAL MED, V116, P317, DOI 10.1007/s00414-002-0307-x; Stone C, 2003, CURR BIOL, V13, pR63, DOI 10.1016/S0960-9822(02)01430-6; THERMAN E, 1985, CANCER GENET CYTOGEN, V16, P1, DOI 10.1016/0165-4608(85)90072-X	28	76	81	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6163	6169		10.1038/sj.onc.1207808	http://dx.doi.org/10.1038/sj.onc.1207808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195139				2022-12-25	WOS:000223261000016
J	Huntington, JT; Shields, JM; Der, CJ; Wyatt, CA; Benbow, U; Slingluff, CL; Brinckerhoff, CE				Huntington, JT; Shields, JM; Der, CJ; Wyatt, CA; Benbow, U; Slingluff, CL; Brinckerhoff, CE			Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells - Role of BRAF mutation and fibroblast growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SINGLE NUCLEOTIDE POLYMORPHISM; MATRIX METALLOPROTEINASE-1; METASTATIC MELANOMA; GENE-EXPRESSION; MALIGNANT MELANOMAS; TUMOR PROGRESSION; RAS MUTATIONS; I COLLAGEN; B-RAF	Melanoma progresses as a multistep process where the thickness of the lesion and depth of tumor invasion are the best prognostic indicators of clinical outcome. Degradation of the interstitial collagens in the extracellular matrix is an integral component of tumor invasion and metastasis, and much of this degradation is mediated by collagenase-1 (MMP-1), a member of the matrix metalloproteinase (MMP) family. MMP-1 levels increase during melanoma progression where they are associated with shorter disease-free survival. The Ras/Raf/ MEK/ERK mitogen-activated protein kinase ( MAPK) pathway is a major regulator of melanoma cell proliferation. Recently, BRAF has been identified as a common site of activating mutations, and, although many reports focus on its growth-promoting effects, this pathway has also been implicated in progression toward metastatic disease. In this study, we describe four melanoma cell lines that produce high levels of MMP-1 constitutively. In each cell line the Ras/Raf/ MEK/ERK pathway is constitutively active and is the dominant pathway driving the production of MMP-1. Activation of this pathway arises due to either an activating mutation in BRAF ( three cell lines) or autocrine fibroblast growth factor signaling ( one cell line). Furthermore, blocking MEK/ ERK activity inhibits melanoma cell proliferation and abrogates collagen degradation, thus decreasing their metastatic potential. Importantly, this inhibition of invasive behavior can occur in the absence of any detectable changes in cell proliferation and survival. Thus, constitutive activation of this MAPK pathway not only promotes the increased proliferation of melanoma cells but is also important for the acquisition of an invasive phenotype.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Physiol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03756 USA; Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of Virginia	Brinckerhoff, CE (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, 1 Med Ctr Dr,602 Rubin, Lebanon, NH 03756 USA.	brinckerhoff@dartmouth.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [T32CA009658, R01CA057653, R29CA057653, R01CA077617, R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77617, T32-CA09658, CA-57653, CA-63071] Funding Source: Medline; NIAMS NIH HHS [AR-26599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Benbow U, 2002, J CELL BIOCHEM, V86, P307, DOI 10.1002/jcb.10225; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Brose MS, 2002, CANCER RES, V62, P6997; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collisson EA, 2003, CANCER RES, V63, P5669; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Ge XK, 2002, CANCER LETT, V179, P133, DOI 10.1016/S0304-3835(02)00004-6; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Gorden A, 2003, CANCER RES, V63, P3955; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hingorani SR, 2003, CANCER RES, V63, P5198; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Johansson N, 2000, J CELL SCI, V113, P227; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Kurschat P, 2000, CLIN EXP DERMATOL, V25, P482, DOI 10.1046/j.1365-2230.2000.00701.x; Laud K, 2003, CANCER RES, V63, P3061; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li SP, 2003, CANCER RES, V63, P3473; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meier F, 2002, BRIT J DERMATOL, V147, P62, DOI 10.1046/j.1365-2133.2002.04867.x; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Nikkola J, 2002, INT J CANCER, V97, P432, DOI 10.1002/ijc.1636; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Rutter JL, 1998, CANCER RES, V58, P5321; Satyamoorthy K, 2003, CANCER RES, V63, P756; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; Tower GB, 2002, BBA-MOL BASIS DIS, V1586, P265, DOI 10.1016/S0925-4439(01)00105-3; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Walker RA, 1999, VIRCHOWS ARCH, V435, P574, DOI 10.1007/s004280050443; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	66	126	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33168	33176		10.1074/jbc.M405102200	http://dx.doi.org/10.1074/jbc.M405102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184373	hybrid			2022-12-25	WOS:000223039700020
J	Jez, JM; Cahoon, RE; Chen, SX				Jez, JM; Cahoon, RE; Chen, SX			Arabidopsis thaliana glutamate-cysteine ligase - Functional properties, kinetic mechanism, and regulation of activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE HOMEOSTASIS; MASS-SPECTROMETRY; MODIFIER SUBUNIT; PLANT; RAT; PURIFICATION; ACCUMULATION; TOLERANCE; SUBSTRATE	In plants, glutathione accumulates in response to different stress stimuli as a protective mechanism, but only limited biochemical information is available on the plant enzymes that synthesize glutathione. Glutamate-cysteine ligase (GCL) catalyzes the first step in glutathione biosynthesis and plays an important role in regulating the intracellular redox environment. Because the putative Arabidopsis thaliana GCL (AtGCL) displays no significant homology to the GCL from bacteria and other eukaryotes, the identity of this protein as a GCL has been debated. We have purified AtGCL from an Escherichia coli expression system and demonstrated that the recombinant enzyme catalyzes the ATP-dependent formation of gamma-glutamylcysteine from glutamate (K-m = 9.1 mM) and cysteine (K-m = 2.7 mM). Glutathione feedback inhibits AtGCL (K-i similar to 1.0 mM). As with other GCL, buthionine sulfoximine and cystamine inactivate the Arabidopsis enzyme but with inactivation rates much slower than those of the mammalian, bacterial, and nematode enzymes. The slower inactivation rates observed with AtGCL suggest that the active site differs structurally from that of other GCL. Global fitting analysis of initial velocity data indicates that a random terreactant mechanism with a preferred binding order best describes the kinetic mechanism of AtGCL. Unlike the mammalian GCL, which consists of a catalytic subunit and a regulatory subunit, AtGCL functions and is regulated as a monomeric protein. In response to redox environment, AtGCL undergoes a reversible conformational change that modulates the enzymatic activity of the monomer. These results explain the reported posttranslational change in AtGCL activity in response to oxidative stress.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						Abbott JJ, 2002, BIOCHEMISTRY-US, V41, P2741, DOI 10.1021/bi0159128; Barker KR, 2003, ANNU REV PHYTOPATHOL, V41, P1, DOI 10.1146/annurev.phyto.41.052002.095647; BOARD PG, 1980, BIOCHIM BIOPHYS ACTA, V613, P534, DOI 10.1016/0005-2744(80)90109-6; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; Brunold Christian, 1997, Progress in Botany, V58, P164; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Copley SD, 2002, GENOME BIOL, V3; DAVIS JS, 1973, BIOCHEM J, V133, P667, DOI 10.1042/bj1330667; Dhankher OP, 2002, NAT BIOTECHNOL, V20, P1140, DOI 10.1038/nbt747; Emanuele JJ, 1997, BIOCHEMISTRY-US, V36, P7264, DOI 10.1021/bi970266r; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fraser JA, 2003, J BIOL CHEM, V278, P46369, DOI 10.1074/jbc.M308035200; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Gomez LD, 2004, PLANT PHYSIOL, V134, P1662, DOI 10.1104/pp.103.033027; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GUPTA AS, 1991, PLANT PHYSIOL, V96, P650, DOI 10.1104/pp.96.2.650; HELL R, 1990, PLANTA, V180, P603, DOI 10.1007/BF02411460; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; KITZ R, 1962, J BIOL CHEM, V237, P3245; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; LEBO RV, 1978, J BIOL CHEM, V253, P2615; LOO JA, 1991, ANAL CHEM, V63, P2488, DOI 10.1021/ac00021a018; Loo JA, 2000, INT J MASS SPECTROM, V200, P175, DOI 10.1016/S1387-3806(00)00298-0; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Luersen K, 2000, MOL BIOCHEM PARASIT, V111, P243, DOI 10.1016/S0166-6851(00)00325-X; MADAMANCHI NR, 1991, PLANT PHYSIOL, V97, P88, DOI 10.1104/pp.97.1.88; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; May MJ, 1998, P NATL ACAD SCI USA, V95, P12049, DOI 10.1073/pnas.95.20.12049; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Schafer HJ, 1997, FEBS LETT, V404, P216, DOI 10.1016/S0014-5793(97)00132-4; Schafer HJ, 1998, PLANT MOL BIOL, V37, P87, DOI 10.1023/A:1005929022061; SCHANDLE VB, 1981, J BIOL CHEM, V256, P7590; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA R, 1977, J BIOL CHEM, V252, P2599; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; VANBUSKIRK GE, 1978, EUR J BIOCHEM, V85, P589; VIOLA RE, 1982, METHOD ENZYMOL, V87, P353; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; YIP B, 1976, J BIOL CHEM, V251, P3563; Zhu YL, 1999, PLANT PHYSIOL, V121, P1169, DOI 10.1104/pp.121.4.1169	51	109	116	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33463	33470		10.1074/jbc.M405127200	http://dx.doi.org/10.1074/jbc.M405127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180996	hybrid			2022-12-25	WOS:000223039700055
J	Kunkel, EJ; Dea, M; Ebens, A; Hytopoulos, E; Melrose, J; Nguyen, D; Ota, KS; Plavec, I; Wang, Y; Watson, SR; Butcher, EC; Berg, EL				Kunkel, EJ; Dea, M; Ebens, A; Hytopoulos, E; Melrose, J; Nguyen, D; Ota, KS; Plavec, I; Wang, Y; Watson, SR; Butcher, EC; Berg, EL			An integrative biology approach for analysis of drug action in models of human vascular inflammation	FASEB JOURNAL			English	Article						endothelium; leukocyte; chemokine; adhesion; systems biology	ENDOTHELIAL-CELLS; ROSUVASTATIN; ACTIVATION; SIMVASTATIN; EXPRESSION; INHIBITOR; ARTHRITIS; STATINS; SYSTEMS	Unexpected drug activities discovered during clinical testing establish the need for better characterization of compounds in human disease-relevant conditions early in the discovery process. Here, we describe an approach to characterize drug function based on statistical analysis of protein expression datasets from multiple primary human cell-based models of inflammatory disease. This approach, termed Biologically Multiplexed Activity Profiling (BioMAP), provides rapid characterization of drug function, including mechanism of action, secondary or off-target activities, and insights into clinical phenomena. Using three model systems containing primary human endothelial cells and peripheral blood mononuclear cells in different environments relevant to vascular inflammation and immune activation, we show that BioMAP profiles detect and discriminate multiple functional drug classes, including glucocorticoids; TNF-alpha antagonists; and inhibitors of HMG-CoA reductase, calcineurin, IMPDH, PDE4, PI-3 kinase, hsp90, and p38 MAPK, among others. The ability of cholesterol lowering HMG-CoA reductase inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activities of these compounds in our BioMAP assays. In addition, the activity profiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK-506 provide a potential explanation for a reduced incidence of posttransplant cardiovascular disease in patients receiving mycophenolic acid. BioMAP profiling can allow integration of meaningful human biology into drug development programs.	Bioseek Inc, Burlingame, CA 94010 USA; Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA	Stanford University	Berg, EL (corresponding author), Bioseek Inc, 863-C Mitten Rd, Burlingame, CA 94010 USA.	eberg@bioseekinc.com	Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI048255, R43AI049048] Funding Source: NIH RePORTER; NIAID NIH HHS [R43 AI049048, R43 AI048255] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abud-Mendoza C, 2003, LUPUS, V12, P607, DOI 10.1191/0961203303lu429oa; Aukrust P, 1998, CIRCULATION, V97, P1136, DOI 10.1161/01.CIR.97.12.1136; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Davidov EJ, 2003, DRUG DISCOV TODAY, V8, P175, DOI 10.1016/S1359-6446(03)02600-X; Davidson M, 2002, AM J CARDIOL, V89, P268, DOI 10.1016/S0002-9149(01)02226-3; Davidson MH, 2002, EXPERT OPIN INV DRUG, V11, P125, DOI 10.1517/13543784.11.1.125; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Kanda H, 2002, J RHEUMATOL, V29, P2024; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Liu WL, 2002, ACTA PHARMACOL SIN, V23, P213; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Melrose J, 1998, J IMMUNOL, V161, P2457; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; Miller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; Plavec I, 2004, P NATL ACAD SCI USA, V101, P1223, DOI 10.1073/pnas.0308221100; Pober JS, 2001, ANN NY ACAD SCI, V941, P12; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959	29	56	61	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1279	+		10.1096/fj.04-1538fje	http://dx.doi.org/10.1096/fj.04-1538fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208272				2022-12-25	WOS:000222327500004
J	Dasgupta, P; Betts, V; Rastogi, S; Joshi, B; Morris, M; Brennan, B; Ordonez-Ercan, D; Chellappan, S				Dasgupta, P; Betts, V; Rastogi, S; Joshi, B; Morris, M; Brennan, B; Ordonez-Ercan, D; Chellappan, S			Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein - Novel links between apoptotic signaling and cell cycle machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RB; KINASE; ASK1; P38; E2F; DEATH; INHIBITOR; INDUCTION; NUCLEUS; MAPKKK	The retinoblastoma protein Rb has antiproliferative and antiapoptotic functions. Our previous studies have shown that certain apoptotic signals can inactivate Rb via the p38 pathway. Here we show that Rb associates with the apoptosis signal-regulating kinase ASK1 in response to specific apoptotic signals. An LXCXE motif on ASK1 was required for Rb binding; this correlated with increased E2F1 transcriptional activity and up-regulation of the proapoptotic protein p73. Overexpression of Rb inhibited ASK1-induced apoptosis; in addition, an ASK1 mutant incapable of binding Rb could not induce apoptosis, indicating that ASK1 has to overcome the antiapoptotic properties of Rb to kill cells. Chromatin immunoprecipitation assays show that in asynchronous cells the p73P1 promoter is occupied predominantly by E2F3; upon tumor necrosis factor (TNF)-alpha stimulation, E2F3 is dissociated from the promoter and replaced by E2F1. At the same time, TNF-alpha stimulation causes Rb to dissociate from the p73P1 promoter. These are promoter-specific events because Rb binds to the mitogenic cdc25A promoter upon TNF-alpha stimulation. These studies suggest that Rb acts as a link between apoptotic and proliferative pathways by interacting with distinct kinases and occupying different promoters.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Rastogi, Shipra/L-1209-2015; Rastogi, Shipra/F-5109-2012	Rastogi, Shipra/0000-0003-3296-4405; 	NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cook JL, 2002, P NATL ACAD SCI USA, V99, P9966, DOI 10.1073/pnas.162082999; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hwang IS, 2002, FEBS LETT, V529, P183, DOI 10.1016/S0014-5793(02)03329-X; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nath N, 1999, J IMMUNOL, V162, P5351; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	30	31	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38762	38769		10.1074/jbc.M312273200	http://dx.doi.org/10.1074/jbc.M312273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15210709	hybrid			2022-12-25	WOS:000223684100087
J	Situ, D; Haimeur, A; Conseil, G; Sparks, KE; Zhang, DW; Deeley, RG; Cole, SPC				Situ, D; Haimeur, A; Conseil, G; Sparks, KE; Zhang, DW; Deeley, RG; Cole, SPC			Mutational analysis of ionizable residues proximal to the cytoplasmic interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1) - Glutamate 1204 is important for both the expression and catalytic activity of the transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; SUBSTRATE-SPECIFICITY; GLUTATHIONE TRANSPORT; FUNCTIONAL IMPORTANCE; LEUKOTRIENE C-4; BINDING; IDENTIFICATION; MRP1/ABCC1; POLAR; SITE	The multidrug resistance protein MRP1 is an ATP-dependent transporter of organic anions and chemotherapeutic agents. A significant number of ionizable amino acids are found in or proximal to the 17 transmembrane (TM) helices of MRP1, and we have investigated 6 of these at the cytoplasmic interface of TM13-17 for their role in MRP1 expression and transport activity. Opposite charge substitutions of TM13 Arg(1046) and TM15 Arg(1131) did not alter MRP1 expression nor did they substantially affect activity. In contrast, opposite charge substitutions of TM16 Arg(1202) and Glu(1204) reduced protein expression by >80%; however, MRP1 expression was not affected when Arg(1202) and Glu(1204) were replaced with neutral or same-charge residues. In addition, organic anion transport levels of the R1202L, R1202G, and R1202K mutants were comparable with wild-type MRP1. In contrast, organic anion transport by E1204L was substantially reduced, whereas transport by E1204D was comparable with wild-type MRP1, with the notable exception of GSH. Opposite charge substitutions of TM16 Arg(1197) and TM17 Arg(1249) did not affect MRP1 expression but substantially reduced transport. Mutants containing like-charge substitutions of Arg(1197) or Arg(1249) were also transport-inactive and no longer bound leukotriene C-4. In contrast, substrate binding by the transport-compromised E1204L mutant remained intact. Furthermore, vanadate-induced trapping of azido-ADP by E1204L was dramatically increased, indicating that this mutation may cause a partial uncoupling of the catalytic and transport activities of MRP1. Thus, Glu(1204) serves a dual role in membrane expression of MRP1 and a step in its catalytic cycle subsequent to initial substrate binding.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Zhang, Dawei/0000-0001-8279-8041				Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Koike K, 2004, J BIOL CHEM, V279, P12325, DOI 10.1074/jbc.M311435200; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, J PHARMACOL EXP THER, V304, P643, DOI 10.1124/jpet.102.044073; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ren XQ, 2003, BRIT J PHARMACOL, V138, P1553, DOI 10.1038/sj.bjp.0705197; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Sakamoto H, 1999, CANCER LETT, V135, P113; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	43	38	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38871	38880		10.1074/jbc.M403832200	http://dx.doi.org/10.1074/jbc.M403832200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208328	hybrid			2022-12-25	WOS:000223684100100
J	Edbauer, D; Kaether, C; Steiner, H; Haass, C				Edbauer, D; Kaether, C; Steiner, H; Haass, C			Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; BETA-APP; TRANSMEMBRANE DOMAIN; ALZHEIMERS-DISEASE; GXXXG MOTIF; PEN-2; PROTEIN; NOTCH; ACCUMULATION; CLEAVAGE	gamma-Secretase is an intramembrane-cleaving aspartyl protease complex that mediates the final cleavage of beta-amyloid precursor protein to liberate the neurotoxic amyloid-beta peptide implicated in Alzheimer's disease. The four proteins presenilin (PS), nicastrin (NCT), APH-1, and PEN-2 are sufficient to reconstitute gamma-secretase activity in yeast. Although PS seems to contribute the catalytic core of the gamma-secretase complex, no distinct function could be attributed to the other components so far. In Caenorhabditis elegans, mutation of a glycine to an aspartic acid within a conserved GXXXG motif in the fourth transmembrane domain of APH-1 causes a loss of function phenotype. Surprisingly, we now found that the human homologue APH-1a carrying the equivalent mutation G122D is fully active in yeast co-expressing PS1, NCT, and PEN-2. To address this discrepancy, we expressed APH-1a G122D in HEK293 cells. As reported previously, overexpressed APH-1a G122D was not incorporated into the gamma-secretase complex. Separate overexpression of PS1, NCT, or PEN- 2 together with APH-1a G122D allowed the formation of heterodimers lacking the other endogenous components. Only the combined overexpression of PS1 and NCT together with APH-1a G122D facilitated the formation of a fully active gamma-secretase complex. Under these conditions, APH-1a G122D supported the production of normal amounts of Abeta. We conclude that cooperative effects may stabilize a trimeric complex of APH-1a G122D together with PS1 and NCT. Upon successful complex assembly, the GXXXG motif becomes dispensable for gamma-secretase activity.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Edbauer, D (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	edbauer@mit.edu	Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gerber D, 2004, J BIOL CHEM, V279, P21177, DOI 10.1074/jbc.M400847200; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Moore DD, 1995, GLOB MOB SURV; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	37	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37311	37315		10.1074/jbc.M406228200	http://dx.doi.org/10.1074/jbc.M406228200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15210705	hybrid			2022-12-25	WOS:000223554600016
J	Huang, XP; Chang, WP; Koelsch, G; Turner, RT; Lupu, F; Tang, J				Huang, XP; Chang, WP; Koelsch, G; Turner, RT; Lupu, F; Tang, J			Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CYTOSOLIC DOMAIN; CLEAVING ENZYME; SORTING SIGNAL; VHS DOMAIN; BACE; TRAFFICKING; ENDOCYTOSIS; CLEAVAGE; SITE	Memapsin 2 (beta-secretase) is the protease that initiates cleavage of amyloid precursor protein (APP) leading to the production of amyloid-beta (Abeta) peptide and the onset of Alzheimer's disease. Both APP and memapsin 2 are Type I transmembrane proteins and are endocytosed into endosomes where APP is cleaved by memapsin 2. Separate endocytic signals are located in the cytosolic domains of these proteins. We demonstrate here that the addition of the ectodomain of memapsin 2 (M2(ED)) to cells transfected with native APP or APP Swedish mutant (APPsw) resulted in the internalization of M2(ED) into endosomes with increased Abeta production. These effects were reduced by treatment with glycosylphosphatidylinositol-specific phospholipase C. The nontransfected parental cells had little internalization of M2(ED). The internalization of M2(ED) was dependent on the endocytosis signal in APP, because the expression of a mutant APP that lacks its endocytosis signal failed to support M2(ED) internalization. These results suggest that exogenously added M2(ED) interacts with the ectodomain of APP on the cell surface leading to the internalization of M2(ED), supported by fluorescence resonance energy transfer experiments. The interactions between the two proteins is not due to the binding of substrate APPsw to the active site of memapsin 2, because neither a potent active site binding inhibitor of memapsin 2 nor an antibody directed to the beta-secretase site of APPsw had an effect on the uptake of M2(ED). In addition, full-length memapsin 2 and APP, immunoprecipitated together from cell lysates, suggested that the interaction of these two proteins is part of the native cellular processes.	Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Zapaq Inc, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Tang, J (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jordan-tang@omrf.ouhsc.edu	Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278	NIA NIH HHS [AG-18933] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Lai A, 1998, J BIOL CHEM, V273, P3732, DOI 10.1074/jbc.273.6.3732; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Scholefield Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/jcb.200303059; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WOLFE MS, 2002, CURR TOP MED CHEM, V4, P371; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	36	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37886	37894		10.1074/jbc.M402130200	http://dx.doi.org/10.1074/jbc.M402130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15197182	hybrid			2022-12-25	WOS:000223554600082
J	Shan, ZZ; Masuko-Hongo, K; Dai, SM; Nakamura, H; Kato, T; Nishioka, K				Shan, ZZ; Masuko-Hongo, K; Dai, SM; Nakamura, H; Kato, T; Nishioka, K			A potential role of 15-deoxy-Delta(12,14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; OXIDE-INDUCED APOPTOSIS; NITRIC-OXIDE; PROSTAGLANDIN D-2; PROTEIN; J(2); ASSOCIATION; METABOLITE; LIGAND; CLASSIFICATION	The cyclopentenone prostaglandin ( PG) J2 is formed within the cyclopentenone ring of the endogenous prostaglandin PG D2 by a nonenzymatic reaction. The PG J family is involved in mediating various biological effects including the regulation of cell cycle progression and inflammatory responses. Here we demonstrate the potential role of 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PG J2) in human articular chondrocyte apoptosis. 15d-PG J2 was released by human articular chondrocytes and found in joint synovial fluids taken from osteoarthritis or rheumatoid arthritis patients. Proinflammatory cytokines such as interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) up-regulated chondrocyte release of 15d-PG J2. PG D2 synthase mRNA expression was upregulated by IL-1beta, TNF-alpha, or nitric oxide. 15d-PG J2 induced apoptosis of chondrocytes from osteoarthritis or rheumatoid arthritis patients as well as control nonarthritic subjects in a time- and dose-dependent manner and in a peroxisome proliferator-activated receptor gamma-dependent manner. Peroxisome proliferator-activated receptor gamma expression was up-regulated by IL-1beta and TNF-alpha. Inhibition of NF-kappaB, and the activation of p38 MAPK were also found to be involved in 15d-PG J2-induced chondrocyte apoptosis. Such signal pathways led to the activation of the downstream pro-apoptotic molecule p53 and caspase cascades. Together, these results suggest that 15d-PGJ2 may play an important role in the pathogenesis of arthritic joint destruction via a regulation of chondrocyte apoptosis.	St Marianna Univ, Sch Med, Inst Med Sci, Dept Bioregulat,Miyamae Ku, Kanagawa 2168512, Japan	Saint Marianna University	Masuko-Hongo, K (corresponding author), St Marianna Univ, Sch Med, Inst Med Sci, Dept Bioregulat,Miyamae Ku, 2-16-1 Sugao, Kanagawa 2168512, Japan.	khongo@marianna-u.ac.jp	Masuko, Kayo/H-7032-2019	Masuko, Kayo/0000-0001-6058-6363; Dai, Sheng-Ming/0000-0001-8876-4205				ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; BLANCO FJ, 1995, AM J PATHOL, V146, P75; Bordji K, 2000, J BIOL CHEM, V275, P12243, DOI 10.1074/jbc.275.16.12243; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P845, DOI 10.1053/joca.2002.0835; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Feng LX, 1998, J CELL BIOCHEM, V71, P302, DOI 10.1002/(SICI)1097-4644(19981101)71:2<302::AID-JCB14>3.0.CO;2-M; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1994, ANN NY ACAD SCI, V744, P161, DOI 10.1111/j.1749-6632.1994.tb52733.x; Green DR, 2003, IMMUNOL REV, V193, P5, DOI 10.1034/j.1600-065X.2003.00045.x; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Hashimoto H, 1998, ARTHRITIS RHEUM, V41, P657, DOI 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.3.CO;2-E; Hashimoto K, 2002, J GASTROINTEST CANC, V32, P7, DOI 10.1385/IJGC:32:1:7; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kim HA, 1999, ARTHRITIS RHEUM, V42, P1528, DOI 10.1002/1529-0131(199907)42:7<1528::AID-ANR28>3.0.CO;2-9; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Kuhn K, 2001, ARTHRITIS RHEUM-US, V44, P1644, DOI 10.1002/1529-0131(200107)44:7<1644::AID-ART287>3.0.CO;2-S; Li LY, 2001, J BIOL CHEM, V276, P38152; Lotz M, 1999, OSTEOARTHR CARTILAGE, V7, P389, DOI 10.1053/joca.1998.0220; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Miwa M, 2000, OSTEOARTHR CARTILAGE, V8, P17, DOI 10.1053/joca.1999.0266; Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271; Ogasawara K, 2002, J IMMUNOL, V169, P3676, DOI 10.4049/jimmunol.169.7.3676; Shakibaei M, 2001, J BIOL CHEM, V276, P13289, DOI 10.1074/jbc.M010859200; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; Tugwood JD, 2002, HUM EXP TOXICOL, V21, P429, DOI 10.1191/0960327102ht282oa; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	46	80	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37939	37950		10.1074/jbc.M402424200	http://dx.doi.org/10.1074/jbc.M402424200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15213234	hybrid			2022-12-25	WOS:000223554600087
J	Bodding, M; Flockerzi, V				Bodding, M; Flockerzi, V			Ca2+ dependence of the Ca(2+)selective TRPV6 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM-CHANNEL; PORE PROPERTIES; PROSTATE-CANCER; WHOLE-CELL; CAT-LIKE; PERMEATION; IDENTIFICATION; TRANSPORT; CURRENTS; PROTEIN	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca2+-sensing Ca2+ channel is constitutively active. Intact cells loaded with fura-2 had an elevated intracellular free Ca2+ concentration ([Ca2+](i)), which decreased to the same level such as in non-transfected cells if external Ca2+ was chelated by EGTA. Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mM EGTA and 100 nM [Ca2+](i) or if the cytosolic Ca2+ buffering remained undisturbed in perforated patch-clamp experiments. If recombinantly expressed TRPV6 forms open channels, one would expect Ca2+-induced current inhibition, because TRPV6 is negatively regulated by internal Ca2+. However, dialyzing solutions with high [Ca2+] such as 1 muM into TRPV6-expressing cells did not block the basal inward current, which was not different from the recordings from non-transfected cells. In contrast, dialyzing 0.5 mM EGTA into TRPV6-expressing cells readily activated Ca2+ inward currents, which were undetectable in non-transfected cells. Interestingly, monovalent cations permeated the TRPV6 channels under conditions where no Ca2+ permeation was detectable, indicating that divalent cations block TRPV6 channels from the extracellular side. Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca2+-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel. In summary, no constitutive open TRPV6 channels were detected in patch-clamp experiments from transfected HEK cells. However, channel activity is highly regulated by intracellular and extracellular divalent cations.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	matthias.boedding@uniklinik-saarland.de						Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jean K, 2002, AM J PHYSIOL-CELL PH, V282, pC665, DOI 10.1152/ajpcell.00443.2001; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2003, J PHYSIOL-LONDON, V551, P729, DOI 10.1113/jphysiol.2003.043349; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	21	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36546	36552		10.1074/jbc.M404679200	http://dx.doi.org/10.1074/jbc.M404679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15184369	hybrid			2022-12-25	WOS:000223453600050
J	Hopkins, BB; Reich, NO				Hopkins, BB; Reich, NO			Simultaneous DNA binding, bending, and base flipping - Evidence for a novel M. EcoRI methyltransferase-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CRYSTAL-STRUCTURE; FACILITATED DIFFUSION; CATALYTIC-PROPERTIES; RIBOZYME KINETICS; STATE KINETICS; PROMOTER DNA; ENDONUCLEASE; FLUORESCENCE; RECOGNITION	We measured the kinetics of DNA bending by M. EcoRI using DNA labeled at both 5'-ends and observed changes in fluorescence resonance energy transfer. Although known to bend its cognate DNA site, energy transfer is decreased upon enzyme binding. This unanticipated effect is shown to be robust because we observe the identical decrease with different dye pairs, when the dye pairs are placed on the respective 3'-ends, the effect is cofactor- and protein-dependent, and the effect is observed with duplexes ranging from 14 through 17 base pairs. The same labeled DNA shows the anticipated increased energy transfer with EcoRV endonuclease, which also bends this sequence, and no change in energy transfer with EcoRI endonuclease, which leaves this sequence unbent. We interpret these results as evidence for an increased end-to-end distance resulting from M. EcoRI binding, mediated by a mechanism novel for DNA methyltransferases, combining DNA bending and an overall expansion of the DNA duplex. The M. EcoRI protein sequence is poorly accommodated into well defined classes of DNA methyltransferases, both at the level of individual motifs and overall alignment. Interestingly, M. EcoRI has an intercalation motif observed in the FPG DNA glycosylase family of repair enzymes. Enzyme-dependent changes in anisotropy and fluorescence resonance energy transfer have similar rate constants, which are similar to the previously determined rate constant for base flipping; thus, the three processes are nearly coincidental. Similar fluorescence resonance energy transfer experiments following AdoMet-dependent catalysis show that the unbending transition determines the steady state product release kinetics.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu						Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BRANNON JH, 1978, J PHYS CHEM-US, V82, P705, DOI 10.1021/j100495a018; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Crellin P, 2004, MOL CELL, V13, P537, DOI 10.1016/S1097-2765(04)00052-8; Eggeling C, 1998, P NATL ACAD SCI USA, V95, P1556, DOI 10.1073/pnas.95.4.1556; EIS PS, 1993, BIOCHEMISTRY-US, V32, P13852, DOI 10.1021/bi00213a014; Fersht A., 1999, STRUCTURE MECH PROTE; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Hiller DA, 2003, BIOCHEMISTRY-US, V42, P14375, DOI 10.1021/bi035520w; Hillisch A, 2001, CURR OPIN STRUC BIOL, V11, P201, DOI 10.1016/S0959-440X(00)00190-1; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Horton NC, 2002, NAT STRUCT BIOL, V9, P42, DOI 10.1038/nsb741; Huang N, 2003, P NATL ACAD SCI USA, V100, P68, DOI 10.1073/pnas.0135427100; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; KASZUBSKA W, 1989, NUCLEIC ACIDS RES, V17, P10403, DOI 10.1093/nar/17.24.10403; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Koval VV, 2004, NUCLEIC ACIDS RES, V32, P926, DOI 10.1093/nar/gkh237; KUBOTA Y, 1979, BIOPHYS CHEM, V9, P105, DOI 10.1016/0301-4622(79)87004-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LANDRY D, 1992, METHOD ENZYMOL, V216, P244; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LI M, 2004, J BIOL CHEM; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Masters KM, 2003, J BIOL CHEM, V278, P31685, DOI 10.1074/jbc.M305201200; MODRICH P, 1976, J BIOL CHEM, V251, P5866; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Perkins TA, 1996, BIOCHEMISTRY-US, V35, P16370, DOI 10.1021/bi961234r; Perona JJ, 1997, J MOL BIOL, V273, P207, DOI 10.1006/jmbi.1997.1315; Powell RM, 2002, J BIOL CHEM, V277, P7776, DOI 10.1074/jbc.M110147200; Radhakrishnan R, 2004, P NATL ACAD SCI USA, V101, P5970, DOI 10.1073/pnas.0308585101; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REICH NO, 1992, BIOCHEMISTRY-US, V31, P1937, DOI 10.1021/bi00122a006; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; Szyf Moshe, 2000, Current Drug Targets, V1, P101, DOI 10.2174/1389450003349362; THOMPSON J, 2004, NUCLEIC ACIDS RES, V25, P4876; TIMINSKAS A, 1995, GENE, V157, P3, DOI 10.1016/0378-1119(94)00783-O; Vamosi G, 1996, BIOPHYS J, V71, P972, DOI 10.1016/S0006-3495(96)79300-1; Wahnon DC, 2001, J AM CHEM SOC, V123, P976, DOI 10.1021/ja003285o; Walter NG, 1997, RNA, V3, P392; Wang XY, 2004, BIOCHEM CELL BIOL, V82, P329, DOI 10.1139/o03-082; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	69	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37049	37060		10.1074/jbc.M404573200	http://dx.doi.org/10.1074/jbc.M404573200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210696	hybrid			2022-12-25	WOS:000223453600108
J	Kersting, MC; Choi, HS; Carman, GM				Kersting, MC; Choi, HS; Carman, GM			Regulation of the yeast EKI1-encoded ethanolamine kinase by inositol and choline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE SYNTHASE; INO1 PROMOTER; GENETIC-REGULATION; PHOSPHATIDYLETHANOLAMINE; EXPRESSION; GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHATIDYLCHOLINE; IDENTIFICATION	Regulation of the EKI1-encoded ethanolamine kinase by inositol and choline was examined in Saccharomyces cerevisiae. Transcription of the EKI1 gene was monitored by following the expression of beta-galactosidase activity driven by a P-EKI1-lacZ reporter gene. The addition of inositol to the growth medium resulted in a dose-dependent decrease in EKI1 expression. Supplementation of choline to inositol-containing growth medium brought about a further decrease in expression, whereas choline supplementation alone had no effect. Analysis of EKI1 expression in ino2Delta, ino4Delta, and opi1Delta mutants indicated that the transcription factors Ino2p, Ino4p, and Opi1p played a role in this regulation. Moreover, mutational analysis showed that the UAS(INO) element in the EKI1 promoter was required for the inositol-mediated regulation. The regulation of EKI1 expression by inositol and choline was confirmed by corresponding changes in ethanolamine kinase mRNA, protein, and activity levels. The repression of ethanolamine kinase by inositol supplementation correlated with a decrease in the incorporation of ethanolamine into CDP-ethanolamine pathway intermediates and into phosphatidylethanolamine and phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MENON AK, 1992, J BIOL CHEM, V267, P15277; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; RATTRAY JBM, 1975, BACTERIOL REV, V39, P197, DOI 10.1128/MMBR.39.3.197-231.1975; Rose MD., 1990, METHODS YEAST GENETI; Sambrok J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x	67	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35353	35359		10.1074/jbc.M405704200	http://dx.doi.org/10.1074/jbc.M405704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201274	hybrid			2022-12-25	WOS:000223303400028
J	Sayers, I; Housden, JEM; Spivey, AC; Helm, BA				Sayers, I; Housden, JEM; Spivey, AC; Helm, BA			The importance of Lys-352 of human immunoglobulin E in Fc epsilon RII/CD23 recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY RECEPTOR; HUMAN IGE-FC; BINDING-SITE; CD23; IDENTIFICATION; FRAGMENT; CELLS; EXPRESSION; ANTIBODIES; SECRETION	The interaction of immunoglobulin E (IgE) with its low affinity receptor (FcepsilonRII/CD23) plays a central role in the initiation and regulation of type I hypersensitivity responses. We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction. These residues were now targeted by site-directed mutagenesis. The IgE-CD23 interaction was assessed by semiquantitative flow cytometry. Replacement of the entire Cepsilon3 A-B loop (residues 341 356) with the homologous rat IgE sequence resulted in complete loss of human CD23 recognition, as did replacement of residues 346-353, indicating that class-specific effector residue(s) are contained within these eight amino acids. Lysine 352 within the A-B loop was identified as contributing directly to human CD23 interaction. Mutation to the rodent homologue glycine or glutamate resulted in a significant reduction in binding compared with native IgE, whereas conservative substitution with arginine effected a small, but statistically significant, enhancement of CD23 binding. Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition. Our results yield new insights into the structural basis of the hIgE-CD23 interaction and hold promise for the rational design of drugs that can manipulate IgE-mediated regulation of the allergic response.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England	University of Sheffield; University of Nottingham; Imperial College London	Helm, BA (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	B.Helm@sheffield.ac.uk		Sayers, Ian/0000-0001-5601-5410				BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BETTLER B, 1992, J BIOL CHEM, V267, P185; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; Bjorklund JEM, 1999, MOL IMMUNOL, V36, P213, DOI 10.1016/S0161-5890(99)00036-X; Chen BH, 2002, IMMUNOLOGY, V107, P373, DOI 10.1046/j.1365-2567.2002.01512.x; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GONZALEZMOLINA A, 1976, J IMMUNOL, V117, P1838; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Helm BA, 1996, J BIOL CHEM, V271, P7494, DOI 10.1074/jbc.271.13.7494; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; Kilmon MA, 2001, J IMMUNOL, V167, P3139, DOI 10.4049/jimmunol.167.6.3139; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NISSIM A, 1993, J IMMUNOL, V150, P1365; PADLAN EA, 1993, BIOCHEM SOC T, V21, P963, DOI 10.1042/bst0210963; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; Sayers I, 1999, CLIN EXP ALLERGY, V29, P585; Sayers I, 1998, BIOCHEMISTRY-US, V37, P16152, DOI 10.1021/bi981456k; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Tsicopoulos A, 2000, CLIN EXP ALLERGY, V30, P602; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; VOGEL M, 1994, EUR J IMMUNOL, V24, P1200, DOI 10.1002/eji.1830240529; WILSON APM, 1993, EUR J IMMUNOL, V23, P240, DOI 10.1002/eji.1830230137; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; YOUNG RJ, 1995, PROTEIN ENG, V8, P193, DOI 10.1093/protein/8.2.193	30	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35320	35325		10.1074/jbc.M404575200	http://dx.doi.org/10.1074/jbc.M404575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199058	hybrid			2022-12-25	WOS:000223303400024
J	Chen, K; Thomas, SR; Albano, A; Murphy, MP; Keaney, JF				Chen, K; Thomas, SR; Albano, A; Murphy, MP; Keaney, JF			Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; STRESS-INDUCED APOPTOSIS; FACTOR-BETA RECEPTOR; OXIDATIVE STRESS; REVERSIBLE INACTIVATION; LIPID-PEROXIDATION; KINASE ACTIVATION; REDOX REGULATION; CELL-SURVIVAL; EGF RECEPTOR	The transactivation of growth factor receptors is an early event in H2O2-induced signaling, although proximal targets in this process remain unclear. We found that inhibition of flavin- or heme-containing proteins eliminated H2O2-induced transactivation of the epidermal growth factor receptor and stimulation of its downstream targets, JNK and Akt. Inhibition of mitochondrial function with rotenone, antimycin A, KCN, carbonylcyanide-m-chlorophenylhydrazone, or oligomycin reproduced this effect, as did generation of mitochondrial DNA-deficient (pseudo-rho(0)) cells. Mitochondrial function had no role in JNK activation in response to UV irradiation or tumor necrosis factor-alpha. The impact of mitochondrial function on H2O2-induced growth factor transactivation was ubiquitous and applied to both the vascular endothelial growth factor (VEGF)-2 receptor and the platelet-derived growth factor-beta receptor in endothelium and fibroblasts, respectively. In contrast, ligand-induced growth factor activation was unrelated to mitochondrial function. Growth factor receptor transactivation and its downstream signaling in response to H2O2 appeared to involve redox-sensitive mitochondrial events as they were abrogated by a mitochondrial-targeted antioxidants but not their nontargeted counterparts. Functionally, we found that mitochondrial-targeted antioxidants inhibited H2O2-induced apoptosis and cell death but had no effect with UV irradiation. These data establish a novel role for the mitochondrion as a proximal target specific to H2O2-induced signaling and growth factor transactivation.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	Boston University; Boston University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.	jkeaney@bu.edu	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Keaney, John/0000-0002-0866-1837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886, P01HL068758, K02HL067206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68758, HL 60886, HL 67206] Funding Source: Medline; NIDDK NIH HHS [DK 55656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BURTON GW, 1983, CIBA F SYMP, V101, P4; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen K, 2003, FREE RADICAL BIO MED, V35, P117, DOI 10.1016/S0891-5849(03)00239-9; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XP, 2001, FREE RADICAL BIO MED, V31, P894, DOI 10.1016/S0891-5849(01)00665-7; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Thomas SR, 2003, ANTIOXID REDOX SIGN, V5, P181, DOI 10.1089/152308603764816541; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wan YS, 2001, INT J ONCOL, V18, P461; WANG X, 2001, J BIOL CHEM; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	53	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35079	35086		10.1074/jbc.M404859200	http://dx.doi.org/10.1074/jbc.M404859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180991	hybrid			2022-12-25	WOS:000223134800120
J	Landino, LM; Skreslet, TE; Alston, JA				Landino, LM; Skreslet, TE; Alston, JA			Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite - Modulation of microtubule assembly kinetics by the thioredoxin reductase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN; LOCALIZATION; DAMAGE; SULFHYDRYLS; NITRATION	Alterations in the redox status of proteins have been implicated in the pathology of several neurodegenerative conditions including Alzheimer and Parkinson diseases. We report that peroxynitrite- and hydrogen peroxide-induced disulfides in the neuron-specific microtubule-associated proteins tau and microtubule-associated protein-2 are substrates for the ubiquitous thioredoxin reductase system composed of thioredoxin reductase, human or Escherichia coli thioredoxin, and NADPH. Tau and microtubule-associated protein-2 cysteine oxidation and reduction were quantitated by monitoring the incorporation of 5-iodoacetamidofluorescein, a thiol-specific labeling reagent. Cysteine oxidation of tau and microtubule-associated protein-2 to disulfides altered the ability of the proteins to promote the assembly of microtubules from purified porcine tubulin. Treatment of tau and microtubule-associated protein-2 with either the thioredoxin reductase system or small molecule reductants fully restores the ability of the MAPs to promote microtubule assembly. Thus changes in the redox state of microtubule-associated proteins may regulate microtubule polymerization in vivo.	Coll William & Mary, Dept Chem, Williamsburg, VA 23187 USA	William & Mary	Landino, LM (corresponding author), Coll William & Mary, Dept Chem, POB 8795, Williamsburg, VA 23187 USA.	lmland@wm.edu			NINDS NIH HHS [R15 NS 38885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS038885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; ANDERSON PJ, 1979, J BIOL CHEM, V254, P2168; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADY ST, 1986, ANN NY ACAD SCI, V466, P199, DOI 10.1111/j.1749-6632.1986.tb38395.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Di Noto L, 1999, Mol Cell Biol Res Commun, V2, P71, DOI 10.1006/mcbr.1999.0153; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Landino LM, 2004, FREE RADICAL BIO MED, V36, P497, DOI 10.1016/j.freeradbiomed.2003.11.026; Landino LM, 2004, BIOCHEM BIOPH RES CO, V314, P555, DOI 10.1016/j.bbrc.2003.12.126; Landino LM, 2002, ARCH BIOCHEM BIOPHYS, V398, P213, DOI 10.1006/abbi.2001.2729; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LONG C, 1968, BIOCH HDB, P782; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Smith MA, 1997, J NEUROSCI, V17, P2653; TRONCOSO JC, 1993, BRAIN RES, V613, P313, DOI 10.1016/0006-8993(93)90918-D; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	32	68	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35101	35105		10.1074/jbc.M405471200	http://dx.doi.org/10.1074/jbc.M405471200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184375	hybrid			2022-12-25	WOS:000223134800122
J	Lee, AYL; Hsu, CH; Wu, SH				Lee, AYL; Hsu, CH; Wu, SH			Functional domains of Brevibacillus thermoruber Lon protease for oligomerization and DNA binding - Role of N-terminal and sensor and substrate discrimination domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MYCOBACTERIUM-SMEGMATIS; MITOCHONDRIAL LON; CRYSTAL-STRUCTURE; CLPAP PROTEASE; LIMITED PROTEOLYSIS; CAPR PROTEIN; LA	Lon protease is a multifunctional enzyme, and its functions include the degradation of damaged proteins and naturally short lived proteins, ATPase and chaperone-like activities, as well as DNA binding. A thermostable Lon protease from Brevibacillus thermoruber WR-249 (Bt-Lon) has been cloned and characterized with an N-terminal domain, a central ATPase domain that includes a sensor and substrate discrimination (SSD) domain, and a C-terminal protease domain. Here we present a detailed structure-function characterization of Bt-Lon, not only dissecting the individual roles of Bt-Lon domains in oligomerization, catalytic activities, chaperone-like activity, and DNA binding activity but also describing the nature of oligomerization. Seven truncated mutants of Bt-Lon were designed, expressed, and purified. Our results show that the N-terminal domain is essential for oligomerization. The truncation of the N-terminal domain resulted in the failure of oligomerization and led to the inactivation of proteolytic, ATPase, and chaperone-like activities but retained the DNA binding activity, suggesting that oligomerization of Bt-Lon is a prerequisite for its catalytic and chaperone-like activities. We further found that the SSD is involved in DNA binding based on gel mobility shift assays. On the other hand, the oligomerization of Bt-Lon proceeds through a dimer 7 tetramer 7 hexamer assembly model revealed by chemical cross-linking experiments. The results also showed that hydrophobic interactions may play important roles in the dimerization of Bt-Lon, and ionic interactions are mainly responsible for the assembly of hexamers.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Wu, SH (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	shwu@gate.sinica.edu.tw	Lee, Alan Yueh-Luen/A-9141-2010; Lee, Alan Yueh-Luen/B-1097-2010; HSU, CHUN-HUA/W-4554-2019	HSU, CHUN-HUA/0000-0002-0008-7383; Lee, Alan Yueh-Luen/0000-0003-0252-0571				AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Botos I, 2004, J STRUCT BIOL, V146, P113, DOI 10.1016/j.jsb.2003.09.003; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1983, J BIOL CHEM, V258, P215; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; Ebel W, 1999, J BACTERIOL, V181, P2236, DOI 10.1128/JB.181.7.2236-2243.1999; FISCHER H, 1993, J BIOL CHEM, V268, P22502; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Fukui T, 2002, J BACTERIOL, V184, P3689, DOI 10.1128/JB.184.13.3689-3698.2002; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GILL RE, 1993, J BACTERIOL, V175, P4538, DOI 10.1128/JB.175.14.4538-4544.1993; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee AYL, 2004, EUR J BIOCHEM, V271, P834, DOI 10.1111/j.1432-1033.2004.03988.x; LIN TH, 1991, J BIOL CHEM, V266, P1635; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Rasulova FS, 1998, FEBS LETT, V432, P179, DOI 10.1016/S0014-5793(98)00859-X; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P11255, DOI 10.1021/bi980945h; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P377, DOI 10.1021/bi971732f; Rudyak SG, 2000, PROTEIN SCI, V9, P1810, DOI 10.1110/ps.9.9.1810; Rudyak SG, 2001, BIOCHEMISTRY-US, V40, P9317, DOI 10.1021/bi0102508; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHMIDT R, 1994, J BACTERIOL, V176, P6528, DOI 10.1128/JB.176.21.6528-6537.1994; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Starkova NN, 1998, FEBS LETT, V422, P218, DOI 10.1016/S0014-5793(98)00012-X; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Vasilyeva OV, 2002, FEBS LETT, V526, P66, DOI 10.1016/S0014-5793(02)03117-4; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	64	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34903	34912		10.1074/jbc.M403562200	http://dx.doi.org/10.1074/jbc.M403562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181012	Green Published, hybrid			2022-12-25	WOS:000223134800101
J	Rouzer, CA; Kingsley, PJ; Wang, HB; Zhang, H; Morrow, JD; Dey, SK; Marnett, LJ				Rouzer, CA; Kingsley, PJ; Wang, HB; Zhang, H; Morrow, JD; Dey, SK; Marnett, LJ			Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; ARACHIDONIC-ACID METABOLITES; HIGHER OXIDATION-STATES; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; ANTIINFLAMMATORY DRUGS; PROSTANOID SYNTHASES; PHOSPHOLIPASE A(2); MONONUCLEAR-CELLS; GENE DISRUPTION	Comprehensive studies of prostaglandin ( PG) synthesis in murine resident peritoneal macrophages ( RPM) responding to bacterial lipopolysaccharide (LPS) revealed that the primary PGs produced by RPM were prostacyclin and PGE(2). Detectable increases in net PG formation occurred within the first hour, and maximal PG formation had occurred by 6 - 10 h after LPS addition. Free arachidonic acid levels rose and peaked at 1 - 2 h after LPS addition and then returned to baseline. Cyclooxygenase-2 (COX-2) and microsomal PGE synthase levels markedly increased upon exposure of RPM to LPS, with the most rapid increases in protein expression occurring 2 - 6 h after addition of the stimulus. RPM constitutively expressed high levels of COX-1. Studies using isoform-selective inhibitors and RPM from mice bearing targeted deletions of ptgs-1 and ptgs-2 demonstrated that COX-1 contributes significantly to PG synthesis in RPM, especially during the initial 1 - 2 h after LPS addition. Selective inhibition of either COX isoform resulted in increased secretion of tumor necrosis factor-alpha ( TNF-alpha); however, this effect was much greater with the COX-1 than with the COX-2 inhibitor. These results demonstrate autocrine regulation of TNF-alpha secretion by endogenous PGs synthesized primarily by COX-1 in RPM and suggest that COX-1 may play a significant role in the regulation of the early response to endotoxemia.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Pharmacol & Drug Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat & Cell & Dev Biol & Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Rouzer, CA (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	c.rouzer@vanderbilt.edu		Rouzer, Carol/0000-0001-6827-1534	NCI NIH HHS [CA 77839] Funding Source: Medline; NCRR NIH HHS [RR 00095] Funding Source: Medline; NICHD NIH HHS [HD 12304, HD 33994] Funding Source: Medline; NIDA NIH HHS [DA 06668] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R37HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006668, R37DA006668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABIKO Y, 1983, FEBS LETT, V154, P297, DOI 10.1016/0014-5793(83)80170-7; BAGGIOLINI M, 1982, IMMUNOBIOLOGY, V161, P369, DOI 10.1016/S0171-2985(82)80094-6; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; BRAY MA, 1976, BRIT J PHARMACOL, V57, pP466; BROWN GP, 1988, AM J PHYSIOL, V254, pC809, DOI 10.1152/ajpcell.1988.254.6.C809; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; CHANG J, 1980, P NATL ACAD SCI-BIOL, V77, P4736, DOI 10.1073/pnas.77.8.4736; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; COOK HW, 1975, BIOCHEM BIOPH RES CO, V65, P464, DOI 10.1016/S0006-291X(75)80170-7; Devaux Y, 2001, J IMMUNOL, V167, P3962, DOI 10.4049/jimmunol.167.7.3962; Dieter P, 1999, MEDIAT INFLAMM, V8, P295, DOI 10.1080/09629359990306; Dieter P, 2000, BIOCHEM BIOPH RES CO, V276, P488, DOI 10.1006/bbrc.2000.3496; Dieter P, 2002, CELL SIGNAL, V14, P199, DOI 10.1016/S0898-6568(01)00243-1; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dooper MMBW, 2002, IMMUNOLOGY, V107, P152, DOI 10.1046/j.1365-2567.2002.01474.x; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Fennekohl A, 2002, J HEPATOL, V36, P328, DOI 10.1016/S0168-8278(01)00277-X; FU JY, 1990, J BIOL CHEM, V265, P16737; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMILTON JA, 1980, CANCER RES, V40, P2273; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOMMA Y, 1985, BIOCHEM J, V229, P643, DOI 10.1042/bj2290643; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; HUMS JL, 1985, ADV PROSTAGLANDIN TH, V15, P205; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kim JG, 2000, IMMUNOL INVEST, V29, P257, DOI 10.3109/08820130009060866; Kingsley PJ, 2003, ANAL BIOCHEM, V314, P8, DOI 10.1016/S0003-2697(02)00643-7; Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084/jem.187.4.517; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kudo I, 1999, ADV EXP MED BIOL, V469, P29; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Liu GZ, 2003, J BIOL CHEM, V278, P14956, DOI 10.1074/jbc.M212229200; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Luttmann W, 1999, CYTOKINE, V11, P127, DOI 10.1006/cyto.1998.0410; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Marnett LJ, 2004, MIL DRUG TH, P15; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MILANO S, 1995, PROSTAG OTH LIPID M, V49, P105, DOI 10.1016/0090-6980(94)00004-G; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Naraba H, 1998, J IMMUNOL, V160, P2974; Ndengele MM, 2000, AM J PHYSIOL-LUNG C, V278, pL1289, DOI 10.1152/ajplung.2000.278.6.L1289; Novak TE, 2003, AM J PHYSIOL-LUNG C, V284, pL84, DOI 10.1152/ajplung.00077.2002; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; SCALES WE, 1989, J LEUKOCYTE BIOL, V45, P416, DOI 10.1002/jlb.45.5.416; Scott KF, 1999, J LEUKOCYTE BIOL, V66, P535, DOI 10.1002/jlb.66.4.535; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SPENGLER RN, 1989, J IMMUNOL, V142, P4346; STOSSEL TP, 1974, J CLIN INVEST, V54, P638, DOI 10.1172/JCI107801; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WATANABE S, 1994, J LIPID MEDIAT CELL, V10, P283; Wong E, 1997, J BIOL CHEM, V272, P9280; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	99	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34256	34268		10.1074/jbc.M402594200	http://dx.doi.org/10.1074/jbc.M402594200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181007	hybrid			2022-12-25	WOS:000223134800024
J	Stilo, R; Liguoro, D; Di Jeso, B; Formisano, S; Consiglio, E; Leonardi, A; Vito, P				Stilo, R; Liguoro, D; Di Jeso, B; Formisano, S; Consiglio, E; Leonardi, A; Vito, P			Physical and functional interaction of CARMA1 and CARMA3 with I kappa kinase gamma-NF kappa B essential modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; LYMPHOCYTE-ACTIVATION; CONTAINING PROTEIN; T-LYMPHOCYTES; FAMILY MEMBER; PKC-THETA; BCL10; APOPTOSIS; REGULATOR; PATHWAY	CARMA proteins are scaffold molecules that contain a caspase recruitment domain and a membrane-associated guanylate kinase-like domain. CARMA1 plays a critical role in mediating activation of the NFkappaB transcription factor following antigen receptor stimulation of both B and T lymphocytes. However, the biochemical mechanism by which CARMA1 regulates activation of NFkappaB remains to be determined. Here we have shown that CARMA1 and CARMA3 physically associate with Ikappa kinase gamma/NFkappaB essential modulator (IkappaKgamma-NEMO) in lymphoid and non-lymphoid cells. CARMA1 participates to an inducible large molecular complex that contains IkappaKgamma/NEMO, Bcl10, and IkappaKalpha/beta kinases. Expression of the NEMO-binding region of CARMA3 exerts a dominant negative effect on Bcl10-mediated activation of NFkappaB. Thus, our results provide direct evidence for physical and functional interaction between CARMA and the IkappaK complex and offer a biochemical framework to understand the molecular activities controlled by CARMA-1, -2, and -3 and Bcl10.	Univ Naples Federico II, BioGeM Consortium, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Lecce, Dipartimento Sci & Tecnol Biol & Ambientali, I-73100 Lecce, Italy; Univ Studi Sannio Benevento, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy	University of Naples Federico II; University of Naples Federico II; University of Salento; University of Sannio	Vito, P (corresponding author), Univ Naples Federico II, BioGeM Consortium, Via S Pansini 5, I-80131 Naples, Italy.	vito@unisannio.it	leonardi, antonio/A-2887-2009; vito, pasquale/ABF-5505-2020	leonardi, antonio/0000-0001-8636-9623; vito, pasquale/0000-0002-5721-7716; di jeso, bruno/0000-0001-8713-5984				Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	31	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34323	34331		10.1074/jbc.M402244200	http://dx.doi.org/10.1074/jbc.M402244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184390	hybrid			2022-12-25	WOS:000223134800031
J	Lai, MC; Tarn, WY				Lai, MC; Tarn, WY			Hypophosphorylated ASF/SF2 binds TAP and is present in messenger ribonucleoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON JUNCTION COMPLEX; RNA EXPORT; SPLICING FACTORS; SR PROTEINS; NUCLEAR IMPORT; RS DOMAIN; PHOSPHORYLATION; MEX67P; TRANSPORTIN-SR2; SURVEILLANCE	Serine/arginine-rich proteins (SR proteins) function in precursor mRNA (pre-mRNA) splicing and may also act as adaptors for mRNA export. SR proteins are dynamically phosphorylated in their RS domain, and differential phosphorylation modulates their splicing activity and subcellular localization. In this study, we investigated the influence of phosphorylation on the function of SR proteins in events occurring during mRNA maturation. Immunoprecipitation experiments showed that the mRNA export receptor TAP associates preferentially with the hypophosphorylated form of shuttling SR proteins, including ASF/SF2. Overexpression of ASF induced subnuclear relocalization of TAP to SR protein-enriched nuclear speckles, suggesting their interaction in vivo. Moreover, the ASF found in a nucleoplasmic fraction rich in heterogeneous nuclear ribonucleoprotein ( hnRNP) complexes is hyperphosphorylated, whereas mature messenger RNP (mRNP)-bound ASF is hypophosphorylated. Therefore, hypophosphorylation of ASF in mRNPs coincides with its higher affinity for TAP, suggesting that dephosphorylation of ASF promotes both its incorporation into mRNPs and recruitment of TAP for mRNA export. Thus, the phosphorylation state of RS domains may modulate the function of mammalian shuttling SR proteins during mRNA maturation or export.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018					Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Herold A, 2001, RNA, V7, P1768; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Yun CY, 2003, J BIOL CHEM, V278, P18050, DOI 10.1074/jbc.M211714200	30	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31745	31749		10.1074/jbc.C400173200	http://dx.doi.org/10.1074/jbc.C400173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15184380	hybrid			2022-12-25	WOS:000222726800100
J	Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L				Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L			Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects	ONCOGENE			English	Article						RAD1; DNA damage; checkpoint; replication	DNA-DAMAGE RESPONSE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MOUSE HUS1; PROTEIN; RAD17; ATR; CHK1; INTERACTS; HOMOLOG	The checkpoint sliding-clamp complex, Rad9/Rad1/Hus1, plays a critical role during initiation of checkpoint signals in response to DNA damage and replication disruption. We investigated the impact of loss of Rad1 on checkpoint function and on DNA replication in mammalian cells. We show that RAD1 is an essential gene for sustained cell proliferation and that loss of Rad1 causes destabilization of Rad9 and Hus1 and consequently disintegration of the sliding-clamp - complex. In Rad1-depleted cells, Atr-dependent Chk1 activation was impaired whereas Atm-mediated Chk2 activation was unaffected, suggesting that the sliding clamp is required primarily in Atr-dependent signal activation. Disruption of sliding-clamp function also caused a major defect in S-phase control. Rad1-depleted cells exhibited an RDS phenotype, indicating that damage-induced S-phase arrest was compromised by Rad1 loss. Furthermore, lack of Rad1 also affected the efficiency of replication recovery from DNA synthesis blockage, resulting in a prolonged S phase. These deficiencies may perpetually generate DNA strand breakage as we have found chromosomal abnormalities in Rad1-depleted cells. We conclude that the Rad9/Rad1/Hus1 complex is essential for Atr-dependent checkpoint signaling, which may play critical roles in the facilitation of DNA replication and in the maintenance of genomic integrity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Li, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, 1515 Holcombe Blvd, Houston, TX 77030 USA.	leili@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA076172, R29CA076172, R01CA091029] Funding Source: NIH RePORTER; NCI NIH HHS [CA76172, CA91029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo JA, 2001, GENE DEV, V15, P2809; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Wang X, 2001, CANCER RES, V61, P7417; Weiss RS, 1999, GENOMICS, V59, P32, DOI 10.1006/geno.1999.5865; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	46	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5586	5593		10.1038/sj.onc.1207753	http://dx.doi.org/10.1038/sj.onc.1207753			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184880				2022-12-25	WOS:000222629500003
J	King, CC; Newton, AC				King, CC; Newton, AC			The adaptor protein Grb14 regulates the localization of 3-phosphoinositide-dependent kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; GROWTH-FACTOR RECEPTOR; ACTIVATED INSULIN-RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE LOCALIZATION; GLUCOSE-HOMEOSTASIS; CARBOXYL-TERMINUS; C ISOZYMES; I RECEPTOR	The metabolic actions of insulin are transduced through the phosphatidylinositol 3-kinase pathway. A criticalcomponentof thispathwayis 3-phosphoinositide-dependent kinase-1 (PDK-1), a PH domain-containing enzyme that catalyzes the activating phosphorylation for many AGC kinases, including Akt and protein kinase C isozymes. We used a directed proteomics-based approach to identify the adaptor protein Grb14, which binds the insulin receptor through an SH2 domain, as a novel PDK-1 binding partner. Interaction of these two proteins is constitutive and mediated by a PDK-1 binding motif on Grb14. Disruption of this motif by point mutation or deletion of the Grb14 SH2 domain prevents the insulin-triggered membrane translocation of PDK-1. The interaction of PDK-1 with Grb14 facilitates Akt function: disruption of the interaction by overexpression of a construct of Grb14 mutated in the PDK-1 binding motif significantly decreases insulin-dependent activation of Akt. Thus, Grb14 serves as an adaptor protein to recruit PDK-1 to activated insulin receptor, thus promoting Akt phosphorylation and transduction of the insulin signal.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NIDDK NIH HHS [DK07233] Funding Source: Medline; NIGMS NIH HHS [GM067946] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067946] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Bevan P, 2001, J CELL SCI, V114, P1429; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Egawa K, 2002, J BIOL CHEM, V277, P38863, DOI 10.1074/jbc.M203132200; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hemming R, 2001, BIOCHEM CELL BIOL, V79, P21, DOI 10.1139/bcb-79-1-21; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Tian XJ, 2002, EMBO J, V21, P1327, DOI 10.1093/emboj/21.6.1327; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	46	31	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37518	37527		10.1074/jbc.M405340200	http://dx.doi.org/10.1074/jbc.M405340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15210700	hybrid			2022-12-25	WOS:000223554600042
J	Kondo, T; Kahn, CR				Kondo, T; Kahn, CR			Altered insulin signaling in retinal tissue in diabetic states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCED DOWN-REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; ANIMAL-MODELS; UP-REGULATION; RISK-FACTORS; RETINOPATHY; ACTIVATION; MUSCLE	Both type 1 and type 2 diabetes can lead to altered retinal microvascular function and diabetic retinopathy. Insulin signaling may also play a role in this process, and mice lacking insulin receptors in endothelial cells are protected from retinal neovascularization. To define the role of diabetes in retinal function, we compared insulin signaling in the retinal vasculature of mouse models of type 1 ( streptozotocin) and type 2 diabetes (ob/ob). In streptozotocin mice, in both retina and liver, insulin receptor (IR) and insulin receptor substrate (IRS)-2 protein and tyrosine phosphorylation were increased by insulin, while IRS-1 protein and its phosphorylation were maintained. By contrast, in ob/ob mice, there was marked down-regulation of IR, IRS-1, and IRS-2 protein and phosphorylation in liver; these were maintained or increased in retina. In both mice, Phosphatidylinositol 3,4,5-trisphosphate generation by acute insulin stimulation was enhanced in retinal endothelial cells. On the other hand, protein levels and phosphorylation of PDK1 and Akt were decreased in retina of both mice. Interestingly, phosphorylation of p38 mitogen-activated protein kinase and ERK1 were responsive to insulin in retina of both mice but were unresponsive in liver. HIF-1alpha and vascular endothelial growth factor were increased and endothelial nitric-oxide synthase was decreased in retina. These observations indicate that, in both insulin-resistant and insulin-deficient diabetic states, there are alterations in insulin signaling, such as impaired PDK/Akt responses and enhanced mitogen-activated protein kinases responses that could contribute to the retinopathy. Furthermore, insulin signaling in retinal endothelial cells is differentially altered in diabetes and is also differentially regulated from insulin signaling in classical target tissues such as liver.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	CLIHON, Residencia Medica/K-4896-2013; Kahn, Ronald/AAY-2435-2021	CLIHON, Residencia Medica/0000-0001-6734-2513; Kahn, Ronald/0000-0002-7583-9228; Kondo, Tatsuya/0000-0003-4830-8955	NIDDK NIH HHS [DK33201, DK31036, DK53105] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053105, R01DK031036, R37DK031036, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler AI, 2002, DIABETES CARE, V25, P894, DOI 10.2337/diacare.25.5.894; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Cardillo C, 1999, CIRCULATION, V100, P820, DOI 10.1161/01.CIR.100.8.820; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chaturvedi N, 2001, DIABETES CARE, V24, P284, DOI 10.2337/diacare.24.2.284; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Henricsson M, 1997, DIABETIC MED, V14, P123, DOI 10.1002/(SICI)1096-9136(199702)14:2<123::AID-DIA306>3.0.CO;2-U; Igarashi M, 2000, EUR J CLIN INVEST, V30, P668; KAHN CR, 1973, J BIOL CHEM, V248, P244; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1995, J BIOL CHEM, V270, P24972, DOI 10.1074/jbc.270.42.24972; Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Reiter CEN, 2003, PROG RETIN EYE RES, V22, P545, DOI 10.1016/S1350-9462(03)00035-1; Rojas FA, 2001, MOL CELL ENDOCRINOL, V183, P63, DOI 10.1016/S0303-7207(01)00597-4; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; ROYSARKAR TK, 1993, AM J OPHTHALMOL, V115, P569, DOI 10.1016/S0002-9394(14)71452-7; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SOLL AH, 1975, J BIOL CHEM, V250, P4702; Suzuki M, 2000, J DIABETES COMPLICAT, V14, P40, DOI 10.1016/S1056-8727(00)00052-0; Ten Vadim S, 2002, Curr Opin Crit Care, V8, P242, DOI 10.1097/00075198-200206000-00008; TOZZO E, 1992, DIABETES, V41, P1609, DOI 10.2337/diabetes.41.12.1609; Vicent D, 2003, J CLIN INVEST, V111, P1373, DOI 10.1172/JCI200315211; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; ZETTERSTROM C, 1992, DIABETES, V41, P818, DOI 10.2337/diabetes.41.7.818	44	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37997	38006		10.1074/jbc.M401339200	http://dx.doi.org/10.1074/jbc.M401339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15201286	hybrid			2022-12-25	WOS:000223554600093
J	Lisman, Q; Urli-Stam, D; Holthuis, JCM				Lisman, Q; Urli-Stam, D; Holthuis, JCM			HOR7, a multicopy suppressor of the Ca(2+)induced growth defect in sphingolipid mannosyltransferase-deficient yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; HEAT-STRESS; PROTEIN; GENE; MUTATIONS; PHOSPHATASE; TOLERANCE; REQUIRES	Yeast mutants defective in sphingolipid mannosylation accumulate inositol phosphorylceramide C (IPC-C), which renders cells Ca2+-sensitive. A screen for loss of function suppressors of the Ca2+-sensitive phenotype previously led to the identification of numerous genes involved in IPC-C synthesis. To better understand the molecular basis of the Ca2+-induced growth defect in IPC-C-overaccumulating cells, we searched for genes whose overexpression restored Ca2+ tolerance in a mutant lacking the IPC mannosyltransferases Csg1p and Csh1p. Here we report the isolation of HOR7 as a multicopy suppressor of the Ca2+-sensitive phenotype of Deltacsg1Deltacsh1 cells. HOR7 belongs to a group of hyperosmolarity-responsive genes and encodes a small (59-residue) type I membrane protein that localizes at the plasma membrane. Hor7p is not required for high Ca2+ or Na+ tolerance. Instead, we find that Hor7p-overproducing cells display an increased resistance to high salt, sensitivity to low pH, and a reduced uptake of methylammonium, an indicator of the plasma membrane potential. These phenotypes are induced through a mechanism independent of the plasma membrane H+-ATPase, Pma1p. Our findings suggest that induction of Hor7p causes a depolarization of the plasma membrane that may counteract a Ca2+-induced influx of toxic cations in IPC-C-overaccumulating cells.	Univ Utrecht, Fac Chem, Dept Membrane Enxymol, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Holthuis, JCM (corresponding author), Univ Utrecht, Fac Chem, Dept Membrane Enxymol, Ctr Biomembranes & Lipid Enzymol, HR Kruytgebouw N605,Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.c.holthuis@chem.uu.nl	Holthuis, Joost/AAL-9157-2020	Holthuis, Joost/0000-0001-8912-1586				Ambesi A, 2000, J EXP BIOL, V203, P155; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kobayashi N, 1996, BIOCHEM BIOPH RES CO, V229, P540, DOI 10.1006/bbrc.1996.1840; Leber A, 1997, FEBS LETT, V411, P211, DOI 10.1016/S0014-5793(97)00692-3; Lisman Q, 2004, J BIOL CHEM, V279, P1020, DOI 10.1074/jbc.M306119200; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; NAVARRE C, 1992, J BIOL CHEM, V267, P6425; Navarre C, 2000, EMBO J, V19, P2515, DOI 10.1093/emboj/19.11.2515; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; Withee JL, 1998, GENETICS, V149, P865; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	40	6	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36390	36396		10.1074/jbc.M406197200	http://dx.doi.org/10.1074/jbc.M406197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208314	hybrid, Green Published			2022-12-25	WOS:000223453600029
J	Clarke, BR; Cuthbertson, L; Whitfield, C				Clarke, BR; Cuthbertson, L; Whitfield, C			Nonreducing terminal modifications determine the chain length of polymannose O antigens of Escherichia coli and couple chain termination to polymer export via an ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-1 CAPSULAR POLYSACCHARIDES; STEAROTHERMOPHILUS NRS 2004/3A; RHIZOBIUM-ETLI CE3; VIBRIO-CHOLERAE O1; COILED-COIL DOMAIN; SHIGELLA-FLEXNERI; KLEBSIELLA-PNEUMONIAE; SALMONELLA-ENTERICA; POLYACRYLAMIDE GELS; SERUM RESISTANCE	The chain length of bacterial lipopolysaccharide O antigens is regulated to give a modal distribution that is critical for pathogenesis. This paper describes the process of chain length determination in the ATP-binding cassette (ABC) transporter-dependent pathway, a pathway that is widespread among Gram-negative bacteria. Escherichia coli O8 and O9/O9a polymannans are synthesized in the cytoplasm, and an ABC transporter exports the nascent polymer across the inner membrane prior to completion of the LPS molecule. The polymannan O antigens have nonreducing terminal methyl groups. The 3-O-methyl group in serotype O8 is transferred from S-adenosylmethionine by the WbdD(O8) enzyme, and this modification terminates polymerization. Methyl groups are added to the O9a polymannan in a reaction dependent on preceding phosphorylation. The bifunctional WbdD(O9a) catalyzes both reactions, but only the kinase activity controls chain length. Chain termination occurs in a mutant lacking the ABC transporter, indicating that it precedes export. An E. coli wbdD(O9a) mutant accumulated O9a polymannan in the cytoplasm, indicating that WbdD activity coordinates polymannan chain termination with export across the inner membrane.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Guelph	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca						Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; BASTIN DA, 1993, MOL MICROBIOL, V7, P725, DOI 10.1111/j.1365-2958.1993.tb01163.x; BATCHELOR RA, 1991, J BACTERIOL, V173, P5699, DOI 10.1128/jb.173.18.5699-5704.1991; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Burns SM, 1998, INFECT IMMUN, V66, P4244; Daniell SJ, 2001, INFECT IMMUN, V69, P4055, DOI 10.1128/IAI.69.6.4055-4064.2001; Delahay RM, 1999, J BIOL CHEM, V274, P35969, DOI 10.1074/jbc.274.50.35969; Duelli DM, 2001, J BACTERIOL, V183, P6054, DOI 10.1128/JB.183.20.6054-6064.2001; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Franco AV, 1998, J BACTERIOL, V180, P2670, DOI 10.1128/JB.180.10.2670-2675.1998; GOLDMAN RC, 1990, J BACTERIOL, V172, P5352, DOI 10.1128/jb.172.9.5352-5359.1990; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Hong M, 1997, MOL MICROBIOL, V24, P779, DOI 10.1046/j.1365-2958.1997.3731744.x; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; JANSSON PE, 1985, CARBOHYD RES, V145, P59, DOI 10.1016/S0008-6215(00)90412-9; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; Kido N, 2000, J BACTERIOL, V182, P2567, DOI 10.1128/JB.182.9.2567-2573.2000; Klee SR, 1997, J BACTERIOL, V179, P2421, DOI 10.1128/jb.179.7.2421-2425.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawton DG, 2002, J BIOL CHEM, V277, P38714, DOI 10.1074/jbc.M203632200; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; Lerouge I, 2003, MOL PLANT MICROBE IN, V16, P1085, DOI 10.1094/MPMI.2003.16.12.1085; Lerouge I, 2001, J BIOL CHEM, V276, P17190, DOI 10.1074/jbc.M101129200; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller J. H., 1972, EXPT MOL GENETICS, P431; Morona R, 2003, FEMS MICROBIOL LETT, V221, P173, DOI 10.1016/S0378-1097(03)00210-6; Morona R, 2003, FEMS MICROBIOL LETT, V221, P213, DOI 10.1016/S0378-1097(03)00217-9; Morona R, 2003, MICROBIOL-SGM, V149, P925, DOI 10.1099/mic.0.26141-0; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; Murray GL, 2003, MOL MICROBIOL, V47, P1395, DOI 10.1046/j.1365-2958.2003.03383.x; Najdenski H, 2003, FEMS IMMUNOL MED MIC, V38, P97, DOI 10.1016/S0928-8244(03)00183-4; Novotny R, 2004, MICROBIOL-SGM, V150, P953, DOI 10.1099/mic.0.26672-0; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; SCHMIDT MA, 1982, FEMS MICROBIOL LETT, V14, P69, DOI 10.1016/0378-1097(82)90045-3; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Stricker J, 2003, J BACTERIOL, V185, P4796, DOI 10.1128/JB.185.16.4796-4805.2003; STROEHER UH, 1992, P NATL ACAD SCI USA, V89, P2566, DOI 10.1073/pnas.89.7.2566; Sugiyama T, 1997, GENE, V198, P111, DOI 10.1016/S0378-1119(97)00300-4; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VanDenBosch L, 1997, MOL MICROBIOL, V23, P765, DOI 10.1046/j.1365-2958.1997.2541625.x; Vinogradov E, 2002, CARBOHYD RES, V337, P961; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; WHITFIELD C, 1989, J GEN MICROBIOL, V135, P2589; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200; [No title captured]	67	94	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35709	35718		10.1074/jbc.M404738200	http://dx.doi.org/10.1074/jbc.M404738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15184370	hybrid			2022-12-25	WOS:000223303400069
J	Liaw, SH; Chang, YJ; Lai, CT; Chang, HC; Chang, GG				Liaw, SH; Chang, YJ; Lai, CT; Chang, HC; Chang, GG			Crystal structure of Bacillus subtilis guanine deaminase - The first domain-swapped structure in the cytidine deaminase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDYLATE DEAMINASE; FUNCTIONAL-ANALYSIS; PROTEIN; INSIGHTS; ENZYMES; ASSOCIATION; MOLSCRIPT; SEQUENCE; CLONING; GENES	Guanine deaminase, a key enzyme in the nucleotide metabolism, catalyzes the hydrolytic deamination of guanine into xanthine. The crystal structure of the 156-residue guanine deaminase from Bacillus subtilis has been solved at 1.17-Angstrom resolution. Unexpectedly, the C-terminal segment is swapped to form an intersubunit active site and an intertwined dimer with an extensive interface of 3900 Angstrom(2) per monomer. The essential zinc ion is ligated by a water molecule together with His(53), Cys(83), and Cys(86). A transition state analog was modeled into the active site cavity based on the tightly bound imidazole and water molecules, allowing identification of the conserved deamination mechanism and specific substrate recognition by Asp(114) and Tyr(156'). The closed conformation also reveals that substrate binding seals the active site entrance, which is controlled by the C-terminal tail. Therefore, the domain swapping has not only facilitated the dimerization but has also ensured specific substrate recognition. Finally, a detailed structural comparison of the cytidine deaminase superfamily illustrates the functional versatility of the divergent active sites found in the guanine, cytosine, and cytidine deaminases and suggests putative specific substrate-interacting residues for other members such as dCMP deaminases.	Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 11221, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Liaw, SH (corresponding author), Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan.	shliaw@ym.edu.tw	Lai, Cheng-Tsung/H-6728-2013	Lai, Cheng-Tsung/0000-0002-1192-2815				BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canbolat O, 1996, BREAST CANCER RES TR, V37, P189, DOI 10.1007/BF01806500; Chang YJ, 2004, ACTA CRYSTALLOGR D, V60, P1152, DOI 10.1107/S0907444904008558; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Durak I, 1997, CANCER INVEST, V15, P212, DOI 10.3109/07357909709039717; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fassbinder F, 2000, FEMS MICROBIOL LETT, V191, P191, DOI 10.1111/j.1574-6968.2000.tb09339.x; GREEN SM, 1995, NAT STRUCT BIOL, V2, P746, DOI 10.1038/nsb0995-746; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Keefe RG, 2000, J BIOL CHEM, V275, P12598, DOI 10.1074/jbc.275.17.12598; Keegan LP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-209; Ko TP, 2003, J BIOL CHEM, V278, P19111, DOI 10.1074/jbc.M300874200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuwahara H, 1999, J BIOL CHEM, V274, P32204, DOI 10.1074/jbc.274.45.32204; Lai WL, 2004, J BIOL CHEM, V279, P13962, DOI 10.1074/jbc.M308849200; Liou JY, 2003, MOL PHARMACOL, V63, P105, DOI 10.1124/mol.63.1.105; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Matsunaga Hiroko, 2003, Journal of Medical Investigation, V50, P64; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nygaard P, 2000, MICROBIOL-UK, V146, P3061, DOI 10.1099/00221287-146-12-3061; Paletzki RF, 2002, NEUROSCIENCE, V109, P15, DOI 10.1016/S0306-4522(01)00352-9; Roberts ELL, 2004, ANAL BIOCHEM, V324, P250, DOI 10.1016/j.ab.2003.09.041; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xiang SB, 1997, BIOCHEMISTRY-US, V36, P4768, DOI 10.1021/bi963091e; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	34	45	48	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35479	35485		10.1074/jbc.M405304200	http://dx.doi.org/10.1074/jbc.M405304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15180998	hybrid			2022-12-25	WOS:000223303400041
J	Berryman, M; Bruno, J; Price, J; Edwards, JC				Berryman, M; Bruno, J; Price, J; Edwards, JC			CLIC-5A functions as a chloride channel in vitro and associates with the cortical actin cytoskeleton in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PLACENTAL MICROVILLI; EPITHELIAL-CELLS; PLASMA-MEMBRANE; PROTEIN; FAMILY; MEMBER; EZRIN; IDENTIFICATION; AKAP350	CLIC-5A is a member of the chloride intracellular channel protein family, which is comprised of six related human genes encoding putative chloride channels. In this study, we found that reconstitution of purified recombinant CLIC-5A into artificial liposomes resulted in a dose-dependent chloride efflux that was sensitive to the chloride channel blocker IAA-94. CLIC-5A was originally isolated as a component of an ezrin-containing cytoskeletal complex from human placental microvilli. Here we show that similar protein complexes can be isolated using either immobilized CLIC-5A or the C-terminal F-actin-binding domain of ezrin and that actin polymerization is required for de novo assembly of these complexes. To investigate the behavior of CLIC-5A in vivo, JEG-3 placental choriocarcinoma cells were stably transfected with epitope-tagged CLIC-5A. In fixed cells, CLIC-5A displayed a polarized distribution and colocalized with ezrin in apical microvilli. Microvillar localization of CLIC-5A was retained after Triton X-100 extraction and was disrupted by treatment with latrunculin B. In transient transfections assays, we mapped a region between residues 20 and 54 of CLIC-5A that is required for targeting of CLIC-5A to microvilli in JEG-3 cells. Interestingly, expression of CLIC-5A in JEG-3 cells did not enhance the rate of iodide efflux in intact cells, suggesting that if CLIC-5A is a chloride channel, its channel activity may be restricted to intracellular membrane compartments in these cells. Regardless of its role in ion transport, CLIC-5A, like ezrin, may play an important role in the assembly or maintenance of F-actin-based structures at the cell cortex.	Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Ohio Univ, Mol & Cellular Biol Program, Athens, OH 45701 USA; St Louis Univ, St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA; St Louis Univ, Dept Med, St Louis, MO 63106 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; Saint Louis University; Saint Louis University	Berryman, M (corresponding author), Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, 237 Life Sci Bldg, Athens, OH 45701 USA.	berryman@ohiou.edu	Bruno, Jonathan/HII-3034-2022		NIDDK NIH HHS [R01 DK 060551] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060551] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENZEEV A, 1986, EXP CELL RES, V164, P335, DOI 10.1016/0014-4827(86)90033-9; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Berryman MA, 2003, CELL MOTIL CYTOSKEL, V56, P159, DOI 10.1002/cm.10141; BRETSCHER A, 1978, J CELL BIOL, V79, P839, DOI 10.1083/jcb.79.3.839; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARLSON RW, 1976, J BIOL CHEM, V251, P4139; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Friedli M, 2003, GENE, V320, P31, DOI 10.1016/S0378-1119(03)00830-8; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Griffon N, 2003, MOL BRAIN RES, V117, P47, DOI 10.1016/S0169-328X(03)00283-3; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; Proutski I, 2002, BIOCHEM BIOPH RES CO, V297, P317, DOI 10.1016/S0006-291X(02)02199-X; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200	30	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34794	34801		10.1074/jbc.M402835200	http://dx.doi.org/10.1074/jbc.M402835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184393	hybrid			2022-12-25	WOS:000223134800087
J	Fournier, KM; Gonzalez, MI; Robinson, MB				Fournier, KM; Gonzalez, MI; Robinson, MB			Rapid trafficking of the neuronal glutamate transporter, EAAC1 - Evidence for distinct trafficking pathways differentially regulated by protein kinase C and platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR TRAFFICKING; CELL-SURFACE EXPRESSION; INSULIN RECRUITS GLUT4; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; SYNAPTIC LOCALIZATION; PLASMA-MEMBRANE; GABA SYNTHESIS; SYNTAXIN 1A; ACTIVATION	The neuronal glutamate transporter, EAAC1, appears to both limit spillover between excitatory synapses and provide precursor for the synthesis of the inhibitory neurotransmitter, gamma-aminobutyric acid. There is evidence for a large intracellular pool of EAAC1 from which transporter is redistributed to the cell surface following activation of protein kinase C ( PKC) or platelet-derived growth factor ( PDGF) receptor by seemingly independent pathways. A variety of biotinylation strategies were employed to measure trafficking of EAAC1 to and from the plasma membrane and to examine the effects of phorbol ester and PDGF on these events. Biotinylation of cell surface protein under trafficking-permissive conditions ( 37 degreesC) resulted in a 2-fold increase in the amount of biotinylated EAAC1 within 15 min in C6 glioma and in primary neuronal cultures, suggesting that EAAC1 has a half-life of similar to 5 - 7 min for residence at the plasma membrane. Both phorbol ester and PDGF increased the amount of transporter labeled under these conditions. Using a reversible biotinylation strategy, a similarly rapid internalization of EAAC1 was observed in C6 glioma. Phorbol ester, but not PDGF, blocked this measure of internalization. Incubation at 18 degreesC, which blocks some forms of intracellular membrane trafficking, inhibited PKC- and PDGF-dependent redistribution of EAAC1 but had no effect on basal trafficking of EAAC1. These studies suggest that both PKC and PDGF accelerate delivery of EAAC1 to the cell surface and that PKC has an additional effect on endocytosis. The data also suggest that basal and regulated pools of EAAC1 exist in distinct compartments.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), 502N Anramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32 MH 014654] Funding Source: Medline; NINDS NIH HHS [NS 39011] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara S G, 1998, Adv Pharmacol, V42, P164; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Beckman ML, 2000, NEUROSCIENTIST, V6, P199, DOI 10.1177/107385840000600310; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Butchbach MER, 2003, J NEUROCHEM, V84, P891, DOI 10.1046/j.1471-4159.2003.01588.x; Cheatham B, 2000, TRENDS ENDOCRIN MET, V11, P356, DOI 10.1016/S1043-2760(00)00308-8; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Crino PB, 2002, EPILEPSIA, V43, P211, DOI 10.1046/j.1528-1157.2002.35001.x; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Deken SL, 2003, J NEUROSCI, V23, P1563; Diamond JS, 2002, NAT NEUROSCI, V5, P291, DOI 10.1038/nn0402-291; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Dowd LA, 1996, MOL PHARMACOL, V49, P465; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375; Ferguson SM, 2003, J NEUROSCI, V23, P9697; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gonzalez MI, 2003, J NEUROSCI, V23, P5589; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2001, NEUROSCI LETT, V311, P161, DOI 10.1016/S0304-3940(01)02180-2; He Y, 2000, J COMP NEUROL, V418, P255; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mathews GC, 2003, J NEUROSCI, V23, P2040; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Miller BT, 1997, PEPTIDES, V18, P1585, DOI 10.1016/S0196-9781(97)00225-8; Miller HP, 1997, J NEUROCHEM, V68, P1564; Moron JA, 2003, J NEUROSCI, V23, P8480; Morpurgo M, 1999, J BIOCHEM BIOPH METH, V38, P17, DOI 10.1016/S0165-022X(98)00027-X; Najimi M, 2002, FEBS LETT, V523, P224, DOI 10.1016/S0014-5793(02)02981-2; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Ribeiro FM, 2003, J NEUROCHEM, V87, P136, DOI 10.1046/j.1471-4159.2003.01974.x; Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Savchenko V, 2003, MOL CELL NEUROSCI, V24, P1131, DOI 10.1016/S1044-7431(03)00235-5; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Sung U, 2003, J NEUROSCI, V23, P1697; SUSARLA BTS, 2002, SOC NEUR ABSTR, V28; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; WIT H, 1999, MOL BIOL CELL, V10, P4163; Yang WB, 2002, J BIOL CHEM, V277, P38350, DOI 10.1074/jbc.M202052200	69	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34505	34513		10.1074/jbc.M404032200	http://dx.doi.org/10.1074/jbc.M404032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15197183	hybrid			2022-12-25	WOS:000223134800053
J	Le Stunff, H; Mikami, A; Giussani, P; Hobson, JP; Jolly, PS; Milstien, S; Spiegel, S				Le Stunff, H; Mikami, A; Giussani, P; Hobson, JP; Jolly, PS; Milstien, S; Spiegel, S			Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; KINASE; ACTIVATION; MOTILITY; PHOSPHOHYDROLASE; TRANSACTIVATION; INVOLVEMENT	Sphingosine-1-phosphate (S1P) is the ligand for a family of specific G protein-coupled receptors that regulate a wide variety of cellular functions, including cytoskeletal rearrangements and cell motility. Because of the pivotal role of S1P, its levels are low and tightly regulated in a spatial-temporal manner through its synthesis catalyzed by sphingosine kinases and degradation by an S1P lyase and specific S1P phosphatases (SPP). Surprisingly, down-regulation of SPP-1 enhanced migration toward epidermal growth factor (EGF); conversely, overexpression of SPP-1, which is localized in the endoplasmic reticulum, attenuated migration toward EGF. To determine whether the inhibitory effect on EGF-induced migration was because of decreased S1P or increased ceramide as a consequence of acylation of increased sphingosine by ceramide synthase, we used fumonisin B1, a specific inhibitor of ceramide synthase. Although fumonisin B1 blocked ceramide production and increased sphingosine, it did not reverse the negative effect of SPP-1 expression on EGF- or S1P-induced chemotaxis. EGF activated the epidermal growth factor receptor to the same extent in SPP-1-expressing cells, yet ERK1/2 activation was impaired. In agreement, PD98059, an inhibitor of the ERK-activating enzyme MEK, decreased EGF- stimulated migration. We next examined the possibility that intracellularly generated S1P might be involved in activating a G protein-coupled S1P receptor important for EGF- directed migration. Treatment with pertussis toxin to inactivate Galpha(i) suppressed EGF- induced migration. Moreover, expression of regulator of G protein signaling 3, which inhibits S1P receptor signaling and completely prevented ERK1/2 activation mediated by S1P receptors, not only reduced migration toward S1P but also markedly reduced migration toward EGF. Collectively, these results suggest that metabolism of S1P by SPP-1 is important for EGF- directed cell migration.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu	LE STUNFF, Hervé/AAA-6882-2019; Giussani, Paola/R-4268-2017	Giussani, Paola/0000-0002-7793-1757	NIGMS NIH HHS [GM 43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Auge N, 2002, ARTERIOSCL THROM VAS, V22, P1990, DOI 10.1161/01.ATV.0000043453.21629.3B; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Budnik LT, 2003, MOL ENDOCRINOL, V17, P1593, DOI 10.1210/me.2002-0371; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Cho H, 2003, BIOCHEM J, V371, P973, DOI 10.1042/BJ20021769; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2002, CANCER RES, V62, P6329; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Stukey J, 1997, PROTEIN SCI, V6, P469; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tanski W, 2002, J SURG RES, V108, P98, DOI 10.1006/jsre.2002.6529; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Whatmore J, 1999, BIOCHEM J, V341, P435, DOI 10.1042/0264-6021:3410435; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	57	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34290	34297		10.1074/jbc.M404907200	http://dx.doi.org/10.1074/jbc.M404907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180992	hybrid			2022-12-25	WOS:000223134800027
J	Ma, HP; Al-Khalili, O; Ramosevac, S; Saxena, S; Liang, YY; Warnock, DG; Eaton, DC				Ma, HP; Al-Khalili, O; Ramosevac, S; Saxena, S; Liang, YY; Warnock, DG; Eaton, DC			Steroids and exogenous gamma-ENaC subunit modulate cation channels formed by alpha-ENaC in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; BETA-SUBUNIT; II CELLS; EXPRESSION; NEDD4; CLONING; RECONSTITUTION	Previous studies using whole-cell recording methods suggest that human B lymphocytes express an amiloride-sensitive, sodium-permeable channel. The present studies aim to determine whether this channel has biophysical properties and a molecular structure related to the alpha, beta, and gamma subunits of the epithelial sodium channel ( ENaC). Reverse transcriptase polymerase chain reaction and Northern blots showed that human B lymphocytes express messages for both alpha- and beta- but not gamma-ENaC. Western blots showed that both alpha- and beta- but not gamma-ENaC proteins are expressed and strongly reduced by antisense oligonucleotides. Patch clamp experiments demonstrated that lymphocyte sodium channels are not active in cell-attached patches. However, membrane stretch can activate a 21-pS nonselective cation channel. The frequency of observance of this channel was significantly reduced by antisense oligonucleotide against alpha-ENaC but not by antisense oligonucleotide against beta-ENaC, indicating that only the alpha subunit of ENaC is necessary to form stretch-activated cation channels. Aldosterone (1.5 muM) reduced the frequency of observance of 21-pS alpha-ENaC channels and simultaneously induced the appearance of spontaneously active 10-pS channels. Antisense oligonucleotide experiments showed that this 10-pS channel is formed from alpha- and beta-ENaC. After expression of exogenous gamma-ENaC, aldosterone again reduced the frequency of observance of the 21-pS alpha-ENaC channel but induced the appearance of a 5-pS channel, presumably a alphabetagamma-ENaC channel. In the absence of aldosterone, the alpha subunit forms an alpha-cryptic channel that is activated by stretch, and in the presence of aldosterone, beta and alpha subunits together form an active channel that is modulated by aldosterone.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; Stevens Inst Technol, Dept Chem & Biol Chem, Hoboken, NJ 07030 USA	Emory University; Emory University; University of Alabama System; University of Alabama Birmingham; Stevens Institute of Technology	Ma, HP (corresponding author), Emory Univ, Sch Med, Dept Physiol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	hma@physio.eory.edu		Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053161, R37DK037963, R01DK057717, R01DK067110, R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01 DK067110, 1R24 DK064399, 1R01 DK57717, 1R37 DK037963, 1R01 DK53161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achard JM, 1996, AM J PHYSIOL-CELL PH, V270, pC224, DOI 10.1152/ajpcell.1996.270.1.C224; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; BRADFORD AL, 1995, AM J PHYSIOL-CELL PH, V269, pC601, DOI 10.1152/ajpcell.1995.269.3.C601; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; Bubien JK, 2001, J BIOL CHEM, V276, P8557, DOI 10.1074/jbc.M008886200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Cui Y, 1997, P NATL ACAD SCI USA, V94, P9962, DOI 10.1073/pnas.94.18.9962; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Jain L, 1998, AM J PHYSIOL-LUNG C, V274, pL475, DOI 10.1152/ajplung.1998.274.4.L475; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Lazrak A, 2000, AM J PHYSIOL-CELL PH, V279, pC762, DOI 10.1152/ajpcell.2000.279.3.C762; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Malik B, 2002, FASEB J, V16, pA477; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Marunaka Y, 1999, J PHYSIOL-LONDON, V515, P669, DOI 10.1111/j.1469-7793.1999.669ab.x; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; YUE G, 1995, P NATL ACAD SCI USA, V92, P8418, DOI 10.1073/pnas.92.18.8418; Zhou ZH, 2002, J MEMBRANE BIOL, V188, P97, DOI 10.1007/s00232-001-0176-0	33	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33206	33212		10.1074/jbc.M405455200	http://dx.doi.org/10.1074/jbc.M405455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15187080	hybrid			2022-12-25	WOS:000223039700025
J	Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A				Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A			Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt	ONCOGENE			English	Article						mTOR; BCL-2; microtubules; Akt; p70S6K; apoptosis	P70 S6 KINASE; MAMMALIAN TARGET; CELL-SURVIVAL; RAPAMYCIN; PROTEIN; GROWTH; LIFE; DEATH; INHIBITION; PATHWAY	The serine/threonine kinase mTOR, the major sensor of cell growth along the PI3K/Akt pathway, can be activated by agents acting on microtubules. Damaged microtubules induce phosphorylation of the Bcl-2 protein and lower the threshold of programmed cell death, both of which are inhibited by rapamycin. In HEK293 cells expressing Akt mutants, the level of Bcl-2 phosphorylation and the threshold of apoptosis induced by taxol or by nocodazole are significantly modified. In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6K(Thr421/Ser424) phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin. Moreover, DN-Akt cells were more sensitive to antitubule agents than CA-Akt cells. In nocodazole-treated HEK293 cells sorted according to cell cycle, the p70S6K(Thr421/Ser424) phosphorylation was associated to the G2/M fraction. More relevant, nocodazole inhibited, in a dose-response manner, mTOR phosphorylation at Ser2448. This activity, potentiated in DN-Akt cells, was not detectable in CA-Akt cells. Our results suggest that death signals originating from damaged microtubules in G2/M can compete with G1 survival pathways at the level of mTOR. These findings have implications for cancer therapy and drug resistance.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; CNR, Inst Biochem Technol, I-20090 Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Florence, Inst Gen Pathol, I-50134 Florence, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	D'Agnano, Igea/AAR-7282-2020; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; D'Agnano, Igea/0000-0002-2646-9224; Gatti, Giuliana/0000-0001-8844-4543				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bevilacqua A, 2003, J BIOL CHEM, V278, P23451, DOI 10.1074/jbc.M210620200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Church AC, 2003, QJM-INT J MED, V96, P91, DOI 10.1093/qjmed/hcg014; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DU L, 2003, P 94 AACR ANN M TOR; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Le XF, 2003, ONCOGENE, V22, P484, DOI 10.1038/sj.onc.1206175; Ling YH, 2002, MOL CANCER THER, V1, P841; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	63	122	128	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5781	5791		10.1038/sj.onc.1207698	http://dx.doi.org/10.1038/sj.onc.1207698			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208671				2022-12-25	WOS:000222629800007
J	Zugaza, JL; Caloca, MJ; Bustelo, XR				Zugaza, JL; Caloca, MJ; Bustelo, XR			Inverted signaling hierarchy between RAS and RAC in T-lymphocytes	ONCOGENE			English	Article						Vav; Rac1; RasGRP1; Ras; phospholipase C; T-lymphocytes	PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTORS; CELL-RECEPTOR SIGNALS; PHOSPHOLIPASE-C; RHO-GTPASES; SELECTIVE INHIBITOR; PLASMA-MEMBRANE; VAV FAMILY; ACTIVATION; PATHWAY	In order to generate coherent biological responses to extracellular stimuli, cells have established synergistic and antagonistic crosstalk between pathways with similar or opposing functions, respectively. Two routes cooperating in the generation of mitogenic and cytoskeletal functions are those induced by Ras and Rho/Rac GTPases. In these signaling interactions, Rho/Rac proteins have been always placed in a downstream position respect to Ras in all cell systems analysed so far. In this report, we describe that such signaling hierarchy does not apply to T-lymphocytes. Thus, we show that both Racl GDP/GTP exchange factors such as Vav and constitutively active versions of Racl can promote the effective stimulation of the Ras pathway in T-lymphocytes. The molecular link for this new type of pathway interconnectivity is RasGRP1, a diacylglycerol-dependent GDP/GTP exchange factor for Ras that translocates to the plasma membrane in a Vav- and Racl-dependent manner. The effect of the Vav/Rac1 pathway on the Ras pathway is highly dependent on the activity of phospholipase C-gamma, the key cellular supplier of intracellular diacylglycerol. Signaling experiments suggest that this crosstalk represents a signaling strategy used by the T-cell receptor to promote robust biological responses of both the Rac/Rho and Ras pathways upon antigen engagement.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Caloca, María-José/K-9357-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2002, HISTOL HISTOPATHOL, V17, P871, DOI 10.14670/HH-17.871; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Diaz-Flores E, 2003, J BIOL CHEM, V278, P29208, DOI 10.1074/jbc.M303165200; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Hogquist K, 2001, Trends Immunol, V22, P69, DOI 10.1016/S1471-4906(00)01845-7; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kranewitter WJ, 1999, FEBS LETT, V455, P123, DOI 10.1016/S0014-5793(99)00857-1; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Ohtsuka T, 1996, BBA-MOL CELL RES, V1310, P223, DOI 10.1016/0167-4889(95)00172-7; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; POWIS G, 1994, CANCER RES, V54, P2419; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; VASSILOPOULOS D, 1995, CLIN IMMUNOL IMMUNOP, V77, P59, DOI 10.1016/0090-1229(95)90137-X; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241; WU J, 1995, MOL CELL BIOL, V15, P4337; Yu H, 2001, J EXP MED, V194, P915, DOI 10.1084/jem.194.7.915; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	48	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5823	5833		10.1038/sj.onc.1207768	http://dx.doi.org/10.1038/sj.onc.1207768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184873				2022-12-25	WOS:000222629800012
J	Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y				Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y			Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform	ONCOGENE			English	Article						IGSF4; TSLC1; homophilic binding; splicing	IMMUNOGLOBULIN SUPERFAMILY; TSLC1 GENE; EXPRESSION; IDENTIFICATION; VCAM-1; LIGAND	SgIGSF (spermatogenic immunoglobulin superfamily) is a recently identified intercellular adhesion molecule of the immunoglobulin superfamily. In a mast-cell cDNA library, we found a clone that resulted from the retention of intron 7 within the mature SgIGSF message. This clone was predicted to encode a soluble isoform of SgIGSF (sSgIGSF) with 336 amino-acid residues because its open reading frame ended just before the transmembrane domain. We constructed a plasmid expressing sSgIGSF fused to the human IgG Fc fragment at its C-terminus (sSgIGSF-Fc), and transfected it into COS-7 cells. The fusion protein was readily detectable in the culture supernatant. Solid-phase binding assay showed that sSgIGSF interacted directly the extracellular domain of membrane-bound SgIGSF (mSgIGSF). We next examined whether this interaction inhibited homophilic binding of mSgIGSF by aggregation assays using L cells that did not express mSgIGSF. A stable L-cell clone that overexpressed mSgIGSF aggregated with each other but not with mock-transfected L cells, indicating that a homophilic interaction of mSgIGSF mediated the aggregation. Addition of sSgIGSF-Fc inhibited the aggregation of L cells overexpressing mSgIGSF in a dose-dependent manner. Moreover, FACScan analyses revealed the specific binding of sSgIGSF-Fc to mSgIGSF expressed in L cells. Binding of sSgIGSF-Fc to mSgIGSF appeared to inhibit homophilic interactions of mSgIGSF.	Osaka Univ, Sch Med, Dept Pathol, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan; Hyogo Med Ctr Adults, Dept Thorac Surg, Akashi, Hyogo 6738558, Japan	Osaka University; Kanazawa University	Ito, A (corresponding author), Kobe Univ, Grad Sch Med, Div Surg Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	akito@med.kobe-u.ac.jp						Budt M, 2002, BIOCHEM BIOPH RES CO, V292, P749, DOI 10.1006/bbrc.2002.6704; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; HAHNE M, 1994, EUR J IMMUNOL, V24, P421, DOI 10.1002/eji.1830240223; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; KAPLAN AJ, 1993, J IMMUNOL, V151, P4022; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MEYER DM, 1995, J IMMUNOL, V155, P3578; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Nakamoto K, 2001, AM J PATHOL, V159, P1363, DOI 10.1016/S0002-9440(10)62523-0; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; Pletcher MT, 2001, GENE, V273, P181, DOI 10.1016/S0378-1119(01)00592-3; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129	21	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5687	5692		10.1038/sj.onc.1207761	http://dx.doi.org/10.1038/sj.onc.1207761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184876				2022-12-25	WOS:000222629500014
J	Soulet, D; Gagnon, B; Rivest, S; Audette, M; Poulin, R				Soulet, D; Gagnon, B; Rivest, S; Audette, M; Poulin, R			A fluorescent probe of polyamine transport accumulates into intracellular acidic vesicles via a two-step mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ORGANIC CATION-TRANSPORT; GOLGI-APPARATUS; MAMMALIAN-CELLS; ORNITHINE DECARBOXYLASE; ENDOPLASMIC-RETICULUM; RECYCLING ENDOSOMES; BOVINE LYMPHOCYTES; PROTON PUMPS; RAT-LIVER	Mammalian polyamine carriers have not yet been molecularly identified. The fluoroprobe Spd-C-2-BODIPY faithfully reports polyamine transport and accumulates almost exclusively in polyamine-sequestering vesicles (PSVs). Polyamines might thus be imported first by a plasma membrane carrier and then sequestered into pre-existing PSVs (model A), or be directly captured by polyamine receptors undergoing endocytosis (model B). Spd-C-2-BODIPY uptake was unaffected in receptor-mediated endocytosis-deficient Chinese hamster ovary cell mutants. PSVs strongly colocalized with acidic vesicles of the late endocytic compartment and the trans Golgi. Virtually perfect colocalization between PSVs and acidic vesicles was found in Chinese hamster ovary cell mutants that are blocked either in the late endosome/lysosome fusion process or in the maturation of multivesicular bodies. Prior inhibition of the V-ATPase dramatically decreased total Spd-C-2-BODIPY accumulation while increasing cytosolic fluorescence. Conversely, cells pre-loaded with the probe slowly released it from PSVs upon V-ATPase inhibition. The present data thus support model A, and indicate that polyamine accumulation is primarily driven by the activity of a vesicular H+:polyamine carrier.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Anat & Pathol, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University; Laval University	Poulin, R (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	Richard.Poulin@crchul.ulaval.ca	Soulet, Denis/E-8677-2011; Soulet, Denis/P-4940-2019	Rivest, Serge/0000-0002-6082-770X; Soulet, Denis/0000-0002-0937-7061				ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; BERGERON RJ, 1986, BIOORG CHEM, V14, P345, DOI 10.1016/0045-2068(86)90001-5; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bour-Dill C, 2000, CYTOMETRY, V39, P16, DOI 10.1002/(SICI)1097-0320(20000101)39:1<16::AID-CYTO4>3.0.CO;2-I; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Casero RA, 2003, BIOCHEM SOC T, V31, P361, DOI 10.1042/BST0310361; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CRAMER CL, 1984, J BIOL CHEM, V259, P5152; Cullis PM, 1999, CHEM BIOL, V6, P717, DOI 10.1016/S1074-5521(00)80019-8; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Dubowchik GM, 1996, J ORG CHEM, V61, P4676, DOI 10.1021/jo960367f; Fujiwara K, 1996, HISTOCHEM CELL BIOL, V106, P465, DOI 10.1007/s004180050065; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Haugland R.P., 2002, HDB FLUORESCENT PROB; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; MACH M, 1982, BIOCHEM BIOPH RES CO, V104, P1327, DOI 10.1016/0006-291X(82)91395-X; Machen TE, 2003, AM J PHYSIOL-CELL PH, V285, pC205, DOI 10.1152/ajpcell.00008.2003; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; Masson J, 1999, PHARMACOL REV, V51, P439; Masuko T, 2003, J NEUROCHEM, V84, P610, DOI 10.1046/j.1471-4159.2003.01558.x; Miller DS, 1999, AM J PHYSIOL-CELL PH, V276, pC955, DOI 10.1152/ajpcell.1999.276.4.C955; Moriyama Y, 1996, J EXP BIOL, V199, P1447; MOSELEY RH, 1995, AM J PHYSIOL-GASTR L, V268, pG480, DOI 10.1152/ajpgi.1995.268.3.G480; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OCONNELL W, 1988, MD COMPUT, V5, P14; Ohashi M, 1999, J CELL SCI, V112, P1125; Ohashi M, 2000, J CELL SCI, V113, P2187; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Parkkinen JJ, 1997, J CELL BIOCHEM, V66, P165, DOI 10.1002/(SICI)1097-4644(19970801)66:2<165::AID-JCB4>3.3.CO;2-D; PEGG AE, 1988, CANCER RES, V48, P759; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; Poulin R, 1998, BIOCHEM J, V330, P1283, DOI 10.1042/bj3301283; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; Roch AM, 1997, HISTOCHEM CELL BIOL, V107, P303, DOI 10.1007/s004180050115; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; Rohn WM, 2000, J CELL SCI, V113, P2093; RUBINSTEIN S, 1994, BIOL CELL, V81, P177, DOI 10.1016/S0248-4900(94)80008-1; SEGLEN PO, 1980, MOL PHARMACOL, V18, P468; Soulet D, 2002, BIOCHEM J, V367, P347, DOI 10.1042/BJ20020764; Sugimoto Y, 2001, P NATL ACAD SCI USA, V98, P12391, DOI 10.1073/pnas.221181998; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; TOMODA H, 1989, J BIOL CHEM, V264, P15445; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Xie XZ, 1997, J BIOL CHEM, V272, P20484, DOI 10.1074/jbc.272.33.20484; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723	56	92	95	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49355	49366		10.1074/jbc.M401287200	http://dx.doi.org/10.1074/jbc.M401287200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15208319	hybrid			2022-12-25	WOS:000225098100105
J	Armengaud, J; Urbonavicius, J; Fernandez, B; Chaussinand, G; Bujnicki, JM; Grosjean, H				Armengaud, J; Urbonavicius, J; Fernandez, B; Chaussinand, G; Bujnicki, JM; Grosjean, H			N-2-methylation of guanosine at position 10 in tRNA is catalyzed by a THUMP domain-containing, S-adenosylmethionine-dependent methyltransferase, conserved in Archaea and Eukaryota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HALOBACTERIUM-VOLCANII; STRUCTURE PREDICTION; PARTIAL-PURIFICATION; MODIFIED NUCLEOSIDES; PROTEIN-STRUCTURE; RIBONUCLEIC-ACID; COG DATABASE; TRM1; YEAST	In sequenced genomes, genes belonging to the cluster of orthologous group COG1041 are exclusively, and almost ubiquitously, found in Eukaryota and Archaea but never in Bacteria. The corresponding gene products exhibit a characteristic Rossmann fold, S-adenosyl-methionine-dependent methyltransferase domain in the C terminus and a predicted RNA-binding THUMP ((t) under bar hiouridine synthases, RNA (m) under bar ethyltransferases, and (p) under bar seudouridine synthases) domain in the N terminus. Recombinant PAB1283 protein from the archaeon Pyrococcus abyssi GE5, a member of COG1041, was purified and shown to behave as a monomeric 39-kDa entity. This protein (EC 2.1.1.32), now renamed (Pab)Trm-G10, which is extremely thermostable, forms a 1:1 complex with tRNA and catalyzes the adenosylmethionine-dependent methylation of the exocyclic amino group (N-2) of guanosine located at position 10. Depending on the experimental conditions used, as well as the tRNA substrate tested, the enzymatic reaction leads to the formation of either N-2-monomethyl (m(2)G) or N-2-dimethylguanosine (m(2)(2)G). Interestingly, (Pab)Trm-G10 exhibits different domain organization and different catalytic site architecture from another, earlier characterized, tRNA-dimethyltransferase from Pyrococcus furiosus ((Pfu)Trm-G26, also known as (Pfu)Trm1, a member of COG1867) that catalyzes an identical two-step dimethylation of guanosine but at position 26 in tRNAs and is also conserved among all sequenced Eukaryota and Archaea. The co-occurrence of these two guanosine dimethyltransferases in both Archaea and Eukaryota but not in Bacteria is a hallmark of distinct tRNAs maturation strategies between these domains of life.	CEA, VALRHO, DSV DIEP SBTN, Serv Biochim Post Genom & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Armengaud, J (corresponding author), CEA, VALRHO, DSV DIEP SBTN, Serv Biochim Post Genom & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France.	armengaud@cea.fr	Urbonavičius, Jaunius/AAB-4740-2022	ARMENGAUD, Jean/0000-0003-1589-445X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P215, DOI 10.1016/S0968-0004(01)01826-6; Armengaud J, 2003, J BIOL CHEM, V278, P31078, DOI 10.1074/jbc.M301891200; Backmann J, 2001, METHOD ENZYMOL, V334, P328; Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6; Bujnicki JM, 2000, FASEB J, V14, P2365, DOI 10.1096/fj.00-0076com; Bujnicki JM, 2004, NUCL ACID M, V15, P139; Bujnicki JM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-10; Bujnicki JM, 2002, J MOL EVOL, V55, P431, DOI 10.1007/s00239-002-2339-8; Bujnicki JM, 2002, J MOL MICROB BIOTECH, V4, P405; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; Constantinesco F, 1998, NUCLEIC ACIDS RES, V26, P3753, DOI 10.1093/nar/26.16.3753; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; EDQVIST J, 1995, BIOCHIMIE, V77, P54, DOI 10.1016/0300-9084(96)88104-1; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; EDQVIST J, 1994, BIOCHEMISTRY-US, V33, P9546, DOI 10.1021/bi00198a021; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; Fitch WM, 2000, TRENDS GENET, V16, P227, DOI 10.1016/S0168-9525(00)02005-9; Fromant M, 2003, NUCLEIC ACIDS RES, V31, P3227, DOI 10.1093/nar/gkg428; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; GANGLOFF J, 1972, BIOCHIM BIOPHYS ACTA, V259, P210, DOI 10.1016/0005-2787(72)90060-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICK JM, 1978, BIOCHIM BIOPHYS ACTA, V518, P158, DOI 10.1016/0005-2787(78)90125-9; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GRAHAM DE, 2000, THESIS U ILLINOIS UR; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Grosjean Henri, 2004, Methods Mol Biol, V265, P357; GUPTA R, 1984, J BIOL CHEM, V259, P9461; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; Hartmann E, 2003, TRENDS GENET, V19, P561, DOI 10.1016/j.tig.2003.08.007; Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; Hopper AK, 2003, GENE DEV, V17, P162, DOI 10.1101/gad.1049103; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; IZZO P, 1977, BIOCHEMISTRY-US, V16, P3576, DOI 10.1021/bi00635a012; Johansson MJO, 2004, RNA, V10, P712, DOI 10.1261/rna.5198204; Kosinski J, 2003, PROTEINS, V53, P369, DOI 10.1002/prot.10545; KRAUS J, 1974, NUCLEIC ACIDS RES, V1, P1479, DOI 10.1093/nar/1.11.1479; KRAUS J, 1974, NUCLEIC ACIDS RES, V1, P1455, DOI 10.1093/nar/1.11.1455; Kurowski MA, 2003, NUCLEIC ACIDS RES, V31, P3305, DOI 10.1093/nar/gkg557; Lebars I, 2003, EMBO J, V22, P183, DOI 10.1093/emboj/cdg022; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; Liu JM, 1998, NUCLEIC ACIDS RES, V26, P5102, DOI 10.1093/nar/26.22.5102; Liu JM, 1999, GENE, V226, P73, DOI 10.1016/S0378-1119(98)00550-2; Liu JM, 2000, NUCLEIC ACIDS RES, V28, P3445, DOI 10.1093/nar/28.18.3445; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Makarova Kira S, 2003, Genome Biol, V4, P115, DOI 10.1186/gb-2003-4-8-115; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Matte-Tailliez O, 2000, TRENDS GENET, V16, P533, DOI 10.1016/S0168-9525(00)02137-5; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; MOTORIN Y, 2004, ENCY LIFE SCI, pA3866; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Niederberger C, 1999, FEBS LETT, V464, P67, DOI 10.1016/S0014-5793(99)01679-8; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; REINHART MP, 1986, NUCLEIC ACIDS RES, V14, P1131, DOI 10.1093/nar/14.3.1131; Rife JP, 1998, NUCLEIC ACIDS RES, V26, P3640, DOI 10.1093/nar/26.16.3640; ROE B, 1973, NATURE-NEW BIOL, V246, P135, DOI 10.1038/newbio246135a0; Rosas-Sandoval G, 2002, P NATL ACAD SCI USA, V99, P16707, DOI 10.1073/pnas.222659199; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; SINDHUPHAK T, 1985, BIOCHIM BIOPHYS ACTA, V824, P66, DOI 10.1016/0167-4781(85)90030-2; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Steinberg S, 1995, RNA, V1, P886; TAKEDA H, 2002, NUCL ACIDS RES S, V2, P229; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; TAYLOR MJ, 1979, BIOCHEMISTRY-US, V18, P5253, DOI 10.1021/bi00590a033; Terns MP, 2002, GENE EXPRESSION, V10, P17; UHLENBECK OC, 1995, RNA, V1, P4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	79	57	59	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37142	37152		10.1074/jbc.M403845200	http://dx.doi.org/10.1074/jbc.M403845200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210688	Green Published, hybrid			2022-12-25	WOS:000223453600118
J	Kacprzak, MM; Peinado, JR; Than, ME; Appel, J; Henrich, S; Lipkind, G; Houghten, RA; Bode, W; Lindberg, I				Kacprzak, MM; Peinado, JR; Than, ME; Appel, J; Henrich, S; Lipkind, G; Houghten, RA; Bode, W; Lindberg, I			Inhibition of furin by polyarginine-containing peptides - Nanomolar inhibition by NONA-D-arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MEDIATED CLEAVAGE; ENDOPROTEASE; ACTIVATION; COMPLEX	Polyarginine-containing peptides represent potent inhibitors of furin, a mammalian endoprotease that plays an important role in metabolism, activation of pathogenic toxins, and viral proliferation. The therapeutic use of D-polyarginines is especially interesting because they are not cleaved by furin and possess inhibitory potency almost equal to L-polyarginines. In this study we attempted to determine the important elements within polyarginines that contribute to effective inhibition. Structure-function analyses of polyarginine peptides showed that inhibition by polyarginine-containing peptides appeared to depend on the total number of basic charges of the positively charged inhibitors bound to the negatively charged substrate binding pocket; peptide positioning did not appear to be rigorously determined. Screening of L- and D-decapeptide positional scanning combinatorial peptide libraries indicated a preference for basic residues in nearly all positions, similar to previous results with hexapeptide libraries. Length and terminal modification studies showed that the most potent D-polyarginine tested was nona-D-arginine (D9R) amide with a K-i of 1.3 nM. D9R amide was shown to protect RAW264.7 cells against anthrax toxemia with an IC50 of 3.7 muM. Because of its high stability, specificity, low toxicity, small molecular weight, and extremely low K-i against furin, D9R amide or its derivatives may represent promising compounds for therapeutic use.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Max Planck Inst Biochem, Dept Struct Res, D-82152 Martinsried, Germany; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Max Planck Society; Torrey Pines Institute for Molecular Studies, California; University of Chicago	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsuhsc.edu	Lindberg, Iris/Q-3825-2019; Than, Manuel/F-7536-2015; Peinado, Juan R/A-3450-2011	Than, Manuel/0000-0002-4707-9225; Peinado, Juan R/0000-0002-0004-7963	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 53517-02] Funding Source: Medline; NIDA NIH HHS [R56 DA005084, R01 DA005084] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Chiron MF, 1997, J BIOL CHEM, V272, P31707, DOI 10.1074/jbc.272.50.31707; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; Fortenberry Y, 2002, J BIOL CHEM, V277, P5175, DOI 10.1074/jbc.M104531200; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Komiyama T, 2003, P NATL ACAD SCI USA, V100, P8205, DOI 10.1073/pnas.1032865100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lindberg I., 1995, METH NEUROSCI, V23, P94; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MERRITT EA, 1997, METHOD ENZYMOL, V24, P946; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; Turk D., 1992, THESIS TU MUENCHEN; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762	29	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36788	36794		10.1074/jbc.M400484200	http://dx.doi.org/10.1074/jbc.M400484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15197180	hybrid			2022-12-25	WOS:000223453600080
J	Sica, F; Di Fiore, A; Merlino, A; Mazzarella, L				Sica, F; Di Fiore, A; Merlino, A; Mazzarella, L			Structure and stability of the non-covalent swapped dimer of bovine seminal ribonuclease - An enzyme tailored to evade ribonuclease protein inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OLIGOMERIC PROTEINS; ANTITUMOR ACTION; RNASE; SUBSTRATE; MOTIONS; BINDING; EVOLUTION; MOLSCRIPT; CELLS	A growing number of pancreatic-type ribonucleases (RNases) present cytotoxic activity against malignant cells. The cytoxicity of these enzymes is related to their resistance to the ribonuclease protein inhibitor (RI). In particular, bovine seminal ribonuclease (BS-RNase) is toxic to tumor cells both in vitro and in vivo. BS-RNase is a covalent dimer with two intersubunit disulfide bridges between Cys(31) of one chain and Cys(32) of the second and vice versa. The native enzyme is an equilibrium mixture of two isomers, MxM and M=M. In the former the two subunits swap their N-terminal helices. The cytotoxic action is a peculiar property of MxM. In the reducing environment of cytosol, M=M dissociates into monomers, which are strongly inhibited by RI, whereas MxM remains as a non-covalent dimer (NCD), which evades RI. We have solved the crystal structure of NCD, carboxyamidomethylated at residues Cys(31) and Cys(32) (NCD-CAM), in a complex with 2'-deoxycitidylyl(3'-5')-2'-deoxyadenosine. The molecule reveals a quaternary structural organization much closer to MxM than to other N-terminal-swapped non-covalent dimeric forms of RNases. Model building of the complexes between these non-covalent dimers and RI reveals that NCD-CAM is the only dimer equipped with a quaternary organization capable of interfering seriously with the binding of the inhibitor. Moreover, a detailed comparative structural analysis of the dimers has highlighted the residues, which are mostly important in driving the quaternary structure toward that found in NCD-CAM.	Univ Naples Federico II, Dipartimento Chim, I-80126 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Salerno	Mazzarella, L (corresponding author), Univ Naples Federico II, Dipartimento Chim, Complesso Univ Monte Sant Angelo,Via Cynthia, I-80126 Naples, Italy.	lelio.mazzarella@unina.it	Merlino, Antonello/AAI-2114-2020; Di Fiore, Anna/AAX-5655-2020; Di Fiore, Anna/AAW-3780-2020	Di Fiore, Anna/0000-0003-2924-5194; Merlino, Antonello/0000-0002-1045-7720				Antignani A, 2001, BIOCHEMISTRY-US, V40, P3492, DOI 10.1021/bi002781m; Avitabile F, 2003, BIOCHEMISTRY-US, V42, P8704, DOI 10.1021/bi0342517; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berisio R, 2003, FEBS LETT, V554, P105, DOI 10.1016/S0014-5793(03)01114-1; Berisio R, 2002, ACTA CRYSTALLOGR D, V58, P441, DOI 10.1107/S0907444901021758; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; Canals A, 2001, STRUCTURE, V9, P967, DOI 10.1016/S0969-2126(01)00659-1; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cinatl J, 2000, ANTICANCER RES, V20, P853; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; D'Alessio G, 1999, EUR J BIOCHEM, V266, P699, DOI 10.1046/j.1432-1327.1999.00912.x; D'Alessio G, 1999, PROG BIOPHYS MOL BIO, V72, P271, DOI 10.1016/S0079-6107(99)00009-7; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; DIDONATO A, 1987, BIOCHEM J, V241, P435, DOI 10.1042/bj2410435; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P306; Haigis MC, 2003, NUCLEIC ACIDS RES, V31, P1024, DOI 10.1093/nar/gkg163; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; Matousek J, 2003, COMP BIOCHEM PHYS C, V136, P343, DOI 10.1016/j.cca.2003.10.005; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAZZARELLA L, 1995, P NATL ACAD SCI USA, V92, P3799, DOI 10.1073/pnas.92.9.3799; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Merlino A, 2004, BIOPOLYMERS, V73, P689, DOI 10.1002/bip.20016; Merlino A, 2004, BIOPHYS J, V86, P2383, DOI 10.1016/S0006-3495(04)74295-2; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; Merlino A, 2002, BIOPOLYMERS, V65, P274, DOI 10.1002/bip.10225; MIKULSKI SM, 1995, INT J ONCOL, V7, P1415; MIKULSKI SM, 1993, INT J ONCOL, V2, P807; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Murthy BS, 1996, BIOCHEMISTRY-US, V35, P3880, DOI 10.1021/bi952429m; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sica F, 2003, PROTEINS, V52, P263, DOI 10.1002/prot.10407; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; Vitagliano L, 1998, PROTEIN SCI, V7, P1691, DOI 10.1002/pro.5560070804; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; Vitagliano L, 1999, J MOL BIOL, V293, P569, DOI 10.1006/jmbi.1999.3158; Wei CW, 2002, FEBS LETT, V531, P421, DOI 10.1016/S0014-5793(02)03577-9; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	59	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36753	36760		10.1074/jbc.M405655200	http://dx.doi.org/10.1074/jbc.M405655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192098	hybrid			2022-12-25	WOS:000223453600076
J	Welsch, CA; Roth, LWA; Goetschy, JF; Movva, NR				Welsch, CA; Roth, LWA; Goetschy, JF; Movva, NR			Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; POSSESSING UNIQUE MECHANISMS; SPHINGOSINE 1-PHOSPHATE; GROWTH-INHIBITION; YEAST-CELLS; PROTEINS; BIOSYNTHESIS; KINASE; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION	Sphingolipids are signaling molecules that influence diverse cellular functions from control of the cell cycle to degradation of plasma membrane proteins. The synthetic sphingolipid-like compound FTY720 is an immunomodulating agent in clinical trials for transplant graft maintenance. In this report, we compare the effects of the natural yeast sphingolipid phytosphingosine with FTY720 in Saccharomyces cerevisiae. We show that the multicopy suppressor genes that induce growth resistance to FTY720 also confer resistance to growth-inhibitory concentrations of phytosphingosine. In addition, mutants for ubiquitination pathway proteins are shown to be resistant to the growth-inhibiting effect of both FTY720 and phytosphingosine. We observe fewer similarities between sphingosine and FTY720 than between FTY720 and phytosphingosine as revealed by genetic studies. Yeast cells lacking the specific sphingosine kinase LCB4 are sensitive to phytosphingosine and FTY720 but resistant to sphingosine, suggesting that FTY720 and phytosphingosine have a more related mechanism of action. Gene expression profile comparisons of sensitive and resistant yeast cells exposed to FTY720 and phytosphingosine highlight a number of similarities. In response to treatment with these compounds, similar to77% of the genes that are regulated >2-fold by FTY720 also respond to phytosphingosine in the same direction in the parent strain. In addition, a close inspection of TAT1 and TAT2 transporters following exposure to phytosphingosine indicates that TAT1 protein is degraded in a similar fashion upon treatment with FTY720 and phytosphingosine. There were differences, however, with respect to the TAT2 protein level and the expression profiles of a subset of genes. The genetic, transcriptional, and biochemical data together indicate that FTY720 and phytosphingosine influence similar pathways in yeast cells. These findings offer further insights into the physiological pathways influenced by these compounds in all eukaryotic cells and help us to understand the therapeutic consequences of FTY720 in humans.	Novartis Pharma AG, Transplantat Res, Novartis Inst Biomed Res Autoimmun & Transplantat, CH-4002 Basel, Switzerland	Novartis	Movva, NR (corresponding author), Novartis Pharma AG, Transplantat Res, Novartis Inst Biomed Res Autoimmun & Transplantat, WSJ 386-906, CH-4002 Basel, Switzerland.	rao.movva@pharma.novartis.com						Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BAGNAT M, 2000, J BIOL CHEM, V275, P2191; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Candelore MR, 2002, BIOCHEM BIOPH RES CO, V297, P600; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Chiba K, 1996, TRANSPLANT P, V28, P1056; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Ehrenhofer-Murray AE, 1998, YEAST, V14, P49, DOI 10.1002/(SICI)1097-0061(19980115)14:1<49::AID-YEA199>3.0.CO;2-T; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Grzanowski A, 2002, CURR GENET, V41, P142, DOI 10.1007/s00294-002-0292-0; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Hoshino Y, 1996, TRANSPLANT P, V28, P1060; Kahan BD, 1998, TRANSPLANT P, V30, P2210, DOI 10.1016/S0041-1345(98)00593-4; Kim S, 2000, GENETICS, V156, P1519; Lee J, 2002, MOL CELLS, V13, P407; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Suzuki S, 1996, Transpl Immunol, V4, P252, DOI 10.1016/S0966-3274(96)80026-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	44	22	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36720	36731		10.1074/jbc.M406179200	http://dx.doi.org/10.1074/jbc.M406179200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190065	hybrid			2022-12-25	WOS:000223453600072
J	Liu, YC; Pelekanakis, K; Woolkalis, MJ				Liu, YC; Pelekanakis, K; Woolkalis, MJ			Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells - Regulation through c-Fos and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAYS; FACTOR GENE; KAPPA-B; ACTIVATION; EGR-1; INFLAMMATION; COAGULATION; INHIBITION; RECEPTOR	Tissue factor is critically important for initiating the activation of coagulation zymogens leading to the generation of thrombin. Quiescent endothelial cells do not express tissue factor on their surface, but many stimuli including cytokines and coagulation proteases can elicit tissue factor synthesis. We challenged human endothelial cells simultaneously with tumor necrosis factor alpha (TNFalpha) and thrombin because many pathophysiological conditions, such as sepsis, diabetes, and coronary artery disease, result in the concurrent presence of circulating inflammatory mediators and activated thrombin. We observed a remarkable synergy in the expression of tissue factor by thrombin plus TNFalpha. This was due to altered regulation of the transcription factors c-Jun and c-Fos. The activation of c-Jun was greater and more sustained than that obtained with either thrombin or TNFalpha alone. Thrombin-stimulated expression of c-Fos was both enhanced and prolonged by the concurrent presence of TNFalpha. These changes support the increased availability of c-Jun/c-Fos AP-1 complexes for mediating transcription at the tissue factor promoter. Transcription factors downstream of the extracellular signal-regulated kinases as well as changes in NFkappaB regulation were not involved in the synergistic increase in tissue factor expression by thrombin and TNFalpha. Thus, concurrent exposure of vascular endothelial cells to cytokines and procoagulant proteases such as thrombin can result in greatly enhanced tissue factor expression on the endothelium, thereby perpetuating the prothrombotic phenotype of the endothelium.	Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Woolkalis, MJ (corresponding author), Thomas Jefferson Univ, Dept Physiol, 411 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Marilyn.Woolkalis@jefferson.edu						Anrather D, 1997, J IMMUNOL, V159, P5620; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edmead C, 1999, ANAL BIOCHEM, V275, P180, DOI 10.1006/abio.1999.4313; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; Gonzalez MA, 2003, AM J MED, V115, P99, DOI 10.1016/j.amjmed.2003.09.016; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; Levi M, 2002, CRIT CARE MED, V30, pS220, DOI 10.1097/00003246-200205001-00008; Lindmark E, 2001, THROMB RES, V103, P249, DOI 10.1016/S0049-3848(01)00313-9; Luther T, 2001, TRENDS CARDIOVAS MED, V11, P307, DOI 10.1016/S1050-1738(01)00129-3; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Matschurat S, 2003, INT J CANCER, V107, P30, DOI 10.1002/ijc.11345; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Merrill J T, 2001, Curr Rheumatol Rep, V3, P293, DOI 10.1007/s11926-001-0033-2; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Reilly MP, 2002, CURR OPIN HEMATOL, V9, P395, DOI 10.1097/00062752-200209000-00002; Takeya H, 2003, BLOOD, V102, P1693, DOI 10.1182/blood-2002-11-3607; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Versteeg HH, 2004, SEMIN HEMATOL, V41, P168, DOI 10.1053/j.seminhematol.2003.11.028; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Xuereb JM, 2000, THROMB HAEMOSTASIS, V84, P129, DOI 10.1055/s-0037-1613980; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	35	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36142	36147		10.1074/jbc.M405039200	http://dx.doi.org/10.1074/jbc.M405039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201277	hybrid			2022-12-25	WOS:000223303400116
J	Suzuki, Y; Moriyoshi, E; Tsuchiya, D; Jingami, H				Suzuki, Y; Moriyoshi, E; Tsuchiya, D; Jingami, H			Negative cooperativity of glutamate binding in the dimeric metabotropic glutamate receptor subtype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ASPARTATE RECEPTOR; PROTEIN-COUPLED RECEPTORS; TRYPTOPHAN FLUORESCENCE; STRUCTURAL BASIS; LIGAND; EXPRESSION; INTERFACE; DOMAIN; OLIGOMERIZATION; PHARMACOLOGY	Metabotropic glutamate receptor (mGluR) subtype 1 is a Class III G-protein-coupled receptor that is mainly expressed on the post-synaptic membrane of neuronal cells. The receptor has a large N-terminal extracellular ligand binding domain that forms a homodimer, however, the intersubunit communication of ligand binding in the dimer remains unknown. Here, using the intrinsic tryptophan fluorescence change as a probe for ligand binding events, we examined whether allosteric properties exist in the dimeric ligand binding domain of the receptor. The indole ring of the tryptophan 110, which resides on the upper surface of the ligand binding pocket, sensed the ligand binding events. From saturation binding curves, we have determined the apparent dissociation constants (K-0.5) of representative agonists and antagonists for this receptor (3.8, 0.46, 40, and 0.89 muM for glutamate, quisqualate, (S)-alpha-methyl-4-carboxy-phenylglycine ((S)-MCPG), and (+)-2-methyl-4-carboxy-phenylglycine (LY367385), respectively). Calcium ions functioned as a positive modulator for agonist but not for antagonist binding (K-0.5 values were 1.3, 0.21, 59, and 1.2 muM for glutamate, quisqualate, (S)-MCPG, and LY367385, respectively, in the presence of 2.0 mM calcium ion). Moreover, a Hill analysis of the saturation binding curves revealed the strong negative cooperativity of glutamate binding between each subunit in the dimeric ligand binding domain. As far as we know, this is the first direct evidence that the dimeric ligand binding domain of mGluR exhibits intersubunit cooperativity of ligand binding.	Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan		Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.	jingami@beri.or.jp						Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P452; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIMBIRD LE, 1976, J BIOL CHEM, V251, P5007; Lin FF, 1997, NEUROPHARMACOLOGY, V36, P917, DOI 10.1016/S0028-3908(97)00078-6; LIU J, 1914, J BIOL CHEM, V279, P15824; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Milligan G, 2001, J CELL SCI, V114, P1265; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; Xu Y, 2003, J BIOL CHEM, V278, P13719, DOI 10.1074/jbc.M212979200; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	34	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35526	35534		10.1074/jbc.M404831200	http://dx.doi.org/10.1074/jbc.M404831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199056	hybrid			2022-12-25	WOS:000223303400047
J	Knappe, S; Wu, F; Madlansacay, MR; Wu, QY				Knappe, S; Wu, F; Madlansacay, MR; Wu, QY			Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE PROTEASES; DENSITY-LIPOPROTEIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA MUTATIONS; SURFACE PROTEOLYTIC-ENZYMES; LDL-RECEPTOR; CARBOXYPEPTIDASE-Z; TYROSINE KINASES; CRD DOMAIN; PROTEIN; BINDING	Corin is a type II transmembrane serine protease and functions as the proatrial natriuretic peptide (pro-ANP) convertase in the heart. In the extracellular region of corin, there are two frizzled-like cysteine-rich domains, eight low density lipoprotein receptor ( LDLR) repeats, a macrophage scavenger receptor-like domain, and a trypsin-like protease domain at the C terminus. To examine the functional importance of the domain structures in the propeptide of corin for pro-ANP processing, we constructed a soluble corin, EKshortCorin, that consists of only the protease domain and contains an enterokinase (EK) recognition sequence at the conserved activation cleavage site. After being activated by EK, EKshortCorin exhibited catalytic activity toward chromogenic substrates but failed to cleave pro-ANP, indicating that certain domain structures in the propeptide are required for pro-ANP processing. We then constructed a series of corin deletion mutants and studied their functions in pro-ANP processing. Compared with that of the full-length corin, a corin mutant lacking frizzled 1 domain exhibited similar to 40% activity, whereas corin mutants lacking single LDLR repeat 1, 2, 3, or 4 had similar to 49, similar to 12, similar to 53, and similar to 77% activity, respectively. We also made corin mutants with a single mutation at a conserved Asp residue that coordinates Ca2+-binding in LDLR repeats 1, 2, 3, or 4 (D300Y, D336Y, D373Y, and D410Y) and showed that these mutants had similar to 25, similar to 11, similar to 16, and similar to 82% pro-ANP processing activity, respectively. Our results indicate that frizzled 1 domain and LDLR repeats 1 - 4 are important structural elements for corin to recognize its physiological substrate, pro-ANP.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94804 USA.	qywu88@yahoo.com		Wu, Qingyu/0000-0003-0561-9315				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Knappe S, 2003, J BIOL CHEM, V278, P52363, DOI 10.1074/jbc.M309991200; Levin ER, 1998, NEW ENGL J MED, V339, P321; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; North CL, 2000, BIOCHEMISTRY-US, V39, P13127, DOI 10.1021/bi0015156; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Song LX, 1997, J BIOL CHEM, V272, P10543; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	35	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34464	34471		10.1074/jbc.M405041200	http://dx.doi.org/10.1074/jbc.M405041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192093	hybrid			2022-12-25	WOS:000223134800048
J	Carvin, CD; Kladde, MP				Carvin, CD; Kladde, MP			Effectors of lysine 4 methylation of histone H3 in Saccharomyces cerevisiae are negative regulators of PHO5 and GAL1-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ELONGATION; GENE-EXPRESSION; PAF1 COMPLEX; IN-VIVO; ACTIVE GENES; H2B; YEAST; PROTEIN; COMPASS	Post-translational modifications of histone amino-terminal tails are a key determinant in gene expression. Histone methylation plays a dual role in gene regulation. Methylation of lysine 9 of histone H3 in higher eukaryotes is associated with transcriptionally inactive heterochromatin, whereas H3 lysine 4 methylation correlates with active chromatin. Methylation of lysine 4 of H3 via Set1, a component of the Saccharomyces cerevisiae COMPASS complex, is regulated by the transcriptional elongation Paf1-Rtf1 and histone ubiquitination Rad6-Bre1 complexes, which are required for the expression of a subset of genes. This suggests that lysine 4 methylation of histone H3 may play an activating role in transcription; however, the mechanism of Set1 function remains unclear. We show here that H3 lysine 4 methylation also negatively regulated gene expression, as strains without Set1 showed enhanced expression of PHO5, wherein chromatin structure plays an important transcriptional regulatory role. Di- and trimethylation of H3 lysine 4 was detected at the PHO5 promoter, and a strain expressing a mutant version of histone H3 with lysine 4 changed to arginine, ( which cannot be methylated) exhibited PHO5 derepression. Moreover, PHO5 was derepressed in strains that lacked components of either the Paf1-Rtf1 elongation or Rad6-Bre1 histone ubiquitination complexes. Lastly, PHO84 and GAL1 - 10 transcription was also increased in set1Delta cells. These results suggest that H3 methylation at lysine 4, in conjunction with transcriptional elongation, may function in a negative feedback pathway for basal transcription of some genes, although being a positive effector at others.	Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Kladde, MP (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA.	kladde@tamu.edu			NCI NIH HHS [R01 CA095525, CA95525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blackwell TK, 2003, CURR BIOL, V13, pR915, DOI 10.1016/j.cub.2003.11.013; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Brachmann CB, 1998, YEAST, V14, P115; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carvin CD, 2003, P NATL ACAD SCI USA, V100, P7743, DOI 10.1073/pnas.1332672100; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Landry J, 2003, MOL CELL BIOL, V23, P5972, DOI 10.1128/MCB.23.17.5972-5978.2003; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi XM, 1996, MOL CELL BIOL, V16, P669; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner SD, 2002, MOL CELL BIOL, V22, P4011, DOI 10.1128/MCB.22.12.4011-4019.2002; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	44	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33057	33062		10.1074/jbc.M405033200	http://dx.doi.org/10.1074/jbc.M405033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180994	hybrid, Green Accepted			2022-12-25	WOS:000223039700006
J	Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O				Janoueix-Lerosey, I; Novikov, E; Monteiro, M; Gruel, N; Schleiermacher, G; Loriod, B; Nguyen, C; Delattre, O			Gene expression profiling of 1p35-36 genes in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; 1p deletion; gene expression profiling; hierarchical clustering	CHROMOSOME-I; SHORT ARM; DELETION; IDENTIFICATION; HYBRIDIZATION; PREDICTION; INSIGHTS; REGIONS; BINDING; PROTEIN	Deletion of the chromosome 1p36 region is a frequent abnormality in neuroblastoma. To gain further insights into the role of this alteration in oncogenesis, we have constructed a specific cDNA microarray representing most known genes and ESTs from the 1p35-36 region and analysed the expression profiles of 15 neuroblastoma cell lines and 28 neuroblastoma tumours. Hierarchical clustering using expression levels of 320 cDNAs from 1p35-36 separated localized or 4S cases without 1p deletion from advanced stages and cell tines. Supervised learning classification enabled to predict reliably the status of chromosome 1p according to its expression profile. Around 15% of the genes or ESTs presented a significantly decreased expression in samples with 1p deletion as compared to 1p-normal samples suggesting that 1p deletion results in a gene dosage effect on a subset of genes critical for the development of 1p-deleted neuroblastoma. Several genes presumed to have functions in neural differentiation (CDC42, VAMP3, CLSTN1), signal transduction in neural cells (GNB1) and cell cycle regulation (STMN1, RPA2, RBAF600, FBXO6, MAD2L2) exhibited a decreased expression in samples presenting 1p deletion. The identification of such genes provides baseline information for further studies to elucidate how these genes could individually or collectively play a critical role in neuroblastoma tumorigenesis.	Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, F-75248 Paris 05, France; Ctr Immunol Marseille Luminy, Equipe TAGC, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Delattre, O (corresponding author), Inst Curie, U509, INSERM, Sect Rech,Lab Pathol Mol Canc, Pavillon Trouillet Rossignol 26,Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Monteiro, Marta/B-2833-2011; loriod, beatrice bl/L-2948-2016; Nguyen, Catherine/M-4119-2016	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; loriod, beatrice bl/0000-0001-5801-2264; Nguyen, Catherine/0000-0001-9376-6360; Monteiro C. Antunes, Marta/0000-0002-0327-0917; delattre, olivier/0000-0002-8730-2276				Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Bo TH, 2002, GENOME BIOL, V3; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHENG NC, 1995, ONCOGENE, V10, P291; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dudoit S. F. J. a. S. T. P, 2000, 576 U CAL DEP STAT; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hepp R, 2001, CELL TISSUE RES, V305, P247, DOI 10.1007/s004410100359; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174; Vogt L, 2001, MOL CELL NEUROSCI, V17, P151, DOI 10.1006/mcne.2000.0937; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L	30	48	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5912	5922		10.1038/sj.onc.1207784	http://dx.doi.org/10.1038/sj.onc.1207784			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195138				2022-12-25	WOS:000222941100005
J	Chen, SY; Dehart, DB; Sulik, KK				Chen, SY; Dehart, DB; Sulik, KK			Protection from ethanol-induced limb malformations by the superoxide dismutase/catalase mimetic EUK-134	FASEB JOURNAL			English	Article						ethanol; antitoxidant; apoptosis	FETAL ALCOHOL SYNDROME; NEURAL CREST CELLS; APICAL ECTODERMAL RIDGE; OXIDATIVE STRESS; FREE-RADICALS; HYDROGEN-PEROXIDE; IN-VITRO; VITAMIN-A; TOXICITY; OXYGEN	Based on previous in vitro studies that have illustrated prevention of ethanol-induced cell death by antioxidants, using an in vivo model, we have tested the anti-teratogenic potential of a potent synthetic superoxide dismutase plus catalase mimetic, EUK-134. The developing limb of C57BL/6J mice, which is sensitive to ethanol-induced reduction defects, served as the model system. On their ninth day of pregnancy, C57BL/6J mice were administered ethanol (two intraperitoneal doses of 2.9 g/kg given 4 h apart) alone or in combination with EUK-134 (two doses of 10 mg/kg). Pregnant control mice were similarly treated with either vehicle or EUK-134, alone. Within 15 h of the initial ethanol exposure, excessive apoptotic cell death was observed in the apical ectodermal ridge (AER) of the newly forming forelimb buds. Forelimb defects, including postaxial ectrodactyly, metacarpal, and ulnar deficiencies, occurred in 67.3% of the ethanol-exposed fetuses that were examined at 18 days of gestation. The right forelimbs were preferentially affected. No limb malformations were observed in control fetuses. Cell death in the AER of embryos concurrently exposed to ethanol and EUK-134 was notably reduced compared with that in embryos from ethanol-treated dams. Additionally, the antioxidant treatment reduced the incidence of forelimb malformations to 35.9%. This work illustrates that antioxidants can significantly improve the adverse developmental outcome that results from ethanol exposure in utero, diminishing the incidence and severity of major malformations that result from exposure to this important human teratogen.	Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chen, SY (corresponding author), Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA.	syc@med.unc.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011605, P60AA011605, K01AA013908] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA013908, AA11605, K01 AA013908] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ahlgren SC, 2002, P NATL ACAD SCI USA, V99, P10476, DOI 10.1073/pnas.162356199; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Anaya-Prado R, 2002, TRANSPLANT P, V34, P2518, DOI 10.1016/S0041-1345(02)03471-1; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Chen SY, 2000, J PHARMACOL EXP THER, V294, P134; Chen SY, 2001, FASEB J, V15, P1649, DOI 10.1096/fj.00-0862fje; Chen SY, 1996, ALCOHOL CLIN EXP RES, V20, P1071, DOI 10.1111/j.1530-0277.1996.tb01948.x; Chen SY, 1996, ALCOHOL, V13, P589; Chen SY, 2000, ALCOHOL, V20, P75, DOI 10.1016/S0741-8329(99)00058-0; CREMIN BJ, 1981, PEDIATR RADIOL, V11, P151, DOI 10.1007/BF00971818; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIS WL, 1990, J CRAN GENET DEV BIO, V10, P277; DEJONGE MH, 1995, PEDIATR RES, V37, P418, DOI 10.1203/00006450-199504000-00006; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Doctrow SR, 2002, J MED CHEM, V45, P4549, DOI 10.1021/jm020207y; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Dunty WC, 2001, ALCOHOL CLIN EXP RES, V25, P1523, DOI 10.1111/j.1530-0277.2001.tb02156.x; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIDOVICH I, 1984, CURR EYE RES, V3, P1, DOI 10.3109/02713688408997181; Gilbert SF, 2003, DEV BIOL, P523; GRUMMER MA, 1993, ALCOHOL CLIN EXP RES, V17, P592, DOI 10.1111/j.1530-0277.1993.tb00805.x; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HERRMANN J, 1980, EUR J PEDIATR, V133, P221, DOI 10.1007/BF00496080; INOUYE M, 1976, Congenital Anomalies, V16, P171; Johnson CS, 2003, DEV BIOL, V259, P583; KOTCH LE, 1992, TERATOLOGY, V46, P323, DOI 10.1002/tera.1420460403; KOTCH LE, 1995, TERATOLOGY, V52, P128, DOI 10.1002/tera.1420520304; Kurose I, 1996, ALCOHOL CLIN EXP RES, V20, pA77, DOI 10.1111/j.1530-0277.1996.tb01736.x; Kyselova Z, 2003, ARCH GERONTOL GERIAT, V36, P221, DOI 10.1016/S0167-4943(02)00167-X; Liu CQ, 2003, DEVELOPMENT, V130, P1327, DOI 10.1242/dev.00354; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Maier SE, 1999, ALCOHOL CLIN EXP RES, V23, P726, DOI 10.1111/j.1530-0277.1999.tb04176.x; Makarenkova H, 1997, J CELL BIOL, V138, P1125, DOI 10.1083/jcb.138.5.1125; MAO GD, 1993, J BIOL CHEM, V268, P416; MILAIRE J, 1985, TERATOLOGY, V32, P433, DOI 10.1002/tera.1420320313; MUKHERJEE AB, 1982, SCIENCE, V218, P700, DOI 10.1126/science.6890235; Mylonas C, 1999, IN VIVO, V13, P295; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5; REINKE LA, 1997, J NUTR, V127, pS889; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; SAUNDERS JW, 1976, DEV BIOL, V50, P16, DOI 10.1016/0012-1606(76)90063-4; Schilling TF, 1999, DEV BIOL, V210, P277, DOI 10.1006/dbio.1999.9214; SPIEGEL PG, 1979, CLIN ORTHOP RELAT R, P58; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; STADTMAN ER, 1995, METHOD ENZYMOL, V258, P379; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAYLOR JR, 1986, MED J AUSTRALIA, V144, P533, DOI 10.5694/j.1326-5377.1986.tb112281.x; Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003; VANRENSBURG LJ, 1981, S AFR MED J, V59, P687; WEBSTER WS, 1983, TERATOLOGY, V27, P231, DOI 10.1002/tera.1420270211; West JR, 2001, ALCOHOL CLIN EXP RES, V25, P1051, DOI 10.1111/j.1530-0277.2001.tb02316.x; Wilkemeyer MF, 2003, P NATL ACAD SCI USA, V100, P8543, DOI 10.1073/pnas.1331636100; ZIMMERMAN EF, 1990, TERATOLOGY, V41, P453, DOI 10.1002/tera.1420410410	61	64	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1234	+		10.1096/fj.03-0850fje	http://dx.doi.org/10.1096/fj.03-0850fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208273				2022-12-25	WOS:000222327500022
J	Jung, CG; Hida, H; Nakahira, K; Ikenaka, K; Kim, HJ; Nishino, H				Jung, CG; Hida, H; Nakahira, K; Ikenaka, K; Kim, HJ; Nishino, H			Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells	FASEB JOURNAL			English	Article						dopamine; transplantation; neural differention; trophic factor; sonic hedgehog	CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; IN-VITRO; TYROSINE-HYDROXYLASE; DEPLETED STRIATUM; TRANSPLANTATION; GENERATION; SURVIVAL; DIFFERENTIATION; ASTROCYTES	Neural stem cells are promising candidates for donor cells in neural transplantation. However, the mechanism by which neural stem cells differentiate into neurons is not well understood. In the present study, a serial analysis of gene expression (SAGE) was carried out to generate a gene file of neural stem (progenitor) cells from the mouse ventral mesencephalon. Among the 15,815 tags investigated, the mRNA of the housekeeping genes (elongation factor 1-alpha, ATPase subunit 6, GAPDH, actin), laminin receptor 1, HSP 70, pleiotrophin, and nestin were highly expressed. Because pleiotrophin (PTN) exhibits mitogenic and trophic effects on neural development and exhibits trophic effects on survival of dopaminergic (DAergic) neurons, we investigated the role of PTN in neurogenesis, especially to DAergic neurons. Here, we show that PTN increased the production of tyrosine hydroxylase (TH)-positive neurons from embryonic stem (ES) cell-derived nestin-positive cells. The expression of Nurr1 mRNA was enhanced by PTN. L-dopa in the culture medium was increased by PTN. This effect was as strong as with sonic hedgehog. Data suggest that PTN mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon, and PTN promotes the production of DAergic neurons from ES cell-derived nestin-positive cells.	Nagoya City Univ, Grad Sch Med Sci, Dept Neurophysiol & Brain Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Saitama Med Sch, Dept Physiol, Moroyama, Saitama 3500495, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Div Learning & Memory Res, Okazaki, Aichi 4448585, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Lab Neural Informat, Okazaki, Aichi 4448585, Japan	Nagoya City University; Saitama Medical University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB)	Jung, CG (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Neurophysiol & Brain Sci, Mizuho Ku, 1 Kawasui, Nagoya, Aichi 4678601, Japan.	jung@med.nagoya-cu.ac.jp		Jung, Cha-Gyun/0000-0002-0225-0658				ALEXANDRA R, 2001, MECH DEVELOP, V105, P93; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Fukamauchi F, 1997, BIOCHEM BIOPH RES CO, V231, P356, DOI 10.1006/bbrc.1997.6101; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gammill LS, 2002, DEVELOPMENT, V129, P5731, DOI 10.1242/dev.00175; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Hida H, 2003, EUR J NEUROSCI, V17, P2127, DOI 10.1046/j.1460-9568.2003.02661.x; Hida H, 1999, NEUROSCI RES, V35, P101, DOI 10.1016/S0168-0102(99)00073-5; HIDA H, 2002, SOC NEUROSCI 2002 AB; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; Nishino H, 2000, EXP NEUROL, V164, P209, DOI 10.1006/exnr.2000.7426; Ohyama K, 1998, DEV BRAIN RES, V107, P219, DOI 10.1016/S0165-3806(97)00220-4; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516	37	70	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1237	+		10.1096/fj.03-0927fje	http://dx.doi.org/10.1096/fj.03-0927fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180956				2022-12-25	WOS:000222327500038
J	Jang, JH; Surh, YJ				Jang, JH; Surh, YJ			Bcl-2 attenuation of oxidative cell death is associated with up-regulation of gamma-glutamylcysteine ligase via constitutive NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; KINASE; SURVIVAL; OVEREXPRESSION; STRESS; EXPRESSION; ERK; PHOSPHORYLATION	Oxidative stress induced by reactive oxygen intermediates often causes cell death via apoptosis, which is regulated by many functional genes and their protein products. The evolutionarily conserved protein Bcl-2 blocks apoptosis induced by a wide array of death signals. Despite extensive research, the molecular milieu that characterizes the anti-apoptotic function of Bcl-2 has not been fully clarified. In this work, we have investigated the role of bcl-2 in protecting against oxidative death induced by H2O2 in cultured rat pheochromocytoma PC12 cells. Transfection with the bcl-2 gene rescued PC12 cells from apoptotic death caused by H2O2. Addition of NF-kappaB inhibitors such as pyrrolidine dithiocarbamate and N-tosyl-L-phenylalanine chloromethyl ketone to the medium aggravated oxidative cell death. PC12 cells overexpressing bcl-2 exhibited relatively high constitutive DNA binding and transcriptional activities of NF-kappaB compared with vector-transfected control cells. Western blot analysis and immunocytochemistry revealed that bcl-2-transfected PC12 cells retained a higher level of p65 (the functionally active subunit of NF-kappaB) in the nucleus compared with vector-transfected controls. In addition, sustained activation of ERK1/2 (upstream of NF-kappaB) was observed in bcl-2-overexpressing cells. In contrast, the cytoplasmic inhibitor IkappaBalpha was present in lower amounts in cells overexpressing bcl-2. The ectopic expression of bcl-2 increased the cellular glutathione level and gamma-glutamylcysteine ligase expression, which were attenuated by NF-kappaB inhibitors. These results suggest that NF-kappaB plays a role in bcl-2-mediated protection against H2O2-induced apoptosis in PC12 cells through augmentation of antioxidant capacity.	Seoul Natl Univ, Coll Pharm, Lab Biochem & Mol Toxicol, Seoul 151742, South Korea	Seoul National University (SNU)	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Lab Biochem & Mol Toxicol, Shinlim Dong, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr						Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bhakar AL, 2002, J NEUROSCI, V22, P8466; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; Chung KC, 2000, J NEUROSCI RES, V59, P117, DOI 10.1002/(SICI)1097-4547(20000101)59:1<117::AID-JNR14>3.0.CO;2-Q; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Foo SY, 1999, TRENDS GENET, V15, P229; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Howard S, 2002, J NEUROCHEM, V83, P914, DOI 10.1046/j.1471-4159.2002.01198.x; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kim DK, 2001, FREE RADICAL BIO MED, V30, P563, DOI 10.1016/S0891-5849(00)00504-9; Kim HJ, 2001, MOL PHARMACOL, V60, P440; Kondo T, 1999, FREE RADICAL RES, V31, P325, DOI 10.1080/10715769900300891; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lawrence MS, 1996, J NEUROSCI, V16, P486; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liang Y, 2003, ONCOGENE, V22, P5515, DOI 10.1038/sj.onc.1206844; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Massaad CA, 2003, NEUROREPORT, V14, P1167, DOI 10.1097/00001756-200306110-00013; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Poulaki V, 2002, AM J PATHOL, V161, P2229, DOI 10.1016/S0002-9440(10)64499-9; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; REGULA KM, 2000, J BIOL CHEM, V275, P38676; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Seyfried J, 2003, FREE RADICAL BIO MED, V34, P1517, DOI 10.1016/S0891-5849(03)00103-5; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WOOD KA, 1994, ANN NY ACAD SCI, V738, P400; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037	65	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38779	38786		10.1074/jbc.M406371200	http://dx.doi.org/10.1074/jbc.M406371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15208316	hybrid			2022-12-25	WOS:000223684100089
J	Alonso, A; Burkhalter, S; Sasin, J; Tautz, L; Bogetz, J; Huynh, H; Bremer, MCD; Holsinger, LJ; Godzik, A; Mustelin, T				Alonso, A; Burkhalter, S; Sasin, J; Tautz, L; Bogetz, J; Huynh, H; Bremer, MCD; Holsinger, LJ; Godzik, A; Mustelin, T			The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; CRYSTAL-STRUCTURE; MAP KINASE; PHOSPHOINOSITIDE PHOSPHATASE; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; INHIBITION; DEPHOSPHORYLATION; PHOSPHORYLATION	The smallest active protein-tyrosine phosphatase yet (only 16 kDa) is described here and given the name VHZ for VH1-like member Z because it belongs to the group of small Vaccinia virus VH1-related dual specific phosphatases exemplified by VHR, VHX, and VHY. Human VHZ is remarkably well conserved through evolution as it has species orthologs in frogs, fish, fly, and Archaea. The gene for VHZ, which we designate as DUSP25, is located on human chromosome 1q23.1 and consists of only two coding exons. VHZ is broadly expressed in tissues and cells, including resting blood lymphocytes, Jurkat T cells, HL-60, and RAMOS. In transfected cells, VHZ was located in the cytosol and in other cells also in the nucleoli. Endogenous VHZ showed a similar but more granular distribution. We show that VHZ is an active phosphatase and analyze its structure by computer modeling, which shows that in comparison with the 185-amino acid residue VHR, the 150-residue VHZ is a shortened version of VHR and contains the minimal set of secondary structure elements conserved in all known phosphatases from this class. The surface charge distribution of VHZ differs from that of VHR and is therefore unlikely to dephosphorylate mitogen-activated protein kinases. The remarkably high degree of conservation of VHZ through evolution may indicate a role in some ancient and fundamental physiological process.	Burnham Inst, Program Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Program Bioinformat, La Jolla, CA 92037 USA; SUGEN Inc, San Francisco, CA 94602 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Pfizer	Mustelin, T (corresponding author), Burnham Inst, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014; Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Bogetz, Jori F./U-2258-2019; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Tautz, Lutz/0000-0002-4075-6238; Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [CA96949] Funding Source: Medline; NIAID NIH HHS [AI35603, AI53585, AI48032, AI55741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055741, R01AI053585, R01AI048032, R01AI035603] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2004, J BIOL CHEM, V279, P4922, DOI 10.1074/jbc.M308978200; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Dorfman K, 1996, ONCOGENE, V13, P925; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Hanlon N, 1998, PROTEIN SCI, V7, P508; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Michalopoulos I, 2004, NUCLEIC ACIDS RES, V32, pD251, DOI 10.1093/nar/gkh060; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Munoz-Alonso MJ, 2000, J BIOL CHEM, V275, P32406, DOI 10.1074/jbc.M000841200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Sasin JM, 2003, BIOINFORMATICS, V19, pi252, DOI 10.1093/bioinformatics/btg1035; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	37	31	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35768	35774		10.1074/jbc.M403412200	http://dx.doi.org/10.1074/jbc.M403412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201283	hybrid			2022-12-25	WOS:000223303400076
J	Munhoz, DC; Netto, LES				Munhoz, DC; Netto, LES			Cytosolic thioredoxin peroxidase I and II are important defenses of yeast against organic hydroperoxide insult - Catalases and peroxiredoxins cooperate in the decomposition of H2O2 by yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; ADAPTIVE RESPONSE; OXIDATIVE STRESS; GLUTATHIONE; ANTIOXIDANT; PROTEIN; GENE; MITOCHONDRIAL; PURIFICATION	The cytosolic thioredoxin peroxidase II (cTPxII/Tsa2p) from Saccharomyces cerevisiae shares 86% identity with the relatively well characterized cytosolic thioredoxin peroxidase I (cTPxI/Tsa1p). In contrast to cTPxI protein, cTPxII is not abundant and is highly inducible by peroxides. Here, we describe a unique phenotype for DeltacTPxII strain; these cells were highly sensitive to tert-butylhydroperoxide (TBHP) but presented resistance to H2O2 in fermentative and respiratory conditions. In contrast, DeltacTPxI strain was very sensitive to both TBHP and H2O2, whatever the carbon source present in the media. These differences in the response of mutant cells to the different kinds of peroxide insult could not be attributed to enzymatic properties of cTPxI and cTPxII since the recombinant proteins showed similar in vitro efficiencies (K-cat/K-m) in the removals of both kinds of peroxide. This specific sensitivity of DeltacTPxII cells to TBHP could not be related to the expression pattern of TSA2 (cytosolic thioredoxin peroxidase II gene) either, since this gene is highly inducible by both H2O2 and TBHP when cells were grown in different conditions. Finally, peroxide-removing assays were performed and showed that catalase activity increased significantly only in DeltacTPxII cells, which appear to be related with the resistance of this strain to H2O2. Taken together, present data indicate that cTPxII and cTPxI are key components of the yeast defense system against organic peroxide insult. In regard to the stress induced by H2O2, catalases (peroxisomal and/or cytosolic) and cTPxII seemed to cooperate with cTPxI in the defense of yeast against this oxidant.	Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo	Netto, LES (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, Brazil.	nettoles@ib.usp.br	Netto, Luis/A-3783-2008	Netto, Luis/0000-0002-4250-9177				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cha MK, 2003, J BIOL CHEM, V278, P34952, DOI 10.1074/jbc.M301819200; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Demasi APD, 2001, FEBS LETT, V509, P430, DOI 10.1016/S0014-5793(01)03215-X; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hong SK, 2002, J BIOL CHEM, V277, P12109, DOI 10.1074/jbc.M111341200; HORTNER H, 1982, EUR J BIOCHEM, V128, P179; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Maris AF, 2001, CURR GENET, V39, P137, DOI 10.1007/s002940100194; Monteiro G, 2004, ARCH BIOCHEM BIOPHYS, V425, P14, DOI 10.1016/j.abb.2004.03.005; Monteiro G, 2002, FREE RADICAL BIO MED, V32, P278, DOI 10.1016/S0891-5849(01)00801-2; Moradas-Ferreira P, 2000, REDOX REP, V5, P277, DOI 10.1179/135100000101535816; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nguyen-nhu NT, 2002, TOXICOL LETT, V135, P219, DOI 10.1016/S0378-4274(02)00280-1; Outten CE, 2004, J BIOL CHEM, V279, P7785, DOI 10.1074/jbc.M312421200; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; PON L, 1991, MOL CELLULAR BIOL YE, V1, P333; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Wong CM, 2003, FREE RADICAL BIO MED, V34, P585, DOI 10.1016/S0891-5849(02)01354-0; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405	39	54	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35219	35227		10.1074/jbc.M313773200	http://dx.doi.org/10.1074/jbc.M313773200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210711	hybrid			2022-12-25	WOS:000223303400012
J	Somerville, RPT; Longpre, JM; Apel, ED; Lewis, RM; Wang, LW; Sanes, JR; Leduc, R; Apte, SS				Somerville, RPT; Longpre, JM; Apel, ED; Lewis, RM; Wang, LW; Sanes, JR; Leduc, R; Apte, SS			ADAMTS7B, the full-length product of the ADAMTS7 gene, is a chondroitin sulfate proteoglycan containing a mucin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; THROMBOSPONDIN MOTIFS; MOLECULAR-CLONING; HEPARAN-SULFATE; FURIN INTERACTS; O-GLYCOSYLATION; FAMILY PROTEIN; METALLOPROTEINASE; CLEAVAGE; DISINTEGRIN	We have characterized ADAMTS7B, the authentic full-length protein product of the ADAMTS7 gene. ADAMTS7B has a domain organization similar to that of ADAMTS12, with a total of eight thrombospondin type 1 repeats in its ancillary domain. Of these, seven are arranged in two distinct clusters that are separated by a mucin domain. Unique to the ADAMTS family, ADAMTS7B is modified by attachment of the glycosaminoglycan chondroitin sulfate within the mucin domain, thus rendering it a proteoglycan. Glycosaminoglycan addition has potentially important implications for ADAMTS7B cellular localization and for substrate recognition. Although not an integral membrane protein, ADAMTS7B is retained near the cell surface of HEK293F cells via interactions involving both the ancillary domain and the prodomain. ADAMTS7B undergoes removal of the prodomain by a multistep furin-dependent mechanism. At least part of the final processing event, i.e. cleavage following Arg(220) (mouse sequence annotation), occurs at the cell surface. ADAMTS7B is an active metalloproteinase as shown by its ability to cleave alpha(2)-macroglobulin, but it does not cleave specific peptide bonds in versican and aggrecan attacked by ADAMTS proteases. Together with ADAMTS12, whose primary structure also predicts a mucin domain, ADAMTS7B constitutes a unique subgroup of the ADAMTS family.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthoped Res Ctr, Cleveland, OH 44195 USA; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke; Washington University (WUSTL)	Apte, SS (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn ND20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@bme.ri.ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NINDS NIH HHS [NS19195] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019195, R37NS019195] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Engbring JA, 2002, CANCER RES, V62, P3549; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li CQ, 2002, THROMB HAEMOSTASIS, V88, P673, DOI 10.1055/s-0037-1613274; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Turcotte CL, 2002, DEV DYNAM, V224, P51, DOI 10.1002/dvdy.10081; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	58	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35159	35175		10.1074/jbc.M402380200	http://dx.doi.org/10.1074/jbc.M402380200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192113	hybrid			2022-12-25	WOS:000223303400006
J	Furuyama, T; Kitayama, K; Shimoda, Y; Ogawa, M; Sone, K; Yoshida-Araki, K; Hisatsune, H; Nishikawa, S; Nakayama, K; Nakayama, K; Ikeda, K; Motoyama, N; Mori, N				Furuyama, T; Kitayama, K; Shimoda, Y; Ogawa, M; Sone, K; Yoshida-Araki, K; Hisatsune, H; Nishikawa, S; Nakayama, K; Nakayama, K; Ikeda, K; Motoyama, N; Mori, N			Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR BINDING PROTEIN-1; C-ELEGANS; CAENORHABDITIS-ELEGANS; SIGNALING PATHWAY; OXIDATIVE STRESS; FAMILY-MEMBER; LIFE-SPAN; CELLS	Members of the Foxo family, Foxo1 (Fkhr), Foxo3 (Fkhrl1), and Foxo4 (Afx), are mammalian homologs of daf-16, which influences life span and energy metabolism in Caenorhabditis elegans. Mammalian FOXO proteins also play important roles in cell cycle arrest, apoptosis, stress resistance, and energy metabolism. In this study, we generated Foxo1-deficient mice to investigate the physiological role of FOXO1. The Foxo1-deficient mice died around embryonic day 11 because of defects in the branchial arches and remarkably impaired vascular development of embryos and yolk sacs. In vitro differentiation of embryonic stem cells demonstrated that endothelial cells derived from wild-type and Foxo1-deficient embryonic stem cells were able to produce comparable numbers of colonies supported by a layer of OP9 stromal cells. Although the morphology of the endothelial cell colonies was identical in both genotypes in the absence of exogenous vascular endothelial growth factor (VEGF), Foxo1-deficient endothelial cells showed a markedly different morphological response compared with wild-type endothelial cells in the presence of exogenous VEGF. These results suggest that Foxo1 is essential to the ability of endothelial cells to respond properly to a high dose of VEGF, thereby playing a critical role in normal vascular development.	Kumamoto Univ, Dept Mol Genet, Natl Inst Longev Sci, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Geriatr Res, Natl inst Longev Sci, Kumamoto 8600811, Japan; Kumamoto Univ, Dept Cell Differentiat, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Kyushu 8128582, Japan; RIKEN, Lab Stem Cell Biol, Ctr Dev Biol, Kyoto 6500047, Japan; Kyoto Univ, Dept Mol Genet, Grad Sch Med, Kyoto 6068501, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kyushu University; RIKEN; Kyoto University	Furuyama, T (corresponding author), Sonoda Womans Univ, Dept Food & Nutr, 7-29-1 Minami Tsukaguchi, Amagasaki, Hyogo 6618520, Japan.	furuyama@sonoda-u.ac.jp		Kitayama, Kazuko/0000-0003-2829-762X; Furuyama, Tatsuo/0000-0001-7349-103X				Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Antebi A, 2000, GENE DEV, V14, P1512; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Jia KL, 2002, DEVELOPMENT, V129, P221; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; Matsumura K, 2003, BLOOD, V101, P1367, DOI 10.1182/blood-2002-05-1329; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Simon AM, 2003, J CELL SCI, V116, P2223, DOI 10.1242/jcs.00429; Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang X, 1999, DEVELOPMENT, V126, P1571; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	45	263	271	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34741	34749		10.1074/jbc.M314214200	http://dx.doi.org/10.1074/jbc.M314214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184386	hybrid			2022-12-25	WOS:000223134800080
J	Liu, F; Dowling, M; Yang, XJ; Kao, GD				Liu, F; Dowling, M; Yang, XJ; Kao, GD			Caspase-mediated specific cleavage of human histone deacetylase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; APOPTOSIS; HDAC4; DEGRADATION; ACTIVATION; SURVIVAL; DOMAIN; PHOSPHORYLATION; COMPLEX	Histone deacetylase 4 (HDAC4) is a class II HDAC implicated in controlling gene expression important for diverse cellular functions, but little is known about how its expression and stability are regulated. We report here that this deacetylase is unusually unstable, with a half-life of less than 8 h. Consistent with the instability of HDAC4 protein, its mRNA was also highly unstable ( with a half-life of less than 4 h). The degradation of HDAC4 could be accelerated by exposure of cells to ultraviolet irradiation. HDAC4 degradation was not dependent on proteasome or CRM1-mediated export activity but instead was caspase-dependent and was detectable in diverse human cancer lines. Of two potential caspase consensus motifs in HDAC4, both lying within a region containing proline-,glutamic acid-, serine, and threonine-rich ( PEST) sequences, we identified, by site-directed mutagenesis, Asp-289 as the prime cleavage site. Notably, this residue is not conserved among other class IIa members, HDAC5, - 7, and - 9. Finally, the induced expression of caspase-cleavable HDAC4 led to markedly increased apoptosis. These results therefore unexpectedly link the regulation of HDAC4 protein stability to caspases, enzymes that are important for controlling cell death and differentiation.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	University of Pennsylvania; McGill University	Kao, GD (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan 180 H, Philadelphia, PA 19104 USA.	Kao@xrt.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA107956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 107956-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Borghi S, 2001, J CELL SCI, V114, P4477; Butts BD, 2003, HORM METAB RES, V35, P763; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hong HN, 2002, NEUROSCI LETT, V334, P63, DOI 10.1016/S0304-3940(02)01066-2; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Huang EY, 2000, GENE DEV, V14, P45; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; KRAKOFF IH, 1968, CANCER RES, V28, P1559; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang SC, 2001, CANCER RES, V61, P2838; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Yang XJ, 2003, CURR OPIN GENET DEV, V13, P143, DOI 10.1016/S0959-437X(03)00015-7; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	49	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34537	34546		10.1074/jbc.M402475200	http://dx.doi.org/10.1074/jbc.M402475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15205465	hybrid			2022-12-25	WOS:000223134800057
J	Rey, O; Reeve, JR; Zhukova, E; Sinnett-Smith, J; Rozengurt, E				Rey, O; Reeve, JR; Zhukova, E; Sinnett-Smith, J; Rozengurt, E			G protein-coupled receptor-mediated phosphorylation of the activation loop of protein kinase D - Dependence on plasma membrane translocation and protein kinase C-epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-TRANSDUCTION PATHWAY; POTENTIATES DNA-SYNTHESIS; CYSTEINE-RICH MOTIFS; D PKD ACTIVATION; PHORBOL ESTERS; IN-VIVO; INTRACELLULAR REDISTRIBUTION; CCKB/GASTRIN RECEPTOR	Protein kinase D (PKD) is a serine/threonine protein kinase activated by G protein-coupled receptor ( GPCR) agonists through an incompletely characterized mechanism that includes its reversible plasma membrane translocation and activation loop phosphorylation via a protein kinase C (PKC)-dependent pathway. To gain a better understanding of the mechanism regulating the activation of PKD in response to GPCR stimulation, we investigated the role of its rapid plasma membrane translocation on its activation loop phosphorylation and identified the endogenous PKC isozyme that mediates that event in vivo. We had found that the activation loop of a PKD mutant, with reduced affinity for diacylglycerol and phorbol esters, was only phosphorylated upon its plasma membrane association. We also found that the activation loop phosphorylation and rapid plasma membrane dissociation of PKD were inhibited either by preventing the plasma membrane translocation of PKCepsilon, through abolition of its interaction with receptor for activated C kinase, or by suppressing the expression of PKCepsilon via specific small interfering RNAs. Thus, this study demonstrates that the plasma membrane translocation of PKD, in response to GPCR stimulation, is necessary for the PKCepsilon-mediated phosphorylation of the activation loop of PKD and that this event requires the translocation of both kinases to the plasma membrane. Based on these and previous results, we propose a model of GPCR-mediated PKD regulation that integrates its changes in distribution, catalytic activity, and multisite phosphorylation.	Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Reeve, James/GYI-8415-2022	Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA 090388, K01 CA 097956] Funding Source: Medline; NIDDK NIH HHS [DK 33580, DK 41301, DK 56930, DK 55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bonfanti M, 1997, CANCER RES, V57, P1442; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2273, DOI 10.1006/jmcc.1997.0466; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fujimoto K, 2000, CANCER LETT, V159, P151, DOI 10.1016/S0304-3835(00)00536-X; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Guha S, 2002, CANCER RES, V62, P1632; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P945, DOI 10.1101/SQB.1988.053.01.109; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	79	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34361	34372		10.1074/jbc.M403265200	http://dx.doi.org/10.1074/jbc.M403265200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190080	hybrid			2022-12-25	WOS:000223134800036
J	Zhao, KS; Zhao, GM; Wu, DL; Soong, Y; Birk, AV; Schiller, PW; Szeto, HH				Zhao, KS; Zhao, GM; Wu, DL; Soong, Y; Birk, AV; Schiller, PW; Szeto, HH			Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCATOR; TOXIN 3-NITROPROPIONIC ACID; OXYGEN SPECIES PRODUCTION; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; TRANSITION PORE; INDUCED APOPTOSIS; CYCLOSPORINE-A; STRESS	Reactive oxygen species (ROS) play a key role in promoting mitochondrial cytochrome c release and induction of apoptosis. ROS induce dissociation of cytochrome c from cardiolipin on the inner mitochondrial membrane (IMM), and cytochrome c may then be released via mitochondrial permeability transition (MPT)dependent or MPT-independent mechanisms. We have developed peptide antioxidants that target the IMM, and we used them to investigate the role of ROS and MPT in cell death caused by t-butylhydroperoxide (tBHP) and 3-nitropropionic acid (3NP). The structural motif of these peptides centers on alternating aromatic and basic amino acid residues, with dimethyltyrosine providing scavenging properties. These peptide antioxidants are cell-permeable and concentrate 1000-fold in the IMM. They potently reduced intracellular ROS and cell death caused by tBHP in neuronal N(2)A cells (EC50 in nM range). They also decreased mitochondrial ROS production, inhibited MPT and swelling, and prevented cytochrome c release induced by Ca2+ in isolated mitochondria. In addition, they inhibited 3NP-induced MPT in isolated mitochondria and prevented mitochondrial depolarization in cells treated with 3NP. ROS and MPT have been implicated in myocardial stunning associated with reperfusion in ischemic hearts, and these peptide antioxidants potently improved contractile force in an ex vivo heart model. It is noteworthy that peptide analogs without dimethyltyrosine did not inhibit mitochondrial ROS generation or swelling and failed to prevent myocardial stunning. These results clearly demonstrate that overproduction of ROS underlies the cellular toxicity of tBHP and 3NP, and ROS mediate cytochrome c release via MPT. These IMM-targeted antioxidants may be very beneficial in the treatment of aging and diseases associated with oxidative stress.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada	Cornell University; Cornell University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Szeto, HH (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA.	hhszeto@med.cornell.edu			NATIONAL INSTITUTE ON DRUG ABUSE [K01DA018268, P01DA008924] Funding Source: NIH RePORTER; NIDA NIH HHS [K01 DA018268, K01 DA018268-01, DA 08924] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BEAL MF, 1995, J NEUROCHEM, V65, P919; BEAL MF, 1993, J NEUROSCI, V13, P4181; Berezowska I, 2003, PEPTIDES, V24, P1195, DOI 10.1016/j.peptides.2003.07.004; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; CROMPTON M, 1993, BASIC RES CARDIOL, V88, P513, DOI 10.1007/BF00795416; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; FLAHERTY JT, 1994, CIRCULATION, V89, P1982, DOI 10.1161/01.CIR.89.5.1982; Fontana M, 2001, BIOCHEM PHARMACOL, V61, P1253, DOI 10.1016/S0006-2952(01)00565-2; Galindo MF, 2003, BRIT J PHARMACOL, V139, P797, DOI 10.1038/sj.bjp.0705309; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kanno T, 2004, FREE RADICAL RES, V38, P27, DOI 10.1080/10715760310001626266; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Lee WT, 2002, NEUROSCIENCE, V112, P707, DOI 10.1016/S0306-4522(02)00097-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YB, 1999, BBA-GEN SUBJECTS, V1428, P1, DOI 10.1016/S0304-4165(99)00040-9; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longoni B, 1997, BIOCHEM BIOPH RES CO, V233, P778, DOI 10.1006/bbrc.1997.6563; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Moosmann B, 2002, MOL PHARMACOL, V61, P260, DOI 10.1124/mol.61.2.260; NAKAMURA M, 1986, J BIOL CHEM, V261, P13923; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pias EK, 2003, J BIOL CHEM, V278, P13294, DOI 10.1074/jbc.M208670200; PICHORNER H, 1995, ARCH BIOCHEM BIOPHYS, V323, P429, DOI 10.1006/abbi.1995.0064; Polster BM, 2001, J BIOL CHEM, V276, P37887; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Rosenstock TR, 2004, J NEUROCHEM, V88, P1220, DOI 10.1046/j.1471-4159.2003.02250.x; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Terada T, 1999, AM J PHYSIOL-GASTR L, V276, pG1435, DOI 10.1152/ajpgi.1999.276.6.G1435; VALOTI M, 1992, BIOCHEM PHARMACOL, V43, P945, DOI 10.1016/0006-2952(92)90597-C; VARDANIS A, 1977, J BIOL CHEM, V252, P807; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wu CL, 2002, AM J PHYSIOL-HEART C, V283, pH783, DOI 10.1152/ajpheart.00193.2002; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhao GM, 2003, J PHARMACOL EXP THER, V307, P947, DOI 10.1124/jpet.103.054775; Zhao KS, 2003, J PHARMACOL EXP THER, V304, P425, DOI 10.1124/jpet.102.040147; Zhao ZQ, 2004, CURR OPIN PHARMACOL, V4, P159, DOI 10.1016/j.coph.2003.10.010	59	594	664	3	91	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34682	34690		10.1074/jbc.M402999200	http://dx.doi.org/10.1074/jbc.M402999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178689	hybrid			2022-12-25	WOS:000223134800073
J	Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M				Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M			Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors	ONCOGENE			English	Article						thyroid; tyrosine kinase inhibitors; RET; MEN2	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; IMATINIB MESYLATE; BLAST CRISIS; GROWTH; ABL; GERMLINE; ACTIVATION; DOMAIN; ZD6474	We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)less than or equal to100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino-acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Astra Zeneca Mereside, Canc Discovery, Macclesfield, Cheshire, England; CNRS, Genet Lab, Lyon, France	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; AstraZeneca; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	RYAN, Anderson/ACG-0319-2022; Billaud, Marc N/M-6954-2013; Ryan, Anderson J/O-7701-2015	RYAN, Anderson/0000-0001-6241-7969; Ryan, Anderson J/0000-0001-6241-7969; Fusco, Alfredo/0000-0003-3332-5197				Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bartsch DK, 2000, EXP CLIN ENDOCR DIAB, V108, P128, DOI 10.1055/s-2000-5806; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; BOLINO A, 1995, ONCOGENE, V10, P2415; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 1997, CANCER RES, V57, P391; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Carlomagno F, 2002, CANCER RES, V62, P1077; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Ciardiello F, 2003, CLIN CANCER RES, V9, P1546; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kasprzak L, 2001, J MED GENET, V38, P784, DOI 10.1136/jmg.38.11.784; La Rosee P, 2002, CANCER RES, V62, P7149; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Machens A, 2003, NEW ENGL J MED, V349, P1517, DOI 10.1056/NEJMoa012915; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Menko FH, 2002, J CLIN ENDOCR METAB, V87, P393, DOI 10.1210/jc.87.1.393; Nagar B, 2002, CANCER RES, V62, P4236; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2002, J CLIN ONCOL, V20, P3568, DOI 10.1200/JCO.2002.20.17.3568; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Wedge SR, 2002, CANCER RES, V62, P4645; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	45	194	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6056	6063		10.1038/sj.onc.1207810	http://dx.doi.org/10.1038/sj.onc.1207810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15184865				2022-12-25	WOS:000223261000005
J	Chae, C; Sharma, S; Hoskins, JR; Wickner, S				Chae, C; Sharma, S; Hoskins, JR; Wickner, S			CbpA, a DnaJ homolog, is a DnaK co-chaperone, and its activity is modulated by CbpM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; FUNCTIONAL CYCLE; REPLICATION; BINDING; HSP70; MONOMERIZATION; EXPRESSION; COMPLEX	The DnaK chaperone system, consisting of DnaK, DnaJ, and GrpE, remodels and refolds proteins during both normal growth and stress conditions. CbpA, one of several DnaJ analogs in Escherichia coli, is known to function as a multicopy suppressor for dnaJ mutations and to bind nonspecifically to DNA and preferentially to curved DNA. We found that CbpA functions as a DnaJ-like co-chaperone in vitro. CbpA acted in an ATP-dependent reaction with DnaK and GrpE to remodel inactive dimers of plasmid P1 RepA into monomers active in P1 DNA binding. Additionally, CbpA participated with DnaK in an ATP-dependent reaction to prevent aggregation of denatured rhodanese. The cbpA gene is in an operon with an open reading frame, yccD, which encodes a protein that has some homology to DafA of Thermus thermophilus. DafA is a protein required for the assembly of ring-like particles that contain trimers each of T. thermophilus DnaK, DnaJ, and DafA. The E. coli YccD was isolated because of its potential functional relationship to CbpA. Purified YccD specifically inhibited both the co-chaperone activity and the DNA binding activity of CbpA, suggesting that YccD modulates the activity of CbpA. We named the product of the yccD gene CbpM for "CbpA modulator."	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr,MSC37-4264, Bethesda, MD 20892 USA.	suewick@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC008710, ZIABC008710] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tucker DL, 2002, J BACTERIOL, V184, P6551, DOI 10.1128/JB.184.23.6551-6558.2002; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	23	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33147	33153		10.1074/jbc.M404862200	http://dx.doi.org/10.1074/jbc.M404862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184371	hybrid			2022-12-25	WOS:000223039700017
J	Dodson, GE; Shi, YL; Tibbetts, RS				Dodson, GE; Shi, YL; Tibbetts, RS			DNA replication defects, spontaneous DNA damage, and ATM-dependent checkpoint activation in replication protein A-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; KINASE-ACTIVITIES; P34 SUBUNIT; RPA; PHOSPHORYLATION; ATRIP; CHK1	Replication protein A (RPA) is a heterotrimeric, single-stranded DNA-binding complex comprised of 70-kDa (RPA1), 32-kDa (RPA2), and 14-kDa (RPA3) subunits that is essential for DNA replication, recombination, and repair in eukaryotes. In addition, recent studies using vertebrate model systems have suggested an important role for RPA in the initiation of cell cycle checkpoints following exposure to DNA replication stress. Specifically, RPA has been implicated in the recruitment and activation of the ATM-Rad3-related protein kinase, ATR, which in conjunction with the related kinase, ATM (ataxia-telangiectasia-mutated), transmits checkpoint signals via the phosphorylation of downstream effectors. In this report, we have explored the effects of RPA insufficiency on DNA replication, cell survival, and ATM/ATR-dependent signal transduction in response to genotoxic stress. RNA interference-mediated suppression of RPA1 caused a slowing of S phase progression, G(2)/M cell cycle arrest, and apoptosis in HeLa cells. RPA-deficient cells demonstrated high levels of spontaneous DNA damage and constitutive activation of ATM, which was responsible for the terminal G(2)/M arrest phenotype. Surprisingly, we found that neither RPA1 nor RPA2 were essential for the hydroxyurea- or UV-induced phosphorylation of the ATR substrates CHK1 and CREB (cyclic AMP-response element-binding protein). These findings reveal that RPA is required for genomic stability and suggest that activation of ATR can occur through RPA-independent pathways.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tibbetts, RS (corresponding author), Univ Wisconsin, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	rstibbetts@wisc.edu		Tibbetts, Randal/0000-0003-2245-2297	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067868] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-067868-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; Liu QH, 2000, GENE DEV, V14, P1448; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Parker AE, 1997, MOL CELL BIOL, V17, P2381, DOI 10.1128/MCB.17.5.2381; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	36	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34010	34014		10.1074/jbc.C400242200	http://dx.doi.org/10.1074/jbc.C400242200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15197179	hybrid			2022-12-25	WOS:000223039700112
J	Romanova, EV; Fosser, KA; Rubakhin, SS; Nuzzo, RG; Sweedler, JV				Romanova, EV; Fosser, KA; Rubakhin, SS; Nuzzo, RG; Sweedler, JV			Engineering the morphology and electrophysiological parameters of cultured neurons by microfluidic surface patterning	FASEB JOURNAL			English	Article						controlled growth; action potential broadening; MALDI-MS; soft lithography; aplysia	GROWTH CONE MORPHOLOGY; BAG CELLS; ABDOMINAL-GANGLION; NEURITE OUTGROWTH; APLYSIA; MODULATION; SUBSTRATE; NETWORKS; MULTIPLE; NEUROPEPTIDES	The ability to control the orientation, morphology, and electrophysiological characteristics of neurons in culture allows the construction of neural circuits with defined physiological properties. Using microfluidic protein deposition onto chemically modified glass, we achieve the controlled growth of Aplysia neurons on geometrical patterns of poly-L-lysine and collagen IV, surrounded by nonadhesive regions of bovine albumin. We investigate the parameters essential for forming functional neuronal networks, the morphology, biochemistry, and electrophysiology under engineered cell culture conditions. We demonstrate that not only the orientation of neurite extension but also the number of primary neurites originating from the cell soma, their length, and branching pattern depend on the spatial constraints presented by the size and shape of the adhesion region on the patterned substrate. In addition, the physicochemical properties of the support layer influence the electrical activity of the cultured neurons. Substrate-dependent changes in the amplitude and in the dynamic parameters of the action potential cause decreased spike broadening in patterned neurons, which reflects changes in the number or functioning of active membrane ion channels. In contrast to morphology and electrophysiology, the neuropeptide content, as determined by mass spectrometry of individual patterned neurons, is not affected by the growth on patterned surfaces. Our results suggest that the morphological and electrophysiological parameters of neurons can be predictably altered/engineered by modulation of the chemical, physical, and topographical features of culture substrates. We also demonstrate that a full suite of techniques is required for functional characterization of neurons on engineered substrates	Univ Illinois, Beckman Inst, Dept Chem, Roger Adams Lab 71, Urbana, IL 61801 USA; Univ Illinois, Federick Seitz Mat Res Lab, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sweedler, JV (corresponding author), Univ Illinois, Beckman Inst, Dept Chem, Roger Adams Lab 71, 600 S Mathews Av, Urbana, IL 61801 USA.	jsweedle@uiuc.edu	Rubakhin, Stanislav S/E-6685-2017; Sweedler, Jonathan V/A-9405-2009	Rubakhin, Stanislav S/0000-0003-0437-1493; Sweedler, Jonathan V/0000-0003-3107-9922; Romanova, Elena/0000-0002-2040-3312				Chang JC, 2001, BIOSENS BIOELECTRON, V16, P527, DOI 10.1016/S0956-5663(01)00166-X; CLARK P, 1993, J CELL SCI, V105, P203; Corey JM, 2003, EXP NEUROL, V184, pS89, DOI 10.1016/S0014-4886(03)00392-3; Delamarche E, 1998, J AM CHEM SOC, V120, P500, DOI 10.1021/ja973071f; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; Folch A, 2000, ANNU REV BIOMED ENG, V2, P227, DOI 10.1146/annurev.bioeng.2.1.227; Fosser KA, 2003, ANAL CHEM, V75, P5775, DOI 10.1021/ac034634a; Garden RW, 1998, P NATL ACAD SCI USA, V95, P3972, DOI 10.1073/pnas.95.7.3972; GLASER EM, 1984, J NEUROSCI METH, V12, P37, DOI 10.1016/0165-0270(84)90045-1; Gruenbaum LM, 1999, LEARN MEMORY, V6, P292; Jung DR, 2001, CRIT REV BIOTECHNOL, V21, P111, DOI 10.1080/20013891081700; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; Kowtha VC, 1998, NEUROSCI LETT, V246, P9, DOI 10.1016/S0304-3940(98)00193-1; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; Lauer L, 2002, BIOMATERIALS, V23, P3123, DOI 10.1016/S0142-9612(02)00056-X; MA MH, 1995, J NEUROSCI, V15, P6720; MATTSON MP, 1988, J NEUROSCI RES, V20, P331, DOI 10.1002/jnr.490200307; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.0.CO;2-C; MCMULLEN NT, 1984, J COMP NEUROL, V222, P383, DOI 10.1002/cne.902220306; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Monahan J, 2001, ANAL CHEM, V73, P3193, DOI 10.1021/ac001426z; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; PAYNE HR, 1992, CELL MOTIL CYTOSKEL, V21, P65, DOI 10.1002/cm.970210108; Prinz AA, 2000, BIOL CYBERN, V82, pL1, DOI 10.1007/PL00007969; ROBINSON PJ, 1971, BIOCHIM BIOPHYS ACTA, V242, P659, DOI 10.1016/0005-2744(71)90160-4; Rubakhin SS, 2003, ANAL CHEM, V75, P5374, DOI 10.1021/ac034498+; Rubakhin SS, 1999, J NEUROPHYSIOL, V81, P1251, DOI 10.1152/jn.1999.81.3.1251; SCHACHER S, 1983, J NEUROSCI, V3, P2403; Scholl M, 2000, J NEUROSCI METH, V104, P65, DOI 10.1016/S0165-0270(00)00325-3; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; Tai HC, 1998, BIOTECHNOL PROGR, V14, P364, DOI 10.1021/bp980035r; Vogt AK, 2003, BIOTECHNOL PROGR, V19, P1562, DOI 10.1021/bp034016f; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wyart C, 2002, J NEUROSCI METH, V117, P123, DOI 10.1016/S0165-0270(02)00077-8; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	38	30	34	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1267	+		10.1096/fj.03-1368fje	http://dx.doi.org/10.1096/fj.03-1368fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208266				2022-12-25	WOS:000222327500018
J	Shakor, ABA; Kwiatkowska, K; Sobota, A				Shakor, ABA; Kwiatkowska, K; Sobota, A			Cell surface ceramide generation precedes and controls Fc gamma RII clustering and phosphorylation in rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID SPHINGOMYELINASE; RICH MEMBRANE RAFTS; NEUTRAL SPHINGOMYELINASE; HUMAN-FIBROBLASTS; BINDING-PROTEIN; LIPID RAFTS; RECEPTOR-II; DOMAINS; MICRODOMAINS; IDENTIFICATION	Despite the role of sphingolipid/cholesterol rafts as signaling platforms for Fcgamma receptor II (FcgammaRII), the mechanism governing translocation of an activated receptor toward the rafts is unknown. We show that at the onset of FcgammaRII cross-linking acid sphingomyelinase is rapidly activated. This enzyme is extruded from intracellular compartments to the cell surface, and concomitantly, exofacially oriented ceramide is produced. Both non-raft and, to a lesser extent, raft sphingomyelin pools were hydrolyzed at the onset of FcgammaRII cross-linking. The time course of ceramide production preceded the recruitment of FcgammaRII to rafts and the receptor phosphorylation. Exogenous C-16-ceramide facilitated clustering of FcgammaRII and its association with rafts. In contrast, inhibition of acid sphingomyelinase diminished both the ceramide generation and clustering of crosslinked FcgammaRII. Under these conditions, tyrosine phosphorylation of FcgammaRII and receptor-accompanying proteins was also reduced. All the inhibitory effects were bypassed by treatment of cells with exogenous ceramide. These data provide evidence that the generation of cell surface ceramide is a prerequisite for fusion of cross-linked FcgammaRII and rafts, which triggers the receptor tyrosine phosphorylation and signaling.	M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Sobota, A (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	a.sobota@nencki.gov.pl	Abdel shakor, Abo bakr/R-7133-2016; Kwiatkowska, Katarzyna/ABE-9713-2021	Abdel shakor, Abo bakr/0000-0003-2792-9066; Kwiatkowska, Katarzyna/0000-0002-0550-8394				Albrektsen T, 2001, BIOCHEM J, V359, P393, DOI 10.1042/0264-6021:3590393; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; FENG SS, 1995, BIOPHYS J, V69, P460, DOI 10.1016/S0006-3495(95)79919-2; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; Hinkovska-Galcheva V, 1998, BLOOD, V91, P4761, DOI 10.1182/blood.V91.12.4761.412k24_4761_4769; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Katsumata O, 2001, J IMMUNOL, V167, P5814, DOI 10.4049/jimmunol.167.10.5814; KOBAYASHI H, 2001, M RIKEN FRONT RES SY; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Korzeniowski M, 2003, BIOCHEMISTRY-US, V42, P5358, DOI 10.1021/bi027135x; Kwiatkowska K, 2003, J CELL SCI, V116, P537, DOI 10.1242/jcs.00254; Kwiatkowska K, 1999, CELL MOTIL CYTOSKEL, V42, P298, DOI 10.1002/(SICI)1097-0169(1999)42:4<298::AID-CM4>3.0.CO;2-Q; Kwiatkowska K, 2001, EUR J IMMUNOL, V31, P989, DOI 10.1002/1521-4141(200104)31:4<989::AID-IMMU989>3.0.CO;2-V; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lansmann S, 2003, EUR J BIOCHEM, V270, P1076, DOI 10.1046/j.1432-1033.2003.03435.x; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Romiti E, 2000, MOL CELL BIOCHEM, V205, P75, DOI 10.1023/A:1007041329052; Romiti E, 2001, FEBS LETT, V506, P163, DOI 10.1016/S0014-5793(01)02878-2; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Shakor ABA, 2003, FEBS LETT, V542, P1, DOI 10.1016/S0014-5793(03)00330-2; Strzelecka-Kiliszek A, 2004, MOL MEMBR BIOL, V21, P101, DOI 10.1080/09687680310001639094; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wilson BS, 2001, J CELL BIOL, V154, P645, DOI 10.1083/jcb.200104049; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; YOSHIDA Y, 1985, J BIOCHEM-TOKYO, V98, P1669, DOI 10.1093/oxfordjournals.jbchem.a135438; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	52	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36778	36787		10.1074/jbc.M402170200	http://dx.doi.org/10.1074/jbc.M402170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194692	hybrid			2022-12-25	WOS:000223453600079
J	Tanida, I; Sou, YS; Ezaki, J; Minematsu-Ikeguchi, N; Ueno, T; Kominami, E				Tanida, I; Sou, YS; Ezaki, J; Minematsu-Ikeguchi, N; Ueno, T; Kominami, E			HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3-and GABA(A) receptor-associated protein-phospholipid conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT MODULATOR; ACTIVATING ENZYME; AUTOPHAGY; GATE-16; YEAST; GABARAP; CELL; DEGRADATION; MAP-LC3; APG7P/CVT2P	In yeast, Atg4/Apg4 is a unique cysteine protease responsible for the cleavage of the carboxyl terminus of Atg8/Apg8/Aut7, a reaction essential for its lipidation during the formation of autophagosomes. However, it is still unclear whether four human Atg4 homologues cleave the carboxyl termini of the three human Atg8 homologues, microtubule-associated protein light chain 3 (LC3), GABARAP, and GATE-16. Using a cell-free system, we found that HsAtg4B, one of the human Atg4 homologues, cleaves the carboxyl termini of these three Atg8 homologues. In contrast, the mutant HsAtg4B(C74A), in which a predicted active site Cys(74) was changed to Ala, lacked proteolytic activity, indicating that Cys(74) is essential for the cleavage activity of cysteine protease. Using phospholipase D, we showed that the modified forms of endogenous LC3 and GABARAP are lipidated and therefore were designated LC3-PL and GABARAP-PL. When purified glutathione S-transferase-tagged HsAtg4B was incubated in vitro with a membrane fraction enriched with endogenous LC3-PL and GABARAP-PL, the mobility of LC3-PL and GABARAP-PL was changed to those of the unmodified proteins. These mobility shifts were not seen when Cys(74) of HsAtg4B was changed to Ala. Overexpression of wild-type HsAtg4B decreased the amount of LC3-PL and GABARAP-PL and increased the amount of unmodified endogenous LC3 and GABARAP in HeLa cells. Expression of CFP-tagged HsAtg4B (CFP-HsAtg4B) and YFP-tagged LC3 in HeLa cells under starvation conditions resulted in a significant decrease in the punctate pattern of distribution of YFP-tagged LC3 and an increase in its cytoplasmic distribution. RNA interference of HsAtg4B increased the amount of LC3-PL in HEK293 cells. Taken together, these results suggest that HsAtg4B negatively regulates the localization of LC3 to a membrane compartment by delipidation.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kominami@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Sou, Yu-shin/0000-0002-7219-9106; Tanida, Isei/0000-0001-8999-3990				Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; HUAN W, 1999, MOL BIOL CELL, V10, P1353; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kadowaki M, 2003, J NUTR, V133, p2052S, DOI 10.1093/jn/133.6.2052S; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Nemoto T, 2003, J BIOL CHEM, V278, P39517, DOI 10.1074/jbc.M300550200; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Scherz-Shouval R, 2003, J BIOL CHEM, V278, P14053, DOI 10.1074/jbc.M212108200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Thumm M, 2001, MOL GENET GENOMICS, V266, P657, DOI 10.1007/s004380100585; Thummel CS, 2001, BIOESSAYS, V23, P677, DOI 10.1002/bies.1096; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	35	271	288	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36268	36276		10.1074/jbc.M401461200	http://dx.doi.org/10.1074/jbc.M401461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15187094	hybrid			2022-12-25	WOS:000223453600015
J	Niwa, R; Matsuda, T; Yoshiyama, T; Namiki, T; Mita, K; Fujimoto, Y; Kataoka, H				Niwa, R; Matsuda, T; Yoshiyama, T; Namiki, T; Mita, K; Fujimoto, Y; Kataoka, H			CYP306A1, a cytochrome P450 enzyme, is essential for ecdysteroid biosynthesis in the prothoracic glands of Bombyx and Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450 ENZYMES; WING DISCS; ECDYSONE; GENES; MORPHOGENESIS; EXPRESSION; MELANOGASTER; SEQUENCES; SILKWORM; INSECTS	Ecdysteroids mediate a wide variety of developmental and physiological events in insects. In the postembryonic development of insects, ecdysone is synthesized in the prothoracic gland (PG). Although many studies have revealed the biochemical and physiological properties of the enzymes for ecdysteroid biosynthesis, most of the molecular identities of these enzymes have not been elucidated. Here we describe an uncharacterized cytochrome P450 gene, designated Cyp306a1, that is essential for ecdysteroid biosynthesis in the PGs of the silkworm Bombyx mori and fruit fly Drosophila melanogaster. Using the microarray technique for analyzing gene expression profiles in PG cells during Bombyx development, we identified two PG-specific P450 genes whose temporal expression patterns are correlated with changes in ecdysteroid titer during development. Amino acid sequence analysis showed that one of the Bombyx P450 genes belongs to the CYP306A1 subfamily. The temporal and spatial expression pattern of the Drosophila Cyp306a1 homolog is essentially the same as that of Bombyx Cyp306a1. We also found that Drosophila Cyp306a1 is disrupted in the phantom (phm) mutant, known also as the Halloween mutant. The morphological defects and decreased expression of ecdysone-inducible genes in phm suggest that this mutant cannot produce a high titer of ecdysone. Finally we demonstrate that S2 cells transfected with Cyp306a1 convert ketodiol to ketotriol via carbon 25 hydroxylation. These results strongly suggest that CYP306A1 functions as a carbon 25 hydroxylase and has an essential role in ecdysteroid biosynthesis during insect development.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Tokyo Inst Technol, Dept Chem & Mat Sci, Meguro Ku, Tokyo 1528551, Japan; Natl Inst Agrobiol Sci, Lab Insect Genome, Tsukuba, Ibaraki 3058643, Japan	University of Tokyo; Tokyo Institute of Technology; National Institute of Agrobiological Sciences - Japan	Niwa, R (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Rm 201,5-1-5 Kashiwanoha, Chiba 2778562, Japan.	rniwa@k.u-tokyo.ac.jp; kataoka@k.u-tokyo.ac.jp						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; BOLLENBACHER WE, 1977, STEROIDS, V29, P47, DOI 10.1016/0039-128X(77)90108-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buszczak M, 1999, DEVELOPMENT, V126, P4581; Casso D, 2000, MECH DEVELOP, V91, P449; Charles JP, 1999, EUR J BIOCHEM, V266, P181, DOI 10.1046/j.1432-1327.1999.00842.x; Chavez VM, 2000, DEVELOPMENT, V127, P4115; Feyereisen R, 1999, ANNU REV ENTOMOL, V44, P507, DOI 10.1146/annurev.ento.44.1.507; Freeman MR, 1999, DEVELOPMENT, V126, P4591; Gilbert LI, 2004, MOL CELL ENDOCRINOL, V215, P1, DOI 10.1016/j.mce.2003.11.003; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; GRIENEISEN ML, 1994, INSECT BIOCHEM MOLEC, V24, P115, DOI 10.1016/0965-1748(94)90078-7; HAAG T, 1987, INSECT BIOCHEM, V17, P291, DOI 10.1016/0020-1790(87)90071-0; HAAG T, 1988, J CHEM SOC PERK T 1, P2353, DOI 10.1039/p19880002353; Harvie PD, 1998, GENETICS, V149, P217; KAPPLER C, 1988, J STEROID BIOCHEM, V31, P891, DOI 10.1016/0022-4731(88)90330-5; Koyama T, 2004, J INSECT PHYSIOL, V50, P123, DOI 10.1016/j.jinsphys.2003.09.009; Kusano K, 2001, J BIOCHEM, V129, P259, DOI 10.1093/oxfordjournals.jbchem.a002853; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; MAROY P, 1988, J INSECT PHYSIOL, V34, P633, DOI 10.1016/0022-1910(88)90071-6; Matsuoka T, 2000, DEV GENES EVOL, V210, P120, DOI 10.1007/s004270050018; Mita K, 2003, P NATL ACAD SCI USA, V100, P14121, DOI 10.1073/pnas.2234984100; Mizoguchi A, 2001, INSECT BIOCHEM MOLEC, V31, P349, DOI 10.1016/S0965-1748(00)00127-2; NAGAKARI M, 1994, J CHEM SOC CHEM COMM, P1761, DOI 10.1039/c39940001761; NATZLE JE, 1992, DEV GENET, V13, P331, DOI 10.1002/dvg.1020130504; NATZLE JE, 1986, J BIOL CHEM, V261, P5575; NATZLE JE, 1988, DEV BIOL, V129, P428, DOI 10.1016/0012-1606(88)90390-9; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Noji T, 2003, INSECT BIOCHEM MOLEC, V33, P671, DOI 10.1016/S0965-1748(03)00048-1; Omura T., 1993, CYTOCHROME P 450; Petryk A, 2003, P NATL ACAD SCI USA, V100, P13773, DOI 10.1073/pnas.2336088100; Poulson D. F., 1945, TRANS CONNECTICUT ACAD ARTS AND SCI, V36, P449; REES HH, 1995, EUR J ENTOMOL, V92, P9; Riddiford Lynn M., 1993, P899; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Roth GE, 2004, P NATL ACAD SCI USA, V101, P1601, DOI 10.1073/pnas.0308212100; Sakurai S, 1998, J INSECT PHYSIOL, V44, P867, DOI 10.1016/S0022-1910(98)00075-4; STAPLETON M, 2002, GENOME BIOL; Takeuchi H, 2002, FEBS LETT, V513, P230, DOI 10.1016/S0014-5793(02)02319-0; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Thummel CS, 2001, DEV CELL, V1, P453, DOI 10.1016/S1534-5807(01)00060-0; Tijet N, 2001, GENE, V262, P189, DOI 10.1016/S0378-1119(00)00533-3; Tsruya R, 2002, GENE DEV, V16, P222, DOI 10.1101/gad.214202; Venkatesh K, 1997, CURR BIOL, V7, P500, DOI 10.1016/S0960-9822(06)00221-1; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Wieschaus E., 1998, DROSOPHILA PRACTICAL, P179; [No title captured]	49	218	231	5	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35942	35949		10.1074/jbc.M404514200	http://dx.doi.org/10.1074/jbc.M404514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15197185	hybrid			2022-12-25	WOS:000223303400095
J	Taron, BW; Colussi, PA; Wiedman, JM; Orlean, P; Taron, CH				Taron, BW; Colussi, PA; Wiedman, JM; Orlean, P; Taron, CH			Human Smp3p adds a fourth mannose to yeast and human glycosylphosphatidylinositol precursors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOINOSITOL PHOSPHOLIPID ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GPI-ANCHOR; MEMBRANE ANCHORS; 3RD MANNOSE; TRANSFERRING PHOSPHOETHANOLAMINE; STRUCTURAL-CHARACTERIZATION; CORE STRUCTURE	Yeast and human glycosylphosphatidylinositol (GPI) precursors differ in the extent to which a fourth mannose is present as a side branch of the third core mannose. A fourth mannose addition to GPIs has scarcely been detected in studies of mammalian GPI synthesis but is an essential step in the Saccharomyces cerevisiae pathway. We report that human SMP3 encodes a functional homolog of the yeast Smp3 GPI fourth mannosyltransferase. Expression of hSMP3 in yeast complements growth and biochemical defects of smp3 mutants and permits in vivo mannosylation of trimannosyl (Man(3))-GPIs. Immunolocalization shows that hSmp3p resides in the endoplasmic reticulum in human cells. Northern analysis of mRNA from human tissues and cell lines indicates that hSMP3 is expressed in most tissues, with the highest levels in brain and colon, but its mRNA is nearly absent from cultured human cell lines. Correspondingly, increasing expression of hSMP3 in cultured HeLa cells causes abundant formation of three putative tetramannosyl (Man(4))-GPIs. Our data indicate that hSmp3p functions as a mannosyltransferase that adds a fourth mannose to certain Man(3)-GPIs during biosynthesis of the human GPI precursor, and suggest it may do so in a tissue-specific manner.	New England Biolabs Inc, Beverly, MA 01915 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Taron, CH (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	taron@neb.com		Taron, Christopher/0000-0001-8149-4556	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEEG MA, 1992, J BIOL CHEM, V267, P18573; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; MUKASA R, 1995, ARCH BIOCHEM BIOPHYS, V318, P182, DOI 10.1006/abbi.1995.1219; NAKANO Y, 1994, ARCH BIOCHEM BIOPHYS, V311, P117, DOI 10.1006/abbi.1994.1216; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1992, J BIOL CHEM, V267, P22673; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Sutterlin C, 1998, BIOCHEM J, V332, P153; TAGUCHI R, 1994, BIOCHEMISTRY-US, V33, P1017, DOI 10.1021/bi00170a021; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; UEDA E, 1993, J BIOL CHEM, V268, P9998; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	44	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36083	36092		10.1074/jbc.M405081200	http://dx.doi.org/10.1074/jbc.M405081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208306	hybrid			2022-12-25	WOS:000223303400110
J	Zhang, H; Shi, XQ; Paddon, H; Hampong, M; Dai, W; Pelech, S				Zhang, H; Shi, XQ; Paddon, H; Hampong, M; Dai, W; Pelech, S			B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; CENTROSOME DUPLICATION; SCHIZOSACCHAROMYCES-POMBE; SPINDLE POLES; CANCER-CELLS; PLK1; CYTOKINESIS; ACTIVATION; NUCLEOPHOSMIN; INHIBITION	Phosphoprotein profiling by Kinetworks(TM) analysis of M-phase-arrested HeLa cells by nocodazole treatment revealed that a novel mitosis-specific phosphorylation event occurred in the nucleolar protein B23/nucleophosmin at a conserved Ser-4 residue. Consistent with the resemblance of the Ser-4 phosphorylation site to the Polo-like kinase 1 (Plk1) consensus recognition sequence, inhibition of Plk1 by a kinase-defective mutation (K82M) abrogated B23 Ser-4 phosphorylation, whereas activation of Plk1 by a constitutively active mutation (T210D) enhanced its phosphorylation following in vivo transfection and in vitro phosphorylation assays. Depletion of endogenous Plk1 by RNA interference abolished B23 Ser-4 phosphorylation. The physical interaction of Plk1 and B23 was further demonstrated by their co-immunoprecipitation and glutathione S-transferase fusion protein pull-down assays. Interference of Ser-4 phosphorylation of B23 induced multiple mitotic defects in HeLa cells, including aberrant numbers of centrosomes, elongation and fragmentation of nuclei, and incomplete cytokinesis. The phenotypes of B23 mutants are reminiscent of a subset of those described previously in Plk1 mutants. Our findings provide insights into the biochemical mechanism underlying the role of Plk1 in mitosis regulation through the identification of Ser-4 in B23 as a major physiological substrate of Plk1.	Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of British Columbia; University of British Columbia; New York Medical College	Pelech, S (corresponding author), Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z3, Canada.	spelech@kinexus.ca						Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Donaldson MM, 2001, J CELL SCI, V114, P2357; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KINTER M, 2000, PROTEIN SEQUENCING I, P147, DOI DOI 10.1002/0471721980; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2003, CELL, V115, P3, DOI 10.1016/S0092-8674(03)00761-X; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Okano-Uchida T, 2003, EMBO J, V22, P5633, DOI 10.1093/emboj/cdg535; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Pelech Steven, 2003, Methods Mol Biol, V218, P99; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	52	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35726	35734		10.1074/jbc.M403264200	http://dx.doi.org/10.1074/jbc.M403264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190079	hybrid			2022-12-25	WOS:000223303400071
J	Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM				Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM			Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid tumor; RET/PTC oncogenes; chemokine receptor	RET TYROSINE KINASE; LUNG-CANCER CELLS; BREAST-CANCER; SIGNALING PATHWAY; INVASIVE GROWTH; HIGH PREVALENCE; BRAF MUTATIONS; IN-VITRO; KAPPA-B; METASTASIS	To identify genes involved in the transformation of thyroid follicular cells, we explored, using DNA oligonucleotide microarrays, the transcriptional response of PC CI3 rat thyroid epithelial cells to the ectopic expression of the RET/PTC oncogenes. We found that RET/PTC was able to induce the expression of CXCR4, the receptor for the chemokine CXCL12/SDF-1alpha/beta. We observed that CXCR4 expression correlated with the transforming ability of the oncoprotein and depended on the integrity of the RET/PTC-RAS/ERK signaling pathway. We found that CXCR4 was expressed in RET/PTC-positive human thyroid cancer cell lines, but not in normal thyroid cells. Furthermore, we found CXCR4 expression in human thyroid carcinomas, but not in normal thyroid samples by immunohistochemistry. Since CXCR4 has been recently implicated in tumor proliferation, motility and invasiveness, we asked whether treatment with SDF-1alpha was able to induce a biological response in thyroid cells. We observed that SDF-1alpha induced S-phase entry and survival of thyroid cells. Invasion through a reconstituted extracellular matrix was also supported by SDF-1alpha and inhibited by a blocking antibody to CXCR4. Taken together, these results suggest that human thyroid cancers bearing RET/PTC rearrangements may use the CXCR4/SDF-1alpha: receptor-ligand pathway to proliferate, survive and migrate.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Dipartimento Oncol, Pisa, Italy; Aarhus Univ Hosp, Mol Diagnost Lab, Dept Clin Biochem, DK-8000 Aarhus, Denmark; Thomas Jefferson Univ, Dept Microbiol Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Aarhus University; Jefferson University; Jefferson University	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.	rosmelil@unina.it	Faviana, Pinuccia/L-5620-2019; Faviana, Pinuccia/ABA-8436-2021; DE FALCO, VALENTINA/C-2061-2015; melillo, rosa marina/O-5255-2015; Basolo, Fulvio/AAC-2727-2019; FAVIANA, PINUCCIA/R-7928-2017	Faviana, Pinuccia/0000-0003-4283-1083; DE FALCO, VALENTINA/0000-0002-8972-7921; Basolo, Fulvio/0000-0003-1657-5020; FAVIANA, PINUCCIA/0000-0003-4283-1083; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barbero S, 2003, CANCER RES, V63, P1969; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bernards R, 2003, NATURE, V425, P247, DOI 10.1038/425247a; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chen YC, 2003, CANCER RES, V63, P4801; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; De Vita G, 2000, CANCER RES, V60, P3727; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kijima T, 2002, CANCER RES, V62, P6304; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kroll TG, 2002, AM J PATHOL, V160, P1941, DOI 10.1016/S0002-9440(10)61142-X; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Ludwig L, 2001, CANCER RES, V61, P4526; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Murakami T, 2002, CANCER RES, V62, P7328; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Powell DJ, 1998, CANCER RES, V58, P5523; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Scotton CJ, 2002, CANCER RES, V62, P5930; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Xu XL, 2003, CANCER RES, V63, P4561; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	58	107	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5958	5967		10.1038/sj.onc.1207790	http://dx.doi.org/10.1038/sj.onc.1207790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184868				2022-12-25	WOS:000222941100010
J	Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R				Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R			Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma	ONCOGENE			English	Article						STAT3; anaplastic large cell lymphoma; NPM-ALK; adenoviral vectors; apoptosis; cell cycle	RECEPTOR TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; NEGATIVE REGULATORS; EXPRESSION; GENE; PROTEINS; MEDIATE; T(2/5); LINES	Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK(+) ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK(+) ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK(+) ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705(tyrosine --> phenylalanine), a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G, cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.	Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Grad Sch Med, Dept Mol Med, Osaka, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Amin, HM (corresponding author), Univ Alberta, Dept Lab Med & Pathol, Fac Med & Dent, Walter MacKenzie Hlth Sci Ctr 4B1, 8440 112 St, Edmonton, AB T6G 2B7, Canada.	raymondmail_65@yahoo.com	Fujio, Yasushi/H-3421-2017; Rassidakis, George/V-9553-2019; Leventaki, Vasiliki/N-8175-2018	Fujio, Yasushi/0000-0003-0828-2930; 				Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Delsol G, 2001, WHO CLASSIFICATION T, P230; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EPSTEIN AL, 1979, CANCER RES, V39, P1748; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Falini B, 1999, BLOOD, V93, P2697; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Mora LB, 2002, CANCER RES, V62, P6659; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; SCHLETTE EJ, 2004, IN PRESS J CLIN ONCO; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wood GS, 1996, BLOOD, V88, P1765, DOI 10.1182/blood.V88.5.1765.bloodjournal8851765; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	47	135	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5426	5434		10.1038/sj.onc.1207703	http://dx.doi.org/10.1038/sj.onc.1207703			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184887				2022-12-25	WOS:000222588400002
J	Ferri, A; Nencini, M; Casciati, A; Cozzolino, M; Angelini, DF; Longone, P; Spalloni, A; Rotilio, G; Carri, MT				Ferri, A; Nencini, M; Casciati, A; Cozzolino, M; Angelini, DF; Longone, P; Spalloni, A; Rotilio, G; Carri, MT			Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells	FASEB JOURNAL			English	Article						apoptosis; neuroinflammation; non-cell autonomous neuroanal death; ROS; superoxide dsimutase	TRANSGENIC MOUSE MODEL; NF-KAPPA-B; COPPER/ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURONS; NITRIC-OXIDE; DIFFERENTIAL EXPRESSION; DEPENDENT APOPTOSIS; GLUTAMATE RELEASE; OXIDATIVE STRESS; SPINAL-CORDS	Mutations in the gene coding for the ubiquitous, anti-oxidant enzyme Cu,Zn superoxide dismutase (SOD1) are associated with familial amyotrophic lateral sclerosis (fALS), a fatal disease characterized by selective loss of motor neurons. Expression of a mutant SOD1 typical of fALS patients restricted to either motor neurons or astrocytes is insufficient to generate a pathological phenotype in mouse models, suggesting that a deleterious interplay between different cell types is necessary for the pathogenesis of the disease. In this study, we demonstrate the actual role of a functional cross-talk between glial and neuronal cells expressing fALS mutant G93A-SOD1, where an increase in the production of reactive oxygen species occurs. We show that human glioblastoma cells expressing G93A-SOD1 induce activation of caspase-1, release of cytokines, and activation of apoptotic pathways in cocultured human neuroblastoma cells also expressing G93A-SOD1. Activation of caspase-1 and caspase-3 is observed also in neuroblastoma lines expressing other fALS-SOD1s (G37R, G85R, and I113T) cocultured with glioblastoma lines expressing the corresponding mutant enzymes. These effects are consequent to activation of inflammatory processes in G93A-glioblastoma cells stimulated by cocultured G93A-neuroblastoma. Furthermore, selective death of embryonal spinal motor neurons from G93A-SOD1 transgenic mice is induced by coculture with G93A-glioblastoma and prevented by inhibition of NO synthase. Proinflammatory cytokines, interferon-gamma, and nitric oxide are among the molecular signals exchanged between glial and neuronal cells that generate a functional interplay between the two cell types. This cross-talk may be crucial for the pathogenesis of SOD1-linked fALS but also for the more common sporadic form of the disease, where markers of increased oxidative stress and of glial activation have been found.	CNR, Ist Neurosci, Sez Psicobiol & Psicofarmacol, Rome, Italy; Ctr Neurobiol Sperimental Mondino Tor Vergata S Lu, Lab Neurochim, Rome, Italy; Fdn Santa Lucia, IRCCS, Rome, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; University of Rome Tor Vergata	Carri, MT (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via della Ric Sci, I-00133 Rome, Italy.	carri@Bio.uniroma2.it	Spalloni, Alida/K-4316-2014; cozzolino, mauro/AAY-2244-2020; Longone, Patrizia/G-8428-2016; Angelini, Daniela F/J-8001-2018; FERRI, ALBERTO/B-7660-2015; Nencini, Monica/ABI-6619-2020; Carri, Maria Teresa/K-5480-2016	Longone, Patrizia/0000-0001-8964-1637; Angelini, Daniela F/0000-0003-4552-9226; FERRI, ALBERTO/0000-0002-4097-0605; COZZOLINO, MAURO/0000-0003-0342-8961; Carri, Maria Teresa/0000-0002-1789-1546; Nencini, Monica/0000-0001-9602-1954; Spalloni, Alida/0000-0002-2661-6677				Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.3.CO;2-O; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Beretta S, 2003, NEUROBIOL DIS, V13, P213, DOI 10.1016/S0969-9961(03)00043-3; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Carri M T, 1997, FEBS Lett, V414, P365; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Casciati A, 2002, J NEUROCHEM, V83, P1019, DOI 10.1046/j.1471-4159.2002.01232.x; Cha CI, 2000, BRAIN RES, V853, P156, DOI 10.1016/S0006-8993(99)02302-1; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferri A, 2000, J NEUROCHEM, V75, P606, DOI 10.1046/j.1471-4159.2000.0750606.x; Fontana G, 2001, NEUROSCIENCE, V106, P183, DOI 10.1016/S0306-4522(01)00272-X; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Gioia C, 2002, J IMMUNOL, V168, P1484, DOI 10.4049/jimmunol.168.3.1484; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kang SJ, 2003, J NEUROSCI, V23, P5455; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Liu DX, 1999, FASEB J, V13, P2318, DOI 10.1096/fasebj.13.15.2318; Luck H, 1963, METHODS ENZYMATIC AN, P885; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nguyen MD, 2001, ANN NEUROL, V50, P630, DOI 10.1002/ana.1256; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Plant LD, 2003, J NEUROSCI, V23, P5531; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rao SD, 2003, J NEUROSCI, V23, P2627; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Roe JA, 2002, FREE RADICAL BIO MED, V32, P169, DOI 10.1016/S0891-5849(01)00778-X; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schmidt H. H. W., 1996, METHODS NITRIC OXIDE, P491; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Yu WH, 2001, J NEUROSCI, V21, P2240, DOI 10.1523/JNEUROSCI.21-07-02240.2001	61	50	54	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1261	+		10.1096/fj.03-1199fje	http://dx.doi.org/10.1096/fj.03-1199fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208263				2022-12-25	WOS:000222327500019
J	Chen, WY; Lee, WC; Hsu, NC; Huang, F; Chung, BC				Chen, WY; Lee, WC; Hsu, NC; Huang, F; Chung, BC			SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MODIFICATION; TRANSCRIPTIONAL ACTIVITY; BINDING PROTEIN; P450SCC GENE; UBIQUITIN; CELLS; TRANSACTIVATION; LOCALIZATION; EXPRESSION; ACTIVATION	Steroidogenic factor 1 (SF-1 or NR5A1), is a Ftz-F1 member of the nuclear receptor superfamily that plays essential roles in endocrine development, steroidogenesis, and gonad differentiation. We investigated modifications that control SF-1 function and found that SF-1 could be conjugated by SUMO-1 both in vitro and in vivo. SF-1 was modified predominantly at Lys(194) and much less at Lys(119) when free SUMO-1 was supplied. Mutations of Lys(194) and Lys(119) enhanced transcriptional activity of SF-1, although the DNA binding activity of SF-1 was not affected. Sequences around Lys(194) and Lys(119) both repressed transcription intrinsically. The Lys(194) motif repressed transcription more efficiently than the Lys(119) domain, consistent with its ability to be a better substrate for SUMO conjugation. Thus, SUMO modification of SF-1 correlates with transcriptional repression. Wild-type but not conjugation-deficient SF-1 was localized at the nuclear speckles together with SUMO-1. Thus, SUMO-1 conjugation could also target SF-1 into nuclear speckles. Collectively, these results suggest that SUMO modification at the repression domains targets SF-1 to nuclear speckles; this could be an important mechanism by which SF-1 is regulated.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chung, BC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbchung@sinica.edu.tw		Huang, Fu/0000-0001-9549-8937; Chen, Wei-Yi/0000-0002-0661-6899; Chung, Bon-chu/0000-0002-8612-0219				Auwerx J, 1999, CELL, V97, P161; Borud B, 2002, MOL ENDOCRINOL, V16, P757, DOI 10.1210/me.16.4.757; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hsu HJ, 2003, DEVELOPMENT, V130, P2107, DOI 10.1242/dev.00427; HU MC, 1990, MOL ENDOCRINOL, V4, P893, DOI 10.1210/mend-4-6-893; HU MC, 1991, BIOCHEM J, V274, P813, DOI 10.1042/bj2740813; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KOMATSU T, 2004, IN PRESS MOL ENDOCRI, V18; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li LA, 1999, MOL ENDOCRINOL, V13, P1588, DOI 10.1210/me.13.9.1588; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Suzuki T, 2003, MOL CELL BIOL, V23, P238, DOI 10.1128/MCB.23.1.238-249.2003; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	31	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38730	38735		10.1074/jbc.M405006200	http://dx.doi.org/10.1074/jbc.M405006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15192092	hybrid			2022-12-25	WOS:000223684100083
J	Harris, EN; Weigel, JA; Weigel, PH				Harris, EN; Weigel, JA; Weigel, PH			Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; ASIALOGLYCOPROTEIN RECEPTOR; BINDING PROTEINS; ACID; TISSUE; SERUM; DISEASE; LIGAND; IDENTIFICATION	The human hyaluronan receptor for endocytosis (hHARE) mediates the endocytic clearance of hyaluronan (HA) and chondroitin sulfate from lymph fluid and blood. Two hHARE isoforms (190 and 315 kDa) are present in sinusoidal endothelial cells of liver, spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A., Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339-349). Here we report the specificity and function of the 190-kDa HARE, expressed without the larger isoform, in Flp-In 293 cell lines (190hHARE cells). Like the native protein, recombinant hHARE contains similar to25 kDa of N-linked oligosaccharides, binds HA in a ligand blot assay, cross-reacts with three anti-rat HARE monoclonal antibodies, and is inactivated by reduction. The 190hHARE cell lines mediated rapid, continuous I-125-HA endocytosis and degradation for >1 day. About 30-50% of the total cellular receptors were on the cell surface, and their recycling time for reutilization was similar to8.5 min. The average K-d for the binding of HA to the 190-kDa hHARE at 4 degreesC was 7 nM with 118,000 total HA binding sites per cell. Competition studies at 37 degreesC indicated that the 190-kDa hHARE binds HA and chondroitin better than dermatan sulfate and chondroitin sulfates A, C, D, and E, but it does not bind to heparin, heparan sulfate, or keratan sulfate. Although competition was observed at 37 degreesC, none of the glycosaminoglycans tested, except HA, competed for I-125-HA binding by 190hHARE cells at 4 degreesC. Anti-HARE monoclonal antibodies #30 and #154, which do not inhibit I-125-HA uptake mediated by the 175-kDa rat HARE, partially blocked HA endocytosis by the 190-kDa hHARE. We conclude that the 190-kDa hHARE can function independently of other hHARE isoforms to mediate the endocytosis of multiple glycosaminoglycans. Furthermore, the rat and human small HARE isoforms have different glycosaminoglycan specificities and sensitivities to inhibition by cross-reacting antibodies.	Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, BMSB,Rm 860,Box 26901, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu						ABATANGELO G, 2000, NEW FRONTIERS MED SC; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLEY PN, 1991, J HEPATOL, V13, P8, DOI 10.1016/0168-8278(91)90856-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; EVERED D, 1989, CIBA F SYMP, V143, P1; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; Freitas JP, 1996, DERMATOLOGY, V192, P46, DOI 10.1159/000246314; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LEBEL L, 1988, J APPL PHYSIOL, V64, P1327, DOI 10.1152/jappl.1988.64.4.1327; LEBOEUF RD, 1987, BIOCHEMISTRY-US, V26, P6052, DOI 10.1021/bi00393a016; LEBOEUF RD, 1986, J BIOL CHEM, V261, P2586; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; OKA JA, 1983, J BIOL CHEM, V258, P253; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	44	67	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36201	36209		10.1074/jbc.M405322200	http://dx.doi.org/10.1074/jbc.M405322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208308	Green Published, hybrid			2022-12-25	WOS:000223453600007
J	Meredith, AL; Thorneloe, KS; Werner, ME; Nelson, MT; Aldrich, RW				Meredith, AL; Thorneloe, KS; Werner, ME; Nelson, MT; Aldrich, RW			Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PIG VAS-DEFERENS; RYANODINE RECEPTORS; CA2+ SPARKS; DIFFERENTIAL REGULATION; OPENING ACTIVITY; ACTIVATION; SUBUNIT; MICE	BK large conductance voltage- and calcium-activated potassium channels respond to elevations in intracellular calcium and membrane potential depolarization, braking excitability of smooth muscle. BK channels are thought to have a particularly prominent role in urinary bladder smooth muscle function and therefore are candidate targets for overactive bladder therapy. To address the role of the BK channel in urinary bladder function, the gene mSlo1 for the pore-forming subunit of the BK channel was deleted. Slo(-/-) mice were viable but exhibited moderate ataxia. Urinary bladder smooth muscle cells of Slo(-/-) mice lacked calcium- and voltage-activated BK currents, whereas local calcium transients ("calcium sparks") and voltage- dependent potassium currents were unaffected. In the absence of BK channels, urinary bladder spontaneous and nerve-evoked contractions were greatly enhanced. Consistent with increased urinary bladder contractility caused by the absence of BK currents, Slo(-/-) mice demonstrate a marked elevation in urination frequency. These results reveal a central role for BK channels in urinary bladder function and indicate that BK channel dysfunction leads to overactive bladder and urinary incontinence.	Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; University of Vermont	Aldrich, RW (corresponding author), Stanford Univ, Dept Cellular & Mol Physiol, 279 Campus Dr,Beckman 173, Stanford, CA 94305 USA.	raldrich@stanford.edu	Werner, Matthias E/A-7141-2008	Nelson, Mark/0000-0002-6608-8784; Meredith, Andrea/0000-0003-1061-2302				ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Brune ME, 2002, J PHARMACOL EXP THER, V303, P387, DOI 10.1124/jpet.102.034553; Butera JA, 2001, BIOORG MED CHEM LETT, V11, P2093, DOI 10.1016/S0960-894X(01)00385-7; Christ GJ, 2001, AM J PHYSIOL-REG I, V281, pR1699, DOI 10.1152/ajpregu.2001.281.5.R1699; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P31; Hashitani H, 2003, BRIT J PHARMACOL, V140, P159, DOI 10.1038/sj.bjp.0705320; Heppner TJ, 1997, AM J PHYSIOL-CELL PH, V273, pC110; Herrera GM, 2003, J PHYSIOL-LONDON, V551, P893, DOI 10.1113/jphysiol.2003.045914; Herrera GM, 2002, J PHYSIOL-LONDON, V541, P483, DOI 10.1113/jphysiol.2002.017707; Herrera GM, 2001, AM J PHYSIOL-CELL PH, V280, pC481, DOI 10.1152/ajpcell.2001.280.3.C481; Herrera GM, 2000, AM J PHYSIOL-REG I, V279, pR60, DOI 10.1152/ajpregu.2000.279.1.R60; Hewawasam P, 2002, BIOORG MED CHEM LETT, V12, P1117, DOI 10.1016/S0960-894X(02)00099-9; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Hu TW, 2004, UROLOGY, V63, P461, DOI 10.1016/j.urology.2003.10.037; Imaizumi Y, 1996, AM J PHYSIOL-CELL PH, V271, pC772, DOI 10.1152/ajpcell.1996.271.3.C772; Imaizumi Y, 1998, J PHYSIOL-LONDON, V510, P705, DOI 10.1111/j.1469-7793.1998.705bj.x; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1528, DOI 10.1152/ajpcell.2000.279.5.C1528; JOYNER AL, 1993, GENE TARGETING PRACT, P1; LI JH, 1995, PHARMACOLOGY, V51, P33, DOI 10.1159/000139314; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Ohi Y, 2001, J PHYSIOL-LONDON, V534, P313, DOI 10.1111/j.1469-7793.2001.t01-3-00313.x; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Petkov GV, 2001, J PHYSIOL-LONDON, V537, P443, DOI 10.1111/j.1469-7793.2001.00443.x; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; THOR KB, 1989, DEV BRAIN RES, V46, P137, DOI 10.1016/0165-3806(89)90151-X; Thorneloe KS, 2003, J PHYSIOL-LONDON, V549, P65, DOI 10.1113/jphysiol.2003.039859; Turner SC, 2003, BIOORG MED CHEM LETT, V13, P2003, DOI 10.1016/S0960-894X(03)00324-X; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wellman GC, 2001, AM J PHYSIOL-CELL PH, V281, pC1029, DOI 10.1152/ajpcell.2001.281.3.C1029	32	276	286	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36746	36752		10.1074/jbc.M405621200	http://dx.doi.org/10.1074/jbc.M405621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15184377	hybrid			2022-12-25	WOS:000223453600075
J	Marshall, S; Nadeau, O; Yamasaki, K				Marshall, S; Nadeau, O; Yamasaki, K			Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes - Differential effects on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; GLYCOGEN-SYNTHASE; SKELETAL-MUSCLE; IN-VIVO; INDUCED DESENSITIZATION; DIFFERENT MECHANISMS; TRANSPORT SYSTEM; AKT ACTIVATION; PATHWAY; TRANSLOCATION	Glucose and glucosamine (GlcN) cause insulin resistance over several hours by increasing metabolite flux through the hexosamine biosynthesis pathway (HBP). To elucidate the early events underlying glucose-induced desensitization, we treated isolated adipocytes with either glucose or GlcN and then measured intracellular levels of glucose-6-P (G-6-P), GlcN-6-P, UDP-GlcNAc, and ATP. Glucose treatment rapidly increased G-6-P levels (t(1/2) < 1 min), which plateaued by 15 min and remained elevated for up to 4 h (glucose ED50 = 4 mM). In glucose-treated cells, GlcN-6-P was undetectable; however, GlcN treatment (2 mM) caused a rapid and massive accumulation of GlcN-6-P. Levels increased by 5 min (similar to 400 nmol/g) and continued to rise over 2 h (t(1/2) similar to 20 min) before reaching a plateau at > 1,400 nmol/g (ED50 = 900 muM). Thus, at high GlcN concentrations, unrestricted flux into the HBP greatly exceeds the biosynthetic capacity of the pathway leading to a rapid buildup of GlcN-6-P. The GlcN-induced rise in GlcN-6-P levels was correlated with ATP depletion, suggesting that ATP loss is caused by phosphate sequestration (with the formation of GlcN-6-P) or the energy demands of phosphorylation. As expected, GlcN and glucose increased UDPGlcNAc levels (t(1/2) similar to 14-18 min), but greater levels were obtained with GlcN (4-5-fold for GlcN, 2-fold for glucose). Importantly, we found that low doses of GlcN (< 250 mu M, ED50 = 80 mu M) could markedly elevate UDP-GlcNAc levels without increasing GlcN-6-P levels or depleting ATP levels. These studies on the dynamic actions of glucose and GlcN on hexosamine levels should be useful in exploring the functional role of the HBP and in avoiding the potential pitfalls in the pharmacological use of GlcN.	Hexos Inc, Woodinville, WA 98072 USA		Marshall, S (corresponding author), Hexos Inc, 18304 NE 153rd St, Woodinville, WA 98072 USA.	Hexos@comcast.net		Yamasaki, Kazumitsu/0000-0002-8414-2393				Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Han DH, 2003, AM J PHYSIOL-ENDOC M, V285, pE1267, DOI 10.1152/ajpendo.00255.2003; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Kang J, 2001, AM J PHYSIOL-ENDOC M, V280, pE428, DOI 10.1152/ajpendo.2001.280.3.E428; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; Lang G., 1974, METHODS ENZYMATIC AN, P1238; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P123; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; Marshall S, 2000, DIABETES ANNUAL/13, P97; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V9, P186; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; Nelson BA, 2002, AM J PHYSIOL-ENDOC M, V282, pE497, DOI 10.1152/ajpendo.00438.2001; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P122; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Schleicher ED, 2000, KIDNEY INT, V58, pS13, DOI 10.1046/j.1523-1755.2000.07703.x; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Virkamaki A, 1999, DIABETES, V48, P1101, DOI 10.2337/diabetes.48.5.1101; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399	36	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35313	35319		10.1074/jbc.M404133200	http://dx.doi.org/10.1074/jbc.M404133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199059	hybrid			2022-12-25	WOS:000223303400023
J	Sun, WC; Yang, J; Liu, XQ				Sun, WC; Yang, J; Liu, XQ			Synthetic two-piece and three-piece split inteins for protein trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMING ENDONUCLEASE; TRICHODESMIUM-ERYTHRAEUM; SPLICING MECHANISM; DNAB INTEIN; PI-SCEI; CYCLIZATION; EVOLUTION; PCC6803; GENE	Inteins are protein-intervening sequences that can self-excise and concomitantly splice together the flanking polypeptides. Two-piece split inteins capable of protein trans-splicing have been found in nature and engineered in laboratories, but they all have a similar split site corresponding to the endonuclease domain of the intein. Can inteins be split at other sites and do trans-splicing? After testing 13 split sites engineered into a Ssp DnaB mini-intein, we report the finding of three new split sites that each produced a two-piece split intein capable of protein trans-splicing. These three functional split sites are located in different loop regions between beta-strands of the intein structure, and one of them is just 11 amino acids from the beginning of the intein. Because different inteins have similar structures and similar beta-strands, these new split sites may be generalized to other inteins. We have also demonstrated for the first time that a three-piece split intein could function in protein trans-splicing. These findings have implications for intein structure-function, evolution, and uses in biotechnology.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Liu, XQ (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.	pxqliu@dal.ca						Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Caspi J, 2003, MOL MICROBIOL, V50, P1569, DOI 10.1046/j.1365-2958.2003.03825.x; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; Ding Y, 2003, J BIOL CHEM, V278, P39133, DOI 10.1074/jbc.M306197200; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Gogarten JP, 2002, ANNU REV MICROBIOL, V56, P263, DOI 10.1146/annurev.micro.56.012302.160741; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Liu XQ, 1997, P NATL ACAD SCI USA, V94, P7851, DOI 10.1073/pnas.94.15.7851; Liu XQ, 2003, J BIOL CHEM, V278, P46826, DOI 10.1074/jbc.M309575200; Liu XQ, 2003, J BIOL CHEM, V278, P26315, DOI 10.1074/jbc.C300202200; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mills KV, 2004, J BIOL CHEM, V279, P20685, DOI 10.1074/jbc.M400887200; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Werner E, 2002, NUCLEIC ACIDS RES, V30, P3962, DOI 10.1093/nar/gkf523; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Yang J, 2004, MOL MICROBIOL, V51, P1185, DOI 10.1046/j.1365-2958.2003.03902.x; Yang JJ, 2003, P NATL ACAD SCI USA, V100, P3513, DOI 10.1073/pnas.0635899100	38	83	101	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35281	35286		10.1074/jbc.M405491200	http://dx.doi.org/10.1074/jbc.M405491200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194682	hybrid			2022-12-25	WOS:000223303400019
J	Wester, MR; Yano, JK; Schoch, GA; Yang, C; Griffin, KJ; Stout, CD; Johnson, EF				Wester, MR; Yano, JK; Schoch, GA; Yang, C; Griffin, KJ; Stout, CD; Johnson, EF			The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ANGSTROM RESOLUTION; BINDING; IDENTIFICATION; METABOLISM; RESIDUES; PROGRAM; PROTEIN; MODEL; SULFAPHENAZOLE	The structure of human P450 2C9 complexed with flurbiprofen was determined to 2.0 Angstrom by x-ray crystallography. In contrast to other structurally characterized P450 2C enzymes, 2C5, 2C8, and a 2C9 chimera, the native catalytic domain of P450 2C9 differs significantly in the conformation of the helix F to helix G region and exhibits an extra turn at the N terminus of helix A. In addition, a distinct conformation of the helix B to helix C region allows Arg-108 to hydrogen bond with Asp-293 and Asn-289 on helix I and to interact directly with the carboxylate of flurbiprofen. These interactions position the substrate for regioselective oxidation in a relatively large active site cavity and are likely to account for the high catalytic efficiency exhibited by P450 2C9 for the regioselective oxidation of several anionic non-steroidal anti-inflammatory drugs. The structure provides a basis for interpretation of a number of observations regarding the substrate selectivity of P450 2C9 and the observed effects of mutations on catalysis.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB8, La Jolla, CA 92037 USA.	dave@scripps.edu; johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM031001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; de Groot MJ, 2002, J MED CHEM, V45, P1983, DOI 10.1021/jm0110791; Dickmann LJ, 2004, MOL PHARMACOL, V65, P842, DOI 10.1124/mol.65.4.842; Flanagan JU, 2003, BIOCHEM J, V370, P921, DOI 10.1042/BJ20021841; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; HELMS V, 1995, BIOPHYS J, V69, P810, DOI 10.1016/S0006-3495(95)79955-6; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Hutzler JM, 2003, ARCH BIOCHEM BIOPHYS, V410, P16; Ibeanu GC, 1996, J BIOL CHEM, V271, P12496, DOI 10.1074/jbc.271.21.12496; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones BC, 1996, DRUG METAB DISPOS, V24, P260; Jones JP, 1996, DRUG METAB DISPOS, V24, P1; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Jung F, 1998, BIOCHEMISTRY-US, V37, P16270, DOI 10.1021/bi981704c; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klose TS, 1998, ARCH BIOCHEM BIOPHYS, V357, P240, DOI 10.1006/abbi.1998.0826; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; LESLIE AGW, 1996, CCP4 NEWLETTER PROTE; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; Ridderstrom M, 2000, BIOCHEM BIOPH RES CO, V270, P983, DOI 10.1006/bbrc.2000.2538; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; TRACY TS, 1995, BIOCHEM PHARMACOL, V49, P1269, DOI 10.1016/0006-2952(95)00048-5; Tsao CC, 2001, BIOCHEMISTRY-US, V40, P1937, DOI 10.1021/bi001678u; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wester MR, 2000, DRUG METAB DISPOS, V28, P354; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862	38	397	408	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35630	35637		10.1074/jbc.M405427200	http://dx.doi.org/10.1074/jbc.M405427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15181000	hybrid			2022-12-25	WOS:000223303400059
J	Williamson, AL; Lecchi, P; Turk, BE; Choe, Y; Hotez, PJ; McKerrow, JH; Cantley, LC; Sajid, M; Craik, CS; Loukas, A				Williamson, AL; Lecchi, P; Turk, BE; Choe, Y; Hotez, PJ; McKerrow, JH; Cantley, LC; Sajid, M; Craik, CS; Loukas, A			A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; ANCYLOSTOMA-CANINUM HOOKWORMS; HAEMONCHUS-CONTORTUS; SCHISTOSOMA-MANSONI; CYSTEINE PROTEINASE; MOLECULAR-CLONING; CATHEPSIN-B; SUBSTRATE-SPECIFICITY; FUNCTIONAL EXPRESSION; PROTECTIVE ANTIGENS	Blood-feeding pathogens digest hemoglobin (Hb) as a source of nutrition, but little is known about this process in multicellular parasites. The intestinal brush border membrane of the canine hookworm, Ancylostoma caninum, contains aspartic proteases (APR-1), cysteine proteases (CP-2), and metalloproteases (MEP-1), the first of which is known to digest Hb. We now show that Hb is degraded by a multi-enzyme, synergistic cascade of proteolysis. Recombinant APR-1 and CP-2, but not MEP-1, digested native Hb and denatured globin. MEP-1, however, did cleave globin fragments that had undergone prior digestion by APR-1 and CP-2. Proteolytic cleavage sites within the Hb alpha and beta chains were determined for the three enzymes, identifying a total of 131 cleavage sites. By scanning synthetic combinatorial peptide libraries with each enzyme, we compared the preferred residues cleaved in the libraries with the known cleavage sites within Hb. The semi-ordered pathway of Hb digestion described here is surprisingly similar to that used by Plasmodium to digest Hb and provides a potential mechanism by which these hemoglobinases are efficacious vaccines in animal models of hookworm infection.	Queensland Inst Med Res, Div Infect Dis & Immunol, Helminth Biol Lab, Brisbane, Qld 4006, Australia; George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20037 USA; George Washington Univ, Inst Proteom Technol & Applicat, Washington, DC 20037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02215 USA; Univ Calif San Francisco, Trop Dis Res Unit, San Francisco, CA 94122 USA; Univ Calif San Francisco, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94122 USA; Univ Queensland, Australian Ctr Int & Trop Hlth, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; George Washington University; George Washington University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; QIMR Berghofer Medical Research Institute; University of Queensland	Loukas, A (corresponding author), Queensland Inst Med Res, Div Infect Dis & Immunol, Helminth Biol Lab, 300 Herston Rd, Brisbane, Qld 4006, Australia.	alexL@qimr.edu.au	Cantley, Lewis C/D-1800-2014; Loukas, Alex/B-7355-2014	Cantley, Lewis C/0000-0002-1298-7653; Loukas, Alex/0000-0002-0896-8441; Hotez, Peter/0000-0001-8770-1042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053247] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-3276, AI-53247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakker N, 2004, VACCINE, V22, P618, DOI 10.1016/j.vaccine.2003.08.025; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bouchard E, 2003, MOL ECOL, V12, P2439, DOI 10.1046/j.1365-294X.2003.01919.x; Brady CP, 1999, INFECT IMMUN, V67, P368, DOI 10.1128/IAI.67.1.368-374.1999; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; BROWN A, 1995, PARASITOLOGY, V110, P555, DOI 10.1017/S0031182000065276; Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Choi KH, 2000, EUR J BIOCHEM, V267, P1516, DOI 10.1046/j.1432-1327.2000.01152.x; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; DON TA, 2004, IN PRESS INT J PARAS; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; HARROP SA, 1995, MOL BIOCHEM PARASIT, V71, P163, DOI 10.1016/0166-6851(95)00045-3; HOTEZ PJ, 2002, CHINA QUART, V172, P1029; HOTEZ PJ, 2004, IN PRESS NEW ENG J M; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; Knox D.P., 2001, P247, DOI 10.1079/9780851994239.0247; Knox DP, 1999, PARASITE IMMUNOL, V21, P201, DOI 10.1046/j.1365-3024.1999.00220.x; LAWRENCE JD, 1973, J PARASITOL, V59, P60, DOI 10.2307/3278572; Lecaille F, 2003, BIOCHEM J, V375, P307, DOI 10.1042/BJ20030468; Lipps G, 1996, J BIOL CHEM, V271, P1717, DOI 10.1074/jbc.271.3.1717; Loukas A, 2004, J INFECT DIS, V189, P1952, DOI 10.1086/386346; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; Mills BJ, 1996, BIOCHEM PHARMACOL, V52, P401, DOI 10.1016/0006-2952(96)00241-9; Mulenga A, 2001, INSECT BIOCHEM MOLEC, V31, P817, DOI 10.1016/S0965-1748(00)00187-9; Murata CE, 2003, J BIOL CHEM, V278, P38022, DOI 10.1074/jbc.M306842200; Ramalho-Ortigao JM, 2003, INSECT BIOCHEM MOLEC, V33, P163, DOI 10.1016/S0965-1748(02)00187-X; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Redmond DL, 1997, MOL BIOCHEM PARASIT, V85, P77, DOI 10.1016/S0166-6851(96)02812-5; ROCHE M, 1966, AM J TROP MED HYG, V15, P1032, DOI 10.4269/ajtmh.1966.15.1032; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shenai BR, 2002, MOL BIOCHEM PARASIT, V122, P99, DOI 10.1016/S0166-6851(02)00075-0; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Smith WD, 2003, PARASITE IMMUNOL, V25, P521, DOI 10.1111/j.0141-9838.2004.00667.x; Smith WD, 2003, PARASITE IMMUNOL, V25, P313, DOI 10.1046/j.1365-3024.2003.00637.x; Smooker PM, 2000, PROTEIN SCI, V9, P2567, DOI 10.1110/ps.9.12.2567; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Vizioli J, 2001, EUR J BIOCHEM, V268, P4027, DOI 10.1046/j.1432-1327.2001.02315.x; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; Williamson AL, 2003, J INFECT DIS, V187, P484, DOI 10.1086/367708; Williamson AL, 2002, FASEB J, V16, P1458, DOI 10.1096/fj.02-0181fje; Williamson AL, 2003, TRENDS PARASITOL, V19, P417, DOI 10.1016/S1471-4922(03)00189-2; Zhan B, 2002, MOL BIOCHEM PARASIT, V120, P291, DOI 10.1016/S0166-6851(01)00453-4	59	130	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35950	35957		10.1074/jbc.M405842200	http://dx.doi.org/10.1074/jbc.M405842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199048	hybrid			2022-12-25	WOS:000223303400096
J	Hanzelmann, P; Hernandez, HL; Menzel, C; Garcia-Serres, R; Huynh, BH; Johnson, MK; Mendel, RR; Schindelin, H				Hanzelmann, P; Hernandez, HL; Menzel, C; Garcia-Serres, R; Huynh, BH; Johnson, MK; Mendel, RR; Schindelin, H			Characterization of MOCS1A, an oxygen-sensitive iron-sulfur protein involved in human molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MOLYBDOPTERIN SYNTHASE; MAGNETIC CIRCULAR-DICHROISM; LYASE ACTIVATING ENZYME; COLI BIOTIN SYNTHASE; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; PYROCOCCUS-FURIOSUS FERREDOXIN; OVERLAPPING READING FRAMES; SITE-DIRECTED MUTAGENESIS; CLUSTER BINDING-SITES; GTP CYCLOHYDROLASE-I	The human proteins MOCS1A and MOCS1B catalyze the conversion of a guanosine derivative to precursor Z during molybdenum cofactor biosynthesis. MOCS1A shares homology with S-adenosylmethionine ( AdoMet)dependent radical enzymes, which catalyze the formation of protein and/or substrate radicals by reductive cleavage of AdoMet through a [4Fe-4S] cluster. Sequence analysis of MOCS1A showed two highly conserved cysteine motifs, one near the N terminus and one near the C terminus. MOCS1A was heterologously expressed in Escherichia coli and purified under aerobic and anaerobic conditions. Individual mutations of the conserved cysteines to serine revealed that all are essential for synthesis of precursor Z in vivo. The type and properties of the iron-sulfur (FeS) clusters were investigated using a combination of UV-visible absorption, variable temperature magnetic circular dichroism, resonance Raman, Mossbauer, and EPR spectroscopies coupled with iron and acid-labile sulfide analyses. The results indicated that anaerobically purified MOCS1A is a monomeric protein containing two oxygen-sensitive FeS clusters, each coordinated by only three cysteine residues. A redox-active [4Fe- 4S](2+,+) cluster is ligated by an N-terminal CX3CX2C motif as is the case with all other AdoMet-dependent radical enzymes investigated thus far. A C-terminal CX2CX13C motif that is unique to MOCS1A and its orthologs primarily ligates a [3Fe- 4S](0) cluster. However, MOCS1A could be reconstituted in vitro under anaerobic conditions to yield a form containing two [4Fe-4S] (2+) clusters. The N-terminal [4Fe- 4S](2+) cluster was rapidly degraded by oxygen via a semistable [2Fe- 2S](2+) cluster intermediate, and the C-terminal [4Fe- 4S](2+) cluster was rapidly degraded by oxygen to yield a semistable [ 3Fe- 4S](0) cluster intermediate.	SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Braunschweig University of Technology; Emory University	Hanzelmann, P (corresponding author), SUNY Stony Brook, Dept Biochem, CMM Bldg,Rm Nr 150, Stony Brook, NY 11794 USA.	petra@csb.sunysb.edu; hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019; García-Serres, Ricardo/E-4344-2012	García-Serres, Ricardo/0000-0001-5203-0568	NIDDK NIH HHS [DK 54835] Funding Source: Medline; NIGMS NIH HHS [GM 47295, GM 62542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM062542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BENNETT DE, 1987, BIOCHIM BIOPHYS ACTA, V911, P71, DOI 10.1016/0167-4838(87)90272-X; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brereton PS, 1999, BIOCHEMISTRY-US, V38, P10594, DOI 10.1021/bi990671d; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Cosper MM, 2004, BIOCHEMISTRY-US, V43, P2007, DOI 10.1021/bi0356653; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DROZDZEWSKI PM, 1988, APPL SPECTROSC, V42, P1575, DOI 10.1366/0003702884429841; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; HUYNH BH, 1980, J BIOL CHEM, V255, P3242; Jameson GNL, 2004, BIOCHEMISTRY-US, V43, P2022, DOI 10.1021/bi035666v; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; Johnson M. K., 1988, METAL CLUSTERS PROTE, P326; Johnson MK, 1999, ADV INORG CHEM, V47, P1, DOI 10.1016/S0898-8838(08)60076-8; Johnson MK, 1982, IRON SULFUR PROTEINS, P367; Kaiser J, 2002, EUR J BIOCHEM, V269, P5264, DOI 10.1046/j.1432-1033.2002.03239.x; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Leimkuhler S, 2003, J BIOL CHEM, V278, P26127, DOI 10.1074/jbc.M303092200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; Matthies A, 2004, P NATL ACAD SCI USA, V101, P5946, DOI 10.1073/pnas.0308191101; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; MENENDEZ C, 1995, ARCH MICROBIOL, V164, P142, DOI 10.1007/s002030050246; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; ONATE YA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P113, DOI 10.1016/0167-4838(93)90237-L; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Reiss J, 2003, HUM MUTAT, V21, P569, DOI 10.1002/humu.10223; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Spiro T. G., 1988, BIOL APPLICATIONS RA, P523; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Ugulava NB, 2002, J AM CHEM SOC, V124, P9050, DOI 10.1021/ja027004j; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	76	113	116	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34721	34732		10.1074/jbc.M313398200	http://dx.doi.org/10.1074/jbc.M313398200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180982	hybrid			2022-12-25	WOS:000223134800078
J	Jimenez, A; Zu, W; Rawe, VY; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Gustafsson, JA; Oko, R; Miranda-Vizuete, A				Jimenez, A; Zu, W; Rawe, VY; Pelto-Huikko, M; Flickinger, CJ; Sutovsky, P; Gustafsson, JA; Oko, R; Miranda-Vizuete, A			Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; MOLECULAR-CLONING; FIBROUS SHEATH; HUMAN TESTIS; PROTEIN; EXPRESSION; RAT; GENE; ACROSOME; KINASE	Mammalian germ cells are endowed with a complete set of thioredoxins (Trx), a class of redox proteins located in specific structures of the spermatid and sperm tail. We report here the characterization, under normal and pathological conditions, of a novel thioredoxin with a germ line-restricted expression pattern, named spermatocyte/ spermatid-specific thioredoxin-3 (SPTRX-3). The human SPTRX-3 gene maps at 9q32, only 50 kb downstream from the TRX-1 gene from which it probably originated as genomic duplication. Therefore, human SPTRX-3 protein comprises a unique thioredoxin domain displaying high homology with the ubiquitously expressed TRX-1. Among the tissues investigated, Sptrx-3 mRNA is found exclusively in the male germ cells at pachytene spermatocyte and round spermatid stages. Light and electron microscopy show SPTRX-3 protein to be predominately located in the Golgi apparatus of pachytene spermatocytes and round and elongated spermatids, with a transient localization in the developing acrosome of round spermatids. In addition, increased levels of SPTRX-3, possibly caused by overexpression, are observed in morphologically abnormal human spermatozoa from infertile men. In addition, SPTRX-3 is identified as a novel postobstruction autoantigen. In this report, we propose that SPTRX-3 can be used as a specific marker for diverse sperm and testis pathologies. SPTRX-3 is the first thioredoxin specific to the Golgi apparatus, and its function within this organelle might be related to the post-translational modification of proteins required for germ cell-specific functions, such as acrosomal biogenesis.	Karolinska Inst, NOVUM, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Obstet & Gynecol, Columbia, MO 65211 USA	Karolinska Institutet; Queens University - Canada; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Tampere University; Tampere University; Tampere University Hospital; University of Virginia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Miranda-Vizuete, A (corresponding author), Karolinska Inst, NOVUM, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anmi@biosci.ki.se	Miranda-Vizuete, Antonio/D-6927-2012; Jiménez, Alberto/A-6234-2009; IBIS, REDOX/J-7473-2017	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Jiménez, Alberto/0000-0003-3685-6479; Sutovsky, Peter/0000-0002-9231-2823	NICHD NIH HHS [HD U54 29009] Funding Source: Medline; NIDDK NIH HHS [P450 DK 45179] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abou-Haila A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173, DOI 10.1006/abbi.2000.1880; Aitken RJ, 2003, MOL HUM REPROD, V9, P645, DOI 10.1093/molehr/gag086; ALEXANDER NJ, 1979, FERTIL STERIL, V32, P253; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Blobel G, 2000, CHEMBIOCHEM, V1, P87; Brede G, 2003, EXP CELL RES, V291, P299, DOI 10.1016/j.yexcr.2003.07.009; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Curry M., 1995, GAMETES SPERMATOZOON, P45; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Eddy E. M., 1994, P29; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Flickinger CJ, 2001, BIOL REPROD, V64, P1451, DOI 10.1095/biolreprod64.5.1451; Flickinger CJ, 1999, J REPROD IMMUNOL, V43, P35, DOI 10.1016/S0165-0378(98)00090-4; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; HANDLEY HH, 1988, BIOL REPROD, V39, P1239, DOI 10.1095/biolreprod39.5.1239; HERMO L, 1991, ANAT REC, V229, P31, DOI 10.1002/ar.1092290106; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; Hirota K, 2002, ANN NY ACAD SCI, V957, P189, DOI 10.1111/j.1749-6632.2002.tb02916.x; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Jimenez A, 2002, MOL HUM REPROD, V8, P710, DOI 10.1093/molehr/8.8.710; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; Jurado J, 2003, J BIOL CHEM, V278, P45546, DOI 10.1074/jbc.M307866200; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Liu F, 2003, GENE, V315, P71, DOI 10.1016/S0378-1119(03)00732-7; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Miranda-Vizuete A, 1998, BIOCHEM BIOPH RES CO, V243, P284, DOI 10.1006/bbrc.1997.8003; Miranda-Vizuete A, 2004, ANTIOXID REDOX SIGN, V6, P25, DOI 10.1089/152308604771978327; Miranda-Vizuete A, 2003, J BIOL CHEM, V278, P44874, DOI 10.1074/jbc.M305475200; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Moreno RD, 2000, BIOL REPROD, V63, P89, DOI 10.1095/biolreprod63.1.89; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; OHTA E, 2003, J BIOL CHEM; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1993, J CELL BIOL, V123, P809, DOI 10.1083/jcb.123.4.809; Oko R., 1998, ENCY REPROD, P602; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Rawe VY, 2002, HUM REPROD, V17, P2119, DOI 10.1093/humrep/17.8.2119; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Rybnikova E, 2000, EUR J NEUROSCI, V12, P1669, DOI 10.1046/j.1460-9568.2000.00059.x; Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sasagawa I, 2001, EUR J BIOCHEM, V268, P3053, DOI 10.1046/j.1432-1327.2001.02200.x; Schultz R, 2003, ENDOCRINOLOGY, V144, P767, DOI 10.1210/en.2002-220642; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Spyrou G, 2001, HUM GENET, V109, P429, DOI 10.1007/s004390100597; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sutovsky P, 2001, HUM REPROD, V16, P250, DOI 10.1093/humrep/16.2.250; Svensson MJ, 2003, CHROMOSOMA, V112, P133, DOI 10.1007/s00412-003-0253-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506	64	54	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34971	34982		10.1074/jbc.M404192200	http://dx.doi.org/10.1074/jbc.M404192200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181017	Green Submitted, hybrid			2022-12-25	WOS:000223134800109
J	Murphy, EJ; Barcelo-Coblijn, G; Binas, B; Glatz, JFC				Murphy, EJ; Barcelo-Coblijn, G; Binas, B; Glatz, JFC			Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; PERFORMANCE LIQUID-CHROMATOGRAPHY; ARACHIDONIC-ACID; ADULT-RAT; SKELETAL-MUSCLE; L-CELLS; LIVER; PHOSPHOLIPIDS; EXPRESSION; PLASMALOGEN	Cell culture systems have demonstrated a role for cytoplasmic fatty acid-binding proteins ( FABP) in lipid metabolism, although a similar function in intact animals is unknown. We addressed this issue using heart fatty acid-binding protein (H-FABP) gene-ablated mice. H-FABP gene ablation reduced total heart fatty acid uptake 40 and 52% for [1-C-14] 16: 0 and [1-C-14] 20: 4n-6 compared with controls, respectively. Similarly, the amount of fatty acid found in the aqueous fraction was reduced 40 and 52% for [1-C-14] 16: 0 and [1-C-14] 20: 4n-6, respectively. Less [1-C-14] 16: 0 entered the triacylglycerol pool, with significant redistribution of fatty acid between the triacylglycerol pool and the total phospholipid pool. Less [1-C-14] 20: 4n-6 entered each lipid pool measured, but these changes did not alter the distribution of tracer among these pools. In gene-ablated mice, significantly more [1-C-14] 16: 0 was targeted to choline and ethanolamine glycerophospholipids, whereas more [1-C-14] 20: 4n-6 was targeted to the phosphatidylinositol ( PtdIns) pool. H-FABP gene ablation significantly increased PtdIns mass 1.4-fold but reduced PtdIns 20: 4n-6 mass 30%. Consistent with a reported effect of FABP on plasmalogen mass, ethanolamine plasmalogen mass was reduced 30% in gene-ablated mice. Further, 20: 4n-6 mass was reduced in each of the three other major phospholipid classes, suggesting H-FABP has a role in maintaining steady-state 20: 4n-6 mass in heart. In summary, H-FABP was important for heart fatty acid uptake and targeting of fatty acids to specific heart lipid pools as well as for maintenance of phospholipid pool mass and acyl chain composition.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA; Cardiovasc Res Inst Maastricht, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands	University of North Dakota Grand Forks; Texas A&M University System; Texas A&M University College Station; Maastricht University	Murphy, EJ (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 501 N Columbia Rd,Rm 3700, Grand Forks, ND 58202 USA.	emurphy@medicine.nodak.edu	Barceló-Coblijn, Gwendolyn/R-4099-2019; Barceló-Coblijn, Gwendolyn/O-1348-2019	Barceló-Coblijn, Gwendolyn/0000-0003-1017-5616				Atkinson LL, 2003, AM J PHYSIOL-ENDOC M, V284, pE923, DOI 10.1152/ajpendo.00360.2002; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Binas B, 2003, AM J PHYSIOL-ENDOC M, V285, pE481, DOI 10.1152/ajpendo.00060.2003; Brockerhoff H, 1975, Methods Enzymol, V35, P315, DOI 10.1016/0076-6879(75)35171-9; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; FREED LM, 1994, BRAIN RES, V645, P41, DOI 10.1016/0006-8993(94)91636-5; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; GLATZ JFC, 1994, BIOCHEM BIOPH RES CO, V199, P639, DOI 10.1006/bbrc.1994.1276; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; Hanhoff T, 2002, MOL CELL BIOCHEM, V239, P45, DOI 10.1023/A:1020502624234; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HOHL CM, 1987, BIOCHIM BIOPHYS ACTA, V921, P356, DOI 10.1016/0005-2760(87)90037-3; Holehouse EL, 1998, BBA-LIPID LIPID MET, V1390, P52, DOI 10.1016/S0005-2760(97)00176-8; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; JOLLY CA, 2002, CELLULAR PROTEINS TH; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; Luiken JJFP, 2003, LIPIDS, V38, P491, DOI 10.1007/s11745-003-1089-6; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; MARCHESELLI VL, 1988, NEUROMETHODS, V7, P83; McHowat J, 2001, Cardiovasc Toxicol, V1, P253, DOI 10.1385/CT:1:4:253; McHowat J, 1997, AM J PHYSIOL-CELL PH, V272, pC450, DOI 10.1152/ajpcell.1997.272.2.C450; McHowat J, 2000, AM J PHYSIOL-HEART C, V278, pH1933, DOI 10.1152/ajpheart.2000.278.6.H1933; MEIJ JTA, 1990, CARDIOVASC RES, V24, P94, DOI 10.1093/cvr/24.2.94; MEIJ JTA, 1989, MOL CELL BIOCHEM, V88, P73; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Murphy EJ, 2000, LIPIDS, V35, P729, DOI 10.1007/s11745-000-0579-x; MURPHY EJ, 1993, LIPIDS, V28, P565, DOI 10.1007/BF02536090; Murphy EJ, 2000, LIPIDS, V35, P891, DOI 10.1007/S11745-000-0598-7; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Prows DR, 1996, CHEM PHYS LIPIDS, V84, P47, DOI 10.1016/S0009-3084(96)02619-9; Qian QH, 1999, CIRC RES, V84, P276, DOI 10.1161/01.RES.84.3.276; RADIN NS, 1988, NEUROMETHODS, V7, P1; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Rosenberger TA, 2002, J LIPID RES, V43, P59; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SADDIK M, 1991, BIOCHIM BIOPHYS ACTA, V1086, P217, DOI 10.1016/0005-2760(91)90010-F; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; SMITH BSW, 1970, CLIN CHIM ACTA, V27, P105, DOI 10.1016/0009-8981(70)90381-5; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; Steinberg SF, 1999, CIRC RES, V85, P1101; STORCH J, 1990, J BIOL CHEM, V265, P7827; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	54	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34481	34488		10.1074/jbc.M314263200	http://dx.doi.org/10.1074/jbc.M314263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194696	hybrid			2022-12-25	WOS:000223134800050
J	Robison, JG; Elliott, J; Dixon, K; Oakley, GG				Robison, JG; Elliott, J; Dixon, K; Oakley, GG			Replication protein A and the Mre11 center dot Rad50 center dot Nbs1 complex co-localize and interact at sites of stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-BINDING-PROTEIN; DEPENDENT NUCLEAR-DYNAMICS; MRE11 COMPLEX; RPA PHOSPHORYLATION; CELLULAR-RESPONSE; DAMAGE RESPONSES; WERNER-SYNDROME; ATM ACTIVATION; HISTONE H2AX	In response to replicative stress, cells relocate and activate DNA repair and cell cycle arrest proteins such as replication protein A (RPA, a three subunit protein complex required for DNA replication and DNA repair) and the MRN complex ( consisting of Mre11, Rad50, and Nbs1; involved in DNA double-strand break repair). There is increasing evidence that both of these complexes play a central role in DNA damage recognition, activation of cell cycle checkpoints, and DNA repair pathways. Here we demonstrate that RPA and the MRN complex co-localize to discrete foci and interact in response to DNA replication fork blockage induced by hydroxyurea (HU) or ultraviolet light (UV). Members of both RPA and the MRN complexes become phosphorylated during S-phase and in response to replication fork blockage. Analysis of RPA and Mre11 in fractionated lysates (cytoplasmic/nucleoplasmic, chromatin-bound, and nuclear matrix fractions) showed increased hyperphosphorylated-RPA and phosphorylated-Mre11 in the chromatin-bound fractions. HU and UV treatment also led to co-localization of hyperphosphorylated RPA and Mre11 to discrete detergent-resistant nuclear foci. An interaction between RPA and Mre11 was demonstrated by co-immunoprecipitation of both protein complexes with anti-Mre11, anti-Rad50, anti-NBS1, or anti-RPA antibodies. Phosphatase treatment with calf intestinal phosphatase or lambda-phosphatase not only de-phosphorylated RPA and Mre11 but also abrogated the ability of RPA and the MRN complex to co-immunoprecipitate. Together, these data demonstrate that RPA and the MRN complex co-localize and interact after HU- or UV-induced replication stress and suggest that protein phosphorylation may play a role in this interaction.	Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Oakley, GG (corresponding author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 3223 Eden Ave, Cincinnati, OH 45267 USA.	Greg.Oakley@uc.edu		Oakley, Gregory/0000-0001-6207-0969	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, T32ES007250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034782] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 06096, T32 ES 07250] Funding Source: Medline; NINDS NIH HHS [R02 NS 34782] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Liu JS, 2001, BIOCHEMISTRY-US, V40, P14661, DOI 10.1021/bi015680c; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Mochan TA, 2003, CANCER RES, V63, P8586; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PETRINI JHJ, 1991, P NATL ACAD SCI USA, V88, P7615, DOI 10.1073/pnas.88.17.7615; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rothstein R, 2000, GENE DEV, V14, P1; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	120	120	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34802	34810		10.1074/jbc.M404750200	http://dx.doi.org/10.1074/jbc.M404750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15180989	hybrid			2022-12-25	WOS:000223134800088
J	Schiffler, B; Zollner, A; Bernhardt, R				Schiffler, B; Zollner, A; Bernhardt, R			Stripping down the mitochondrial cholesterol hydroxylase system, a kinetics study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL STEROID HYDROXYLASES; SITE-DIRECTED MUTAGENESIS; IRON PROTEIN ADRENODOXIN; SIDE-CHAIN CLEAVAGE; ELECTRON-TRANSPORT; BOVINE ADRENODOXIN; CYTOCHROME P450(SCC); COMPLEX-FORMATION; ESCHERICHIA-COLI; LYSINE RESIDUES	The origin of steroid hormones in mammals is cholesterol that is metabolized by the mitochondrial CYP11A1 system. The cytochrome P450 is fed with reduction equivalents via a small electron transfer chain consisting of NADPH, adrenodoxin reductase, and adrenodoxin. Though the redox behavior of the individual protein components has been studied previously, the kinetics of the system in its entirety has not yet been analyzed. In this study we combine surface plasmon resonance experiments to determine the binding constants for the different pairs of redox partners with measurements of the pre-steady-state kinetics of the different reaction steps of this system and steady-state kinetics. We could correlate the individual protein-protein interactions with the effect of distinct reduction-oxidation steps on the overall catalytic activity of the CYP11A1 system. For the first time, we were able to follow the reduction of each of the protein components of this system within one measurement when we mixed all oxidized protein components with NADPH. These measurements allowed the determination of the individual apparent rate constants for the reduction of all three proteins involved. In addition, variation of the ionic strength in these experiments revealed different optimum salt concentrations for the reduction of adrenodoxin reductase and adrenodoxin, respectively, and unraveled dramatically changing reduction rates of CYP11A1 by adrenodoxin.	Univ Saarland, Nat Wissensch Tech Fak 3, FR Biochem 88, D-66041 Saarbrucken, Germany	Saarland University	Bernhardt, R (corresponding author), Univ Saarland, Nat Wissensch Tech Fak 3, FR Biochem 88, POB 151150, D-66041 Saarbrucken, Germany.	ritabern@mx.uni-saarland.de						ADAMOVICH TB, 1989, BIOCHIM BIOPHYS ACTA, V996, P247, DOI 10.1016/0167-4838(89)90254-9; Beckert V, 1997, J BIOL CHEM, V272, P4883, DOI 10.1074/jbc.272.8.4883; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; CHU JW, 1973, J BIOL CHEM, V248, P5183; CHU JW, 1973, J BIOL CHEM, V248, P2089; ESTABROOK RW, 1973, IRON SULPHUR PROTEIN, V1, P193; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; Hannemann F, 2001, J BIOL CHEM, V276, P1369, DOI 10.1074/jbc.M007589200; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; Ivanov YD, 1999, BIOCHEM MOL BIOL INT, V47, P327; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KATAGIRI M, 1977, BIOCHEM BIOPH RES CO, V77, P804, DOI 10.1016/S0006-291X(77)80049-1; Kimura T, 1978, Methods Enzymol, V52, P132; KIMURA T, 1965, BIOCHEM BIOPH RES CO, V20, P373, DOI 10.1016/0006-291X(65)90585-1; KIMURA T, 1967, J BIOL CHEM, V242, P485; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1977, J BIOL CHEM, V252, P2908; LAMBETH JD, 1976, J BIOL CHEM, V251, P4299; LAMBETH JD, 1979, J BIOL CHEM, V254, P2766; LAMBETH JD, 1976, J BIOL CHEM, V251, P7545; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; SAGARA Y, 1987, J BIOCHEM-TOKYO, V102, P1333, DOI 10.1093/oxfordjournals.jbchem.a122178; Schiffler B, 2003, BIOCHEM BIOPH RES CO, V312, P223, DOI 10.1016/j.bbrc.2003.09.214; Schiffler B, 2001, J BIOL CHEM, V276, P36225, DOI 10.1074/jbc.M102320200; SHIKITA M, 1974, P NATL ACAD SCI USA, V71, P1441, DOI 10.1073/pnas.71.4.1441; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; TAKIKAWA O, 1978, ARCH BIOCHEM BIOPHYS, V190, P300, DOI 10.1016/0003-9861(78)90279-5; TULS J, 1989, J BIOL CHEM, V264, P16421; TULS J, 1987, J BIOL CHEM, V262, P10020; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; UHLMANN H, 1995, THESIS HUMBOLDT U BE; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; WADA A, 1992, J BIOL CHEM, V267, P22877; WATARI H, 1966, BIOCHEM BIOPH RES CO, V24, P106, DOI 10.1016/0006-291X(66)90417-7; Zollner A, 2002, J INORG BIOCHEM, V91, P644, DOI 10.1016/S0162-0134(02)00463-4	44	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34269	34276		10.1074/jbc.M402798200	http://dx.doi.org/10.1074/jbc.M402798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181009	hybrid			2022-12-25	WOS:000223134800025
J	Bock, HH; Jossin, Y; May, P; Bergner, O; Herz, J				Bock, HH; Jossin, Y; May, P; Bergner, O; Herz, J			Apolipoprotein E receptors are required for Reelin-induced proteasomal degradation of the neuronal adaptor protein Disabled-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL PLATE DEVELOPMENT; BRAIN-DEVELOPMENT; MONOCLONAL-ANTIBODIES; SIGNALING PATHWAY; TYROSINE KINASES; NERVOUS-SYSTEM; MOUSE-BRAIN; UBIQUITIN; MICE; PHOSPHORYLATION	The cytoplasmic adaptor protein Disabled-1 (Dab1) is necessary for the regulation of neuronal positioning in the developing brain by the secreted molecule Reelin. Binding of Reelin to the neuronal apolipoprotein E receptors apoER2 and very low density lipoprotein receptor induces tyrosine phosphorylation of Dab1 and the subsequent activation or relocalization of downstream targets like phosphatidylinositol 3 (PI3)-kinase and Nckbeta. Disruption of Reelin signaling leads to the accumulation of Dab1 protein in the brains of genetically modified mice, suggesting that Reelin limits its own action in responsive neurons by down-regulating the levels of Dab1 expression. Here, we use cultured primary embryonic neurons as a model to demonstrate that Reelin treatment targets Dab1 for proteolytic degradation by the ubiquitin-proteasome pathway. We show that tyrosine phosphorylation of Dab1 but not PI3-kinase activation is required for its proteasomal targeting. Genetic deficiency in the Dab1 kinase Fyn prevents Dab1 degradation. The Reelin-induced Dab1 degradation also depends on apoER2 and very low density lipoprotein receptor in a gene-dose dependent manner. Moreover, pharmacological blockade of the proteasome prevents the formation of a proper cortical plate in an in vitro slice culture assay. Our results demonstrate that signaling through neuronal apoE receptors can activate the ubiquitin-proteasome machinery, which might have implications for the role of Reelin during neurodevelopment and in the regulation of synaptic transmission.	Univ Freiburg, Dept Med 2, D-79104 Freiburg, Germany; Univ Freiburg, Zentrum Neurowissensch, D-79104 Freiburg, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Catholic Univ Louvain, Dev Genet Unit, B-1200 Brussels, Belgium	University of Freiburg; University of Freiburg; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite Catholique Louvain	Herz, J (corresponding author), Univ Freiburg, Dept Med 2, Albertstr 23, D-79104 Freiburg, Germany.	hans.bock@zfn.uni-freiburg.de; joachim.herz@utsouthwestern.edu	Bock, Hans/AAF-2635-2021	Jossin, Yves/0000-0001-8466-7432	NHLBI NIH HHS [HL20948, HL63762, R37 HL063762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Beffert U, 2004, J NEUROSCI, V24, P1897, DOI 10.1523/JNEUROSCI.4084-03.2004; Benhayon D, 2003, MOL BRAIN RES, V112, P33, DOI 10.1016/S0169-328X(03)00032-9; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Herrick TM, 2002, DEVELOPMENT, V129, P787; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Jossin Y, 2003, J NEUROSCI, V23, P9953; Jossin Y, 2004, J NEUROSCI, V24, P514, DOI 10.1523/JNEUROSCI.3408-03.2004; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Niu S, 2004, NEURON, V41, P71, DOI 10.1016/S0896-6273(03)00819-5; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; Park TJ, 2003, BIOCHEM BIOPH RES CO, V302, P671, DOI 10.1016/S0006-291X(03)00247-X; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 2001, NEURON, V31, P929, DOI 10.1016/S0896-6273(01)00436-6; Rice DS, 1998, DEVELOPMENT, V125, P3719; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Yamanouchi H, 1997, ACTA NEUROPATHOL, V93, P528, DOI 10.1007/s004010050648; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yasha TC, 1997, CLIN NEUROPATHOL, V16, P17; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	62	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33471	33479		10.1074/jbc.M401770200	http://dx.doi.org/10.1074/jbc.M401770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175346	hybrid			2022-12-25	WOS:000223039700056
J	Pacheco, R; Ciruela, F; Casado, V; Mallol, J; Gallart, T; Lluis, C; Franco, R				Pacheco, R; Ciruela, F; Casado, V; Mallol, J; Gallart, T; Lluis, C; Franco, R			Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE; CAMP; ERYTHROCYTE; LYMPHOCYTES; EXPRESSION; MECHANISMS; PLASMA	Metabotropic glutamate receptors (mGluR) are present in cells of the nervous system, where they are activated by one of the main neurotransmitters, glutamate. They are also expressed in cells outside the nervous system. We identified and characterized two receptors belonging to group I mGluR, mGlu1R and mGlu5R, in human cell lines of lymphoid origin and in resting and activated lymphocytes from human peripheral blood. Both are highly expressed in the human Jurkat T cell line, whereas mGlu5R is expressed only in the human B cell line SKW6.4. In blood lymphocytes, mGlu5R is expressed constitutively, whereas mGlu1R is expressed only upon activation via the T cell receptor-CD3 complex. Group I receptors in the central nervous system are coupled to phospholipase C, whereas in blood lymphocytes, activation of mGlu5R does not trigger this signaling pathway, but instead activates adenylate cyclase. On the other hand, mGlu5R does not mediate ERK1/2 activation, whereas mGlu1R, which is coupled neither to phospholipase C nor to calcium channels and whose activation does not increase cAMP, activates the mitogen-activated protein kinase cascade. The differential expression of mGluR in resting and activated lymphocytes and the different signaling pathways that are triggered when mGlu1Rs or mGlu5Rs are activated point to a key role of glutamate in the regulation of T cell physiological function. The study of the signaling pathways ( cAMP production and ERK1/2 phosphorylation) and the proliferative response obtained in the presence of glutamate analogs suggests that mGlu1R and mGlu5R have distinct functions. mGlu5R mediates the reported inhibition of cell proliferation evoked by glutamate, which is reverted by the activation of inducible mGlu1R. This is a novel non-inhibitory action mechanism for glutamate in lymphocyte activation. mGlu1R and mGlu5R thus mediate opposite glutamate effects in human lymphocytes.	Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Barcelona, Div Immunol, Hosp Clin & Prov, Fdn Clin, Barcelona 08026, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Franco, R (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, Marti Franques 1, E-08028 Barcelona, Spain.	r.franco@bq.ub.es	Ciruela, F./A-5096-2013; Mallol, Josefa/I-4194-2015; Franco, Rafael/C-3694-2015; Casadó, Vicent/K-1660-2014	Ciruela, F./0000-0003-0832-3739; Mallol, Josefa/0000-0002-2479-4162; Franco, Rafael/0000-0003-2549-4919; Casadó, Vicent/0000-0002-1764-3825; Pacheco, Rodrigo/0000-0001-8057-9806				Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; Arslan G, 2002, N-S ARCH PHARMACOL, V365, P150, DOI 10.1007/s002100100456; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Dale LB, 2002, NEUROCHEM INT, V41, P319, DOI 10.1016/S0197-0186(02)00073-6; Divino JC, 1998, J ENDOCRINOL, V156, P519, DOI 10.1677/joe.0.1560519; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Ganor Y, 2003, J IMMUNOL, V170, P4362, DOI 10.4049/jimmunol.170.8.4362; Kostanyan IA, 1997, IMMUNOL LETT, V58, P177, DOI 10.1016/S0165-2478(97)00086-2; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; Lombardi G, 2001, BRIT J PHARMACOL, V133, P936, DOI 10.1038/sj.bjp.0704134; Mirabet M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/sj.bjp.0701495; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Ramstad C, 2000, CELL SIGNAL, V12, P557, DOI 10.1016/S0898-6568(00)00097-8; Sorensen SD, 2003, NEUROPHARMACOLOGY, V44, P699, DOI 10.1016/S0028-3908(03)00053-4; Storto M, 2000, J NEUROIMMUNOL, V109, P112, DOI 10.1016/S0165-5728(00)00269-1; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Tsai PJ, 1999, METABOLISM, V48, P1455, DOI 10.1016/S0026-0495(99)90159-2; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; WINDER DG, 1993, J NEUROSCI, V13, P38	22	102	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33352	33358		10.1074/jbc.M401761200	http://dx.doi.org/10.1074/jbc.M401761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184389	Green Published, hybrid			2022-12-25	WOS:000223039700042
J	Rivas, M; Mellstrom, B; Naranjo, JR; Santisteban, P				Rivas, M; Mellstrom, B; Naranjo, JR; Santisteban, P			Transcriptional repressor DREAM interacts with thyroid transcription factor-1 and regulates thyroglobulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; SURFACTANT PROTEIN-C; POTASSIUM CHANNELS; EPITHELIAL-CELLS; BINDING PROTEIN; NUCLEAR-PROTEIN; GROWTH-FACTOR; TSH RECEPTOR; PROMOTER; THYROTROPIN	Tissue-specific gene expression depends on the interaction between tissue-specific and general transcription factors. DREAM is a Ca2+-dependent transcriptional repressor widely expressed in the brain where it participates in nociception through its control of prodynorphin gene expression. In the periphery, DREAM is highly expressed in the thyroid gland, the immune system, and the reproductive organs. Here, we show that DREAM interacts with thyroid-specific transcription factor TTF-1 and regulates the expression of the thyroglobulin (Tg) gene. The mechanism also involves binding of DREAM to the thyroglobulin promoter and blockage of TTF-1-mediated transactivation. The TSH/cAMP pathway and Ca2+ signaling regulate DREAM-mediated transcriptional repression of the thyroglobulin gene. Furthermore, chromatin immunoprecipitation experiments in FRTL-5 cells confirmed that Tg is a bona fide target gene for DREAM transrepression in thyroid follicular cells.	CSIC, CNB, Dpto Biol Mol & Celular, Madrid 28049, Spain; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Naranjo, JR (corresponding author), CSIC, CNB, Dpto Biol Mol & Celular, Campus Cantoblanco, Madrid 28049, Spain.	naranjo@cnb.csic.es	Santisteban, Pilar/E-7829-2016; NARANJO, Jose R/K-1950-2014	Santisteban, Pilar/0000-0002-2758-796X; NARANJO, Jose R/0000-0002-0270-3469				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CORDA D, 1985, J BIOL CHEM, V260, P9230; DAMANTE G, 1988, MOL CELL ENDOCRINOL, V58, P279, DOI 10.1016/0303-7207(88)90165-7; Damante G, 2001, PROG NUCLEIC ACID RE, V66, P307; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Ledo F, 2002, EMBO J, V21, P4583, DOI 10.1093/emboj/cdf440; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Medina DL, 2002, MOL ENDOCRINOL, V16, P33, DOI 10.1210/me.16.1.33; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; Perrone L, 1999, J BIOL CHEM, V274, P4640, DOI 10.1074/jbc.274.8.4640; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Spitzweg C, 1998, J CLIN ENDOCR METAB, V83, P1746, DOI 10.1210/jc.83.5.1746; Spreafico F, 2001, MOL CELL NEUROSCI, V17, P1, DOI 10.1006/mcne.2000.0913; Sussel L, 1999, DEVELOPMENT, V126, P3359; Takahashi Y, 2000, GENE DEV, V14, P804; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	50	59	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33114	33122		10.1074/jbc.M403526200	http://dx.doi.org/10.1074/jbc.M403526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15181011	hybrid			2022-12-25	WOS:000223039700013
J	Vijayan, KV; Liu, Y; Li, TT; Bray, PF				Vijayan, KV; Liu, Y; Li, TT; Bray, PF			Protein phosphatase 1 associates with the integrin alpha(IIb) subunit and regulates signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; INTEGRIN ALPHA(IIB)BETA(3); DEPHOSPHORYLATION EVENTS; BINDING PROTEIN; PLATELET; KINASE; ACTIVATION; PHOSPHORYLATION; ADHESION; AVIDITY	Regulation of integrin activation occurs by specific interactions among cytoplasmic proteins and integrin alpha and beta cytoplasmic tails. We report that the catalytic subunit of protein phosphatase 1 (PP1c) constitutively associates with the prototypic integrin alpha(IIb)beta(3) in platelets and in cell lines overexpressing the integrin. PP1c binds directly to the cytoplasmic domain of integrin alpha(IIb) subunit containing a conserved PP1c binding motif (989)KVGF(992). Anchored PP1c is inactive, while thrombin-induced platelet aggregation or fibrinogen-alpha(IIb)beta(3) engagement caused PP1c dissociation and concomitant activation as revealed by dephosphorylation of PP1c substrate, myosin light chain. Inhibition of ligand binding to activated alpha(IIb)beta(3) blocks PP1c dissociation and represses PP1c activation. These studies reveal a previously unrecognized role for integrins whereby the alpha subunit cytoplasmic tail localizes the machinery for initiating and temporally maintaining the regulatory signaling activity of a phosphatase.	Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA	Baylor College of Medicine	Vijayan, KV (corresponding author), Baylor Coll Med, Dept Med, Thrombosis Res Sect, 1 Baylor Plaza,BCM 286,N1319, Houston, TX 77030 USA.	vvijayan@bcm.tmc.edu; pbray@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057488, P50HL065967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57488, HL65967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; Bettoun DJ, 2002, J BIOL CHEM, V277, P24847, DOI 10.1074/jbc.C200187200; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Cohen PTW, 2002, J CELL SCI, V115, P241; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hedman H, 1996, SCAND J IMMUNOL, V44, P239, DOI 10.1046/j.1365-3083.1996.d01-305.x; HEDMAN H, 1992, J IMMUNOL, V149, P2295; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Larkin D, 2004, J BIOL CHEM, V279, P27286, DOI 10.1074/jbc.M402159200; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Mauco G, 1997, CELL SIGNAL, V9, P117, DOI 10.1016/S0898-6568(96)00119-2; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; MURATA K, 1995, J CELL BIOCHEM, V57, P120, DOI 10.1002/jcb.240570112; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Obergfell A, 2002, BLOOD, V100, p122A; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shock David D., 1994, Journal of Tissue Culture Methods, V16, P249, DOI 10.1007/BF01540661; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Vijayan KV, 2003, J BIOL CHEM, V278, P3860, DOI 10.1074/jbc.M208680200	29	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33039	33042		10.1074/jbc.C400239200	http://dx.doi.org/10.1074/jbc.C400239200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15205468	hybrid			2022-12-25	WOS:000223039700002
J	Carnero, A; Beach, DH				Carnero, A; Beach, DH			Absence of p21(WAF1) cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation	ONCOGENE			English	Article						oncogenic cooperation; c-myc; ras; waf1; PI3k	SKIN CARCINOGENESIS; EMBRYO FIBROBLASTS; TUMOR SUPPRESSION; TRANSGENIC MICE; ACTIVATED RAS; HA-RAS; P53; TRANSFORMATION; APOPTOSIS; CELLS	The absence of p21(waf1) combined with an ectopic expression of c-myc prevents ras-induced senescence in mouse embryo fibroblasts. Extension of lifespan after c-myc transduction into p21-null cells was followed at later passages by apoptosis of a large fraction of c-myc-overexpressing p21-null cells. This apoptotic effect could be overridden by inactivation of the p53 tumor suppressor or oncogenic Pas expression. Ras-induced inhibition of apoptosis is mediated by PI3K activation. These results suggest a functional relationship between Pas and myc that may explain their oncogenic cooperation. The number of foci formed by myc + Pas increased cooperatively in the absence of p21(waf1). Thus, the reciprocal cooperation between myc and ras in a p21-null background during cellular immortalization lead to increased oncogenic cooperation between Pas and myc.	CNIO, Expt Therapeut Programme, Madrid, Spain; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	Centro Nacional de Investigaciones Oncologicas (CNIO); University of London; University College London	Carnero, A (corresponding author), CNIO, Expt Therapeut Programme, Madrid, Spain.	acarnero@cnio.es	IBIS, CANCER/P-3323-2015	Carnero, Amancio/0000-0003-4357-3979				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HARVEY M, 1993, ONCOGENE, V8, P2457; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANGDON WY, 1989, ONCOGENE RES, V4, P253; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg WC, 1999, CANCER RES, V59, P2050; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6006	6011		10.1038/sj.onc.1207839	http://dx.doi.org/10.1038/sj.onc.1207839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195145				2022-12-25	WOS:000222941100016
J	Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG				Narayan, S; Jaiswal, AS; Kang, D; Srivastava, P; Das, GM; Gairola, CG			Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro	ONCOGENE			English	Article						cigarette smoke condensate; normal breast epithelial cells; anchorage-independent growth; transformation; Bcl-xL/Bax; neuropilin-1	PASSIVE SMOKING; ACTIVE SMOKING; GROWTH-FACTOR; TUMOR-CELLS; CANCER RISK; KAPPA-B; EXPRESSION; NEUROPILIN-1; GADD45; GENES	In the present study, we showed that a single-dose treatment of normal breast epithelial cell line, MCF10A, for 72h with cigarette smoke condensate (CSC) resulted in a transformed phenotype. The anchorage-dependent growth of these cells was decreased due to increased cell cycle arrest in S-G(2)/M phase; however, the surviving cells developed resistance due to an increased Bcl-xL to Bax ratio. Levels of PCNA and gadd45 proteins - involved in DNA repair in response to genomic damage - were increased, suggesting that the cells were responding to CSC-induced genomic damage. The transformation of MCF10A cells was determined by their colony-forming efficiency in soft-agar in an anchorage-independent manner. CSC-treated MCF10A cells efficiently formed colonies in soft-agar. We then re-established cell lines from the soft-agar colonies and further examined the persistence of their transforming characteristics. The re-established cell lines, when plated after 17 passages without CSC treatment, still formed colonies in the soft-agar. An increased staining of neuropilin-1 (NRP-1) further showed a transformation characteristic of MCF10A cells treated with CSC. In summary, our results suggest that CSC is capable of transforming the MCF10A cells in vitro, supporting the role cigarette smoking and increased risk for breast cancer.	Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Gainesville, FL 32610 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	State University System of Florida; University of Florida; Roswell Park Cancer Institute; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Dept Anat & Cell Biol, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093				Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bachelder RE, 2001, CANCER RES, V61, P5736; Band PR, 2003, BIOMED PHARMACOTHER, V57, P110; Band PR, 2002, LANCET, V360, P1044, DOI 10.1016/S0140-6736(02)11140-8; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; HALL PA, 1995, ONCOGENE, V10, P2427; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lash TL, 1999, AM J EPIDEMIOL, V149, P5; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Millikan RC, 1998, CANCER EPIDEM BIOMAR, V7, P371; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Morabia A, 2002, EPIDEMIOLOGY, V13, P744, DOI 10.1097/00001648-200211000-00026; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Rodgman A, 2000, HUM EXP TOXICOL, V19, P573, DOI 10.1191/096032700701546514; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Russo I.H., 2001, J WOMENS CANC, V3, P29; Russo J, 2002, ENVIRON MOL MUTAGEN, V39, P254, DOI 10.1002/em.10052; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SMITH SJ, 1994, BRIT J CANCER, V70, P112, DOI 10.1038/bjc.1994.258; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SOULE HD, 1990, CANCER RES, V50, P6075; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611; TAIT L, 1990, CANCER RES, V50, P6087; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Tomlinson IPM, 2001, BREAST CANCER RES, V3, P299, DOI 10.1186/bcr311; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; [No title captured]	57	60	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5880	5889		10.1038/sj.onc.1207792	http://dx.doi.org/10.1038/sj.onc.1207792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208684				2022-12-25	WOS:000222941100002
J	Alexander, DE; Kaczorowski, DJ; Jackson-Fisher, AJ; Lowery, DM; Zanton, SJ; Pugh, BF				Alexander, DE; Kaczorowski, DJ; Jackson-Fisher, AJ; Lowery, DM; Zanton, SJ; Pugh, BF			Inhibition of TATA binding protein dimerization by RNA polymerase III transcription initiation factor Brf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TFIIIB-DNA COMPLEXES; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; DIMER DISSOCIATION; TERNARY COMPLEX; YEAST TFIIIB; TBP; PROMOTER; GENE; MUTATIONS	The Brf1 subunit of TFIIIB plays an important role in recruiting the TATA-binding protein (TBP) to the upstream region of genes transcribed by RNA polymerase III. When TBP is not bound to promoters, it sequesters its DNA binding domain through dimerization. Promoter assembly factors therefore might be required to dissociate TBP into productively binding monomers. Here we show that Saccharomyces cerevisiae Brf1 induces TBP dimers to dissociate. The high affinity TBP binding domain of Brf1 is not sufficient to promote TBP dimer dissociation but in addition requires the TFIIB homology domain of Brf1. A model is proposed to explain how two distinct functional domains of Brf1 work in concert to dissociate TBP into monomers.	Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, N Frear Lab 452, University Pk, PA 16803 USA.	bfp2@psu.edu			NIGMS NIH HHS [R01 GM059055, GM059055] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hahn S, 2000, GENE DEV, V14, P719; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; KASSAVETIS GA, 1994, RAV S MOL C, V3, P107; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kou HP, 2004, J BIOL CHEM, V279, P20966, DOI 10.1074/jbc.M401535200; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Persinger J, 1999, MOL CELL BIOL, V19, P5218; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	46	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32401	32406		10.1074/jbc.M405782200	http://dx.doi.org/10.1074/jbc.M405782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15190063	hybrid			2022-12-25	WOS:000222849700053
J	Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV				Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV			Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2	ONCOGENE			English	Article						diallyl trisulfide; JNK; ERK; Bcl-2; apoptosis; prostate cancer	OCCURRING ORGANOSULFUR COMPOUNDS; METABOLIC OXIDATIVE STRESS; PROTEIN-KINASE; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; ALLIUM VEGETABLES; CYTOCHROME-C; P38 MAPK; DISULFIDE	Garlic-derived organosulfides (OSCs) including diallyl trisulfide (DATS) are highly effective in affording protection against chemically induced cancer in animals. Evidence is also mounting to indicate that some naturally occurring OSCs can suppress proliferation of cancer cells by causing apoptosis, but the sequence of events leading to proapoptotic effect of OSCs is poorly defined. Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate that DATS is a significantly more potent apoptosis inducer than diallyl sulfide (DAS) or diallyl disulfide (DADS). DATS-induced apoptosis in PC-3 cells was associated with phosphorylation of Bcl-2, reduced Bcl-2: Bax interaction, and cleavage of procaspase-9 and -3. Bcl-2 overexpressing PC-3 cells were significantly more resistant to apoptosis induction by DATS compared with vector-transfected control cells. DATS treatment resulted in activation of extracellular-signal regulated kinase 1/2 (ERK1/2) and c-jun N-terminal kinase 1 (JNK1) and/or JNK2, but not p38 mitogen-activated protein kinase. Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125. Moreover, JNK inhibitor afforded significant protection against DATS-induced apoptosis in both cells. DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. Overexpression of catalase inhibited DATS-mediated activation of JNK1/2, but not ERK1\/2, and apoptosis induction in DU145 cells suggesting involvement of hydrogen peroxide as a second messenger in DATS-induced apoptosis. In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol & Med, Pittsburgh, PA 15261 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roswell Park Cancer Institute	Singh, SV (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Res Pavil,Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu			NATIONAL CANCER INSTITUTE [R01CA101753, R01CA095191, R01CA096989] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1996, CANCER RES, V56, P1851; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DORANT E, 1993, BRIT J CANCER, V67, P424, DOI 10.1038/bjc.1993.82; Fang GF, 1998, CANCER RES, V58, P3202; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Filomeni G, 2003, CANCER RES, V63, P5940; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2001, J NUTR, V131, p1061S, DOI 10.1093/jn/131.3.1061S; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; Sheen LY, 1996, FOOD CHEM TOXICOL, V34, P971, DOI 10.1016/S0278-6915(96)00066-X; Shirin H, 2001, CANCER RES, V61, P725; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	53	224	235	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5594	5606		10.1038/sj.onc.1207747	http://dx.doi.org/10.1038/sj.onc.1207747			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184882				2022-12-25	WOS:000222629500004
J	Bauer, DE; Harris, MH; Plas, DR; Lum, JJ; Hammerman, PS; Rathmell, JC; Riley, JL; Thompson, CB				Bauer, DE; Harris, MH; Plas, DR; Lum, JJ; Hammerman, PS; Rathmell, JC; Riley, JL; Thompson, CB			Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand	FASEB JOURNAL			English	Article						growth factor; interleukin-3; glucose metabolism; cell size	FACTOR-INDEPENDENT SURVIVAL; GLUCOSE-METABOLISM; CARBOHYDRATE-METABOLISM; KINASE; GROWTH; LYMPHOCYTES; ACTIVATION; AKT; PHYTOHAEMAGGLUTININ; EXPRESSION	The relationship between growth factor-dependent cell growth and proliferation and the up-regulation of cellular metabolism required to support these processes remains poorly defined. Here, we demonstrate that cell growth, proliferation, and glucose metabolism are coordinately regulated by interleukin-3 (IL-3) in cytokine-dependent cells. Surprisingly, glycolytic activity is stimulated to a greater extent than would be expected based on the rate of cell growth or proliferation. IL-3 signaling exerts a direct effect on glycolytic commitment independent of cell growth control. These results are not restricted to IL-3 as the cytokines IL-7 and IL-2 have similar effects on glucose metabolism when assayed in factor-dependent cell lines or primary lymphocytes, respectively. Growth factor stimulation leads cells to consume less oxygen and produce more lactate per glucose, indicative of conversion from oxidative to glycolytic metabolism. The enforced rate of glucose metabolism is in excess of that required to support cell growth; accordingly, if extracellular glucose is reduced, cells retain the ability to grow and proliferate by derepressing oxidative metabolism. These data suggest that the high rate of glycolysis observed in response to growth factor stimulation is a primary effect rather than a homeostatic response to increased cell growth.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu		Lum, Julian/0000-0002-5624-3541; Riley, James/0000-0002-1057-576X	NCI NIH HHS [R01 CA105463, K01 CA091905, K01 CA91905-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA091905, R01CA105463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COOPER EH, 1963, BRIT J HAEMATOL, V9, P101, DOI 10.1111/j.1365-2141.1963.tb05446.x; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; CULVENOR JG, 1976, BIOCHIM BIOPHYS ACTA, V437, P354, DOI 10.1016/0304-4165(76)90005-2; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUPPY M, 1995, BRIT J HAEMATOL, V91, P752, DOI 10.1111/j.1365-2141.1995.tb05381.x; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; Koebmann BJ, 2002, J BACTERIOL, V184, P3909, DOI 10.1128/JB.184.14.3909-3916.2002; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krauss S, 2000, FASEB J, V14, P2581, DOI 10.1096/fj.00-0064com; KUTCHAI H, 1984, AM J PHYSIOL, V247, P107; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Parry RV, 2003, J IMMUNOL, V171, P166, DOI 10.4049/jimmunol.171.1.166; Peuchen S, 1996, NEUROSCIENCE, V71, P855, DOI 10.1016/0306-4522(95)00480-7; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Riley JL, 2001, J IMMUNOL, V166, P4943, DOI 10.4049/jimmunol.166.8.4943; ROOS D, 1970, BIOCHIM BIOPHYS ACTA, V222, P565, DOI 10.1016/0304-4165(70)90182-0; SAGONE AL, 1974, CELL IMMUNOL, V14, P443, DOI 10.1016/0008-8749(74)90195-6; Salway J.G., 2017, METABOLISM GLANCE; SAPICO V, 1970, J BIOL CHEM, V245, P3252; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VOET D, 2002, FUNDAMENTALS BIOCHEM; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893	40	130	137	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1303	+		10.1096/fj.03-1001fje	http://dx.doi.org/10.1096/fj.03-1001fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180958	Green Accepted			2022-12-25	WOS:000222327500028
J	Sakamoto, S; Potla, R; Larner, AC				Sakamoto, S; Potla, R; Larner, AC			Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; DNA; PROTEIN; GAMMA; EXPRESSION; INDUCTION; ELEMENT; ALPHA; STAT1	Posttranslational modification of histones by acetylation, methylation or phosphorylation has emerged as a major mechanism to modify chromatin structure and gene expression. In most cases, transcriptionally active genes display enhanced binding of acetylated histones in their promoters. Activation of histone acetyltransferases or inhibition of histone deacetylases (HDACs) allows chromatin to assume a more open state permitting transcriptional activators to form a preinitiation complex. To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. However, IFNbeta activation of IRF-1, which requires tyrosine-phosphorylated Stat1 homodimers binding to a gamma interferon activation sequence in its promoter is not affected by TSA. Exposure of cells to TSA does not alter tyrosine phosphorylation of Stat1 or Stat2. TSA treatment of cells also does not alter the binding of Stat 1 or Stat2 to the endogenous ISG54 promoter. However, IFNbeta-stimulated binding of RNA polymerase II to the ISG54 promoter is prevented by TSA. Interestingly, ectopic expression of IRF9 reverses the inhibitory actions of TSA, suggesting that IRF9 functions to recruit RNA polymerase II to the promoter of interferon-stimulated genes. This particular function of IRF9 requires the activity of histone deacetylases.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Larner, AC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.org			NCI NIH HHS [CA77366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kraus TA, 2003, J BIOL CHEM, V278, P13033, DOI 10.1074/jbc.M212972200; Larner AC, 2000, CANC DRUG DISC DEV, V5, P393; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	22	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40362	40367		10.1074/jbc.M406400200	http://dx.doi.org/10.1074/jbc.M406400200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15194680	hybrid			2022-12-25	WOS:000223916800019
J	Bate, C; Reid, S; Williams, A				Bate, C; Reid, S; Williams, A			Phospholipase A(2) inhibitors or platelet-activating factor antagonists prevent prion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; PROTEIN ACCUMULATION; PAF-ACETHER; CELLS; PRP; ENDOCYTOSIS; PROPAGATION; CONVERSION; NEUROTOXICITY; TUBULATION	A key feature of prion diseases is the conversion of the cellular prion protein (PrPC) into disease-related isoforms (PrPSc), the deposition of which is thought to lead to neurodegeneration. In this study a pharmacological approach was used to determine the metabolic pathways involved in the formation of protease-resistant PrP (PrPres) in three prion-infected cell lines (ScN2a, SMB, and ScGT1 cells). Daily treatment of these cells with phospholipase A(2) (PLA(2)) inhibitors for 7 days prevented the accumulation of PrPres. Glucocorticoids with anti-PLA(2) activity also prevented the formation of PrPres and reduced the infectivity of SMB cells. Treatment with platelet-activating factor (PAF) antagonists also reduced the PrPres content of cells, while the addition of PAF reversed the inhibitory effect of PLA(2) inhibitors on PrPres formation. ScGT1 cells treated with PLA(2) inhibitors or PAF antagonists for 7 days remained clear of detectable PrPres when grown in control medium for a further 12 weeks. Treatment of non-infected cells with PLA(2) inhibitors or PAF antagonists reduced PrPC levels suggesting that limiting cellular PrPC may restrict prion formation in infected cells. These data indicate a pivotal role for PLA(2) and PAF in controlling PrPres formation and identify them as potential therapeutic agents.	Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Sch Vet, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland; Univ Strathclyde, Dept Stat & Modeling Sci, Glasgow G1 1XW, Lanark, Scotland; Univ London Royal Vet Coll, Dept Pathol & Infect Dis, N Mymms AL9 7TA, Herts, England	University of Glasgow; University of Glasgow; University of Strathclyde; University of London; University of London Royal Veterinary College	Bate, C (corresponding author), Univ Glasgow, Sch Vet, Dept Vet Pathol, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	c.bate@vet.gla.ac.uk		Reid, Stuart/0000-0002-6872-9071				Abraham IM, 2001, J NEUROENDOCRINOL, V13, P749, DOI 10.1046/j.1365-2826.2001.00705.x; Aihara N, 2000, GENES CELLS, V5, P397, DOI 10.1046/j.1365-2443.2000.00333.x; Bate C, 2004, J BIOL CHEM, V279, P14983, DOI 10.1074/jbc.M313061200; Bate C, 2002, NEUROREPORT, V13, P1695, DOI 10.1097/00001756-200209160-00025; BAZILL GW, 1990, CANCER RES, V50, P7505; Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; BERGELSON LD, 1985, FEBS LETT, V190, P305, DOI 10.1016/0014-5793(85)81306-5; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 2001, J BIOL CHEM, V276, P47361, DOI 10.1074/jbc.M108508200; DEARMOND SJ, 1993, J NEUROCHEM, V61, P1589, DOI 10.1111/j.1471-4159.1993.tb09792.x; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; FLOWER RJ, 1986, AGENTS ACTIONS, V17, P255, DOI 10.1007/BF01982616; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X; KORTH R, 1987, EUR J PHARMACOL, V142, P331, DOI 10.1016/0014-2999(87)90071-9; Kuwahara C, 2000, BIOCHEM BIOPH RES CO, V268, P763, DOI 10.1006/bbrc.2000.2152; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MAZIERE JC, 1988, FEBS LETT, V236, P115, DOI 10.1016/0014-5793(88)80296-5; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; OUTRAM GW, 1974, NATURE, V249, P855, DOI 10.1038/249855a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Sauer H, 2003, FREE RADICAL BIO MED, V35, P586, DOI 10.1016/S0891-5849(03)00360-5; Shin BA, 1999, J NAT PROD, V62, P1554, DOI 10.1021/np990303a; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945	44	31	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36405	36411		10.1074/jbc.M404086200	http://dx.doi.org/10.1074/jbc.M404086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210691	hybrid			2022-12-25	WOS:000223453600031
J	Hao, G; Xie, LJ; Gross, SS				Hao, G; Xie, LJ; Gross, SS			Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; ARGININE METABOLISM; MESSENGER-RNAS; L-CITRULLINE; LYASE; MITOCHONDRIA; CELLS; NO; LOCALIZATION	Prior studies have demonstrated that the substrate for NO synthesis, L-arginine, can be regenerated from the NOS co-product L-citrulline. This requires the sequential action of two enzymes, argininosuccinate synthetase (AS) and argininosuccinate lyase (AL). AS activity has been shown to be rate-limiting for high output NO synthesis by immunostimulant-activated cells and represents a potential site for metabolic control of NO synthesis. We now demonstrate that NO mediates reversible S-nitrosylation and inactivation of AS in vitro and in lipopolysaccharide-treated cells and mice. Using a novel mass spectrometry-based method, we show that Cys-132 in human AS is the sole target for S-nitrosylation among five Cys residues. Mutagenesis studies confirm that S-nitrosylation of Cys-132 is both necessary and sufficient for the inhibition of AS by NO donors. S-nitroso-AS content is regulated by cellular glutathione levels and selectively influences NO production when citrulline is provided to cells as a protosubstrate of NOS but not when L-arginine is provided. A phylogenetic comparison of AS sequences suggests that Cys-132 evolved as a site for post-translational regulation of activity in the AS in NOS-expressing species, endowing NO with the capacity to limit its own synthesis by restricting arginine availability.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Biochem & Struct Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	ssgross@mail.med.cornell.edu			NHLBI NIH HHS [HL 50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Cohen NS, 1996, J CELL BIOCHEM, V61, P81, DOI 10.1002/(SICI)1097-4644(19960401)61:1<81::AID-JCB10>3.3.CO;2-Z; Farghali H, 1999, METHOD FIND EXP CLIN, V21, P395, DOI 10.1358/mf.1999.21.6.541919; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROSS SS, 1993, ADV EXP MED BIOL, V338, P295; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Gross SS, 1996, METHOD ENZYMOL, V268, P159; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1995, BIOCHEM BIOPH RES CO, V215, P148, DOI 10.1006/bbrc.1995.2445; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; KUMAR S, 1985, P NATL ACAD SCI USA, V82, P6745, DOI 10.1073/pnas.82.20.6745; Kurz S, 1997, J CLIN INVEST, V99, P369, DOI 10.1172/JCI119166; Lane P, 1999, SEMIN NEPHROL, V19, P215; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; ROSENTHAL GA, 1969, BIOCHEM J, V112, P415, DOI 10.1042/bj1120415; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3; Yoon JH, 2000, FEBS LETT, V474, P175, DOI 10.1016/S0014-5793(00)01599-4	41	66	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36192	36200		10.1074/jbc.M404866200	http://dx.doi.org/10.1074/jbc.M404866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15192091	hybrid			2022-12-25	WOS:000223453600006
J	Gajewski, A; Csaszar, E; Foisner, R				Gajewski, A; Csaszar, E; Foisner, R			A phosphorylation cluster in the chromatin-binding region regulates chromosome association of LAP2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER NUCLEAR-MEMBRANE; PHASE-SPECIFIC PHOSPHORYLATION; LEM-DOMAIN; LAMIN-A; STRUCTURE DYNAMICS; P34(CDC2) KINASE; BUILDING-BLOCKS; HUMAN-DISEASE; POLYPEPTIDE 2; TAIL DOMAIN	LAP2alpha is a LEM family protein associated with nucleoplasmic A-type lamins and chromatin in interphase. Like lamins and other lamina proteins LAP2alpha is cytoplasmic in metaphase, but it associates with chromosomes prior to nuclear envelope formation in late anaphase to telophase. In vitro phosphorylation analysis and mass spectrometry identified a cluster of at least three mitotic cyclin-dependent kinase 1 phosphorylation sites in the C-terminal chromatin-binding region of LAP2alpha as well as four additional potential sites in the cluster, some of which were targeted alternatively in LAP2alpha mutated at the major sites. LAP2alpha mutants containing serine 3 alanine mutations at all seven sites revealed a clear phenotype. Mutated LAP2alpha remained associated with chromosomes throughout mitosis, but the dissociation of lamins into the cytoplasm and nuclear envelope disassembly were not affected. These data demonstrate the in vivo significance of mitotic phosphorylation for the dynamic behavior of LAP2alpha in the cell cycle and show that, unlike the interaction with lamins, the chromatin association of LAP2alpha is regulated by multiple mitosis-specific phosphorylation at sites clustered within a defined region in the C terminus of the protein.	Med Univ Vienna, Max F Perutz Labs, Univ Dept Vienna Bioctr, Dept Med Biochem, A-1030 Vienna, Austria; Med Univ Vienna, Max F Perutz Labs, Univ Dept Vienna Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Foisner, R (corresponding author), Med Univ Vienna, Max F Perutz Labs, Univ Dept Vienna Bioctr, Dept Med Biochem, Dr Bohrgasse 9, A-1030 Vienna, Austria.	Roland.Foisner@univie.ac.at	Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647				Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIDGER JM, 1993, J CELL SCI, V104, P297; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; Dechat T, 2000, J CELL SCI, V113, P3473; Dechat T, 2000, J STRUCT BIOL, V129, P335, DOI 10.1006/jsbi.2000.4212; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Dreger M, 1999, BIOCHEMISTRY-US, V38, P9426, DOI 10.1021/bi990645f; Durauer A, 2000, J CHROMATOGR A, V890, P145, DOI 10.1016/S0021-9673(00)00241-7; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Foisner R, 2001, J CELL SCI, V114, P3791; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; Foisner Roland, 2003, ScientificWorldJournal, V3, P1; Goldberg M, 1999, P NATL ACAD SCI USA, V96, P2852, DOI 10.1073/pnas.96.6.2852; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOZAK P, 1995, J CELL SCI, V108, P635; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Jagatheesan G, 1999, J CELL SCI, V112, P4651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Malecz N, 1996, J BIOL CHEM, V271, P8203, DOI 10.1074/jbc.271.14.8203; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Markiewicz E, 2002, MOL BIOL CELL, V13, P4401, DOI 10.1091/mbc.E02-07-0450; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; OZAKI T, 1994, ONCOGENE, V9, P2649; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Spann TP, 2002, J CELL BIOL, V156, P603, DOI 10.1083/jcb.200112047; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Vlcek S, 1999, EMBO J, V18, P6370, DOI 10.1093/emboj/18.22.6370; Vlcek S, 2002, J BIOL CHEM, V277, P18898, DOI 10.1074/jbc.M200048200; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535	46	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35813	35821		10.1074/jbc.M402546200	http://dx.doi.org/10.1074/jbc.M402546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208326	hybrid			2022-12-25	WOS:000223303400082
J	Tkach, JM; Glover, JR				Tkach, JM; Glover, JR			Amino acid substitutions in the C-terminal AAA(+) module of Hsp104 prevent substrate recognition by disrupting oligomerization and cause high temperature inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-LOCALIZATION; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATPASE DOMAIN; YEAST; PROPAGATION; CLPB	Hsp104 is an important determinant of thermotolerance in yeast and is an unusual molecular chaperone that specializes in the remodeling of aggregated proteins. The structural requirements for Hsp104-substrate interactions remain unclear. Upon mild heat shock Hsp104 formed cytosolic foci in live cells that indicated co-localization of the chaperone with aggregates of thermally denatured proteins. We generated random amino acid substitutions in the C-terminal 199 amino acid residues of a GFP-Hsp104 fusion protein, and we used a visual screen to identify mutants that remained diffusely distributed immediately after heat shock. Multiple amino acid substitutions were required for loss of heat-inducible redistribution, and this correlated with complete loss of nucleotide-dependent oligomerization. Based on the multiply substituted proteins, several single amino acid substitutions were generated by site-directed mutagenesis. The singly substituted proteins retained the ability to oligomerize and detect substrates. Intriguingly, some derivatives of Hsp104 functioned well in prion propagation and multiple stress tolerance but failed to protect yeast from extreme thermal stress. We demonstrate that these proteins co-aggregate in the presence of other thermolabile proteins during heat treatment both in vitro and in vivo suggesting a novel mechanism for uncoupling the function of Hsp104 in acute severe heat shock from its functions at moderate temperatures.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Glover, JR (corresponding author), Univ Toronto, Dept Biochem, Rm 5302 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	john.glover@utoronto.ca						Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Fujita K, 1998, BIOCHEM BIOPH RES CO, V248, P542, DOI 10.1006/bbrc.1998.9008; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Kawai R, 1999, CELL STRESS CHAPERON, V4, P46, DOI 10.1054/csac.1999.0076; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Tuite MF, 1996, TRENDS GENET, V12, P467, DOI 10.1016/0168-9525(96)10045-7; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	52	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35692	35701		10.1074/jbc.M400782200	http://dx.doi.org/10.1074/jbc.M400782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15178690	hybrid			2022-12-25	WOS:000223303400067
J	Igarashi, RY; Dos Santos, PC; Niehaus, WG; Dance, IG; Dean, DR; Seefeldt, LC				Igarashi, RY; Dos Santos, PC; Niehaus, WG; Dance, IG; Dean, DR; Seefeldt, LC			Localization of a catalytic intermediate bound to the FeMo-cofactor of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOLYBDENUM IRON PROTEIN; MOFE-PROTEIN; ANGSTROM RESOLUTION; SUBSTRATE REDUCTION; ALPHA-SUBUNIT; BINDING; HISTIDINE-195; ACETYLENE; INHIBITOR	Nitrogenase catalyzes the biological reduction of N-2 to ammonia ( nitrogen fixation) as well as the reduction of a number of alternative substrates, including acetylene (HC = CH) to ethylene (H2C = CH2). It is known that the metallocluster FeMo-cofactor located within the nitrogenase MoFe protein component provides the site of substrate reduction, but the exact site where substrates bind and are reduced on the FeMo-cofactor remains unknown. We have recently shown that the alpha-70 residue of the MoFe protein plays a significant role in defining substrate access to the active site; alpha-70 approaches one face of the FeMo-cofactor, and when valine is substituted by alanine at this position, the substituted nitrogenase is able to accommodate a reduction of the larger alkyne propargyl alcohol (HC = CCH2OH, propargyl-OH). During this reduction, a substrate-derived intermediate can be trapped on the FeMo-cofactor resulting in an S = 1/2 spin system with a novel electron paramagnetic resonance spectrum. In the present work, trapping of the propargyl-OH-derived or propargyl amine (HC = CCH2NH2, propargyl-NH2)- derived intermediates is shown to be dependent on pH and the presence of histidine at position alpha-195. It is concluded that these catalytic intermediates are stabilized and thereby trapped by H-bonding interactions between either the - OH group or the - NH3+ group and the imidazole epsilon-NH of alpha-195(His). Thus, for the first time it is possible to establish the location of a bound substrate-derived intermediate on the FeMo-cofactor. Refinement of the binding mode and site was accomplished by the use of density functional and force field calculations pointing to an eta(2) coordination at Fe-6 of the FeMo-cofactor.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Univ New S Wales, Sch Chem Sci, Sydney, NSW 2052, Australia	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University; University of New South Wales Sydney	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	deandr@vt.edu; seefeldt@cc.usu.edu		Dos Santos, Patricia/0000-0002-3364-0931; Seefeldt, Lance/0000-0002-6457-9504	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Benton PMC, 2001, BIOCHEMISTRY-US, V40, P13816, DOI 10.1021/bi011571m; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Chang FC, 1997, BIOCHEMISTRY-US, V36, P9013, DOI 10.1021/bi970783+; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dance I, 2003, CHEM COMMUN, P324, DOI 10.1039/b211036a; DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452; Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015; Delley B., 1995, MODERN DENSITY FUNCT, V2, P221; Demadis KD, 1996, INORG CHEM, V35, P4038, DOI 10.1021/ic960098b; Dilworth MJ, 1998, BIOCHEMISTRY-US, V37, P17495, DOI 10.1021/bi9812017; Durrant MC, 2002, BIOCHEMISTRY-US, V41, P13934, DOI 10.1021/bi025623z; Edgcomb SP, 2002, PROTEINS, V49, P1, DOI 10.1002/prot.10177; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fisher K, 2000, BIOCHEMISTRY-US, V39, P15570, DOI 10.1021/bi0017834; Graton J, 1999, J CHEM SOC PERK T 2, P997, DOI 10.1039/a809265f; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LEE HI, 2004, IN PRESS J AM CHEM S; Malinak SM, 1997, J AM CHEM SOC, V119, P1662, DOI 10.1021/ja963475s; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Mayer SM, 2002, J CHEM SOC DALTON, P802, DOI 10.1039/b107336b; PHAM DN, 1993, BIOCHEMISTRY-US, V32, P13725, DOI 10.1021/bi00212a043; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; SCHROCK RR, 1988, INORG CHEM, V27, P3574, DOI 10.1021/ic00293a027; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; SEEFELDT LC, 1995, BIOCHEMISTRY-US, V34, P5382, DOI 10.1021/bi00016a009; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100	36	68	69	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34770	34775		10.1074/jbc.M403194200	http://dx.doi.org/10.1074/jbc.M403194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181010	hybrid			2022-12-25	WOS:000223134800084
J	Jette, C; Peterson, PW; Sandoval, IT; Manos, EJ; Hadley, E; Ireland, CM; Jones, DA				Jette, C; Peterson, PW; Sandoval, IT; Manos, EJ; Hadley, E; Ireland, CM; Jones, DA			The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; ABERRANT CRYPT FOCI; EPITHELIAL STEM-CELL; BETA-CATENIN; DOWN-REGULATION; CYCLIN D1; SODIUM-BUTYRATE; CDX2 EXPRESSION; ACID SYNTHESIS; HOMEOBOX GENE	Development of normal colon epithelial cells proceeds through a systematic differentiation of cells that emerge from stem cells within the base of colon crypts. Genetic mutations in the adenomatous polyposis coli (APC) gene are thought to cause colon adenoma and carcinoma formation by enhancing colonocyte proliferation and impairing differentiation. We currently have a limited understanding of the cellular mechanisms that promote colonocyte differentiation. Herein, we present evidence supporting a lack of retinoic acid biosynthesis as a mechanism contributing to the development of colon adenomas and carcinomas. Microarray and reverse transcriptase-PCR analyses revealed reduced expression of two retinoid biosynthesis genes: retinol dehydrogenase 5 (RDH5) and retinol dehydrogenase L (RDHL) in colon adenomas and carcinomas as compared with normal colon. Consistent with the adenoma and carcinomas samples, seven colon carcinoma cell lines also lacked expression of RDH5 and RDHL. Assessment of RDH enzymatic activity within these seven cell lines showed poor conversion of retinol into retinoic acid when compared with normal cells such as normal human mammary epithelial cells. Reintroduction of wild type APC into an APC-deficient colon carcinoma cell line (HT29) resulted in increased expression of RDHL without affecting RDH5. APC-mediated induction of RDHL was paralleled by increased production of retinoic acid. Investigations into the mechanism responsible for APC induction of RDHL indicated that beta-catenin fails to repress RDHL. The colon-specific transcription factor CDX2, however, activated an RDHL promoter construct and induced endogenous RDHL. Finally, the induction of RDHL by APC appears dependent on the presence of CDX2. We propose a novel role for APC and CDX2 in controlling retinoic acid biosynthesis and in promoting a retinoid-induced program of colonocyte differentiation.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Rm 5262, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu			NIGMS NIH HHS [5T32 GM 07464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BLANER WS, 1999, RETINOIDS BIOCH MOL, P117; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Buckhaults P, 2001, CANCER RES, V61, P6996; Cerignoli F, 2002, CANCER RES, V62, P1196; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; DE LUCA LM, 1994, NUTR REV, V52, P45; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EE HC, 1995, AM J PATHOL, V147, P586; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; GLICK AB, 1991, DEVELOPMENT, V111, P1081; Guo XJ, 2002, CANCER RES, V62, P1654; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Maden M, 1999, BIOESSAYS, V21, P809, DOI 10.1002/(SICI)1521-1878(199910)21:10<809::AID-BIES2>3.0.CO;2-0; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mariadason JM, 2001, CANCER RES, V61, P3465; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murakami R, 1999, CELL MOL BIOL, V45, P661; NARISAWA T, 1976, CANCER RES, V36, P1379; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; NOY N, 1999, HANDB EXP PHARM, V139, P3; NZEGWU H, 1991, GUT, V32, P1324, DOI 10.1136/gut.32.11.1324; NZEGWU HC, 1992, GUT, V33, P794, DOI 10.1136/gut.33.6.794; OTORI K, 1995, CANCER RES, V55, P4743; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; PERUMAL AS, 1968, BIOCHIM BIOPHYS ACTA, V170, P399, DOI 10.1016/0304-4165(68)90019-6; PERUMAL AS, 1966, BIOCHIM BIOPHYS ACTA, V124, P95, DOI 10.1016/0304-4165(66)90316-3; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Rexer BN, 2001, CANCER RES, V61, P7065; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Soref CM, 2001, J BIOL CHEM, V276, P24194, DOI 10.1074/jbc.M100332200; Sparks AB, 1998, CANCER RES, V58, P1130; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; VOGEL S, 1999, RETINOIDS BIOCH MOL, P31; Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149; Wright NA, 2000, INT J EXP PATHOL, V81, P117, DOI 10.1046/j.1365-2613.2000.00146.x; Zheng Y, 1997, CARCINOGENESIS, V18, P2119, DOI 10.1093/carcin/18.11.2119; Zheng Y, 1999, CARCINOGENESIS, V20, P255, DOI 10.1093/carcin/20.2.255; ZILE M, 1977, J NUTR, V107, P552, DOI 10.1093/jn/107.4.552; ZILE M, 1970, ARCH BIOCHEM BIOPHYS, V140, P210, DOI 10.1016/0003-9861(70)90024-X	68	54	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34397	34405		10.1074/jbc.M314021200	http://dx.doi.org/10.1074/jbc.M314021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190067	hybrid			2022-12-25	WOS:000223134800040
J	Mitsushima, M; Suwa, A; Amachi, T; Ueda, K; Kioka, N				Mitsushima, M; Suwa, A; Amachi, T; Ueda, K; Kioka, N			Extracellular signal-regulated kinase activated by epidermal growth factor and cell adhesion interacts with and phosphorylates vinexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; MAP KINASE; CYTOSKELETAL ORGANIZATION; TRANSCRIPTION FACTORS; ESTROGEN-RECEPTOR; STRESS FIBERS; DOCKING SITES; IN-VIVO; MITOGEN; INTEGRIN	Extracellular signal-regulated kinase 1/2 (ERK1/2) is activated by various extracellular stimuli including growth factors and cytokines and plays a pivotal role in regulating cell proliferation and differentiation by phosphorylating nuclear transcription factors. Recently, it was reported that activated ERK1/2 also concentrates at adhesion sites and regulates cell spreading and migration. Vinexin is a focal adhesion protein regulating both cell spreading and growth factor signaling. We show here that vinexin was directly phosphorylated by ERK1/2 upon stimulation with growth factors. ERK1/2 phosphorylated the linker region of vinexin between the second and third SH3 domains. Site-directed mutagenesis revealed that ERK2 mainly phosphorylated the serine 189 residue of vinexin beta. Furthermore, vinexin beta interacted with ERK1/2 both in vitro and in vivo. Vinexin interacted with the active but not inactive form of ERK1/2. A putative DEF ( docking for ERK FXFP) domain located in the linker region of vinexin was required for the interaction with ERK1/2 and efficient phosphorylation of vinexin beta by ERK2. Finally, we showed that cell adhesion to fibronectin also induced the association of vinexin beta with ERK2 and the phosphorylation of vinexin beta. Furthermore, vinexin and ERK were co-localized to the periphery of cells during cell spreading on fibronectin. Together, these results suggest that vinexin is a novel substrate of ERK2 and may play roles in ERK-dependent cell regulation during cell spreading as well as in growth factor-induced responses.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; TUJAGUE M, 2003, J BIOL CHEM; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wakabayashi M, 2003, J BIOL CHEM, V278, P21709, DOI 10.1074/jbc.M211004200; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	48	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34570	34577		10.1074/jbc.M402304200	http://dx.doi.org/10.1074/jbc.M402304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184391	hybrid			2022-12-25	WOS:000223134800061
J	Joly, N; Bohm, A; Boos, W; Richet, E				Joly, N; Bohm, A; Boos, W; Richet, E			MalK, the ATP-binding cassette component of the Escherichia coli maltodextrin transporter, inhibits the transcriptional activator MalT by antagonizing inducer binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; GENE-EXPRESSION; PROTEIN; REGULON; REGULATOR; SYSTEM; DOMAIN; ENZYME; MOTIF; ENCODES	MalK, the ATP-binding cassette component of the Escherichia coli maltodextrin transporter, has long been known to control negatively the activity of MalT, a transcriptional activator dedicated to the maltose regulon. By using a biochemical approach and the soluble form of MalK as a model substrate, we demonstrate that MalK alone inhibits transcription activation by MalT in a purified transcription system. The inhibitory effect observed in vitro is relieved by maltotriose and by two malT mutations and one malK mutation known to interfere with MalT repression by MalK in vivo. MalK interacts directly with the activator in the absence of maltotriose but not in the presence of maltotriose. Conversely, MalK inhibits maltotriose binding by MalT. Altogether, these data strongly suggest that MalK and maltotriose compete for MalT binding. Part, if not all, of the MalK-binding site is located on DT1, the N-terminal domain of MalT. All of these features indicate that MalK inhibits MalT by the same mechanism as two other proteins, MalY and Aes, that also act as negative effectors of MalT by antagonizing maltotriose binding by MalT. These results offer new insights into the mechanism by which gene regulation can be accomplished by the ATPase component of a bacterial ATP-binding cassette-type importer.	Inst Pasteur, Unite Genet Mol, CNRS, URA 2172, F-75724 Paris 15, France; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Konstanz	Richet, E (corresponding author), Inst Pasteur, Unite Genet Mol, CNRS, URA 2172, 25 Rue Dr Roux, F-75724 Paris 15, France.	erichet@pasteur.fr	Joly, Nicolas/H-6851-2018	Joly, Nicolas/0000-0003-2731-3827				Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 2000, TRENDS GENET, V16, P404, DOI 10.1016/S0168-9525(00)02086-2; Braun V, 2003, CURR OPIN MICROBIOL, V6, P173, DOI 10.1016/S1369-5274(03)00022-5; BUKAU B, 1986, J BACTERIOL, V166, P884, DOI 10.1128/jb.166.3.884-891.1986; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Clausen T, 2000, EMBO J, V19, P831, DOI 10.1093/emboj/19.5.831; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; DARDONVILLE B, 1990, J BACTERIOL, V172, P1846, DOI 10.1128/jb.172.4.1846-1852.1990; Davidson AL, 2002, SCIENCE, V296, P1038, DOI 10.1126/science.1072484; De Schrijver A, 1999, MICROBIOL-UK, V145, P1287, DOI 10.1099/13500872-145-6-1287; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; Joly N, 2002, J BIOL CHEM, V277, P16606, DOI 10.1074/jbc.M200991200; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RICHET E, 1987, J BIOL CHEM, V262, P12647; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schlegel A, 2002, J BACTERIOL, V184, P3069, DOI 10.1128/JB.184.11.3069-3077.2002; Schreiber V, 1999, J BIOL CHEM, V274, P33220, DOI 10.1074/jbc.274.47.33220; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Valdez F, 1999, MICROBIOL-UK, V145, P2365, DOI 10.1099/00221287-145-9-2365; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I	33	45	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33123	33130		10.1074/jbc.M403615200	http://dx.doi.org/10.1074/jbc.M403615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180985	hybrid			2022-12-25	WOS:000223039700014
J	Longpre, JM; Leduc, R				Longpre, JM; Leduc, R			Identification of prodomain determinants involved in ADAMTS-1 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; PROPROTEIN CONVERTASE; THROMBOSPONDIN MOTIFS; FURIN; DISINTEGRIN; ACTIVATION; BINDING; CLONING; FAMILY; GENE	The metalloprotease ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin type I motif), similarly to other members of the ADAMTS family, is initially synthesized as a zymogen, proADAMTS-1, that undergoes proteolytic processing at the prodomain/catalytic domain junction by serine proteinases of the furin-like family of proprotein convertases. The goals of this study were to identify residues of the prodomain that play an essential role in ADAMTS-1 processing and to determine the identity of the convertase required for zymogen processing. To gain insight into the putative roles of specific prodomain residues in ADAMTS-1 biosynthesis, we performed biosynthetic labeling experiments in transiently transfected human embryonic kidney 293 cells expressing wild-type and prodomain mutants of proADAMTS-1. Cells expressing wild-type ADAMTS-1 initially produced a 110-kDa zymogen form that was later converted to an 87-kDa form, which was also detected in the media. Although convertases such as PACE4 and PC6B processed proADAMTS-1, we found that furin was the most efficient enzyme at producing the mature ADAMTS-1 87-kDa moiety. Site-directed mutagenesis of the two putative furin recognition sequences found within the ADAMTS-1 prodomain (RRNR173 and RKKR235) revealed that Arg(235) was the sole processing site. Use of the Golgi disturbing agent, Brefeldin A, and monensin suggests that the cleavage of proADAMTS-1 takes place in the Golgi apparatus prior to its secretion. Conserved residues within the prodomain of other ADAMTS members hinted that they might act as maturation determinants. Replacement with alanine of selected residues Cys(106), Tyr(108), Gly(110), Cys(125), and Cys(181) and residues encompassing the 137-144 sequence significantly affected the biosynthetic profile of the enzyme. Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Leduc, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.	Richard.Leduc@USherbrooke.ca						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Denault JB, 2000, PROTEIN EXPRES PURIF, V19, P113, DOI 10.1006/prep.2000.1215; Denault JB, 2002, FEBS LETT, V527, P309, DOI 10.1016/S0014-5793(02)03249-0; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Taniguchi T, 2002, BIOCHEM BIOPH RES CO, V290, P878, DOI 10.1006/bbrc.2001.6282; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33237	33245		10.1074/jbc.M313151200	http://dx.doi.org/10.1074/jbc.M313151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15184385	hybrid			2022-12-25	WOS:000223039700029
J	Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH				Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH			Identification of a Myb-responsive enhancer of the chicken C/EBP beta gene	ONCOGENE			English	Article						Myb; C/EBP beta; target gene; chromatin; enhancer	LEUCINE-ZIPPER PROTEINS; RECEPTOR FUSION PROTEIN; I-HYPERSENSITIVE SITES; V-MYB; C-MYB; TRANSCRIPTION FACTOR; MYELOMONOCYTIC CELLS; MYELOID CELLS; MIM-1 GENE; NF-M	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) that disrupts myelomonocytic differentiation and transforms myelomonocytic cells. It is thought that the biological effects of v-Myb are caused by deregulation of specific target genes. The CCAAT box/enhancer binding protein beta (C/EBPbeta), a member of the basic region-leucine zipper (bzip) class of transcription factors, which itself plays an important role during myelomonocytic differentiation, has previously been shown to be regulated by Myb. Here we have addressed the mechanism by which v-Myb affects C/EBPbeta expression. We have employed the mapping of DNase I hypersensitive sites (DHSs) in chromatin as a tool to detect in vivo target sites of v-Myb. Our data identify a DHS downstream of the C/EBPbeta gene that appears to be specific for v-myb-transformed myeloblasts. We have confirmed by chromatin immunoprecipitation that v-Myb is bound to this region in vivo. Furthermore, we have found that ectopic expression of v-Myb in a myelomonocytic cell line is able to induce a DHS downstream of the C/EBPbeta gene, showing for the first time that v-Myb can affect chromatin structure. Reporter gene experiments demonstrate that the downstream DHS acts as a Myb-dependent enhancing element in transiently as well as in stably transfected myelomonocytic cells. Previous work has shown that v-Myb acts on the C/EBPbeta promoter; it now appears that Myb stimulates C/EBPbeta expression by acting on the promoter as well as on an enhancer of the C/EBPbeta gene. Interestingly, the mechanisms by which Myb acts on both elements differ; while Myb activation of the promoter requires the cooperation with C/EBPbeta, activation of the enhancer by Myb is independent of C/EBPbeta. Apart from the identification of a novel Myb-dependent enhancer, our work demonstrates the potential of chromatin structure analysis for the identification of Myb target sites.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kintscher J, 2003, DNA CELL BIOL, V22, P201, DOI 10.1089/104454903321655828; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SCOTT LM, 1992, BLOOD, V80, P1725; Sippel AE, 1996, METHOD ENZYMOL, V274, P233; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Yamanaka R, 1998, INT J MOL MED, V1, P213; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	58	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5807	5814		10.1038/sj.onc.1207722	http://dx.doi.org/10.1038/sj.onc.1207722			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195136				2022-12-25	WOS:000222629800010
J	Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V				Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V			Activated p53 suppresses the histone methyltransferase EZH2 gene	ONCOGENE			English	Article						senescence; p53; EZH2; repression; HMTase; G2/M arrest	HUMAN-DIPLOID FIBROBLASTS; POLYCOMB-GROUP PROTEINS; LIFE-SPAN; CELL-DIFFERENTIATION; TELOMERASE ACTIVITY; SENESCENCE; MECHANISMS; EXPRESSION; PROLIFERATION; PATHWAY	Replicative senescence is an irreversible cell cycle arrest that limits the proliferation of damaged cells and may be an important tumor suppression mechanism in vivo. This process is regulated at critical steps by the tumor suppressor p53. To identify genes that may regulate the senescence process, we performed cDNA microarray analysis of gene expression in senescent, young proliferating, and hTERT-immortalized primary human fibroblasts. The histone methyltransferase (HMTase), EZH2, was specifically downregulated in senescent cells. Activated p53 suppressed EZH2 gene expression through repression of the EZH2 gene promoter. This activity of p53 requires intact p53 transactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 transcriptional target p2l(waf1) inactivating RB/E2F pathways. In addition, the knockdown of EZH2 expression retards cell proliferation and induces G2/M arrest. We suggest that the p53-dependent suppression of EZH2 expression is a novel pathway that contributes to p53-mediated G2/M arrest. EZH2 associated complex possesses HMTase activity and is involved in epigenetic regulation. Activated p53 suppresses EZH2 expression, suggesting a further role for p53 in epigenetic regulation and in the maintenance of genetic stability. Suppression of EZH2 expression in tumors by p53 may lead to novel approaches to control cancer progression.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Tang, Xiaohu/AAX-4577-2021; Milyavsky, Michael/E-8306-2011; Shats, Igor/AAD-8775-2019	Shats, Igor/0000-0001-6449-5979; Erez, Neta/0000-0001-6506-9074				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACLEAN K, 1994, ONCOGENE, V9, P719; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Raaphorst FM, 2000, J IMMUNOL, V164, P1, DOI 10.4049/jimmunol.164.1.1; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAY JW, 1993, ONCOGENE, V8, P1407; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	66	160	186	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5759	5769		10.1038/sj.onc.1207706	http://dx.doi.org/10.1038/sj.onc.1207706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208672				2022-12-25	WOS:000222629800005
J	Jaschke, B; Milz, S; Vogeser, M; Michaelis, C; Vorpahl, M; Schomig, A; Kastrati, A; Wessely, R				Jaschke, B; Milz, S; Vogeser, M; Michaelis, C; Vorpahl, M; Schomig, A; Kastrati, A; Wessely, R			Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drugeluting stents to prevent neointima formation following vascular injury	FASEB JOURNAL			English	Article						restenosis; cell cycle; drug-coated stents	DRUG-ELUTING STENTS; IN-VIVO; DEFICIENT MICE; RAPAMYCIN; ATHEROSCLEROSIS; HYPERPLASIA; P53; PROGRESSION; P27(KIP1); STENOSIS	In-stent restenosis is a hyperproliferative disease which can be successfully treated by drug-eluting stents releasing compounds that exhibit cell-cycle inhibitory properties to inhibit coronary smooth muscle cell (CASMC) proliferation and migration, resembling the key pathomechanisms of in-stent restenosis. Cyclin-dependent kinases (CDK) are key regulators of the eukaryotic cell cycle. CDK activity may be blocked by novel compounds such as flavopiridol. Therefore, CDK inhibitors are attractive drugs to be used for the local prevention of in-stent restenosis. In this study, we demonstrate that flavopiridol leads to potent inhibition of CASMC proliferation and migration. Molecular effects on cell-cycle regulatory mechanisms and distribution were evaluated by post-transcriptional assessment of distinct cyclins and cyclin-dependent kinase inhibitor (CKI) levels and flow cytometry. Cellular necrosis and apoptosis was assessed in CASMC and coronary endothelial cells. Flavopiridol induced a potent antiproliferative effect by cell-cycle inhibition in G(1) and G(2)/M and led to increased protein levels of CKIs p21(cip1) and p27(kip1) as well as p53 in CASMC. Hyperphosphorylation of retinoblastoma protein was abrogated and mitogen-mediated smooth muscle cell migration significantly reduced. No accelerated cytotoxicity or increased apoptosis was detectable. Flavopiridol-coated stents, implanted in rat carotid arteries, led to significant decrease of neointima formation. As proof of principle, our results demonstrate that stents eluting CDK inhibitors such as flavopiridol effectively inhibit neointima formation. Therefore, this new class of therapeutics may be suitable for further clinical investigations on drug-eluting stents to prevent in-stent restenosis.	Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Med Klin 1, D-8000 Munich, Germany; Univ Munich, Anat Anstalt, D-8000 Munich, Germany; Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-8000 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Klin Chem, D-8000 Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; University of Munich; Technical University of Munich; University of Munich	Wessely, R (corresponding author), Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	rwessely@dhm.mhn.de	, Kastrati/Y-2389-2019; Milz, Stefan/J-8218-2012	Milz, Stefan/0000-0002-3859-2107				Abizaid A, 2004, J AM COLL CARDIOL, V43, P1118, DOI 10.1016/j.jacc.2004.01.023; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Braun-Dullaeus RC, 2003, J LAB CLIN MED, V141, P179, DOI 10.1067/mlc.2003.23; Brusselbach S, 1998, INT J CANCER, V77, P146; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; Carlson B, 1999, CANCER RES, V59, P4634; Castro C, 2004, ATHEROSCLEROSIS, V172, P31, DOI 10.1016/j.atherosclerosis.2003.09.003; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; CLOWES AW, 1983, LAB INVEST, V49, P208; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Diez-Juan A, 2003, CIRC RES, V92, P402, DOI 10.1161/01.RES.0000059306.71961.ED; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Grenadier E, 2002, CATHETER CARDIO INTE, V55, P303, DOI 10.1002/ccd.10130; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kim KS, 2000, J MED CHEM, V43, P4126, DOI 10.1021/jm000231g; Kitada S, 2000, BLOOD, V96, P393; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Mancini D, 2003, CIRCULATION, V108, P48, DOI 10.1161/01.CIR.0000070421.38604.2B; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; MILZ S, 1994, J ANAT, V185, P103; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Phillips JW, 2003, CIRCULATION, V107, P2244, DOI 10.1161/01.CIR.0000065604.56839.18; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Reed SI, 1997, CANCER SURV, V29, P7; Roque M, 2001, LAB INVEST, V81, P895, DOI 10.1038/labinvest.3780298; Ruef J, 1999, CIRCULATION, V100, P659, DOI 10.1161/01.CIR.100.6.659; Sata M, 2003, ARTERIOSCL THROM VAS, V23, P1548, DOI 10.1161/01.ATV.0000089327.48154.32; Schwartz RS, 2002, CIRCULATION, V106, P1867, DOI 10.1161/01.CIR.0000033485.20594.6F; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Sedlacek HH, 2000, DRUGS, V59, P435, DOI 10.2165/00003495-200059030-00004; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sriram V, 2001, CIRCULATION, V103, P2414; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Suzuki T, 2001, CIRCULATION, V104, P1188, DOI 10.1161/hc3601.093987; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Virmani R, 2003, HEART, V89, P133, DOI 10.1136/heart.89.2.133; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wessely R, 1998, CIRCULATION, V98, P450, DOI 10.1161/01.CIR.98.5.450; Wessely R, 2003, HUM MOL GENET, V12, P177, DOI 10.1093/hmg/ddg018; Zhai SP, 2002, BIOMED CHROMATOGR, V16, P379, DOI 10.1002/bmc.166	50	23	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1285	+		10.1096/fj.04-1646fje	http://dx.doi.org/10.1096/fj.04-1646fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180955				2022-12-25	WOS:000222327500008
J	Volk, DE; Beasley, DWC; Kallick, DA; Holbrook, MR; Barrett, ADT; Gorenstein, DG				Volk, DE; Beasley, DWC; Kallick, DA; Holbrook, MR; Barrett, ADT; Gorenstein, DG			Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORNE ENCEPHALITIS-VIRUS; DENGUE-VIRUS; NEUTRALIZING-ANTIBODY; SEROLOGIC EVIDENCE; NMR; MEXICO; GLYCOPROTEIN; RESOLUTION; INFECTION; HORSES	The solution structure of domain III from the New York West Nile virus strain 385-99 (WN-rED3) has been determined by NMR methods. The West Nile domain III structure is a beta-barrel structure formed from seven anti-parallel beta-strands in two beta-sheets. One anti-parallel beta-sheet consists of beta-strands beta1 (Phe(299)-Asp(307)), beta2 (Val(313)-Tyr(319)), beta4 (Arg(354)-Leu(355)), and beta5 (Lys(370)-Glu(376)) arranged so that beta2 is flanked on either side by beta1 and beta5. The short beta4 flanks the end of the remaining side of beta5. The remaining anti-parallel beta-sheet is formed from strands beta3 (Ile(340)-Val(343)), beta6 (Gly(380)-Arg(388)), and beta7 (Gln(391)-Lys(399)) arranged with beta6 at the center. Residues implicated in antigenic differences between different West Nile virus strains (and other flaviviruses) and neutralization are located on the outer surface of the protein. Characterization of the binding of monoclonal antibodies to WN-rED3 mutants, which were identified through neutralization escape experiments, indicate that antibody neutralization directly correlates with binding affinities. These studies provide an insight into theoretical virus-receptor interaction points, structure of immunogenic determinants, and potential targets for antiviral agents against West Nile virus and highlight differences between West Nile virus and other flavivirus structures that may represent critical determinants of virulence.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Gorenstein, DG (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Route 1147, Galveston, TX 77555 USA.	david@nmr.utmb.edu	Holbrook, Michael/AAT-6865-2020; Volk, David/H-7956-2019	Holbrook, Michael/0000-0002-0824-2667; Volk, David/0000-0002-4372-6915; Kallick, Deborah/0000-0003-4241-2532	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007536] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007536-06] Funding Source: Medline; PHS HHS [U01 A1054827] Funding Source: Medline; ODCDC CDC HHS [U90CCU618754] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Blitvich BJ, 2003, EMERG INFECT DIS, V9, P853; CASE DA, 1999, AMBER6; CLORE GM, 1994, METHOD ENZYMOL, V239, P249; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Estrada-Franco JG, 2003, EMERG INFECT DIS, V9, P1604, DOI 10.3201/eid0912.030564; Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee YC, 2004, J BIOMOL NMR, V29, P399, DOI 10.1023/B:JNMR.0000032617.88899.4b; Lin CW, 2003, J VIROL, V77, P2600, DOI 10.1128/JVI.77.4.2600-2606.2003; Lorono-Pino MA, 2003, EMERG INFECT DIS, V9, P857; MANDL CW, 1989, J VIROL, V63, P564, DOI 10.1128/JVI.63.2.564-571.1989; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200; Zeller HG, 2004, EUR J CLIN MICROBIOL, V23, P147, DOI 10.1007/s10096-003-1085-1	25	91	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38755	38761		10.1074/jbc.M402385200	http://dx.doi.org/10.1074/jbc.M402385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15190071	hybrid			2022-12-25	WOS:000223684100086
J	Seyrantepe, V; Landry, K; Trudel, S; Hassan, JA; Morales, CR; Pshezhetsky, AV				Seyrantepe, V; Landry, K; Trudel, S; Hassan, JA; Morales, CR; Pshezhetsky, AV			Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL SIALIDASE; PLASMA-MEMBRANE; GANGLIOSIDE SIALIDASE; NEUROBLASTOMA-CELLS; CYTOSOLIC SIALIDASE; GM1 GANGLIOSIDE; NEURAMINIDASE; EXPRESSION; PROSAPOSIN; CLONING	Three different mammalian sialidases have been described as follows: lysosomal (Neu1, gene NEU1), cytoplasmic (Neu2, gene NEU2), and plasma membrane (Neu3, gene NEU3). Because of mutations in the NEU1 gene, the inherited deficiency of Neu1 in humans causes the severe multisystemic neurodegenerative disorder sialidosis. Galactosialidosis, a clinically similar disorder, is caused by the secondary Neu1 deficiency because of genetic defects in cathepsin A that form a complex with Neu1 and activate it. In this study we describe a novel lysosomal lumen sialidase encoded by the NEU4 gene on human chromosome 2. We demonstrate that Neu4 is ubiquitously expressed in human tissues and has broad substrate specificity by being active against sialylated oligosaccharides, glycoproteins, and gangliosides. In contrast to Neu1, Neu4 is targeted to lysosomes by the mannose 6-phospate receptor and does not require association with other proteins for enzymatic activity. Expression of Neu4 in the cells of sialidosis and galactosialidosis patients results in clearance of storage materials from lysosomes suggesting that Neu4 may be useful for developing new therapies for these conditions.	Univ Montreal, Hop St Justine, Serv Genet Med, Dept Med Genet, Montreal, PQ H3T 1C5, Canada; McGill Univ, Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Universite de Montreal; McGill University	Pshezhetsky, AV (corresponding author), Univ Montreal, Hop St Justine, Serv Genet Med, Dept Med Genet, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	alexei.pchejetski@umontreal.ca	Morales, Carlos R./H-1055-2011	A, Pshezhetsky/0000-0002-6612-1062				Akita H, 1997, HISTOCHEM CELL BIOL, V107, P495, DOI 10.1007/s004180050137; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V2, P495; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDETTE RA, 1986, J BIOL CHEM, V261, P2016; Comelli EM, 2003, GENE, V321, P155, DOI 10.1016/j.gene.2003.08.005; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; FINGERHUT R, 1992, EUR J BIOCHEM, V208, P623, DOI 10.1111/j.1432-1033.1992.tb17227.x; GRAHAM Y, 1984, CENTRIFUGATION PRACT, P161; HIRAIWA M, 1988, J BIOCHEM-TOKYO, V103, P86, DOI 10.1093/oxfordjournals.jbchem.a122245; HIRAIWA M, 1987, J BIOCHEM-TOKYO, V101, P1273, DOI 10.1093/oxfordjournals.jbchem.a121991; Igdoura SA, 1996, CELL TISSUE RES, V283, P385, DOI 10.1007/s004410050549; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; Kornfeld S., 2001, METABOLIC MOL BASES, P3469; Lefrancois S, 1999, J LIPID RES, V40, P1593; Lefrancois S, 2002, J BIOL CHEM, V277, P17188, DOI 10.1074/jbc.M200343200; Li SC, 2001, BIOCHEM J, V360, P233, DOI 10.1042/0264-6021:3600233; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; MANZI AE, 2003, CURRENT PROTOCOLS MO, V3; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCHNEIDERJAKOB HR, 1991, BIOL CHEM H-S, V372, P443, DOI 10.1515/bchm3.1991.372.1.443; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thomas G.H., METABOLIC MOL BASES, V3, P3507; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; WU GS, 1991, J NEUROCHEM, V56, P95, DOI 10.1111/j.1471-4159.1991.tb02567.x; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	45	97	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37021	37029		10.1074/jbc.M404531200	http://dx.doi.org/10.1074/jbc.M404531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213228	hybrid			2022-12-25	WOS:000223453600105
J	Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD				Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD			Interleukin-1 beta stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells	ONCOGENE			English	Article						IL-8; MAPK; ROS; gastric cancer; IL-1 beta	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HELICOBACTER-PYLORI; MESSENGER-RNA; TRANSCRIPTION FACTOR; ACTIVATION; ANGIOGENESIS; CANCER; LINE; GENE	Recent studies have suggested that the expression of interleukin-8 (IL-8) directly correlates with the vascularity of human gastric carcinomas. In this study, the effect of IL-1beta on IL-8 expression in human gastric cancer TMK-1 cells and the underlying signal transduction pathways were investigated. IL-1beta induced the IL-8 expression in a time- and concentration-dependent manner. IL-1beta induced the activation of extracellular signal-regulated kinases-1/2 and P38 mitogen-activated protein kinase ( MAPK), but not the activation of c-jun amino-terminal kinse and Akt. Specific inhibitors of MEK-1 (PD980590) and P38 MAPK (SB203580) were found to suppress the IL-8 expression and the IL-8 promoter activity. Expression of vectors encoding a mutated-type MEK-1 and P38 MAPK resulted in decrease in the IL-8 promoter activity. IL-1beta also induced the production of reactive oxygen species (ROS). N-acetyl cysteine (NAC) prevented the IL-1beta-induced ROS production and IL-8 expression. In addition, exogenous H2O2 could induce the IL-8 expression. Deletional and site-directed mutagenesis studies on the IL-8 promoter revealed that activator protein-1 (AP-1) and nuclear factor (NF)-kappaB sites were required for the IL-1beta-induced IL-8 transcription. Electrophoretic mobility shift assay confirmed that IL-1beta increased the DNA-binding activity of AP-1 and NF-kappaB. Inhibitor ( PD980590, SB203580) and ROS scavenger ( NAC) studies revealed that the upstream signalings for the transcription factors AP-1 and NF-kappaB were MAPK and ROS, respectively. Conditioned media from the TMK-1 cells pretreated with IL-1beta could remarkably stimulate the in vitro growth of HUVEC and this effect was partially abrogated by IL-8-neutralizing antibodies. The above results suggest that MAPK-AP-1 and ROS-NF-kappaB signaling pathways are involved in the IL-1beta-induced IL-8 expression and that these paracrine signaling pathways induce endothelial cell proliferation.	Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, Kwangju 501190, South Korea; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9200934, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Chonnam National University; Kanazawa University; University of Texas System; UTMD Anderson Cancer Center	Jung, YD (corresponding author), Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, 5 Hakdong, Kwangju 501190, South Korea.	ydjung@chonnam.ac.kr	KIM, MI HA/E-9765-2013; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				Anthonsen MW, 2001, J BIOL CHEM, V276, P35344, DOI 10.1074/jbc.M105264200; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Duval C, 2003, FREE RADICAL BIO MED, V35, P1589, DOI 10.1016/j.freeradbiomed.2003.09.008; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Ganesh S, 1996, CANCER-AM CANCER SOC, V77, P1035, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1035::AID-CNCR5>3.0.CO;2-G; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goede V, 1998, LAB INVEST, V78, P1385; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guiraldes E, 2001, J PEDIATR GASTR NUTR, V33, P127, DOI 10.1097/00005176-200108000-00006; Harris GK, 2003, MUTAT RES-FUND MOL M, V533, P183, DOI 10.1016/j.mrfmmm.2003.08.025; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirschi K K, 1997, EXS, V79, P419; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Katsuyama K, 2001, J BIOCHEM, V129, P585, DOI 10.1093/oxfordjournals.jbchem.a002894; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Kitadai Y, 1998, AM J PATHOL, V152, P93; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lo YYC, 1998, J CELL BIOCHEM, V69, P19, DOI 10.1002/(SICI)1097-4644(19980401)69:1<19::AID-JCB3>3.0.CO;2-Y; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Schwarz M, 1997, KIDNEY INT, V52, P1521, DOI 10.1038/ki.1997.482; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Straubinger RK, 2003, INFECT IMMUN, V71, P2693, DOI 10.1128/IAI.71.5.2693-2703.2003; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Wang MC, 1999, J GASTROENTEROL, V34, P10; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	40	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6603	6611		10.1038/sj.onc.1207867	http://dx.doi.org/10.1038/sj.onc.1207867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208668				2022-12-25	WOS:000223530800007
J	Seye, CI; Yu, NP; Gonzalez, FA; Erb, L; Weisman, GA				Seye, CI; Yu, NP; Gonzalez, FA; Erb, L; Weisman, GA			The P2Y(2) nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; TRANSACTIVATION; MIGRATION; RHOA; PHOSPHORYLATION; FAMILY; CDC42	UTP stimulates the expression of pro-inflammatory vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells through activation of the P2Y(2) nucleotide receptor P2Y(2)R. Here, we demonstrated that activation of the P2Y(2)R induced rapid tyrosine phosphorylation of vascular endothelial growth factor receptor (VEGFR)-2 in human coronary artery endothelial cells (HCAEC). RNA interference targeting VEGFR-2 or inhibition of VEGFR-2 tyrosine kinase activity abolishes P2Y(2)R-mediated VCAM-1 expression. Furthermore, VEGFR-2 and the P2Y(2)R co-localize upon UTP stimulation. Deletion or mutation of two Src homology-3-binding sites in the C-terminal tail of the P2Y(2)R or inhibition of Src kinase activity abolished the P2Y(2)R-mediated transactivation of VEGFR-2 and subsequently inhibited UTP-induced VCAM-1 expression. Moreover, activation of VEGFR-2 by UTP leads to the phosphorylation of Vav2, a guanine nucleotide exchange factor for Rho family GTPases. Using a binding assay to measure the activity of the small GTPases Rho, we found that stimulation of HCAEC by UTP increased the activity of RhoA and Rac1 (but not Cdc42). Significantly, a dominant negative form of RhoA inhibited P2Y(2)R-mediated VCAM-1 expression, whereas expression of dominant negative forms of Cdc42 and Rac1 had no effect. These data indicate a novel mechanism whereby a nucleotide receptor transactivates a receptor tyrosine kinase to generate an inflammatory response associated with atherosclerosis.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Seye, CI (corresponding author), Univ Missouri, Dept Biochem, M743 Med Sci Bldg, Columbia, MO 65212 USA.	seyec@missouri.edu	Yu, Ningpu/D-4266-2009	Erb, Laurie/0000-0001-6372-3378	NCRR NIH HHS [RR15565] Funding Source: Medline; NIA NIH HHS [AG18357] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Di Virgilio F, 2002, BRIT J PHARMACOL, V135, P831, DOI 10.1038/sj.bjp.0704524; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; ERLINGE D, 1995, EUR J PHARM-MOLEC PH, V289, P135, DOI 10.1016/0922-4106(95)90178-7; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; MalamSouley R, 1996, J CELL PHYSIOL, V166, P57, DOI 10.1002/(SICI)1097-4652(199601)166:1<57::AID-JCP7>3.0.CO;2-F; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Seta K, 2003, J BIOL CHEM, V278, P9019, DOI 10.1074/jbc.M208017200; Seye CI, 2003, J BIOL CHEM, V278, P24960, DOI 10.1074/jbc.M301439200; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; [No title captured]	31	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35679	35686		10.1074/jbc.M401799200	http://dx.doi.org/10.1074/jbc.M401799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15175347	hybrid			2022-12-25	WOS:000223303400065
J	Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T				Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T			Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells	ONCOGENE			English	Article						death receptor 5; histone deacetylase inhibitors; TRAIL; apoptosis; Bid; caspases	TRAIL-INDUCED APOPTOSIS; WAF1/CIP1 GENE PROMOTER; DECOY RECEPTORS; LEUKEMIA-CELLS; LIGAND TRAIL; HUMAN COLON; SP1 SITES; TUMORICIDAL ACTIVITY; KILLER/DR5 GENE; GROWTH ARREST	Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ, Dept Appl Biochem, Kyoto 6068522, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1999, J IMMUNOL, V162, P2597; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang Y, 2001, CANCER RES, V61, P6918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Inoue H, 2002, INT J MOL MED, V9, P521; Jang YJ, 2003, CANCER LETT, V194, P107, DOI 10.1016/S0304-3835(02)00680-8; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LaVallee TM, 2003, CANCER RES, V63, P468; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Mitsiades N, 2001, CANCER RES, V61, P2704; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagane M, 2000, CANCER RES, V60, P847; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; Oh SC, 2001, MOL CELLS, V11, P192; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tang XM, 2002, CANCER RES, V62, P4903; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	59	240	251	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6261	6271		10.1038/sj.onc.1207830	http://dx.doi.org/10.1038/sj.onc.1207830			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208660				2022-12-25	WOS:000223399000010
J	Cheng, GJ; Ritsick, D; Lambeth, JD				Cheng, GJ; Ritsick, D; Lambeth, JD			Nox3 regulation by NOXO1, p47(phox), and p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SUPEROXIDE-GENERATING OXIDASE; PHAGOCYTE NADPH OXIDASE; COLON EPITHELIAL-CELLS; NAD(P)H OXIDASE; ACTIVATION DOMAIN; SH3 DOMAIN; GROWTH; PROTEINS; PHOSPHORYLATION	gp91(phox) (Nox2), the catalytic subunit of the superoxide-generating respiratory burst oxidase, is regulated by subunits p47(phox) and p67(phox). Nox1, a homolog of gp91(phox), is regulated by NOXO1 and NOXA1, homologs of p47(phox) and p67(phox), respectively. For both Nox1 and gp91(phox), an organizer protein ( NOXO1 or p47(phox)) cooperates with an activator protein ( NOXA1 or p67(phox)) to regulate the catalytic subunit. Herein, we investigate the subunit regulation of Nox3 compared with that of other Nox enzymes. Nox3, like gp91(phox), was activated by p47(phox) plus p67(phox). Whereas gp91(phox) activity required the protein kinase C activator phorbol myristate acetate (PMA), Nox3 activity was already high without PMA, but was further stimulated similar to 30% by PMA. gp91(phox) was also activated by NOXO1/NOXA1 and required PMA for high activity. gp91(phox) regulation required an intact activation domain in the activator protein, as neither p67(phox)( V204A) nor NOXA1(V205A) were effective. In contrast, p67(phox)( V204A) was effective ( along with p47(phox)) in activating Nox3. Unexpectedly, Nox3 was strongly activated by NOXO1 in the absence of NOXA1 or p67(phox). Nox3 activity was regulated by PMA only when p47(phox) but not NOXO1 was present, consistent with the phosphorylation-regulated autoinhibitory region in p47(phox) but not in NOXO1. Deletion of the autoinhibitory region from p47(phox) rendered this subunit highly active in the absence of PMA toward both gp91(phox) and Nox3, and high activity required an activator subunit. The unique regulation of Nox3 supports a model in which multiple interactions with regulatory subunits stabilize an active conformation of the catalytic subunit.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.	dlambe@emory.edu		Cheng, Guangjie/0000-0002-9368-379X	NATIONAL CANCER INSTITUTE [R01CA084138] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Chamulitrat W, 2003, ONCOGENE, V22, P6045, DOI 10.1038/sj.onc.1206654; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LAMBETH JD, 2003, RECENT ADV RES UPDAT, V4, P31; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Perner A, 2003, GUT, V52, P231, DOI 10.1136/gut.52.2.231; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Yang S, 2001, J BIOL CHEM, V276, P5452, DOI 10.1074/jbc.M001004200; Yuzawa S, 2003, ACTA CRYSTALLOGR D, V59, P1479, DOI 10.1107/S0907444903011636	43	118	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34250	34255		10.1074/jbc.M400660200	http://dx.doi.org/10.1074/jbc.M400660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181005	hybrid			2022-12-25	WOS:000223134800023
J	Ng, Y; Tan, I; Lim, L; Leung, T				Ng, Y; Tan, I; Lim, L; Leung, T			Expression of the human myotonic dystrophy kinase-related Cdc42-binding kinase gamma is regulated by promoter DNA methylation and Sp1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN PHOSPHATASE; CATALYTIC-ACTIVITY; CDC42 EFFECTOR; RHO-KINASE; ALPHA; TRANSCRIPTION; GENE; PHOSPHORYLATION; LOCALIZATION; PROTEINS	Myotonic dystrophy kinase-related Cdc42 binding kinases (MRCKs) are family members most related to the myotonic dystrophy kinase (DMPK), RhoA-binding kinase (ROK), and citron kinase. Two highly conserved members, MRCKalpha and -beta, have been previously identified and characterized. We now describe a novel isoform, MRCKgamma, which is functionally and structurally related to members of this kinase family. We show these kinases to have marked similarities in their genomic organization, substrate phosphorylation, and catalytic autoinhibition. Unlike MRCKalpha and -beta, which are expressed ubiquitously, MRCKgamma mRNA was only expressed in heart and skeletal muscle. In cultured cells, MRCKgamma showed differential expression with high levels of expression only in certain cell lines. DNA analysis showed that lack of expression is correlated with promoter DNA methylation. We have mapped the methylation sites in the MRCKgamma promoter. Significantly, agents that suppressed DNA methylation caused increases in the expression of the kinase in low-expressing cells, further supporting the notion that promoter DNA methylation plays an important role in the expression of MRCKgamma. Analysis of the MRCKgamma promoter has also revealed two proximal Sp1 sites that are essential for transcriptional activity. We conclude that both promoter DNA methylation and Sp1 binding are important regulators for MRCKgamma expression.	Natl Univ Singapore, Dept Anat, Inst Mol & Cell Biol, GSK IMCB Grp, Singapore 138673, Singapore; UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore; University of London; University College London	Leung, T (corresponding author), Natl Univ Singapore, Dept Anat, Inst Mol & Cell Biol, GSK IMCB Grp, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbthoml@imcb.a-star.edu.sg						Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Chotai KA, 1998, J MED GENET, V35, P472, DOI 10.1136/jmg.35.6.472; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GARG LC, 1989, J BIOL CHEM, V264, P2134; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KRUGER T, 1995, EMBO J, V14, P2661, DOI 10.1002/j.1460-2075.1995.tb07264.x; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Moncrieff CL, 1999, GENOMICS, V57, P297, DOI 10.1006/geno.1999.5769; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Suetsugu S, 2003, INT REV CYTOL, V229, P245, DOI 10.1016/S0074-7696(03)29006-9; Sumi T, 2001, J BIOL CHEM, V276, P23092, DOI 10.1074/jbc.C100196200; Tan I, 2003, GENE, V304, P107, DOI 10.1016/S0378-1119(02)01185-X; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Turner CE, 2000, J CELL SCI, V113, P4139; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zhao SJ, 2003, CANCER RES, V63, P2624; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	32	13	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34156	34164		10.1074/jbc.M405252200	http://dx.doi.org/10.1074/jbc.M405252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194684	hybrid			2022-12-25	WOS:000223134800013
J	Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW				Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW			Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice	ONCOGENE			English	Article						medulloblastoma; IGF2; sonic hedgehog; RCAS/tv-a; neural progenitors	HUMAN HOMOLOG; I RECEPTOR; N-MYC; GENE; PROTEIN; PROLIFERATION; MUTATIONS; SYSTEM; ACTIVATION; ALLELE	Medulloblastoma (MB) is a malignant brain tumor that arises in the cerebellum of children. Activation of the Sonic hedgehog/Patched (Shh/Ptc) signaling pathway in neural progenitor cells of the cerebellum induces MBs in mice. The incomplete penetrance of tumor formation in mice, coupled with the low frequency of mutations in Shh/Ptc pathway genes in human tumors, suggests that other signaling molecules cooperate with Shh to enhance MB formation. We modeled the ability of insulin-like growth factor (IGF) signaling to induce MB using the RCAS/tv-a system, which allows postnatal gene transfer and expression in a cell-type-specific manner. We used RCAS retroviral vectors to target expression of Shh, IGF2, and activated Akt to nestin-expressing neural progenitors in the cerebella of newborn mice. The incidence of Shh-induced tumor formation (15%) was enhanced by coexpression with IGF2 (39%) and Akt (48%). Neither IGF2 nor Akt caused tumors when expressed independently. The induced tumors showed upregulated expression of insulin receptor substrate 1 and phosphorylated forms of IGF1 receptor and Akt, mimicking activated IGF signaling found in human MBs. These results indicate that combined activation of the Shh/Ptc and IGF signaling pathways is an important mechanism in MB pathogenesis.	Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84132 USA; Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19112 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol & Cell Biol, New York, NY 10021 USA	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fults, DW (corresponding author), Univ Utah, Sch Med, Dept Neurosurg, 30 North 1900 East, Salt Lake City, UT 84132 USA.	daniel.fults@hsc.utah.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; COFFIN CM, 1990, MODERN PATHOL, V3, P164; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; EASTER SS, 1993, J NEUROSCI, V13, P285; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; Fults D, 2000, NEURO-ONCOLOGY, V2, P71, DOI 10.1093/neuonc/2.2.71; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wolter M, 1997, CANCER RES, V57, P2581; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	37	186	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6156	6162		10.1038/sj.onc.1207818	http://dx.doi.org/10.1038/sj.onc.1207818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195141				2022-12-25	WOS:000223261000015
J	Chavakis, T; Cines, DB; Rhee, JS; Liang, OD; Schubert, U; Hammes, HP; Higazi, AA; Nawroth, PP; Preissner, KT; Bdeir, K				Chavakis, T; Cines, DB; Rhee, JS; Liang, OD; Schubert, U; Hammes, HP; Higazi, AA; Nawroth, PP; Preissner, KT; Bdeir, K			Regulation of neovascularization by human neutrophil peptides (aleph-defensins): a link between inflammation and angiogenesis	FASEB JOURNAL			English	Article						integrin; adhesion; fibronectin; endothelial; apoptosis	ACTIVATED HUMAN NEUTROPHILS; MOLECULAR-WEIGHT KININOGEN; LOW-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; VASCULAR CELLS; INTEGRIN; BINDING; FIBRONECTIN; RECEPTOR	Angiogenesis, the growth of new blood vessels, is a complex biological process that is orchestrated by several growth factors and components of the extracellular matrix, including fibronectin (FN) and its receptor the integrin alpha5beta1. Angiogenesis is a critical part of inflammation and wound repair, but the mechanism by which vascular proliferation and migration is regulated by inflammatory cells is not completely understood. We have previously shown that human neutrophil peptides (HNPs), also known as alpha-defensins, which are secreted in high concentrations when neutrophils are activated, bind specifically to FN in the extracellular matrix and inhibit plasminogen activation. Therefore, we asked whether HNPs act as a link between inflammation and angiogenesis. alpha5beta1-Mediated endothelial cell adhesion and migration to FN, both under control conditions and under stimulation by vascular endothelial growth factor (VEGF), were inhibited specifically and in a dose-dependent manner by HNPs, whereas endothelial cell adhesion and migration to other components of the extracellular matrix, such as vitronectin, collagen, or fibrinogen/fibrin were not. Consistent with this finding, HNPs bound to and promoted the binding of fibronectin to alpha5beta1 integrin in arginineglycine-aspartic acid (RGD)-independent manner. HNPs also completely inhibited VEGF-induced proliferation and induced apoptosis of endothelial cells in a dose-dependent manner. Moreover, HNPs inhibited capillary tube formation in three-dimensional fibrin-matrices as well as neovascularization in vivo in the chicken chorioallantoic membrane assay. Taken together, these data indicate that HNPs can regulate angiogenesis by affecting endothelial cell adhesion and migration in an FN-dependent manner as well as endothelial cell proliferation. These findings provide new insight into the role of inflammatory cells in angiogenesis and might provide a platform for developing a novel class of anti-angiogenesis drugs.	Univ Heidelberg, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; Univ Clin Mannheim, Dept Internal Med, Mannheim, Germany	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; University of Pennsylvania; Ruprecht Karls University Heidelberg	Chavakis, T (corresponding author), Univ Heidelberg, Dept Internal Med 1, INF 410, D-69120 Heidelberg, Germany.	triantafyllos.chavakis@med.uni-heidelberg	Hammes, Hans-Peter/S-3719-2019; Chavakis, Triantafyllos/ABE-8845-2020		NHLBI NIH HHS [HL58107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010664] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Fakhri N, 2003, BIOL CHEM, V384, P423, DOI 10.1515/BC.2003.048; AUSPRUNK DH, 1975, AM J PATHOL, V79, P597; Barnathan ES, 1997, AM J PATHOL, V150, P1009; Bdeir K, 1999, BLOOD, V94, P2007; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2002, J CLIN INVEST, V109, P693, DOI 10.1172/JCI200215218; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Higazi AA, 2000, BLOOD, V96, P1393; Higazi AAR, 1997, BLOOD, V89, P4290, DOI 10.1182/blood.V89.12.4290; Higazi AAR, 1996, J BIOL CHEM, V271, P17650, DOI 10.1074/jbc.271.30.17650; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lee S, 2002, J CLIN INVEST, V110, P1105, DOI 10.1172/JCI200215755; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Levy O, 1996, EUR J HAEMATOL, V56, P263; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Nassar T, 2002, BLOOD, V100, P4026, DOI 10.1182/blood-2002-04-1080; NYGAARD SD, 1993, AM J RESP CELL MOL, V8, P193, DOI 10.1165/ajrcmb/8.2.193; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scapini P, 2002, J IMMUNOL, V168, P5798, DOI 10.4049/jimmunol.168.11.5798; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; Webb NJA, 1998, CYTOKINE, V10, P254, DOI 10.1006/cyto.1997.0297; YANG JT, 1993, DEVELOPMENT, V119, P1093	39	108	118	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1306	+		10.1096/fj.03-1009fje	http://dx.doi.org/10.1096/fj.03-1009fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208269				2022-12-25	WOS:000222327500015
J	Bond, M; Sala-Newby, GB; Newby, AC				Bond, M; Sala-Newby, GB; Newby, AC			Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability - A novel mechanism regulating smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; VASCULAR INJURY; GROWTH-FACTORS; EXPRESSION; P27(KIP1); INHIBITORS; FIBRONECTIN; DEGRADATION; MODULATION; INDUCTION	Smooth muscle cell (SMC) proliferation is suppressed in intact blood vessels but stimulated in atherosclerosis, restenosis after angioplasty, and vein graft disease. The cyclin-dependent kinase inhibitors, including p27(Kip1), play important roles in maintaining SMC quiescence. Levels of p27(Kip1) are dependent on attachment to and the composition of the extracellular matrix (ECM). Here we sought to elucidate mechanisms underlying the ECM-dependent regulation of p27(Kip1) and hence, SMC proliferation. Serum stimulation decreased p27(Kip1) levels in isolated SMC but not in rat aorta. The effect was posttranslational and mediated by proteasomal degradation. We studied the S-phase-associated kinase protein-2 (Skp2), an F-box protein involved in ubiquitination and proteasome-mediated degradation. Skp-2 protein is strongly induced by serum from undetectable levels in isolated SMCs but remains undetectable in aorta; Skp-2 mRNA is also lower in aorta. Overexpression of wild-type Skp-2 in SMCs decreased p27(Kip1) levels, whereas dominant negative F-box deleted mutant (DeltaF-Skp-2) Skp-2 increased p27(Kip1) levels. Furthermore, hyperphosphorylation of retinoblastoma protein and SMC proliferation were also reciprocally affected by wild-type and dominant negative Skp-2. Skp-2 expression was absolutely dependent on cell attachment to the ECM and was inhibited by laminin and type-1 fibrillar collagen but increased by fibronectin. Expression of Skp-2 protein, but not mRNA, was associated with focal adhesion kinase (FAK) activity and inhibited by overexpression of FAK-related non-kinase and a dominant negative FAK(Y397F) mutant. Furthermore, the inhibition of Skp-2 expression by dominant negative FAK was reversed by the proteasome inhibitor MG-132. Taken together, these data demonstrate that the vascular ECM controls SMC proliferation via FAK-dependent regulation of Skp-2 protein stability.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England	University of Bristol	Bond, M (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	mark.bond@bris.ac.uk	Bond, Mark/AAG-9293-2019	Bond, Mark/0000-0003-2788-278X				Adams J, 2003, EXPERT OPIN THER PAT, V13, P45, DOI 10.1517/eotp.13.1.45.20919; Assoian RK, 1996, J CLIN INVEST, V98, P2436, DOI 10.1172/JCI119059; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Dufourcq P, 2002, CARDIOVASC RES, V53, P952, DOI 10.1016/S0008-6363(01)00547-8; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FINGERLE J, 1987, INT ANGIOL, V6, P65; Fouty BW, 2001, AM J RESP CELL MOL, V25, P652, DOI 10.1165/ajrcmb.25.5.4592; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; Hedin U, 1997, ARTERIOSCL THROM VAS, V17, P1977, DOI 10.1161/01.ATV.17.10.1977; Izzard TD, 2002, CARDIOVASC RES, V53, P242, DOI 10.1016/S0008-6363(01)00444-8; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Kinsella MG, 2003, ARTERIOSCL THROM VAS, V23, P608, DOI 10.1161/01.ATV.0000063109.94810.EE; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Moiseeva EP, 2001, CARDIOVASC RES, V52, P372, DOI 10.1016/S0008-6363(01)00399-6; Morla AO, 2000, BIOCHEM BIOPH RES CO, V272, P298, DOI 10.1006/bbrc.2000.2769; NEWBY AC, 1993, CARDIOVASC RES, V27, P1173, DOI 10.1093/cvr/27.7.1173; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Roy J, 2002, EXP CELL RES, V273, P169, DOI 10.1006/excr.2001.5427; Seki R, 2003, AM J HEMATOL, V73, P230, DOI 10.1002/ajh.10379; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; SOYOMBO AA, 1995, J THORAC CARDIOV SUR, V109, P2, DOI 10.1016/S0022-5223(95)70415-9; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Thyberg J, 1997, J HISTOCHEM CYTOCHEM, V45, P837, DOI 10.1177/002215549704500608; Troncone G, 2003, J CLIN PATHOL, V56, P587, DOI 10.1136/jcp.56.8.587; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124	42	53	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37304	37310		10.1074/jbc.M404307200	http://dx.doi.org/10.1074/jbc.M404307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15208331	hybrid			2022-12-25	WOS:000223554600015
J	Meng, TC; Buckley, DA; Galic, S; Tiganis, T; Tonks, NK				Meng, TC; Buckley, DA; Galic, S; Tiganis, T; Tonks, NK			Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; REDOX REGULATION; IN-VIVO; FACTOR RECEPTOR; HYDROGEN-PEROXIDE; TRANSDUCTION; INACTIVATION; 1B; PHOSPHORYLATION; INTERMEDIATE	Many studies have illustrated that the production of reactive oxygen species (ROS) is important for optimal tyrosine phosphorylation and signaling in response to diverse stimuli. Protein-tyrosine phosphatases (PTPs), which are important regulators of signal transduction, are exquisitely sensitive to inhibition after generation of ROS, and reversible oxidation is becoming recognized as a general physiological mechanism for regulation of PTP function. Thus, production of ROS facilitates a tyrosine phosphorylation-dependent cellular signaling response by transiently inactivating those PTPs that normally suppress the signal. In this study, we have explored the importance of reversible PTP oxidation in the signaling response to insulin. Using a modified in-gel PTP assay, we show that stimulation of cells with insulin resulted in the rapid and transient oxidation and inhibition of two distinct PTPs, which we have identified as PTP1B and TC45, the 45-kDa spliced variant of the T cell protein-tyrosine phosphatase. We investigated further the role of TC45 as a regulator of insulin signaling by combining RNA interference and the use of substrate-trapping mutants. We have shown that TC45 is an inhibitor of insulin signaling, recognizing the beta-subunit of the insulin receptor as a substrate. The data also suggest that this strategy, using ligand-induced oxidation to tag specific PTPs and using interference RNA and substrate-trapping mutants to illustrate their role as regulators of particular signal transduction pathways, may be applied broadly across the PTP family to explore function.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Cold Spring Harbor Laboratory; Monash University	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu	Galic, Sandra/C-6098-2014; Meng, Tzu-Ching/G-5426-2019; Tiganis, Tony/AAV-3495-2020	Galic, Sandra/0000-0002-7611-5619; Meng, Tzu-Ching/0000-0001-7693-2021; Tiganis, Tony/0000-0002-8065-9942	NATIONAL CANCER INSTITUTE [T32CA009311, R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09311-23, CA53840] Funding Source: Medline; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2004, TOP CURR GENET, V5, P201; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Berhanu P, 1997, J BIOL CHEM, V272, P22884, DOI 10.1074/jbc.272.36.22884; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Cantrell DA, 2001, J CELL SCI, V114, P1439; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Huang DS, 2002, J BIOL CHEM, V277, P18151, DOI 10.1074/jbc.M104252200; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ibarra-Sanchez MD, 2001, ONCOGENE, V20, P4728, DOI 10.1038/sj.onc.1204648; Isomaa B, 2003, LIFE SCI, V73, P2395, DOI 10.1016/S0024-3205(03)00646-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meng TC, 2003, METHOD ENZYMOL, V366, P304; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Persson C, 2004, P NATL ACAD SCI USA, V101, P1886, DOI 10.1073/pnas.0304403101; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; SALMEEN A, 2004, IN PRESS ANTIOXID RE; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Tennagels N, 2000, FEBS LETT, V479, P67, DOI 10.1016/S0014-5793(00)01879-2; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TONKS NK, 2003, HDB CELL SIGNALLING, V108, P641; van der Wijk T, 2003, J BIOL CHEM, V278, P13968, DOI 10.1074/jbc.M300632200; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	60	219	227	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37716	37725		10.1074/jbc.M404606200	http://dx.doi.org/10.1074/jbc.M404606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15192089	Green Accepted, hybrid			2022-12-25	WOS:000223554600063
J	Chua, J; Deretic, V				Chua, J; Deretic, V			Mycobacterium tuberculosis reprograms waves of phosphatidylinositol 3-phosphate on phagosomal organelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; MEDIATED PHAGOCYTOSIS; DISTINCT ROLES; MATURATION; RAB5; 3-KINASE; CHOLESTEROL; TRAFFICKING; ASSOCIATION; PROTEINS	The potent human pathogen Mycobacterium tuberculosis persists in macrophages within a specialized, immature phagosome by interfering with the pathway of phagolysosome biogenesis. The molecular mechanisms underlying this process remain to be fully elucidated. Here, using four-dimensional microscopy, we detected on model phagosomes, which normally mature into phagolysosomes, the existence of cyclical waves of phosphatidylinositol 3-phosphate (PI3P), a membrane trafficking regulatory lipid essential for phagosomal acquisition of lysosomal characteristics. We show that mycobacteria interfere with the dynamics of PI3P on phagosomal organelles by altering the timing and characteristics of the PI3P waves on phagosomes. The default program of cyclical PI3P waves on model phagosomes is composed of an initial stage (phase I), represented by a strong PI3P burst occurring only upon the completion of phagosome formation, and a subsequent stage (phase II) of recurring PI3P waves on maturing phagosomes with the average periodicity of 20 min. Mycobacteria alter this program in two ways: (i) by inducing, in a cholesterol-dependent fashion, a neo-phase I* of premature PI3P production, coinciding with the process of mycobacterial entry into the macrophage, and (ii) by inhibiting the calmodulin-dependent phase II responsible for the acquisition of lysosomal characteristics. We conclude that the default pathway of phagosomal maturation into the phagolysosome includes temporally organized cyclical waves of PI3P on phagosomal membranes and that this process is targeted for reprogramming by mycobacteria as they prevent phagolysosome formation.	Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ Michigan, Sch Med, Program Biomed Sci, Ann Arbor, MI 48109 USA	University of New Mexico; University of New Mexico; University of Michigan System; University of Michigan	Deretic, V (corresponding author), Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.	vderetic@salud.unm.edu		Chua, Jennifer/0000-0001-8156-5174; Deretic, Vojo/0000-0002-3624-5208				BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brumell JH, 2004, CURR OPIN MICROBIOL, V7, P78, DOI 10.1016/j.mib.2003.12.005; Carabeo RA, 2003, P NATL ACAD SCI USA, V100, P6771, DOI 10.1073/pnas.1131289100; Cardelli J, 2001, TRAFFIC, V2, P311, DOI 10.1034/j.1600-0854.2001.002005311.x; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Chua J, 2004, CURR OPIN MICROBIOL, V7, P71, DOI 10.1016/j.mib.2003.12.011; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dramsi S, 2002, J CELL BIOL, V156, P943, DOI 10.1083/jcb.200202121; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gerlich D, 2003, NAT CELL BIOL, pS14, DOI 10.1038/ncb1033; Gerlich D, 2001, NAT CELL BIOL, V3, P852, DOI 10.1038/ncb0901-852; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Henry RM, 2004, J CELL BIOL, V164, P185, DOI 10.1083/jcb.200307080; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kurosu H, 2001, J BIOCHEM-TOKYO, V130, P73, DOI 10.1093/oxfordjournals.jbchem.a002964; Lawe DC, 2003, MOL BIOL CELL, V14, P2935, DOI 10.1091/mbc.E02-09-0591; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Malik ZA, 2001, J IMMUNOL, V166, P3392, DOI 10.4049/jimmunol.166.5.3392; Manders EMM, 1999, J CELL BIOL, V144, P813, DOI 10.1083/jcb.144.5.813; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Platani M, 2002, NAT CELL BIOL, V4, P502, DOI 10.1038/ncb809; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smart EJ, 2002, METHOD ENZYMOL, V353, P131; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; VEIGL ML, 1989, PHARMACOL THERAPEUT, V44, P181, DOI 10.1016/0163-7258(89)90066-1; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527; Vergne I, 2003, TRAFFIC, V4, P600, DOI 10.1034/j.1600-0854.2003.00120.x; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Walker DM, 2001, CURR BIOL, V11, P1600, DOI 10.1016/S0960-9822(01)00501-2; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; XU SM, 1994, J IMMUNOL, V153, P2568; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zamboni DS, 2003, MOL MICROBIOL, V49, P965, DOI 10.1046/j.1365-2958.2003.03626.x; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	67	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36982	36992		10.1074/jbc.M405082200	http://dx.doi.org/10.1074/jbc.M405082200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210698	hybrid			2022-12-25	WOS:000223453600101
J	Kaabeche, K; Lemonnier, J; Le Mee, S; Caverzasio, J; Marie, PJ				Kaabeche, K; Lemonnier, J; Le Mee, S; Caverzasio, J; Marie, PJ			Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE KINASE; SRC-FAMILY; NEGATIVE REGULATION; CELL-PROLIFERATION; COUPLED RECEPTORS; FGF RECEPTORS; EGF RECEPTOR; RING FINGER; PHOSPHORYLATION	Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation. However, the FGF signaling mechanisms controlling osteoblast function are poorly understood. Here, we identified a role for the Src family members Lyn and Fyn in osteoblast differentiation promoted by constitutive activation of FGF receptor-2 (FGFR2). We show that the overactive FGFR2 S252W mutation induced decreased Src family kinase tyrosine phosphorylation and activity associated with decreased Lyn and Fyn protein expression in human osteoblasts. Pharmacological stimulation of Src family kinases or transfection with Lyn or Fyn vectors repressed alkaline phosphatase (ALP) up-regulation induced by overactive FGFR2. Inhibition of proteasome activity restored normal Lyn and Fyn expression and ALP activity in FGFR2 mutant osteoblasts. Immunoprecipitation studies showed that Lyn, Fyn, and FGFR2 interacted with the ubiquitin ligase c-Cbl and ubiquitin. Transfection with c-Cbl in which the RING finger was disrupted or with c-Cbl with a point mutation that abolishes the binding ability of the Cbl phosphotyrosine-binding domain restored Src kinase activity and Lyn, Fyn, and FGFR2 levels and reduced ALP up-regulation in mutant osteoblasts. Thus, constitutive FGFR2 activation induces c-Cbl-dependent Lyn and Fyn proteasome degradation, resulting in reduced Lyn and Fyn kinase activity, increased ALP expression, and FGFR2 down-regulation. This reveals a common Cbl-mediated negative feedback mechanism controlling Lyn, Fyn, and FGFR2 degradation in response to overactive FGFR2 and indicates a role for Cbl-dependent down-regulation of Lyn and Fyn in osteoblast differentiation induced by constitutive FGFR2 activation.	Univ Paris 07, Hop Lariboisiere, INSERM, U606,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France; Serv Bone Dis, CH-1211 Geneva 14, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marie, PJ (corresponding author), Univ Paris 07, Hop Lariboisiere, INSERM, U606,Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	pierre.marie@larib.inserm.fr						Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Bresnick S, 1998, J CRANIOFAC SURG, V9, P92, DOI 10.1097/00001665-199801000-00020; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756-3282(03)00222-9; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hay E, 2004, J BIOL CHEM, V279, P1650, DOI 10.1074/jbc.M300969200; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; HURLEY MM, 2001, PRINCIPLES BONE BIOL, V1, P825; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kyo S, 2003, GENES CELLS, V8, P825, DOI 10.1046/j.1365-2443.2003.00679.x; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Lemonnier J, 2001, J BONE MINER RES, V16, P832, DOI 10.1359/jbmr.2001.16.5.832; Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820; Leu TH, 2003, FRONT BIOSCI-LANDMRK, V8, pS28, DOI 10.2741/980; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li Y, 1997, LEUKEMIA RES, V21, P391, DOI 10.1016/S0145-2126(96)00078-1; Lomri A, 1998, J CLIN INVEST, V101, P1310; Lomri A, 2001, J BONE MINER RES, V16, P705, DOI 10.1359/jbmr.2001.16.4.705; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Maschberger P, 2000, J BIOL CHEM, V275, P19159, DOI 10.1074/jbc.M910257199; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sanjay A., 2001, SCI STKE; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; ZAISI SK, 2004, EMBO J, V23, P790; ZHAN X, 1994, J BIOL CHEM, V269, P20221	65	65	70	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36259	36267		10.1074/jbc.M402469200	http://dx.doi.org/10.1074/jbc.M402469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15190072	hybrid			2022-12-25	WOS:000223453600014
J	Murphy, BM; Creagh, EM; Martin, SJ				Murphy, BM; Creagh, EM; Martin, SJ			Interchain proteolysis, in the absence of a dimerization stimulus, can initiate apoptosis-associated caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; GRANZYME-B; CELL-DEATH; PROTEASE; FADD; MECHANISM; PATHWAY; MODEL; CPP32; FLICE	Caspases coordinate the internal demolition of the cell that is seen during apoptosis. Proteolytic processing of caspases is observed during apoptosis, and this correlates with conversion of inactive caspase proenzymes into their active two-chain forms. However, recent studies have suggested that caspase-8 is activated through dimerization and that interchain proteolysis is not sufficient for activation of this caspase. This proposal casts doubt upon whether caspase-8 is productively activated by granzyme B during granule-dependent cytotoxic T lymphocyte or natural killer cell-mediated killing, for example. Contrary to the dimerization model, we show that direct proteolysis of caspase-8 by the cytotoxic T lymphocyte protease granzyme B, or by caspase-6, produces an active enzyme that displays robust proteolytic activity toward synthetic as well as natural caspase-8 substrates. These data suggest that enforced dimerization of caspase-8 zymogens by scaffold proteins such as Fas-associated protein with death domain (FADD), although important in certain contexts, is not a prerequisite for activation of this protease.	Univ Dublin Trinity Coll, Dept Genet, Smurfit Inst, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Dept Genet, Smurfit Inst, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Creagh, Emma/AAX-1064-2021; Murphy, Brona/D-4873-2012; Murphy, Brona/P-2544-2019	Creagh, Emma/0000-0001-7631-4370; Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Martin, Seamus/0000-0002-8539-3143				Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200	17	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36916	36922		10.1074/jbc.M402039200	http://dx.doi.org/10.1074/jbc.M402039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210716	Green Published, hybrid			2022-12-25	WOS:000223453600094
J	Debaigt, C; Hirling, H; Steiner, P; Vincent, JP; Mazella, J				Debaigt, C; Hirling, H; Steiner, P; Vincent, JP; Mazella, J			Crucial role of neuron-enriched endosomal protein of 21 kDa in sorting between degradation and recycling of internalized G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTENSIN RECEPTORS; BINDING-PROPERTIES; ENDOCYTIC PATHWAY; SYNTAXIN 13; TRAFFICKING; EXPRESSION; COMPLEXES; TERMINUS; RESIDUE; MOUSE	Recycling of endocytosed G-protein-coupled receptors involves a series of molecular events through early and recycling endosomes. The purpose of this work was to study the role of neuron-enriched endosomal protein of 21 kDa (NEEP21) in the recycling process of neurotensin receptors-1 and -2. Here we showed that suppression of NEEP21 expression does not modify the internalization rate of both receptors but strongly inhibited the recycling of the neurotensin receptor-2. In contrast, overexpression of NEEP21 changes the behavior of the neurotensin receptor-1 from a non-recycling to a recycling state. Recycling of the neurotensin receptor-2 involves both the phosphatidylinositol 3-kinase and the recycling endosome pathways, whereas recycling of the neurotensin receptor-1 induced by overexpression of NEEP21 only occurs by the phosphatidylinositol 3-kinase-dependent pathway. Taken together, these results confirm the essential role of NEEP21 in the recycling mechanism and show that this protein acts at the level of early endosomes to promote sorting of receptors toward a recycling pathway.	CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, F-06560 Valbonne, France; Ecole Polytech Fed Lausanne, Fac Sci Vie, CH-1015 Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, Unite Mixte Rech 6097, 660 Route Lucioles, F-06560 Valbonne, France.	mazella@ipmc.cnrs.fr	Mazella, Jean/A-6767-2012					Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hermanns S, 1997, GLIA, V21, P299; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Liang W, 2003, J BIOL CHEM, V278, P39773, DOI 10.1074/jbc.M304482200; Martin S, 2002, J CELL SCI, V115, P165; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	21	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35687	35691		10.1074/jbc.M402751200	http://dx.doi.org/10.1074/jbc.M402751200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15187090	hybrid			2022-12-25	WOS:000223303400066
J	Longo, KA; Wright, WS; Kang, S; Gerin, I; Chiang, SH; Lucas, PC; Opp, MR; MacDougald, OA				Longo, KA; Wright, WS; Kang, S; Gerin, I; Chiang, SH; Lucas, PC; Opp, MR; MacDougald, OA			Wnt10b inhibits development of white and brown adipose tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; BETA-CATENIN; GENE FAMILY; ADAPTIVE THERMOGENESIS; DIABETES-MELLITUS; TRANSGENIC MICE; GROWTH-FACTORS; CELL-GROWTH; ADIPOGENESIS; LIPODYSTROPHY	Wnt is a family of secreted signaling proteins that regulate diverse developmental processes. Activation of canonical Wnt signaling by Wnt10b inhibits differentiation of preadipocytes in vitro. To determine whether Wnt signaling blocks adipogenesis in vivo, we created transgenic mice in which Wnt10b is expressed from the FABP4 promoter. Expression of Wnt10b in adipose impairs development of this tissue throughout the body, with a decline of similar to50% in total body fat and a reduction of similar to60% in weight of epididymal and perirenal depots. FABP4-Wnt10b mice resist accumulation of adipose tissue when fed a high fat diet. Furthermore, transgenic mice are more glucose-tolerant and insulin-sensitive than wild type mice. Expression of Wnt10b from the FABP4 promoter also blocks development of brown adipose tissue. Interscapular tissue of FABP4-Wnt10b mice has the visual appearance of white adipose tissue but expresses neither brown (e.g. uncoupling protein 1) nor white adipocyte markers. Transgenic mice are unable to maintain a core body temperature when placed in a cold environment, providing further evidence that Wnt10b inhibits development of brown adipose tissue. Although food intake is not altered in FABP4-Wnt10b mice, oxygen consumption is decreased. Thus, FABP4-Wnt10b mice on a chow diet gain more weight than controls, largely because of an increase in weight of skin. In summary, inhibition by Wnt10b of white and brown adipose tissue development results in lean mice without lipodystrophic diabetes.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7620 Med Sci 2,1301 E Catherine Dr, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Longo, Kenneth A/A-5631-2010	MacDougald, Ormond/0000-0001-6907-7960; Hahn, Wendy/0000-0002-4374-5876; Opp, Mark/0000-0002-9831-9866; Lucas, Peter/0000-0003-4880-7172	NIDDK NIH HHS [DK51563, DK62876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062876, R01DK051563, R01DK062876] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Feely RS, 2000, EXP GERONTOL, V35, P417, DOI 10.1016/S0531-5565(00)00095-4; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	39	266	286	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35503	35509		10.1074/jbc.M402937200	http://dx.doi.org/10.1074/jbc.M402937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190075	hybrid			2022-12-25	WOS:000223303400044
J	Reuben, PM; Sun, YB; Cheung, HS				Reuben, PM; Sun, YB; Cheung, HS			Basic calcium phosphate crystals activate p44/42 MAPK signal transduction pathway via protein kinase C mu in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; ANGIOTENSIN-II; INDUCTION; ANTISENSE; COLLAGENASE; INHIBITION; GROWTH; OLIGODEOXYNUCLEOTIDES; METALLOPROTEINASE-1	Although basic calcium phosphate (BCP) crystals are common in osteoarthritis, the crystal-induced signal transduction pathways in human fibroblasts have not been fully comprehended. We have previously demonstrated that the induction of matrix metalloproteinases (MMP) 1 and 3 by BCP crystals follows both the calcium-dependent protein kinase C (PKC) pathway and the calcium-independent p44/42 mitogen-activated protein kinase (p44/42 MAPK) pathway. Although we showed that the calcium-dependent PKC pathway was characterized by calcium-dependent PKCalpha, here we show that the calcium-independent p44/42 MAPK pathway is mediated by calcium-independent PKCmu. Inhibition of PKCmu synthesis and activity by antisense oligodeoxynucleotides and H-89 (N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide), respectively, results in the inhibition of p44/42 MAPK activation, thus demonstrating that p44/42 MAPK activity is dependent upon PKCmu. Reverse transcription-polymerase chain reaction and Western blotting also show that inhibition of PKCmu results in the inhibition of MMP-1 and MMP-3 mRNA and protein expression as a result of p44/42 MAPK inhibition. These results now lead us to the conclusion that BCP crystal activation of human fibroblasts follows two pathways: 1) the calcium-dependent PKC pathway characterized by PKCalpha and 2) the calcium-independent p44/42 MAPK pathway mediated by PKCmu, which operate independently leading to an increase in mitogenesis and MMP synthesis and ultimately complementing each other for the efficient regulation of cellular responses to BCP crystal stimulation of human fibroblasts.	Vet Adm Med Ctr, Res Serv, Miami, FL 33125 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33125 USA; Univ Miami, Dept Biomed Engn, Coral Gables, FL 33146 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Miami	Cheung, HS (corresponding author), Vet Adm Med Ctr, Res Serv, 1201 NW 16th St, Miami, FL 33125 USA.	hcheung@med.miami.edu			NIAMS NIH HHS [AR38421-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; Bai G, 2001, OSTEOARTHR CARTILAGE, V9, P416, DOI 10.1053/joca.2000.0407; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Berts A, 1999, MOL PHARMACOL, V55, P296, DOI 10.1124/mol.55.2.296; Brogley MA, 1999, J CELL PHYSIOL, V180, P215, DOI 10.1002/(SICI)1097-4652(199908)180:2<215::AID-JCP9>3.0.CO;2-J; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cheung, 1980, J TISS CULT METHODS, V6, P39, DOI 10.1007/BF01665905; CHEUNG HS, 1993, JOINT CARTILAGE DEGR, P209; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cohen RI, 1996, MOL BRAIN RES, V43, P193, DOI 10.1016/S0169-328X(96)00176-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EVANS RW, 1994, CALCIFIED TISSUE INT, V36, P645; Fleming I, 1998, BIOCHEM J, V333, P719, DOI 10.1042/bj3330719; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HALVERSON PB, 1986, ANN RHEUM DIS, V45, P603, DOI 10.1136/ard.45.7.603; Halverson PB, 1998, OSTEOARTHR CARTILAGE, V6, P324, DOI 10.1053/joca.1998.0131; HALVERSON PB, 2001, ARTHRITIS ALLIED CON, P2371; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; IZANT JG, 1989, CELL MOTIL CYTOSKEL, V14, P81, DOI 10.1002/cm.970140117; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Larocca JN, 1997, J NEUROSCI RES, V50, P743, DOI 10.1002/(SICI)1097-4547(19971201)50:5<743::AID-JNR11>3.0.CO;2-2; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1021, DOI 10.1002/art.1780340812; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Reuben PM, 2002, J BIOL CHEM, V277, P15190, DOI 10.1074/jbc.M200278200; Reuben PM, 2001, CONNECT TISSUE RES, V42, P1, DOI 10.3109/03008200109014244; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROTHENBERG RJ, 1988, AM J PHYSIOL-CELL PH, V23, pC554; Ryan LM, 1999, RHEUM DIS CLIN N AM, V25, P257, DOI 10.1016/S0889-857X(05)70066-1; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUMACHER HR, 1968, ARTHRITIS RHEUM-US, V11, P426, DOI 10.1002/art.1780110308; STEIN CA, 1988, CANCER RES, V48, P2659; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35719	35725		10.1074/jbc.M403406200	http://dx.doi.org/10.1074/jbc.M403406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190081	hybrid			2022-12-25	WOS:000223303400070
J	Tzameli, I; Fang, H; Ollero, M; Shi, H; Hamm, JK; Kievit, P; Hollenberg, AN; Flier, JS				Tzameli, I; Fang, H; Ollero, M; Shi, H; Hamm, JK; Kievit, P; Hollenberg, AN; Flier, JS			Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-GENE-EXPRESSION; ENHANCER BINDING-PROTEIN; PPAR-GAMMA; INSULIN-RESISTANCE; LIPID-METABOLISM; OXIDIZED LDL; FATTY-ACIDS; C/EBP-BETA; ADIPOGENESIS; ALPHA	Peroxisome proliferator-activated receptor-gamma(PPARgamma) is a nuclear hormone receptor that is critical for adipogenesis and insulin sensitivity. Ligands for PPARgamma include some polyunsaturated fatty acids and prostanoids and the synthetic high affinity antidiabetic agents thiazolidinediones. However, the identity of a biologically relevant endogenous PPARgamma ligand is unknown, and limited insight exists into the factors that may regulate production of endogenous PPARgamma ligands during adipocyte development. To address this question, we created a line of 3T3-L1 preadipocytes that carry a beta-galactosidase-based PPARgamma ligand-sensing vector system. In this system, induction of adipogenesis resulted in elevated beta-galactosidase activity that signifies activation of PPARgamma via its ligand-binding domain (LBD) and suggests generation and/or accumulation of a ligand moiety. The putative endogenous ligand appeared early in adipogenesis in response to increases in cAMP, accumulated in the medium, and dissipated later in adipogenesis. Organically extracted and high pressure liquid chromatography-fractionated conditioned media from differentiating cells, but not from mature adipocytes, were enriched in this activity. One or more components within the organic extract activated PPARgamma through interaction with its LBD, induced lipid accumulation in 3T3-L1 cells as efficiently as the differentiation mixture, and competed for binding of rosiglitazone to the LBD of PPARgamma. The active species appears to be different from other PPARgamma ligands identified previously. Our findings suggest that a novel biologically relevant PPARgamma ligand is transiently produced in 3T3-L1 cells during adipogenesis.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flier, JS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Finard 202,330 Brookline Ave, Boston, MA 02215 USA.	jflier@caregroup.harvard.edu	Ollero, Mario/AAJ-3545-2020; Flier, jeffrey/AAG-6223-2019; Ollero, Mario/Q-6147-2018	Ollero, Mario/0000-0003-3590-706X	NIDDK NIH HHS [2P30 DK46200-11, DKR3728082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; de Urquiza AM, 1999, P NATL ACAD SCI USA, V96, P13270, DOI 10.1073/pnas.96.23.13270; Fajas L, 2003, J LIPID RES, V44, P1652, DOI 10.1194/jlr.M300248-JLR200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 2000, AM J RESP CRIT CARE, V161, pS120, DOI 10.1164/ajrccm.161.supplement_1.ltta-24; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lenhard JM, 1997, BIOCHEM PHARMACOL, V54, P801, DOI 10.1016/S0006-2952(97)00229-3; Madsen L, 2003, BIOCHEM J, V375, P539, DOI 10.1042/BJ20030503; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; Takamura T, 2001, EUR J PHARMACOL, V422, P23, DOI 10.1016/S0014-2999(01)01053-6; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; WONG WT, 1992, AM J PHYSIOL, V262, pC91, DOI 10.1152/ajpcell.1992.262.1.C91; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	58	151	175	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36093	36102		10.1074/jbc.M405346200	http://dx.doi.org/10.1074/jbc.M405346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190061	hybrid			2022-12-25	WOS:000223303400111
J	Yakymovych, I; Heldin, CH; Souchelnytskyi, S				Yakymovych, I; Heldin, CH; Souchelnytskyi, S			Smad2 phosphorylation by type I receptor - Contribution of arginine 462 and cysteine 463 in the C terminus of Smad2 for specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; STRUCTURAL BASIS; GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; L3 LOOP; ACTIVATION; KINASE; RECOGNITION; SUBSTRATE; PROTEINS	Transforming growth factor-beta (TGFbeta) is a potent regulator of cell proliferation, differentiation, motility, and apoptosis. TGFbeta binds to and activates serine/threonine kinase receptors that phosphorylate Smad2 and Smad3 intracellular signal transducers at two C-terminal serine residues. Here we show that substitutions of Arg-462 and Cys-463 residues, which are in proximity of the C-terminal serine residues, inhibited TGFbeta type I receptor-dependent phosphorylation of the C-terminal Smad2 peptides and full-length GST-Smad2 proteins in vitro. In vivo, mutation of Arg-462 and Cys-463 inhibited TGFbeta1-stimulated phosphorylation of the C-terminal serine residues in Smad2. Moreover, Smad2 with mutated Arg-462 and Cys-463 was less efficient in activation of the Smad2-responsive activin-responsive element-containing luciferase reporter ARE-luc, as compared with the wild-type protein. Thus, Arg-462 and Cys-463, which are in proximity of the C-terminal serine residues, contribute to recognition and phosphorylation of the C terminus of Smad2 by type I TGFbeta receptor.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011	Souchelnytskyi, Serhiy/0000-0001-8243-9276				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hassel S, 2004, PROTEOMICS, V4, P1346, DOI 10.1002/pmic.200300770; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Yakmovych I, 2001, FASEB J, V15, P553; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u	28	3	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35781	35787		10.1074/jbc.M404377200	http://dx.doi.org/10.1074/jbc.M404377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15210694	hybrid			2022-12-25	WOS:000223303400078
J	Fitzsimons, CP; Monczor, F; Fernandez, N; Shayo, C; Davio, C				Fitzsimons, CP; Monczor, F; Fernandez, N; Shayo, C; Davio, C			Mepyramine, a histamine H-1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCUPANCY MODEL; ANTAGONIST; ACTIVATION; AFFINITY; DESENSITIZATION; PHARMACOLOGY; MECHANISMS; EXPRESSION; TIOTIDINE; CALCIUM	Accurate characterization of the molecular mechanisms of the action of ligands is an extremely important issue for their appropriate research, pharmacological, and therapeutic uses. In view of this fact, the aim of the present work was to investigate the mechanisms involved in the actions of mepyramine at the guinea pig H-1 receptor stably expressed in Chinese hamster ovary cells. We found that mepyramine is able to decrease the basal constitutive activity of the guinea pig H-1 receptor, to bind with high affinity to a G(q/11) protein-coupled form of the receptor and to promote a G protein-coupled inactive state of the H-1 receptor that interferes with the G(q/11)-mediated signaling of the endogenously expressed ATP receptor, as predicted by the Cubic Ternary Complex Model of receptor occupancy. The effect of mepyramine on ATP-induced signaling was specifically neutralized by Galpha(11) overexpression, indicating that mepyramine is able to reduce G protein availability for other non-related receptors associated with the same signaling pathway. Finally, we found a loss of mepyramine efficacy in decreasing basal levels of intracellular calcium at high Galpha(11) expression levels, which can be theoretically explained in terms of high H-1 receptor constitutive activity. The whole of the present work sheds new light on H-1 receptor pharmacology and the mechanisms H-1 receptor inverse agonists could use to exert their observed negative efficacy.	Univ Buenos Aires, Fac Farm & Bioquim, Catedra Fis, Lab Radioisotopos, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, RA-1113 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Davio, C (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Catedra Fis, Lab Radioisotopos, Junin 956,PB, RA-1113 Buenos Aires, DF, Argentina.	cardavio@ffyb.uba.ar		Fitzsimons, Carlos P./0000-0002-1556-2650				Anthes JC, 2002, EUR J PHARMACOL, V449, P229, DOI 10.1016/S0014-2999(02)02049-6; Asghar AUR, 2000, EUR J PHARMACOL, V398, P131, DOI 10.1016/S0014-2999(00)00281-8; Bakker RA, 2000, EUR J PHARMACOL, V387, pR5, DOI 10.1016/S0014-2999(99)00803-1; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Brown GP, 1998, J PHARMACOL EXP THER, V286, P376; CarmanKrzan M, 1997, N-S ARCH PHARMACOL, V355, P431, DOI 10.1007/PL00004965; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; CASALE TB, 1985, BIOCHEM PHARMACOL, V34, P3285, DOI 10.1016/0006-2952(85)90347-8; Chen G, 2000, MOL PHARMACOL, V57, P125; DELEAN A, 1982, MOL PHARMACOL, V22, P290; Dickenson JM, 1998, BRIT J PHARMACOL, V124, P1491, DOI 10.1038/sj.bjp.0701977; DINI S, 1991, AGENTS ACTIONS, V33, P181, DOI 10.1007/BF01993161; Fernandez N, 2002, MOL PHARMACOL, V62, P1506, DOI 10.1124/mol.62.6.1506; Fitzsimons C, 2002, BIOCHEM PHARMACOL, V63, P1785, DOI 10.1016/S0006-2952(02)00975-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATTORI Y, 1991, BRIT J PHARMACOL, V103, P1573, DOI 10.1111/j.1476-5381.1991.tb09829.x; Hill SJ, 1997, PHARMACOL REV, V49, P253; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Kakiuchi M, 1997, JPN J PHARMACOL, V73, P291, DOI 10.1254/jjp.73.291; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LIU YJ, 1992, BRIT J PHARMACOL, V106, P233, DOI 10.1111/j.1476-5381.1992.tb14322.x; MARTIN MW, 1984, J PHARMACOL EXP THER, V230, P424; McLoughlin DJ, 2000, J NEUROCHEM, V74, P347, DOI 10.1046/j.1471-4159.2000.0740347.x; Megson AC, 2001, MOL PHARMACOL, V59, P1012, DOI 10.1124/mol.59.5.1012; Miller TR, 1999, J BIOMOL SCREEN, V4, P249, DOI 10.1177/108705719900400506; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Monczor F, 2003, MOL PHARMACOL, V64, P512, DOI 10.1124/mol.64.2.512; ROBERTSON MJ, 1994, TRENDS PHARMACOL SCI, V15, P364, DOI 10.1016/0165-6147(94)90156-2; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 2003, J PHARMACOL EXP THER, V305, P1104, DOI 10.1124/jpet.103.049619; Shayo C, 2001, MOL PHARMACOL, V60, P1049, DOI 10.1124/mol.60.5.1049; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; TRAIFFORT E, 1994, J NEUROCHEM, V62, P507; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Vauquelin G, 2001, TRENDS PHARMACOL SCI, V22, P343, DOI 10.1016/S0165-6147(00)01739-9; Wade SM, 2001, MOL PHARMACOL, V59, P532, DOI 10.1124/mol.59.3.532; Walsh Garry M, 2002, Expert Opin Drug Saf, V1, P225, DOI 10.1517/14740338.1.3.225; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994; Yakuo I, 2001, PHARMACOL TOXICOL, V89, P171, DOI 10.1111/j.0901-9928.2001.890405.x	45	51	52	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34431	34439		10.1074/jbc.M400738200	http://dx.doi.org/10.1074/jbc.M400738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192105	Green Published, hybrid			2022-12-25	WOS:000223134800044
J	Huang, SC; Jagadeeswaran, R; Liu, ES; Benz, EJ				Huang, SC; Jagadeeswaran, R; Liu, ES; Benz, EJ			Protein 4.1R, a microtubule-associated protein involved in microtubule aster assembly in mammalian mitotic extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRIN-ACTIN-BINDING; CYTOPLASMIC DYNEIN; FUNCTIONAL-CHARACTERIZATION; NONERYTHROID ISOFORM; MESSENGER-RNA; CELL-CYCLE; IN-VITRO; SPINDLE; TUBULIN; ORGANIZATION	Non-erythroid protein 4.1R ( 4.1R) consists of a complex family of isoforms. We have shown that 4.1R isoforms localize at the mitotic spindle/spindle poles and associate in a complex with the mitotic-spindle organization proteins Nuclear Mitotic Apparatus protein ( NuMA), dynein, and dynactin. We addressed the mitotic function of 4.1R by investigating its association with microtubules, the main component of the mitotic spindles, and its role in mitotic aster assembly in vitro. 4.1R appears to partially co-localize with microtubules throughout the mitotic stages of the cell cycle. In vitro sedimentation assays showed that 4.1R isoforms directly interact with microtubules. Glutathione S-transferase (GST) pull-down assays using GST-4.1R fusions and mitotic cell extracts further showed that the association of 4.1R with tubulin results from both the membrane-binding domain and C-terminal domain of 4.1R. Moreover, 4.1R, but not actin, is a mitotic microtubule-associated protein; 4.1R associates with microtubules in the microtubule pellet of the mitotic asters assembled in mammalian cell-free mitotic extract. The organization of microtubules into asters depends on 4.1R in that immunodepletion of 4.1R from the extract resulted in randomly dispersed microtubules. Furthermore, adding a 135-kDa recombinant 4.1R reconstituted the mitotic asters. Finally, we demonstrated that a mitotic 4.1R isoform appears to form a complex in vivo with tubulin and NuMA in highly synchronized mitotic HeLa extracts. Our results suggest that a 135-kDa non-erythroid 4.1R is important to cell division, because it participates in the formation of mitotic spindles and spindle poles through its interaction with mitotic microtubules.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Pediat, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	Huang, SC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, D610,44 Binney St, Boston, MA 02115 USA.	shu-ching_huang@dfci.harvard.edu	Jagadeeswaran, Ramasamy/C-9987-2013	Ramasamy, Jagadeesh/0000-0002-7906-4239	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL061295, R01HL044985, R01HL061295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61295, HL 44985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Chasis JA, 1996, BLOOD, V87, P5324, DOI 10.1182/blood.V87.12.5324.bloodjournal87125324; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1988, BIOCHEM J, V255, P217; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Dionne MA, 2000, J BIOL CHEM, V275, P12346, DOI 10.1074/jbc.275.16.12346; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Haren L, 2002, J CELL SCI, V115, P1815; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HUANG SC, 1992, T ASSOC AM PHYSICIAN, V105, P165; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; Kontrogianni-Konstantopoulos A, 2001, J BIOL CHEM, V276, P20679, DOI 10.1074/jbc.M010581200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 2004, J BIOL CHEM, V279, P27591, DOI 10.1074/jbc.M402813200; Lallena MJ, 1997, J CELL SCI, V110, P239; Mack GJ, 2001, P NATL ACAD SCI USA, V98, P14434, DOI 10.1073/pnas.261371298; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; OCONNOR PM, 1995, CELL CYCLE MAT METHO, P63; Ohara R, 1999, DEV BRAIN RES, V117, P127, DOI 10.1016/S0165-3806(99)00110-8; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra MK, 2003, BLOOD, V101, P4164, DOI 10.1182/blood-2002-06-1796; Perez-Ferreiro CM, 2001, J BIOL CHEM, V276, P44785, DOI 10.1074/jbc.M107369200; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ramez M, 2003, KIDNEY INT, V63, P1321, DOI 10.1046/j.1523-1755.2003.00870.x; Rusan NM, 2002, J CELL BIOL, V158, P997, DOI 10.1083/jcb.200204109; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; Tran YK, 1999, CANCER RES, V59, P35; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Walensky LD, 1999, J NEUROSCI, V19, P6457; Whitehead CM, 1998, J CELL SCI, V111, P2551	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34595	34602		10.1074/jbc.M404051200	http://dx.doi.org/10.1074/jbc.M404051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184364	hybrid			2022-12-25	WOS:000223134800064
J	Lariviere, L; Morera, S				Lariviere, L; Morera, S			Structural evidence of a passive base-flipping mechanism for beta-glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; CRYSTAL-STRUCTURES; RECOGNITION; BINDING; REPAIR; SUBSTRATE; ACID; IDENTIFICATION; KINETICS; EXCISION	beta-Glucosyltransferase (BGT) is a DNA-modifying enzyme and a glycosyltransferase. This inverting enzyme transfers glucose from UDP-glucose to the 5-hydroxymethyl cytosine bases of T4 phage DNA. From previous structural analyses we showed that Asp-100 and Asn-70 were, respectively, the catalytic base and the key residue for specific DNA recognition (Lariviere, L., Gueguen-Chaignon, V., and Morera, S. ( 2003) J. Mol. Biol. 330, 1077 - 1086). Here, we supply biochemical evidence supporting their essential roles in catalysis. We have also shown previously that BGT uses a base-flipping mechanism to access 5-hydroxymethyl cytosine (Lariviere, L., and Morera, S. ( 2002) J. Mol. Biol. 324, 483 - 490). Whether it is an active or a passive process remains unclear, as is the case for all DNA cleaving and modifying enzymes. Here, we report two crystal structures: (i) BGT in complex with a 13-mer DNA containing an A: G mismatch and (ii) BGT in a ternary complex with UDP and an oligonucleotide containing a single central G: C base pair. The binary structure reveals a specific complex with the flipped-out, mismatched adenine exposed to the active site. Unexpectedly, the other structure shows the non-productive binding of an intermediate flipped-out base. Our structural analysis provides clear evidence for a passive process.	CNRS, Unite Propre Rech 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Morera, S (corresponding author), CNRS, Unite Propre Rech 9063, Lab Enzymol & Biochim Struct, Batiment 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	morera@lebs.cnrs-gif.fr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN X, 2001, NUCLEIC ACIDS RES, V19, P3784; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Hosfield DJ, 2001, PROG NUCLEIC ACID RE, V68, P315; JOSSE J, 1962, J BIOL CHEM, V237, P1968; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; Kurzeck J., 2002, THESIS RUHR U BOCHUM; Lariviere L, 2003, J MOL BIOL, V330, P1077, DOI 10.1016/S0022-2836(03)00635-1; Lariviere L, 2002, J MOL BIOL, V324, P483, DOI 10.1016/S0022-2836(02)01091-4; Lariviere L, 2002, ACTA CRYSTALLOGR D, V58, P1484, DOI 10.1107/S0907444902012969; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESLIE AGW, 1992, JOINT CCP4 ESRF EAMC, V26; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Morera S, 2001, J MOL BIOL, V311, P569, DOI 10.1006/jmbi.2001.4905; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pasternack LB, 1996, NUCLEIC ACIDS RES, V24, P2740, DOI 10.1093/nar/24.14.2740; Quevillon-Cheruel S, 2003, J SYNCHROTRON RADIAT, V10, P4, DOI 10.1107/S0909049502017284; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wibley JEA, 2003, MOL CELL, V11, P1647, DOI 10.1016/S1097-2765(03)00235-1; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200	40	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34715	34720		10.1074/jbc.M404394200	http://dx.doi.org/10.1074/jbc.M404394200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15178685	hybrid			2022-12-25	WOS:000223134800077
J	Ruiz, A; Munoz, I; Serrano, R; Gonzalez, A; Simon, E; Arino, J				Ruiz, A; Munoz, I; Serrano, R; Gonzalez, A; Simon, E; Arino, J			Functional characterization of the Saccharomyces cerevisiae VHS3 gene - A regulatory subunit of the Ppz1 protein phosphatase with novel, phosphatase-unrelated functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PSEUDOHYPHAL DIFFERENTIATION; SALT TOLERANCE; INVASIVE GROWTH; MOLECULAR CHARACTERIZATION; MOONLIGHTING PROTEINS; SIGNAL-TRANSDUCTION; SURFACE FLOCCULIN; ION HOMEOSTASIS; FISSION YEAST	The yeast gene VHS3 (YOR054c) has been recently identified as a multicopy suppressor of the G(1)/S cell cycle blockade of a conditional sit4 and hal3 mutant. Vhs3 is structurally related to Hal3, a negative regulatory subunit of the Ser/Thr protein phosphatase Ppz1 important for cell integrity, salt tolerance, and cell cycle control. Phenotypic analyses using vhs3 mutants and overexpressing strains clearly show that Vhs3 has functions reminiscent to those of Hal3 and contrary to those of Ppz1. Mutation of Vhs3 His(459), equivalent to the supposedly functionally relevant His(90) in the plant homolog AtHal3a, did not affect Vhs3 functions mentioned above. Similarly to Hal3, Vhs3 binds in vivo to the C-terminal catalytic moiety of Ppz1 and inhibits in vitro its phosphatase activity. Therefore, our results indicate that Vhs3 plays a role as an inhibitory subunit of Ppz1. We have found that the vhs3 and hal3 mutations are synthetically lethal. Remarkably, lethality is not suppressed by deletion of PPZ1, PPZ2, or both phosphatase genes, indicating that it is not because of an excess of Ppz phosphatase activity. Furthermore, a Vhs3 version carrying the H459A mutation did not rescue the synthetically lethal phenotype. A conditional vhs3 tetO: HAL3 double mutant displays, in the presence of doxycycline, a flocculation phenotype that is dependent on the presence of Flo8 and Flo11. These results indicate that, besides its role as Ppz1 inhibitory subunit, Vhs3 ( and probably Hal3) might have important Ppz-independent functions.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed 5, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Zhang, Ning/F-1387-2014; González, Asier/A-7064-2012; Arino, Joaquin/D-3756-2011; Ruiz, Amparo/AAZ-2317-2021	Arino, Joaquin/0000-0002-6774-2987; Ruiz, Amparo/0000-0002-3947-4540; Munoz Munoz, Ivan/0000-0002-1606-5445; Arino Carmona, Joaquin/0000-0002-0390-4270				ADAMS A, 1997, METHODS YEAST GENETI, P147; Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Arino J, 2002, EUR J BIOCHEM, V269, P1072, DOI 10.1046/j.0014-2956.2002.02753.x; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bony M, 1998, YEAST, V14, P25, DOI 10.1002/(SICI)1097-0061(19980115)14:1<25::AID-YEA197>3.3.CO;2-3; Calero F, 2000, J BACTERIOL, V182, P394, DOI 10.1128/JB.182.2.394-399.2000; Clotet J, 1999, MOL CELL BIOL, V19, P2408; Clotet J, 1996, J BIOL CHEM, V271, P26349, DOI 10.1074/jbc.271.42.26349; Davydenko SG, 2004, YEAST, V21, P463, DOI 10.1002/yea.1063; de Nadal E, 1999, J BACTERIOL, V181, P6456, DOI 10.1128/JB.181.20.6456-6462.1999; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; de Nadal E, 2001, J BIOL CHEM, V276, P14829, DOI 10.1074/jbc.M010824200; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Gagiano M, 2003, MOL MICROBIOL, V47, P119, DOI 10.1046/j.1365-2958.2003.03247.x; Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1016/S1567-1356(02)00133-2; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Garcia-Gimeno MA, 2003, J BIOL CHEM, V278, P47744, DOI 10.1074/jbc.M306157200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Kuchin S, 2002, MOL CELL BIOL, V22, P3994, DOI 10.1128/MCB.22.12.3994-4000.2002; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Lambrechts MG, 1996, P NATL ACAD SCI USA, V93, P8419, DOI 10.1073/pnas.93.16.8419; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LIU HP, 1992, GENETICS, V132, P665; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Munoz I, 2003, YEAST, V20, P157, DOI 10.1002/yea.938; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; Pan XW, 2000, CURR OPIN MICROBIOL, V3, P567, DOI 10.1016/S1369-5274(00)00142-9; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; POSAS F, 1992, J BIOL CHEM, V267, P11734; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Ruiz A, 2003, EUKARYOT CELL, V2, P937, DOI 10.1128/EC.2.5.937-948.2003; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TRECO DA, 1998, CURRENT PROTOCOLS MO; Venturi GM, 2000, GENETICS, V155, P69; Verstrepen KJ, 2003, APPL MICROBIOL BIOT, V61, P197, DOI 10.1007/s00253-002-1200-8; Vissi E, 2001, YEAST, V18, P115, DOI 10.1002/1097-0061(20010130)18:2<115::AID-YEA653>3.0.CO;2-G; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Williams-Hart T, 2002, GENETICS, V160, P1423; Yenush L, 2002, EMBO J, V21, P920, DOI 10.1093/emboj/21.5.920; Zhang NS, 2003, GENE, V303, P121, DOI 10.1016/S0378-1119(02)01142-3; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	61	37	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34421	34430		10.1074/jbc.M400572200	http://dx.doi.org/10.1074/jbc.M400572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15192104	hybrid			2022-12-25	WOS:000223134800043
J	Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y				Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y			Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference	ONCOGENE			English	Article						gene therapy; melanoma; lentiviral vector; BRAF; RNAi; MAPK	GENE-EXPRESSION; HAIRPIN RNAS; BETA-CATENIN; T-CELLS; INTEGRIN; SUPPRESSION; MODULATION; ACTIVATION; MUTATIONS; DELIVERY	Oncogenic mutations of molecules involved in the mitogen-activated protein kinase (MAPK) pathways provide signals mediating both tumor growth and invasion in various cancers including melanomas. BRAF somatic mutations, found in 66% of melanomas, have NIH3T3 transforming ability with the elevated kinase activity in vitro. We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild type or the most frequently mutated form of BRAF (V599E) in 10 melanoma cell lines, and found that RNAi inhibited the growth of most melanoma cell lines in vitro as well as in vivo, which was accompanied by decrease of both BRAF protein and ERK phosphorylation. Interestingly, the mutated BRAF (V599E)-specific siRNA inhibited the growth and MAPK activity of only melanoma cell lines with this mutation. Furthermore, BRAF RNAi inhibited matrigel invasion of melanoma cells accompanied with a decrease of matrix metalloproteinase activity and beta(1) integrin expression. These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype of melanoma cells through the MAPK activation and is an attractive molecular target for melanoma treatment. The lentivirus-mediated RNAi specific for oncogenic mutations may be a powerful technique for gene therapy of cancer.	Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; RIKEN, Tsukuba Inst, BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki 3050074, Japan	Keio University; University of Tokyo; RIKEN	Kawakami, Y (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yutakawa@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Miyoshi, Hiroyuki/G-9808-2013; Miyagishi, Makoto/L-8174-2016; Sumimoto, Hidetoshi/AAE-6873-2020	Kawakami, Yutaka/0000-0003-4836-2855; Miyagishi, Makoto/0000-0001-7654-3616; 				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Genersch E, 2000, J CELL SCI, V113, P4319; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hingorani SR, 2003, CANCER RES, V63, P5198; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIYAGISHI M, IN PRESS J GENE MED; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NATALI PG, 1993, INT J CANCER, V54, P68, DOI 10.1002/ijc.2910540112; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Petitclerc E, 1999, CANCER RES, V59, P2724; Puyraimond A, 1999, J CELL SCI, V112, P1283; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Satyamoorthy K, 2003, CANCER RES, V63, P756; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vaisanen A, 1999, J PATHOL, V188, P56; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	140	158	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6031	6039		10.1038/sj.onc.1207812	http://dx.doi.org/10.1038/sj.onc.1207812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208655				2022-12-25	WOS:000223261000002
J	Bowman, EJ; Graham, LA; Stevens, TH; Bowman, BJ				Bowman, EJ; Graham, LA; Stevens, TH; Bowman, BJ			The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTEOLIPID SUBUNIT; PROTON PUMP; YEAST; GENE; SYNTHASE; BAFILOMYCINS; INHIBITORS; MUTATIONS; IDENTIFICATION	The vacuolar H+-ATPase is inhibited with high specificity and potency by bafilomycin and concanamycin, macrolide antibiotics with similar structures. We previously reported that mutation at three residues in subunit c of the vacuolar ATPase from Neurospora crassa conferred strong resistance to bafilomycin but little or no resistance to concanamycin ( Bowman, B. J., and Bowman, E. J. ( 2002) J. Biol. Chem. 277, 3965 - 3972). We have identified additional mutated sites in subunit c that confer resistance to bafilomycin. Furthermore, by subjecting a resistant mutant to a second round of mutation we isolated strains with increased resistance to both bafilomycin and concanamycin. In all of these strains the second mutation is also in subunit c, suggesting it forms at least part of the concanamycin binding site. Site-directed mutagenesis of the gene encoding subunit c in Saccharomyces cerevisiae showed that single mutations in each of the residues identified in one of the double mutants of N. crassa conferred resistance to both bafilomycin and concanamycin. Mutations at the corresponding sites in the VMA11 and VMA16 genes of S. cerevisiae, which encode the c' and c" subunits, did not confer resistance to the drugs. In all, nine residues of subunit c have been implicated in drug binding. The positions of these residues support a model in which the drug binding site is a pocket formed by helices 1, 2, and 4. We hypothesize that the drugs inhibit by preventing the rotation of the c subunits.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of California System; University of California Santa Cruz; University of Oregon	Bowman, BJ (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	bowman@biology.ucsc.edu		Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R25GM058903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006, GM58903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1988, J BIOL CHEM, V263, P8796; Beutler JA, 2003, CURR MED CHEM, V10, P787, DOI 10.2174/0929867033457827; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2000, J BIOL CHEM, V275, P167, DOI 10.1074/jbc.275.1.167; Bowman EJ, 2003, J BIOL CHEM, V278, P44147, DOI 10.1074/jbc.M306595200; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1997, BIOMEMBRANE, P861; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Farina C, 2001, FARMACO, V56, P113, DOI 10.1016/S0014-827X(01)01013-8; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Harrison M, 2003, J BIOENERG BIOMEMBR, V35, P337, DOI 10.1023/A:1025728915565; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Shen RC, 2003, J AM CHEM SOC, V125, P7889, DOI 10.1021/ja0352350; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	48	108	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33131	33138		10.1074/jbc.M404638200	http://dx.doi.org/10.1074/jbc.M404638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180988	hybrid			2022-12-25	WOS:000223039700015
J	Hor, S; Pirzer, H; Dumoutier, L; Bauer, F; Wittmann, S; Sticht, H; Renauld, JC; Malefyt, RD; Fickenscher, H				Hor, S; Pirzer, H; Dumoutier, L; Bauer, F; Wittmann, S; Sticht, H; Renauld, JC; Malefyt, RD; Fickenscher, H			The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HERPESVIRUS SAIMIRI; INTERFERON-GAMMA; INDUCIBLE FACTOR; CUTTING EDGE; MELANOMA DIFFERENTIATION; GROWTH TRANSFORMATION; IL-TIF; CYTOKINE; IL-10	The cellular members of the interleukin-10 (IL-10) cytokine family share sequence homology with IL-10, whereas their sites of expression and their functions are divergent. One of these factors, AK155 or IL-26, was discovered because of its overexpression in human T lymphocytes after growth transformation by the simian rhadinovirus herpesvirus saimiri. In addition, the gene is transcribed in various types of primary and immortalized T-cells. Here we describe epithelial cells, namely colon carcinoma cells and keratinocytes, as targets of this T-cellular lymphokine. Purified recombinant IL-26 induced the rapid phosphorylation of the signal transducer and activator of transcription factors 1 and 3. As a result, secretion of IL-10 and IL-8, as well as cell surface expression of CD54 were enhanced. Moreover, we show that the IL-26 protein binds to heparin, is released from the cell surface, and can be functionally inhibited by heparin. The sensitivity to recombinant IL-26 of various cell lines strictly correlated with the expression of the long chain of the IL-20 receptor. Because blocking antibodies against either the short chain of the IL-10 receptor or the long chain of the IL-20 receptor inhibited IL-26-dependent signal transduction, and transient expression of these receptor chains induced IL-26 responsivity in non-sensitive cells, we propose that the IL-20 receptor 1 and IL-10 receptor 2 chains participate in forming the IL-26 receptor. Targeting epithelial cells, the T-cell lymphokine IL-26 is likely to play a role in local mechanisms of mucosal and cutaneous immunity.	Heidelberg Univ, Dept Virol, D-69120 Heidelberg, Germany; Cambridge Inst Med Res, Cambridge CB2 2XY, England; Catholic Univ Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Erlangen Nurnberg, Bioinformat Unit, Dept Biochem, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; DNAX Res Inst Mol & Cellular Biol Inc, Dept Pharmacol, Palo Alto, CA 94304 USA	Ruprecht Karls University Heidelberg; University of Cambridge; Ludwig Institute for Cancer Research; Universite Catholique Louvain; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Fickenscher, H (corresponding author), Heidelberg Univ, Dept Virol, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	helmut.fickenscher@med.uni-heidelberg.de	Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010; Renauld, Jean-Christophe/B-7268-2012	Fickenscher, Helmut/0000-0003-0043-1153; Sticht, Heinrich/0000-0001-5644-045X; de Waal Malefyt, Rene/0000-0002-2663-383X; Dumoutier, Laure/0000-0002-6645-684X; Renauld, Jean-Christophe/0000-0003-1736-2131				BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2002, EUR CYTOKINE NETW, V13, P5; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Dumoutier L, 2000, GENES IMMUN, V1, P488, DOI 10.1038/sj.gene.6363716; Fernandez-Botran R, 1999, CYTOKINE, V11, P313, DOI 10.1006/cyto.1998.0438; Fickenscher H, 2002, METHOD MICROBIOL, V32, P657; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Goris A, 2002, GENES IMMUN, V3, P470, DOI 10.1038/sj.gene.6363913; Goris A, 2001, GENES IMMUN, V2, P284, DOI 10.1038/sj.gene.6363772; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knappe A, 1997, J VIROL, V71, P9124, DOI 10.1128/JVI.71.12.9124-9133.1997; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Liao YC, 2002, J IMMUNOL, V169, P4288, DOI 10.4049/jimmunol.169.8.4288; LIU Y, 1994, J IMMUNOL, V152, P1821; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; Sheikh F, 2004, J IMMUNOL, V172, P2006, DOI 10.4049/jimmunol.172.4.2006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	45	110	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33343	33351		10.1074/jbc.M405000200	http://dx.doi.org/10.1074/jbc.M405000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178681	hybrid			2022-12-25	WOS:000223039700041
J	Xu, B; Koenig, RJ				Xu, B; Koenig, RJ			An RNA-binding domain in the thyroid hormone receptor enhances transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTORS; RESPONSE ELEMENT; ESCHERICHIA-COLI; GENE-EXPRESSION; MESSENGER-RNA; COACTIVATOR; PROTEINS; PURIFICATION; SEQUENCES; COMPLEX	Thyroid hormone plays important roles in development, differentiation, and metabolic homeostasis by binding to nuclear thyroid hormone receptors, which regulate target gene expression by interacting with DNA response elements and coregulatory proteins. We show that thyroid hormone receptors also are single-stranded RNA binding proteins and that this binding is functionally significant. By using a series of deletion mutants, a novel RNA-binding domain was localized to a 41-amino acid segment of thyroid hormone receptor alpha1 between the second zinc finger and the ligand-binding domain. This RNA-binding domain was necessary and sufficient for thyroid hormone receptor binding to the steroid receptor RNA activator (SRA). Although SRA does not bind directly to steroid receptors, it has been identified as a steroid receptor coactivator, and was thought not to be a coactivator for thyroid hormone receptors. However, transfection studies revealed that SRA enhances thyroid hormone induction of appropriate reporter genes and that the thyroid hormone receptor RNA-binding domain is important for this enhancement. We conclude that thyroid hormone receptors bind RNA through a novel domain and that the interaction of this domain with SRA, and perhaps other RNAs, enhances thyroid hormone receptor function.	Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol Diabet & Metab, 5560 MSRB-2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	rkoenig@umich.edu			NIDDK NIH HHS [DK44155, P60 DK20572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155, P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Glass CK, 2000, GENE DEV, V14, P121; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Wu YF, 2001, J BIOL CHEM, V276, P3929, DOI 10.1074/jbc.M006743200; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	31	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33051	33056		10.1074/jbc.M404930200	http://dx.doi.org/10.1074/jbc.M404930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15180993	hybrid			2022-12-25	WOS:000223039700005
J	Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM				Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM			ER beta exerts multiple stimulative effects on human breast carcinoma cells	ONCOGENE			English	Article						breast carcinoma; estrogen receptor; matrix metalloproteinases (MMPs)	ESTROGEN-RECEPTOR-BETA; MESSENGER-RNA EXPRESSION; MATRIX METALLOPROTEINASE-2; METASTATIC PHENOTYPE; ALPHA; GENE; PROLIFERATION; TRANSFECTION; PROTEINASE; INVASION	Recent studies of ERs in breast cancer have demonstrated the existence of ERbeta in addition to ERalpha. Some clinical data indicated that ERbeta had prognostic value for patient's survival, which suggested that ERbeta plays a key role in breast cancer development and,metastasis. To test this hypothesis, we generated an ERbeta high-expression cell line by reintroduced human ERbeta cDNA into MDA-MB-435 cells. We demonstrated that ERbeta exerted multiple tumor-stimulative effects on human breast carcinoma cells both in vivo and in vitro. In in vitro studies, ERbeta was able to increase the proliferation and invasion of MDA-MB-435 cells significantly, while these effects were totally estradiol independent. Also, this stimulation was characterized by downregulation of p2l and upregulation of MMP-9, as well as transcriptional factor Est-1. In in vivo studies, we also demonstrated that ERbeta-transfected MDA-MB-435 cells grew much faster and had more pulmonary metastasis than mock or wild-type cells in nude mice. In ERbeta-transfected MDA-MB-435 xenografts, ERbeta caused significant reduction in p2l protein levels. Similar effects of ERbeta on MMP-9 and Ets-1 expression noted in vitro studies were also observed in the in vivo studies. These in vitro and in vivo studies indicated that ERbeta exerted multiple stimulative effects on breast cancer development and metastasis.	Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China; Fudan Univ, Dept Surg, Canc Hosp, Inst Canc, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Fudan University	Ding, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	jding@mail.shcnc.ac.cn; zhimingshao@yahoo.com	LIU, GANG/AAR-4584-2021	LIU, GANG/0000-0001-6620-176X				Albini A, 1998, Pathol Oncol Res, V4, P230; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bhat RA, 1998, J STEROID BIOCHEM, V67, P233, DOI 10.1016/S0960-0760(98)00115-0; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; Dotzlaw H, 1999, CANCER RES, V59, P529; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hu YF, 1998, INT J ONCOL, V12, P1225; Irwin JC, 1996, J CLIN INVEST, V97, P438, DOI 10.1172/JCI118433; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1998, CANCER RES, V58, P3197; Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Shao ZM, 2002, INT J CANCER, V98, P234, DOI 10.1002/ijc.10183; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sillem M, 1999, EUR J GYNAECOL ONCOL, V20, P367; Tonetti DA, 2003, J STEROID BIOCHEM, V87, P47, DOI 10.1016/j.jsbmb.2003.07.003; Urquidi V, 2002, CLIN CANCER RES, V8, P61; vanGolen KL, 1996, CLIN EXP METASTAS, V14, P95, DOI 10.1007/BF00121206; Wen XF, 2002, ONCOL REP, V9, P937	32	63	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5799	5806		10.1038/sj.onc.1207765	http://dx.doi.org/10.1038/sj.onc.1207765			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208676				2022-12-25	WOS:000222629800009
J	Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E				Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E			Strict regulation of CAIX(G250/MN) by HIF-1 alpha in clear cell renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; G250/CAIX; gene regulation; hypoxia; von Hippel-Lindau	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARBONIC-ANHYDRASE-IX; TRANSCRIPTIONAL REGULATION; NORMAL KIDNEY; DNA-BINDING; EXPRESSION; GENE; PROTEIN; CANCER; IDENTIFICATION	Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss of functional von Hippel-Lindau (VHL) protein and high, homogeneous expression of the G250(MN) protein, an isoenzyme of the carbonic anhydrase family. High expression of G250(MN) is found in all ccRCCs, but not in most normal tissues, including normal human kidney. We specifically studied the mechanism of transcriptional regulation of the CAIX(G250) gene in RCC. Previous studies identified Sp1 and hypoxia-inducible factor (HIF) as main regulatory transcription factors of G250(MN) in various non-RCC backgrounds. However, G250(MN) regulation in RCC has not been studied and may be differently regulated in view of the HIF accumulation under normoxic conditions due to VHL mutations. Transient transfection of different G250(MN) promoter constructs revealed strong promoter activity in G250(MN) -positive RCC cell lines, but no activity in G250(MN) -negative cell lines. DNase-I footprint and handshift analysis demonstrated that Sp1 and HIF-1alpha proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX promoter activity, indicating their critical importance for the activation of G250 expression in RCC. A close correlation between HIF-1alpha expression and G250(MN) expression was observed. In contrast, no relationship between HIF-2alpha expression and G250(MN) was seen. The participation of cofactor CBP/p300 in the regulation of G250 transcription was shown. In conclusion, HIF-1alpha and Sp1, in combination with CBP/p300, are crucial elements for G250(MN) expression in ccRCC, and CAIX(G250) can be regarded as a unique HIF-1alpha: target gene in ccRCC.	Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Oosterwijk, E (corresponding author), Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, 190-RT NCMLS,POB 9101, NL-6500 HB Nijmegen, Netherlands.	e.oosterwijk@uro.umcn.nl	Verhaegh, Gerald/L-4708-2015; de Weijert, Mirjam/F-3192-2016; Schalken, Jack A/B-1277-2014; Oosterwijk, Egbert/P-5466-2014	Verhaegh, Gerald/0000-0003-0227-2280; Schalken, Jack A/0000-0001-8274-7797; 				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beasley NJP, 2001, CANCER RES, V61, P5262; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Bui MHT, 2003, CLIN CANCER RES, V9, P802; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; EBERT T, 1990, CANCER RES, V50, P5531; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Grabmaier K, 2000, INT J CANCER, V85, P865, DOI 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Kaanders JHAM, 2002, CANCER RES, V62, P7066; Kaluz S, 1999, J BIOL CHEM, V274, P32588, DOI 10.1074/jbc.274.46.32588; Kaluz S, 2003, CANCER RES, V63, P917; Kaluzova M, 2001, BIOCHEM J, V359, P669, DOI 10.1042/0264-6021:3590669; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Loncaster JA, 2001, CANCER RES, V61, P6394; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; OOSTERWIJK E, 1986, INT J CANCER, V38, P489, DOI 10.1002/ijc.2910380406; Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J, 2001, MOL CLONING LAB MANU; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Uemura H, 1999, BRIT J CANCER, V81, P741, DOI 10.1038/sj.bjc.6690757; Verhaegh GW, 2000, J BIOL CHEM, V275, P37496, DOI 10.1074/jbc.M006293200; Vet JAM, 1998, AM J CLIN PATHOL, V110, P647, DOI 10.1093/ajcp/110.5.647; Wiesener MS, 2001, CANCER RES, V61, P5215; Wykoff CC, 2000, CANCER RES, V60, P7075	36	143	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5624	5631		10.1038/sj.onc.1207764	http://dx.doi.org/10.1038/sj.onc.1207764			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184875				2022-12-25	WOS:000222629500007
J	Eissing, T; Conzelmann, H; Gilles, ED; Allgower, F; Bullinger, E; Scheurich, P				Eissing, T; Conzelmann, H; Gilles, ED; Allgower, F; Bullinger, E; Scheurich, P			Bistability analyses of a caspase activation model for receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CYTOCHROME-C; CATALYTIC-PROPERTIES; SIGNALING PATHWAYS; POSITIVE-FEEDBACK; IAP PROTEINS; CELL-DEATH; INHIBITOR; COMPLEX; MITOCHONDRIA	Apoptosis is an important physiological process crucially involved in development and homeostasis of multicellular organisms. Although the major signaling pathways have been unraveled, a detailed mechanistic understanding of the complex underlying network remains elusive. We have translated here the current knowledge of the molecular mechanisms of the death-receptor-activated caspase cascade into a mathematical model. A reduction down to the apoptotic core machinery enables the application of analytical mathematical methods to evaluate the system behavior within a wide range of parameters. Using parameter values from the literature, the model reveals an unstable status of survival indicating the need for further control. Based on recent publications we tested one additional regulatory mechanism at the level of initiator caspase activation and demonstrated that the resulting system displays desired characteristics such as bistability. In addition, the results from our model studies allowed us to reconcile the fast kinetics of caspase 3 activation observed at the single cell level with the much slower kinetics found at the level of a cell population.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Stuttgart, Inst Syst Theory Engn, D-70550 Stuttgart, Germany; Univ Stuttgart, Inst Syst Dynam & Control, D-70550 Stuttgart, Germany; Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany	University of Stuttgart; University of Stuttgart; University of Stuttgart; Max Planck Society	Scheurich, P (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Peter.Scheurich@izi.uni-stuttgart.de	Allgöwer, Frank/F-3909-2011; Bullinger, Eric/B-6772-2008	Allgöwer, Frank/0000-0002-3702-3658; Bullinger, Eric/0000-0002-8889-8286; Eissing, Thomas/0000-0003-4378-3423				Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ditzel M, 2002, TRENDS CELL BIOL, V12, P449, DOI 10.1016/S0962-8924(02)02366-8; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P768, DOI 10.1038/77589; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Krippner-Heidenreich A, 2002, J BIOL CHEM, V277, P44155, DOI 10.1074/jbc.M207399200; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Luo KQ, 2003, BIOCHEM BIOPH RES CO, V304, P217, DOI 10.1016/S0006-291X(03)00559-X; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tyas L, 2000, EMBO REP, V1, P266, DOI 10.1093/embo-reports/kvd050; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; [No title captured]	46	225	228	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36892	36897		10.1074/jbc.M404893200	http://dx.doi.org/10.1074/jbc.M404893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15208304	Green Published, hybrid			2022-12-25	WOS:000223453600091
J	Ghosh, AK; Reddi, AL; Rao, NL; Duan, L; Band, V; Band, H				Ghosh, AK; Reddi, AL; Rao, NL; Duan, L; Band, V; Band, H			Biochemical basis for the requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation of a target tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; PROTOONCOGENE C-CBL; NEGATIVE REGULATOR; T-CELLS; PHOSPHORYLATION SITE; MEDIATED UBIQUITINYLATION; RECIPROCAL REGULATION; SIGNAL-TRANSDUCTION	Members of the Cbl family of ubiquitin ligases have emerged as crucial negative regulators of tyrosine kinase signaling. These proteins preferentially interact with and target activated tyrosine kinases for ubiquitinylation, thereby facilitating the lysosomal sorting of receptor tyrosine kinases or proteasomal degradation of nonreceptor tyrosine kinases. Recent work has indicated a crucial role of the target kinase activity in Cbl-dependent ubiquitinylation and degradation, but the biochemical basis for this requirement is not understood. Here, we have used the Src-family kinase Fyn, a well characterized Cbl target, to address this issue. Using defined Fyn mutants, we demonstrate that the kinase activity of Fyn is crucial for its Cbl-dependent ubiquitinylation and degradation, but a low level of ubiquitinylation and degradation of kinase-inactive Fyn mutants was consistently observed. Mutational induction of an open conformation enhanced the susceptibility of kinase-active Fyn to Cbl but was insufficient to promote the ubiquitinylation and degradation of kinase-inactive Fyn. Notably, the Cbl-dependent degradation of Fyn did not require the Fyn-mediated phosphorylation of Cbl. Finally, we show that the major determinant of the susceptibility of Fyn protein to Cbl-dependent ubiquitinylation and degradation is the extent to which it physically associates with Cbl; kinase activity of Fyn serves as a critical determinant to promote its association with Cbl, which we demonstrate is mediated by multiple protein-protein interactions. Our results strongly suggest that promotion of association with Cbl is the primary mechanism by which the kinase activity of the targets of Cbl contributes to their susceptibility to Cbl.	Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare Res Inst, Dept Med,Div Mol Oncol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare Res Inst, Dept Med,Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60201 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, H (corresponding author), ENH Res Inst, 1001 Univ Pl, Evanston, IL 60201 USA.	h-band@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA087986, R01CA070195, R01CA099900, R01CA076118, R01CA099163, R01CA081076] Funding Source: NIH RePORTER; NCI NIH HHS [CA99163, CA 99900, CA 87986, CA 76118, CA 81076, CA 70195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kitazawa H, 1998, J NEUROPHYSIOL, V79, P137, DOI 10.1152/jn.1998.79.1.137; Klapper LN, 2000, CANCER RES, V60, P3384; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miura-Shimura Y, 2003, J BIOL CHEM, V278, P38495, DOI 10.1074/jbc.M305656200; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Molinero LL, 2003, J LEUKOCYTE BIOL, V73, P815, DOI 10.1189/jlb.0602329; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; RAO N, 2002, SIGNAL TRANSDUCTION, V1, P29; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Standaert ML, 2002, ENDOCRINOLOGY, V143, P1705, DOI 10.1210/en.143.5.1705; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	82	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36132	36141		10.1074/jbc.M404189200	http://dx.doi.org/10.1074/jbc.M404189200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15208330	hybrid			2022-12-25	WOS:000223303400115
J	Otto, VI; Schurpf, T; Folkers, G; Cummings, RD				Otto, VI; Schurpf, T; Folkers, G; Cummings, RD			Sialylated complex-type N-glycans enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; GOLGI VESICLE MEMBRANES; LINKED OLIGOSACCHARIDES; CEREBROSPINAL-FLUID; GLYCOSYLATION SITES; CIRCULATING ICAM-1; ENDOTHELIAL-CELLS; MUTANT DEFICIENT; INTERFERON-GAMMA	Intercellular adhesion molecule-1 (ICAM-1) occurs as both a membrane and a soluble, secreted glycoprotein (sICAM-1). ICAM-1 on endothelial cells mediates leukocyte adhesion by binding to leukocyte function associated antigen-1 (LFA-1) and macrophage antigen-1 (Mac-1). Recombinant mouse sICAM-1 induces the production of macrophage inflammatory protein-2 (MIP-2) in mouse astrocytes by a novel LFA-1- and Mac-1-independent mechanism. Here we showed that N-glycan structures of sICAM-1 influence its ability to induce MIP-2 production. sICAM-1 expressed in Chinese hamster ovary (CHO) cells was a more potent inducer of MIP-2 production than sICAM-1 expressed in HEK 293 cells, suggesting that post-translational modification of sICAM-1 could influence its signaling activity. To explore the roles of glycosylation in sICAM-1 activity, we expressed sICAM-1 in mutant CHO cell lines differing in glycosylation, including Lec2, Lec8, and Lec1 as well as in CHO cells cultured in the presence of the alpha-mannosidase-I inhibitor kifunensine. Signaling activity of sICAM-1 lacking sialic acid was reduced 3-fold compared with sICAM-1 from CHO cells. The activity of sICAM-1 lacking both sialic acid and galactose was reduced 12-fold, whereas the activity of sICAM-1 carrying only high mannose-type N-glycans was reduced 12-26-fold. sICAM-1 glycoforms carrying truncated glycans retained full ability to bind to LFA-1 on leukocytes. Thus, sialylated and galactosylated complex-type N-glycans strongly enhanced the ability of sICAM-1 to induce MIP-2 production in astrocytes but did not alter its binding to LFA-1 on leukocytes. Glycosylation could therefore serve as a means to regulate specifically the signaling function of sICAM-1 in vivo.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8057 Zurich, Switzerland	University of Oklahoma System; University of Oklahoma Health Sciences Center; Swiss Federal Institutes of Technology Domain; ETH Zurich	Otto, VI (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	vivianne.otto@pharma.ethz.ch	Schürpf, Thomas/E-7380-2012	Otto, Vivianne/0000-0002-1157-0186; Folkers, Gerd/0000-0002-3620-705X; Schurpf, Thomas/0000-0003-3023-1136	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI48075] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLANTYNE CM, 1989, NUCLEIC ACIDS RES, V17, P5853, DOI 10.1093/nar/17.14.5853; BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; Bloom JW, 1996, BIOCHEMISTRY-US, V35, P1856, DOI 10.1021/bi952354m; Bragonzi A, 2000, BBA-GEN SUBJECTS, V1474, P273, DOI 10.1016/S0304-4165(00)00023-4; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Greenwood J, 2002, VASC PHARMACOL, V38, P315, DOI 10.1016/S1537-1891(02)00199-4; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377, DOI 10.1152/ajpgi.1998.275.2.G377; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTIN S, 1993, ANTIMICROB AGENTS CH, V37, P1278, DOI 10.1128/AAC.37.6.1278; Massa PT, 1996, J NEUROCHEM, V67, P1831; MCCABE SM, 1993, CELL IMMUNOL, V150, P364, DOI 10.1006/cimm.1993.1204; MCEVER RP, 1997, J CLIN INVEST, V100, P97; MEYER DM, 1995, J IMMUNOL, V155, P3578; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; NEMANSKY M, 1995, EUR J BIOCHEM, V227, P880, DOI 10.1111/j.1432-1033.1995.tb20214.x; Nyame AK, 2002, J PARASITOL, V88, P890, DOI 10.1645/0022-3395(2002)088[0890:DEOLFL]2.0.CO;2; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; PLOEGH HL, 2002, CURRENT PROTOCOLS PR; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; Rossi P, 2002, BIOCHEM CELL BIOL, V80, P41, DOI 10.1139/o01-209; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shrikant P, 1996, J IMMUNOL, V157, P1819; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STANLEY P, 1985, MOL CELL BIOL, V5, P1204, DOI 10.1128/MCB.5.6.1204; Stanley P, 2000, BIOCHEM J, V351, P79, DOI 10.1042/0264-6021:3510079; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; WINZLER R J, 1955, Methods Biochem Anal, V2, P279, DOI 10.1002/9780470110188.ch10	59	33	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35201	35209		10.1074/jbc.M404947200	http://dx.doi.org/10.1074/jbc.M404947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201278	hybrid			2022-12-25	WOS:000223303400010
J	Sharma, C; Pradeep, A; Wong, L; Rana, A; Rana, B				Sharma, C; Pradeep, A; Wong, L; Rana, A; Rana, B			Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; GASTRIC-CANCER CELLS; PPAR-GAMMA; GENE-EXPRESSION; COLORECTAL-CANCER; NUCLEAR RECEPTORS; ADIPOCYTE DIFFERENTIATION; HEPATOCELLULAR CARCINOMAS; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS	The transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to the family of nuclear hormone receptors and consists of two isotypes, PPARgamma1 and PPARgamma2. Our earlier studies have shown that troglitazone (TZD)-mediated activation of PPARgamma2 in hepatocytes inhibits growth and attenuates cyclin D1 transcription via modulating CREB levels. Because this process of growth inhibition was also associated with an inhibition of beta-catenin expression at a post-translational level, our aim was to elucidate the mechanism involved. beta-Catenin is a multifunctional protein, which can regulate cell-cell adhesion by interacting with E-cadherin and other cellular processes via regulating target gene transcription in association with TCF/LEF transcription factors. Two adenomatous polyposis coli (APC)-dependent proteasomal degradation pathways, one involving glycogen synthase kinase 3beta (GSK3beta) and the other involving p53-Siah-1, degrade excess beta-catenin in normal cells. Our immunofluorescence and Western blot studies indicated a TZD-dependent decrease in cytoplasmic and membrane-bound beta-catenin, indicating no increase in its membrane translocation. This was associated with a reduction in E-cadherin expression. PPARgamma2 activation inhibited GSK3beta kinase activity, and pharmacological inhibition of GSK3beta activity was unable to restore beta-catenin expression following PPARgamma2 activation. Additionally, this beta-catenin degradation pathway was operative in cells, with inactivating mutations of both APC and p53. Inhibition of the proteasomal pathway inhibited PPARgamma2-mediated degradation of beta-catenin, and incubation with TZD increased ubiquitination of beta-catenin. We conclude that PPARgamma2-mediated suppression of beta-catenin levels involves a novel APC/GSK3beta/p53-independent ubiquitination-mediated proteasomal degradation pathway.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Cardiovasc Res Inst, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Div Hematol Oncol, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center	Rana, B (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol, Cardiovasc Res Inst, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.	brana@medicine.tamu.edu	Rana, Ajay/ABE-3739-2020	Rana, Ajay/0000-0003-0951-2566	NIGMS NIH HHS [R01GM055835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABARZUA P, 1995, CANCER RES, V55, P3490; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Edvardsson U, 1999, J LIPID RES, V40, P1177; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Ohta T, 2002, INT J ONCOL, V21, P37; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qin CH, 2003, CANCER RES, V63, P958; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schoonjans K, 1996, J LIPID RES, V37, P907; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Sharma C, 2004, J BIOL CHEM, V279, P16927, DOI 10.1074/jbc.M309045200; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	73	117	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35583	35594		10.1074/jbc.M403143200	http://dx.doi.org/10.1074/jbc.M403143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15190077	hybrid			2022-12-25	WOS:000223303400054
J	Mate, MJ; Kleanthous, C				Mate, MJ; Kleanthous, C			Structure-based analysis of the metal-dependent mechanism of H-N-H endonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW CONFORMATIONAL DYNAMICS; DNA-BINDING; TRANSITION-METALS; CRYSTAL-STRUCTURE; DUAL RECOGNITION; NUCLEASE DOMAIN; COLICIN E9; HNH MOTIF; COMPLEX; IMMUNITY	Controversy surrounds the metal-dependent mechanism of H-N-H endonucleases, enzymes involved in a variety of biological functions, including intron homing and DNA repair. To address this issue we determined the crystal structures for complexes of the H-N-H motif containing bacterial toxin colicin E9 with Zn2+, Zn2+ . DNA, and Mg2+ . DNA. The structures show that the rigid V-shaped architecture of the active site does not undergo any major conformational changes on binding to the minor groove of DNA and that the same interactions are made to the nucleic acid regardless of which metal ion is bound to the enzyme. The scissile phosphate contacts the single metal ion of the motif through distortion of the DNA brought about by the insertion of the Arg-96-Glu-100 salt bridge into the minor groove and a network of contacts to the DNA phosphate backbone that straddle the metal site. The Mg2+-bound structure reveals an unusual coordination scheme involving two H-N-H histidine residues, His-102 and His-127. The mechanism of DNA cleavage is likely related to that of other single metal ion-dependent endonucleases, such as I-PpoI and Vvn, although in these enzymes the single alkaline earth metal ion is coordinated by oxygen-bearing amino acids. The structures also provide a rationale as to why H-N-H endonucleases are inactive in the presence of Zn2+ but active with other transition metal ions such as Ni2+. This is because of coordination of the Zn2+ ion through a third histidine, His-131." Active" transition metal ions are those that bind more weakly to the H-N-H motif because of the disengagement of His-131, which we suggest allows a water molecule to complete the catalytic cycle.	Univ York, Dept Biol, Heslington YO10 5Y2, England	University of York - UK	Kleanthous, C (corresponding author), Univ York, Dept Biol, Area 10,POB 373, Heslington YO10 5Y2, England.	ck11@york.ac.uk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; DeLano WL, 2002, PYMOL USERS MANUAL; Drouin M, 2000, NUCLEIC ACIDS RES, V28, P4566, DOI 10.1093/nar/28.22.4566; Dudev T, 2001, J PHYS CHEM B, V105, P4446, DOI 10.1021/jp004602g; Filippo Joseph San, 2002, Journal of Molecular Biology, V324, P933; Friedhoff P, 1999, NAT STRUCT BIOL, V6, P112; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; Keeble AH, 2002, BIOCHEMISTRY-US, V41, P10234, DOI 10.1021/bi020174o; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ku WY, 2002, NUCLEIC ACIDS RES, V30, P1670, DOI 10.1093/nar/30.7.1670; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; Kuhlmann UC, 1999, FEBS LETT, V463, P1, DOI 10.1016/S0014-5793(99)01499-4; LAVIE A, 1994, BIOCHEMISTRY-US, V33, P5469, DOI 10.1021/bi00184a016; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Malik HS, 2000, TRENDS BIOCHEM SCI, V25, P414, DOI 10.1016/S0968-0004(00)01623-6; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pommer AJ, 1999, J BIOL CHEM, V274, P27153, DOI 10.1074/jbc.274.38.27153; Pommer AJ, 2001, J MOL BIOL, V314, P735, DOI 10.1006/jmbi.2001.5189; Pommer AJ, 1998, BIOCHEM J, V334, P387, DOI 10.1042/bj3340387; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Sui MJ, 2002, PROTEIN SCI, V11, P2947, DOI 10.1110/ps.0220602; Walker DC, 2002, NUCLEIC ACIDS RES, V30, P3225, DOI 10.1093/nar/gkf420; Whittaker SBM, 1998, J BIOMOL NMR, V12, P145, DOI 10.1023/A:1008272928173; Whittaker SBM, 2000, PROTEIN SCI, V9, P713	38	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34763	34769		10.1074/jbc.M403719200	http://dx.doi.org/10.1074/jbc.M403719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15190054	hybrid			2022-12-25	WOS:000223134800083
J	Khan, S; Guevara, C; Fujii, G; Parry, D				Khan, S; Guevara, C; Fujii, G; Parry, D			P14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts	ONCOGENE			English	Article						ARF; DNA damage; ionizing radiation; MDM2; p53	ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; NUCLEOLAR-LOCALIZATION; RIBONUCLEOTIDE DEPLETION; CELLULAR-RESPONSE; DEFICIENT MICE; FEEDBACK LOOP; MDM2; P19(ARF); P14(ARF)	Ionizing radiation leads to rapid stabilization and activation of the p53 tumor suppressor. Previous reports demonstrate that murine p19ARF cooperates with p53 in the cellular response to gamma irradiation. Here, we show that endogenous ARF sequentially interacts with p53 and MDM2 following irradiation of primary human and mouse embryonic fibroblasts. Shortly after irradiation, p14ARF binds p53 independently of MDM2. As nuclear pools of p53 decline, endogenous p14ARF co-immunoprecipitates with MDM2 and is localized within the nucleolus. Interestingly, p14ARF nucleolar localization during this response is abrogated in cells lacking functional p53. Taken together, our data suggest that human and murine ARF contribute to the mammalian DNA damage response.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Parry, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, 901 Calif Ave, Palo Alto, CA 94304 USA.	david.parry@dnax.org						Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Groth A, 2000, J BIOL CHEM, V275, P27473; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KHANNA KK, 1993, ONCOGENE, V8, P3307; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	41	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6040	6046		10.1038/sj.onc.1207824	http://dx.doi.org/10.1038/sj.onc.1207824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195142				2022-12-25	WOS:000223261000003
J	Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I				Jonckheere, N; Perrais, M; Mariette, C; Batra, SK; Aubert, JP; Pigny, P; Van Seuningen, I			A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis	ONCOGENE			English	Article						MUC4; pancreatic cancer; TGF-beta; transcription; mucin; Smad4; acetylation	GROWTH-FACTOR-BETA; DPC4 INACTIVATION; CANCER; EXPRESSION; PROMOTER; INDUCTION; SEQUENCE; CELLS	MUC4 encodes a large transmembrane mucin that is overexpressed in pancreatic adenocarcinomas. The molecular mechanisms responsible for that altered pattern of expression are unknown. TGF-beta, a pleiotropic cytokine, regulates numerous genes involved in pancreatic carcinogenesis via activation of the Smads proteins and MUC4 promoter is rich in Smad-binding elements. Our aim was to study whether the regulation of MUC4 expression by TGF-beta in pancreatic cancer cells was strictly dependent on Smad4 activity. Three pancreatic cancer cell lines, CAPAN-1 (MUC4 + /Smad4-), CAPAN-2 (MUC4 + /Smad4+) and PANC-1 (MUC4-/Smad4 +), were used. By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4. When Smad4 is mutated and inactive, TGF-beta activates MUC4 expression via MAPK, PI3K and PKA signaling pathways. Absence of expression in PANC-1 cells is due to historic deacetylation. Altogether, these results indicate that upregulation of MUC4 by TGF-beta is restricted to well-differentiated pancreatic cancer cells, and point out a novel mechanism for TGF-beta as a key molecule in targeting MUC4 overexpression in pancreatic adenocarcinomas.	INSERM, U560, F-59045 Lille, France; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Eppley Canc Ctr, Omaha, NE USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center	Van Seuningen, I (corresponding author), INSERM, U560, Place Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016; Jonckheere, Nicolas/J-6028-2013	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Jonckheere, Nicolas/0000-0002-0496-0661	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hruban RH, 2001, J GASTROINTEST SURG, V5, P583, DOI 10.1016/S1091-255X(01)80099-8; Huguier M, 1999, AM J SURG, V177, P257, DOI 10.1016/S0002-9610(99)00003-3; Kim YS, 1999, ANN ONCOL, V10, P51, DOI 10.1023/A:1008332602541; Lichtenstein D R, 1995, Gastrointest Endosc Clin N Am, V5, P237; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Sakorafas GH, 2000, CANCER TREAT REV, V26, P29, DOI 10.1053/ctrv.1999.0144; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schutte M, 1996, CANCER RES, V56, P2527; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wilentz RE, 2000, CANCER RES, V60, P2002	38	49	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5729	5738		10.1038/sj.onc.1207769	http://dx.doi.org/10.1038/sj.onc.1207769			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184872	Green Published			2022-12-25	WOS:000222629800002
J	Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH				Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH			RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts	ONCOGENE			English	Article						RBMY; hepatocellular carcinoma; hepatoblastoma; RNA-binding motif; SRGY box	HEPATITIS-B-VIRUS; HUMAN Y-CHROMOSOME; HEPATOCELLULAR-CARCINOMA; GENE FAMILY; SPERMATOGENESIS; AZOOSPERMIA; TUMORS; OVEREXPRESSION; AMPLIFICATION; ORGANIZATION	The RNA-binding motif (RRM) gene on Y chromosome (RBMY), encoding a male germ cell-specific RNA-binding protein associated with spermatogenesis, was found inserted by hepatitis B virus (HBV) DNA in one childhood hepatocellular carcinoma (HCC). This study is aimed to explore the oncogenic potential of the RBMY protein. The RBMY transcripts, expressed exclusively in the testis of normal people, were detected by reverse transcription-polymerase chain reaction in 36% of HCCs from 90 males and in 67% of hepatoblastoma from six boys. The nontumor liver counter parts, cirrhotic liver tissues from children with biliary atresia, and other types of cancers, such as bile duct, colon, stomach, lung, prostate, and kidney, were all negative for RBMY expression. One to four types of RBMY transcripts, including wild type and variants with N-terminal RRM deletion, C-terminal SRGY (serine-arginine-glycine-tyrosine) boxes deletion, or deletion of both domains, were found in the testis and liver cancer tissues. The wild-type RBMY protein was expressed in the nucleus and demonstrated its tumorigenicity by transformation of mouse fibroblast NIH3T3 cells and in vivo tumor formation. The RBMY variant protein with deletion of C-terminal exons 9-12 was trapped in the cytoplasm and showed decreased tumorigenicity. Our results suggest that RBMY is a new candidate oncogene specific for male liver cancer.	Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Surg, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Urol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chang, MH (corresponding author), Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	mhchang@ha.mc.ntu.edu.tw		PU, YEONG-SHIAU/0000-0002-2859-3966; Chang, Mei Hwei/0000-0002-3648-9261; Ni, Yen-Hsuan/0000-0002-1158-5249; CHEN, CHIUNG-NIEN/0000-0003-1192-5220; LEE, PO-HUANG/0000-0001-5831-035X; JENG, YUNG-MING/0000-0002-3878-4491				Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; Chai NN, 1997, GENOMICS, V45, P355, DOI 10.1006/geno.1997.4944; Chai NN, 1998, GENOMICS, V49, P283, DOI 10.1006/geno.1998.5255; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; CHEN JY, 1986, BRIT J EXP PATHOL, V67, P279; CHEN WJ, 1988, J PEDIATR SURG, V23, P457, DOI 10.1016/S0022-3468(88)80448-2; DING SF, 1994, J HEPATOL, V20, P672, DOI 10.1016/S0168-8278(05)80359-9; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 1998, J CELL SCI, V111, P1255; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Flickinger JC, 1997, CANC PRINCIPLES PRAC, P1087; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; IWAMA T, 1994, CANCER, V73, P2065, DOI 10.1002/1097-0142(19940415)73:8<2065::AID-CNCR2820730809>3.0.CO;2-O; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kume T, 1999, HISTOPATHOLOGY, V34, P502, DOI 10.1111/j.1365-2559.1999.00686.x; Lee CL, 1998, EUR J CANCER, V34, P2064, DOI 10.1016/S0959-8049(98)00281-0; Lin T M, 1977, Taiwan Yi Xue Hui Za Zhi, V76, P656; Lin Y., 1996, Annals Academy of Medicine Singapore, V25, P22; Lingenfelter PA, 2001, MAMM GENOME, V12, P538, DOI 10.1007/s00335001-0003-z; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mercatante D, 2000, PHARMACOL THERAPEUT, V85, P237, DOI 10.1016/S0163-7258(99)00067-4; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; NI YH, 1991, CANCER, V8, P1731; NISHIDA N, 1994, CANCER RES, V54, P3107; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Tsuei DJ, 2002, J MED VIROL, V68, P513, DOI 10.1002/jmv.10240; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Venables JP, 1999, CURR OPIN GENET DEV, V9, P346, DOI 10.1016/S0959-437X(99)80052-5; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933	40	29	31	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5815	5822		10.1038/sj.onc.1207773	http://dx.doi.org/10.1038/sj.onc.1207773			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184870				2022-12-25	WOS:000222629800011
J	Kevil, CG; Pruitt, H; Kavanagh, TJ; Wilkerson, J; Farin, F; Moellering, D; Darley-Usmar, VM; Bullard, DC; Patel, RP				Kevil, CG; Pruitt, H; Kavanagh, TJ; Wilkerson, J; Farin, F; Moellering, D; Darley-Usmar, VM; Bullard, DC; Patel, RP			Regulation of endothelial glutathione by ICAM-1: implications for inflammation	FASEB JOURNAL			English	Article						intercellular adhesion molecule-1; MAEC; GSH; GCL	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INTERCELLULAR-ADHESION MOLECULE-1; MODIFIER SUBUNIT GENE; FACTOR-KAPPA-B; OXIDATIVE STRESS; ACTIVATOR PROTEIN-1; DEFICIENT MICE; REDOX STATE; IN-VITRO; CELLS	The role of glutathione (GSH) in inflammation is largely discussed from the context of providing reducing equivalents to detoxify reactive oxygen and nitrogen species. Inflammation is now recognized to be an underlying cause of many vascular diseases including atherosclerosis, a disease in which endothelial GSH concentrations are decreased. However, mechanisms that control GSH levels are poorly understood. Key players in the inflammatory process are endothelial adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1). This adhesion molecule is present constitutively and can be induced by a variety of inflammatory stimuli. In this study, using mouse aortic endothelial cells (MAEC) deficient in ICAM-1, we demonstrate a novel interplay between constitutive ICAM-1 and cellular GSH. Deficiency of ICAM-1 was associated with an approximately twofold increase in total GSH content. Inhibiting glutamate-cysteine ligase (GCL), the enzyme that catalyses the rate-limiting step in GSH biosynthesis, prevented the increase in GSH. In addition, the catalytic subunit of GCL was increased (approximate to 1.6-fold) in ICAM-1 deficient relative to wild-type cells, suggesting that constitutive ICAM-1 represses GCL expression. Furthermore, the ratio of reduced (GSH) to oxidized (GSSG) glutathione was also increased suggesting a role for ICAM-1 in modulating cellular redox status. Interestingly, increasing cytosolic GSH in wild-type mouse endothelial cells decreased constitutive ICAM-1, suggesting the presence of an inverse and reciprocal pathway. To test the effects of inducible ICAM-1 on GSH, cells were stimulated with the proinflammatory cytokine TNF-alpha. TNF-alpha stimulated production of ICAM-1, which was however not associated with induction of GSH. In contrast, supplementation of endothelial cells with GSH before TNF-alpha addition, inhibited induction of ICAM-1. These data suggest a novel regulatory pathway between constitutive ICAM-1 and GSH synthesis in the endothelium and are discussed in the context of modulating the inflammatory response.	Louisiana State Univ, Dept Pathol, Shreveport, LA USA; Univ Alabama, Dept Pathol, Birmingham, AL USA; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA USA; Univ Alabama, Ctr Free Radical Biol, Birmingham, AL USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham	Patel, RP (corresponding author), Univ Alabama, Dept Pathol, 901 19th St S,BMR-2,Room 307, Birmingham, AL 35294 USA.	patel@path.uab.edu	Darley-Usmar, Victor/F-7656-2010; Kevil, Christopher/G-9318-2011	Patel, Rakesh/0000-0002-1526-4303; Darley-Usmar, Victor/0000-0001-8921-7086; Moellering, Douglas/0000-0003-2040-4187; Kevil, Christopher/0000-0003-0863-7260	NHLBI NIH HHS [R01 HL-70146] Funding Source: Medline; NIEHS NIH HHS [R01 ES-10167] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010167] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi T, 2000, BRIT J PHARMACOL, V129, P1014, DOI 10.1038/sj.bjp.0703127; Ault JG, 2003, EXP CELL RES, V285, P9, DOI 10.1016/S0014-4827(03)00012-0; Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Diaz D, 2001, TOXICOL LETT, V123, P33, DOI 10.1016/S0378-4274(01)00377-0; Dickinson DA, 2003, BIOL CHEM, V384, P527, DOI 10.1515/BC.2003.061; EGAWA K, 1994, EXPERIENTIA, V50, P958, DOI 10.1007/BF01923487; Greenwood J, 2002, VASC PHARMACOL, V38, P315, DOI 10.1016/S1537-1891(02)00199-4; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Kevil CG, 2001, ACTA PHYSIOL SCAND, V173, P151, DOI 10.1046/j.1365-201X.2001.00901.x; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; Kobayashi SD, 2003, J LEUKOCYTE BIOL, V73, P315, DOI 10.1189/jlb.1002481; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Moellering D, 1999, FEBS LETT, V448, P292, DOI 10.1016/S0014-5793(99)00371-3; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Moellering DR, 2002, BIOCHEM J, V362, P51, DOI 10.1042/0264-6021:3620051; Nageh MF, 1997, ARTERIOSCL THROM VAS, V17, P1517, DOI 10.1161/01.ATV.17.8.1517; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; Okayama N, 1997, AM J PHYSIOL-CELL PH, V273, pC1581, DOI 10.1152/ajpcell.1997.273.5.C1581; Papi A, 2002, FASEB J, V16, P1934, DOI 10.1096/fj.02-0118fje; Patel SS, 1998, CIRCULATION, V97, P75, DOI 10.1161/01.CIR.97.1.75; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Rahman I, 2000, BIOCHEM PHARMACOL, V60, P1041, DOI 10.1016/S0006-2952(00)00392-0; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Tsakadze NL, 2002, TRENDS CARDIOVAS MED, V12, P101, DOI 10.1016/S1050-1738(01)00157-8; Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001; Zhao XY, 2001, AM J PHYSIOL-LUNG C, V281, pL879, DOI 10.1152/ajplung.2001.281.4.L879	39	50	53	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2004	18	9					1321	+		10.1096/fj.03-1401fje	http://dx.doi.org/10.1096/fj.03-1401fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15180961				2022-12-25	WOS:000222327500024
J	Skowronek, KR; Guo, F; Zheng, Y; Nassar, N				Skowronek, KR; Guo, F; Zheng, Y; Nassar, N			The C-terminal basic tail of RhoG assists the guanine nucleotide exchange factor trio in binding to phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; STRUCTURAL BASIS; DBL FAMILY; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; AXON GUIDANCE; HIGH-AFFINITY; GEF TRIO; PROTEIN; RAC	The multidomain protein Trio regulates among others neuronal outgrowth and axonal guidance in vertebrates and invertebrates. Trio contains two Dbl-homology/pleckstrin homology (DH/PH) tandem domains that activate several RhoGTPases. Here, we present the x-ray structure of the N-terminal DH/PH, hereafter TrioN, refined to 1.7-Angstrom resolution. We show that the relative orientations of the DH and PH domains of TrioN and free Dbs are similar. However, this relative orientation is dissimilar to Dbs in the Dbs/Cdc42 structure. In vitro nucleotide exchange experiments catalyzed by TrioN show that RhoG is similar to 3 x more efficiently exchanged than Rac and support the conclusion that RhoG is likely the downstream target of TrioN. Residues 54 and 69, which are not conserved between the two GTPases, are responsible for this specificity. Dot-blot assay reveals that the TrioN-PH domain does not detectably bind phosphatidylinositol 3,4-bisphosphate, PtdIns(3,4) P-2, or other phospholipids. This finding is supported by our three-dimensional structure and affinity binding experiments. Interestingly, the presence of RhoG but not Rac or a C-terminal-truncated RhoG mutant allows TrioN to bind PtdIns( 3,4) P2 with a micromolar affinity constant. We conclude the variable C-terminal basic tail of RhoG specifically assists the recruitment of the TrioN-PH domain to specific membrane-bound phospholipids. Our data suggest a role for the phosphoinositide 3-kinase, PI 3-kinase, in modulating the Trio/RhoG signaling pathway.	SUNY Stony Brook, Dept Physiol & Biophys, Hlth Sci Ctr, Stony Brook, NY 11794 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Nassar, N (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Hlth Sci Ctr, Basic Sci Tower, Stony Brook, NY 11794 USA.	nicolas.nassar@sunysb.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NCRR NIH HHS [RR-01646] Funding Source: Medline; NIDDK NIH HHS [T32-DK07521-16] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bateman J, 2001, J CELL SCI, V114, P1973; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bellanger JM, 2003, BIOL CELL, V95, P625, DOI 10.1016/j.biolcel.2003.10.002; Blangy A, 2000, J CELL SCI, V113, P729; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Seipel K, 2001, J CELL SCI, V114, P389; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Skowronek K, 2003, ACTA CRYSTALLOGR D, V59, P1273, DOI 10.1107/S0907444903009442; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VAN AL, 1997, GENE DEV, V11, P2295; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	69	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37895	37907		10.1074/jbc.M312677200	http://dx.doi.org/10.1074/jbc.M312677200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15199069	hybrid			2022-12-25	WOS:000223554600083
J	Gavard, J; Marthiens, V; Monnet, C; Lambert, M; Mege, RM				Gavard, J; Marthiens, V; Monnet, C; Lambert, M; Mege, RM			N-cadherin activation substitutes for the cell contact control in cell cycle arrest and myogenic differentiation - Involvement of p120 AND beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; RHO-FAMILY GTPASES; 3-DIMENSIONAL CULTURES; ACTIN CYTOSKELETON; STRIATED-MUSCLE; EXPRESSION; ADHESION; GROWTH; LOCALIZATION; INHIBITION	N-cadherin is expressed throughout skeletal myogenesis and has been proposed to be involved in the differentiation program of myogenic precursors. Here, we further characterize the N-cadherin involvement and its mechanism of action at the onset of differentiation, through controlled N-cadherin activation by plating isolated C2 myoblasts on surfaces coated with a chimeric Ncad-Fc homophilic ligand (N-cadherin ectodomain fused to the immunoglobulin G Fc fragment). We show that N-cadherin activation substitutes for the cell density in myogenic differentiation by promoting myogenin and troponin T expression. In addition, N-cadherin adhesion participates to the associated cell cycle arrest through the nuclear accumulation of cyclin-dependent kinase inhibitors p21 and p27. Mouse primary myoblast cultures exhibited similar responses to N-cadherin as C2 cells. RNA interference knockdowns of the N-cadherin-associated cytoplasmic proteins p120 and beta-catenin produced opposite effects on the differentiation pathway. p120 silencing resulted in a decreased myogenic differentiation, associated with a reduction in cadherin-catenin content, which may explain its action on myogenic differentiation. beta-Catenin silencing led to a stimulatory effect on myogenin expression, without any effect on cell cycle. Our results demonstrate that N-cadherin adhesion may account for cell-cell contact-dependent cell cycle arrest and differentiation of myogenic cells, involving regulation through p120 and beta-catenins.	Inst Fer Moulin, INSERM, U440, UPMC, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mege, RM (corresponding author), Inst Fer Moulin, INSERM, U440, UPMC, 17 Rue Fer Moulin, F-75005 Paris, France.	mege@fer-a-moulin.inserm.fr	Marthiens, Veronique/D-8673-2017; Mege, Rene Marc/M-9569-2013; Gavard, Julie/I-5487-2012; Gavard, Julie/I-5487-2012	Gavard, Julie/0000-0002-7985-9007; Mege, Rene-Marc/0000-0001-8128-5543; MONNET, Celine/0000-0003-0492-5062; marthiens, veronique/0000-0002-1360-0617; Gavard, Julie/0000-0003-3107-2026				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Brand-Saberi B, 1999, CELL TISSUE RES, V296, P199, DOI 10.1007/s004410051281; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Charlton CA, 1997, J CELL BIOL, V138, P331, DOI 10.1083/jcb.138.2.331; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; CIFUENTESDIAZ C, 1995, MECH DEVELOP, V50, P85, DOI 10.1016/0925-4773(94)00327-J; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; Goichberg P, 2001, J CELL SCI, V114, P1309; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOLT CE, 1994, P NATL ACAD SCI USA, V91, P10844, DOI 10.1073/pnas.91.23.10844; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Kaufmann U, 1999, CELL TISSUE RES, V296, P191, DOI 10.1007/s004410051280; Knudsen KA, 1990, CURR OPIN CELL BIOL, V2, P902, DOI 10.1016/0955-0674(90)90090-2; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Marthiens V, 2002, MOL CELL NEUROSCI, V20, P458, DOI 10.1006/mcne.2002.1130; Marthiens W, 2002, BIOL CELL, V94, P315, DOI 10.1016/S0248-4900(02)00005-9; MEGE RM, 1992, J CELL SCI, V103, P897; Monnet C, 2003, EUR J NEUROSCI, V18, P542, DOI 10.1046/j.1460-9568.2003.02777.x; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; Seghatoleslami MR, 2000, J CELL BIOCHEM, V77, P252, DOI 10.1002/(SICI)1097-4644(20000501)77:2<252::AID-JCB8>3.0.CO;2-J; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TASSIN AM, 1988, DEV BIOL, V129, P37, DOI 10.1016/0012-1606(88)90159-5; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973	57	50	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36795	36802		10.1074/jbc.M401705200	http://dx.doi.org/10.1074/jbc.M401705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15194693	hybrid			2022-12-25	WOS:000223453600081
J	Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS				Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS			Involvement of c-Src kinase in the regulation of TGF-beta 1-induced apoptosis	ONCOGENE			English	Article						TGF-beta 1; apoptosis; c-Src; hepatocellular carcinoma; caspases	FOCAL ADHESION KINASE; GROWTH-FACTOR-BETA; HUMAN HEPATOCELLULAR-CARCINOMA; FAO HEPATOMA-CELLS; TGF-BETA; TYROSINE KINASES; BINDING-SITE; II RECEPTOR; ACTIVATION; SMAD2	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-beta1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-beta1-induced apoptosis. TGF-beta1 induced transient activation of c-Src and its subsequent caspase-mediated degradation concomitant with cell death in FaO hepatoma cells, which are sensitive to TGF-beta1. In response to TGF-beta1, activated c-Src was translocated into the cytoplasmic membrane, then relocated to the nuclei of apoptotic cells during its cleavage. In TGF-beta1-induced apoptotic cells, c-Src maintained its tight association with p85 FAK fragment cleaved by caspases, possibly contributing to focal adhesion disassembly. TGF-beta1-induced apoptosis was enhanced by either inhibition of c-Src activity using PP1 or PP2, or by overexpression of dominant-negative c-Src. In contrast, overexpression of constitutively active c-Src inhibited apoptosis suppressing TGF-beta1-induced activation of p38, JNK and caspases. In many HCC cell lines resistant to TGF-beta1, enhanced c-Src activity was detected. We hypothesize that activated c-Src in HCC may contribute to resistance against the apoptotic and/or antiproliferative properties of TGF-beta1.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul, South Korea; LG Life Sci, Taejon, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Ajou University; Catholic University of Korea; LG Life Sciences Ltd; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, 5 Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Eom, Young Woo/0000-0002-5985-6490; Choi, Kyeong Sook/0000-0003-2331-0856	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Crouch DH, 1996, ONCOGENE, V12, P2689; DECAESTECKER MP, 2000, J NATL CANCER I, V92, P555; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; ITO N, 1991, CANCER RES, V51, P4080; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kawate S, 1999, INT J ONCOL, V14, P127; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Lee JH, 1999, WORLD J GASTROENTERO, V5, P289; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	36	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6272	6281		10.1038/sj.onc.1207856	http://dx.doi.org/10.1038/sj.onc.1207856			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208664				2022-12-25	WOS:000223399000011
J	Elad-Sfadia, G; Haklai, R; Balan, E; Kloog, Y				Elad-Sfadia, G; Haklai, R; Balan, E; Kloog, Y			Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; H-RAS; ROD PHOSPHODIESTERASE; DELTA-SUBUNIT; CELL-LINES; N-RAS; BINDING; FAMILY; EXPRESSION; PROTEINS	Depending on the cellular context, Ras can activate characteristic effectors by mechanisms still poorly understood. Promotion by galectin-1 of Ras activation of Raf-1 but not of phosphoinositide 3-kinase (PI3-K) is one such mechanism. In this report, we describe a mechanism controlling selectivity of K-Ras4B (K-Ras), the most important Ras oncoprotein. We show that galectin-3 acts as a selective binding partner of activated K-Ras. Galectin-3 co-immunoprecipitated significantly better with K-Ras-GTP than with K-Ras-GDP, H-Ras, or N-Ras and colocalized with green fluorescent protein-K-Ras(G12V), not with green fluorescent protein-H-Ras(G12V), in the cell membrane. Co-transfectants of K-Ras/galectin-3, but not of H-Ras/galectin-3, exhibited enhanced and prolonged epidermal growth factor-stimulated increases in Ras-GTP, Raf-1 activity, and PI3-K activity. Extracellular signal-regulated kinase (ERK) activity, however, was attenuated in K-Ras/galectin-3 and in K-Ras(G12V)/galectin-3 co-transfectants. Galectin-3 antisense RNA inhibited the epidermal growth factor-stimulated increase in K-Ras-GTP but enhanced ERK activation and augmented K-Ras(G12V) transformation activity. Thus, unlike galectin-1, which prolongs Ras activation of ERK and inhibits PI3-K, K-Ras-GTP/galectin-3 interactions promote, in addition to PI3-K and Raf-1 activation, a third inhibitory signal that attenuates active ERK. These experiments established a novel and specific mechanism controlling the duration and selectivity of signals of active K-Ras, which is extremely important in many human tumors.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il						Akahani S, 1997, CANCER RES, V57, P5272; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Bresalier RS, 1997, CANCER, V80, P776; Camby I, 2001, BRAIN PATHOL, V11, P12; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elad G, 1999, BBA-MOL CELL RES, V1452, P228, DOI 10.1016/S0167-4889(99)00144-5; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Goi T, 1999, MOL CELL BIOL, V19, P1731; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HUBERT M, 1995, EXP CELL RES, V220, P397, DOI 10.1006/excr.1995.1331; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kayser K, 2000, VIRCHOWS ARCH, V437, P284, DOI 10.1007/s004280000207; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rotblat B, 2004, CANCER RES, V64, P3112, DOI 10.1158/0008-5472.CAN-04-0026; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2; VICIANA PR, 1996, EMBO J, V15, P2442; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271	52	219	224	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34922	34930		10.1074/jbc.M312697200	http://dx.doi.org/10.1074/jbc.M312697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15205467	hybrid			2022-12-25	WOS:000223134800103
J	Jeong, SM; Lee, KY; Shin, DH; Chung, HY; Jeon, SH; Seong, RH				Jeong, SM; Lee, KY; Shin, DH; Chung, HY; Jeon, SH; Seong, RH			Nitric oxide inhibits glucocorticoid-induced apoptosis of thymocytes by repressing the SRG3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; DENDRITIC CELLS; GENE-EXPRESSION; UP-REGULATION; SYNTHASE; RECEPTOR; ACTIVATION; DEATH; TRANSCRIPTION; LYMPHOCYTES	Nitric oxide ( NO) plays many roles in the immune system. It has been known that NO rescues thymocytes from glucocorticoid (GC)-induced apoptosis. However, the downstream target of NO in the protection from GC-induced thymocyte apoptosis has yet to be identified. We previously reported that GC sensitivity of developing thymocytes is dependent on the expression level of SRG3. In the present report, we found that NO repressed the SRG3 expression in both primary thymocytes and 16610D9 thymoma cells. Specifically, NO down-regulated the transcription of SRG3 via the inactivation of the transcription factor Sp1 DNA-binding activity to the SRG3 promoter. In addition, overexpression of SRG3 by a heterologous promoter reduced NO-mediated rescue of thymocytes from GC-induced apoptosis. These observations strongly suggest that NO may be involved in protecting immature thymocytes from GC-induced apoptosis by repressing the SRG3 expression in thymus.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Jeon, SH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	jeonsho@snu.ac.kr; rhseong@plaza.snu.ac.kr		Seong, Rho/0000-0001-5699-0718				Aiello S, 2000, J IMMUNOL, V164, P4649, DOI 10.4049/jimmunol.164.9.4649; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chen Y, 2001, CELL IMMUNOL, V214, P72, DOI 10.1006/cimm.2001.1880; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Jondal M, 1995, Curr Top Microbiol Immunol, V200, P67; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Ko M, 2004, J BIOL CHEM, V279, P21916, DOI 10.1074/jbc.M402145200; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Kroncke KD, 2001, FASEB J, V15, P2503, DOI 10.1096/fj.01-0240hyp; Lu LN, 1996, J IMMUNOL, V157, P3577; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Pazirandeh A, 2002, FASEB J, V16, P727, DOI 10.1096/fj.01-0891fje; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Tai XG, 1997, J IMMUNOL, V158, P4696; Wagner DH, 1996, J EXP MED, V184, P1631, DOI 10.1084/jem.184.5.1631; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHAO Y, 1995, J IMMUNOL, V154, P6346	36	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34373	34379		10.1074/jbc.M403461200	http://dx.doi.org/10.1074/jbc.M403461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187086	hybrid			2022-12-25	WOS:000223134800037
J	Liger, D; Graille, M; Zhou, CZ; Leulliot, N; Quevillon-Cheruel, S; Blondeau, K; Janin, J; van Tilbeurgh, H				Liger, D; Graille, M; Zhou, CZ; Leulliot, N; Quevillon-Cheruel, S; Blondeau, K; Janin, J; van Tilbeurgh, H			Crystal structure and functional characterization of yeast YLR011wp, an enzyme with NAD(P)H-FMN and ferric iron reductase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED FLAVODOXIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; FLAVIN REDUCTASE; PROTEIN; AZOREDUCTASE; PURIFICATION; ACTIVATION; RESOLUTION	Flavodoxins are involved in a variety of electron transfer reactions that are essential for life. Although FMN-binding proteins are well characterized in prokaryotic organisms, information is scarce for eukaryotic flavodoxins. We describe the 2.0-Angstrom resolution crystal structure of the Saccharomyces cerevisiae YLR011w gene product, a predicted flavoprotein. YLR011wp indeed adopts a flavodoxin fold, binds the FMN cofactor, and self-associates as a homodimer. Despite the absence of the flavodoxin key fingerprint motif involved in FMN binding, YLR011wp binds this cofactor in a manner very analogous to classical flavodoxins. YLR011wp closest structural homologue is the homodimeric Bacillus subtilis Yhda protein (25% sequence identity) whose homodimer perfectly superimposes onto the YLR011wp one. Yhda, whose function is not documented, has 53% sequence identity with the Bacillus sp. OY1-2 azoreductase. We show that YLR011wp has an NAD(P)H-dependent FMN reductase and a strong ferricyanide reductase activity. We further demonstrate a weak but specific reductive activity on azo dyes and nitrocompounds.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, F-91405 Orsay, France; CNRS, Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, Batiment 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	GRAILLE, Marc/D-3242-2014; Zhou, Cong-Zhao/E-9174-2011; Leulliot, Nicolas/AAA-7160-2019; Janin, Joel/I-2958-2012	GRAILLE, Marc/0000-0002-7853-5852; Zhou, Cong-Zhao/0000-0002-6881-7151; Leulliot, Nicolas/0000-0003-0283-4298; 				BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; Chen HZ, 2004, PROTEIN EXPRES PURIF, V34, P302, DOI 10.1016/j.pep.2003.12.016; CHIKUBA K, 1994, BIOCHEM BIOPH RES CO, V198, P1170, DOI 10.1006/bbrc.1994.1165; Drennan CL, 1999, J MOL BIOL, V294, P711, DOI 10.1006/jmbi.1999.3151; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; FUKUYAMA K, 1992, J MOL BIOL, V225, P775, DOI 10.1016/0022-2836(92)90400-E; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y; MAYHEW SG, 1975, FLAVODOXINS ELECT TR; Moutaouakkil A, 2003, ARCH BIOCHEM BIOPHYS, V413, P139, DOI 10.1016/S0003-9861(03)00096-1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Schroder I, 2003, FEMS MICROBIOL REV, V27, P427, DOI 10.1016/S0168-6445(03)00043-3; SIMONDSEN RP, 1980, MOL CELL BIOCHEM, V33, P13; Suzuki Y, 2001, J BIOL CHEM, V276, P9059, DOI 10.1074/jbc.M008083200; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Watanabe M, 1998, J BIOL CHEM, V273, P23922, DOI 10.1074/jbc.273.37.23922; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996; Zhang L, 2001, BIOCHEM BIOPH RES CO, V283, P531, DOI 10.1006/bbrc.2001.4776	34	63	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34890	34897		10.1074/jbc.M405404200	http://dx.doi.org/10.1074/jbc.M405404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184374	Green Published, hybrid			2022-12-25	WOS:000223134800099
J	Randau, L; Schauer, S; Ambrogelly, A; Salazar, JC; Moser, J; Sekine, S; Yokoyama, S; Soll, D; Jahn, D				Randau, L; Schauer, S; Ambrogelly, A; Salazar, JC; Moser, J; Sekine, S; Yokoyama, S; Soll, D; Jahn, D			tRNA recognition by glutamyl-tRNA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; DELTA-AMINOLEVULINIC-ACID; ESCHERICHIA-COLI; 1-SEMIALDEHYDE AMINOTRANSFERASE; IDENTITY DETERMINANTS; TRANSFER RNA(GLU); CRYSTAL-STRUCTURE; ACCEPTOR STEM; SYNTHETASE; NUCLEOTIDES	During the first step of porphyrin biosynthesis in Archaea, most bacteria, and in chloroplasts glutamyl-tRNA reductase (GluTR) catalyzes the NADPH-dependent reduction of glutamyl-tRNA to glutamate-1-semialdehyde. Elements in tRNA(Glu) important for utilization by Escherichia coli GluTR were determined by kinetic analysis of 51 variant transcripts of E. coli Glu-tRNA(Glu). Base U8, the U13*G22**A46 base triple, the tertiary Watson-Crick base pair 19*56, and the lack of residue 47 are required for GluTR recognition. All of these bases contribute to the formation of the unique tertiary core of E. coli tRNAGlu. Two tRNA(Glu) molecules lacking the entire anticodon stem/loop but retaining the tertiary core structure remained substrates for GluTR, while further decreasing tRNA size toward a minihelix abolished GluTR activity. RNA footprinting experiments revealed the physical interaction of GluTR with the tertiary core of Glu-tRNA(Glu). E. coli GluTR showed clear selectivity against mischarged Glu-tRNA(Gln). We concluded that the unique tertiary core structure of E. coli tRNA(Glu) was sufficient for E. coli GluTR to distinguish specifically its glutamyl-tRNA substrate.	Tech Univ Braunschweig, Inst Mikrobiol, D-38023 Braunschweig, Germany; Yale Univ, Dept Mol Biophys, New Haven, CT 06520 USA; Yale Univ, Dept Biochem, New Haven, CT 06520 USA; SPring 8, RIKEN Harima Inst, Cellular Signaling Lab, Mikazuki, Hyogo 6795148, Japan; SPring 8, RIKEN Harima Inst, Structurome Grp, Mikazuki, Hyogo 6795148, Japan	Braunschweig University of Technology; Yale University; Yale University; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu; d.jahn@tu-bs.de	Salazar, Juan/D-9368-2014; Yokoyama, Shigeyuki/N-6911-2015; Garrido, Juan Carlos Salazar/H-2672-2017; Sekine, Shun-ichi/N-5450-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Garrido, Juan Carlos Salazar/0000-0002-2096-2050; Sekine, Shun-ichi/0000-0001-8174-8704; Jahn, Dieter/0000-0002-4064-9205; Randau, Lennart/0000-0002-2780-2076				AVISSAR YJ, 1990, J BACTERIOL, V172, P1656, DOI 10.1128/jb.172.3.1656-1659.1990; BARON C, 1991, J BIOL CHEM, V266, P20375; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BERESTEN S, 1992, NUCLEIC ACIDS RES, V20, P1523, DOI 10.1093/nar/20.7.1523; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Freist W, 1997, BIOL CHEM, V378, P1313; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1992, PLANT PHYSIOL BIOCH, V30, P245; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; LEE CP, 1991, J BIOL CHEM, V266, P18012; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; Mayer C, 2002, NUCLEIC ACIDS RES, V30, P2844, DOI 10.1093/nar/gkf411; Moser J, 2002, BIOCHEM SOC T, V30, P579, DOI 10.1042/bst0300579; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; ONEILL GP, 1988, J BACTERIOL, V170, P3810, DOI 10.1128/jb.170.9.3810-3816.1988; PETERSON D, 1988, PLANT MOL BIOL, V11, P293, DOI 10.1007/BF00027386; ROGERS KC, 1993, BIOCHEMISTRY-US, V32, P14210, DOI 10.1021/bi00214a021; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Schauer S, 2003, PROTEIN EXPRES PURIF, V31, P271, DOI 10.1016/S1046-5928(03)00184-0; Schauer S, 2002, J BIOL CHEM, V277, P48657, DOI 10.1074/jbc.M206924200; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Sekine S, 1999, EUR J BIOCHEM, V261, P354, DOI 10.1046/j.1432-1327.1999.00293.x; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sekine S, 1996, J MOL BIOL, V256, P685, DOI 10.1006/jmbi.1996.0118; Sekine S, 2001, NAT STRUCT BIOL, V8, P203, DOI 10.1038/84927; SMITH MA, 1992, BIOCHEMISTRY-US, V31, P11249, DOI 10.1021/bi00160a041; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STANGETHOMANN N, 1994, P NATL ACAD SCI USA, V91, P7947, DOI 10.1073/pnas.91.17.7947; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; WAKAO H, 1989, J BIOL CHEM, V264, P20363; WEINSTEIN JD, 1986, PLANT PHYSIOL, V82, P1096, DOI 10.1104/pp.82.4.1096; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WILLOWS RD, 1995, BBA-GENE STRUCT EXPR, V1263, P228, DOI 10.1016/0167-4781(95)00105-P	45	25	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34931	34937		10.1074/jbc.M401529200	http://dx.doi.org/10.1074/jbc.M401529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15194701	hybrid			2022-12-25	WOS:000223134800104
J	Sinkins, WG; Goel, M; Estacion, M; Schilling, WP				Sinkins, WG; Goel, M; Estacion, M; Schilling, WP			Association of immunophilins with mammalian TRPC channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; FK506-BINDING PROTEIN; POTENTIAL CHANNELS; RELEASE CHANNEL; FKBP12; CALCINEURIN; BINDS; FK506; COMPLEX	Drosophila photoreceptor channels TRP and TRPL are held in a large signalplex by the scaffolding protein, INAD. Immunophilin FKBP59, another member of the signalplex, binds to both INAD and TRPL. Mutation P702Q or P709Q in the highly conserved TRPL sequence (LPPPFNVLP709)-L-701, eliminates TRPL interaction with FKBP59. The first leucylprolyl (LP) dipeptide in this region is conserved in mammalian TRPC channel proteins. However, the second LP is changed to isoleucylprolyl (IP) in TRPC1, - C4, and - C5, and valylprolyl (VP) in TRPC3, - C6, and - C7. The purpose of the present study was to determine if mammalian FKBP12 or FKBP52 interact with TRPC channel proteins. Using TRPC-specific antibodies, immunoprecipitations from Sf9 cells individually co-expressing each of the TRPC proteins along with the immunophilins showed that TRPC3, - C6, and - C7 interact with FKBP12, whereas TRPC1, - C4, and - C5 interact with FKBP52. The binding of FKBP12 and FKBP52 was specific and could be displaced by the immunosuppressant drug FK506, at concentrations of 0.5 and 10 muM, respectively. To evaluate TRPC-immunophilin interactions in vivo, immunoprecipitations were performed using membrane lysates of rat cerebral cortex. FKBP12 co-immunoprecipitated with TRPC3, - C6, and - C7 from rat brain, whereas FKBP52 was found to associate with TRPC1, - C4, and - C5. The association of immunophilins with the TRPC channels in rat brain lysates could be displaced by FK506. Receptor-mediated activation of TRPC6, stably expressed in HEK cells, was significantly inhibited by FK506, which also disrupted interaction between TRPC6 and the endogenous immunophilin found in HEK cells. Pro to Gln mutations in the first LP dipeptide in the putative FKBP binding domain eliminated FKBP12 and FKBP52 interaction with TRPC3 and - C6, and TRPC1 and - C4, respectively. However, mutual swap of VP and IP in TRPC3 and TRPC5 did not alter the association or the selectivity of the channels for their respective immunophilin binding partner. These results suggest that immunophilins are TRPC channel accessory proteins that play an important role in the mechanism of channel activation following receptor stimulation.	Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University	Schilling, WP (corresponding author), Case Western Reserve Univ, Sch Med, Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Rm R322,2500 MetroHlth Dr, Cleveland, OH 44109 USA.	wschilling@metrohealth.org	Estacion, Mark/H-2444-2011	Estacion, Mark/0000-0002-7271-1165	NIGMS NIH HHS [GM 52019] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052019] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Carmody M, 2001, FEBS LETT, V505, P97, DOI 10.1016/S0014-5793(01)02787-9; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Goel M, 2001, J BIOL CHEM, V276, P38762, DOI 10.1074/jbc.M104125200; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; Marks Andrew R., 1996, Methods (Orlando), V9, P177, DOI 10.1006/meth.1996.0024; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MONTELL C, 2001, SCI STKE, V90, P1; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	38	83	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34521	34529		10.1074/jbc.M401156200	http://dx.doi.org/10.1074/jbc.M401156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15199065	hybrid			2022-12-25	WOS:000223134800055
J	Zhang, Y; Karas, M; Zhao, H; Yakar, S; LeRoith, D				Zhang, Y; Karas, M; Zhao, H; Yakar, S; LeRoith, D			14-3-3 sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FORKHEAD TRANSCRIPTION FACTOR; ACCELERATES G(1) PHASE; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; CYCLIN-D1 EXPRESSION; SIGNAL TRANSDUCTION; DNA-DAMAGE; IGF-I	We investigated the role of 14-3-3sigma protein in insulin-like growth factor-I (IGF-I) receptor signaling. It has been previously shown that 14-3-3sigma negatively regulates cell cycle especially in response to p53-sensitive DNA damage. In this study we demonstrated that 14-3-3sigma is a positive mediator of IGF-I receptor-induced cell proliferation. Treatment with IGF-I increased 14-3-3sigma mRNA and protein levels about 4-fold, in a time-dependent manner in MCF-7 breast cancer cells. Preincubation with the phosphoinositide 3'-kinase inhibitor LY294002 significantly reduced the effects of IGF-I on 14-3-3sigma gene expression in these cells, suggesting that this effect of IGF-I occurs via the phosphoinositide 3'-kinase pathway. 14-3-3sigma is induced by IGF-I in MCF-7 cells, which express wild-type p53, as well as in MCF-7 cells transfected with a small interference RNA targeting duplex that reduced p53 expression levels. These results suggest that IGF-I induces 14-3-3sigma expression in a manner that is independent of p53. Using the small interference RNA strategy, we demonstrated that a 70-75% reduction of 14-3-3sigma mRNA levels resulted in a similar decrease in the effects of IGF-I on cell cycle progression and proliferation in MCF-7 cells. This effect was also associated with a reduction in IGF-I-induced cyclin D1 expression. Taken together, these results suggest that 14-3-3sigma positively mediates IGF-I-induced cell cycle progression.	NIDDK, Diabet Branch, NIH, Sect Mol & Cellular Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Sect Mol & Cellular Physiol, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055017] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FILMUS J, 1994, ONCOGENE, V9, P3627; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GILLETT C, 1994, CANCER RES, V54, P1812; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Murray SA, 2003, ONCOGENE, V22, P1703, DOI 10.1038/sj.onc.1206327; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Ozes ON, 1999, NATURE, V401, P82; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perry JE, 1998, PROSTATE, V35, P117; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sfacteria A, 2003, J COMP PATHOL, V128, P245, DOI 10.1053/jcpa.2002.0622; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang WF, 1996, J MOL EVOL, V43, P384; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	59	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34353	34360		10.1074/jbc.M401300200	http://dx.doi.org/10.1074/jbc.M401300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187095	hybrid			2022-12-25	WOS:000223134800035
J	Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T				Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T			Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction	ONCOGENE			English	Article						p53 tumor suppressor gene; DNA binding; SPR imaging; EMSA; polypyrrole	TRANSCRIPTION FACTOR; MUTANT P53; LABEL-FREE; BINDING; PROTEIN; CANCER; GENES; APOPTOSIS; MUTATIONS; SEQUENCE	The greatest challenge in the postgenomic era is the description of proteome interactions, such as protein-protein or protein-DNA interactions. Surface plasmon resonance (SPR) is an optical technique in which binding of an analyte to the surface changes the refractive index at the surface/solution interface. Molecular interactions are analysed in real time without a labeling step. Currently, the limit to SPR imaging is the small number of reactions that can be simultaneously analysed. Using a novel grafting technology and a new imaging system, we increased the throughput of SPR imaging. The interaction between p53 and DNA was chosen as a paradigm for validation of this assay. Using a tagged DNA methodology, we simultaneously targeted multiple DNA sequences on a single chip. The interaction between p53 and these DNA sequences was monitored by SPR imaging. Qualitative and quantitative analysis provides results similar to those obtained with conventional technologies.	UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, F-75019 Paris, France; Univ Paris 11, Lab Charles Fabry, Inst Opt, CNRS,UMR 8501, F-91403 Orsay, France; Dept Rech Fondamentale Mat Condensee, CREAB, UMR 5819, CEA,CNRS,UJF, F-38054 Grenoble, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Soussi, T (corresponding author), UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, 4 Rue Chine, F-75019 Paris, France.	thierry.soussi@tnn.ap-hop-paris.fr	Canva, Michael TG/D-4014-2009	Canva, Michael TG/0000-0001-5286-2380; soussi, thierry/0000-0001-8184-3293				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Deppert W, 2000, J CELL BIOCHEM, P115; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Guedon P, 2000, ANAL CHEM, V72, P6003, DOI 10.1021/ac000122+; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Livache T, 2003, J PHARMACEUT BIOMED, V32, P687, DOI 10.1016/S0731-7085(03)00176-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muller BF, 1996, ONCOGENE, V12, P1941; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soussi T, 2003, HUM MUTAT, V21, P192, DOI 10.1002/humu.10189; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; TOKINO T, 1994, HUM MOL GENET, V3, P1357; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107	32	41	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5543	5550		10.1038/sj.onc.1207639	http://dx.doi.org/10.1038/sj.onc.1207639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184889				2022-12-25	WOS:000222588400014
J	Papadopoulos, MC; Manley, GT; Krishna, S; Verkman, AS				Papadopoulos, MC; Manley, GT; Krishna, S; Verkman, AS			Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema	FASEB JOURNAL			English	Article						AQP4; astrocyte; knockout mice; water transport	FULMINANT HEPATIC-FAILURE; WATER CHANNELS; RAT-BRAIN; MESSENGER-RNA; INJURY; EXPRESSION; MICE; MODEL; PATHOPHYSIOLOGY; HYPONATREMIA	Aquaporin-4 (AQP4) is the major water channel in the brain, expressed predominantly in astroglial cell membranes. Initial studies in AQP4-deficient mice showed reduced cellular brain edema following water intoxication and ischemic stroke. We hypothesized that AQP4 deletion would have the opposite effect (increased brain swelling) in vasogenic (noncellular) edema because of impaired removal of excess brain water through glial limitans and ependymal barriers. In support of this hypothesis, we found higher intracranial pressure (ICP, 52 +/- 6 vs. 26 +/- 3 cm H2O) and brain water content (81.2 +/- 0.1 vs. 80.4 +/- 0.1%) in AQP4-deficient mice after continuous intraparenchymal fluid infusion. In a freeze-injury model of vasogenic brain edema, AQP4-deficient mice had remarkably worse clinical outcome, higher ICP (22 +/- 4 vs. 9 +/- 1 cm H2O), and greater brain water content (80.9 +/- 0.1 vs. 79.4 +/- 0.1%). In a brain tumor edema model involving stereotactic implantation of melanoma cells, tumor growth was comparable in wildtype and AQP4-deficient mice. However, AQP4-deficient mice had higher ICP (39 +/- 4 vs. 19 +/- 5 cm H2O at seven days postimplantation) and corresponding accelerated neurological deterioration. Thus, AQP4-mediated transcellular water movement is crucial for fluid clearance in vasogenic brain edema, suggesting AQP4 activation and/or up-regulation as a novel therapeutic option in vasogenic brain edema.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; St George Hosp, Sch Med, Dept Cellular & Mol Sci, London SW17 0RE, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; St Georges University London	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Krishna, Sanjeev/0000-0003-0066-0634; Papadopoulos, Marios/0000-0001-9174-4176	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT NJ, 2004, IN PRESS NEUROCHEM I; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; BLAKEMORE WF, 1972, J NEUROCYTOL, V1, P69, DOI 10.1007/BF01098647; Blei AT, 2001, METAB BRAIN DIS, V16, P85, DOI 10.1023/A:1011670713730; BONDAREFF W, 1973, AM J ANAT, V136, P277, DOI 10.1002/aja.1001360303; Brightman MW, 2002, J NEUROCYTOL, V31, P595, DOI 10.1023/A:1025783326667; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; KAYE AH, 1986, CANCER RES, V46, P1367; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514, DOI 10.1152/ajpheart.1994.267.2.H514; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Matkowskyj KA, 1999, AM J PHYSIOL-GASTR L, V277, pG455, DOI 10.1152/ajpgi.1999.277.2.G455; Nielsen S, 1997, J NEUROSCI, V17, P171; OURY TD, 1993, J BIOL CHEM, V268, P15394; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Thapar K, 2001, BRAIN TUMORS ENCY AP, P189; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531	41	580	647	1	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					1291	+		10.1096/fj.04-1723fje	http://dx.doi.org/10.1096/fj.04-1723fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15208268				2022-12-25	WOS:000222327500006
J	Swietnicki, W; O'Brien, S; Holman, K; Cherry, S; Brueggemann, E; Tropea, JE; Hines, HB; Waugh, DS; Ulrich, RG				Swietnicki, W; O'Brien, S; Holman, K; Cherry, S; Brueggemann, E; Tropea, JE; Hines, HB; Waugh, DS; Ulrich, RG			Novel protein-protein interactions of the Yersinia pestis type III secretion system elucidated with a matrix analysis by surface plasmon resonance and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; YOP SECRETION; HELA-CELLS; SALMONELLA-TYPHIMURIUM; TRANSLOCATORS YOPB; VIRULENCE FACTORS; CHAPERONE SYCE; ENTEROCOLITICA; PSEUDOTUBERCULOSIS; BACTERIAL	Binary complexes formed by components of the Yersinia pestis type III secretion system were investigated by surface plasmon resonance (SPR) and matrix-assisted laser desorption time-of-flight mass spectrometry. Pairwise interactions between 15 recombinant Yersinia outer proteins (Yops), regulators, and chaperones were first identified by SPR. Mass spectrometry confirmed over 80% of the protein-protein interactions suggested by SPR, and new binding partners were further characterized. The Yop secretion protein (Ysc) M2 of Yersinia enterocolitica and LcrQ of Y. pestis, formerly described as ligands only for the specific Yop chaperone (Syc) H, formed stable complexes with SycE. Additional previously unreported complexes of YscE with the translocation regulator protein TyeA and the thermal regulator protein YmoA and multiple potential protein contacts by YscE, YopK, YopH, and LcrH were also identified. Because only stably folded proteins were examined, the interactions we identified are likely to occur either before or after transfer through the injectosome to mammalian host cells and may have relevance to understanding disease processes initiated by the plague bacterium.	USA, Med Res Inst Infect Dis, Lab Mol Immunol, Frederick, MD 21702 USA; NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ulrich, RG (corresponding author), USA, Med Res Inst Infect Dis, Lab Mol Immunol, 1425 Porter St, Frederick, MD 21702 USA.	ulrich@ncifcrf.gov	Swietnicki, Wieslaw/GOP-2576-2022; Swietnicki, Wieslaw/AAL-2452-2021; Swietnicki, Wieslaw/AAU-1536-2020	Swietnicki, Wieslaw/0000-0002-9354-8184	NATIONAL CANCER INSTITUTE [ZIABC010342, Z01BC010342] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson K, 1999, INFECT IMMUN, V67, P2567, DOI 10.1128/IAI.67.5.2567-2574.1999; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Barz C, 2000, FEBS LETT, V482, P139, DOI 10.1016/S0014-5793(00)02045-7; Birtalan S, 2001, NAT STRUCT BIOL, V8, P974, DOI 10.1038/nsb1101-974; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; Brandler P, 1998, J IMMUNOL, V161, P4195; Cambronne ED, 2000, MOL MICROBIOL, V37, P263, DOI 10.1046/j.1365-2958.2000.01974.x; Cambronne ED, 2002, J BACTERIOL, V184, P5880, DOI 10.1128/JB.184.21.5880-5893.2002; Cheng LW, 1999, J BIOL CHEM, V274, P22102, DOI 10.1074/jbc.274.31.22102; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Darwin KH, 2001, EMBO J, V20, P1850, DOI 10.1093/emboj/20.8.1850; Day JB, 2000, INFECT IMMUN, V68, P6466, DOI 10.1128/IAI.68.11.6466-6471.2000; Du YD, 2002, INFECT IMMUN, V70, P1453, DOI 10.1128/IAI.70.3.1453-1460.2002; Evdokimov AG, 2002, ACTA CRYSTALLOGR D, V58, P398, DOI 10.1107/S090744490200015X; Evdokimov AG, 2001, ACTA CRYSTALLOGR D, V57, P793, DOI 10.1107/S0907444901004875; Fields KA, 1999, INFECT IMMUN, V67, P5395, DOI 10.1128/IAI.67.10.5395-5408.1999; Fox Jeffrey D, 2003, Methods Mol Biol, V205, P99; Francis MS, 2000, MOL MICROBIOL, V38, P85, DOI 10.1046/j.1365-2958.2000.02112.x; Francis MS, 1998, MOL MICROBIOL, V29, P799, DOI 10.1046/j.1365-2958.1998.00973.x; Francis MS, 2001, MOL MICROBIOL, V42, P1075, DOI 10.1046/j.1365-2958.2001.02702.x; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Lawton DG, 2002, J BIOL CHEM, V277, P38714, DOI 10.1074/jbc.M203632200; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; Madrid C, 2002, INT J MED MICROBIOL, V291, P425; McDonald C, 2003, J BIOL CHEM, V278, P18514, DOI 10.1074/jbc.M301226200; Montagna LG, 2001, J BIOL CHEM, V276, P5005, DOI 10.1074/jbc.M009045200; Neyt C, 1999, MOL MICROBIOL, V31, P143, DOI 10.1046/j.1365-2958.1999.01154.x; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; Nieto JM, 2002, J BACTERIOL, V184, P629, DOI 10.1128/JB.184.3.629-635.2002; Payne PL, 1999, J BACTERIOL, V181, P2852, DOI 10.1128/JB.181.9.2852-2862.1999; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; SKURNIK M, 1992, J BACTERIOL, V174, P2047, DOI 10.1128/jb.174.6.2047-2051.1992; Smith CL, 2001, MOL MICROBIOL, V42, P967, DOI 10.1046/j.0950-382x.2001.02711.x; Stainier I, 2000, MOL MICROBIOL, V37, P1005, DOI 10.1046/j.1365-2958.2000.02026.x; Stainier I, 1997, MOL MICROBIOL, V26, P833, DOI 10.1046/j.1365-2958.1997.6281995.x; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Tardy F, 1999, EMBO J, V18, P6793, DOI 10.1093/emboj/18.23.6793; WATTIAU P, 1994, P NATL ACAD SCI USA, V91, P10493, DOI 10.1073/pnas.91.22.10493; Wilharm G, 2003, PROTEIN EXPRES PURIF, V31, P167, DOI 10.1016/S1046-5928(03)00183-9; Woestyn S, 1996, MOL MICROBIOL, V20, P1261, DOI 10.1111/j.1365-2958.1996.tb02645.x; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x; YOTHER J, 1986, J BACTERIOL, V165, P443, DOI 10.1128/jb.165.2.443-447.1986; ZAVYALOV VP, 1995, FEBS LETT, V371, P65, DOI 10.1016/0014-5793(95)00878-D	46	30	31	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38693	38700		10.1074/jbc.M405217200	http://dx.doi.org/10.1074/jbc.M405217200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15213222	hybrid			2022-12-25	WOS:000223684100078
J	Lorch, JH; Klessner, J; Park, JK; Getsios, S; Wu, YL; Stack, MS; Green, KJ				Lorch, JH; Klessner, J; Park, JK; Getsios, S; Wu, YL; Stack, MS; Green, KJ			Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITOR; BETA-CATENIN; E-CADHERIN; MONOCLONAL-ANTIBODY; PROSTATE-CANCER; DOWN-REGULATION; ZD1839 IRESSA; FACTOR-ALPHA; DESMOPLAKIN; PLAKOGLOBIN	The epidermal growth factor receptor (EGFR) has been proposed as a key modulator of cadherin-containing intercellular junctions, particularly in tumors that overexpress this tyrosine kinase. Here the EGFR tyrosine kinase inhibitor PKI166 and EGFR blocking antibody C225, both of which are used clinically to treat head and neck cancers, were used to determine the effects of EGFR inhibition on intercellular junction assembly and adhesion in oral squamous cell carcinoma cells. EGFR inhibition resulted in a transition from a fibroblastic morphology to a more epithelial phenotype in cells grown in low calcium; under these conditions cadherin-mediated cell-cell adhesion is normally reduced, and desmosomes are absent. The accumulated levels of desmoglein 2 (Dsg2) and desmocollin 2 increased 1.7-2.0-fold, and both desmosomal cadherin and plaque components were recruited to cell-cell borders. This redistribution was paralleled by an increase in Dsg2 and desmoplakin in the Triton-insoluble cell fraction, suggesting that EGFR blockade promotes desmosome assembly. Importantly, E-cadherin expression and solubility were unchanged. Furthermore, PKI166 blocked tyrosine phosphorylation of Dsg2 and plakoglobin following epidermal growth factor stimulation, whereas no change in phosphorylation was detected for E-cadherin and beta-catenin. The increase in Dsg2 protein was in part due to the inhibition of matrix metalloproteinase-dependent proteolysis of this desmosomal cadherin. These morphological and biochemical changes were accompanied by an increase in intercellular adhesion based on functional assays at all calcium concentrations tested. Our results suggest that EGFR inhibition promotes desmosome assembly in oral squamous cell carcinoma cells, resulting in increased cell-cell adhesion.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Lorch, JH (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA080621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80621] Funding Source: Medline; NIAMS NIH HHS [R01 AR 41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE 12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Al Moustafa AE, 2002, LUNG CANCER, V37, P49, DOI 10.1016/S0169-5002(02)00025-9; Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; Anderson NG, 2002, FRONT BIOSCI-LANDMRK, V7, pD1926, DOI 10.2741/anderson; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; ANGST BD, 1990, J CELL SCI, V97, P247; Bruns CJ, 2000, CANCER RES, V60, P2926; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; Depondt J, 1999, EUR J ORAL SCI, V107, P183, DOI 10.1046/j.0909-8836.1999.eos1070305.x; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Ghosh S, 2002, CANCER-AM CANCER SOC, V95, P2524, DOI 10.1002/cncr.10997; GRANDIS JR, 1993, CANCER RES, V53, P3579; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Herbst RS, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.35644; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 2001, J INVEST DERMATOL, V117, P26, DOI 10.1046/j.0022-202x.2001.01400.x; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Janmaat ML, 2003, DRUG TODAY, V39, P61; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Laird AD, 2003, EXPERT OPIN INV DRUG, V12, P51, DOI 10.1517/eoid.12.1.51.21253; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Mellinghoff IK, 2002, CANCER RES, V62, P5254; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; Motoyama AB, 2002, CANCER RES, V62, P3151; Myers JN, 2002, ARCH OTOLARYNGOL, V128, P875, DOI 10.1001/archotol.128.8.875; Noe V, 2001, J CELL SCI, V114, P111; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shimizu T, 2001, DERMATOLOGY, V202, P203, DOI 10.1159/000051637; Shiozaki H, 1995, Nihon Rinsho, V53, P1602; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; VALLES AM, 1990, CELL REGUL, V1, P975, DOI 10.1091/mbc.1.13.975; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wells A, 2000, ADV CANCER RES, V78, P31; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yang ZB, 2004, CLIN CANCER RES, V10, P658, DOI 10.1158/1078-0432.CCR-0382-03	54	118	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37191	37200		10.1074/jbc.M405123200	http://dx.doi.org/10.1074/jbc.M405123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15205458	hybrid			2022-12-25	WOS:000223453600123
J	Perlow-Poehnelt, RA; Likhterov, I; Scicchitano, DA; Geacintov, NE; Broyde, S				Perlow-Poehnelt, RA; Likhterov, I; Scicchitano, DA; Geacintov, NE; Broyde, S			The spacious active site of a Y-family DNA polymerase facilitates promiscuous nucleotide incorporation opposite a bulky carcinogen-DNA adduct - Elucidating the structure-function relationship through experimental and computational approaches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BENZO<A>PYRENE DIOL EPOXIDE; I KLENOW FRAGMENT; POLYCYCLIC AROMATIC-HYDROCARBONS; MINOR-GROOVE INTERACTIONS; TEMPLATE-PRIMER JUNCTION; ESCHERICHIA-COLI PLASMID; LESION-BYPASS; SEQUENCE CONTEXT; DEOXYGUANOSINE ADDUCTS; MUTAGENIC SPECIFICITY	Y-family DNA polymerases lack some of the mechanisms that replicative DNA polymerases employ to ensure fidelity, resulting in higher error rates during replication of undamaged DNA templates and the ability to bypass certain aberrant bases, such as those produced by exposure to carcinogens, including benzo[a]pyrene (BP). A tumorigenic metabolite of BP, (+)-anti-benzo-[a] pyrene diol epoxide, attacks DNA to form the major 10S (+)-trans-anti-[BP]-N-2-dG adduct, which has been shown to be mutagenic in a number of prokaryotic and eukaryotic systems. The 10S (+)-trans-anti-[BP]-N-2-dG adduct can cause all three base substitution mutations, and the SOS response in Escherichia coli increases bypass of bulky adducts, suggesting that Y-family DNA polymerases are involved in the bypass of such lesions. Dpo4 belongs to the DinB branch of the Y-family, which also includes E. coli pol IV and eukaryotic pol kappa. We carried out primer extension assays in conjunction with molecular modeling and molecular dynamics studies in order to elucidate the structure-function relationship involved in nucleotide incorporation opposite the bulky 10S (+)-trans-anti-[BP]-N-2-dG adduct by Dpo4. Dpo4 is able to bypass the 10S (+)-trans-anti-[BP]-N-2-dG adduct, albeit to a lesser extent than unmodified guanine, and the V-max values for insertion of all four nucleotides opposite the adduct by Dpo4 are similar. Computational studies suggest that 10S (+)-trans-anti-[BP]-N-2-dG can be accommodated in the active site of Dpo4 in either the anti or syn conformation due to the limited protein-DNA contacts and the open nature of both the minor and major groove sides of the nascent base pair, which can contribute to the promiscuous nucleotide incorporation opposite this lesion.	NYU, Dept Biol, New York, NY 10003 USA; NYU, Dept Chem, New York, NY 10003 USA	New York University; New York University	Broyde, S (corresponding author), NYU, Dept Biol, New York, NY 10003 USA.	broyde@nyu.edu			NATIONAL CANCER INSTITUTE [R01CA076660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010581] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76660] Funding Source: Medline; NIEHS NIH HHS [ES 10581] Funding Source: Medline; PHS HHS [CZA 28038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u; Alekseyev YO, 2002, BIOCHEMISTRY-US, V41, P4467, DOI 10.1021/bi015850l; Alekseyev YO, 2001, BIOCHEMISTRY-US, V40, P2282, DOI 10.1021/bi002245u; Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; Cheatham TE, 1999, J BIOMOL STRUCT DYN, V16, P845, DOI 10.1080/07391102.1999.10508297; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; CONNEY AH, 1982, CANCER RES, V42, P4875; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cook JW, 1933, J CHEM SOC, P395, DOI 10.1039/jr9330000395; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Duvauchelle JB, 2002, NUCLEIC ACIDS RES, V30, P2061, DOI 10.1093/nar/30.9.2061; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gonzalez M, 2002, BIOESSAYS, V24, P141, DOI 10.1002/bies.10040; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Grimmer G, 1997, INT ARCH OCC ENV HEA, V69, P231, DOI 10.1007/s004200050141; GRIMMER G, 1993, POLYCYCLIC AROMATIC COMPOUNDS : SYNTHESIS, PROPERTIES, ANALYTICAL MEASUREMENTS, OCCURRENCE AND BIOLOGICAL EFFECTS, P31; Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925; Harvey SC, 1998, J COMPUT CHEM, V19, P726, DOI 10.1002/(SICI)1096-987X(199805)19:7<726::AID-JCC4>3.0.CO;2-S; HINGERTY BE, 1985, BIOPOLYMERS, V24, P427, DOI 10.1002/bip.360240302; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; KOKOSKA RJ, 2003, J BIOL CHEM, V30, P30; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; LING H, 2004, P NATL ACAD SCI USA, V13, P13; Lipinski LJ, 1998, INT J ONCOL, V13, P269; MACKAY W, 1992, CARCINOGENESIS, V13, P1415, DOI 10.1093/carcin/13.8.1415; MAO B, 1995, CARCINOGENESIS, V16, P357, DOI 10.1093/carcin/16.2.357; MEEHAN T, 1979, NATURE, V277, P410, DOI 10.1038/277410a0; Mezei M, 1997, J COMPUT CHEM, V18, P812, DOI 10.1002/(SICI)1096-987X(19970430)18:6<812::AID-JCC6>3.0.CO;2-V; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Perlow RA, 2003, J MOL BIOL, V327, P797, DOI 10.1016/S0022-2836(03)00187-6; Perlow RA, 2002, J MOL BIOL, V322, P291, DOI 10.1016/S0022-2836(02)00751-9; Perlow RA, 2001, J MOL BIOL, V309, P519, DOI 10.1006/jmbi.2001.4674; PERRIN JL, 1993, POLYCYCLIC AROMATIC COMPOUNDS : SYNTHESIS, PROPERTIES, ANALYTICAL MEASUREMENTS, OCCURRENCE AND BIOLOGICAL EFFECTS, P337; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; Pirogov N, 1998, CHEM RES TOXICOL, V11, P381, DOI 10.1021/tx980006q; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; RODRIGUEZ H, 1993, BIOCHEMISTRY-US, V32, P1759, DOI 10.1021/bi00058a009; RODRIGUEZ H, 1995, MUTAT RES-FUND MOL M, V326, P29, DOI 10.1016/0027-5107(95)00149-D; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shcherbakova Polina V, 2003, Sci Aging Knowledge Environ, V2003, pRE3, DOI 10.1126/sageke.2003.8.re3; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; Shukla R, 1997, BIOCHEMISTRY-US, V36, P13263, DOI 10.1021/bi971195z; Shukla R, 1997, BIOCHEMISTRY-US, V36, P10256, DOI 10.1021/bi970541+; Shukla R, 1999, CARCINOGENESIS, V20, P261, DOI 10.1093/carcin/20.2.261; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Tan J, 2000, CHEM RES TOXICOL, V13, P811, DOI 10.1021/tx000094q; Vaisman A, 2002, MUTAT RES-FUND MOL M, V510, P9, DOI 10.1016/S0027-5107(02)00248-8; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; Volk DE, 2003, BIOCHEMISTRY-US, V42, P1410, DOI 10.1021/bi026745u; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Xie XM, 1999, BIOCHEMISTRY-US, V38, P2956, DOI 10.1021/bi9825605; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9; Yin J, 2004, DNA REPAIR, V3, P323, DOI 10.1016/j.dnarep.2003.11.012; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o	108	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36951	36961		10.1074/jbc.M404332200	http://dx.doi.org/10.1074/jbc.M404332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15210693	hybrid			2022-12-25	WOS:000223453600098
J	de Souza-Pinto, NC; Harris, CC; Bohr, VA				de Souza-Pinto, NC; Harris, CC; Bohr, VA			p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria	ONCOGENE			English	Article						p53; mitochondrial DNA; DNA repair; BER; uracil	MICROSATELLITE INSTABILITY; POLYMERASE-GAMMA; LYASE ACTIVITY; NUCLEAR-DNA; URACIL; IDENTIFICATION; INVOLVEMENT; INCISION; BINDING; PROTEIN	The tumor suppressor p53 protein stimulates nuclear base excision repair (BER) in vitro. In response to certain cellular stresses, p53 translocates to mitochondria, where it can trigger an apoptotic response. However, a potential role for p53 in modulating mitochondrial DNA repair has not yet been examined. In this study, we show that p53 also modulates mitochondrial BER. Uracil-initiated BER incorporation, which measures flux through the entire BER pathway, was lower in mitochondrial extracts from nonstressed p53 knockout mice than in wild type. The addition of recombinant p53 complemented the BER incorporation in p53 knockout extracts and stimulated BER in wt extracts. The activities of three major mitochondrial DNA glycosylases were similar in extracts from wild-type and knockout animals. Likewise, AP endonuclease activity was unaffected by the absence of p53. Gel shift experiments with recombinant p53 demonstrated that p53 did not bind to the uracil-containing substrate used in the repair assay. Polymerase gamma gap-filing activity was less efficient in p53 knockout extracts, but it was complemented with the addition of recombinant p53. Thus, we conclude that p53 may participate in mtBER by stimulating the repair synthesis incorporation step.	NIA, Lab Mol Gerontol, GRC,IRP, NIH, Baltimore, MD 21224 USA; NCI, Human Carcinogenesis Lab, CTR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, GRC,IRP, NIH, 5600 Nathon Shock Dr,Box 1, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; EVANS MK, 1993, CANCER RES, V53, P5377; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Krokan HE, 1997, BIOCHEM J, V325, P1; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; NILSEN H, 1997, NUCLEIC ACIDS RES, V21, P2579; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; TAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V216, P715, DOI 10.1006/bbrc.1995.2680; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Yamada NA, 2002, CANCER RES, V62, P6061; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	38	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6559	6568		10.1038/sj.onc.1207874	http://dx.doi.org/10.1038/sj.onc.1207874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208669				2022-12-25	WOS:000223530800003
J	Bocharov, AV; Baranova, IN; Vishnyakova, TG; Remaley, AT; Csako, G; Thomas, F; Patterson, AP; Eggerman, TL				Bocharov, AV; Baranova, IN; Vishnyakova, TG; Remaley, AT; Csako, G; Thomas, F; Patterson, AP; Eggerman, TL			Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TOLL-LIKE RECEPTOR-4; APOLIPOPROTEIN-A-I; INTESTINAL EPITHELIAL-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; GOLGI-APPARATUS; SR-BI; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; CHOLESTERYL ESTER	Human scavenger receptor class B type I, CLA-1, mediates lipopolysaccharide (LPS) binding and internalization (Vishnyakova, T.G., Bocharov, A.V., Baranova, I.N., Chen, Z., Remaley, A.T., Csako, G., Eggerman, T.L., and Patterson, A. P. (2003) J. Biol. Chem. 278, 22771-22780). Because one of the recognition motifs in SR-B1 ligands is the anionic amphipathic alpha-helix, we analyzed the effects of model amphipathic alpha-helical-containing peptides on LPS uptake and LPS-stimulated cytokine production. The L-37pA model peptide, containing two class A amphipathic helices, bound with high affinity (K-d=0.94 mug/ml) to CLA-1-expressing HeLa cells with a 10-fold increased capacity when compared with mock transfected HeLa cells. Both LPS and L-37pA colocalized with anti-CLA-1 antibody and directly bound CLA-1 as determined by cross-linking. SR-BI/CLA-1 ligands such as HDL, apoA-I, and L-37pA efficiently competed against iodinated L-37pA. Bacterial LPS, lipoteichoic acid, and hsp60 also competed against iodinated L-37pA. Model peptides blocked uptake of iodinated LPS in both mock transfected and CLA-1-overexpressing HeLa cells. Bound and internalized Alexa-L-37pA and BODIPY-LPS colocalized at the cell surface and perinuclear compartment. Both ligands were predominantly transported to the Golgi complex, colocalizing with the Golgi markers bovine serum albumin-ceramide, anti-Golgin97 antibody, and cholera toxin subunit B. A 100-fold excess of L-37pA nearly eliminated BODIPY-LPS binding and internalization. L-37pA and its D-amino acid analogue, D-37pA peptide were similarly effective in blocking LPS, Gram-positive bacterial wall component lipoteichoic acid and bacterial heat shock protein Gro-EL-stimulated cytokine secretion in THP-1 cells. In the same culture media used for the cytokine stimulation study, neither L-37pA nor D-37pA affected the Limulus amebocyte lysate activity of LPS, indicating that LPS uptake and cytokine stimulation were blocked independently of LPS neutralization. These results demonstrate that amphipathic helices of exchangeable apolipoproteins may represent a general host defense mechanism against inflammation.	NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA; NIH, Dept Lab Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bocharov, AV (corresponding author), NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, 6707 Democracy Blvd,Rm 697,MSC5460, Bethesda, MD 20892 USA.	abocharov@mail.cc.nih.gov; eggermant@extra.niddk.nih.gov			CLINICAL CENTER [Z01CL010306] Funding Source: NIH RePORTER	CLINICAL CENTER		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Chen W, 1999, J IMMUNOL, V162, P3212; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cockerill GW, 2001, CIRCULATION, V103, P108; COHEN J, 1985, LANCET, V2, P1069; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; FAIRWELL T, 1987, P NATL ACAD SCI USA, V84, P4796, DOI 10.1073/pnas.84.14.4796; Garber DW, 2001, J LIPID RES, V42, P545; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Han Chang-Hoon, 2002, J Vet Sci, V3, P265; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Hirata M, 1995, Prog Clin Biol Res, V392, P317; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; KANG YH, 1990, J LEUKOCYTE BIOL, V48, P316, DOI 10.1002/jlb.48.4.316; KRIEGSMANN J, 1993, CELL MOL BIOL, V39, P791; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Levels JHM, 2001, INFECT IMMUN, V69, P2821, DOI 10.1128/IAI.69.5.2821-2828.2001; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Magee T, 2002, BIOL RES, V35, P127, DOI 10.4067/S0716-97602002000200003; Matveev S, 2001, EUR J BIOCHEM, V268, P5609, DOI 10.1046/j.1432-1033.2001.02496.x; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Moudry R, 1997, SHOCK, V7, P175, DOI 10.1097/00024382-199703000-00004; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Ogata M, 1997, INFECT IMMUN, V65, P2160, DOI 10.1128/IAI.65.6.2160-2167.1997; Periti P, 1999, INT J ANTIMICROB AG, V12, P97, DOI 10.1016/S0924-8579(99)00044-8; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Risso A, 1998, CELL IMMUNOL, V189, P107, DOI 10.1006/cimm.1998.1358; Schulthess G, 2000, BIOCHEMISTRY-US, V39, P12623, DOI 10.1021/bi0011633; Seternes T, 2001, J EXP BIOL, V204, P4055; Shah PK, 2001, CIRCULATION, V104, P2376, DOI 10.1161/hc4401.098467; SHNYRA A, 1995, INFECT IMMUN, V63, P865, DOI 10.1128/IAI.63.3.865-873.1995; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsuneyama K, 2001, J HEPATOL, V35, P156, DOI 10.1016/S0168-8278(01)00084-8; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Van Lenten BJ, 2002, CIRCULATION, V106, P1127, DOI 10.1161/01.CIR.0000030182.35880.3E; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; van OOsten M, 2001, J ENDOTOXIN RES, V7, P381, DOI 10.1177/09680519010070050601; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Zhang GH, 1995, APMIS, V103, P721	58	51	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36072	36082		10.1074/jbc.M314264200	http://dx.doi.org/10.1074/jbc.M314264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15199068	hybrid			2022-12-25	WOS:000223303400109
J	Goldschmidt, V; Paillart, JC; Rigourd, ML; Ehresmann, B; Aubertin, AM; Ehresmann, C; Marquet, R				Goldschmidt, V; Paillart, JC; Rigourd, ML; Ehresmann, B; Aubertin, AM; Ehresmann, C; Marquet, R			Structural variability of the initiation complex of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE COMPLEMENTARY; PRIMER ACTIVATION SIGNAL; STRAND DNA-SYNTHESIS; PSI-C LOOP; TRANSFER-RNA; SECONDARY STRUCTURE; VIRAL-RNA; EFFICIENT INITIATION; NUCLEOCAPSID PROTEIN	HIV-1 reverse transcription is initiated from a tRNA(3)(Lys) molecule annealed to the viral RNA at the primer binding site (PBS), but the structure of the initiation complex of reverse transcription remains controversial. Here, we performed in situ structural probing, as well as in vitro structural and functional studies, of the initiation complexes formed by highly divergent isolates (MAL and NL4.3/HXB2). Our results show that the structure of the initiation complex is not conserved. In MAL, and according to sequence analysis in 14% of HIV-1 isolates, formation of the initiation complex is accompanied by complex rearrangements of the viral RNA, and extensive interactions with tRNA(3)(Lys) are required for efficient initiation of reverse transcription. In NL4.3, HXB2, and most isolates, tRNA(3)(Lys) annealing minimally affects the viral RNA structure and no interaction outside the PBS is required for optimal initiation of reverse transcription. We suggest that in MAL, extensive interactions with tRNA(3)(Lys) are required to drive the structural rearrangements generating the structural elements ultimately recognized by reverse transcriptase. In NL4.3 and HXB2, these elements are already present in the viral RNA prior to tRNA(3)(Lys) annealing, thus explaining that extensive interactions with the primer are not required. Interestingly, such interactions are required in HXB2 mutants designed to use a non-cognate tRNA as primer (tRNA(His)). In the latter case, the extended interactions are required to counteract a negative contribution associate with the alternate primer.	Univ Strasbourg, IBMC, CNRS Conventionnee, Unite Propre Rech 9002, F-67084 Strasbourg, France; Univ Strasbourg, Inst Virol, INSERM, UMR544, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Marquet, R (corresponding author), Univ Strasbourg, IBMC, CNRS Conventionnee, Unite Propre Rech 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	r.marquet@ibmc.u-strasbg.fr	Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Dupuy LC, 2003, J VIROL, V77, P8756, DOI 10.1128/JVI.77.16.8756-8764.2003; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fosse P, 1998, J MOL BIOL, V275, P731, DOI 10.1006/jmbi.1997.1487; Freund F, 2001, NUCLEIC ACIDS RES, V29, P2757, DOI 10.1093/nar/29.13.2757; Gabor J, 2002, J VIROL, V76, P9096, DOI 10.1128/JVI.76.18.9096-9102.2002; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Goldschmidt V, 2003, NUCLEIC ACIDS RES, V31, P850, DOI 10.1093/nar/gkg187; Goldschmidt V, 2002, J BIOL CHEM, V277, P43233, DOI 10.1074/jbc.M205295200; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Iwatani Y, 2003, J BIOL CHEM, V278, P14185, DOI 10.1074/jbc.M211618200; Kang SM, 1999, VIROLOGY, V257, P95, DOI 10.1006/viro.1999.9615; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kuiken C, 2000, HUMAN RETROVIRUSES A; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Le Grice SFJ, 2003, BIOCHEMISTRY-US, V42, P14349, DOI 10.1021/bi030201q; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Miller JT, 2001, J BIOL CHEM, V276, P27721, DOI 10.1074/jbc.M100513200; MOOG C, 1994, ANTIVIR RES, V24, P275, DOI 10.1016/0166-3542(94)90075-2; Morris S, 2002, J VIROL, V76, P7571, DOI 10.1128/JVI.76.15.7571-7577.2002; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Rigourd M, 2003, NUCLEIC ACIDS RES, V31, P5764, DOI 10.1093/nar/gkg754; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	49	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35923	35931		10.1074/jbc.M404473200	http://dx.doi.org/10.1074/jbc.M404473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15194685	hybrid			2022-12-25	WOS:000223303400093
J	Marz, P; Probst, A; Lang, S; Schwager, M; Rose-John, S; Otten, U; Ozbek, S				Marz, P; Probst, A; Lang, S; Schwager, M; Rose-John, S; Otten, U; Ozbek, S			Ataxin-10, the spinocerebellar ataxia type 10 neurodegenerative disorder protein, is essential for survival of cerebellar neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLINICAL-FEATURES; REPEAT EXPANSION; ATTCT REPEAT; PATHOGENESIS; FRATAXIN; REGION	Spinocerebellar ataxia (SCA) type 10, an autosomal dominant disease characterized by cerebellar ataxia, is caused by a novel pentanucleotide (ATTCT) repeat expansion in the SCA10 gene. Although clinical features of the disease are well characterized, nothing is known so far about the affected SCA10 gene product, ataxin-10 (Atx-10). We have cloned the rat SCA10 gene and expressed the corresponding protein in HEK293 cells. Atx-10 has an apparent molecular mass of similar to55 kDa and belongs to the family of armadillo repeat proteins. In solution, it tends to form homotrimeric complexes, which associate via a tip-to-tip contact with the concave sides of the molecules facing each other. Atx-10 immunostaining of mouse and human brain sections revealed a predominantly cytoplasmic and perinuclear localization with a clear restriction to olivocerebellar regions. Knock down of SCA10 in primary neuronal cells by small interfering RNAs resulted in an increased apoptosis of cerebellar neurons, arguing for a loss-of-function phenotype in SCA10 patients.	Univ Basel, Inst Physiol, CH-4051 Basel, Switzerland; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Basel; University of Basel; University of Kiel; University of Basel	Marz, P (corresponding author), Univ Basel, Inst Physiol, Vesalgasse 1, CH-4051 Basel, Switzerland.	p.maerz@unibas.ch	Özbek, Suat/D-3701-2014; Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Ozbek, Suat/0000-0003-2569-3942				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; HARDING AE, 1981, J MED GENET, V18, P436, DOI 10.1136/jmg.18.6.436; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Lin X, 2003, CYTOGENET GENOME RES, V100, P184, DOI 10.1159/000072853; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; Matsuura T, 2004, AM J HUM GENET, V74, P1216, DOI 10.1086/421526; Paulson H, 2002, LANCET NEUROL, V1, P471, DOI 10.1016/S1474-4422(02)00234-X; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; Rasmussen A, 2001, ANN NEUROL, V50, P234, DOI 10.1002/ana.1081; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Tapscott SJ, 2000, SCIENCE, V289, P1701, DOI 10.1126/science.289.5485.1701; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 2000, NEUROBIOL DIS, V7, P523, DOI 10.1006/nbdi.2000.0346	26	42	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35542	35550		10.1074/jbc.M405865200	http://dx.doi.org/10.1074/jbc.M405865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15201271	hybrid			2022-12-25	WOS:000223303400049
J	Singh, A; Rosenthal, PJ				Singh, A; Rosenthal, PJ			Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; HALOFANTRINE RESISTANCE; CHLOROQUINE RESISTANCE; DRUG-RESISTANCE; PROTEINASE; MEFLOQUINE; MUTATIONS; ANTIMALARIALS; EXPRESSION; INDUCTION	Cysteine protease inhibitors are being studied as possible new antimalarial agents. To evaluate the potential for resistance to these compounds, we subjected chloroquine-resistant (W2 strain) Plasmodium falciparum to increasing concentrations of a vinyl sulfone cysteine protease inhibitor. After incubation with 1-200 nM morpholine urea-leucine-homophenylalanine-phenyl vinyl sulfone over approximately 8 months, highly resistant parasites (similar to100-fold increases in IC50) were selected. The vinyl sulfone-resistant parasites were also resistant to related peptidyl inhibitors, but had only modest (similar to2-fold) decreases in sensitivity to other cysteine protease inhibitors. Compared with the parental strain, resistant parasites showed no changes in multiplication rates, but elevations in cysteine protease activity, falcipain-2 and falcipain-3 copy numbers, transcription of falcipain genes, and levels of these target proteases in trophozoites. Resistant parasites grown in the absence of the vinyl sulfone for 12 weeks showed partial reversion, with increased inhibitor sensitivity and apparent decreases in copy numbers of falcipain-2 and falcipain-3. The sequences of falcipain-1, falcipain-2, and falcipain-3 were identical in sensitive and resistant parasites. The accumulation of a vinyl sulfone inhibitor was decreased approximately 9-fold in resistant parasites. In summary, parasites resistant to a cysteine protease inhibitor were selected, although the acquisition of high level resistance required extended exposure to the inhibitor and this resistance was somewhat unstable. Resistance was specific for the type of protease inhibitor used for the selection and appeared to be mediated both by alterations in inhibitor transport and by a previously unidentified mechanism in P. falciparum, the amplification of genes encoding targets of enzyme inhibitors.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.	rosnthl@itsa.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035800, R29AI035800, R01AI035800] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BANYAL HS, 1986, EXP PARASITOL, V62, P61, DOI 10.1016/0014-4894(86)90008-1; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; ODUOLA AMJ, 1988, EXP PARASITOL, V67, P354, DOI 10.1016/0014-4894(88)90082-3; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; PEEL SA, 1994, AM J TROP MED HYG, V51, P648, DOI 10.4269/ajtmh.1994.51.648; Pickard AL, 2003, ANTIMICROB AGENTS CH, V47, P2418, DOI 10.1128/AAC.47.8.2418-2423.2003; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; Rosenthal PJ, 2001, INFEC DIS S, P325; Rosenthal PJ, 2002, CURR PHARM DESIGN, V8, P1659, DOI 10.2174/1381612023394197; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Singh A, 2002, BIOCHEM J, V368, P273, DOI 10.1042/BJ20020753; Singh A, 2001, ANTIMICROB AGENTS CH, V45, P949, DOI 10.1128/AAC.45.3.949-951.2001; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; WILSON CM, 1993, MOL BIOCHEM PARASIT, V57, P151, DOI 10.1016/0166-6851(93)90252-S; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6	36	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35236	35241		10.1074/jbc.M404235200	http://dx.doi.org/10.1074/jbc.M404235200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15192087	hybrid			2022-12-25	WOS:000223303400014
J	Albinsson, S; Nordstrom, I; Hellstrand, P				Albinsson, S; Nordstrom, I; Hellstrand, P			Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; RAT PORTAL-VEIN; GENE-EXPRESSION; PROTEIN-KINASE; INTRALUMINAL PRESSURE; MOLECULAR-MECHANISMS; ORGAN-CULTURE; LIM-KINASE; ACTIVATION	Stretch of the vascular wall by the intraluminal blood pressure stimulates protein synthesis and contributes to the maintenance of the smooth muscle contractile phenotype. The expression of most smooth muscle specific genes has been shown to be regulated by serum response factor and stimulated by increased actin polymerization. Hence we hypothesized that stretch-induced differentiation is promoted by actin polymerization. Intact mouse portal veins were cultured under longitudinal stress and compared with unstretched controls. In unstretched veins the rates of synthesis of several proteins associated with the contractile/cytoskeletal system (alpha-actin, calponin, SM22alpha, tropomyosin, and desmin) were dramatically lower than in stretched veins, whereas other proteins (beta-actin and heat shock proteins) were synthesized at similar rates. The cytoskeletal proteins beta-actin and vimentin were weakly stretch-sensitive. Inhibition of Rho-associated kinase by culture of stretched veins with Y-27632 produced similar but weaker effects compared with the absence of mechanical stress. Induction of actin polymerization by jasplakinolide increased SM22alpha synthesis in unstretched veins to the level in stretched veins. Stretch stimulated Rho activity and phosphorylation of the actin-severing protein cofilin-2, although both effects were slow in onset (Rho-GTP, > 15 min; cofilin-P, > 1 h). Cofilin-2 phosphorylation of stretched veins was inhibited by Y-27632. The F/G-actin ratio after 24 h of culture was significantly greater in stretched than in unstretched veins, as shown by both ultracentrifugation and confocal imaging with phalloidin/DNase I labeling. The results show that stretch of the vascular wall stimulates increased actin polymerization, activating synthesis of smooth muscle-specific proteins. The effect is partially, but probably not completely, mediated via Rho-associated kinase and cofilin downstream of Rho.	Lund Univ, Div Mol & Cellular Physiol, Dept Physiol Sci, Ctr Biomed, SE-22184 Lund, Sweden	Lund University	Hellstrand, P (corresponding author), BMC F12, SE-22184 Lund, Sweden.	Per.Hellstrand@mphy.lu	Albinsson, Sebastian/B-4105-2010	Albinsson, Sebastian/0000-0001-6936-3967				ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; Birukov KG, 1997, CIRC RES, V81, P895; Birukov KG, 1998, ARTERIOSCL THROM VAS, V18, P922, DOI 10.1161/01.ATV.18.6.922; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cipolla MJ, 2002, FASEB J, V16, P72, DOI 10.1096/cj.01-0104hyp; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Jakkaraju S, 2003, TRENDS CARDIOVAS MED, V13, P330, DOI 10.1016/j.tcm.2003.08.004; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MALMQVIST U, 1990, CIRC RES, V66, P832, DOI 10.1161/01.RES.66.3.832; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Numaguchi K, 1999, CIRC RES, V85, P5; OWENS GK, 1995, PHYSIOL REV, V75, P487; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang L, 2004, AM J RESP CELL MOL, V31, P54, DOI 10.1165/rcmb.2003-0240OC; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zeidan A, 2000, CIRC RES, V87, P228, DOI 10.1161/01.RES.87.3.228; Zeidan A, 2004, FEBS LETT, V562, P141, DOI 10.1016/S0014-5793(04)00220-0; Zeidan A, 2003, ARTERIOSCL THROM VAS, V23, P1528, DOI 10.1161/01.ATV.0000090129.75275.C2; Zeidan A, 2003, AM J PHYSIOL-CELL PH, V284, pC1387, DOI 10.1152/ajpcell.00508.2002; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	43	124	127	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34849	34855		10.1074/jbc.M403370200	http://dx.doi.org/10.1074/jbc.M403370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184395	hybrid			2022-12-25	WOS:000223134800094
J	Argast, GM; Campbell, JS; Brooling, JT; Fausto, N				Argast, GM; Campbell, JS; Brooling, JT; Fausto, N			Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR-ALPHA; EGF RECEPTOR; TRANSFORMING GROWTH; LIVER-REGENERATION; EPITHELIAL-CELLS; DNA-REPLICATION; TGF-ALPHA; MICE; PROLIFERATION	Tumor necrosis factor (TNF) has multiple biological effects such as participating in inflammation, apoptosis, and cell proliferation, but the mechanisms of its effects on epithelial cell proliferation have not been examined in detail. At the early stages of liver regeneration, TNF functions as a priming agent for hepatocyte replication and increases the sensitivity of hepatocytes to growth factors such as transforming growth factor alpha (TGFalpha); however, the mechanisms by which TNF interacts with growth factors and enhances hepatocyte replication are not known. Using the AML-12 hepatocyte cell line, we show that TNF stimulates proliferation of these cells through transactivation of the epidermal growth factor receptor ( EGFR). The transactivation mechanism involves the release of TGFalpha into the medium through activation of the metalloproteinase TNFalpha-converting enzyme ( also known as ADAM 17). Binding of the ligand to EGFR initiates a mitogenic cascade through extracellular signal-regulated kinases 1 and 2 and the partial involvement of protein kinase B. TNF-induced release of TGFalpha and activation of EGFR signaling were inhibited by TNFalpha protease inhibitor-1, an agent that interferes with TNFalpha-converting enzyme activity. We suggest that TNF-induced transactivation of EGFR may provide an early signal for the entry of hepatocytes into the cell cycle and may integrate proliferative and survival pathways at the start of liver regeneration.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Boulder	Fausto, N (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	nfausto@u.washington.edu		Campbell, Jean/0000-0002-9187-2204	NCI NIH HHS [CA 23226] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07032-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023226, R37CA023226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blindenbacher A, 2003, HEPATOLOGY, V38, P674, DOI 10.1053/jhep.2003.50378; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Chen WNU, 2004, J BIOL CHEM, V279, P18488, DOI 10.1074/jbc.M310874200; Chiu H, 2003, TOXICOL APPL PHARM, V193, P218, DOI 10.1016/j.taap.2003.07.003; Chobotova K, 2002, J CLIN ENDOCR METAB, V87, P5769, DOI 10.1210/jc.2002-020069; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gallucci RM, 2000, J IMMUNOL, V164, P872, DOI 10.4049/jimmunol.164.2.872; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Kalmes A, 2001, ANN NY ACAD SCI, V947, P42; Kheradmand F, 2002, J CELL SCI, V115, P839; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; SEGER R, 1994, J BIOL CHEM, V269, P25699; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallenius V, 2001, ENDOCRINOLOGY, V142, P2953, DOI 10.1210/en.142.7.2953; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Xiao ZQ, 2001, AM J PHYSIOL-GASTR L, V281, pG111, DOI 10.1152/ajpgi.2001.281.1.G111; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	39	88	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34530	34536		10.1074/jbc.M405703200	http://dx.doi.org/10.1074/jbc.M405703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15199050	hybrid			2022-12-25	WOS:000223134800056
J	Nadeau, KJ; Leitner, JW; Gurerich, I; Draznin, B				Nadeau, KJ; Leitner, JW; Gurerich, I; Draznin, B			Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GENE-EXPRESSION; SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; DIABETES-MELLITUS; GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; ADIPOSE-TISSUE; FATTY RATS; KINASE	Sterol regulatory element-binding proteins (SREBPs) are transcription factors that regulate enzymes required for cholesterol and fatty acid synthesis. Expression of SREBP-1 is enhanced by insulin; however, the actual insulin-signaling cascades employed are yet unclear. We determined the roles of the phosphatidylinositol (PI) 3-kinase and mitogen-activated protein (MAP) kinase-dependent pathways in the effect of mediating insulin on SREBP-1 in L-6 skeletal muscle cells and 3T3 L1 adipocytes, using wortmannin or LY294002 to inhibit the PI 3-kinase pathway, and PD98059 to inhibit the MAP kinase-dependent pathway. In myocytes, insulin increased SREBP-1 protein in a dose-dependent manner. 1 and 10 nM insulin significantly increased expression of total cellular SREBP-1 protein at 24 and 48 h, nuclear SREBP-1 protein at 24 h, and SREBP-1a mRNA at 24 h. Although wortmannin and LY294002 had no effect on this aspect of insulin action, PD98059 completely blocked each of these responses. Transfection of a dominant negative mutant of Ras similarly blocked the insulin effect on SREBP-1. In contrast, in adipocytes, the insulin effect on SREBP-1 was mediated via the PI 3-kinase and not the MAP kinase pathway. In conclusion, although insulin increases skeletal muscle SREBP-1 expression in a dose-dependent fashion via the MAP kinase-dependent signaling pathway, insulin action on adipocyte SREBP-1 is mediated via the PI 3-kinase signaling pathway. In the state of insulin resistance, characterized by selective inhibition of the PI 3-kinase pathway, the usual stimulation of lipogenesis by insulin in adipocytes may be inhibited, whereas intramyocellular lipogenesis via the MAP kinase pathway of insulin may continue unabated.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Metab & Diabet, Denver, CO 80262 USA; Denver VA Med Ctr, Vet Affairs Res Serv, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Nadeau, KJ (corresponding author), Pediat Endocrinol Box 256,1056 E 19th Ave, Denver, CO 80218 USA.	kristen.nadeau@UCHSC.edu						Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; Bajaj M, 2003, DIABETES, V52, P1364, DOI 10.2337/diabetes.52.6.1364; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722; Gunton JE, 2003, J CLIN ENDOCR METAB, V88, P1323, DOI 10.1210/jc.2002-021394; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim SJ, 1997, BIOCHEM J, V323, P621, DOI 10.1042/bj3230621; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kim YB, 2002, DIABETES, V51, P443, DOI 10.2337/diabetes.51.2.443; Kotzka J, 2000, J LIPID RES, V41, P99; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Kuhlmann J, 2003, DIABETES, V52, P138, DOI 10.2337/diabetes.52.1.138; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Montagnani M, 2002, J BIOL CHEM, V277, P1794, DOI 10.1074/jbc.M103728200; OBERKOFLER H, 2002, BIOCHIM BIOPHYS ACTA, V3, P19353; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Sewter C, 2002, DIABETES, V51, P1035, DOI 10.2337/diabetes.51.4.1035; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598	40	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34380	34387		10.1074/jbc.M403596200	http://dx.doi.org/10.1074/jbc.M403596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15187085	hybrid			2022-12-25	WOS:000223134800038
J	Oorni, K; Sneck, M; Bromme, D; Pentikainen, MO; Lindstedt, KA; Mayranpaa, M; Aitio, H; Kovanen, PT				Oorni, K; Sneck, M; Bromme, D; Pentikainen, MO; Lindstedt, KA; Mayranpaa, M; Aitio, H; Kovanen, PT			Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-RETENTION HYPOTHESIS; APO-B LIPOPROTEINS; ARTERIAL PROTEOGLYCANS; FUNCTIONAL EXPRESSION; CHOLESTEROL ESTERIFICATION; PHOSPHOLIPASE A(2); APOLIPOPROTEIN-B; FUSION; LDL; GLYCOSAMINOGLYCANS	During atherogenesis, low density lipoprotein (LDL) particles in the arterial intima become modified and fuse to form extracellular lipid droplets. Proteolytic modification of apolipoprotein (apo) B-100 may be one mechanism of droplet formation from LDL. Here we studied whether the newly described acid protease cathepsin F can generate LDL-derived lipid droplets in vitro. Treatment of LDL particles with human recombinant cathepsin F led to extensive degradation of apoB-100, which, as determined by rate zonal flotation, electron microscopy, and NMR spectroscopy, triggered both aggregation and fusion of the LDL particles. Two other acid cysteine proteases, cathepsins S and K, which have been shown to be present in the arterial intima, were also capable of degrading apoB-100, albeit less efficiently. Cathepsin F treatment resulted also in enhanced retention of LDL to human arterial proteoglycans in vitro. Cultured monocyte-derived macrophages were found to secrete active cathepsin F. In addition, similarly with cathepsins S and K, cathepsin F was found to be localized mainly within the macrophage-rich areas of the human coronary atherosclerotic plaques. These results suggest that proteolytic modification of LDL by cathepsin F may be one mechanism leading to the extracellular accumulation of LDL-derived lipid droplets within the proteoglycan-rich extracellular matrix of the arterial intima during atherogenesis.	Wihuri Res Inst, FIN-00140 Helsinki, Finland; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Helsinki, Natl Biol NMR Lab Finland, FIN-00014 Helsinki, Finland	Wihuri Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Helsinki	Oorni, K (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	kati.oorni@wri.fi	Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250; Mayranpaa, Mikko/0000-0002-0877-9640	NIAMS NIH HHS [AR 46182, AR 48669] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182, R01AR048669] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ala-Korpela M, 1998, J LIPID RES, V39, P1705; Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; CLEVIDENCE BA, 1984, ARTERIOSCLEROSIS, V4, P196, DOI 10.1161/01.ATV.4.3.196; De Vries HE, 1998, FASEB J, V12, P111, DOI 10.1096/fasebj.12.1.111; Forte T, 1972, Adv Lipid Res, V10, P1; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; Hakala JK, 2001, ARTERIOSCL THROM VAS, V21, P1053, DOI 10.1161/01.ATV.21.6.1053; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1994, ATHEROSCLEROSIS, V105, P227, DOI 10.1016/0021-9150(94)90053-1; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; Levin M, 2003, ARTERIOSCL THROM VAS, V23, P1801, DOI 10.1161/01.ATV.0000092872.54026.8D; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; Naghavi M, 2002, ATHEROSCLEROSIS, V164, P27, DOI 10.1016/S0021-9150(02)00018-7; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; Pentikainen MO, 1997, J BIOL CHEM, V272, P25283, DOI 10.1074/jbc.272.40.25283; Pentikainen MO, 1996, J LIPID RES, V37, P2638; Pentikainen MO, 2001, J LIPID RES, V42, P916; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; POLACEK D, 1988, J LIPID RES, V29, P797; PRICE CA, 1982, CENTRIFUGATION DENSI, P18; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Saren P, 1996, J IMMUNOL, V157, P4159; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; TAILLEUX A, 1993, J LIPID RES, V34, P719; TIRZIU D, 1995, ATHEROSCLEROSIS, V112, P101, DOI 10.1016/0021-9150(94)05405-8; TURIK B, 2000, BIOCH BIOPYYS ACTA, V1477, P98; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	69	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34776	34784		10.1074/jbc.M310814200	http://dx.doi.org/10.1074/jbc.M310814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15184381	hybrid			2022-12-25	WOS:000223134800085
J	Shi, H; Tzameli, I; Bjorbaek, C; Flier, JS				Shi, H; Tzameli, I; Bjorbaek, C; Flier, JS			Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SOCS-BOX MOTIF; RECEPTOR SUBSTRATE-1; ADIPOSE-TISSUE; MICE LACKING; OBESITY; RESISTANCE; GROWTH; DEGRADATION; PHOSPHORYLATION	Many proinflammatory cytokines and hormones have been demonstrated to be involved in insulin resistance. However, the molecular mechanisms whereby these cytokines and hormones inhibit insulin signaling are not completely understood. We observed that several cytokines and hormones that induce insulin resistance also stimulate SOCS3 expression in 3T3-L1 adipocytes and that SOCS3 mRNA is increased in adipose tissue of obese/diabetic mice. We then hypothesized that SOCS3 may mediate cytokine- and hormone-induced insulin resistance. By using SOCS3-deficient adipocytes differentiated from mouse embryonic fibroblasts, we found that SOCS3 deficiency increases insulin-stimulated IRS1 and IRS2 phosphorylation, IRS-associated phosphatidylinositol 3-kinase activity, and insulin-stimulated glucose uptake. Moreover, lack of SOCS3 substantially limits the inhibitory effects of tumor necrosis factor-alpha to suppress IRS1 and IRS2 tyrosine phosphorylation, phosphatidylinositol 3-kinase activity, and glucose uptake in adipocytes. The ameliorated insulin signaling in SOCS3-deficient adipocytes is mainly due to the suppression of tumor necrosis factor-alpha-induced IRS1 and IRS2 protein degradation. Therefore, our data suggest that endogenous SOCS3 expression is a key determinant of basal insulin signaling and is an important molecular mediator of cytokine- induced insulin resistance in adipocytes. We conclude that SOCS3 plays an important role in mediating insulin resistance and may be an excellent target for therapeutic intervention in insulin resistance and type II diabetes.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, 330 Brookline Ave,Finard 202, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019; Bjorbaek, Christian/S-4727-2019					Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Chen XL, 2001, BIOCHEM BIOPH RES CO, V283, P933, DOI 10.1006/bbrc.2001.4882; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Shi H, 2002, FASEB J, V16, P1808, DOI 10.1096/fj.02-0255fje; Shiba T, 1998, DIABETIC MED, V15, P435, DOI 10.1002/(SICI)1096-9136(199805)15:5<435::AID-DIA566>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takano A, 2001, DIABETES, V50, P1891, DOI 10.2337/diabetes.50.8.1891; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wang ZW, 2000, BIOCHEM BIOPH RES CO, V277, P20, DOI 10.1006/bbrc.2000.3615; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	39	179	187	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34733	34740		10.1074/jbc.M403886200	http://dx.doi.org/10.1074/jbc.M403886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15181014	hybrid			2022-12-25	WOS:000223134800079
J	Clark, KD; Garczynski, SF; Arora, A; Crim, JW; Strand, MR				Clark, KD; Garczynski, SF; Arora, A; Crim, JW; Strand, MR			Specific residues in plasmatocyte-spreading peptide are required for receptor binding and functional antagonism of insect immune cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; IDENTIFIES CRITICAL RESIDUES; BIOLOGICAL-ACTIVITY; FOREIGN TARGETS; MOTH; ENCAPSULATION; HEMOCYTES; HEMOLYMPH; CYTOKINE	Plasmatocyte-spreading peptide (PSP) is a 23-amino acid cytokine that activates a class of insect immune cells called plasmatocytes. PSP consists of two regions: an unstructured N terminus (1-6) and a highly structured core (7-23). Prior studies identified specific residues in both the structured and unstructured regions required for biological activity. Most important for function were Arg(13), Phe(3), Cys(7), Cys(19), and the N-terminal amine of Glu(1). Here we have built on these results by conducting cell binding and functional antagonism studies. Alanine replacement of Met(12) (M12A) resulted in a peptide with biological activity indistinguishable from PSP. Competitive binding experiments using unlabeled and I-125-M12A generated an IC50 of 0.71 nM and indicated that unlabeled M12A, at concentrations greater than or equal to100 nM, completely blocked binding of label to hemocytes. We then tested the ability of other peptide mutants to displace I-125-M12A at a concentration of 100 nM. In the structured core, we found that Cys(7) and Cys(19) were essential for cell binding and functional antagonism, but these effects were likely because of the importance of these residues for maintaining the tertiary structure of PSP. Arg(13), in contrast, was also essential for binding and activity but is not required for maintenance of structure. In the unstructured N-terminal region, deletion of the phenyl group from Phe(3) yielded a peptide that reduced binding of I-125-M12A 326-fold. This and all other mutants of Phe(3) we bioassayed were unable to antagonize PSP. Deletion of Glu1 in contrast had almost no effect on binding and was a strong functional antagonist. Experiments using a photoaffinity analog indicated that PSP binds to a single 190-kDa protein.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison	Strand, MR (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.	mrstrand@bugs.ent.uga.edu	Clark, Kevin/GQA-9811-2022; Crim, Joe/GWC-6878-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Breslav M, 1997, TETRAHEDRON LETT, V38, P2219, DOI 10.1016/S0040-4039(97)00328-6; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; Clark KD, 2001, J BIOL CHEM, V276, P18491, DOI 10.1074/jbc.M100579200; Crim JW, 2002, PEPTIDES, V23, P2045, DOI 10.1016/S0196-9781(02)00192-4; Gardiner EMM, 1999, J INSECT PHYSIOL, V45, P113, DOI 10.1016/S0022-1910(98)00092-4; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hrabal R, 1996, PROTEIN SCI, V5, P195; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Lavine MD, 2001, J INSECT PHYSIOL, V47, P965, DOI 10.1016/S0022-1910(01)00071-3; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; Pech LL, 1996, J CELL SCI, V109, P2053; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; STRAND MR, 1990, ANN ENTOMOL SOC AM, V83, P538, DOI 10.1093/aesa/83.3.538; Tada M, 2003, J BIOL CHEM, V278, P10778, DOI 10.1074/jbc.M211251200; Vergnolle N, 2003, TRENDS NEUROSCI, V26, P496, DOI 10.1016/S0166-2236(03)00208-X; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	26	27	28	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33246	33252		10.1074/jbc.M401157200	http://dx.doi.org/10.1074/jbc.M401157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15192108	hybrid			2022-12-25	WOS:000223039700030
J	Sordet, O; Liao, ZY; Liu, H; Antony, S; Stevens, EV; Kohlhagen, G; Fu, HQ; Pommier, Y				Sordet, O; Liao, ZY; Liu, H; Antony, S; Stevens, EV; Kohlhagen, G; Fu, HQ; Pommier, Y			Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CLEAVAGE COMPLEXES; CELL APOPTOSIS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; DAMAGE; GLUTATHIONE; ACTIVATION; CAMPTOTHECIN; INDUCTION	Topoisomerase I is an essential enzyme that relaxes DNA supercoiling by forming covalent DNA cleavage complexes, which are normally transient. Topoisomerase I-DNA complexes can be trapped by anticancer drugs (camptothecins) as well as by endogenous and exogenous DNA lesions. We show here that arsenic trioxide (a potent inducer of apoptosis that induces the intracellular accumulation of reactive oxygen species and targets mitochondria) induces cellular topoisomerase I cleavage complexes. Bcl-2 overexpression and quenching of reactive oxygen species, which prevent arsenic trioxide-induced apoptosis, also prevent the formation of topoisomerase I-DNA complexes, whereas enhancement of reactive oxygen species accumulation promotes these complexes. The caspase inhibitor, benzyloxycarbonyl-VAD partially prevents arsenic trioxide-induced topoisomerase I-DNA complexes and apoptosis, suggesting that activated caspases further maintain intracellular levels of reactive oxygen species that induce the formation of topoisomerase I-DNA complexes. Down-regulation of topoisomerase I expression decreases arsenic trioxide-induced apoptotic DNA fragmentation. Thus, we propose that arsenic trioxide induces topoisomerase I-DNA complexes that participate in chromatin fragmentation and programmed cell death during apoptosis.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Sordet, Olivier/M-3271-2014	Sordet, Olivier/0000-0001-6027-4925	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Antony S, 2003, CANCER RES, V63, P7428; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; Davison K, 2003, LEUKEMIA, V17, P931, DOI 10.1038/sj.leu.2402876; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Jia PM, 2001, CHINESE MED J-PEKING, V114, P19; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li DS, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454712; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Matsui M, 1999, J INVEST DERMATOL, V113, P26, DOI 10.1046/j.1523-1747.1999.00630.x; MATTERN MR, 1993, ONCOL RES, V5, P467; McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155; Miller WH, 2002, CANCER RES, V62, P3893; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; Pulido MD, 2003, MUTAT RES-FUND MOL M, V533, P227, DOI 10.1016/j.mrfmmm.2003.07.015; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rojewski MT, 2004, CHEM RES TOXICOL, V17, P119, DOI 10.1021/tx034104+; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Zhang Y, 2003, CELL BIOL INT, V27, P953, DOI 10.1016/S1065-6995(03)00164-1; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	55	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33968	33975		10.1074/jbc.M404620200	http://dx.doi.org/10.1074/jbc.M404620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15178684	hybrid			2022-12-25	WOS:000223039700107
J	Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR				Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR			Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O(6-)alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrum	ONCOGENE			English	Article						Mgmt; Msh6; lacI; DNA mismatch repair; transgenic shuttle-phage; O-6 -alkylguanine; liver; small intestine; Big Blue (TM)	DNA-REPAIR METHYLTRANSFERASE; ELEVATED MUTANT FREQUENCIES; ESCHERICHIA-COLI; MISMATCH-REPAIR; LIPID-PEROXIDATION; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; NITRIC-OXIDE; ALKYLATION SENSITIVITY; INDUCED TUMORIGENESIS; METHYLATING AGENT	O-6-methylguanine methyltransferase, Mgmt, constitutes the first line of defense against O-6-alkylguanine, which can result in G: C to A: T transitions upon DNA replication. Mgmt has been found in organisms as diverse as archaebacteria and mammals. This evolutionary conservation suggests that all organisms may be exposed to either endogenous or environmental alkylating agents. We thus hypothesized that tissues of Mgmt(-/-) mice would exhibit elevated mutant frequencies. Employing the Big Blue(TM) transgenic system, we evaluated lacI mutants rescued from liver and small intestinal DNA of young Mgmt(-/-) mice. Interestingly, while there was a small difference between Mgmt(-/-) mice and controls with respect to lacI mutant frequency, no differences attributable to Mgmt deficiency were apparent in the mutational spectra. Although mutations stemming from O-6-guanine alkylations would be predicted to be cumulative, we found no evidence of an Mgmt-dependent alteration in mutation spectrum in DNA samples from 12 month-old mice. To optimize our ability to detect mutations resulting from O-6-alkylguanine-induced G: T mismatches, mice with combined deficiencies of Mgmt and the DNA mismatch repair molecule, Msh6, were analysed. In spite of this strategy, we observed no significant differences between Mgmt(-/-) Msh6(-/-) and Msh6(-/-) mouse lacI mutations, except for a trend towards a greater percentage (of total transitions) of G: C to A: T changes in Mgmt(-/-) Msh6(-/-) livers. Therefore, despite the striking evolutionary conservation of Mgmt, deficiency of this gene did not significantly impact the spontaneous laeI mutational spectrum in vivo.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	University of Calgary; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	jirik@ucalgary.ca			NATIONAL CANCER INSTITUTE [R01CA149261, R01CA075576, R01CA055042] Funding Source: NIH RePORTER; NCI NIH HHS [CA55042, R01 CA149261, CA75576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arrault X, 2002, MUTAGENESIS, V17, P353, DOI 10.1093/mutage/17.4.353; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bawa S, 1999, MUTAT RES-FUND MOL M, V430, P99, DOI 10.1016/S0027-5107(99)00163-3; Benjamin N, 2000, ANN ZOOTECH, V49, P207, DOI 10.1051/animres:2000118; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; Cariello NF, 1997, NUCLEIC ACIDS RES, V25, P136, DOI 10.1093/nar/25.1.136; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de Boer JG, 1998, MUTAGENESIS, V13, P109; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Georgiadis P, 2000, CANCER EPIDEM BIOMAR, V9, P299; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; Ishikawa T, 2001, MUTAT RES-FUND MOL M, V477, P41, DOI 10.1016/S0027-5107(01)00094-X; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; Jansen M, 2001, EUR J HAEMATOL, V67, P2, DOI 10.1034/j.1600-0609.2001.067001002.x; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KLEIN JC, 1990, NUCLEIC ACIDS RES, V18, P4131, DOI 10.1093/nar/18.14.4131; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Major G N, 1998, J Hepatobiliary Pancreat Surg, V5, P355, DOI 10.1007/s005340050059; Mark SC, 2002, ONCOGENE, V21, P7126, DOI 10.1038/sj.onc.1205861; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MINNICK DT, 1993, CANCER RES, V53, P997; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97, DOI 10.1128/CMR.12.1.97; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nair J, 1998, CANCER EPIDEM BIOMAR, V7, P435; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Pauly GT, 2001, CHEM RES TOXICOL, V14, P894, DOI 10.1021/tx010032f; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; PROVOST GS, 1993, MUTAT RES, V288, P133; Quillardet P, 2000, MUTAT RES-GEN TOX EN, V470, P177, DOI 10.1016/S1383-5718(00)00103-0; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Rogozin IB, 2001, HUM MUTAT, V17, P83, DOI 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E; Roth RB, 2000, MUTAT RES-REV MUTAT, V462, P107, DOI 10.1016/S1383-5742(00)00021-1; Sakumi K, 1997, CANCER RES, V57, P2415; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; Stuart GR, 2000, GENETICS, V154, P1291; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Vidal A, 1998, MUTAGENESIS, V13, P367, DOI 10.1093/mutage/13.4.367; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Walter CA, 2001, ANN NY ACAD SCI, V928, P132; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Zhou ZQ, 2001, P NATL ACAD SCI USA, V98, P12566, DOI 10.1073/pnas.221232998	73	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5931	5940		10.1038/sj.onc.1207791	http://dx.doi.org/10.1038/sj.onc.1207791			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208683				2022-12-25	WOS:000222941100007
J	Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D				Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D			Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis	ONCOGENE			English	Article						ras oncogene; cell cycle; human tumours; epithelial; fibroblast; senescence	HUMAN BREAST-CANCER; INDUCED SENESCENCE; ACTIVATION; P16(INK4A); MUTATIONS; P21(CIP1); TUMORS; GROWTH; KINASE; GENES	Using microinjection of recombinant protein to directly control 'expression' levels, we have compared the proliferative response to ras oncogene activation in two normal cell types - fibroblast and thyroid epithelial cell which give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentration-dependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1) was observed in both cell types, but p16(Ink4a) was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growth-inhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16(Ink4a) and p21(WAF1), but is consistent with a differential ability of p21(WAF1) to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.	Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Fac Med Nord, F-13916 Marseille, France	Cardiff University; UDICE-French Research Universities; Aix-Marseille Universite	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Bredel M, 1999, BRAIN RES REV, V29, P232, DOI 10.1016/S0165-0173(98)00057-5; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LEMOINE NR, 1989, ONCOGENE, V4, P159; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	26	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5994	5999		10.1038/sj.onc.1207798	http://dx.doi.org/10.1038/sj.onc.1207798			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208687				2022-12-25	WOS:000222941100014
J	Wang, L; Pan, Y; Dai, JL				Wang, L; Pan, Y; Dai, JL			Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors	ONCOGENE			English	Article						MKK4; MAP kinase; oncogenes; apoptosis	METASTASIS SUPPRESSOR GENE; JUN NH2-TERMINAL KINASE; LUNG-CARCINOMA CELLS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; CANCER; GROWTH; JNK; TRANSFORMATION	MKK4, located in close proximity to p53 gene, is thought to be a tumor suppressor and a metastasis suppressor gene. A low-rate MKK4 gene alteration has been found in a few tumor types, including breast and pancreatic. A suppressor activity for prostate and ovarian tumor metastasis has also been suggested. To understand the pathobiologic roles of MKK4 in tumorigenesis, we examined the phenotypic changes in response to perturbation of the MKK4 expression in breast and pancreatic cancer cell lines. Ectopic expression of MKK4 by adenoviral delivery in MKK4-negative cancer lines stimulated the cell proliferation and invasion, whereas knockdown of MKK4 expression by small interference RNA in an MKK4-positive breast cancer cell line, MDA-MB-231, resulted in decreased anchorage-independent growth, suppressed tumor growth in mouse xenograft model, and increased cell susceptibility to apoptosis brought by stress signals such as serum deprivation. These results argue that MKK4 functions as a pro-oncogenic molecule instead of a suppressor in breast and pancreatic tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org						Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chae KS, 2002, EUR J CANCER, V38, P2048, DOI 10.1016/S0959-8049(02)00147-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kim HL, 2001, CANCER RES, V61, P2833; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Teng DHF, 1997, CANCER RES, V57, P4177; Wang L, 2003, CANCER RES, V63, P4724; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoshida BA, 1999, CANCER RES, V59, P5483	35	85	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2004	23	35					5978	5985		10.1038/sj.onc.1207802	http://dx.doi.org/10.1038/sj.onc.1207802			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184866				2022-12-25	WOS:000222941100012
J	Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM				Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM			The Ras-related protein AGS1/RASD1 suppresses cell growth	ONCOGENE			English	Article						AGS1; RASD1; Dexras1; G-protein; apoptosis; cancer	SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BINDING PROTEIN; GENE; IDENTIFICATION; DEXRAS1; INTEGRATION; ACTIVATION; HORMONE	AGS1/RASD1 is a Ras-related protein identified as a dexamethasone-inducible cDNA and as a signal regulator in various functional and protein-interaction screens. As an initial approach to define the role of AGS1/RASD1 as a Ras-family member, we determined its influence on cell growth/survival. In clonogenic assays with NIH-3T3 murine fibroblast cells, the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549, AGS1/RASD1 markedly diminished the number of G418-resistant colonies, whereas the Ras subgroup member K-Ras was without effect. A549 cell infection with adenovirus engineered to express AGS1/RASD1 (Ad.AGS1) inhibited log phase growth in vitro and increased the percentage of cells undergoing apoptosis. The anti-growth action was also observed in vivo as the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude mice. These data indicate that AGS1/RASD1, a member of the Ras superfamily of small G-proteins that often promotes cell growth and tumor expansion, plays an active role in preventing aberrant cell growth.	Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; NE Ohio Univ, Coll Med, Dept Physiol & Pharmacol, Rootstown, OH 44272 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med & Genet, Baton Rouge, LA 70803 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Louisiana State Univ, Ctr Hlth Sci, Stanley S Scott Canc Ctr, Baton Rouge, LA 70803 USA	Louisiana State University System; Northeast Ohio Medical University (NEOMED); Louisiana State University System; Louisiana State University; Louisiana State University Health Sciences Center at Shreveport; West Virginia University; Louisiana State University System; Louisiana State University	Lanier, SM (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH90531] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Der C J, 1989, Cancer Treat Res, V47, P73; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 2003, BBA-GENE STRUCT EXPR, V1627, P85, DOI 10.1016/S0167-4781(03)00079-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; Koga T, 2002, CANCER GENET CYTOGEN, V136, P113, DOI 10.1016/S0165-4608(02)00527-7; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Lanson NA, 2003, CANCER RES, V63, P7936; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Stacey MW, 1999, GENE CHROMOSOME CANC, V25, P191, DOI 10.1002/(SICI)1098-2264(199906)25:2<191::AID-GCC16>3.0.CO;2-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Vargiu P, 2004, ONCOGENE, V23, P559, DOI 10.1038/sj.onc.1207161	25	86	91	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5858	5863		10.1038/sj.onc.1207774	http://dx.doi.org/10.1038/sj.onc.1207774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184869				2022-12-25	WOS:000222629800016
